PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Mathews, F; Yudkin, P; Neil, A				Mathews, F; Yudkin, P; Neil, A			Influence of maternal nutrition on outcome of pregnancy: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							BIRTH-WEIGHT; DIET; WOMEN	Objective To investigate the relations of maternal diet and smoking during pregnancy to placental and birth weights at term. Design Prospective cohort study. Setting District general hospital in the south of England. Participants 693 pregnant nulliparous white women with singleton pregnancies who were selected from antenatal booking clinics with stratified random sampling. Main outcome measures Birth and placental weights at term. Results Placental and birth weights were unrelated to the intake of any macronutrient Early in pregnancy, vitamin C was the only micronutrient independently associated with birth weight after adjustment for maternal height and smoking. Each In mg increase in vitamin C was associated with a 50.8 g (95% confidence interval 4.6 g to 97.0 g) increase in birth weight Vitamin C, vitamin E, and folate were each associated with placental weight after adjustment for maternal characteristics. In simultaneous regression, however, vitamin C was the only nutrient predictive of placental weight: each In mg increase in vitamin C was associated with a 3.2% (0.4 to 6.1) rise in placental weight No nutrient late in pregnancy was associated with either placental or birth weight. Conclusions Concern over the impact of maternal nutrition on the health of the infant has been premature, Maternal nutrition, at least in industrialised populations, seems to have only a small effect on placental and birth weights. Other possible determinants of fetal and placental growth should be investigated.	Univ Oxford, Inst Hlth Sci, Div Publ Hlth & Primary Hlth Care, Oxford OX3 7LF, England	University of Oxford	Mathews, F (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		li, tao/B-2402-2008					ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barker DJP, 1992, FETAL INFANT ORIGINS; Bingham SA, 1997, EUR J CANCER PREV, V6, P118; BINGHAM SA, 1994, BRIT J NUTR, V72, P619, DOI 10.1079/BJN19940064; BINGHAM SA, 1991, DESIGN CONCEPTS NUTR, P151; BOLLING K, 1997, SMOKING PREGNANCY SU; BOTTING B, 1993, POPULATION TRENDS, V74, P27; Campbell DM, 1996, BRIT J OBSTET GYNAEC, V103, P273, DOI 10.1111/j.1471-0528.1996.tb09718.x; Foster K, 1997, INFANT FEEDING 1995; Fraser R, 1997, BRIT J OBSTET GYNAEC, V104, P645, DOI 10.1111/j.1471-0528.1997.tb11972.x; Godfrey K, 1996, BRIT MED J, V312, P410, DOI 10.1136/bmj.312.7028.410; Godfrey KM, 1997, BRIT J OBSTET GYNAEC, V104, P663, DOI 10.1111/j.1471-0528.1997.tb11975.x; Gregory J., 1990, DIETARY NUTR SURVEY; HASTE FM, 1991, BRIT J NUTR, V65, P347, DOI 10.1079/BJN19910095; KNIGHT GJ, 1985, CLIN CHEM, V31, P118; KRAMER MS, 1994, COCHRANE LIB; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V43, P461; MAHOMED K, 1993, COCHRANE LIB; Mathews F, 1996, NUTR RES REV, V9, P175, DOI 10.1079/NRR19960011; Mathews F, 1998, J HUM NUTR DIET, V11, P151, DOI 10.1046/j.1365-277X.1998.00085.x; MATHEWS F, IN PRESS ANN CLIN BI; Office of Population Censuses and Surveys, 1980, CLASS OCC; Robinson S, 1996, EUR J CLIN NUTR, V50, P302; RUSH D, 1989, EFFECTIVE CARE PREGN, P255; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; Willett W, 1990, NUTR EPIDEMIOLOGY, P92	27	233	237	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					339	343		10.1136/bmj.319.7206.339	http://dx.doi.org/10.1136/bmj.319.7206.339			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435950	Green Published, Bronze			2022-12-24	WOS:000082001700014
J	Tsevat, J; Sherman, SN; McElwee, JA; Mandell, KL; Simbartl, LA; Sonnenberg, FA; Fowler, FJ				Tsevat, J; Sherman, SN; McElwee, JA; Mandell, KL; Simbartl, LA; Sonnenberg, FA; Fowler, FJ			The will to live among HIV-infected patients	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	19th Annual Meeting of the Society-for-Medical-Decision-Making	OCT 25-29, 1997	HOUSTON, TX	Soc Med Decis Making			QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; HEALTH STATES; VALUES; OUTCOMES; UTILITIES	Background: Patients infected with HIV value both longevity and health, Objective: To understand how HIV-infected patients value their health. Design: Interview study. Setting: Regional treatment center for HIV. Patients: 51 patients with HIV infection. Measurements: Life-satisfaction, health rating, time-tradeoff, and standard-gamble scores. Results: Of the 51 patients, 49% (95% CI, 35% to 63%) said that their life was better currently than it was before they contracted HIV infection; only 29% said that life was currently worse. The mean (+/- SD) time-tradeoff score was 0.95 +/- 0.10, indicating that, on average, patients would give up no more than 5% of their remaining life expectancy in their current state of health in exchange for a shorter but healthy life. The average health rating score was 71.0 +/- 18.7 on a scale of 0 to 100, and the average standard-gamble score was 0.80 +/- 0.27. Factors contributing to life satisfaction and time-tradeoff scores included spirituality and having children. Conclusion: Many patients with HIV have a strong will to live, and many feel that life with HIV is better than it was before they became infected.	Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res,Infect Dis Ctr, Cincinnati, OH 45267 USA; SNS Res, Cincinnati, OH 45241 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Div Gen Internal Med, New Brunswick, NJ 08903 USA; Univ Massachusetts, Survey Res Ctr, Boston, MA 02125 USA	University System of Ohio; University of Cincinnati; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Massachusetts System; University of Massachusetts Boston	Tsevat, J (corresponding author), Univ Cincinnati, Med Ctr, Div Gen Internal Med, Sect Outcomes Res,Infect Dis Ctr, Box 670535, Cincinnati, OH 45267 USA.	Joel.Tsevat@uc.edu			AHRQ HHS [1 R01 HS 09103-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Andrews F. M., 1976, SOCIAL INDICATORS WE; Carson V B, 1993, J Assoc Nurses AIDS Care, V4, P18; CLEARY PD, 1993, MED CARE, V31, P569, DOI 10.1097/00005650-199307000-00001; FOWLER FJ, 1995, MED DECIS MAKING, V15, P195, DOI 10.1177/0272989X9501500301; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; Klitzman R., 1997, BEING POSITIVE LIVES; LAMPING DL, 1994, PSYCHOL HEALTH, V9, P31, DOI 10.1080/08870449408407458; OLEARY JF, 1995, MED DECIS MAKING, V15, P132, DOI 10.1177/0272989X9501500205; Owens DK, 1997, QUAL LIFE RES, V6, P77, DOI 10.1023/A:1026473613487; PEARSON SD, 1995, J GEN INTERN MED, V10, P557, DOI 10.1007/BF02640365; REVICKI DA, 1995, MED CARE, V33, pAS173; STANGE KC, 1994, J GEN INTERN MED, V9, P278, DOI 10.1007/BF02599656; Tsevat J, 1996, MED CARE, V34, P44, DOI 10.1097/00005650-199601000-00004; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; TSEVAT J, 1995, ANN INTERN MED, V122, P514, DOI 10.7326/0003-4819-122-7-199504010-00007; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; Wu AW, 1997, QUAL LIFE RES, V6, P531, DOI 10.1023/A:1018460132567	18	83	83	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					194	198		10.7326/0003-4819-131-3-199908030-00006	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	222ME	10428736				2022-12-24	WOS:000081788700005
J	Singh, A; Crockard, HA				Singh, A; Crockard, HA			Quantitative assessment of cervical spondylotic myelopathy by a simple walking test	LANCET			English	Article							SPINAL-CORD INJURY; RHEUMATOID-ARTHRITIS	Background We developed a 30 m walking test as a quantifiable measure of severity of cervical spondylotic myelopathy (CSM), which will be of use in determining the effects of decompressive surgical treatment. Methods Preoperative measurements were made in 41 patients with CSM of 30 m walking times, number of steps taken over this distance, myelopathy disability index (MDI), and Nurick scores. The walking factors were compared with a similar number of age-matched and sex-matched controls. The individuals in the study were patients with CSM and no other relevant pathology consecutively referred for decompressive surgery to the National Hospital for Neurology and Neurosurgery. Findings Both walking time and the number of steps taken were significantly worse in pre-operative patients than in controls. The walking data were highly reproducible over three trials. Postoperatively, there was a significant improvement in walking time (p=0.0018) and number of steps taken (p=5.87x10(-6)). Only two of 41 patients were worse postoperatively. There was also a significant improvement in MDI (two-tailed Wilcoxon, related samples; p<0.0001) and Nurick scores (two-tailed Wilcoxon p<0.0001) postoperatively. The preoperative and postoperative walking scores were significantly and equally correlated with the MDI and Nurick scores. Interpretation Timed walks are an easily performed, quantitative, and valid means of assessing CSM and the effects of surgery.	UCL Natl Hosp Neurol & Neurosurg, Dept Neurol Surg, London WC1N 3BG, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	Crockard, HA (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurol Surg, Queen Sq, London WC1N 3BG, England.	A.Crockard@ion.uci.ac.uk						ALLEN KL, 1952, J NEUROL NEUROSUR PS, V15, P20, DOI 10.1136/jnnp.15.1.20; BAKAY L, 1970, J NEUROL NEUROSUR PS, V33, P20; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Casey ATH, 1996, ANN RHEUM DIS, V55, P901, DOI 10.1136/ard.55.12.901; CLARKE E, 1956, BRAIN, V79, P483, DOI 10.1093/brain/79.3.483; DITUNNO JF, 1992, PARAPLEGIA, V30, P90, DOI 10.1038/sc.1992.31; DONOVAN WH, 1990, J NEURO REHAB, V4, P39; Dun-Rankin P., 1983, SCALING METHODS; GONZALEZFERIA L, 1975, ACTA NEUROCHIR, V31, P185, DOI 10.1007/BF01406291; HADLEY MN, 1995, PRINCIPLES SPINAL SU, P531; HERMANN J, 1994, ADV NEUROSURG, P266; HIRABAYASHI K, 1983, SPINE, V8, P693, DOI 10.1097/00007632-198310000-00003; HOLDEN MK, 1984, PHYS THER, V64, P35, DOI 10.1093/ptj/64.1.35; LINDSAY KW, 1991, NEUROLOGY NEUROSURGE, P373; NURICK S, 1972, BRAIN, V95, P87; RANAWAT CS, 1979, J BONE JOINT SURG AM, V61, P1003, DOI 10.2106/00004623-197961070-00006; ROGERS L, 1961, J NEUROSURG, V18, P490, DOI 10.3171/jns.1961.18.4.0490; ROGERS L, 1961, J BONE JOINT SURG BR, V43, P3, DOI 10.1302/0301-620X.43B1.3; SCOVILLE WB, 1961, J NEUROSURG, V18, P423, DOI 10.3171/jns.1961.18.4.0423; STREINER DI, 1996, MEASURING CHANGE HLT, P163; SYPERT GW, 1992, DISORDERS CERVICAL S, P407; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WATERS RL, 1991, PARAPLEGIA, V29, P573, DOI 10.1038/sc.1991.85	23	94	99	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					370	373		10.1016/S0140-6736(98)10199-X	http://dx.doi.org/10.1016/S0140-6736(98)10199-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437865				2022-12-24	WOS:000081764900011
J	Hahn, WC; Counter, CM; Lundberg, AS; Beijersbergen, RL; Brooks, MW; Weinberg, RA				Hahn, WC; Counter, CM; Lundberg, AS; Beijersbergen, RL; Brooks, MW; Weinberg, RA			Creation of human tumour cells with defined genetic elements	NATURE			English	Article							LARGE T-ANTIGEN; TELOMERASE ACTIVITY; EPITHELIAL-CELLS; HUMAN-FIBROBLASTS; TRANSFORMATION; EXPRESSION; SENESCENCE; ONCOGENE; SARCOMA; CANCER	During malignant transformation, cancer cells acquire genetic mutations that override the normal mechanisms controlling: cellular proliferation. Primary rodent cells are efficiently converted into tumorigenic cells by the coexpression of cooperating oncogenes(1,2). However, similar experiments with human cells have consistently failed to yield tumorigenic transformants(3-5), indicating a fundamental difference in the biology of human and rodent cells. The few reported successes in the creation of human tumour cells have depended on the use of chemical or physical agents to achieve immortalization(6), the selection of rare, spontaneously arising immortalized cells(7-10), or the use of an entire viral genome(11). We show here that the ectopic expression of the telomerase catalytic subunit (hTERT)(12) in combination with two oncogenes (the simian virus 40 large-T oncoprotein and an oncogenic allele of H-ras) results in direct tumorigenic conversion of normal human epithelial and fibroblast cells. These results demonstrate that disruption of the intracellular pathways regulated by large-T, oncogenic ras and telomerase suffices to create a human tumor cell.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Duke University	Weinberg, RA (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	weinberg@wi.mit.edu		Beijersbergen, Roderick/0000-0003-0116-4130; Counter, Christopher M/0000-0003-0748-3079				Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Burger AM, 1998, INT J ONCOL, V13, P1043; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; FEUER G, 1995, J VIROL, V69, P1328, DOI 10.1128/JVI.69.2.1328-1333.1995; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; Kang KS, 1998, MOL CARCINOGEN, V21, P225, DOI 10.1002/(SICI)1098-2744(199804)21:4<225::AID-MC1>3.3.CO;2-O; Kim JW, 1997, INFORM SYST RES, V8, P25, DOI 10.1287/isre.8.1.25; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kipling D, 1997, EUR J CANCER, V33, P792, DOI 10.1016/S0959-8049(97)00060-9; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lustig AJ, 1999, P NATL ACAD SCI USA, V96, P3339, DOI 10.1073/pnas.96.7.3339; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Nakamura TM, 1998, CELL, V92, P587, DOI 10.1016/S0092-8674(00)81123-X; OBRIEN W, 1986, P NATL ACAD SCI USA, V83, P8659; Reddel RR, 1997, BIOCHEMISTRY-MOSCOW+, V62, P1254; RHIM JS, 1985, SCIENCE, V227, P1250, DOI 10.1126/science.2579430; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; STEVENSON M, 1986, MOL CELL BIOL, V6, P3410, DOI 10.1128/MCB.6.10.3410; YOAKUM GH, 1985, SCIENCE, V227, P1174, DOI 10.1126/science.3975607; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408	30	1866	1948	1	116	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					464	468		10.1038/22780	http://dx.doi.org/10.1038/22780			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440377				2022-12-24	WOS:000081715000054
J	Strous, M; Fuerst, JA; Kramer, EHM; Logemann, S; Muyzer, G; van de Pas-Schoonen, KT; Webb, R; Kuenen, JG; Jetten, MSM				Strous, M; Fuerst, JA; Kramer, EHM; Logemann, S; Muyzer, G; van de Pas-Schoonen, KT; Webb, R; Kuenen, JG; Jetten, MSM			Missing lithotroph identified as new planctomycete	NATURE			English	Article							ANAEROBIC AMMONIUM OXIDATION; ORDER PLANCTOMYCETALES; BUDDING BACTERIA; REACTOR; DIVERSITY; EVOLUTION; PIRELLA	With the increased use of chemical fertilizers in agriculture, many densely populated countries face environmental problems associated with high ammonia emissions. The process of anaerobic ammonia oxidation ('anammox') is one of the most innovative technological advances in the removal of ammonia nitrogen from waste water(1,2). This new process combines ammonia and nitrite directly into dinitrogen gas(3). Until now, bacteria capable of anaerobically oxidizing ammonia had never been found and were known as "lithotrophs missing from nature"(4). Here we report the discovery of this missing lithotroph and its identification as a new, autotrophic member of the order Planctomycetales, one of the major distinct divisions of the Bacteria(5). The new planctomycete grows extremely slowly, dividing only once every two weeks. At present, it cannot be cultivated by conventional microbiological techniques. The identification of this bacterium as the one responsible for anaerobic oxidation of ammonia makes an important contribution to the problem of unculturability.	Delft Univ Technol, Dept Biotechnol, NL-2628 BC Delft, Netherlands; Univ Queensland, Dept Microbiol & Parasitol, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Netherlands Inst Sea Res, NL-1790 AB Den Burg, Netherlands	Delft University of Technology; University of Queensland; University of Queensland; Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Jetten, MSM (corresponding author), Delft Univ Technol, Dept Biotechnol, Julianalaan 67, NL-2628 BC Delft, Netherlands.		Muyzer, Gerard/ABE-5834-2020; Curto, Ana Q/O-6849-2015; Strous, Marc/B-4064-2017; Fuerst, John/I-8649-2012; Jetten, Mike/B-8834-2011; Muyzer, Gerard/A-3161-2013	Muyzer, Gerard/0000-0002-2422-0732; Curto, Ana Q/0000-0003-3568-9322; Strous, Marc/0000-0001-9600-3828; Fuerst, John/0000-0002-6451-8533; Jetten, Mike/0000-0002-4691-7039; 				BRODA E, 1977, Z ALLG MIKROBIOL, V17, P491, DOI 10.1002/jobm.3630170611; Byers HK, 1998, FEMS MICROBIOL ECOL, V25, P391, DOI 10.1111/j.1574-6941.1998.tb00491.x; DELONG EF, 1993, LIMNOL OCEANOGR, V38, P924, DOI 10.4319/lo.1993.38.5.0924; FUERST JA, 1995, MICROBIOL-UK, V141, P1493, DOI 10.1099/13500872-141-7-1493; FUERST JA, 1991, P NATL ACAD SCI USA, V88, P8184, DOI 10.1073/pnas.88.18.8184; Fuerst JA, 1997, APPL ENVIRON MICROB, V63, P254, DOI 10.1128/AEM.63.1.254-262.1997; Fuqua C, 1998, CURR OPIN MICROBIOL, V1, P183, DOI 10.1016/S1369-5274(98)80009-X; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Jetten MSM, 1997, WATER SCI TECHNOL, V35, P171, DOI 10.2166/wst.1997.0341; KONIG E, 1984, ARCH MICROBIOL, V138, P200, DOI 10.1007/BF00402120; LIESACK W, 1986, ARCH MICROBIOL, V145, P361, DOI 10.1007/BF00470872; Lindsay MR, 1997, MICROBIOL-UK, V143, P739, DOI 10.1099/00221287-143-3-739; Ludwig W, 1998, ELECTROPHORESIS, V19, P554, DOI 10.1002/elps.1150190416; Neef A, 1998, MICROBIOL-UK, V144, P3257, DOI 10.1099/00221287-144-12-3257; SCHLESNER H, 1986, SYST APPL MICROBIOL, V8, P174, DOI 10.1016/S0723-2020(86)80072-8; Strous M, 1997, WATER RES, V31, P1955, DOI 10.1016/S0043-1354(97)00055-9; Strous M, 1998, APPL MICROBIOL BIOT, V50, P589, DOI 10.1007/s002530051340; Van De Graaf Astrid A., 1996, Microbiology (Reading), V142, P2187; vandeGraaf AA, 1997, MICROBIOL-SGM, V143, P2415, DOI 10.1099/00221287-143-7-2415; Vergin KL, 1998, APPL ENVIRON MICROB, V64, P3075; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987; Zarda B, 1997, ARCH MICROBIOL, V168, P185, DOI 10.1007/s002030050486	22	1103	1300	40	775	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					446	449		10.1038/22749	http://dx.doi.org/10.1038/22749			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440372				2022-12-24	WOS:000081715000049
J	Greenough, A				Greenough, A			Chronic lung disease of prematurity - prevention by inhaled corticosteroids?	LANCET			English	Editorial Material							METERED-DOSE INHALER; PRETERM; INFANTS; DEXAMETHASONE; STEROIDS; DELIVERY; AEROSOL		Univ London Kings Coll Hosp, Sch Med & Dent, Dept Child Hlth, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Greenough, A (corresponding author), Univ London Kings Coll Hosp, Sch Med & Dent, Dept Child Hlth, Denmark Hill, London SE5 9RS, England.							Arnon S, 1996, PEDIATR PULM, V21, P231; Bhuta T, 1998, ARCH DIS CHILD-FETAL, V79, pF26, DOI 10.1136/fn.79.1.F26; Cole CH, 1999, NEW ENGL J MED, V340, P1005, DOI 10.1056/NEJM199904013401304; Dimitriou G, 1997, EUR J PEDIATR, V156, P51; Fok TF, 1999, ARCH DIS CHILD-FETAL, V80, pF203, DOI 10.1136/fn.80.3.F203; Fok TF, 1997, PEDIATR PULM, V24, P204; Giep T, 1996, AM J PERINAT, V13, P5, DOI 10.1055/s-2007-994193; Greenough A, 1998, LANCET, V352, P835, DOI 10.1016/S0140-6736(05)60002-5; Groneck P, 1999, PEDIATR PULM, V27, P383, DOI 10.1002/(SICI)1099-0496(199906)27:6<383::AID-PPUL4>3.0.CO;2-V; HALLIDAY HL, DELAYED GREATER 3 WE; Kovacs L, 1998, ACTA PAEDIATR, V87, P792, DOI 10.1080/080352598750013905; Ng PC, 1998, J CLIN ENDOCR METAB, V83, P2390, DOI 10.1210/jc.83.7.2390; OCALLAGHAN C, 1992, ARCH DIS CHILD-FETAL, V67, P20, DOI 10.1136/adc.67.1_Spec_No.20	13	5	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					266	267		10.1016/S0140-6736(99)00176-2	http://dx.doi.org/10.1016/S0140-6736(99)00176-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440296				2022-12-24	WOS:000081646000002
J	Sotiropoulos, A; Gineitis, D; Copeland, J; Treisman, R				Sotiropoulos, A; Gineitis, D; Copeland, J; Treisman, R			Signal-regulated activation of serum response factor is mediated by changes in actin dynamics	CELL			English	Article							GENE-EXPRESSION; TRANSCRIPTIONAL ACTIVATION; FILAMENT TURNOVER; SWINHOLIDE-A; ZINC-FINGER; BINDING; VINCULIN; COFILIN; PROTEIN; KINASE	Serum response factor (SRF) regulates transcription of many serum-inducible and muscle-specific genes. Using a functional screen, we identified LIM kinase-l as a potent activator of SRF. We show that SRF activation by LIM kinase-l is dependent on its ability to regulate actin treadmilling. LIM kinase activity is not essential for SRF activation by serum, but signals depend on alterations in actin dynamics. Studies with actin-binding drugs, the actin-specific C2 toxin, and actin overexpression demonstrate that G-actin level controls SRF. Regulation of actin dynamics is necessary for serum induction of a subset of SRF target genes, including vinculin, cytoskeletal actin, and srf itself, and also suffices for their activation. Actin treadmilling provides a convergence point for both serum- and LIM kinase-1-induced signaling to SRF.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.	treisman@icrf.icnet.uk	Sotiropoulos, Athanassia/P-4269-2017	Treisman, Richard/0000-0002-9658-0067; Sotiropoulos, Athanassia/0000-0002-7265-1473				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Beckerle MC, 1998, CELL, V95, P741, DOI 10.1016/S0092-8674(00)81697-9; BENZEEV A, 1990, CELL REGUL, V1, P621, DOI 10.1091/mbc.1.9.621; BERNARD O, 1994, CELL GROWTH DIFFER, V5, P1159; BERSHADSKY AD, 1995, J CELL SCI, V108, P1183; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BUBB MR, 1995, J BIOL CHEM, V270, P3463, DOI 10.1074/jbc.270.8.3463; BUBB MR, 1994, J BIOL CHEM, V269, P14869; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Carnac G, 1998, MOL BIOL CELL, V9, P1891, DOI 10.1091/mbc.9.7.1891; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Edwards DC, 1999, J BIOL CHEM, V274, P11352, DOI 10.1074/jbc.274.16.11352; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; Higuchi O, 1996, FEBS LETT, V396, P81, DOI 10.1016/0014-5793(96)01072-1; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HILL CS, 1994, EMBO J, V13, P5421, DOI 10.1002/j.1460-2075.1994.tb06877.x; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Lappalainen P, 1997, EMBO J, V16, P5520, DOI 10.1093/emboj/16.18.5520; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Lyubimova A, 1997, J CELL BIOCHEM, V65, P469, DOI 10.1002/(SICI)1097-4644(19970615)65:4<469::AID-JCB3>3.0.CO;2-M; Machesky LM, 1999, CURR OPIN CELL BIOL, V11, P117, DOI 10.1016/S0955-0674(99)80014-3; MIZUNO K, 1994, ONCOGENE, V9, P1605; MOHUN T, 1987, EMBO J, V6, P667, DOI 10.1002/j.1460-2075.1987.tb04806.x; MOISEYEVA EP, 1993, J BIOL CHEM, V268, P4318; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; REUNER KH, 1995, EUR J BIOCHEM, V230, P32, DOI 10.1111/j.1432-1033.1995.0032i.x; Reuner KH, 1996, BIOCHEM J, V319, P843, DOI 10.1042/bj3190843; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; RYSECK RP, 1989, EXP CELL RES, V180, P537, DOI 10.1016/0014-4827(89)90080-3; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Saito S, 1998, J BIOCHEM-TOKYO, V123, P571; SAMPATH P, 1991, BIOCHEMISTRY-US, V30, P1973, DOI 10.1021/bi00221a034; SARTORELLI V, 1990, GENE DEV, V4, P1811, DOI 10.1101/gad.4.10.1811; SCHEVZOV G, 1995, DNA CELL BIOL, V14, P689, DOI 10.1089/dna.1995.14.689; Schluter K, 1997, BBA-MOL CELL RES, V1359, P97, DOI 10.1016/S0167-4889(97)00100-6; Sepulveda JL, 1998, MOL CELL BIOL, V18, P3405, DOI 10.1128/MCB.18.6.3405; Spencer JA, 1996, J BIOL CHEM, V271, P16535, DOI 10.1074/jbc.271.28.16535; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; VANDEKERCKHOVE J, 1988, J BIOL CHEM, V263, P696; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wei L, 1998, J BIOL CHEM, V273, P30287, DOI 10.1074/jbc.273.46.30287; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	53	558	566	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					159	169		10.1016/S0092-8674(00)81011-9	http://dx.doi.org/10.1016/S0092-8674(00)81011-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428028	Bronze			2022-12-24	WOS:000081632300006
J	Lucas, GM; Chaisson, RE; Moore, RD				Lucas, GM; Chaisson, RE; Moore, RD			Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions	ANNALS OF INTERNAL MEDICINE			English	Article						anti-HIV agents; protease inhibitors; RNA, viral; CD4 lymphocytecount; urban health services	HUMAN-IMMUNODEFICIENCY-VIRUS; PLASMA HIV-1 RNA; PROTEASE INHIBITORS; TYPE-1 RNA; INFECTION; PROGRESSION; DISEASE; PREDICTORS; INDINAVIR; ADHERENCE	Background: In clinical trials, highly active antiretroviral therapy (HAART) reduces plasma HIV-1 RNA levels to less than 500 copies/mL in 60% to 90% of patients with HIV-1 infection. The performance of such therapy outside of the clinical trial setting is unclear. Objective: To determine factors associated with failure to suppress HIV-1 RNA levels and adverse drug reactions in a cohort of patients in whom protease inhibitor-containing therapy was begun in a large urban clinic. Design: Retrospective cohort study. Setting: Johns Hopkins HIV Clinic in Baltimore, Maryland. Patients: 273 protease inhibitor-naive patients began taking a protease inhibitor regimen containing at least one other antiretroviral drug to which the patients had not previously been exposed. Measurements: Demographic variables, plasma HIV-1 RNA levels, CD4(+) lymphocyte counts, and adverse drug reactions. Results: Levels of HIV-1 RNA were undetectable in 42% of the cohort at 1 to 90 days, in 44% at 3 to 7 months, and in 37% at 7 to 14 months. Factors associated with failure to suppress viral load at two or more time points included higher rates of missed clinic appointments, nonwhite ethnicity, age 40 years or younger, injection drug use, lower baseline CD4(+) lymphocyte count, and higher baseline viral load. In a multivariate model, only higher rates of missed clinic appointments were independently associated with viral suppression at 1 year. Ritonavir was associated with adverse drug reactions about twice as frequently as indinavir or nelfinavir, and women experienced significantly more adverse effects than men. Conclusions: Unselected patients in whom HAART is started in a clinic setting achieve viral suppression substantially less frequently than do patients in controlled clinical trials. Missed clinic visits were the most important risk factor for failure to suppress HIV-l RNA levels. Studies are needed to identify interventions that maximize the performance of HAART in inner-city clinics.	Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Johns Hopkins University	Moore, RD (corresponding author), 1830 E Monument St,Room 8059, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA11602] Funding Source: Medline; PHS HHS [R01-H507809] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; CLUMECK N, 1998, 5 C RETR OPP INF FEB, P386; Cohen OJ, 1998, NEW ENGL J MED, V339, P341, DOI 10.1056/NEJM199807303390511; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DEEKS S, 1998, 5 C RETR OPP INF FEB, P419; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Drusano GL, 1998, J INFECT DIS, V178, P360, DOI 10.1086/515631; Eldred LJ, 1998, J ACQ IMMUN DEF SYND, V18, P117, DOI 10.1097/00042560-199806010-00003; Flexner C, 1998, NEW ENGL J MED, V338, P1281, DOI 10.1056/NEJM199804303381808; FRIEDLAND GH, 1991, J ACQ IMMUN DEF SYND, V4, P144; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hecht FM, 1998, NEW ENGL J MED, V339, P307, DOI 10.1056/NEJM199807303390504; HOGG RS, 1994, LANCET, V344, P1120, DOI 10.1016/S0140-6736(94)90631-9; Hughes MD, 1997, ANN INTERN MED, V126, P929, DOI 10.7326/0003-4819-126-12-199706150-00001; KAHN J, 1998, 5 C RETR OPP INF CHI, P208; Kaufmann D, 1998, LANCET, V351, P723, DOI 10.1016/S0140-6736(98)24010-4; KISSINGER P, 1995, J NATL MED ASSOC, V87, P19; LEVINE AM, 1987, J CLIN ONCOL, V5, P1469, DOI 10.1200/JCO.1987.5.9.1469; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; Moore RD, 1996, AM J MED, V101, P34, DOI 10.1016/S0002-9343(96)00077-0; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *ROCH LAB, 1997, INV SAQ MES CAPS PRO; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAG M, 1997, INF DIS SOC AM 35 AN, P112; TURNER J, 1995, CHEST, V108, P394, DOI 10.1378/chest.108.2.394; Vanhove GF, 1996, JAMA-J AM MED ASSOC, V276, P1955, DOI 10.1001/jama.276.24.1955; WOOD PR, 1985, ANN ALLERGY, V54, P400	31	689	713	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					81	+		10.7326/0003-4819-131-2-199907200-00002	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419445				2022-12-24	WOS:000081509700001
J	Meyers, EN; Martin, GR				Meyers, EN; Martin, GR			Differences in left-right axis pathways in mouse and chick: Functions of FGF8 and SHH	SCIENCE			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; PITX2; EMBRYOGENESIS; EXPRESSION; XENOPUS; EMBRYOS; GENE; MORPHOGENESIS	A molecular pathway leading to left-right asymmetry in the chick embryo has been described, in which FGF8 is a right determinant and Sonic Hedgehog a left determinant. Here evidence is presented that the Fgf8 and Sonic Hedgehog genes are required for left-right axis determination in the mouse embryo, but that they have different functions from those previously reported in the chick. In the mouse FGF8 is a left determinant and Sonic Hedgehog is required to prevent left determinants from being expressed on the right.	Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Martin, GR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA.	gmartin@itsa.ucsf.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001216, R01HD034380] Funding Source: NIH RePORTER; NICHD NIH HHS [HD01216, R01 HD34380] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Boettger T, 1999, CURR BIOL, V9, P277, DOI 10.1016/S0960-9822(99)80119-5; Campione M, 1999, DEVELOPMENT, V126, P1225; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Dufort D, 1998, DEVELOPMENT, V125, P3015; Harvey RP, 1998, CELL, V94, P273, DOI 10.1016/S0092-8674(00)81468-3; Izraeli S, 1999, NATURE, V399, P691, DOI 10.1038/21429; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; Levin M, 1997, BIOESSAYS, V19, P287, DOI 10.1002/bies.950190406; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Logan M, 1998, CELL, V94, P307, DOI 10.1016/S0092-8674(00)81474-9; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; Meyers EN, 1998, NAT GENET, V18, P136, DOI 10.1038/ng0298-136; MEYERS EN, UNPUB; Neubuser A, 1997, CELL, V90, P247, DOI 10.1016/S0092-8674(00)80333-5; Nomura M, 1998, NATURE, V393, P786, DOI 10.1038/31693; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Pagan-Westphal SM, 1998, CELL, V93, P25, DOI 10.1016/S0092-8674(00)81143-5; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; STURM K, 1993, METHOD ENZYMOL, V225, P164; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	30	252	256	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					403	406		10.1126/science.285.5426.403	http://dx.doi.org/10.1126/science.285.5426.403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411502				2022-12-24	WOS:000081465900053
J	Platt, ML; Glimcher, PW				Platt, ML; Glimcher, PW			Neural correlates of decision variables in parietal cortex	NATURE			English	Article							REPRESENTATION; INTENTION; SELECTION; MEMORY; MONKEY	Decision theory proposes that humans and animals decide what to do in a given situation by assessing the relative value of each possible response, This assessment can be computed, in part, from the probability that each action will result In a gain and the magnitude of the gain expected, Here we show that the gain (or reward) a monkey can expect to realize from an eye-movement response modulates the activity of neurons in the lateral intraparietal area, an area of primate cortex that is thought to transform visual signals into eye-movement commands, We also show that the activity of these neurons is sensitive to the probability that a particular response will result in a gain, When animals can choose freely between two alternative responses, the choices subjects make and neuronal activation in this area are both correlated with the relative amount of gain that the animal can expect from each response. Our data indicate that a decision-theoretic model may provide a powerful new framework for studying the neural processes that intervene between sensation and action.	NYU, Ctr Neural Sci, New York, NY 10003 USA	New York University	Platt, ML (corresponding author), NYU, Ctr Neural Sci, New York, NY 10003 USA.	mplatt@cns.nyu.edu						ARNAULD A, 1982, ART THINKING PORT RO; ASANUMA H, 1967, J NEUROPHYSIOL, V30, P35, DOI 10.1152/jn.1967.30.1.35; Basso MA, 1997, NATURE, V389, P66, DOI 10.1038/37975; Bechara A, 1998, J NEUROSCI, V18, P428; BERNOULLI D, 1982, WORKS; Bernstein Nikolai, 1984, HUMAN MOTOR ACTIONS, P77, DOI DOI 10.1016/S0166-4115(08)61370-9; Bracewell RM, 1996, J NEUROPHYSIOL, V76, P1457, DOI 10.1152/jn.1996.76.3.1457; CATANIA AC, 1963, J EXP ANAL BEHAV, V6, P299, DOI 10.1901/jeab.1963.6-299; DAVENPORT JW, 1966, PSYCHON SCI, V4, P187; Descartes R., 1972, TREATISE MAN; DEVILLIERS PA, 1976, PSYCHOL BULL, V83, P1131, DOI DOI 10.1037/0033-2909.83.6.1131; Dorris MC, 1998, J NEUROSCI, V18, P7015; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; GLIMCHER PW, 1992, NATURE, V355, P542, DOI 10.1038/355542a0; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GOLDBERG ME, 1990, COLD SPRING HARB SYM, V55, P729; Gottlieb JP, 1998, NATURE, V391, P481, DOI 10.1038/35135; HERRNSTEIN RJ, 1961, J EXP ANAL BEHAV, V4, P267, DOI 10.1901/jeab.1961.4-267; HERRNSTEIN RJ, 1980, ALLOCATION INDIVIDUA, P143; Kahneman D., 1982, JUDGEMENT UNCERTAINT; KREBS JR, 1978, NATURE, V275, P27, DOI 10.1038/275027a0; Pavlov I.P., 1927, CONDITIONED REFLEXES; Penfield W., 1975, MYSTERY MIND CRITICA; Platt M. L., 1997, Society for Neuroscience Abstracts, V23, P16; Platt ML, 1997, J NEUROPHYSIOL, V78, P1574, DOI 10.1152/jn.1997.78.3.1574; PLATT ML, 1998, INVEST OPHTH VIS SCI, V39, P326; PYKE GH, 1977, Q REV BIOL, V52, P137, DOI 10.1086/409852; SCHALL JD, 1993, NATURE, V366, P467, DOI 10.1038/366467a0; Schoener T. W., 1971, A Rev Ecol Syst, V2, P369, DOI 10.1146/annurev.es.02.110171.002101; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Sherrington CS, 1906, INTEGRATIVE ACTION N, DOI 10.1037/13798-000; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STADDON JER, 1978, PSYCHOL REV, V85, P436, DOI 10.1037/0033-295X.85.5.436; Stephens D.W., 1986, pi; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; von Holst E, 1973, BEHAV PHYSL ANIMALS; WEISS PAUL, 1941, COMPAR PSYCHOL MONOGR, V17, P1	37	1139	1151	1	70	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					233	238		10.1038/22268	http://dx.doi.org/10.1038/22268			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	217MP	10421364				2022-12-24	WOS:000081503800035
J	Rochon, PA; Gurwitz, JH				Rochon, PA; Gurwitz, JH			Prescribing for seniors - Neither too much nor too little	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MYOCARDIAL-INFARCTION; REPLACEMENT; WOMEN		Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; Univ Toronto, Dept Med, Clin Epidemiol & Hlth Care Res Program, Toronto, ON, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Baycrest; University of Toronto; University of Toronto; University of Toronto	Rochon, PA (corresponding author), Univ Toronto, Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.		Rochon, Paula A/J-2918-2016	Rochon, Paula A/0000-0002-5973-4151				[Anonymous], 1991, JAMA, V265, P3255; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Barakat K, 1999, LANCET, V353, P955, DOI 10.1016/S0140-6736(98)07114-1; Berlowitz DR, 1998, NEW ENGL J MED, V339, P1957, DOI 10.1056/NEJM199812313392701; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; Col NF, 1997, JAMA-J AM MED ASSOC, V277, P1140, DOI 10.1001/jama.277.14.1140; Gottlieb SS, 1998, NEW ENGL J MED, V339, P489, DOI 10.1056/NEJM199808203390801; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Handa VL, 1996, J AM GERIATR SOC, V44, P1; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Josse R, 1996, CAN MED ASSOC J, V155, P1113; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; MYERS MG, 1995, GUIDELINES TREATMENT; National Osteoporosis Foundation, 1998, PHYS GUID PREV TREAT; Recker RR, 1999, ANN INTERN MED, V130, P897, DOI 10.7326/0003-4819-130-11-199906010-00005; Redelmeier DA, 1998, NEW ENGL J MED, V338, P1516, DOI 10.1056/NEJM199805213382106; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; Soumerai SB, 1999, NEW ENGL J MED, V340, P722, DOI 10.1056/NEJM199903043400909; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Spurgeon D, 1999, BRIT MED J, V318, P961, DOI 10.1136/bmj.318.7189.961b; Steinbrook R, 1998, NEW ENGL J MED, V338, P1541, DOI 10.1056/NEJM199805213382111; TAMBLYN R, 1999, EVALUATION IMPACT RE	24	90	94	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					113	115		10.1001/jama.282.2.113	http://dx.doi.org/10.1001/jama.282.2.113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411177				2022-12-24	WOS:000081376800002
J	Alberman, E; Noble, JM				Alberman, E; Noble, JM			Commentary: Food should be fortified with folic acid	BRITISH MEDICAL JOURNAL			English	Editorial Material							NEURAL-TUBE DEFECTS; PREVENTION		St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Alberman, E (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England.							DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Mathews F, 1998, BRIT J OBSTET GYNAEC, V105, P954, DOI 10.1111/j.1471-0528.1998.tb10257.x; Murphy M, 1996, ARCH DIS CHILD-FETAL, V75, pF133, DOI 10.1136/fn.75.2.F133; Wald NJ, 1998, LANCET, V351, P834, DOI 10.1016/S0140-6736(05)78966-2; Wald NJ, 1998, ARCH INTERN MED, V158, P862, DOI 10.1001/archinte.158.8.862; Wild J, 1997, LANCET, V350, P30, DOI 10.1016/S0140-6736(05)66239-3	6	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					93	93						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398634				2022-12-24	WOS:000081438200032
J	Westphal, RS; Tavalin, SJ; Lin, JW; Alto, NM; Fraser, IDC; Langeberg, LK; Sheng, M; Scott, JD				Westphal, RS; Tavalin, SJ; Lin, JW; Alto, NM; Fraser, IDC; Langeberg, LK; Sheng, M; Scott, JD			Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; D-ASPARTATE RECEPTORS; POSTSYNAPTIC DENSITY; ANCHORING PROTEIN; SUBUNIT NR1; PDZ-DOMAIN; BINDING; SCAFFOLD; CHANNEL; IDENTIFICATION	Regulation of N-methyl-D-aspartate (NMDA) receptor activity by kinases and phosphatases contributes to the modulation of synaptic transmission. Targeting of these enzymes near the substrate is proposed to enhance phosphorylation-dependent modulation. Yotiao, an NMDA receptor-associated protein, bound the type I protein phosphatase (PP1) and the adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase (PKA) holoenzyme. Anchored PP1 was active, limiting channel activity, whereas PKA activation overcame constitutive PP1 activity and conferred rapid enhancement of NMDA receptor currents. Hence, yotiao is a scaffold protein that physically attaches PP1 and PKA to NMDA receptors to regulate channel activity.	Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA; Howard Hughes Med Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Howard Hughes Medical Institute; Oregon Health & Science University; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, 3181 SW Sam Jackson Rd, Portland, OR 97201 USA.		Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	NIGMS NIH HHS [GM 48231] Funding Source: Medline; NINDS NIH HHS [NS10202, F32 NS010202, NS10543] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS010543, F32NS010202] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; BLANK T, 1997, P NATL ACAD SCI USA, V94, P14853; Brenman JE, 1998, J NEUROSCI, V18, P8805; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CARR DW, 1992, J BIOL CHEM, V267, P13376; CERNE R, 1993, NEUROSCI LETT, V161, P124, DOI 10.1016/0304-3940(93)90275-P; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CHOI KY, 1994, CELL, V78, P499; Corbin J D, 1974, Methods Enzymol, V38, P287; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dransfield DT, 1997, BIOCHEM J, V322, P801, DOI 10.1042/bj3220801; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Ehlers MD, 1998, J NEUROSCI, V18, P720; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSKEN ZE, 1996, PROTEIN TARGETING PR; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupp JJ, 1996, MOL PHARMACOL, V50, P1680; LESTER RAJ, 1993, J NEUROSCI, V13, P1088; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; Lin JW, 1998, J NEUROSCI, V18, P2017; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Niethammer M, 1998, NEURON, V20, P693, DOI 10.1016/S0896-6273(00)81009-0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Printen JA, 1997, SCIENCE, V275, P1475, DOI 10.1126/science.275.5305.1475; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; REINHART PH, 1995, J NEUROSCI, V15, P4572; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; Schmidt PH, 1999, J BIOL CHEM, V274, P3055, DOI 10.1074/jbc.274.5.3055; SCOTT JD, 1985, P NATL ACAD SCI USA, V82, P4379, DOI 10.1073/pnas.82.13.4379; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; Snyder GL, 1998, J NEUROSCI, V18, P10297; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; Westphal RS, 1998, SCIENCE, V280, P1258, DOI 10.1126/science.280.5367.1258; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wilson GF, 1998, P NATL ACAD SCI USA, V95, P10938, DOI 10.1073/pnas.95.18.10938; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X; Ziff EB, 1997, NEURON, V19, P1163, DOI 10.1016/S0896-6273(00)80409-2	50	411	428	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					93	96		10.1126/science.285.5424.93	http://dx.doi.org/10.1126/science.285.5424.93			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390370				2022-12-24	WOS:000081199800037
J	Wolf, SG; Frenkiel, D; Arad, T; Finkel, SE; Kolter, R; Minsky, A				Wolf, SG; Frenkiel, D; Arad, T; Finkel, SE; Kolter, R; Minsky, A			DNA protection by stress-induced biocrystallization	NATURE			English	Article							BACILLUS-SUBTILIS; ESCHERICHIA-COLI; HELICOBACTER-PYLORI; STATIONARY-PHASE; OXIDATIVE-STRESS; BINDING PROTEIN; NONHEME IRON; DPS; FERRITIN; COMPLEXES	The crystalline state is considered to be incompatible with life. However, in living systems exposed to severe environmental assaults, the sequestration of vital macromolecules in intracellular crystalline assemblies may provide an efficient means for protection. Here we report a generic defence strategy found in Escherichia coli, involving co-crystallization of its DNA with the stress-induced protein Dps(1,2). We show that when purified Dps and DNA interact, extremely stable crystals form almost instantaneously, within which DNA is sequestered and effectively protected against varied assaults. Crystalline structures with similar lattice spacings are formed in E. coli in which Dps is slightly over expressed, as well as in starved wild-type bacteria. Hence, DNA-Dps co-crystallization is proposed to represent a binding mode that provides wide-range protection of DNA by sequestration. The rapid induction and large-scale production of Dps in response to stress, as well as the presence of Dps homologues in many distantly related bacteria, indicate that DNA protection by biocrystallization may be crucial and widespread in prokaryotes.	Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Weizmann Institute of Science; Weizmann Institute of Science; Harvard University; Harvard Medical School	Minsky, A (corresponding author), Weizmann Inst Sci, Dept Organ Chem, IL-76100 Rehovot, Israel.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				Allen MJ, 1997, NUCLEIC ACIDS RES, V25, P2221, DOI 10.1093/nar/25.11.2221; ALMIRON M, 1992, GENE DEV, V6, P2646, DOI 10.1101/gad.6.12b.2646; ALTUVIA S, 1994, MOL MICROBIOL, V13, P265, DOI 10.1111/j.1365-2958.1994.tb00421.x; BERNARDIN WD, 1986, J MOL BIOL, V189, P503; Bozzi M, 1997, J BIOL CHEM, V272, P3259, DOI 10.1074/jbc.272.6.3259; CHEN L, 1995, MOL MICROBIOL, V18, P295, DOI 10.1111/j.1365-2958.1995.mmi_18020295.x; EVANS DJ, 1995, GENE, V153, P123, DOI 10.1016/0378-1119(94)00774-M; FLARDH K, 1992, J BACTERIOL, V174, P6780, DOI 10.1128/JB.174.21.6780-6788.1992; FRAZIER BA, 1993, J BACTERIOL, V175, P966, DOI 10.1128/JB.175.4.966-972.1993; Grant RA, 1998, NAT STRUCT BIOL, V5, P294, DOI 10.1038/nsb0498-294; GRIFFITH J, 1994, P NATL ACAD SCI USA, V91, P8224, DOI 10.1073/pnas.91.17.8224; HOBOT JA, 1985, J BACTERIOL, V162, P960, DOI 10.1128/JB.162.3.960-971.1985; KOLTER R, 1993, ANNU REV MICROBIOL, V47, P855, DOI 10.1146/annurev.micro.47.1.855; LOEWEN PC, 1994, ANNU REV MICROBIOL, V48, P53, DOI 10.1146/annurev.mi.48.100194.000413; Martinez A, 1997, J BACTERIOL, V179, P5188, DOI 10.1128/jb.179.16.5188-5194.1997; PENA MMO, 1995, ARCH MICROBIOL, V163, P337, DOI 10.1007/BF00404206; PENA MMO, 1995, J BIOL CHEM, V270, P22478, DOI 10.1074/jbc.270.38.22478; PINSINCE JM, 1992, J MOL BIOL, V228, P409, DOI 10.1016/0022-2836(92)90830-D; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; ROBINOW C, 1994, MICROBIOL REV, V58, P211, DOI 10.1128/MMBR.58.2.211-232.1994; TUPPER AE, 1994, EMBO J, V13, P258, DOI 10.1002/j.1460-2075.1994.tb06256.x; Wai SN, 1997, MICROBIOL IMMUNOL, V41, P461, DOI 10.1111/j.1348-0421.1997.tb01879.x	22	282	296	0	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					83	85		10.1038/21918	http://dx.doi.org/10.1038/21918			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403254				2022-12-24	WOS:000081255700056
J	Feighner, SD; Tan, CP; McKee, KK; Palyha, OC; Hreniuk, DL; Pong, SS; Austin, CP; Figueroa, D; MacNeil, D; Cascieri, MA; Nargund, R; Bakshi, R; Abramovitz, M; Stocco, R; Kargman, S; O'Neill, G; Van der Ploeg, LHT; Evans, J; Patchett, AA; Smith, RG; Howard, AD				Feighner, SD; Tan, CP; McKee, KK; Palyha, OC; Hreniuk, DL; Pong, SS; Austin, CP; Figueroa, D; MacNeil, D; Cascieri, MA; Nargund, R; Bakshi, R; Abramovitz, M; Stocco, R; Kargman, S; O'Neill, G; Van der Ploeg, LHT; Evans, J; Patchett, AA; Smith, RG; Howard, AD			Receptor for motilin identified in the human gastrointestinal system	SCIENCE			English	Article							GROWTH-HORMONE SECRETAGOGUE; BINDING-SITES; SMOOTH-MUSCLE; SEQUENCE; RABBIT; EXPRESSION; LOCALIZATION; ERYTHROMYCIN; PRECURSOR; PITUITARY	Motilin is a 22-amino acid peptide hormone expressed throughout the gastrointestinal (GI) tract of humans and other species. It affects gastric motility by stimulating interdigestive antrum and duodenal contractions. A heterotrimeric guanosine triphosphate-binding protein (G protein)-coupled receptor for motilin was isolated from human stomach, and its amino acid sequence was found to be 52 percent identical to the human receptor for growth hormone secretagogues. The macrolide antibiotic erythromycin also interacted with the cloned motilin receptor, providing a molecular basis for its effects on the human GI tract. The motilin receptor is expressed in enteric neurons of the human duodenum and colon. Development of motilin receptor agonists and antagonists may be useful in the treatment of multiple disorders of GI motility.	Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA; Merck Res Labs, Dept Human Genet, West Point, PA 19486 USA; Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Kirkland, PQ H3H 3L1, Canada; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Huffington Ctr Aging, Houston, TX 77030 USA	Merck & Company; Merck & Company; Merck & Company; Merck & Company; Baylor College of Medicine; Baylor College of Medicine	Howard, AD (corresponding author), Merck Res Labs, Dept Metab Disorders, Bldg RY-80Y-265,126 E Lincoln Ave, Rahway, NJ 07065 USA.	howarda@merck.com		MacNeil, Doug/0000-0001-7089-0668				Benson DA, 1998, NUCLEIC ACIDS RES, V26, P1, DOI 10.1093/nar/26.1.1; BOND CT, 1988, MOL ENDOCRINOL, V2, P175, DOI 10.1210/mend-2-2-175; BRENNER S, 1993, NATURE, V366, P265, DOI 10.1038/366265a0; BROWN JC, 1973, CAN J BIOCHEM CELL B, V51, P533, DOI 10.1139/o73-066; BUTTON D, 1993, CELL CALCIUM, V14, P663, DOI 10.1016/0143-4160(93)90091-J; DAIKH DI, 1989, DNA-J MOLEC CELL BIO, V8, P615, DOI 10.1089/dna.1989.8.615; Depoortere I, 1997, AM J PHYSIOL-GASTR L, V272, pG994, DOI 10.1152/ajpgi.1997.272.5.G994; DEPOORTERE I, 1993, PEPTIDES, V14, P1153, DOI 10.1016/0196-9781(93)90169-H; DEPOORTERE I, 1995, REGUL PEPTIDES, V55, P227, DOI 10.1016/0167-0115(94)00111-A; Depoortere I, 1997, BRAIN RES, V777, P103; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; ITOH Z, 1984, AM J PHYSIOL, V247, pG688, DOI 10.1152/ajpgi.1984.247.6.G688; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; Kenakin T, 1996, PHARMACOL REV, V48, P413; MACIELAG MJ, 1992, PEPTIDES, V13, P565, DOI 10.1016/0196-9781(92)90090-P; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; McKee KK, 1997, MOL ENDOCRINOL, V11, P415, DOI 10.1210/me.11.4.415; MILLER P, 1995, PEPTIDES, V16, P11, DOI 10.1016/0196-9781(94)00148-Y; PEETERS T, 1989, AM J PHYSIOL, V257, pG470, DOI 10.1152/ajpgi.1989.257.3.G470; PEETERS TL, 1988, REGUL PEPTIDES, V23, P171, DOI 10.1016/0167-0115(88)90025-0; Petrukhin K, 1998, NAT GENET, V19, P241, DOI 10.1038/915; Poitras P, 1996, PEPTIDES, V17, P701, DOI 10.1016/0196-9781(96)00053-8; Poitras P, 1994, GUT PEPTIDES BIOCH P, P261; Porter AJ, 1997, GASTROENTEROLOGY, V113, P1916, DOI 10.1016/S0016-5085(97)70011-8; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SAKAI T, 1994, REGUL PEPTIDES, V53, P249, DOI 10.1016/0167-0115(94)90173-2; Scarpignato C, 1997, DIGEST DIS, V15, P112, DOI 10.1159/000171626; SEINO Y, 1987, FEBS LETT, V223, P74, DOI 10.1016/0014-5793(87)80512-4; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; Tonini M, 1996, PHARMACOL RES, V33, P217, DOI 10.1006/phrs.1996.0030; WEBER FH, 1993, AM J GASTROENTEROL, V88, P485; YANO H, 1989, FEBS LETT, V249, P248, DOI 10.1016/0014-5793(89)80633-7	33	305	372	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2184	2188		10.1126/science.284.5423.2184	http://dx.doi.org/10.1126/science.284.5423.2184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381885				2022-12-24	WOS:000081099300054
J	Coninx, R; Mathieu, C; Debacker, M; Mirzoev, F; Ismaelov, A; de Haller, R; Meddings, DR				Coninx, R; Mathieu, C; Debacker, M; Mirzoev, F; Ismaelov, A; de Haller, R; Meddings, DR			First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons	LANCET			English	Article							HIV-INFECTION	Background We assessed a programme of tuberculosis control in a prison setting in Baku, Azerbaijan. The programme used first-line therapy and DOTS (directly observed treatment, short course). Methods 467 patients had sputum-positive tuberculosis. Their treatment regimens followed WHO guidelines, and they had regular clinical examinations and dietary supplements. Isolates were tested by standard methods for resistance to isoniazid, rifampicin, ethambutol, and streptomycin in three laboratories. Treatment success was defined as three consecutive negative sputum smears at end of treatment. Factors independently associated with treatment failure were estimated by logistic regression. Findings Drug-resistance data on admission were available for 131 patients. 55% of patients had strains of Mycobacterium tuberculosis resistant to two or more antibiotics. Mortality during treatment was 11%, and 13% of patients defaulted. Overall, treatment was successful in 54% of patients, and in 71% of those completing treatment. 104 patients completed a full treatment regimen and remained sputum-positive. Resistance to two or more antibiotics, a positive sputum result at the end of initial treatment, cavitary disease, and poor compliance were independently associated with treatment failure. Interpretation The effectiveness of a DOTS programme with first-line therapy fell short of the 85% target set by WHO. First-line therapy may not be sufficient in settings with a high degree of resistance to antibiotics.	Int Comm Red Cross, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Republ Stadyum, Baku, Azerbaijan		Coninx, R (corresponding author), Int Comm Red Cross, 19 Ave Paix, CH-1202 Geneva, Switzerland.	rconinx@icrc.org		Mirzayev, Fuad/0000-0001-6658-0325				BRAUN MM, 1989, JAMA-J AM MED ASSOC, V261, P393, DOI 10.1001/jama.261.3.393; CANETTI G, 1969, B WORLD HEALTH ORGAN, V41, P21; CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; Coninx R, 1998, BRIT MED J, V316, P1423, DOI 10.1136/bmj.316.7142.1423; DROBNIEWSKI F, 1995, LANCET, V346, P948, DOI 10.1016/S0140-6736(95)91562-1; *EUR CTR EP MON AI, 1996, 52 EUR CTR EP MON AI, P11; Pablos-Mendez A, 1998, NEW ENGL J MED, V338, P1641, DOI 10.1056/NEJM199806043382301; Siddiqi SH, 1989, BACTEC TB SYSTEM PRO; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SNIDER DE, 1989, JAMA-J AM MED ASSOC, V261, P436, DOI 10.1001/jama.261.3.436; *WHO, 1997, GLOB TUB CONTR, P66; *WHO, 1995, WKLY EPIDEMIOL REC, V70, P21; *WHO, 1997, ANT DRUG RES WORLD W, P117; *WHO, 1997, TUB CONTR REF SIT; *WHO, 1997, TREATM TUB DISTR LEV; World Health Organization, 1995, WHO REP TUB EP 1995	16	90	99	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					969	973		10.1016/S0140-6736(98)08341-X	http://dx.doi.org/10.1016/S0140-6736(98)08341-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459906				2022-12-24	WOS:000079421600012
J	Kirkpatrick, PJ				Kirkpatrick, PJ			Time to reconsider treatment options for intracranial aneurysms	LANCET			English	Editorial Material									Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Kirkpatrick, PJ (corresponding author), Addenbrookes Hosp, Dept Neurosurg, Hills Rd, Cambridge CB2 2QQ, England.							INGALL TJ, 1989, STROKE, V20, P718, DOI 10.1161/01.STR.20.6.718; Schievink WI, 1997, NEW ENGL J MED, V336, P28, DOI 10.1056/NEJM199701023360106; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; Wiebers D, 1998, NEW ENGL J MED, V339, P1725, DOI 10.1056/nejm199812103392401	4	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					942	943		10.1016/S0140-6736(98)00278-5	http://dx.doi.org/10.1016/S0140-6736(98)00278-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459898				2022-12-24	WOS:000079421600004
J	Stahl, EA; Dwyer, G; Mauricio, R; Kreitman, M; Bergelson, J				Stahl, EA; Dwyer, G; Mauricio, R; Kreitman, M; Bergelson, J			Dynamics of disease resistance polymorphism at the Rpm1 locus of Arabidopsis	NATURE			English	Article							MOLECULAR POPULATION-GENETICS; PSEUDOMONAS-SYRINGAE; THALIANA; RECOMBINATION; EPIDEMIOLOGY; PARASITES; SELECTION; GENES	The co-evolutionary 'arms race'(1) is a widely accepted model for the evolution of host-pathogen interactions. This model predicts that variation for disease resistance will be transient, and that host populations generally will be monomorphic at disease-resistance (R-gene) loci. However, plant populations show considerable polymorphism at R-gene loci involved in pathogen recognition(2). Here we have tested the arms-race model in Arabidopsis thaliana by analysing sequences flanking Rpm1, a gene conferring the ability to recognize Pseudomonas pathogens carrying AvrRpm1 or AvrB (ref. 3). We reject the arms-race hypothesis: resistance and susceptibility alleles at this locus have co-existed for millions of years. To account for the age of alleles and the relative levels of polymorphism within allelic classes, we use coalescence theory to model the long-term accumulation of nucleotide-polymorphism in the context of the short-term ecological dynamics of disease resistance. This analysis supports a 'trench warfare' hypothesis, in which advances and retreats of resistance-allele frequency maintain variation for disease resistance as a dynamic polymorphism(4,5).	Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Bergelson, J (corresponding author), Univ Chicago, Comm Genet, Chicago, IL 60637 USA.	jbergels@midway.uchicago.edu	Dwyer, Greg/L-1134-2015	Dwyer, Greg/0000-0002-7387-2075; Bergelson, Joy/0000-0001-7893-7387	NIGMS NIH HHS [R01 GM057994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bergelson J, 1998, GENETICS, V148, P1311; Bergelson J, 1996, AM NAT, V148, P536, DOI 10.1086/285938; Caicedo AL, 1999, P NATL ACAD SCI USA, V96, P302, DOI 10.1073/pnas.96.1.302; DAWKINS R, 1979, PROC R SOC SER B-BIO, V205, P489, DOI 10.1098/rspb.1979.0081; Grant MR, 1998, P NATL ACAD SCI USA, V95, P15843, DOI 10.1073/pnas.95.26.15843; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; Hamilton W.D., 1982, Life Sciences Research Report, P269; HAMILTON WD, 1990, P NATL ACAD SCI USA, V87, P3566, DOI 10.1073/pnas.87.9.3566; HIRANO SS, 1990, ANNU REV PHYTOPATHOL, V28, P155, DOI 10.1146/annurev.py.28.090190.001103; Hudson R.R., 1990, Oxford Surveys in Evolutionary Biology, V7, P1; HUDSON RR, 1988, GENETICS, V120, P831; Innan H, 1996, GENETICS, V143, P1761; JAYAKAR S D, 1970, Theoretical Population Biology, V1, P140, DOI 10.1016/0040-5809(70)90032-8; JUDSON OP, 1995, GENET RES, V65, P175, DOI 10.1017/S0016672300033267; Kawabe A, 1997, MOL BIOL EVOL, V14, P1303, DOI 10.1093/oxfordjournals.molbev.a025740; Kimura M, 1985, NEUTRAL THEORY MOL E; Kunkel BN, 1996, TRENDS GENET, V12, P63, DOI 10.1016/0168-9525(96)81402-8; May R.M., 1985, Linnean Society Symposium Series, P243; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672300014634, 10.1017/S0016672308009579]; McDonald JH, 1998, MOL BIOL EVOL, V15, P377, DOI 10.1093/oxfordjournals.molbev.a025934; NEI M, 1986, MOL BIOL EVOL, V3, P418; OKane SL, 1997, NOVON, V7, P323, DOI 10.2307/3391949; Purugganan MD, 1999, GENETICS, V151, P839; Purugganan MD, 1998, P NATL ACAD SCI USA, V95, P8130, DOI 10.1073/pnas.95.14.8130; REDEI GP, 1975, ANNU REV GENET, V9, P111, DOI 10.1146/annurev.ge.09.120175.000551; Rozas J, 1997, COMPUT APPL BIOSCI, V13, P307; TAJIMA F, 1989, GENETICS, V123, P585; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WOLFE KH, 1989, J MOL EVOL, V29, P208, DOI 10.1007/BF02100204	30	450	462	0	65	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					667	671		10.1038/23260	http://dx.doi.org/10.1038/23260			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458161				2022-12-24	WOS:000082032900054
J	Schlegel, M; Osterwalder, JJ; Galeazzi, RL; Vernazza, PL				Schlegel, M; Osterwalder, JJ; Galeazzi, RL; Vernazza, PL			Comparative efficacy of three mumps vaccines during disease outbreak in eastern Switzerland: cohort study	BRITISH MEDICAL JOURNAL			English	Article							MEASLES; RUBELLA		Inst Clin Microbiol & Immunol, CH-9001 St Gallen, Switzerland; Kantonsspital, Dept Med, CH-9007 St Gallen, Switzerland; Kantonsspital, Emergency Dept, CH-9007 St Gallen, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen; Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Vernazza, PL (corresponding author), Inst Clin Microbiol & Immunol, CH-9001 St Gallen, Switzerland.							ANDERSON RM, 1990, LANCET, V335, P641, DOI 10.1016/0140-6736(90)90420-A; D'Argenio P, 1998, VACCINE, V16, P818, DOI 10.1016/S0264-410X(97)00270-3; *EXP PROGR IMM, 1993, WKLY EPIDEMIOL REC, V68, P83; Germann D, 1996, SCAND J INFECT DIS, V28, P235, DOI 10.3109/00365549609027163; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					352	353		10.1136/bmj.319.7206.352	http://dx.doi.org/10.1136/bmj.319.7206.352			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435956	Bronze, Green Published			2022-12-24	WOS:000082001700019
J	Mazmanian, SK; Liu, G; Hung, TT; Schneewind, O				Mazmanian, SK; Liu, G; Hung, TT; Schneewind, O			Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall	SCIENCE			English	Article							GRAM-POSITIVE BACTERIA; RESISTANCE; EXPRESSION; VANCOMYCIN	Surface proteins of Gram-positive bacteria are linked to the bacterial cell wall by a mechanism that involves cleavage of a conserved Leu-Pro-X-Thr-Gly (LPXTG) motif and that occurs during assembly of the peptidoglycan cell wall. A Staphylococcus aureus mutant defective in the anchoring of surface proteins was isolated and shown to carry a mutation in the srtA gene. Overexpression of srtA increased the rate of surface protein anchoring, and homologs of srtA were found in other pathogenic Gram-positive bacteria. The protein specified by srtA, sortase, may be a useful target for the development of new antimicrobial drugs.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Schneewind, O (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Ton-That, Hung/AAB-6155-2020; Mazmanian, Sarkis/ABD-7729-2021	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007104] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 07323, AI33987] Funding Source: Medline; NIGMS NIH HHS [T32GM07104] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger-Bachi Brigitte, 1994, Trends in Microbiology, V2, P389, DOI 10.1016/0966-842X(94)90617-3; BOOTHBY D, 1971, ANAL BIOCHEM, V44, P645, DOI 10.1016/0003-2697(71)90255-7; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Kopp U, 1996, MICROB DRUG RESIST, V2, P29, DOI 10.1089/mdr.1996.2.29; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Sieradzki K, 1999, NEW ENGL J MED, V340, P517, DOI 10.1056/NEJM199902183400704; STROMING.JL, 1973, JOHNS HOPKINS MED J, V133, P63; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; TONTHAT H, IN PRESS J BIOL CHEM; UHLEN M, 1984, J BACTERIOL, V159, P713; WALSH CT, 1993, SCIENCE, V261, P308, DOI 10.1126/science.8392747	20	745	813	1	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					760	763		10.1126/science.285.5428.760	http://dx.doi.org/10.1126/science.285.5428.760			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427003				2022-12-24	WOS:000081765100062
J	Cooper, C; Coggon, D				Cooper, C; Coggon, D			Physical activity and knee osteoarthritis	LANCET			English	Editorial Material							RISK		Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England	University of Southampton	Cooper, C (corresponding author), Univ Southampton, Southampton Gen Hosp, Environm Epidemiol Unit, MRC, Southampton SO16 6YD, Hants, England.							COOPER C, 1995, J RHEUMATOL S43, V22, P1012; Lane NE, 1996, ANN RHEUM DIS, V55, P682, DOI 10.1136/ard.55.9.682; Maetzel A, 1997, J RHEUMATOL, V24, P1599; McAlindon TE, 1999, AM J MED, V106, P151, DOI 10.1016/S0002-9343(98)00413-6; NEGRET P, 1994, BR J RHEUMATOL, V33, P267; ROOS H, 1994, AM J SPORT MED, V22, P219, DOI 10.1177/036354659402200211; Spector TD, 1996, ARTHRITIS RHEUM, V39, P988, DOI 10.1002/art.1780390616; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA	8	18	22	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2177	2178		10.1016/S0140-6736(99)90094-6	http://dx.doi.org/10.1016/S0140-6736(99)90094-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392979				2022-12-24	WOS:000081091300007
J	Peshkin, BN; Lerman, C				Peshkin, BN; Lerman, C			Genetic counselling for hereditary breast cancer	LANCET			English	Editorial Material							OVARIAN CANCER; BRCA1; FAMILIES; PREDISPOSITION; SUSCEPTIBILITY		Georgetown Univ, Med Ctr, Washington, DC 20007 USA	Georgetown University	Peshkin, BN (corresponding author), Georgetown Univ, Med Ctr, Washington, DC 20007 USA.		Lerman, Caryn/AHC-5180-2022					Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Croyle RT, 1997, HEALTH PSYCHOL, V16, P63, DOI 10.1037/0278-6133.16.1.63; Cull A, 1998, BRIT J CANCER, V77, P830, DOI 10.1038/bjc.1998.135; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; LERMAN C, 1994, J CLIN ONCOL, V12, P843, DOI 10.1200/JCO.1994.12.4.843; Lerman C, 1998, J CLIN ONCOL, V16, P1650, DOI 10.1200/JCO.1998.16.5.1650; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Patenaude AF, 1996, PSYCHO-ONCOLOGY, V5, P241; Watson M, 1999, BRIT J CANCER, V79, P868, DOI 10.1038/sj.bjc.6690139; Watson M, 1996, PSYCHO-ONCOL, V5, P233	10	6	6	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2176	2177		10.1016/S0140-6736(99)90078-8	http://dx.doi.org/10.1016/S0140-6736(99)90078-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392978				2022-12-24	WOS:000081091300006
J	Lu, PJ; Wulf, G; Zhou, XZ; Davies, P; Lu, KP				Lu, PJ; Wulf, G; Zhou, XZ; Davies, P; Lu, KP			The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein	NATURE			English	Article							PAIRED HELICAL FILAMENTS; SUBSTRATE RECOGNITION; DISEASE; DEMENTIA; MITOSIS; CHROMOSOME-17; EXPRESSION; MUTATIONS; ISOFORMS; DISTINCT	One of the neuropathological hallmarks of Alzheimer's disease is the neurofibrillary tangle, which contains paired helical filaments (PHFs) composed of the microtubule-associated protein tau(1,2). Tau is hyperphosphorylated in PHFs(3-5), and phosphorylation of tau abolishes its ability to bind microtubules and promote microtubule assembly(6,7). Restoring the function of phosphorylated tau might prevent or reverse PHF formation in Alzheimer's disease. Phosphorylation on a serine or threonine that precedes proline (pS/T-P) alters the rate of prolyl isomerization and creates a binding site for the WW domain of the prolyl isomerase Pin1 (refs 8-14), Pin1 specifically isomerizes pS/T-P bonds and regulates the function of mitotic phosphoproteins(8-10,12). Here we show that Pin1 binds to only one pT-P motif in tau and copurifies with PHFs, resulting in depletion of soluble Pin1 in the brains of Alzheimers disease patients. Pin1 can restore the ability of phosphorylated tau to bind microtubules and promote microtubule assembly in vitro, As depletion of Pin1 induces mitotic arrest and apoptotic cell death(8), sequestration of Pin1 into PHFs may contribute to neuronal death. These findings provide a new insight into the pathogenesis of Alzheimer's disease.	Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10461 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine	Lu, KP (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA.		Wulf, Gerburg/AAS-6713-2021					ALONSO AD, 1994, P NATL ACAD SCI USA, V91, P5562, DOI 10.1073/pnas.91.12.5562; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Clark LN, 1998, P NATL ACAD SCI USA, V95, P13103, DOI 10.1073/pnas.95.22.13103; Crenshaw DG, 1998, EMBO J, V17, P1315, DOI 10.1093/emboj/17.5.1315; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1992, J BIOL CHEM, V267, P564; Hong M, 1998, SCIENCE, V282, P1914, DOI 10.1126/science.282.5395.1914; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Illenberger S, 1998, MOL BIOL CELL, V9, P1495, DOI 10.1091/mbc.9.6.1495; IQBAL K, 1994, FEBS LETT, V349, P104, DOI 10.1016/0014-5793(94)00650-4; Jicha GA, 1997, J NEUROCHEM, V69, P2087; Kondratick CM, 1996, J NEUROCHEM, V67, P2405; Kosik KS, 1996, ANN NY ACAD SCI, V777, P114, DOI 10.1111/j.1749-6632.1996.tb34409.x; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; Lu KP, 1996, NATURE, V380, P544; LU KP, IN PRESS PROG CELL C; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Nagy Z, 1997, ACTA NEUROPATHOL, V93, P294, DOI 10.1007/s004010050617; Preuss U, 1998, EUR J CELL BIOL, V76, P176, DOI 10.1016/S0171-9335(98)80032-0; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Schutkowski M, 1998, BIOCHEMISTRY-US, V37, P5566, DOI 10.1021/bi973060z; Shen MH, 1998, GENE DEV, V12, P706, DOI 10.1101/gad.12.5.706; Spillantini MG, 1998, BRAIN PATHOL, V8, P387; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P7737, DOI 10.1073/pnas.95.13.7737; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Vincent I, 1997, J NEUROSCI, V17, P3588; VINCENT IJ, 1992, P NATL ACAD SCI USA, V89, P2878, DOI 10.1073/pnas.89.7.2878; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; YOSHIDA H, 1993, J NEUROCHEM, V61, P1183, DOI 10.1111/j.1471-4159.1993.tb03642.x	30	602	630	0	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					784	788						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391244				2022-12-24	WOS:000081101600054
J	Matray, TJ; Kool, ET				Matray, TJ; Kool, ET			A specific partner for abasic damage in DNA	NATURE			English	Article							APURINIC APYRIMIDINIC SITES; DEOXYRIBONUCLEIC-ACID; REPLICATION FIDELITY; OLIGODEOXYNUCLEOTIDES; FLUORESCENCE; SELECTIVITY; POLYMERASES; MECHANISM; INSERTION; CRYSTAL	In most-models of DNA replication, Watson-Crick hydrogen bonding drives the incorporation of nucleotides into the new strand of DNA and maintains the complementarity of bases with the template strand. Studies with nonpolar analogues of thymine and adenine, however, have shown that replication is still efficient in the absence of hydrogen bonds(1-4). The replication of base pairs might also be influenced by steric exclusion, whereby inserted nucleotides need to be the correct size and shape to fit the active site against a template base(5,6). A simple steric-exclusion model map not require Watson-Crick hydrogen bonding to explain the fidelity of replication, nor should canonical purine and pyrimidine shapes be necessary for enzymatic synthesis of a base pair if each can fit into the DNA double helix without steric strain(6). Here we test this idea by using a pyrene nucleoside triphosphate (dPTP) in which the fluorescent 'base' is nearly as large as an entire Watson-Crick base pair. We show that the non-hydrogen-bonding dPTP is efficiently and specifically inserted by DNA polymerases opposite sites that lack DNA bases. The efficiency of this process approaches that of a natural base pair and the specificity is 10(2)-10(4)-fold. We use these properties to sequence abasic lesions in DNA, which are a common form of DNA damage in vivo(7). In addition to their application in identifying such genetic lesions, our results show that neither hydrogen bonds nor purine and pyrimidine structures are required to form a base pair with high efficiency and selectivity. These findings confirm that steric complementarity is an important factor in the fidelity of DNA synthesis.	Univ Rochester, Dept Chem, Rochester, NY 14627 USA	University of Rochester	Kool, ET (corresponding author), Univ Rochester, Dept Chem, Rochester, NY 14627 USA.							Denissenko MF, 1996, SCIENCE, V274, P430, DOI 10.1126/science.274.5286.430; Diederichsen U, 1998, ANGEW CHEM INT EDIT, V37, P1655, DOI 10.1002/(SICI)1521-3773(19980703)37:12<1655::AID-ANIE1655>3.0.CO;2-2; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Fygenson DK, 1997, J BIOL CHEM, V272, P27931, DOI 10.1074/jbc.272.44.27931; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Goodman MF, 1997, P NATL ACAD SCI USA, V94, P10493, DOI 10.1073/pnas.94.20.10493; HOARD DE, 1965, J AM CHEM SOC, V87, P1785, DOI 10.1021/ja01086a031; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; IDE H, 1993, BIOCHEMISTRY-US, V32, P8276, DOI 10.1021/bi00083a031; Kiefer JR, 1998, NATURE, V391, P304, DOI 10.1038/34693; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; LAWRENCE CW, 1990, NUCLEIC ACIDS RES, V18, P2153, DOI 10.1093/nar/18.8.2153; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LOEB LA, 1986, ANNU REV GENET, V20, P201, DOI 10.1146/annurev.ge.20.120186.001221; Matray TJ, 1998, J AM CHEM SOC, V120, P6191, DOI 10.1021/ja9803310; Maulik G, 1999, NUCLEIC ACIDS RES, V27, P1316, DOI 10.1093/nar/27.5.1316; MILLICAN TA, 1984, NUCLEIC ACIDS RES, V12, P7435, DOI 10.1093/nar/12.19.7435; MISHRA MC, 1991, J CHEM SOC CHEM COMM, P1276; Morales JC, 1998, NAT STRUCT BIOL, V5, P950, DOI 10.1038/2925; Moran S, 1997, P NATL ACAD SCI USA, V94, P10506, DOI 10.1073/pnas.94.20.10506; Moran S, 1997, J AM CHEM SOC, V119, P2056, DOI 10.1021/ja963718g; Paris PL, 1998, NUCLEIC ACIDS RES, V26, P3789, DOI 10.1093/nar/26.16.3789; PazElizur T, 1997, BIOCHEMISTRY-US, V36, P1766, DOI 10.1021/bi9621324; RANDALL SK, 1987, J BIOL CHEM, V262, P6864; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; SAGHER D, 1983, BIOCHEMISTRY-US, V22, P4518, DOI 10.1021/bi00288a026; SCHAAPER RM, 1983, P NATL ACAD SCI-BIOL, V80, P487, DOI 10.1073/pnas.80.2.487; Shibutani S, 1997, J BIOL CHEM, V272, P13916, DOI 10.1074/jbc.272.21.13916; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; WEISS B, 1972, ADV ENZYMOL REL AREA, V60, P1	30	216	233	2	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					704	708		10.1038/21453	http://dx.doi.org/10.1038/21453			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385125				2022-12-24	WOS:000080932800065
J	Alter, MJ; Kruszon-Moran, D; Nainan, OV; McQuillan, GM; Gao, FX; Moyer, LA; Kaslow, RA; Margolis, HS				Alter, MJ; Kruszon-Moran, D; Nainan, OV; McQuillan, GM; Gao, FX; Moyer, LA; Kaslow, RA; Margolis, HS			The prevalence of hepatitis C virus infection in the United States, 1988 through 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	IX Triennial International Symposium on Viral Hepatitis and Liver Disease	APR 21-25, 1996	ROME, ITALY				NON-B-HEPATITIS; SEXUALLY-TRANSMITTED DISEASES; HUMAN-IMMUNODEFICIENCY-VIRUS; NON-A; RISK-FACTORS; VIRAL-HEPATITIS; LIVER-DISEASE; BLOOD-DONORS; EPIDEMIOLOGY; TRANSFUSION	Background Because many persons with chronic hepatitis C virus (HCV) infection are asymptomatic, population-based serologic studies are needed to estimate the prevalence of the infection and to develop and evaluate prevention efforts. Methods We performed tests for antibody to HCV (anti-HCV) on serum samples from 21,241 persons six years old or older who participated in the third National Health and Nutrition Examination Survey, conducted during 1988 through 1994. We determined the prevalence of HCV RNA by means of nucleic acid amplification and the genotype by means of sequencing. Results The overall prevalence of anti-HCV was 1.8 percent, corresponding to an estimated 3.9 million persons nationwide (95 percent confidence interval, 3.1 million to 4.8 million) with HCV infection. Sixty-five percent of the persons with HCV infection were 30 to 49 years old. Seventy-four percent were positive for HCV RNA, indicating that an estimated 2.7 million persons in the United States (95 percent confidence interval, 2.4 million to 3.0 million) were chronically infected, of whom 73.7 percent were infected with genotype 1 (56.7 percent with genotype la, and 17.0 percent with genotype Ib). Among subjects 17 to 59 years of age, the strongest factors independently associated with HCV infection were illegal drug use and high-risk sexual behavior. Other factors independently associated with infection included poverty, having had 12 or fewer years of education, and having been divorced or separated. Neither sex nor racial-ethnic group was independently associated with HCV infection. Conclusions In the United States, about 2.7 million persons are chronically infected with HCV. People who use illegal drugs or engage in high-risk sexual behavior account for most persons with HCV infection. (N Engl J Med 1999;341:556-62.) (C)1999, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; NIAID, Bethesda, MD 20892 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Alter, MJ (corresponding author), Ctr Dis Control & Prevent, Hepatitis Branch, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mailstop G37, Atlanta, GA 30333 USA.							ALTER HJ, 1972, ANN INTERN MED, V77, P691, DOI 10.7326/0003-4819-77-5-691; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Alter MJ, 1997, HEPATOLOGY, V26, pS62, DOI 10.1002/hep.510260711; ALTER MJ, 1982, J INFECT DIS, V145, P886, DOI 10.1093/infdis/145.6.886; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; ALTER MJ, 1989, JAMA-J AM MED ASSOC, V262, P1201, DOI 10.1001/jama.262.9.1201; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; COLEMAN RM, 1983, J CLIN MICROBIOL, V18, P287, DOI 10.1128/JCM.18.2.287-291.1983; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; EZZATI T, 1993, 1992 P SURV RES METH, P339; FRANCIS DP, 1984, AM J MED, V76, P69, DOI 10.1016/0002-9343(84)90752-6; Kahn HA, 1989, STAT METHODS EPIDEMI; KUO G, 1989, SCIENCE, V244, P362, DOI 10.1126/science.2496467; LANPHEAR BP, 1994, INFECT CONT HOSP EP, V15, P745; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; LEE FK, 1985, J CLIN MICROBIOL, V22, P641, DOI 10.1128/JCM.22.4.641-644.1985; MANSELL CJ, 1995, SEMIN LIVER DIS, V15, P15, DOI 10.1055/s-2007-1007260; Mast EE, 1997, SEMIN PEDIAT INFECT, V8, P17; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; MOHADJER L, 1996, NATL HLTH NUTR EXAMI; Mosley J W, 1965, Tech Bull Regist Med Technol, V35, P183; Nainan OV, 1996, J VIROL METHODS, V61, P127, DOI 10.1016/0166-0934(96)02077-0; National Center for Health Statistics, 1994, VITAL HLTH STAT, V1; *NIH CONS DEV C PA, 1997, HEPATOLOGY S1, V26, P25; PANLILIO AL, 1995, J AM COLL SURGEONS, V180, P16; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SEEFF LB, 1975, AM J MED SCI, V270, P355, DOI 10.1097/00000441-197509000-00018; SHAH BV, 1991, SUDAAN USERS MANUAL; Shapiro CN, 1996, J BONE JOINT SURG AM, V78A, P1791, DOI 10.2106/00004623-199612000-00001; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; THOMAS DL, 1994, J INFECT DIS, V169, P990, DOI 10.1093/infdis/169.5.990; THOMAS DL, 1995, J INFECT DIS, V171, P768, DOI 10.1093/infdis/171.4.768; Thomas SL, 1997, EUR J CLIN MICROBIOL, V16, P711, DOI 10.1007/BF01709250; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x	41	2099	2157	0	76	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					556	562		10.1056/NEJM199908193410802	http://dx.doi.org/10.1056/NEJM199908193410802			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	227CV	10451460				2022-12-24	WOS:000082061500002
J	Choudhury, D; Thompson, A; Stojanoff, V; Langermann, S; Pinkner, J; Hultgren, SJ; Knight, SD				Choudhury, D; Thompson, A; Stojanoff, V; Langermann, S; Pinkner, J; Hultgren, SJ; Knight, SD			X-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli	SCIENCE			English	Article							MACROMOLECULAR STRUCTURES; ANOMALOUS DIFFRACTION; PROTEIN STRUCTURES; TYPE-1 FIMBRIAE; PILUS; ENTEROBACTERIACEAE; RECOGNITION; REFINEMENT; ALIGNMENT	Type 1 pili-adhesive fibers expressed in most members of the Enterobacteriaceae family-mediate binding to mannose receptors on host cells through the FimH adhesin. Pilus biogenesis proceeds by way of the chaperone/usher pathway. The x-ray structure of the FimC-FimH chaperone-adhesin complex from uropathogenic Escherichia coli at 2.5 angstrom resolution reveals the basis for carbohydrate recognition and for pilus assembly. The carboxyl-terminal pilin domain of FimH has an immunoglobulin-like fold, except that the seventh strand is missing, leaving part of the hydrophobic core exposed. A donor strand complementation mechanism in which the chaperone donates a strand to complete the pilin domain explains the basis for both chaperone function and pilus biogenesis.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Swedish Univ Agr Sci, Uppsala Biomed Ctr, Dept Mol Biol, S-75324 Uppsala, Sweden; European Mol Biol Lab, Grenoble Outstn, F-38042 Grenoble, France; European Synchrotron Radiat Facil, F-38400 Grenoble, France; Medimmune Inc, Gaithersburg, MD 20878 USA	Washington University (WUSTL); Swedish University of Agricultural Sciences; European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF); AstraZeneca; Medimmune	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	hullgren@borcim.wustl.edu; stefan@xray.bmc.uu.se	stojanoff, vivian/I-7290-2012; Knight, Stefan/D-4315-2015	stojanoff, vivian/0000-0002-6650-512X; Knight, Stefan/0000-0002-7180-8758; Pinkner, Jerome/0000-0002-7389-7440	NIAID NIH HHS [R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRINTON CC, 1965, T NEW YORK ACAD SCI, V27, P1003, DOI 10.1111/j.2164-0947.1965.tb02342.x; Brunger A. T, 1993, XPLOR MANUAL VERSION; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; HANSON MS, 1988, J BACTERIOL, V170, P3350, DOI 10.1128/jb.170.8.3350-3358.1988; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JONES CH, 1995, P NATL ACAD SCI USA, V92, P2081, DOI 10.1073/pnas.92.6.2081; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; Knight S, 1997, ACTA CRYSTALLOGR D, V53, P207, DOI 10.1107/S0907444996011511; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KNIGHT SD, UNPUB; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGFELT KA, 1990, INFECT IMMUN, V58, P1995, DOI 10.1128/IAI.58.6.1995-1998.1990; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LANGERMANN S, UNPUB; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellecchia M, 1998, NAT STRUCT BIOL, V5, P885, DOI 10.1038/2325; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Schembri MA, 1996, FEMS MICROBIOL LETT, V137, P257, DOI 10.1016/0378-1097(96)00067-5; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Terwilliger TC, 1997, ACTA CRYSTALLOGR D, V53, P571, DOI 10.1107/S0907444997005398; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	37	504	525	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1061	1066		10.1126/science.285.5430.1061	http://dx.doi.org/10.1126/science.285.5430.1061			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446051				2022-12-24	WOS:000082033100044
J	Maekawa, M; Ishizaki, T; Boku, S; Watanabe, N; Fujita, A; Iwamatsu, A; Obinata, T; Ohashi, K; Mizuno, K; Narumiya, S				Maekawa, M; Ishizaki, T; Boku, S; Watanabe, N; Fujita, A; Iwamatsu, A; Obinata, T; Ohashi, K; Mizuno, K; Narumiya, S			Signaling from rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase	SCIENCE			English	Article							DEPOLYMERIZING FACTOR; MYOSIN PHOSPHATASE; FILAMENT TURNOVER; IN-VIVO; COFILIN; PHOSPHORYLATION; DYNAMICS; IDENTIFICATION; ASSOCIATION; MUSCLE	The actin cytoskeleton undergoes extensive remodeling during cell morphogenesis and motility. The small guanosine triphosphatase Rho regulates such remodeling, but the underlying mechanisms of this regulation remain unclear. Cofilin exhibits actin-depolymerizing activity that is inhibited as a result of its phosphorylation by LIM-kinase. Cofilin was phosphorylated in N1E-115 neuroblastoma cells during lysophosphatidic acid-induced, Rho-mediated neurite retraction. This phosphorylation was sensitive to Y-27632, a specific inhibitor of the Rho-associated kinase ROCK. ROCK, which is a downstream effector of Rho, did not phosphorylate cofilin directly but phosphorylated LIM-kinase, which in turn was activated to phosphorylate cofilin, Overexpression of LIM-kinase in HeLa cells induced the formation of actin stress fibers in a Y-27632-sensitive manner. These results indicate that phosphorylation of LIM-kinase by ROCK and consequently increased phosphorylation of cofilin by LIM-kinase contribute to Rho-induced reorganization of the actin cytoskeleton.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan; Chiba Univ, Fac Sci, Dept Biol, Chiba 2638522, Japan; Tohoku Univ, Grad Sch Sci, Inst Biol, Sendai, Miyagi 9808578, Japan	Kyoto University; Kirin Brewery Company Limited; Chiba University; Tohoku University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.		Boku, Shuken/H-2776-2017; Ohashi, Kazumasa/U-7028-2019; Mizuno, Kensaku/G-8631-2015	Ohashi, Kazumasa/0000-0001-7617-403X; 				AGNEW BJ, 1995, J BIOL CHEM, V270, P17582, DOI 10.1074/jbc.270.29.17582; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Burridge K, 1997, TRENDS CELL BIOL, V7, P342, DOI 10.1016/S0962-8924(97)01127-6; Carlier MF, 1997, J CELL BIOL, V136, P1307, DOI 10.1083/jcb.136.6.1307; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kimura K, 1998, J BIOL CHEM, V273, P5542, DOI 10.1074/jbc.273.10.5542; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Maekawa M, UNPUB; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; MORGAN TE, 1993, J CELL BIOL, V122, P623, DOI 10.1083/jcb.122.3.623; Moriyama K, 1996, GENES CELLS, V1, P73, DOI 10.1046/j.1365-2443.1996.05005.x; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; Okano I, 1995, J BIOL CHEM, V270, P31321, DOI 10.1074/jbc.270.52.31321; ONO S, 1994, J BIOL CHEM, V269, P15280; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; WATANABE N, 1997, EMBO J, V16, P1307; Welch MD, 1997, CURR OPIN CELL BIOL, V9, P54, DOI 10.1016/S0955-0674(97)80152-4; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	25	1239	1273	3	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					895	898		10.1126/science.285.5429.895	http://dx.doi.org/10.1126/science.285.5429.895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436159				2022-12-24	WOS:000081860900051
J	Semsarian, C; Wu, MJ; Ju, YK; Marciniec, T; Yeoh, T; Allen, DG; Harvey, RP; Graham, RM				Semsarian, C; Wu, MJ; Ju, YK; Marciniec, T; Yeoh, T; Allen, DG; Harvey, RP; Graham, RM			Skeletal muscle hypertrophy is mediated by a Ca2+-dependent calcineurin signalling pathway	NATURE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; CARDIAC-HYPERTROPHY; SIGNALING PATHWAYS; FIBER-TYPE; GROWTH; PROLIFERATION; ACTIVATION; CELLS	Skeletal muscle hypertrophy and regeneration are important adaptive responses to both physical activity and pathological stimuli(1). Failure to maintain these processes underlies the loss of skeletal muscle mass and strength that occurs with ageing and in myopathies(2). Here we show that stable expression of a gene encoding insulin-like growth factor 1 (IGF-1) in C2C12 skeletal muscle cells, or treatment of these cells with recombinant IGF-1 or with insulin and dexamethasone, results in hypertrophy of differentiated myotubes and a switch to glycolytic metabolism. Treatment with IGF-1 or insulin and dexamethasone mobilizes intracellular calcium, activates the Ca2+/calmodulin-dependent phosphatase calcineurin, and induces the nuclear translocation of the transcription factor NF-ATc1. Hypertrophy is suppressed by the calcineurin inhibitors cyclosporin A or FK506, but not by inhibitors of the MAP-kinase or phosphatidylinositol-3-OH kinase pathways. Injecting rat latissimus dorsi muscle with a plasmid encoding IGF-1 also activates calcineurin, mobilizes satellite cells and causes a switch to glycolytic metabolism. We propose that growth-factor-induced skeletal-muscle hypertrophy and changes in myofibre phenotype are mediated by calcium mobilization and are critically regulated by the calcineurin/NF-ATc1 signalling pathway.	St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia; Univ Sydney, Dept Physiol, Sydney, NSW 2006, Australia; Univ New S Wales, Sch Biochem & Mol Genet, Kensington, NSW 2033, Australia	St Vincents Hospital Sydney; Victor Chang Cardiac Research Institute; University of Sydney; University of New South Wales Sydney	Graham, RM (corresponding author), St Vincents Hosp, Victor Chang Cardiac Res Inst, Darlinghurst, NSW 2010, Australia.	b.graham@victorchang.unsw.edu.au		Harvey, Richard/0000-0002-9950-9792				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/er.17.5.481; Fruman David A., 1996, Methods (Orlando), V9, P146, DOI 10.1006/meth.1996.0020; GIORGINO F, 1995, J CLIN INVEST, V96, P1473, DOI 10.1172/JCI118184; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; Ju YK, 1998, J PHYSIOL-LONDON, V508, P153, DOI 10.1111/j.1469-7793.1998.153br.x; KAZAKI M, 1997, J BIOL CHEM, V272, P4964; Luo ZY, 1998, NAT MED, V4, P1092, DOI 10.1038/2578; Lyakh L, 1997, MOL CELL BIOL, V17, P2475, DOI 10.1128/MCB.17.5.2475; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Montano MM, 1997, ENDOCR RES, V23, P37, DOI 10.1080/07435809709031841; Musaro A, 1999, MOL CELL BIOL, V19, P3115; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Pette D, 1997, Int Rev Cytol, V170, P143, DOI 10.1016/S0074-7696(08)61622-8; Renganathan M, 1998, J BIOL CHEM, V273, P28845, DOI 10.1074/jbc.273.44.28845; ROSENBLATT JD, 1992, J APPL PHYSIOL, V73, P2538, DOI 10.1152/jappl.1992.73.6.2538; Semsarian C, 1999, BIOCHEM J, V339, P443, DOI 10.1042/0264-6021:3390443; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; TESCH PA, 1984, J APPL PHYSIOL, V56, P35, DOI 10.1152/jappl.1984.56.1.35; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; Zhang WG, 1999, CIRC RES, V84, P722, DOI 10.1161/01.RES.84.6.722; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	30	360	379	2	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					576	581		10.1038/23054	http://dx.doi.org/10.1038/23054			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448861				2022-12-24	WOS:000081854800059
J	Augustin, I; Rosenmund, C; Sudhof, TC; Brose, N				Augustin, I; Rosenmund, C; Sudhof, TC; Brose, N			Munc13-1 is essential for fusion competence of glutamatergic synoptic vesicles	NATURE			English	Article							TRANSMITTER RELEASE; CENTRAL SYNAPSE; RECEPTOR; PROBABILITY; EXOCYTOSIS; CULTURE; FAMILY; POOL	Neurotransmitter release at synapses between nerve cells is mediated by calcium-triggered exocytotic fusion of synaptic vesicles'. Before fusion, vesicles dock at the presynaptic release site where they mature to a fusion-competent state(1,2). Here we identify Munc13-1, a brain-specific presynaptic phorbol ester receptor(3,4), as an essential protein for synaptic vesicle maturation. We show that glutamatergic hippocampal neurons from mice lacking Munc13-1 form ultrastructurally normal synapses whose synaptic-vesicle cycle is arrested at the maturation step. Transmitter release from mutant synapses cannot be triggered by action potentials, calcium-ionophores or hypertonic sucrose solution. In contrast, release evoked by alpha-latrotolrin is indistinguishable from wild-type controls, indicating that the toxin can bypass Munc13-1-mediated vesicle maturation. A small subpopulation of synapses of any given glutamatergic neuron as well as all synapses of GABA (gamma-aminobutyric acid)-containing neurons are unaffected by Munc13-1 loss, demonstrating the existence of multiple and transmitter-specific synaptic vesicle maturation processes in synapses.	Max Planck Inst Expt Med, AG Mol Neurobiol, D-37075 Gottingen, Germany; Max Planck Inst Biophys Chem, Abt Membranbiophys, D-37077 Gottingen, Germany; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, Dallas, TX 75235 USA	Max Planck Society; Max Planck Society; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Brose, N (corresponding author), Max Planck Inst Expt Med, AG Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.		Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444				BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Boyer C, 1998, J NEUROSCI, V18, P5294, DOI 10.1523/JNEUROSCI.18-14-05294.1998; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; Martin TFJ, 1998, VITAM HORM, V54, P207, DOI 10.1016/S0083-6729(08)60926-7; Rosenmund C, 1996, NEURON, V16, P1197, DOI 10.1016/S0896-6273(00)80146-4; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; STEVENS CF, 1995, P NATL ACAD SCI USA, V92, P846, DOI 10.1073/pnas.92.3.846; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13; ZUCKER RS, 1973, J PHYSIOL-LONDON, V229, P787, DOI 10.1113/jphysiol.1973.sp010167; Zucker RS, 1996, NEURON, V17, P1049, DOI 10.1016/S0896-6273(00)80238-X	17	534	551	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					457	461		10.1038/22768	http://dx.doi.org/10.1038/22768			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440375				2022-12-24	WOS:000081715000052
J	Einsle, O; Messerschmidt, A; Stach, P; Bourenkov, GP; Bartunik, HD; Huber, R; Kroneck, PMH				Einsle, O; Messerschmidt, A; Stach, P; Bourenkov, GP; Bartunik, HD; Huber, R; Kroneck, PMH			Structure of cytochrome c nitrite reductase	NATURE			English	Article							WOLINELLA-SUCCINOGENES; DESULFOVIBRIO-DESULFURICANS; NITROSOMONAS-EUROPAEA; ENTERIC BACTERIA; ESCHERICHIA-COLI; NITROGEN-CYCLE; AMMONIA; PURIFICATION; OXYGEN; ENZYME	The enzyme cytochrome c nitrite reductase catalyses the six-electron reduction of nitrite to ammonia as one of the key steps in the biological nitrogen cycle(1), where it participates in the anaerobic energy metabolism of dissimilatory nitrate ammonification(2). Here we report on the crystal structure of this enzyme from the microorganism Sulfurospirillum deleyianum, which we solved by multiwavelength anomalous dispersion methods. We propose a reaction scheme for the transformation of nitrite based on structural and spectroscopic information. Cytochrome c nitrite reductase is a functional dimer, with 10 dose-packed haem groups of type c and an unusual lysine-coordinated high-spin haem at the active site. By comparing the haem arrangement of this nitrite reductase with that of other multihaem cytochromes, we have been able to identify a family of proteins in which the orientation of haem groups is conserved whereas structure and function are not.	Univ Konstanz, Fak Biol, D-78457 Constance, Germany; Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; DESY, Arbeitsgrp Prot Dynam, MPG ASMB, D-22603 Hamburg, Germany	University of Konstanz; Max Planck Society; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY)	Kroneck, PMH (corresponding author), Univ Konstanz, Fak Biol, D-78457 Constance, Germany.	einsle@biochem.mpg.de	Messerschmidt, Albrecht/A-8337-2008; Bourenkov, Gleb P/C-7794-2017	Bourenkov, Gleb P/0000-0002-2617-5920; Einsle, Oliver/0000-0001-8722-2893				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berks BC, 1995, BBA-BIOENERGETICS, V1232, P97, DOI 10.1016/0005-2728(95)00092-5; BLACKMORE R, 1986, BIOCHEM J, V233, P547, DOI 10.1042/bj2330547; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cole J, 1996, FEMS MICROBIOL LETT, V136, P1; COLE JA, 1980, FEMS MICROBIOL LETT, V7, P65, DOI 10.1111/j.1574-6941.1980.tb01578.x; DARWIN A, 1993, MOL MICROBIOL, V9, P1255, DOI 10.1111/j.1365-2958.1993.tb01255.x; Eaves DJ, 1998, MOL MICROBIOL, V28, P205, DOI 10.1046/j.1365-2958.1998.00792.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GODDEN JW, 1991, SCIENCE, V253, P438, DOI 10.1126/science.1862344; HUSSAIN H, 1994, MOL MICROBIOL, V12, P153, DOI 10.1111/j.1365-2958.1994.tb01004.x; Igarashi N, 1997, NAT STRUCT BIOL, V4, P276, DOI 10.1038/nsb0497-276; Iverson TM, 1998, NAT STRUCT BIOL, V5, P1005, DOI 10.1038/2975; LAFORTELLE ED, 1997, CRYSTALLOGR COMPUT, V7, P1; LIU MC, 1981, J BIOL CHEM, V256, P3159; LIU MC, 1983, FEMS MICROBIOL LETT, V19, P201, DOI 10.1016/0378-1097(83)90060-5; MORENO C, 1993, EUR J BIOCHEM, V212, P79, DOI 10.1111/j.1432-1033.1993.tb17635.x; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SCHRODER I, 1985, ARCH MICROBIOL, V140, P380, DOI 10.1007/BF00446982; SCHUMACHER W, 1994, BIOCHEM BIOPH RES CO, V205, P911, DOI 10.1006/bbrc.1994.2751; Schumacher W, 1997, TRANSITION METALS IN MICROBIAL METABOLISM, P329; SCHUMACHER W, 1991, ARCH MICROBIOL, V156, P70, DOI 10.1007/BF00418190; Strehlitz B, 1996, ANAL CHEM, V68, P807, DOI 10.1021/ac950692n; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; Vijgenboom, 1998, BIOL ELECT TRANSFER, P197, DOI 10.1007/978-94-011-5133-7_14; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Zumft WG, 1997, MICROBIOL MOL BIOL R, V61, P533, DOI 10.1128/.61.4.533-616.1997	30	274	283	4	74	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					476	480		10.1038/22802	http://dx.doi.org/10.1038/22802			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440380				2022-12-24	WOS:000081715000057
J	Kume, K; Zylka, MJ; Sriram, S; Shearman, LP; Weaver, DR; Jin, XW; Maywood, ES; Hastings, MH; Reppert, SM				Kume, K; Zylka, MJ; Sriram, S; Shearman, LP; Weaver, DR; Jin, XW; Maywood, ES; Hastings, MH; Reppert, SM			mCRY1 and mCRY2 are essential components of the negative limb of the circadian clock feedback loop	CELL			English	Article							DROSOPHILA PERIOD GENE; SUPRACHIASMATIC NUCLEUS; MESSENGER-RNA; LIGHT; PROTEIN; MOUSE; EXPRESSION; TRANSCRIPTION; CRYPTOCHROME; TIMELESS	We determined that two mouse cryptochrome genes, mCry1 and mCry2, act in the negative limb of the clock feedback loop. In cell lines, mPER proteins (alone or in combination) have modest effects on their cellular location and ability to inhibit CLOCK:BMAL1-mediated transcription. This suggested cryptochrome involvement in the negative limb of the feedback loop. Indeed, mCry1 and mCry2 RNA levels are reduced in the central and peripheral clocks of Clock/Clock mutant mice. mCRY1 and mCRY2 are nuclear proteins that interact with each of the mPER proteins, translocate each mPER protein from cytoplasm to nucleus, and are rhythmically expressed in the suprachiasmatic circadian clock. Luciferase reporter gene assays show that mCRY1 or mCRY2 alone abrogates CLOCK:BMAL1-E box-mediated transcription. The mPER and mCRY proteins appear to inhibit the transcriptional complex differentially.	Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; University of Cambridge	Kume, K (corresponding author), Massachusetts Gen Hosp, Lab Dev Chronobiol, Serv Pediat, Boston, MA 02114 USA.	reppert@helix.mgh.harvard.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Hastings, Michael Harvey/0000-0001-8576-6651; Weaver, David/0000-0001-7941-6719; Kume, Kazuhiko/0000-0003-4232-1657	NICHD NIH HHS [R37 HD14427] Funding Source: Medline; NIMH NIH HHS [MH12067, MH11547] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD014427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH012067, F31MH011547] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; EDERY I, 1994, P NATL ACAD SCI USA, V91, P2260, DOI 10.1073/pnas.91.6.2260; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hastings M.H., 1999, J NEUROSCI, V11, P1; Herzog ED, 1998, NAT NEUROSCI, V1, P708, DOI 10.1038/3708; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Koike N, 1998, FEBS LETT, V441, P427, DOI 10.1016/S0014-5793(98)01597-X; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; Reppert SM, 1998, NEURON, V21, P1, DOI 10.1016/S0896-6273(00)80234-2; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takahata S, 1998, BIOCHEM BIOPH RES CO, V248, P789, DOI 10.1006/bbrc.1998.9012; Takumi T, 1999, GENES CELLS, V4, P67, DOI 10.1046/j.1365-2443.1999.00238.x; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WEAVER DR, 1993, MOL BRAIN RES, V20, P313, DOI 10.1016/0169-328X(93)90058-W; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Zylka MJ, 1998, NEURON, V21, P1115, DOI 10.1016/S0896-6273(00)80628-5; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	44	1227	1264	6	110	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					193	205		10.1016/S0092-8674(00)81014-4	http://dx.doi.org/10.1016/S0092-8674(00)81014-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428031	Bronze			2022-12-24	WOS:000081632300009
J	Cheng, KH; Leung, SL; Hoekman, HW; Beekhuis, WH; Mulder, PGH; Geerards, AJM; Kijlstra, A				Cheng, KH; Leung, SL; Hoekman, HW; Beekhuis, WH; Mulder, PGH; Geerards, AJM; Kijlstra, A			Incidence of contact-lens-associated microbial keratitis and its related morbidity	LANCET			English	Article							ULCERATIVE KERATITIS; EXTENDED-WEAR; ACANTHAMOEBA-KERATITIS; PSEUDOMONAS-AERUGINOSA; CORNEAL ULCERS; OVERNIGHT WEAR; RISK-FACTORS; USERS; CONTAMINATION; ENGLAND	Background The incidence of contact-lens-associated microbial keratitis is uncertain and its related morbidity in the general population of contact-lens wearers is not known. We examined these issues in a prospective epidemiological study. Methods We surveyed all practising ophthalmologists in the Netherlands to identify all new cases of microbial keratitis reported during a 3-month period in 1996. Follow-up telephone calls were made to examine ocular morbidity. We undertook annual nationwide telephone surveys between 1994 and 1997 to estimate the prevalence of contact-lens wear. Findings Of 440 ophthalmologists contacted, 379 provided information. There were 92 cases of microbial keratitis; 17 used daily-wear rigid gas-permeable lenses, 63 daily-wear soft lenses, and 12 extended-wear soft lenses. The estimated annualised incidence of microbial keratitis was 1.1 per 10 000 (95% CI 0.6-1.7) users of daily-wear rigid gas-permeable lenses, 3.5 per 10 000 (2.7-4.5) users of daily-wear soft lenses, and 20.0 per 10 000 (10.3-35.0) users of extended-wear soft lenses (p<0.00001 for comparison between all groups), Five of the 92 patients achieved a final visual acuity of 20/70 or less. Pseudomonas and Serratia sop were the organisms most commonly isolated, Pseudomonas keratitis accounted for the largest mean diameter of corneal ulcers, the highest mean number of days in hospital, the greatest number of mean outpatients visits, and the poorest visual acuity outcome. Interpretation The incidence of microbial keratitis among users of extended-wear soft contact lenses in the Netherlands is similar to that reported in the USA during 1989. Awareness of risk factors and improvement in contact-lens materials have not led to a decrease in incidence. Overnight wear should be strongly discouraged.	Netherlands Ophthalm Res Inst, Dept Ophthalmoimmunol, NL-1100 AC Amsterdam, Netherlands; Univ Amsterdam, Dept Ophthalmol, Amsterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Coll Econ, Drenthe, Netherlands; Rotterdam Eye Hosp, Rotterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Erasmus University Rotterdam; Rotterdam Eye Hospital	Kijlstra, A (corresponding author), Netherlands Ophthalm Res Inst, Dept Ophthalmoimmunol, POB 12141, NL-1100 AC Amsterdam, Netherlands.							BATES A K, 1989, Eye (London), V3, P803; COHEN EJ, 1987, OPHTHALMOLOGY, V94, P109; COSTER DJ, 1987, BRIT J OPHTHALMOL, V71, P96, DOI 10.1136/bjo.71.2.96; DART JKG, 1988, BRIT J OPHTHALMOL, V72, P926, DOI 10.1136/bjo.72.12.926; DART JKG, 1991, LANCET, V338, P650, DOI 10.1016/0140-6736(91)91231-I; DONZIS PB, 1987, AM J OPHTHALMOL, V104, P325, DOI 10.1016/0002-9394(87)90219-4; ERIE JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P1665, DOI 10.1001/archopht.1993.01090120087027; GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P104, DOI 10.1001/archopht.1991.01080010106041; IMAYASU M, 1994, OPHTHALMOLOGY, V101, P371; KAMATA R, 1985, OPHTHALMOLOGY, V92, P1452; KOCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1453, DOI 10.1001/archopht.1990.01070120101038; KOIDOUTSILIGIANNI A, 1989, AM J OPHTHALMOL, V108, P64, DOI 10.1016/S0002-9394(14)73262-3; LASS JH, 1981, AM J OPHTHALMOL, V92, P384, DOI 10.1016/0002-9394(81)90529-8; LAZACHEK GW, 1971, ARCH OPHTHALMOL-CHIC, V86, P599, DOI 10.1001/archopht.1971.01000010601020; LIESEGANG TJ, 1980, AM J OPHTHALMOL, V90, P38, DOI 10.1016/S0002-9394(14)75075-5; Lim-Bon-Siong R, 1998, AM J OPHTHALMOL, V125, P169, DOI 10.1016/S0002-9394(99)80087-7; Mathers WD, 1996, AM J OPHTHALMOL, V121, P129, DOI 10.1016/S0002-9394(14)70577-X; MAYO MS, 1987, J CLIN MICROBIOL, V25, P1398, DOI 10.1128/JCM.25.8.1398-1400.1987; MUMMERT R, 1994, BAUSCH LOMB ANN REPO, P2; Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225; ORMEROD LD, 1986, ARCH OPHTHALMOL-CHIC, V104, P79; POGGIO EC, 1989, NEW ENGL J MED, V321, P779, DOI 10.1056/NEJM198909213211202; RADFORD CF, 1995, BRIT MED J, V310, P1567, DOI 10.1136/bmj.310.6994.1567; Radford CF, 1998, BRIT J OPHTHALMOL, V82, P1387, DOI 10.1136/bjo.82.12.1387; Rapuano CJ, 1999, OPHTHALMOLOGY, V106, P422; SCHEIN OD, 1994, ARCH OPHTHALMOL-CHIC, V112, P186, DOI 10.1001/archopht.1994.01090140062024; SCHEIN OD, 1989, NEW ENGL J MED, V321, P773, DOI 10.1056/NEJM198909213211201; STEHRGREEN JK, 1989, AM J OPHTHALMOL, V107, P331, DOI 10.1016/0002-9394(89)90654-5; STEIN RM, 1988, AM J OPHTHALMOL, V105, P632, DOI 10.1016/0002-9394(88)90056-6; Taylor HR, 1996, ARCH OPHTHALMOL-CHIC, V114, P248, DOI 10.1001/archopht.1996.01100130244001; WILSON LA, 1990, AM J OPHTHALMOL, V110, P193, DOI 10.1016/S0002-9394(14)76991-0; 1988, LANCET, V1, P1437	32	372	384	0	42	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					181	185		10.1016/S0140-6736(98)09385-4	http://dx.doi.org/10.1016/S0140-6736(98)09385-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421298				2022-12-24	WOS:000081504200008
J	Jamora, C; Yamanouye, N; Van Lint, J; Laudenslager, J; Vandenheede, JR; Faulkner, DJ; Malhotra, V				Jamora, C; Yamanouye, N; Van Lint, J; Laudenslager, J; Vandenheede, JR; Faulkner, DJ; Malhotra, V			G beta gamma-mediated regulation of Golgi organization is through the direct activation of protein kinase D	CELL			English	Article							HETEROTRIMERIC-G-PROTEINS; CONSTITUTIVE TRANSPORT VESICLES; C-MU; DOMAIN; RECEPTOR; BINDING; EPSILON	We have shown previously that the py subunits of the heterotrimeric G proteins regulate the organization of the pericentriolarly localized Golgi stacks. In this report, evidence is presented that the downstream target of G beta gamma is protein kinase D (PKD), an isoform of protein kinase C. PKD, unlike other members of this class of serine/threonine kinases, contains a pleckstrin homology (PH) domain. Our results demonstrate that G beta gamma directly activates PKD by interacting with its PH domain. Inhibition of PKD activity through the use of pharmacological agents, synthetic peptide substrates, and, more specifically, the PH domain of PKD prevents G beta gamma-mediated Golgi breakdown. Our findings suggest a possible mechanism by which the direct interaction of G beta gamma with PKD regulates the dynamics of Golgi membranes and protein secretion.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Salk Inst, Dept Canc Biol, San Diego, CA 92186 USA; Catholic Univ Louvain, Fac Geneeskunde, Afdeling Biochem, B-3000 Louvain, Belgium	University of California System; University of California San Diego; University of California System; University of California San Diego; Scripps Institution of Oceanography; Salk Institute; Universite Catholique Louvain	Malhotra, V (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Van Lint, Johan/P-9073-2019; Yamanouye, Norma/I-3348-2013; Malhotra, Vivek/O-9811-2014	Yamanouye, Norma/0000-0001-6007-0199; Malhotra, Vivek/0000-0001-6198-7943; Van Lint, Johan/0000-0002-0275-571X				Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; Glick BS, 1998, CELL, V95, P883, DOI 10.1016/S0092-8674(00)81713-4; Gschwendt M, 1998, FEBS LETT, V421, P165, DOI 10.1016/S0014-5793(97)01530-5; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; LEHEL C, 1995, P NATL ACAD SCI USA, V92, P1406, DOI 10.1073/pnas.92.5.1406; Lippincott-Schwartz J, 1998, CURR OPIN CELL BIOL, V10, P52, DOI 10.1016/S0955-0674(98)80086-0; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; Nishikawa K, 1998, J BIOL CHEM, V273, P23126, DOI 10.1074/jbc.273.36.23126; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Prestle J, 1996, J CELL BIOL, V134, P1401, DOI 10.1083/jcb.134.6.1401; Sable CL, 1998, J BIOL CHEM, V273, P29600, DOI 10.1074/jbc.273.45.29600; Simon JP, 1996, J CELL BIOL, V135, P355, DOI 10.1083/jcb.135.2.355; SLUSAREWICZ P, 1994, CELL BIOL LAB HDB, P509; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; TAKIZAWA PA, 1993, CELL, V73, P1079, DOI 10.1016/0092-8674(93)90638-7; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Westermann P, 1996, BIOCHEM J, V320, P651, DOI 10.1042/bj3200651	28	233	236	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					59	68		10.1016/S0092-8674(00)80606-6	http://dx.doi.org/10.1016/S0092-8674(00)80606-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412981	Bronze			2022-12-24	WOS:000081451000008
J	Wu, ZD; Puigserver, P; Andersson, U; Zhang, CY; Adelmant, G; Mootha, V; Troy, A; Cinti, S; Lowell, B; Scarpulla, RC; Spiegelman, BM				Wu, ZD; Puigserver, P; Andersson, U; Zhang, CY; Adelmant, G; Mootha, V; Troy, A; Cinti, S; Lowell, B; Scarpulla, RC; Spiegelman, BM			Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1	CELL			English	Article							BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN HOMOLOG; DIET-INDUCED THERMOGENESIS; ACTIVATED RECEPTOR-GAMMA; SKELETAL-MUSCLE; TRANSCRIPTION FACTOR; DNA-BINDING; GENE-EXPRESSION; NUCLEAR; OBESITY	Mitochondrial number and function are altered in response to external stimuli in eukaryotes. While several transcription/replication factors directly regulate mitochondrial genes, the coordination of these factors into a program responsive to the environment is not understood. We show here that PGC-1, a cold-inducible coactivator of nuclear receptors, stimulates mitochondrial biogenesis and respiration in muscle cells through an induction of uncoupling protein 2 (UCP-2) and through regulation of the nuclear respiratory factors (NRFs). PGC-1 stimulates a powerful induction of NRF-1 and NRF-5 gene expression; in addition, PGC-1 binds to and coactivates the transcriptional function of NRF-1 on the promoter for mitochondrial transcription factor A (mtTFA), a direct regulator of mitochondrial DNA replication/transcription. These data elucidate a pathway that directly links external physiological stimuli to the regulation of mitochondrial biogenesis and function.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol & Metab, Boston, MA 02115 USA; Univ Ancona, Fac Med & Chirurg, Ist Morfol Umana Normale Anat, I-60020 Ancona, Italy	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Marche Polytechnic University	Spiegelman, BM (corresponding author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.	bruce_spiegelman@dfci.harvard.edu	Andersson, Ulf/ABD-5162-2021	Andersson, Ulf/0000-0003-0316-3860; CINTI, Saverio/0000-0003-0362-5017; Wu, Zhidan/0000-0001-7289-9420	NIDDK NIH HHS [DK54477] Funding Source: Medline; NIGMS NIH HHS [GM32525] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK054477, R01DK054477] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032525, R56GM032525] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; BOUCHARD C, 1990, NEW ENGL J MED, V322, P1477, DOI 10.1056/NEJM199005243222101; BOUILLAUD F, 1986, J BIOL CHEM, V261, P1487; BROOKS SL, 1980, NATURE, V286, P274, DOI 10.1038/286274a0; Camirand A, 1998, ENDOCRINOLOGY, V139, P428, DOI 10.1210/en.139.1.428; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Flier JS, 1997, NAT GENET, V15, P223, DOI 10.1038/ng0397-223; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; GUGNEJA S, 1995, MOL CELL BIOL, V15, P102, DOI 10.1128/MCB.15.1.102; Gugneja S, 1997, J BIOL CHEM, V272, P18732, DOI 10.1074/jbc.272.30.18732; Gugneja S, 1996, MOL CELL BIOL, V16, P5708; Hamann A, 1996, ENDOCRINOLOGY, V137, P21, DOI 10.1210/en.137.1.21; HIMMSHAGEN J, 1989, CAN J PHYSIOL PHARM, V67, P394, DOI 10.1139/y89-063; HIMMSHAGEN J, 1990, FASEB J, V4, P2890, DOI 10.1096/fasebj.4.11.2199286; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kopecky J, 1995, J CLIN INVEST, V96, P2914, DOI 10.1172/JCI118363; Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231; Levine James A., 1999, Science (Washington D C), V283, P212, DOI 10.1126/science.283.5399.212; LOWELL BB, 1993, NATURE, V366, P740, DOI 10.1038/366740a0; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Maniatis T., 1989, LAB MANUAL, Vsecond; NELSON BD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P275, DOI 10.1016/0005-2728(90)90266-7; NICHOLLS D, 1986, BIOCHEM SOC T, V14, P223, DOI 10.1042/bst0140223; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Ricquier D, 1997, PROG NUCLEIC ACID RE, V56, P83, DOI 10.1016/S0079-6603(08)61003-X; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; Scarpulla RC, 1997, J BIOENERG BIOMEMBR, V29, P109, DOI 10.1023/A:1022681828846; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SHADEL GS, 1993, J BIOL CHEM, V268, P16083; Shimokawa T, 1998, BIOCHEM BIOPH RES CO, V251, P374, DOI 10.1006/bbrc.1998.9479; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089	44	2993	3122	6	249	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					115	124		10.1016/S0092-8674(00)80611-X	http://dx.doi.org/10.1016/S0092-8674(00)80611-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412986	Bronze			2022-12-24	WOS:000081451000013
J	Rowland-Jones, S				Rowland-Jones, S			HIV infection: where have all the T cells gone?	LANCET			English	Editorial Material							CD4(+); REPERTOIRE; TURNOVER; THERAPY; AIDS		John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England	University of Oxford	Rowland-Jones, S (corresponding author), John Radcliffe Hosp, Inst Mol Med, Human Immunol Unit, Oxford OX3 9DS, England.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Haynes BF, 1999, J CLIN INVEST, V103, P921, DOI 10.1172/JCI5201E1; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Kalams SA, 1998, J EXP MED, V188, P2199, DOI 10.1084/jem.188.12.2199; Li TS, 1998, LANCET, V351, P1682, DOI 10.1016/S0140-6736(97)10291-4; Macallan DC, 1998, P NATL ACAD SCI USA, V95, P708, DOI 10.1073/pnas.95.2.708; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wilson JDK, 1998, J EXP MED, V188, P785, DOI 10.1084/jem.188.4.785; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543	17	23	23	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 3	1999	354	9172					5	7		10.1016/S0140-6736(99)90017-X	http://dx.doi.org/10.1016/S0140-6736(99)90017-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406356				2022-12-24	WOS:000081243200005
J	Crowcroft, NS; Infuso, A; Ilef, D; Le Guenno, B; Desenclos, JC; Van Loock, F; Clement, J				Crowcroft, NS; Infuso, A; Ilef, D; Le Guenno, B; Desenclos, JC; Van Loock, F; Clement, J			Risk factors for human hantavirus infection: Franco-Belgian collaborative case-control study during 1995-6 epidemic	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Sci Inst Publ Hlth Louis Pasteur, Dept Epidemiol, Infect Dis Unit, Brussels, Belgium; Reseau Natl Sante Publ, St Maurice, France; Direct Rag Affaires Sanit & Sociales Nord, Lille, France; Inst Pasteur, Ctr Natl Reference Fievres Hemorrag & Arbovirus, Paris, France; Queen Astrid Mil Hosp, Natl Reference Ctr Hantavirus Infect, Belgian Zoonosis Workgrp, B-1120 Brussels, Belgium	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Queen Astrid Military Hospital	Crowcroft, NS (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England.	mcrowcro@ogks.co.uk						Clement J, 1997, EMERG INFECT DIS, V3, P205, DOI 10.3201/eid0302.970218; CLEMENT J, 1994, LANCET, V343, P114, DOI 10.1016/S0140-6736(94)90841-9; LEGUENNO B, 1994, MED MALADIES INFECT, V24, P512, DOI 10.1016/S0399-077X(05)81257-0; LeGuenno B, 1997, MED MALADIES INFECT, V27, P703, DOI 10.1016/S0399-077X(97)80179-5; VANLOOCK F, IN PRESS CLIN INFECT	5	41	44	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1737	1738		10.1136/bmj.318.7200.1737	http://dx.doi.org/10.1136/bmj.318.7200.1737			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381709	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000081216900031
J	Graves, LE; Segal, S; Goodwin, EB				Graves, LE; Segal, S; Goodwin, EB			TRA-1 regulates the cellular distribution of the tra-2 mRNA in C. elegans	NATURE			English	Article							SEX-DETERMINING GENE; NEMATODE CAENORHABDITIS-ELEGANS; ZINC FINGER PROTEINS; MOLECULAR ANALYSIS; TRANSFORMATION; HEDGEHOG; MEMBER; FAMILY	The GLI protein family is involved in several key developmental processes in both vertebrates and invertebrates, The Drosophila GLI protein, Cubitus interuptus (Ci), regulates segment polarity and wing and leg development. In vertebrates, the GLI proteins control neural, lung, bone and gut development(1), In the nematode Caenorhabditis elegans, the GLI family member TRA-1 is necessary for normal sexual development(2,3). GLI, Ci and TRA-1 each contain five zinc-finger domains and bind the identical DNA sequence. Previous analyses are consistent with these proteins being transcription factors(4,5). Here we show that TRA-1 can act post-transcriptionally to govern gene activity. Our results indicate that the binding of TRA-1 to the 3' untranslated region of tra-2 regulates the export of tra-2 messenger RNA from the nucleus. The fact that TRA-1 is part of a conserved family of proteins raises the possibility that GLI family members are both transcriptional and post-transcriptional regulators of gene expression.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Goodwin, EB (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.	ebg778@nwu.edu						Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BRENNER S, 1974, GENETICS, V77, P71; FIRE A, 1992, GENET ANAL-BIOMOL E, V9, P151, DOI 10.1016/1050-3862(92)90042-4; Goodwin EB, 1997, DEVELOPMENT, V124, P749; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HODGKIN J, 1993, GENETICS, V133, P543; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1986, GENETICS, V114, P15; HODGKIN JA, 1977, GENETICS, V86, P275; Jan E, 1997, EMBO J, V16, P6301, DOI 10.1093/emboj/16.20.6301; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; KUWABARA PE, 1992, TRENDS GENET, V8, P164, DOI 10.1016/0168-9525(92)90218-S; Kuwabara PE, 1998, DEV BIOL, V204, P251, DOI 10.1006/dbio.1998.9062; KUWAMURA S, 1992, P ESO C HIGH RESOLUT, V2, P461; Mello C, 1995, METHOD CELL BIOL, V48, P451; OKKEMA PG, 1991, EMBO J, V10, P171, DOI 10.1002/j.1460-2075.1991.tb07933.x; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; Stutz F, 1998, GENE DEV, V12, P3303, DOI 10.1101/gad.12.21.3303; Weed M, 1997, MATRIX BIOL, V16, P53, DOI 10.1016/S0945-053X(97)90072-X; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	22	33	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					802	805						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391248				2022-12-24	WOS:000081101600058
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Test tube kidneys	SCIENCE			English	Article									Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Sikorski, R (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.							Humes HD, 1999, NAT BIOTECHNOL, V17, P451, DOI 10.1038/8626	1	0	0	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 18	1999	284	5422					1952	1952						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JA	10400538				2022-12-24	WOS:000080932700034
J	Ohndorf, UM; Rould, MA; He, Q; Pabo, CO; Lippard, SJ				Ohndorf, UM; Rould, MA; He, Q; Pabo, CO; Lippard, SJ			Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins	NATURE			English	Article							ANTICANCER DRUG CISPLATIN; INTRASTRAND CROSS-LINK; HMG-DOMAIN; DUPLEX; BOX; ADDUCT; CRYSTAL; SRY	The anticancer activity of cis-diamminedichloroplatinum(II) (cisplatin) arises from its ability to damage DNA, with the major adducts formed being intrastrand d(GpG) and d(ApG) crosslinks(1). These-crosslinks bend and unwind the duplex, and the altered structure attracts high-mobility-group domain (HMG) and other proteins(2). This binding of HMG-domain proteins to cisplatin-modified DNA-has been postulated to mediate the antitumour properties of the drug(3,4). Many HMG-domain proteins recognize altered DNA structures such as four-way junctions and cisplatin-modified DNA(5), but until now:the molecular basis for this recognition was unknown. Here we describe mutagenesis, hydroxyl-radical footprinting and X-ray studies that elucidate the structure of a 1:1. cisplatin-modified DNA/HMG-domain complex Domain A of the structure-specific HMG-domain protein HMG1 binds to the widened minor groove of a 16-base-pair DNA duplex containing a site-specific cis-[Pt(NH3)(2){d(GpG)-N7(1),-N7(2)}] adduct, The DNA is strongly kinked at a hydrophobic notch created at the platinum-DNA crosslink and protein binding extends exclusively to the 3' side of the platinated strand. A phenylalanine residue at position 37 intercalates into a hydrophobic notch created at the platinum crosslinked d(GpG) site and binding of the domain is dramatically reduced in a mutant in which alanine is substituted for phenylalanine at this position.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Lippard, SJ (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.	lippard@lippard.mit.edu						BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Balaeff A, 1998, PROTEINS, V30, P113, DOI 10.1002/(SICI)1097-0134(19980201)30:2<113::AID-PROT2>3.0.CO;2-O; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BernersPrice SJ, 1997, EUR J BIOCHEM, V243, P782, DOI 10.1111/j.1432-1033.1997.00782.x; Broadhurst RW, 1995, BIOCHEMISTRY-US, V34, P16608, DOI 10.1021/bi00051a008; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; CHOW CS, 1995, BIOCHEMISTRY-US, V34, P2956, DOI 10.1021/bi00009a027; Dickerson RE, 1998, NUCLEIC ACIDS RES, V26, P1906, DOI 10.1093/nar/26.8.1906; Dunham SU, 1997, BIOCHEMISTRY-US, V36, P11428, DOI 10.1021/bi9709452; Dunham SU, 1998, J AM CHEM SOC, V120, P5395, DOI 10.1021/ja9742592; FALCIOLA L, 1994, NUCLEIC ACIDS RES, V22, P285, DOI 10.1093/nar/22.3.285; Gelasco A, 1998, BIOCHEMISTRY-US, V37, P9230, DOI 10.1021/bi973176v; HARDING JJ, 1994, REDOX REP, V1, P34, DOI 10.1080/13510002.1994.11746953; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEPRE CA, 1990, NUCLEIC ACIDS MOL BI, P9, DOI DOI 10.1007/978-3-642-84150-7_2; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Read C., 1995, NUCL ACIDS MOL BIOL, P222; Rould MA, 1997, METHOD ENZYMOL, V276, P461, DOI 10.1016/S0076-6879(97)76072-5; SHERMAN SE, 1988, J AM CHEM SOC, V110, P7368, DOI 10.1021/ja00230a017; Takahara PM, 1996, J AM CHEM SOC, V118, P12309, DOI 10.1021/ja9625079; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Weiss MA, 1997, J BIOMOL STRUCT DYN, V15, P177, DOI 10.1080/07391102.1997.10508185; WEMER MH, 1995, CELL, V81, P705; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054; Yoshioka K, 1999, BIOCHEMISTRY-US, V38, P589, DOI 10.1021/bi981834l; ZAMBLE DB, 1995, TRENDS BIOCHEM SCI, V20, P435, DOI 10.1016/S0968-0004(00)89095-7; Zhai XQ, 1998, BIOCHEMISTRY-US, V37, P16307, DOI 10.1021/bi981708h; Zlatanova J, 1998, FASEB J, V12, P791, DOI 10.1096/fasebj.12.10.791	30	505	515	1	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					708	712		10.1038/21460	http://dx.doi.org/10.1038/21460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385126				2022-12-24	WOS:000080932800066
J	Miotti, PG; Taha, TET; Kumwenda, NI; Broadhead, R; Mtimavalye, LAR; Van der Hoeven, L; Chiphangwi, JD; Liomba, G; Biggar, RJ				Miotti, PG; Taha, TET; Kumwenda, NI; Broadhead, R; Mtimavalye, LAR; Van der Hoeven, L; Chiphangwi, JD; Liomba, G; Biggar, RJ			HIV transmission through breastfeeding - A study in Malawi	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TO-CHILD TRANSMISSION; BREAST-MILK; POSTNATAL TRANSMISSION; HIV-1-INFECTED WOMEN; P24 ANTIGEN; MOTHER; TYPE-1; INFECTION; COHORT	Context Understanding the risk of human immunodeficiency virus (HIV) transmission through breastfeeding is essential for advising HIV-infected mothers and formulating public health policy recommendations. Objective To measure the frequency, timing, and risk factors of HIV transmission through breast milk. Design Prospective cohort study conducted between 1994 and 1997, with follow-up of infants through 24 months of age. Setting Postnatal clinic of tertiary care hospital, Blantyre, Malawi. Participants A total of 672 infants (HIV-negative at birth) born to HIV-infected women who had not received antiretroviral drugs during or after pregnancy. Main Outcome Measure Incidence of HIV in breastfed infants by age and maternal and infant risk factors for HIV transmission, using proportional hazard models to derive risk ratios (RRs) and 95% confidence intervals (Cls). Results Forty-seven children became HIV-infected while breastfeeding but none after breastfeeding had stopped. The cumulative infection rate while breastfeeding, from month 1 to the end of months 5, 11, 17, and 23, was 3.5%, 7.0%, 8.9%, and 10.3 %, respectively. Incidence per month was 0.7% during age 1 to 5 months, 0.6% during age 6 to 11 months, and 0.3% during age 12 to 17 months (P = .01 for trend). The only factors significantly associated with low risk of postnatal HIV transmission in a multivariate model were high maternal parity (RR, 0.23; 95% CI, 0.09-0.56) and older maternal age (RR, 0.44; 95% CI, 0.23-0.84), Conclusions Our data suggest that the risk of HIV infection is highest in the early months of breastfeeding, which should be considered in formulating breastfeeding policy recommendations.	Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Malawi Coll Med, Blantyre, Malawi; NCI, NIH, Bethesda, MD USA	Johns Hopkins University; University of Malawi; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Miotti, PG (corresponding author), NIAID, Div Aids, NIH, Room 4109,6700 B Rockledge Dr,MSC 7626, Bethesda, MD 20892 USA.	pm122m@nih.gov	Kumwenda, Newton/ADL-6890-2022	Kumwenda, Newton/0000-0003-2622-4339; Taha, Taha/0000-0001-9814-4894	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI035173, Z01AI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [N01-AI-35173-117] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bertolli J, 1996, J INFECT DIS, V174, P722, DOI 10.1093/infdis/174.4.722; Biggar RJ, 1997, J ACQ IMMUN DEF SYND, V14, P368, DOI 10.1097/00042560-199704010-00010; Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Biggar RJ, 1997, AIDS, V11, P1375, DOI 10.1097/00002030-199711000-00012; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; BULTERYS M, 1995, AIDS, V9, P93; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DATTA P, 1994, J INFECT DIS, V170, P1134, DOI 10.1093/infdis/170.5.1134; DUNN DT, 1995, AIDS, V9, pF7, DOI 10.1097/00002030-199509000-00001; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Ekpini ER, 1997, LANCET, V349, P1054, DOI 10.1016/S0140-6736(96)06444-6; Guay LA, 1996, PEDIATRICS, V98, P438; John GC, 1996, EPIDEMIOL REV, V18, P149, DOI 10.1093/oxfordjournals.epirev.a017922; Kuhn L, 1997, AM J PUBLIC HEALTH, V87, P926, DOI 10.2105/AJPH.87.6.926; LAWRENCE R, 1994, BREASTFEEDING GUIDE, P28; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; Lewis P, 1998, J INFECT DIS, V177, P34, DOI 10.1086/513816; NAGELKERKE NJD, 1995, J ACQ IMMUN DEF SYND, V8, P176; NDUATI RW, 1995, J INFECT DIS, V172, P1461, DOI 10.1093/infdis/172.6.1461; NDUATI RW, 1994, LANCET, V344, P1432, DOI 10.1016/S0140-6736(94)90596-7; NDUATI RW, 1998, 12 WORLD AIDS C JUN; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; RUFF AJ, 1994, J ACQ IMMUN DEF SYND, V7, P68; RYDER RW, 1991, AIDS, V5, P709, DOI 10.1097/00002030-199106000-00010; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Southern S O, 1998, J Hum Virol, V1, P328; Tess BH, 1998, AIDS, V12, P513, DOI 10.1097/00002030-199805000-00013; THOMAS DG, 1977, COMPUT BIOMED RES, V10, P373, DOI 10.1016/0010-4809(77)90006-4; *UNICEF UNAIDS WHO, 1998, HIV INF FEED IMPL GU; VANDEPERRE P, 1993, LANCET, V341, P914, DOI 10.1016/0140-6736(93)91210-D; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; VandePerre P, 1997, LANCET, V350, P221, DOI 10.1016/S0140-6736(05)62390-2	33	232	241	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					744	749		10.1001/jama.282.8.744	http://dx.doi.org/10.1001/jama.282.8.744			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463709	Bronze			2022-12-24	WOS:000082118800025
J	Sauer, FG; Futterer, K; Pinkner, JS; Dodson, KW; Hultgren, SJ; Waksman, G				Sauer, FG; Futterer, K; Pinkner, JS; Dodson, KW; Hultgren, SJ; Waksman, G			Structural basis of chaperone function and pilus biogenesis	SCIENCE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; PAPD CHAPERONE; SUBUNIT RECOGNITION; OUTER-MEMBRANE; PROTEIN; CRYSTALLOGRAPHY; ASSOCIATION; SUPERFAMILY; REFINEMENT; URINARY	Many Gram-negative pathogens assemble architecturally and functionally diverse adhesive pill on their surfaces by the chaperone-usher pathway, Immunoglobulin-like periplasmic chaperones escort pilus subunits to the usher, a large protein complex that facilitates the translocation and assembly of subunits across the outer membrane. The crystal structure of the PapD-PapK chaperone-subunit complex, determined at 2.4 angstrom resolution, reveals that the chaperone functions by donating its G(1) beta strand to complete the immunoglobulin-like fold of the subunit via a mechanism termed donor strand complementation. The structure of the PapD-PapK complex also suggests that during pilus biogenesis, every subunit completes the immunoglobulin-like fold of its neighboring subunit via a mechanism termed donor strand exchange.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, 660 S Euclid Ave, St Louis, MO 63110 USA.			Futterer, Klaus/0000-0001-7445-5372	NIAID NIH HHS [R01AI29549] Funding Source: Medline; NIDDK NIH HHS [R01DK51406] Funding Source: Medline; NIGMS NIH HHS [R01GM54033] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1996, ACTA CRYSTALLOGR D, V52, P32; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Bullitt E, 1996, P NATL ACAD SCI USA, V93, P12890, DOI 10.1073/pnas.93.23.12890; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HULL RA, 1981, INFECT IMMUN, V33, P933, DOI 10.1128/IAI.33.3.933-938.1981; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1996, ESCHERICHIA COLI SAL, P2730; Hung DL, 1996, EMBO J, V15, P3792, DOI 10.1002/j.1460-2075.1996.tb00753.x; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; Jones CH, 1997, EMBO J, V16, P6394, DOI 10.1093/emboj/16.21.6394; JONES EY, 1993, CURR OPIN STRUC BIOL, V3, P846, DOI 10.1016/0959-440X(93)90147-D; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; KUEHN MJ, 1993, SCIENCE, V262, P1234, DOI 10.1126/science.7901913; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; MCPHERSON A, 1990, EUR J BIOCHEM, V189, P23; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; Soto GE, 1998, EMBO J, V17, P6155, DOI 10.1093/emboj/17.21.6155; STRIKER R, 1995, MOL MICROBIOL, V16, P1021, DOI 10.1111/j.1365-2958.1995.tb02327.x; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; Thanassi DG, 1998, CURR OPIN MICROBIOL, V1, P223, DOI 10.1016/S1369-5274(98)80015-5; Thanassi DG, 1998, P NATL ACAD SCI USA, V95, P3146, DOI 10.1073/pnas.95.6.3146	36	326	340	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1058	1061		10.1126/science.285.5430.1058	http://dx.doi.org/10.1126/science.285.5430.1058			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446050				2022-12-24	WOS:000082033100043
J	Yu, W; Nagaoka, H; Jankovic, M; Misulovin, Z; Suh, HY; Rolink, A; Melchers, F; Meffre, E; Nussenzweig, MC				Yu, W; Nagaoka, H; Jankovic, M; Misulovin, Z; Suh, HY; Rolink, A; Melchers, F; Meffre, E; Nussenzweig, MC			Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization	NATURE			English	Article							V(D)J RECOMBINATION; TRANSGENIC MICE; BONE-MARROW; RECEPTOR; GENE; LYMPHOCYTES; TOLERANCE; ANTIBODY; MOUSE; ELIMINATION	Models of B-cell-development in the immune system suggest that only those immature B cells in the bone marrow that undergo receptor editing express V(D)J-recombination-activating genes (RAGs)(1-3). Here we investigate the regulation of RAG expression in transgenic mice carrying a bacterial artificial chromosome that encodes a green fluorescent. protein reporter instead of RAG2 (ref. 4). We find that the reporter is expressed in all immature B cells in the bone marrow and spleen. Endogenous RAG messenger RNA is expressed in immature beeps in bone marrow and spleen and decreases by two orders of magnitude as they acquire higher levels of surface immunoglobulin M (IgM). Once RAG expression is stopped it is not re-induced during immune responses. Our findings may help to reconcile a series of apparently contradictory observations, and suggest a new model for the mechanisms that regulate allelic exclusion, receptor editing and tolerance.	Rockefeller Univ, Lab Mol Immunol, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Inst Mol Genet & Genet Engn, YU-11001 Belgrade, Yugoslavia; Basel Inst Immunol, CH-4005 Basel, Switzerland	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	Nussenzweig, MC (corresponding author), Rockefeller Univ, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.	nussen@rockvax.rockfeller.edu	Nussenzweig, Michel/AAE-7292-2019					ALLMAN DM, 1992, J IMMUNOL, V149, P2533; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COLECLOUGH C, 1981, NATURE, V290, P372, DOI 10.1038/290372a0; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Han SH, 1996, SCIENCE, V274, P2094, DOI 10.1126/science.274.5295.2094; Han SH, 1997, SCIENCE, V278, P301, DOI 10.1126/science.278.5336.301; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hertz M, 1998, NATURE, V394, P292, DOI 10.1038/28419; Hikida M, 1996, SCIENCE, V274, P2092, DOI 10.1126/science.274.5295.2092; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; Meffre E, 1998, J EXP MED, V188, P765, DOI 10.1084/jem.188.4.765; Melamed D, 1998, CELL, V92, P173, DOI 10.1016/S0092-8674(00)80912-5; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Papavasiliou F, 1997, SCIENCE, V278, P298, DOI 10.1126/science.278.5336.298; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; STORB U, 1995, IMMUNOGLOBULIN GENES, P345; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859	30	318	323	0	5	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					682	687		10.1038/23287	http://dx.doi.org/10.1038/23287			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458165				2022-12-24	WOS:000082032900058
J	Kidd, FL; Isaac, JTR				Kidd, FL; Isaac, JTR			Developmental and activity-dependent regulation of kainate receptors at thalamocortical synapses	NATURE			English	Article							LONG-TERM POTENTIATION; HIPPOCAMPAL INTERNEURONS; SYNAPTIC TRANSMISSION; GLUTAMATE RECEPTORS; CRITICAL PERIOD; AMPA RECEPTORS; ACTIVATION; NEURONS; CORTEX; RECTIFICATION	Most of the fast excitatory synaptic transmission in the mammalian brain is mediated by ionotrophic glutamate receptors, of which there are three subtypes: AMPA (alpha-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate), NMDA (N-methyl-D-aspartate) and kainate. Although kainate-receptor subunits (GluR5-7, KA1 and 2) are widely expressed in the mammalian central nervous system(1,2), little is known about their function. The development of pharmacological agents that distinguish between AMPA and kainate receptors has now allowed the functions of kainate receptors to be investigated(3,4). The modulation of synaptic transmission by kainate receptors(5-7) and their synaptic activation(8-14) in a variety of brain regions have been reported. The expression of kainate receptor subunits is developmentally regulated(1,2) but their role in plasticity and development is unknown. Here we show that developing thalamocortical synapses express postsynaptic kainate receptors as well as AMPA receptors; however, the two receptor subtypes do not colocalize. During the critical period for experience-dependent plasticity, the kainate-receptor contribution to transmission decreases; a similar decrease occurs when long-term potentiation is induced in vitro. This indicates that during development there is activity-dependent regulation of the expression of kainate receptors at thalamocortical synapses.	Univ Bristol, MRC, Ctr Synapt Plast, Dept Anat, Bristol BS8 1TD, Avon, England	University of Bristol	Isaac, JTR (corresponding author), Univ Bristol, MRC, Ctr Synapt Plast, Dept Anat, Bristol BS8 1TD, Avon, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; BOWIE D, 1995, NEURON, V15, P453, DOI 10.1016/0896-6273(95)90049-7; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Chittajallu R, 1996, NATURE, V379, P78, DOI 10.1038/379078a0; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; CRAIR MC, 1995, NATURE, V375, P325, DOI 10.1038/375325a0; DeVries SH, 1999, NATURE, V397, P157, DOI 10.1038/16462; Feldman DE, 1998, NEURON, V21, P347, DOI 10.1016/S0896-6273(00)80544-9; FOX K, 1995, NEURON, V15, P485, DOI 10.1016/0896-6273(95)90136-1; Frerking M, 1998, NAT NEUROSCI, V1, P479, DOI 10.1038/2194; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Isaac JTR, 1997, NEURON, V18, P269, DOI 10.1016/S0896-6273(00)80267-6; KAMBOJ SK, 1995, J PHYSIOL-LONDON, V486, P297, DOI 10.1113/jphysiol.1995.sp020812; Kullmann DM, 1998, TRENDS NEUROSCI, V21, P8, DOI 10.1016/S0166-2236(97)01150-8; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; Li P, 1999, NATURE, V397, P161, DOI 10.1038/16469; Paternain AV, 1998, NEUROPHARMACOLOGY, V37, P1249, DOI 10.1016/S0028-3908(98)00098-7; PATERNAIN AV, 1995, NEURON, V14, P185, DOI 10.1016/0896-6273(95)90253-8; PATNEAU DK, 1990, J NEUROSCI, V10, P2385; RodriguezMoreno A, 1997, NEURON, V19, P893, DOI 10.1016/S0896-6273(00)80970-8; Rozov A, 1998, J PHYSIOL-LONDON, V511, P361, DOI 10.1111/j.1469-7793.1998.361bh.x; RUANO D, 1995, NEURON, V14, P1009, DOI 10.1016/0896-6273(95)90339-9; Toth K, 1998, NAT NEUROSCI, V1, P572, DOI 10.1038/2807; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; Washburn MS, 1997, J NEUROSCI, V17, P9393; WILDING TJ, 1995, MOL PHARMACOL, V47, P582	30	187	189	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					569	573		10.1038/23040	http://dx.doi.org/10.1038/23040			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448859				2022-12-24	WOS:000081854800057
J	Cook, PJ; Lawrence, BA; Ludwig, J; Miller, TR				Cook, PJ; Lawrence, BA; Ludwig, J; Miller, TR			The medical costs of gunshot injuries in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIREARM-RELATED INJURIES; WOUNDS; HOSPITALIZATION; CHARGES	Context The cost of treating gunshot injuries imposes a financial burden on society. Estimates of such costs are relevant to evaluation of gun violence reduction programs and may help guide reimbursement policies. Objectives To develop reliable US estimates of the medical costs of treating gunshot injuries and to present national estimates for the sources of payment for treating these injuries. Design and Setting Cost analysis using E-coded discharge data from hospitals in Maryland for 1994-1995 and New York for 1994 and from emergency departments in South Carolina for 1997, Other sources of data included the National Electronic Injury Surveillance System for 1994 incidence of nonfatal gun injuries, the National Spinal Cord Injury Statistical Center database for 1988-1992 estimates of lifetime medical costs of gun injuries, and the 1994 Vital Statistics census for incidence of fatal gun injuries. Main Outcome Measures Estimated national acute-care and follow-up treatment costs and payment sources for gunshot injuries. Results At a mean medical cost per injury of about $17 000, the 134 445 (95% confidence interval [CI], 109 465-159 425) gunshot injuries in the United States in 1994 produced $2.3 billion (95% CI, $2.1 billion-$2.5 billion) in lifetime medical costs (in 1994 dollars, using a 3% real discount rate), of which $1.1 billion (49%) was paid by US taxpayers. Gunshot injuries due to assaults accounted for 74% of total costs. Conclusions Gunshot injury costs represent a substantial burden to the medical care system. Nearly half this cost is borne by US taxpayers.	Duke Univ, Sanford Inst Publ Policy, Durham, NC 27708 USA; Natl Publ Serv Res Inst, Landoven, MD USA; Georgetown Univ, Georgetown Publ Policy Inst, Washington, DC USA	Duke University; Georgetown University	Cook, PJ (corresponding author), Duke Univ, Sanford Inst Publ Policy, Durham, NC 27708 USA.			Miller, Ted/0000-0002-0958-2639; Cook, Philip/0000-0001-5094-9052				ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; BRICK M, 1992, STAT EVALUATION COST; *BUR CENS, 1998, 1994 VIT STAT CENS D, P109; Davis Y, 1996, J SAFETY RES, V27, P83, DOI 10.1016/0022-4375(96)00002-3; DeVivo MJ, 1997, SPINAL CORD, V35, P809, DOI 10.1038/sj.sc.3100501; DISCHINGER PC, 1992, AM PUBL HLTH ASS NOV; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; KIZER KW, 1995, JAMA-J AM MED ASSOC, V273, P1768, DOI 10.1001/jama.273.22.1768; Lipscomb J., 1996, COST EFFECTIVENESS H, P214; MARTIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P3048, DOI 10.1001/jama.260.20.3048; MAX W, 1993, HLTH AFF MILLWOOD, V12, P17; Miller TR, 1997, ACCIDENT ANAL PREV, V29, P329, DOI 10.1016/S0001-4575(97)00007-9; MILLER TR, 1989, ACCIDENT ANAL PREV, V21, P303, DOI 10.1016/0001-4575(89)90022-5; MILLER TR, 1995, DATABOOK NONFATAL IN; Miller TR, 1996, TXB PENETRATING TRAU, P49; MOCK C, 1994, J TRAUMA, V36, P516, DOI 10.1097/00005373-199404000-00010; MORABITO D, 1989, REPORT CALIFORNIA DE; *NAT CTR HLTH CAR, 1992, NAT HOSP DISCH SURV; *NAT HIGHW TRANSP, 1983, EC COSTS SOC MOT VEH; Roberts RR, 1999, JAMA-J AM MED ASSOC, V281, P644, DOI 10.1001/jama.281.7.644; U. S. Bureau of the Census, 1996, STAT ABSTR US 1996; Vassar MJ, 1996, JAMA-J AM MED ASSOC, V275, P1734, DOI 10.1001/jama.275.22.1734; WEBSTER DW, 1992, ARCH SURG-CHICAGO, V127, P694; WEISSMAN JS, 1992, HEALTH AFFAIR, V11, P148, DOI 10.1377/hlthaff.11.2.148; WINTEMUTE GJ, 1992, J TRAUMA, V33, P556, DOI 10.1097/00005373-199210000-00011; [No title captured]	26	104	104	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					447	454		10.1001/jama.282.5.447	http://dx.doi.org/10.1001/jama.282.5.447			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442660	Bronze			2022-12-24	WOS:000081784900021
J	Watanabe, Y; Nurse, P				Watanabe, Y; Nurse, P			Cohesin Rec8 is required for reductional chromosome segregation at meiosis	NATURE			English	Article							SISTER-CHROMATID COHESION; YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; ANAPHASE TRANSITION; GENE; RECOMBINATION; CENTROMERES; METAPHASE; NUCLEAR; RAD21	When cells exit from mitotic cell division, their sister chromatids lose cohesion and separate to opposite poles of the dividing cell, resulting in equational chromosome segregation. In contrast, the reductional segregation of the first stage of meiotic cell division (meiosis I) requires that sister chromatids remain associated through their centromeres and move together to the same pole. Centromeric cohesion is lost as cells exit from meiosis II and sister chromatids can then separate(1-4). The fission yeast cohesin protein Reed is specific to and required for meiosis(5-8). Here we show that Rec8 appears in the centromeres and adjacent chromosome arms during the pre-meiotic S phase. Centromeric Red persists throughout meiosis I and disappears at anaphase of meiosis II. When the rec8 gene is deleted, sister chromatids separate at meiosis I, resulting in equational rather than reductional chromosome segregation. We propose that the persistence of Rec8 at centromeres during meiosis I maintains sister-chromatid cohesion, and that its presence in the centromere-adjacent regions orients the kinetochores so that sister chromatids move to the same pole. This results in the reductional pattern of chromosome segregation necessary to reduce a diploid zygote to haploid gametes.	Imperial Canc Res Fund, Cell Cycle Lab, London WC2A 3PX, England	Cancer Research UK	Watanabe, Y (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Tokyo 113, Japan.	ywatanab@ims.u-tokyo.ac.jp		Watanabe, Yoshinori/0000-0002-5488-4812				Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; Bickel SE, 1996, BIOESSAYS, V18, P293, DOI 10.1002/bies.950180407; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; KISHIDA M, 1994, CURR GENET, V25, P497, DOI 10.1007/BF00351668; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Nabeshima K, 1998, MOL BIOL CELL, V9, P3211, DOI 10.1091/mbc.9.11.3211; NAKASEKO Y, 1984, J BACTERIOL, V157, P334, DOI 10.1128/JB.157.1.334-336.1984; Nomura N, 1994, DNA Res, V1, P223, DOI 10.1093/dnares/1.5.223; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4	29	419	435	3	43	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					461	464		10.1038/22774	http://dx.doi.org/10.1038/22774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440376				2022-12-24	WOS:000081715000053
J	Bhopal, R; Unwin, N; White, M; Yallop, J; Walker, L; Alberti, KGMM; Harland, J; Patel, S; Ahmad, N; Turner, C; Watson, B; Kaur, D; Kulkarni, A; Laker, M; Tavridou, A				Bhopal, R; Unwin, N; White, M; Yallop, J; Walker, L; Alberti, KGMM; Harland, J; Patel, S; Ahmad, N; Turner, C; Watson, B; Kaur, D; Kulkarni, A; Laker, M; Tavridou, A			Heterogeneity of coronary heart disease risk factors in Indian, Pakistani, Bangladeshi, and European origin populations: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK; MYOCARDIAL-INFARCTION; INSULIN RESISTANCE; ARTERY DISEASE; SOUTH ASIANS; PREVALENCE; BRADFORD; GLUCOSE; OBESITY; CHINESE	Objective To compare coronary risk factors and disease prevalence among Indians, Pakistanis, and Bangladeshis, and in all South Asians (these three groups together) with Europeans. Design Cross sectional survey. Setting Newcastle upon Tyne. Participants 259 Indian, 305 Pakistani, 120 Bangladeshi, and 825 European men and women aged 25-74 years. Main outcome measures Social and economic circumstances, lifestyle, self reported symptoms and diseases, blood pressure, electrocardiogram, and anthropometric, haematological, and biochemical measurements. Results There were differences in social and economic circumstances, lifestyles, anthropometric measures and disease both bet tween Indians, Pakistanis, and Bangladeshis and between all South Asians and Europeans. Bangladeshis and Pakistanis were the poorest groups. For most risk factors, the Bangladeshis (particularly men) fared the worst: smoking was most common (57%) in that group, and Bangladeshis had the highest concentrations of triglycerides (2.04 mmol/l) and fasting blood glucose (6.6 mmol/l) and the lowest concentration of high density lipoprotein cholesterol (0.97 mmol/l). Blood pressure, however, was lowest in Bangladeshis. Bangladeshis were the shortest(men 164 cm tall v 170 cm for Indians and 174 cm for Europeans). A higher proportion of Pakistani and Bangladeshi men had diabetes (22.4% and 26.6% respectively) than Indians (15.2%). Comparisons of all South Asians with Europeans hid some important differences, but South Asians were still disadvantaged in a wide range of risk factors. Findings in women were similar. Conclusion Risk of coronary heart disease is not uniform among South Asians, and there are important differences between Indians, Pakistanis, and Bangladeshis for many coronary risk factors. The belief that, except for insulin resistance, South Asians have lo lower levels of coronary risk factors than Europeans is incorrect, and may have arisen fi om combining ethnic subgroups and examining a narrow range of factors.	Univ Newcastle Upon Tyne, Sch Med, Div Epidemiol & Publ Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Royal Victoria Infirm, Dept Med, Wellcome Labs, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Royal Victoria Infirm, Dept Epidemiol & Publ Hlth, Wellcome Labs, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Sch Med, Dept Clin Biochem, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK; Newcastle University - UK	Bhopal, R (corresponding author), Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland.		White, Martin J. R./G-2410-2010	Unwin, Nigel/0000-0002-1368-1648; Patel, Sheila/0000-0002-0626-1899	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acheson D., 1998, INDEPENDENT INQUIRY; [Anonymous], 1992, STAT PACK SOC SCI SP; ARMITAGE P, 1994, STAT METHODS MED RES, P436; Balarajan R, 1996, HLTH TRENDS, V28, P45; Barker D. J. P., 1994, MOTHERS BABIES DIS L; *BEDF SCI, 1993, OPER MAN MIN MICR SM; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; Bhopal R, 1996, BRIT MED J, V312, P375; BHOPAL RS, 1991, J PUBLIC HEALTH MED, V13, P244; BURRIN JM, 1985, ANN CLIN BIOCHEM, V22, P327, DOI 10.1177/000456328502200401; Church J., 1996, SOCIAL FOCUS ETHNIC; COLDMAN AJ, 1988, J EPIDEMIOL COMMUN H, V42, P390, DOI 10.1136/jech.42.4.390; Coleman D, 1996, DEMOGRAPHIC CHARACTE; ENAS EA, 1992, AM J CARDIOL, V70, P945, DOI 10.1016/0002-9149(92)90744-J; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; FOWLER PBS, 1985, LANCET, V2, P1363; GUPTA S, 1995, BRIT MED J, V311, P1035, DOI 10.1136/bmj.311.7012.1035; Harland JO, 1997, J EPIDEMIOL COMMUN H, V51, P636, DOI 10.1136/jech.51.6.636; HARRINGTON B, 1993, NEWCASTLE HLTH LIFES; HUGHES LO, 1989, BRIT MED J, V299, P537, DOI 10.1136/bmj.299.6698.537; JACOBSON MS, 1987, LANCET, V2, P656, DOI 10.1016/S0140-6736(87)92443-3; KARN V, 1996, EMPLOYMENT ED HOUSIN; KNIGHT T, 1993, J EPIDEMIOL COMMUN H, V47, P89, DOI 10.1136/jech.47.2.89; KNIGHT TM, 1992, BRIT HEART J, V67, P343; MARMOT MG, 1984, STUDIES MED POPULATI; MCKEIGUE P, 1994, CORONARY HEART DIS S; MCKEIGUE PM, 1988, BRIT MED J, V297, P903, DOI 10.1136/bmj.297.6653.903; MCKEIGUE PM, 1989, J CLIN EPIDEMIOL, V42, P597, DOI 10.1016/0895-4356(89)90002-4; MCKEIGUE PM, 1991, LANCET, V337, P382, DOI 10.1016/0140-6736(91)91164-P; MCKEIGUE PM, 1985, LANCET, V2, P1086; Mendall MA, 1998, BRIT MED J, V316, P953, DOI 10.1136/bmj.316.7136.953; Modood T., 1997, ETHNIC MINORITIES BR; NATH BS, 1988, LANCET, V2, P39, DOI 10.1016/S0140-6736(88)92962-5; NAZROO JY, 1997, HLTH BRITAINS ETHNIC; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PEACH C, 1996, ETHNIC MINORITY POPU; PETRIE JC, 1990, RECOMMENDATIONS BLOO; Prineas R., 1982, MINNESOTA CODE MANUA; RAMAIYA KL, 1991, BRIT MED J, V303, P271, DOI 10.1136/bmj.303.6797.271; RATCLIFE P, 1996, SOCIAL GEOGRAPHY ETH; Rose G, 1982, CARDIOVASCULAR SURVE; Rudat K., 1994, BLACK MINORITY ETHNI; SHAUKAT N, 1994, POSTGRAD MED J, V70, P315, DOI 10.1136/pgmj.70.823.315; SHAUNAK S, 1986, BRIT MED J, V293, P1169, DOI 10.1136/bmj.293.6555.1169; Unwin N, 1997, J EPIDEMIOL COMMUN H, V51, P160, DOI 10.1136/jech.51.2.160; *WHO MONICA PROJ, 1988, WORLD HLTH STAT Q, V41, P115; WILLIAMS R, 1993, J EPIDEMIOL COMMUN H, V47, P96, DOI 10.1136/jech.47.2.96; WILLIAMS R, 1994, INT J EPIDEMIOL, V23, P28, DOI 10.1093/ije/23.1.28	48	408	409	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					215	+		10.1136/bmj.319.7204.215	http://dx.doi.org/10.1136/bmj.319.7204.215			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417082	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000081720300021
J	Bader, M; Muse, W; Ballou, DP; Gassner, C; Bardwell, JCA				Bader, M; Muse, W; Ballou, DP; Gassner, C; Bardwell, JCA			Oxidative protein folding is driven by the electron transport system	CELL			English	Article							DISULFIDE BOND FORMATION; AEROBIC RESPIRATORY-CHAIN; BD TERMINAL OXIDASE; ESCHERICHIA-COLI; FORMATION INVIVO; IN-VIVO; ENDOPLASMIC-RETICULUM; DSBA; PURIFICATION; PATHWAY	Disulfide bond formation is catalyzed in vivo by DsbA and DsbB. Here we reconstitute this oxidative folding system using purified components. We have found the sources of oxidative power for protein folding and show how disulfide bond formation is linked to cellular metabolism. We find that disulfide bond formation and the electron transport chain are directly coupled. DsbB uses quinones as electron accepters, allowing various choices for electron transport to support disulfide bond formation. Electrons flow via cytochrome bo oxidase to oxygen under aerobic conditions or via cytochrome bd oxidase under partially anaerobic conditions. Under truly anaerobic conditions, menaquinone shuttles electrons to alternate final electron accepters such as fumarate. This flexibility reflects the vital nature of the disulfide catalytic system.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Bardwell, JCA (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.	jbardwel@umich.edu	dballou@umich.edu, David P/A-1298-2007					Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Bader M, 1999, NAT CELL BIOL, V1, pE57, DOI 10.1038/11025; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BARDWELL JCA, 1994, MOL MICROBIOL, V14, P199, DOI 10.1111/j.1365-2958.1994.tb01281.x; BELIN P, 1994, MOL GEN GENET, V242, P23, DOI 10.1007/BF00277344; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; BULL C, 1981, J BIOL CHEM, V256, P2673; COTTER PA, 1990, J BACTERIOL, V172, P6333, DOI 10.1128/jb.172.11.6333-6338.1990; Cuozzo JW, 1999, NAT CELL BIOL, V1, P130, DOI 10.1038/11047; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Gilbert HF, 1997, J BIOL CHEM, V272, P29399, DOI 10.1074/jbc.272.47.29399; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; Hennecke J, 1997, J BIOL CHEM, V272, P189; JANDER G, 1994, EMBO J, V13, P5121, DOI 10.1002/j.1460-2075.1994.tb06841.x; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Junemann S, 1997, BBA-BIOENERGETICS, V1321, P107, DOI 10.1016/S0005-2728(97)00046-7; JUNEMANN S, 1995, BIOCHEMISTRY-US, V34, P14861; KAYSSER TM, 1995, BIOCHEMISTRY-US, V34, P13491, DOI 10.1021/bi00041a029; KITA K, 1984, J BIOL CHEM, V259, P3368; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; MILLER MJ, 1983, J BIOL CHEM, V258, P9159; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; Rumbley JN, 1997, BBA-PROTEIN STRUCT M, V1340, P131, DOI 10.1016/S0167-4838(97)00036-8; Tseng CP, 1996, J BACTERIOL, V178, P1094, DOI 10.1128/jb.178.4.1094-1098.1996; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P84, DOI 10.1016/0005-2728(77)90071-8; WUNDERLICH M, 1993, PROTEIN SCI, V2, P717, DOI 10.1002/pro.5560020503; ZAPUN A, 1993, BIOCHEMISTRY-US, V32, P5083, DOI 10.1021/bi00070a016; Zeng H, 1998, J BACTERIOL, V180, P3681, DOI 10.1128/JB.180.14.3681-3685.1998	34	308	321	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					217	227		10.1016/S0092-8674(00)81016-8	http://dx.doi.org/10.1016/S0092-8674(00)81016-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428033	Bronze			2022-12-24	WOS:000081632300011
J	Higgins, LM; Frankel, G; Connerton, I; Goncalves, NS; Dougan, G; MacDonald, TT				Higgins, LM; Frankel, G; Connerton, I; Goncalves, NS; Dougan, G; MacDonald, TT			Role of bacterial intimin in colonic hyperplasia and inflammation	SCIENCE			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; CELL-BINDING DOMAIN; EPITHELIAL-CELLS; T-CELLS; MICE; PROTEIN; RESPONSES; SIGNALS; DISEASE; GENE	Enteropathogenic Escherichia coli (EPEC) cells adhere to gut epithelial cells through intimin alpha: the ligand for a bacterially derived epithelial transmembrane protein called the translocated intimin receptor, Citrobacter rodentium colonizes the mouse colon in a similar fashion and uses a different intimin: intimin beta. Intimin alpha was found to costimulate submitogenic signals through the T cell receptor. Dead intimin beta(+) C. rodentium, intimin a-transfected C. rodentium or E. coli strain K12, and EPEC induced mucosal hyperplasia identical to that caused by C. rodentium live infection, as well as a massive T helper cell-type 1 immune response in the colonic mucosa, Mutation of cysteine-937 of intimin to alanine reduced costimulatory activity in vitro and prevented immunopathology in vivo. The mucosal changes elicited by C. rodentium were interferon-gamma-dependent. Immunopathology induced by intimin enables the bacteria to promote conditions that are favorable for increased microbial colonization.	St Bartholomews & Royal London Sch Med & Dent, Dept Paediat Gastroenterol, London EC1A 7BE, England; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England; Univ Nottingham, Sch Biol Sci, Div Food Sci, Loughborough LE12 5RD, Leics, England	University of London; Queen Mary University London; Imperial College London; University of Nottingham	Higgins, LM (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Paediat Gastroenterol, London EC1A 7BE, England.			Connerton, Ian/0000-0001-8652-8938; Higgins, Lisa/0000-0003-2672-1490	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADUROBIE J, 1998, J CLIN MICROBIOL, V36, P662; Bajaj-Elliott M, 1998, J CLIN INVEST, V102, P1473, DOI 10.1172/JCI2792; Brandtzaeg P, 1998, CHEM IMMUNOL, V71, P1; DONNENBERG MS, 1993, J BACTERIOL, V175, P4670, DOI 10.1128/JB.175.15.4670-4680.1993; Ebert EC, 1996, CELL IMMUNOL, V167, P108, DOI 10.1006/cimm.1996.0013; Eckmann L, 1996, J IMMUNOL, V156, P2894; Frankel G, 1996, J BIOL CHEM, V271, P20359, DOI 10.1074/jbc.271.34.20359; FRANKEL G, 1995, INFECT IMMUN, V63, P4323, DOI 10.1128/IAI.63.11.4323-4328.1995; Frankel G, 1998, MOL MICROBIOL, V30, P911, DOI 10.1046/j.1365-2958.1998.01144.x; FRANKEL G, 1994, INFECT IMMUN, V62, P1835, DOI 10.1128/IAI.62.5.1835-1842.1994; Hartland EL, 1999, MOL MICROBIOL, V32, P151, DOI 10.1046/j.1365-2958.1999.01338.x; Higgins LM, 1999, INFECT IMMUN, V67, P3031, DOI 10.1128/IAI.67.6.3031-3039.1999; HIGGINS LM, UNPUB; Hobbie S, 1997, J IMMUNOL, V159, P5550; Kelly G, 1999, NAT STRUCT BIOL, V6, P313; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kenny B, 1996, MOL MICROBIOL, V20, P313, DOI 10.1111/j.1365-2958.1996.tb02619.x; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lai LC, 1997, INFECT IMMUN, V65, P2211, DOI 10.1128/IAI.65.6.2211-2217.1997; Leach MW, 1996, AM J PATHOL, V148, P1503; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Schesser K, 1998, MOL MICROBIOL, V28, P1067, DOI 10.1046/j.1365-2958.1998.00851.x; SPITZ J, 1995, AM J PHYSIOL-GASTR L, V268, pG374, DOI 10.1152/ajpgi.1995.268.2.G374	24	120	120	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					588	591		10.1126/science.285.5427.588	http://dx.doi.org/10.1126/science.285.5427.588			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417389				2022-12-24	WOS:000081609500039
J	Lee, J; Ishihara, A; Oxford, G; Johnson, B; Jacobson, K				Lee, J; Ishihara, A; Oxford, G; Johnson, B; Jacobson, K			Regulation of cell movement is mediated by stretch-activated calcium channels	NATURE			English	Article							KERATOCYTES; LOCOMOTION; TRANSLOCATION; MICROFILAMENT; MECHANISM; ADHESIONS; MIGRATION; DYNAMICS; TENSION; RELEASE	Intracellular calcium regulates many of the molecular processes that are essential for cell movement(1). It is required for the production of actomyosin-based contractile forces(2-4) the regulation of the structure and dynamics of the actin cytoskeleton(5,6), and the formation and disassembly of cell-substratum adhesions(7,8). Calcium also serves as a second messenger in many biochemical signal-transduction pathways(7). However, despite the pivotal role of calcium in motile processes; it is not clear how calcium regulates overall cell movement. Here we show that transient increases in intracellular calcium, [Ca2+](i), during the locomotion of fish epithelial keratocytes, occur more frequently in cells that become temporarily 'stuck' to the substratum or when subjected to mechanical stretching. We find that calcium transients arise from the activation of stretch-activated calcium channels, which triggers an influx of extracellular calcium. In addition, the subsequent increase in [Ca2+](i) is involved in detachment of the rear cell margin. Thus, we have defined a mechanism by which cells can detect and transduce mechanical forces into biochemical signals that can modulate locomotion.	Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Mol & Cell Physiol, Chapel Hill, NC 27599 USA; Univ Connecticut, Dept Physiol & Neurobiol, Storrs, CT 06269 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Connecticut	Lee, J (corresponding author), Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA.							Anderson KI, 1996, J CELL BIOL, V134, P1209, DOI 10.1083/jcb.134.5.1209; BRUNDAGE RA, 1991, SCIENCE, V254, P703, DOI 10.1126/science.1948048; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; GALBRAITH CG, 1997, MOL BIOL CELL S, V8, P385; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; HAMILL OP, 1992, P NATL ACAD SCI USA, V89, P7462, DOI 10.1073/pnas.89.16.7462; HARTWIG JH, 1988, CELL MOTIL CYTOSKEL, V10, P117, DOI 10.1002/cm.970100116; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; Ishihara A, 1997, BIOTECHNIQUES, V23, P268, DOI 10.2144/97232st01; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; Lee J, 1997, J CELL SCI, V110, P2833; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; Palecek SP, 1998, J CELL SCI, V111, P929; Pommerenke H, 1996, EUR J CELL BIOL, V70, P157; REES DA, 1989, CELL MOTIL CYTOSKEL, V13, P112, DOI 10.1002/cm.970130206; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SACKIN H, 1996, MOL BIOL MEMBRANE TR, P201; Sjaastad MD, 1997, BIOESSAYS, V19, P47, DOI 10.1002/bies.950190109; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; STROHMEIER R, 1984, EXP CELL RES, V154, P412, DOI 10.1016/0014-4827(84)90165-4; Svitkina TM, 1997, J CELL BIOL, V139, P397, DOI 10.1083/jcb.139.2.397; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0	30	305	318	1	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					382	386		10.1038/22578	http://dx.doi.org/10.1038/22578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432119				2022-12-24	WOS:000081590000055
J	Otto, CM; Lind, BK; Kitzman, DW; Gersh, BJ; Siscovick, DS				Otto, CM; Lind, BK; Kitzman, DW; Gersh, BJ; Siscovick, DS		Cardiovascular Hlth Study	Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NORMAL CORONARY-ARTERIES; DOPPLER-ECHOCARDIOGRAPHY; NATURAL-HISTORY; ANGINA-PECTORIS; EARLY LESION; STENOSIS; PROGRESSION; ADULTS; DISEASE; EXPRESSION	Background Although aortic-valve stenosis is clearly associated with adverse cardiovascular outcomes, it is unclear whether valve sclerosis increases the risk of cardiovascular events. Methods We assessed echocardiograms obtained at base line from 5621 men and women 65 years of age or older who were enrolled in a population-based prospective study, On echocardiography, the aortic valve was normal in 70 percent (3919 subjects), sclerotic without outflow obstruction in 29 percent (1610), and stenotic in 2 percent (92), The subjects were followed for a mean of 5.0 years to assess the risk of death from any cause and of death from cardiovascular causes. Cardiovascular morbidity was defined as new episodes of myocardial infarction, angina pectoris, congestive heart failure, or stroke. Results There was a stepwise increase in deaths from any cause (P for trend, <0.001) and deaths from cardiovascular causes (P for trend, <0.001) with increasing aortic-valve abnormality; the respective rates were 14.9 and 6.1 percent in the group with normal aortic valves, 21.9 and 10.1 percent in the group with aortic sclerosis, and 41.3 and 19.6 percent in the group with aortic stenosis, The relative risk of death from cardiovascular causes among subjects without coronary heart disease at base line was 1.66 (95 percent confidence interval, 1.23 to 2.23) for those with sclerotic valves as compared with those with normal valves, after adjustment for age and sex. The relative risk remained elevated after further adjustment for clinical factors associated with sclerosis (relative risk, 1.52; 95 percent confidence interval, 1.12 to 2.05), The relative risk of myocardial infarction was 1.40 (95 percent confidence interval, 1.07 to 1.83) among subjects with aortic sclerosis, as compared with those with normal aortic valves. Conclusions Aortic sclerosis is common in the elderly and is associated with an increase of approximately 50 percent in the risk of death from cardiovascular causes and the risk of myocardial infarction, even in the absence of hemodynamically significant obstruction of left ventricular outflow. (N Engl J Med 1999;341:142-7) (C) 1999, Massachusetts Medical Society.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA; Wake Forest Univ, Sch Med, Div Cardiol, Winston Salem, NC USA; Mayo Clin, Div Cardiol, Rochester, MN USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Wake Forest University; Mayo Clinic	Otto, CM (corresponding author), Univ Washington, Div Cardiol, Box 356422, Seattle, WA 98195 USA.			Otto, Catherine/0000-0002-0527-9392	NHLBI NIH HHS [N01-HC85081, N01-HC85079, N01-HC85080] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085080, N01HC085079, N01HC085081] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARONOW WS, 1987, AM J CARDIOL, V59, P998, DOI 10.1016/0002-9149(87)91144-1; Boon A, 1997, HEART, V78, P472, DOI 10.1136/hrt.78.5.472; BRENER SJ, 1995, J AM COLL CARDIOL, V25, P305, DOI 10.1016/0735-1097(94)00406-G; CHIZNER MA, 1980, AM HEART J, V99, P419, DOI 10.1016/0002-8703(80)90375-0; DEUTSCHER S, 1984, J CHRON DIS, V37, P407, DOI 10.1016/0021-9681(84)90108-5; FAGGIANO P, 1992, AM J CARDIOL, V70, P229, DOI 10.1016/0002-9149(92)91280-H; FRANK S, 1973, BRIT HEART J, V35, P41; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Gardin J M, 1992, J Am Soc Echocardiogr, V5, P63; GARDIN JM, 1992, J AM SOC ECHOCARDIOG, V5, P550; GEORGESON S, 1990, J AM COLL CARDIOL, V15, P751, DOI 10.1016/0735-1097(90)90271-P; GOTOH T, 1995, AM J CARDIOL, V76, P928, DOI 10.1016/S0002-9149(99)80263-X; HOAGLAND PM, 1985, AM J CARDIOL, V55, P744, DOI 10.1016/0002-9149(85)90149-3; HORSTKOTTE D, 1988, EUR HEART J, V9, P57, DOI 10.1093/eurheartj/9.suppl_E.57; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; Julius BK, 1997, CIRCULATION, V95, P892; Kaufmann P, 1996, J AM COLL CARDIOL, V28, P745, DOI 10.1016/0735-1097(96)00194-5; LINDROOS M, 1993, J AM COLL CARDIOL, V21, P1220, DOI 10.1016/0735-1097(93)90249-Z; MARCUS ML, 1982, NEW ENGL J MED, V307, P1362, DOI 10.1056/NEJM198211253072202; MOHLER ER, 1991, CLIN CARDIOL, V14, P995, DOI 10.1002/clc.4960141210; NADELL R, 1983, J AM COLL CARDIOL, V2, P258, DOI 10.1016/S0735-1097(83)80161-2; OBRIEN KD, 1995, CIRCULATION, V92, P2163, DOI 10.1161/01.CIR.92.8.2163; OBrien KD, 1996, ARTERIOSCL THROM VAS, V16, P523, DOI 10.1161/01.ATV.16.4.523; OKEEFE JH, 1987, MAYO CLIN PROC, V62, P986, DOI 10.1016/S0025-6196(12)65068-X; OLSSON M, 1994, J AM COLL CARDIOL, V23, P1162, DOI 10.1016/0735-1097(94)90606-8; OLSSON M, 1994, J AM COLL CARDIOL, V24, P1664, DOI 10.1016/0735-1097(94)90172-4; Omran H, 1996, HEART, V75, P377, DOI 10.1136/hrt.75.4.377; OTTO CM, 1994, CIRCULATION, V90, P844, DOI 10.1161/01.CIR.90.2.844; Otto CM, 1997, CIRCULATION, V95, P2262, DOI 10.1161/01.CIR.95.9.2262; OTTO CM, 1989, J AM COLL CARDIOL, V13, P545, DOI 10.1016/0735-1097(89)90590-1; PETER M, 1993, CHEST, V103, P1715, DOI 10.1378/chest.103.6.1715; PETROPOULAKIS PN, 1995, CIRCULATION, V92, P1437, DOI 10.1161/01.CIR.92.6.1437; ROGER VL, 1990, AM HEART J, V119, P331, DOI 10.1016/S0002-8703(05)80024-9; Stewart BF, 1997, J AM COLL CARDIOL, V29, P630, DOI 10.1016/S0735-1097(96)00563-3; TEERLINK JR, 1997, CIRCULATION S1, V96, P82; TURINA J, 1987, EUR HEART J, V8, P471, DOI 10.1093/oxfordjournals.eurheartj.a062307	36	916	960	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					142	147		10.1056/NEJM199907153410302	http://dx.doi.org/10.1056/NEJM199907153410302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403851				2022-12-24	WOS:000081413800002
J	Geisler, WS				Geisler, WS			Motion streaks provide a spatial code for motion direction	NATURE			English	Article							VISUAL AREA MT; HUMAN-VISION; ORIENTATION; SELECTIVITY; PATTERNS; NEURONS; MACAQUE; CORTEX; MODEL	Although many neurons in the primary visual cortex (V1) of primates are direction selective(1), they provide ambiguous information about the direction of motion of a stimulus(2,3), There is evidence that one of the ways in which the visual system resolves this ambiguity is by computing, from the responses of V1 neurons, velocity components in two or more spatial orientations and then combining these velocity components(2-9). Here I consider another potential neural mechanism for determining motion direction. When a localized image feature moves fast enough, it should become smeared in space owing to temporal integration in the visual system, creating a spatial signal-a 'motion streak'-oriented in the direction of the motion. The orientation masking and adaptation experiments reported here show that these spatial signals for motion direction exist in the human visual system for feature speeds above about 1 feature width per 100 ms. Computer simulations show that this psychophysical finding is consistent with the known response properties of V1 neurons, and that these spatial signals, when appropriately processed, are sufficient to determine motion direction in natural images.	Univ Texas, Dept Psychol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Geisler, WS (corresponding author), Univ Texas, Dept Psychol, Austin, TX 78712 USA.			Geisler, Wilson/0000-0003-4630-6614				ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; ADELSON EH, 1982, NATURE, V300, P523, DOI 10.1038/300523a0; ALBRIGHT TD, 1984, J NEUROPHYSIOL, V52, P1106, DOI 10.1152/jn.1984.52.6.1106; ANDERSON CH, 1990, NATURE, V343, P419, DOI 10.1038/343419b0; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; Burr DC, 1997, P ROY SOC B-BIOL SCI, V264, P431, DOI 10.1098/rspb.1997.0061; DERRINGTON A, 1991, VISION RES, V31, P139, DOI 10.1016/0042-6989(91)90081-F; DEVALOIS RL, 1982, VISION RES, V22, P531, DOI 10.1016/0042-6989(82)90112-2; Geisler WS, 1997, VISUAL NEUROSCI, V14, P897, DOI 10.1017/S0952523800011627; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; MARR D, 1981, PROC R SOC SER B-BIO, V211, P151, DOI 10.1098/rspb.1981.0001; MORGAN MJ, 1989, NATURE, V340, P385, DOI 10.1038/340385a0; RAMACHAN.VS, 1974, PERCEPTION, V3, P97, DOI 10.1068/p030097; Simoncelli EP, 1998, VISION RES, V38, P743, DOI 10.1016/S0042-6989(97)00183-1; Smith A. T., 1994, VISUAL DETECTION MOT; STONE LS, 1990, VISION RES, V30, P1049, DOI 10.1016/0042-6989(90)90114-Z; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322	17	243	245	1	22	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					65	69		10.1038/21886	http://dx.doi.org/10.1038/21886			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403249				2022-12-24	WOS:000081255700051
J	Weber, TK; Chin, HM; Rodriguez-Bigas, M; Keitz, B; Gilligan, R; O'Malley, L; Urf, E; Diba, N; Pazik, J; Petrelli, NJ				Weber, TK; Chin, HM; Rodriguez-Bigas, M; Keitz, B; Gilligan, R; O'Malley, L; Urf, E; Diba, N; Pazik, J; Petrelli, NJ			Novel hMLH1 and hMSH2 germline mutations in African Americans with colorectal cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONPOLYPOSIS COLON-CANCER; DNA MISMATCH REPAIR; MLH1 MUTATIONS; HNPCC FAMILIES; SSCP ANALYSIS; HEREDITARY; GENE; SURVIVAL; HOMOLOG; LOCUS	Context Germline mutations of the DNA mismatch repair(MMR) genes hMLH1 and hMSH2 have been shown to cosegregate with the colorectal cancer phenotype in multiple hereditary non polyposis colorectal cancer (HNPCC) pedigrees. However, the frequency of these mutations among African American patients with colorectal cancer is unknown. Objective To investigate the frequency of germline alterations of the DNA MMR genes hMLH1 and hMSH2 among African Americans affected by HNPCC and early-age onset colorectal cancer. Design, Setting, and Patients Forty unrelated African American HNPCC and early-age onset colorectal cancer patients (8 women, 3 men) were identified from the cancer registry at a National Cancer institute-designated referral center, 11 of whom were available for and agreed to study participation from January 1997 to February 1998. The mean age of the subjects was 44 years. An additional 50 age- and sex-matched African Americans without personal or family history of colorectal, endometrial, ovarian, urinary tract, or upper gastrointestinal tract malignancy were also studied as a polymorphism control population. In all subjects, genomic DNA was amplified by polymerase chain reaction for all hMLH1 and hMSH2 exons and screened using single-strand conformation polymorphism (SSCP) analysis. Samples demonstrating significant SSCP shifts underwent automated nucleotide sequencing analysis. Main Outcome Measure Frequency of hMLH1 and hMSH2 germline alterations in the affected and control subjects. Results Germline hMLH1 and hMSH2 mutations were detected in 3 (27%) of the African American colorectal cancer probands studied. Each mutation was novel. Two hMLH1 (an A-->T transversion at codon 26 and a GG-->AT substitution across codons 177 and 178) mutations and 1 hMSH2 mutation (a C-->T transition at codon 389) were identified in 3 female study subjects. Six other hMLH1 and hMSH2 alterations were detected but were presumed to be polymorphisms. Neither missense mutation (at codons 26 and 389) was detected in the control population. Conclusions The results of our analysis support an association between the 3 mutations reported and predisposition to colorectal cancer. Further studies are needed to define DNA MMR gene-associated colorectal cancer in African Americans, an understudied population at increased risk of fatal colorectal cancer.	Roswell Pk Canc Inst, Div Surg Oncol, Buffalo, NY 14263 USA; Catholic Univ, Coll Med, St Vincents Hosp, Dept Surg, Suwon, South Korea; Univ Manchester, Fac Med, Manchester, Lancs, England	Roswell Park Cancer Institute; Catholic University of Korea; University of Manchester	Weber, TK (corresponding author), Roswell Pk Canc Inst, Div Surg Oncol, Elm & Carlton St, Buffalo, NY 14263 USA.	weber@sc3102.med.buffalo.edu			NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Beck NE, 1997, HUM GENET, V99, P219, DOI 10.1007/s004390050343; BORING CC, 1992, CA-CANCER J CLIN, V42, P7, DOI 10.3322/canjclin.42.1.7; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Cooper GS, 1997, CANCER EPIDEM BIOMAR, V6, P283; FAN E, 1993, MUTAT RES, V288, P85, DOI 10.1016/0027-5107(93)90210-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Froggatt NJ, 1996, EUR J CANCER, V32A, P178, DOI 10.1016/0959-8049(95)00464-5; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; Jessup JM, 1996, CANCER-AM CANCER SOC, V78, P918; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; KOLODNER RD, 1995, CANCER RES, V55, P242; Laken SJ, 1997, NAT GENET, V17, P79, DOI 10.1038/ng0997-79; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; Lewis CM, 1996, CANCER RES, V56, P1382; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LYNCH HT, 1991, SEMIN ONCOL, V18, P337; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Mauillon JL, 1996, CANCER RES, V56, P5728; MAYBERRY RM, 1995, J NATL CANCER I, V87, P1686, DOI 10.1093/jnci/87.22.1686; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Moisio AL, 1996, AM J HUM GENET, V59, P1243; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NAROD SA, 1991, LANCET, V338, P82; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Pang QS, 1997, MOL CELL BIOL, V17, P4465, DOI 10.1128/MCB.17.8.4465; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PELTOMAKI P, 1995, GASTROENTEROLOGY, V109, P2031, DOI 10.1016/0016-5085(95)90774-2; Percesepe A, 1997, INT J CANCER, V71, P373, DOI 10.1002/(SICI)1097-0215(19970502)71:3<373::AID-IJC12>3.0.CO;2-H; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; PURTILO DT, 1987, CANCER GENET CYTOGEN, V24, P11, DOI 10.1016/0165-4608(87)90079-3; RodriguezBigas MA, 1996, DIS COLON RECTUM, V39, P649, DOI 10.1007/BF02056944; Sankila R, 1996, GASTROENTEROLOGY, V110, P682, DOI 10.1053/gast.1996.v110.pm8608876; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TANNERGARD P, 1995, CANCER RES, V55, P6092; Tomlinson IPM, 1997, J MED GENET, V34, P39, DOI 10.1136/jmg.34.1.39; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Viel A, 1997, GENE CHROMOSOME CANC, V18, P8, DOI 10.1002/(SICI)1098-2264(199701)18:1<8::AID-GCC2>3.0.CO;2-7; Wahlberg SS, 1997, INT J CANCER, V74, P134, DOI 10.1002/(SICI)1097-0215(19970220)74:1<134::AID-IJC22>3.3.CO;2-1; Warthin AS, 1925, J CANCER RES CLIN, V9, P279; Watson P, 1998, CANCER, V83, P259, DOI 10.1002/(SICI)1097-0142(19980715)83:2<259::AID-CNCR9>3.0.CO;2-L; Weber T, 1996, LANCET, V348, P465, DOI 10.1016/S0140-6736(05)64545-X; Weber TK, 1997, CANCER RES, V57, P3798; White RL, 1998, CANCER RES, V58, P4038; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Xia L, 1996, CANCER RES, V56, P2289; Yamamoto H, 1998, CANCER RES, V58, P997; 1999, MSH2 MLH1 MUTATION D	61	38	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2316	2320		10.1001/jama.281.24.2316	http://dx.doi.org/10.1001/jama.281.24.2316			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386556	Bronze			2022-12-24	WOS:000080925600031
J	Yuan, ZM; Shioya, H; Ishiko, T; Sun, XG; Gu, JJ; Huang, YY; Lu, H; Kharbanda, S; Weichselbaum, R; Kufe, D				Yuan, ZM; Shioya, H; Ishiko, T; Sun, XG; Gu, JJ; Huang, YY; Lu, H; Kharbanda, S; Weichselbaum, R; Kufe, D			P73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage	NATURE			English	Article							PROTEIN; P53; ACTIVATION; RADIATION; AGENTS; GROWTH	The protein p73 is a structural and functional homologue of the p53 tumour-suppressor protein but, unlike p53, it is not induced in response to DNA damage(1,2). The tyrosine kinase c-Abl is activated by certain DNA-damaging agents(3) and contributes to the induction of programmed cell death (apoptosis) by p53-dependent and p53-independent mechanisms(4). Here we show that c-Abl binds to p73 in cells, interacting through its SH3 domain with the carboxy-terminal homo-oligomerization domain of p73, c-Abl phosphorylates p73 on a tyrosine residue at position 99 both in vitro and in cells that have been exposed to ionizing radiation. Our results show that c-Abl stimulates p73-mediated transactivation and apoptosis. This regulation of p73 by c-Abl in response to PNA damage is also demonstrated by a failure of ionizing-radiation-induced apoptosis after disruption of the c-Abl-p73 interaction. These findings show that p73 is regulated by a c-Abl-dependent mechanism and that p73 participates in the apoptotic response to DNA damage.	Harvard Univ, Sch Publ Hlth, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Oregon Health & Science University; University of Chicago	Kufe, D (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Biol, 665 Huntington Ave, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu		Huang, Ying/0000-0003-1145-3606				BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KASTAN MB, 1991, CANCER RES, V51, P6304; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Luo CM, 1996, J BIOL CHEM, V271, P4497; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Zhu JH, 1998, CANCER RES, V58, P5061	21	519	530	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					814	817		10.1038/21704	http://dx.doi.org/10.1038/21704			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391251				2022-12-24	WOS:000081101600061
J	Lidegaard, O				Lidegaard, O			Commentary: Oral contraceptives and myocardial infarction: reassuring new findings	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark	University of Copenhagen; Herlev & Gentofte Hospital	Lidegaard, O (corresponding author), Univ Copenhagen, Herlev Hosp, Dept Obstet & Gynaecol, DK-2730 Herlev, Denmark.							Lewis MA, 1997, CONTRACEPTION, V56, P129, DOI 10.1016/S0010-7824(97)00118-2; Poulter NR, 1997, LANCET, V349, P1202, DOI 10.1016/S0140-6736(97)02358-1	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1583	1584						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428552				2022-12-24	WOS:000080913100020
J	Miller, HI				Miller, HI			Policy forum: Genetic engineering - A rational approach to labeling biotech-derived foods	SCIENCE			English	Article									Stanford Univ, Hoover Inst, Stanford, CA 94305 USA; Competit Enterprise Inst, Washington, DC 20036 USA	Stanford University	Miller, HI (corresponding author), Stanford Univ, Hoover Inst, Stanford, CA 94305 USA.	miller@hoover.stanford.edu						AYERS T, 1998, SCIENCE, V281, P714; CHRISPEELS M, 1994, PLANTS GENES AGR, P348; *CTR FOOD SAF APPL, 1996, FOODS DER NEW PLANT; *FOOD DRUG LAW I, 1993, COMP FOOD DRUG LAWS, P30; GOODMAN RM, 1987, SCIENCE, V236, P48, DOI 10.1126/science.236.4797.48; *I FOOD TECHN, 1996, APPR OV PLANTS INH T; JAMES C, 1998, ISAAA BRIEFS, V8; MILLER HI, 1993, JAMA-J AM MED ASSOC, V269, P910; MILLER HI, 1997, POLICY CONTROVERSY B, pCH3; National Research Council, 1989, FIELD TEST GEN MOD O; *NIH OFF DIR, 1992, NAT BIOT POL BOARD R, pE27; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; TAKEMOTO K, 1994, GENOBASE 1 1 ESCHERI; WILLIAMS N, 1998, SCIENCE, V281, P769; 1992, FED REG         0529, V57, P22984	15	14	15	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 28	1999	284	5419					1471	1472		10.1126/science.284.5419.1471	http://dx.doi.org/10.1126/science.284.5419.1471			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	200PD	10383324				2022-12-24	WOS:000080548100020
J	Diwan, VK; Thorson, A				Diwan, VK; Thorson, A			Sex, gender, and tuberculosis	LANCET			English	Article									Nord Sch Publ Hlth, S-40242 Gothenburg, Sweden		Diwan, VK (corresponding author), Nord Sch Publ Hlth, Box 12133, S-40242 Gothenburg, Sweden.			Thorson, Anna/0000-0002-8703-6561				DIWAN VK, 1998, GENDER TUBERCULOSIS; Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96; KUMARESAN JA, 1996, GLOBAL BURDEN DIS RI; Kurasawa T, 1990, Kekkaku, V65, P47; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; SHAABAN MA, 1990, EUR RESPIR J, V3, P187; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	7	98	104	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1000	1001		10.1016/S0140-6736(99)01318-5	http://dx.doi.org/10.1016/S0140-6736(99)01318-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459926				2022-12-24	WOS:000079421600047
J	Haddow, JE; Palomaki, GE; Allan, WC; Williams, JR; Knight, GJ; Gagnon, J; O'Heir, CE; Mitchell, ML; Hermos, RJ; Waisbren, SE; Faix, JD; Klein, RZ				Haddow, JE; Palomaki, GE; Allan, WC; Williams, JR; Knight, GJ; Gagnon, J; O'Heir, CE; Mitchell, ML; Hermos, RJ; Waisbren, SE; Faix, JD; Klein, RZ			Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOTHYROIDISM; IMMUNOGLOBULINS; BINDING; WOMEN	Background When thyroid deficiency occurs simultaneously in a pregnant woman and her fetus, the child's neuropsychological development is adversely affected. Whether developmental problems occur when only the mother has hypothyroidism during pregnancy is not known. Methods In 1996 and 1997,we measured thyrotropin in stored serum samples collected from 25,216 pregnant women between January 1987 and March 1990. We then located 47 women with serum thyrotropin concentrations at or above the 99.7th percentile of the values for all the pregnant women, 15 women with values between the 98th and 99.6th percentiles, inclusive, in combination with low thyroxine levels, and 124 matched women with normal values. Their seven-to-nine-year-old children, none of whom had hypothyroidism as newborns, underwent 15 tests relating to intelligence, attention, language, reading ability, school performance, and visual-motor performance. Results The children of the 62 women with high serum thyrotropin concentrations performed slightly less well on all 15 tests. Their full-scale IQ scares on the Wechsler Intelligence Scale for Children, third edition, averaged 4 points lower than those of the children of the 124 matched control women (P=0.06); 15 percent had scores of 85 or less, as compared with 5 percent of the matched control children. Of the 62 women with thyroid deficiency, 48 were not treated for the condition during the pregnancy under study. The full-scale IQ scores of their children averaged 7 points lower than those of the 124 matched control children (P=0.005); 19 percent had scores of 85 or less. Eleven years after the pregnancy under study, 64 percent of the untreated women and 4 percent of the matched control women had confirmed hypothyroidism. Conclusions Undiagnosed hypothyroidism in pregnant women may adversely affect their fetuses; therefore, screening for thyroid deficiency during pregnancy may be warranted. (N Engl J Med 1999;341:549-55.) (C)1999, Massachusetts Medical Society.	Fdn Blood Res, Scarborough, ME 04074 USA; New England Newborn Screening Program, Jamaica Plain, MA USA; Childrens Hosp, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Boston, MA USA; Dartmouth Med Sch, Hanover, NH USA	Foundation for Blood Research (FBR); Harvard University; Boston Children's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Dartmouth College	Haddow, JE (corresponding author), Fdn Blood Res, 69 US Rte 1, Scarborough, ME 04074 USA.		Fahimifar, Sepideh/M-5303-2019		NICHD NIH HHS [R01-HD31183] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031183] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Beery K. E, 1989, DEV TEST VISUAL MOTO, V3rd; CHO BY, 1988, ENDOCRINOL JAPON, V35, P819; CONNERS CK, 1994, CPT COMPUTER PROGRAM; CONNORS MH, 1986, PEDIATRICS, V78, P287; Dussault JH, 1999, OBSTET GYNECOL, V93, P15, DOI 10.1016/S0029-7844(98)00369-X; FORT P, 1988, J CLIN ENDOCR METAB, V66, P645, DOI 10.1210/jcem-66-3-645; Gardner LI, 1975, ENDOCRINE GENETIC DI, P234; GOLDSMITH RE, 1973, J CLIN ENDOCR METAB, V37, P265, DOI 10.1210/jcem-37-2-265; HADDOW JE, 1983, OBSTET GYNECOL, V62, P556; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; Hollingshead A.B., 1975, 4 FACTOR INDEX SOCIA; KLEIN RZ, 1991, CLIN ENDOCRINOL, V35, P41, DOI 10.1111/j.1365-2265.1991.tb03494.x; MAN EB, 1969, AM J OBSTET GYNECOL, V104, P898, DOI 10.1016/0002-9378(69)90644-9; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MARKWARDT F, 1989, PEABODY INDIVIDUAL A; MATSUURA N, 1990, ENDOCRINOL JAPON, V37, P369; MATSUURA N, 1990, ENDOCRINOL JAPON, V37, pA767; MITCHELL ML, 1976, CLIN CHEM, V22, P1912; NEWCOMER P, 1991, TEST LANGUAGE DEV, V2; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PHAROAH POD, 1984, CLIN ENDOCRINOL, V21, P265, DOI 10.1111/j.1365-2265.1984.tb03468.x; Pop VJ, 1999, CLIN ENDOCRINOL, V50, P149, DOI 10.1046/j.1365-2265.1999.00639.x; SUTHERLAND JM, 1960, NEW ENGL J MED, V263, P336, DOI 10.1056/NEJM196008182630703; Trites R., 1989, GROOVED PEGBOARD TES; Volpe J., 1995, NEUROLOGY NEWBORN, P43; Wechsler D., 1991, WISC 3 WECHSLER INTE	26	1590	1718	3	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1999	341	8					549	555		10.1056/NEJM199908193410801	http://dx.doi.org/10.1056/NEJM199908193410801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227CV	10451459				2022-12-24	WOS:000082061500001
J	Engels, EA; Rosenberg, PS; O'Brien, TR; Goedert, JJ				Engels, EA; Rosenberg, PS; O'Brien, TR; Goedert, JJ		Multicenter Hemophilia Cohort Study	Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: A measure of current immune suppression	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; RNA LEVELS; ANTIRETROVIRAL THERAPY; LYMPHOCYTE COUNTS; TYPE-1 INFECTION; PROGNOSTIC VALUE; IN-VIVO; AIDS; MACROPHAGES; PROGRESSION	Background: For patients infected with HIV, plasma HIV viral load in early disease predicts long-term prognosis. However, the implications of viral load measurements late in HIV disease are uncertain. Objective: To evaluate the relation between plasma HIV viral load and subsequent risk for disease progression in patients with late-stage HIV disease. Design: Retrospective cohort study. Setting: 16 treatment centers for patients with hemophilia. Patients: 389 patients with hemophilia and late-stage HIV disease (CD4 count < 200 cells/mm(3)). Measurements: Plasma HIV viral load was measured at baseline. Patients were followed for AIDS-related illnesses (primary outcome) and, specifically, Pneumocystis carinii pneumonia (secondary outcome). Results: HIV viral load strongly predicted AIDS-related illness. For patients with viral loads less than 4.00 log(10) copies/mL, the 1-year actuarial risk was 0% and the 5-year risk was 25%. For patients with viral loads of at least 6.00 log(10) copies/mL, the 1-year actuarial risk was 42% and the 5-year risk was 78%. A linear relation existed between viral load a nd risk for AIDS-related illness (hazard ratio, 2.37 per log(10) copies/mL; P < 0.001). In addition, viral load most strongly predicted risk for illness immediately after viral load testing; this predictive relation attenuated over time (P = 0.002). These findings changed little after adjustment for CD4 cell counts that were updated during follow-up. In the first year after viral load was measured, it predicted occurrence of P, carinii pneumonia (hazard ratio, 4.69 per log(10) copies/mL; P < 0.001). Conclusions: In patients with hemophilia and late-stage HIV disease, viral load predicts disease progression independently of CD4 cell counts. Because viral load most strongly predicts progression immediately after load is measured, it seems to reflect the current level of immunosuppression.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, Rockville, MD 20822 USA; NCI, Biostat Branch, Div Canc Epidemiol & Genet, Rockville, MD 20822 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Engels, EA (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, 6120 Execut Blvd,EPS 8005, Rockville, MD 20822 USA.	engelse@exchange.nih.gov		Rosenberg, Philip/0000-0001-6349-9126	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [Z01CP010115, N01CP033002] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CP-33002] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BOOM R, 1990, J CLIN MICROBIOL, V28, P495, DOI 10.1128/JCM.28.3.495-503.1990; CHATURVEDI S, 1995, J INFECT DIS, V171, P320, DOI 10.1093/infdis/171.2.320; Coombs RW, 1996, J INFECT DIS, V174, P704, DOI 10.1093/infdis/174.4.704; Council of State and Territorial Epidemiologists, 1987, MMWR MORB MORTAL S1, V36, p1S; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P52; *DEP HLTH HUM SERV, 1998, MMWR-MORBID MORTAL W, V47, P43; FLETCHER MA, 1987, DIAGN CLIN IMMUNOL, V5, P69; FREEDMAN LS, 1992, STAT MED, V11, P167, DOI 10.1002/sim.4780110204; GalettoLacour A, 1996, J INFECT DIS, V173, P1388, DOI 10.1093/infdis/173.6.1388; GOEDERT JJ, 1989, NEW ENGL J MED, V321, P1141, DOI 10.1056/NEJM198910263211701; HARRISON TS, 1995, J INFECT DIS, V172, P665, DOI 10.1093/infdis/172.3.665; HASTIE TJ, 1990, GEN ADDITIVE MODELS, P22; Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772; KLEIN JP, 1997, KSURVIVAL ANAL TECHN, P83; Komanduri KV, 1998, NAT MED, V4, P953, DOI 10.1038/nm0898-953; KRONER BL, 1994, J ACQ IMMUN DEF SYND, V7, P279; Ledergerber B, 1999, LANCET, V353, P863, DOI 10.1016/S0140-6736(99)01122-8; Lepri AC, 1998, AIDS, V12, P1639, DOI 10.1097/00002030-199813000-00011; LYLES R, 1999, 6 C RETR OPP INF 31; Maas JJ, 1998, J INFECT DIS, V178, P1024, DOI 10.1086/515655; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Miller V, 1999, ANN INTERN MED, V130, P570, DOI 10.7326/0003-4819-130-7-199904060-00005; MURDER J, 1994, J CLIN MICROBIOL, V32, P292; O'Brien TR, 1998, J ACQ IMMUN DEF SYND, V18, P155, DOI 10.1097/00042560-199806010-00007; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; OBrien WA, 1997, ANN INTERN MED, V126, P939, DOI 10.7326/0003-4819-126-12-199706150-00002; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Read C, 1983, ENCY STAT SCI, V3, P86; SHIRATSUCHI H, 1994, J CLIN INVEST, V93, P885, DOI 10.1172/JCI117044; TOLLERUD DJ, 1991, J CLIN LAB ANAL, V5, P255; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; WAGNER RP, 1992, AM REV RESPIR DIS, V146, P1434, DOI 10.1164/ajrccm/146.6.1434	36	17	17	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					256	+		10.7326/0003-4819-131-4-199908170-00004	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454946				2022-12-24	WOS:000082012500003
J	Gardner, K; Chapple, A				Gardner, K; Chapple, A			Barriers to referral in patients with angina: qualitative study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY; REVASCULARIZATION; ACCESS; RATES; CARE; UK	Objectives To explore barriers to patients being referred for possible revascularisation. Design Qualitative study using semi-structured interviews. Participants 16 patients aged under 75 years with stable angina and their doctors. Setting General practice in Toxteth, Liverpool. Results Fear of both hospitals and medical tests was common and largely hidden from the doctors. Patients felt they were old, had low expectations of treatment, viewed angina as a chronic illness, and knew little about new developments in angina treatment Patients and doctors had difficulty in recognising angina symptoms that were not textbook definitions amid multiple comorbidity. Patients saw doctors as busy and did not want to bother them with their condition. Cultural gaps and communication difficulties existed despite all but one patient having English as their first language. Conclusions Listening to patients is vital to address inequitable access to health services: how patients are treated by doctors today affects acceptability of referral tomorrow. Primary care groups in deprived areas should work With communities to address local fears. This will involve collaboration between primary, secondary, and tertiary care. Cultural gaps exist between patients and doctors in deprived areas, and diagnostic confusion can occur particularly in die presence of other psychological and physical morbidity. Adequate time and resources-for example, education for doctors and patients and provision of interpreters-need to he provided if inequitable access to revascularisation procedures is to be addressed.	Princes Pk Hlth Ctr, Liverpool L8 OSY, Merseyside, England; Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Gardner, K (corresponding author), Princes Pk Hlth Ctr, Liverpool L8 OSY, Merseyside, England.							ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; BEERY TA, 1995, HEART LUNG, V24, P427, DOI 10.1016/S0147-9563(95)80020-4; BENSHLOMO Y, 1995, J EPIDEMIOL COMMUN H, V49, P200, DOI 10.1136/jech.49.2.200; BLACK N, 1995, J EPIDEMIOL COMMUN H, V49, P408, DOI 10.1136/jech.49.4.408; Chapple A, 1998, J Health Serv Res Policy, V3, P153; FORREST D, 1995, HEART DIS PREVENTION; Green J, 1998, BMJ-BRIT MED J, V316, P1230, DOI 10.1136/bmj.316.7139.1230; Hoddinott P, 1997, FAM PRACT, V14, P307, DOI 10.1093/fampra/14.4.307; Kee F, 1993, Qual Health Care, V2, P87, DOI 10.1136/qshc.2.2.87; LEAR JT, 1994, J R SOC MED, V84, P661; Morse JM, 1999, QUAL HEALTH RES, V9, P5, DOI 10.1177/104973299129121622; Morse JM, 1997, QUAL HEALTH RES, V7, P445, DOI 10.1177/104973239700700401; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; PENDLETON D, 1984, CONSULTATOIN APPROAC; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; Popay J, 1996, SOC SCI MED, V42, P759, DOI 10.1016/0277-9536(95)00341-X; Ruston A, 1998, BRIT MED J, V316, P1060; SHAUKAT N, 1993, BRIT MED J, V307, P717, DOI 10.1136/bmj.307.6906.717; Tesch R, 1990, ANAL TYPES SOFTWARE	19	59	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					418	421		10.1136/bmj.319.7207.418	http://dx.doi.org/10.1136/bmj.319.7207.418			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445924	Green Published, Bronze			2022-12-24	WOS:000082098900018
J	Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER				Ely, JW; Osheroff, JA; Ebell, MH; Bergus, GR; Levy, BT; Chambliss, ML; Evans, ER			Analysis of questions asked by family doctors regarding patient care	BRITISH MEDICAL JOURNAL			English	Article							EVIDENCE-BASED MEDICINE; INFORMATION NEEDS; CLINICAL QUESTIONS; PHYSICIANS	Objectives To characterise the information needs of: family doctors by collecting the questions they asked about patient care during consultations and to classify these in ways that would be useful to developers of knowledge bases. Design Observational study in which investigators visited doctors for two half days and collected their questions. Taxonomies were developed to characterise the clinical topic and generic type of information sought for each question. Setting Eastern Iowa. Participants Random sample of 103 family doctors. Main outcome measures Number of questions posed, pursued, and answered; topic and generic type of information sought for each question; time spent pursuing answers; information resources used. Results Participants asked a total of 1101 questions. Questions about drug prescribing obstetrics and gynaecology, and adult infectious disease were most common and comprised 36% of all questions. The taxonomy of generic questions included 69 categories; the three most common types, comprising 24% of all questions, were "What is the cause of symptom X?" "What is the dose of drug X?" and "How should I manage disease or finding X?" Answers to most questions (702, 64%) were not immediately pursued, but, of those pursued, most (318, 80%) were answered. Doctors spent an average of less than 2 minutes pursuing an answer, and they used readily available print and human resources. Only two questions led to a formal literature search. Conclusions Family doctors in this study did not pursue answers to most of their questions. Questions about patient care can be organised into a limited number of generic types, which could help guide the efforts of knowledge base developers.	Univ Iowa, Coll Med, Dept Family Med, Iowa City, IA 52242 USA; Amer Coll Phys, Amer Soc Internal Med, Philadelphia, PA USA; Michigan State Univ, Dept Family Practice, E Lansing, MI 48824 USA; Moses Cone Hosp Family Med Residency, Greensboro, NC USA; Univ Iowa, Student Hlth Serv, Iowa City, IA USA	University of Iowa; American College of Physicians; Michigan State University; Moses Cone Memorial Hospital; University of Iowa	Ely, JW (corresponding author), Univ Iowa, Coll Med, Dept Family Med, 200 Hawkins Dr,01291-D PFP, Iowa City, IA 52242 USA.		Bergus, George/AAS-9522-2021	Levy, Barcey/0000-0002-3315-4116				Chambliss ML, 1996, J FAM PRACTICE, V43, P140; CIMINO JJ, 1993, B MED LIBR ASSOC, V81, P195; COVELL DG, 1985, ANN INTERN MED, V103, P596, DOI 10.7326/0003-4819-103-4-596; EBELL MH, 1998, MD COMPUTING, V15, P189; ELY JW, 1992, J FAM PRACTICE, V35, P265; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; GORMAN PN, 1994, B MED LIBR ASSOC, V82, P140; GORMAN PN, 1995, MED DECIS MAKING, V15, P113, DOI 10.1177/0272989X9501500203; GREER AL, 1987, JAMA-J AM MED ASSOC, V258, P2739, DOI 10.1001/jama.258.19.2739; Haug JD, 1997, B MED LIBR ASSOC, V85, P223; HUTH EJ, 1994, ANN INTERN MED, V120, P889, DOI 10.7326/0003-4819-120-10-199405150-00012; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; OSHEROFF JA, 1991, ANN INTERN MED, V114, P576, DOI 10.7326/0003-4819-114-7-576; REYNOLDS RD, 1995, J FAM PRACTICE, V41, P583; Sackett DL, 1998, JAMA-J AM MED ASSOC, V280, P1336, DOI 10.1001/jama.280.15.1336; Sackett DL, 1997, EVIDENCE BASED MED P; Shaughnessy AF, 1998, J FAM PRACTICE, V47, P425; Smith R, 1996, BRIT MED J, V313, P1062; TIMPKA T, 1989, Scandinavian Journal of Primary Health Care, V7, P105, DOI 10.3109/02813438909088656; VERHOEVEN AAH, 1995, B MED LIBR ASSOC, V83, P85; WILSON SR, 1989, USE CRITICAL INCIDEN; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	23	338	343	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					358	361		10.1136/bmj.319.7206.358	http://dx.doi.org/10.1136/bmj.319.7206.358			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435959	Bronze, Green Published			2022-12-24	WOS:000082001700021
J	Conradt, B; Horvitz, HR				Conradt, B; Horvitz, HR			The TRA-1A sex determination protein of C. elegans regulates sexually dimorphic cell deaths by repressing the egl-1 cell death activator gene	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; TRANSCRIPTIONAL REGULATION; CUBITUS INTERRUPTUS; SIGNALING PATHWAY; IN-VITRO; APOPTOSIS; DROSOPHILA; NUCLEUS; FAMILY; DIFFERENTIATION	The hermaphrodite-specific neurons (HSNs) of the nematode Caenorhabditis elegans are generated embryonically in both hermaphrodites and males but undergo programmed cell death in males. The gene egl-1 encodes a BH3-containing cell death activator that is required for programmed cell death in C. elegans. Gain-of-function (gf) mutations in egl-1 cause the inappropriate programmed cell death of the HSNs in hermaphrodites. These mutations lie 5.6 kb downstream of the egl-1 transcription unit and disrupt the binding of the TRA-1A zinc finger protein, the terminal global regulator of somatic sexual fate. This disruption results in the activation of the egl-1 gene in the HSNs not only in males but also in hermaphrodites. Our findings suggest that in hermaphrodites TRA-1A represses egl-1 transcription in the HSNs to prevent these neurons from undergoing programmed cell death.	MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02319 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Horvitz, HR (corresponding author), Max Planck Inst Neurobiol, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.	horvitz@mit.edu	Conradt, Barbara/K-2665-2014	Conradt, Barbara/0000-0002-3731-4308	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024663, R37GM024663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24663] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; BENEDYK MJ, 1994, GENE DEV, V8, P105, DOI 10.1101/gad.8.1.105; Bloom L, 1997, P NATL ACAD SCI USA, V94, P3414, DOI 10.1073/pnas.94.7.3414; BREEDLOVE SM, 1986, J NEUROBIOL, V17, P157, DOI 10.1002/neu.480170304; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CLARK SG, 1994, GENETICS, V137, P987; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Davis EC, 1996, BRAIN RES, V734, P10, DOI 10.1016/0006-8993(96)00298-3; DEBONO M, 1995, GENE DEV, V9, P155, DOI 10.1101/gad.9.2.155; del Peso L, 1998, J BIOL CHEM, V273, P33495, DOI 10.1074/jbc.273.50.33495; DESAI C, 1989, GENETICS, V121, P703; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ELLIS RE, 1991, DEVELOPMENT, V112, P591; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HUNTER CP, 1990, CELL, V63, P1193, DOI 10.1016/0092-8674(90)90415-B; Imaizumi K, 1997, J BIOL CHEM, V272, P18842, DOI 10.1074/jbc.272.30.18842; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Johnson RL, 1998, CURR OPIN GENET DEV, V8, P450, DOI 10.1016/S0959-437X(98)80117-2; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; KIM RJ, 1989, J NEUROSCI, V9, P3176; KONISHI M, 1985, NATURE, V315, P145, DOI 10.1038/315145a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mello C, 1995, METHOD CELL BIOL, V48, P451; Metzstein MM, 1998, TRENDS GENET, V14, P410, DOI 10.1016/S0168-9525(98)01573-X; Metzstein MM, 1996, NATURE, V382, P545, DOI 10.1038/382545a0; MEYER BJ, 1997, C ELEGANS, V2, P209; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NORDEEN EJ, 1985, SCIENCE, V229, P671, DOI 10.1126/science.4023706; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PERRY MD, 1994, GENETICS, V138, P317; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; Priess J. R., 1997, C ELEGANS 2; Sambrook JFE, 1989, MOL CLONING LAB MANU; Sasaki H, 1997, DEVELOPMENT, V124, P1313; SHIMELL MJ, 1994, SCIENCE, V264, P968, DOI 10.1126/science.7909957; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THORN RS, 1994, J NEUROBIOL, V25, P1039, DOI 10.1002/neu.480250902; TRENT C, 1983, GENETICS, V104, P619; TRENT C, 1991, MECH DEVELOP, V34, P43, DOI 10.1016/0925-4773(91)90090-S; TRUMAN JW, 1984, ANNU REV NEUROSCI, V7, P171; Vaux DL, 1997, CELL, V90, P389, DOI 10.1016/S0092-8674(00)80497-3; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404; ZARKOWER D, 1993, NUCLEIC ACIDS RES, V21, P3691, DOI 10.1093/nar/21.16.3691; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	55	171	185	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					317	327		10.1016/S0092-8674(00)81961-3	http://dx.doi.org/10.1016/S0092-8674(00)81961-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458607	Bronze			2022-12-24	WOS:000081950300007
J	Ritchie, ME; Olff, H				Ritchie, ME; Olff, H			Spatial scaling laws yield a synthetic theory of biodiversity	NATURE			English	Article							BODY-SIZE; FRACTAL LANDSCAPES; DIVERSITY; ABUNDANCE; PLANT	Ecologists still search for common principles that predict well-known responses of biological diversity to different factors(1-4) Such factors include the number of available niches in space(5-7), productivity(8-10), area(10), species' body size(11-14) and habitat fragmentation. Here we show that all these patterns can arise from simple constraints on how organisms acquire resources in space. We use spatial scaling laws to describe how species of different sizes find food in patches of varying size and resource concentration. We then derive a mathematical rule for the minimum similarity in size of species that share these resources. This packing rule yields a theory of species diversity that predicts relations between diversity and productivity more effectively than previous models(8-10). Size and diversity patterns for locally coexisting East African grazing mammals and North American savanna plants strongly support these predictions. The theory also predicts relations between diversity and area and between diversity and habitat fragmentation. Thus, spatial scaling laws provide potentially unifying first principles that may explain many important patterns of species diversity.	Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA; Agr Univ Wageningen, Dept Environm Sci, Trop Nat Conservat & Vertebrate Ecol Grp, NL-6708 PD Wageningen, Netherlands	Utah System of Higher Education; Utah State University; Wageningen University & Research	Ritchie, ME (corresponding author), Utah State Univ, Dept Fisheries & Wildlife, Logan, UT 84322 USA.	ritchie@cc.usu.edu	Olff, Han/A-8516-2008	Olff, Han/0000-0003-2154-3576				[Anonymous], 2001, PLANT STRATEGIES VEG; Belovsky GE, 1997, EVOL ECOL, V11, P641, DOI 10.1023/A:1018430201230; BROWN JH, 1993, AM NAT, V142, P573, DOI 10.1086/285558; BROWN JH, 1981, AM ZOOL, V21, P877; DAMUTH J, 1981, NATURE, V290, P699, DOI 10.1038/290699a0; Hubbell SP, 1997, CORAL REEFS, V16, pS9, DOI 10.1007/s003380050237; Huston, 1994, BIOL DIVERSITY COEXI; HUTCHINSON GE, 1959, AM NAT, V93, P117, DOI 10.1086/282063; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; JONES CG, 1991, J ANIM ECOL, V60, P767, DOI 10.2307/5413; KINGDON J, 1979, E AFRICAN MAMMALS AT, V1; MACARTHUR RH, 1964, AM NAT, V98, P387, DOI 10.1086/282334; Mandelbrot B. B., 1983, FRACTAL GEOMETRY NAT; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; MILNE BT, 1992, AM NAT, V139, P32, DOI 10.1086/285312; Milne BT, 1997, WILDLIFE AND LANDSCAPE ECOLOGY, P32; MORSE DR, 1985, NATURE, V314, P731, DOI 10.1038/314731a0; O'Neill RV, 1988, LANDSCAPE ECOL, V2, P63, DOI 10.1007/BF00138908; PALMER MW, 1992, AM NAT, V139, P375, DOI 10.1086/285332; Prins H.H.T., 1998, P449; Ritchie ME, 1998, ECOLOGY, V79, P165, DOI 10.1890/0012-9658(1998)079[0165:HEOPAN]2.0.CO;2; Ritchie ME, 1998, EVOL ECOL, V12, P309, DOI 10.1023/A:1006552200746; Rosenzweig Michael L., 1995, DOI 10.1017/CBO9780511623387.002; ROSENZWEIG ML, 1994, SPECIES DIVERSITY EC, P52; SCHLUTER D, 1994, SPECIES DIVERSITY EC; SCHOENER TW, 1974, THEOR POPUL BIOL, V6, P265, DOI 10.1016/0040-5809(74)90013-6; Siemann E, 1996, NATURE, V380, P704, DOI 10.1038/380704a0; SINCLAIR ARE, 1979, SERENGCTI DYNAMICS E; TILMAN D, 1994, SPECIES DIVERSITY EC, P13; WRIGHT DH, 1983, OIKOS, V41, P496, DOI 10.2307/3544109	30	291	302	3	110	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					557	560		10.1038/23010	http://dx.doi.org/10.1038/23010			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448857	Green Published			2022-12-24	WOS:000081854800053
J	Amado, RG; Chen, ISY				Amado, RG; Chen, ISY			Biomedicine - Lentiviral vectors - the promise of gene therapy within reach?	SCIENCE			English	Editorial Material							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; NONDIVIDING CELLS; IN-VIVO; TRANSDUCTION; INTEGRATION; EXPRESSION; DELIVERY; HIV		Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Hematol Oncol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Amado, RG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Div Hematol Oncol, Los Angeles, CA 90095 USA.	ramado@ucla.edu						Akkina RK, 1996, J VIROL, V70, P2581, DOI 10.1128/JVI.70.4.2581-2585.1996; AN DS, IN PRESS J VIROL; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; DONAHUE RE, 1998, BLOOD S1, V92; Herzog RW, 1999, NAT MED, V5, P56, DOI 10.1038/4743; Kafri T, 1999, J VIROL, V73, P576, DOI 10.1128/JVI.73.1.576-584.1999; Kafri T, 1997, NAT GENET, V17, P314, DOI 10.1038/ng1197-314; Kim VN, 1998, J VIROL, V72, P811, DOI 10.1128/JVI.72.1.811-816.1998; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; Miyoshi H, 1999, SCIENCE, V283, P682, DOI 10.1126/science.283.5402.682; Miyoshi H, 1997, P NATL ACAD SCI USA, V94, P10319, DOI 10.1073/pnas.94.19.10319; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Poeschla EM, 1998, NAT MED, V4, P354, DOI 10.1038/nm0398-354; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; Snyder RO, 1999, NAT MED, V5, P64, DOI 10.1038/4751; TAKAHASHI M, IN PRESS J VIROL; Uchida N, 1998, P NATL ACAD SCI USA, V95, P11939, DOI 10.1073/pnas.95.20.11939; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	21	132	163	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					674	676		10.1126/science.285.5428.674	http://dx.doi.org/10.1126/science.285.5428.674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454923				2022-12-24	WOS:000081765100031
J	Tesmer, JJG; Sunahara, RK; Johnson, RA; Gosselin, G; Gilman, AG; Sprang, SR				Tesmer, JJG; Sunahara, RK; Johnson, RA; Gosselin, G; Gilman, AG; Sprang, SR			Two-metal-ion catalysis in adenylyl cyclase	SCIENCE			English	Article							SITE-DIRECTED MUTAGENESIS; DNA-POLYMERASE-BETA; REVERSE-TRANSCRIPTASE; CRYSTAL-STRUCTURE; GUANYLYL CYCLASES; CYTOSOLIC DOMAINS; RNA-POLYMERASE; MECHANISM; BINDING; COMPLEX	Adenylyl cyclase (AC) converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate, a ubiquitous second messenger that regulates many cellular functions. Recent structural studies have revealed much about the structure and function of mammalian AC but have not fully defined its active site or catalytic mechanism. Four crystal structures were determined of the catalytic domains of AC in complex with two different ATP analogs and various divalent metal ions. These structures provide a model for the enzyme-substrate complex and conclusively demonstrate that two metal ions bind in the active site. The similarity of the active site of AC to those of DNA polymerases suggests that the enzymes catalyze phosphoryl transfer by the same two-metal-ion mechanism and likely have evolved from a common ancestor.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; SUNY Stony Brook, Hlth Sci Ctr, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; Univ Montpellier 2, Chim Bioorgan Lab, F-34095 Montpellier 5, France	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite de Montpellier	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NIDDK NIH HHS [DK38828, DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371, R01DK038828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Artymiuk PJ, 1997, NATURE, V388, P33, DOI 10.1038/40310; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COOPER DMF, 1998, ADV 2 MESSENGER PHOS, V32; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Doublie S, 1998, CURR OPIN STRUC BIOL, V8, P704, DOI 10.1016/S0959-440X(98)80089-4; Doublie S, 1999, STRUCTURE, V7, pR31, DOI 10.1016/S0969-2126(99)80017-3; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GARBERS DL, 1975, J BIOL CHEM, V250, P8449; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P11536, DOI 10.1021/bi960364x; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; KING GC, 1986, BIOCHEMISTRY-US, V25, P36, DOI 10.1021/bi00349a006; LESLIE AGW, 1997, MOSFLM 5 50 IMAGE PL; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; Liu Y, 1997, P NATL ACAD SCI USA, V94, P13414, DOI 10.1073/pnas.94.25.13414; PADMAJA N, 1991, B CHEM SOC JPN, V64, P1359, DOI 10.1246/bcsj.64.1359; PANDEY VN, 1994, J BIOL CHEM, V269, P13259; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12762, DOI 10.1021/bi9529566; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; SARAFIANOS SG, 1995, J BIOL CHEM, V270, P19729, DOI 10.1074/jbc.270.34.19729; SHELDRICK WS, 1978, ACTA CRYSTALLOGR B, V34, P2324, DOI 10.1107/S0567740878008067; SHOSHANI I, UNPUB; SLABY I, 1984, BIOCHEM BIOPH RES CO, V122, P1410, DOI 10.1016/0006-291X(84)91248-8; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; Sunahara RK, 1998, J BIOL CHEM, V273, P16332, DOI 10.1074/jbc.273.26.16332; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; SUNAHAVA I, UNPUB; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Tesmer JJG, 1998, CURR OPIN STRUC BIOL, V8, P713, DOI 10.1016/S0959-440X(98)80090-0; VARUGHESE KI, 1982, J AM CHEM SOC, V104, P3398, DOI 10.1021/ja00376a026; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zimmermann G, 1998, J BIOL CHEM, V273, P19650, DOI 10.1074/jbc.273.31.19650	45	268	276	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					756	760		10.1126/science.285.5428.756	http://dx.doi.org/10.1126/science.285.5428.756			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427002				2022-12-24	WOS:000081765100061
J	Tyler, CW				Tyler, CW			Neuroscience - Is art lawful?	SCIENCE			English	Editorial Material									Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Tyler, CW (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							Arnheim R., 1988, POWER CTR STUDY COMP; BRENNAN SE, 1985, LEONARDO, V18, P170, DOI 10.2307/1578048; HANSON HM, 1959, J EXP PSYCHOL, V58, P321, DOI 10.1037/h0042606; Kandinsky W., 1947, POINT LINE PLANE; Martindale C., 1990, CLOCKWORK MUSE PREDI; Ramachandran V.S., 1999, J CONSCIOUSNESS STUD, V6, P15, DOI [10.1179/174327908X392906, DOI 10.1179/174327908X392906]	6	13	13	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					673	674		10.1126/science.285.5428.673	http://dx.doi.org/10.1126/science.285.5428.673			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10454922				2022-12-24	WOS:000081765100030
J	Ballard, JO				Ballard, JO			Anticoagulant-induced thrombosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; INDUCED SKIN NECROSIS; WARFARIN		Penn State Univ, Milton S Hershey Med Ctr, Geisinger Hlth Syst,Coll Med, Sect Hematol Oncol H046, Hershey, PA 17033 USA	Geisinger Health System; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Ballard, JO (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Geisinger Hlth Syst,Coll Med, Sect Hematol Oncol H046, POB 850, Hershey, PA 17033 USA.							BAUER KA, 1987, BLOOD, V70, P343; COMP PC, 1990, SEMIN THROMB HEMOST, V16, P293, DOI 10.1055/s-2007-1002682; DANGELO SV, 1986, J CLIN INVEST, V77, P416, DOI 10.1172/JCI112319; FIORE L, 1995, WILLIAMS HEMATOLOGY, P1562; Greinacher A, 1999, CIRCULATION, V99, P73, DOI 10.1161/01.CIR.99.1.73; MAGNANI HN, 1993, THROMB HAEMOSTASIS, V70, P554; Sallah S, 1997, THROMB HAEMOSTASIS, V78, P785; WARKENTIN TE, 1995, NEW ENGL J MED, V332, P1330, DOI 10.1056/NEJM199505183322003; Warkentin TE, 1997, ANN INTERN MED, V127, P804, DOI 10.7326/0003-4819-127-9-199711010-00005; Warkentin TE, 1996, AM J MED, V101, P502, DOI 10.1016/S0002-9343(96)00258-6; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1	11	13	13	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					310	312		10.1001/jama.282.4.310	http://dx.doi.org/10.1001/jama.282.4.310			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432014				2022-12-24	WOS:000081596800003
J	Boulton, M; Beck, E; Walters, S; Miller, D				Boulton, M; Beck, E; Walters, S; Miller, D			General practice and the care of children with HIV infection: 6 month prospective interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; PRACTITIONERS; INVOLVEMENT; VIEWS; WOMEN; AIDS	Objectives To describe the use of primary care services by children infected with HIV and to explore the attitudes of their parents to the role of general practitioners in their children's care. Design A 6 month prospective study. Quantitative analysis of "contact diaries" kept by parents; qualitative analysis of face to face interviews with parents. Participants Parents of children receiving care at a regional referral centre in London. Results Twenty four families (80% response rate) were recruited to the study. In 19 families the mother was black African. Half the children had been diagnosed with symptomatic HIV infection, half with AIDS. All the children were registered with a general practitioner who knew of the child's HIV infection. In five families there had initially been tensions in their relationship with their general practitioner but by the time of the study all but one family had established at least an "acceptable" relationship Children with symptomatic HIV infection saw their general practitioner a mean of 7.5 times per patient year; for children with AIDS the figure was 5.8. Parents regarded the paediatric HIV team at the hospital as their primary source of medical care. Three factors constrained their use of general practice: their own anxieties about distinguishing "normal" symptoms from those related to HIV infection; their view that. their general practitioner did not feel competent to treat HIV infected children; and their concerns about maintaining confidentiality in the surgery. Conclusions Parents remain oriented towards. the paediatric HIV team as their primary source of medical care and use general practice largely for routine prescriptions for their children. Any further development of the general practitioner's role will need to build on existing relationships with specialist providers and take account of parents' concerns.	Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England	Imperial College London; Imperial College London	Boulton, M (corresponding author), Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England.	m.boulton@ic.ac.uk	BOULTON, Mary/X-9056-2019	BOULTON, Mary/0000-0002-2247-8318				BECK EJ, 1997, HOSP COMMUNITY SERVI; BOULTON M, 1997, EXPERIENCE FAMILIES; CLARKE AE, 1993, FAM PRACT, V10, P8, DOI 10.1093/fampra/10.1.8; *COMM DIS SURV CTR, 1998, COMMUN DIS REP CDR W, V8, P386; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GUTHRIE B, 1995, INT J STD AIDS, V6, P84, DOI 10.1177/095646249500600204; Huby G, 1998, AIDS CARE, V10, pS83, DOI 10.1080/09540129850124398; KING MB, 1988, BRIT MED J, V297, P182, DOI 10.1136/bmj.297.6642.182; KING MB, 1989, J ROY COLL GEN PRACT, V39, P280; Madge S, 1998, BRIT J GEN PRACT, V48, P1329; MANSFIELD SJ, 1989, J ROY COLL GEN PRACT, V39, P104; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253; Shaw M, 1996, BRIT MED J, V312, P1463, DOI 10.1136/bmj.312.7044.1463; SHELDON J, 1993, FAM PRACT, V10, P396, DOI 10.1093/fampra/10.4.396; SINGH S, 1993, BRIT J GEN PRACT, V43, P182; Smith S, 1996, BRIT MED J, V312, P416, DOI 10.1136/bmj.312.7028.416	16	4	4	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					232	235		10.1136/bmj.319.7204.232	http://dx.doi.org/10.1136/bmj.319.7204.232			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417088	Bronze, Green Published			2022-12-24	WOS:000081720300027
J	Kimura, K; Rybenkov, VV; Crisona, NJ; Hirano, T; Cozzarelli, NR				Kimura, K; Rybenkov, VV; Crisona, NJ; Hirano, T; Cozzarelli, NR			13S condensin actively reconfigures DNA by introducing global positive writhe: Implications for chromosome condensation	CELL			English	Article							TOPOISOMERASE-II; SUPERCOILED DNA; PROTEIN FAMILY; IN-VITRO; SMC; SEGREGATION; MECHANISM; BINDING; RECOMBINATION; REPLICATION	Xenopus 13S condensin converts interphase chromatin into mitotic-like chromosomes, and, in the presence of ATP and a type I topoisomerase, introduces (+) supercoils into DNA. The specific production of (+) trefoil knots in the presence of condensin and a type II topoisomerase shows that condensin reconfigures DNA by introducing an ordered, global, (+) writhe. Knotting required ATP hydrolysis and cell cycle-specific phosphorylation of condensin. Condensin bound preferentially to (+) supercoiled DNA in the presence of ATP but not in its absence. Our results suggest a mechanism for the compaction of chromatin by condensin during mitosis.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California Berkeley; Cold Spring Harbor Laboratory	Kimura, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926, R01GM031655] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 53926, GM 31655] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; BELMONT AS, 1994, J CELL BIOL, V127, P287, DOI 10.1083/jcb.127.2.287; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; BHATTACHARYYA A, 1991, J MOL BIOL, V221, P1191, DOI 10.1016/0022-2836(91)90928-Y; Britton RA, 1998, GENE DEV, V12, P1254, DOI 10.1101/gad.12.9.1254; CRISONA NJ, 1994, J MOL BIOL, V243, P437, DOI 10.1006/jmbi.1994.1671; DARCY LD, 1997, KNOTS 96, P267; Earnshaw WC, 1991, CURR OPIN STRUC BIOL, V1, P237, DOI 10.1016/0959-440X(91)90068-5; HIRAGA S, 1992, ANNU REV BIOCHEM, V61, P283; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LAEMMLI UK, 1978, COLD SPRING HARB SYM, V42, P351; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; MUKHERJEE S, 1988, P NATL ACAD SCI USA, V85, P6287, DOI 10.1073/pnas.85.17.6287; MUSGRAVE DR, 1991, P NATL ACAD SCI USA, V88, P10397, DOI 10.1073/pnas.88.23.10397; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; RIPPE K, 1995, TRENDS BIOCHEM SCI, V20, P500, DOI 10.1016/S0968-0004(00)89117-3; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; Rybenkov VV, 1997, SCIENCE, V277, P690, DOI 10.1126/science.277.5326.690; SAITOH N, 1994, J CELL BIOL, V127, P303, DOI 10.1083/jcb.127.2.303; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SNOUNOU G, 1983, J MOL BIOL, V167, P211, DOI 10.1016/S0022-2836(83)80043-6; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; Sutani T, 1997, NATURE, V388, P798, DOI 10.1038/42062; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WASSERMAN SA, 1986, SCIENCE, V232, P951, DOI 10.1126/science.3010458; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zlatanova J, 1998, FASEB J, V12, P421, DOI 10.1096/fasebj.12.6.421	37	264	275	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					239	248		10.1016/S0092-8674(00)81018-1	http://dx.doi.org/10.1016/S0092-8674(00)81018-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428035	Bronze			2022-12-24	WOS:000081632300013
J	van Heemst, D; James, F; Poggeler, S; Berteaux-Lecellier, V; Zickler, D				van Heemst, D; James, F; Poggeler, S; Berteaux-Lecellier, V; Zickler, D			Spo76p is a conserved chromosome morphogenesis protein that links the mitotic and meiotic programs	CELL			English	Article							SISTER-CHROMATID COHESION; SORDARIA-MACROSPORA; SACCHAROMYCES-CEREVISIAE; SYNAPTONEMAL COMPLEX; MATING-TYPE; MEIOSIS; RECOMBINATION; GENE; ORGANIZATION; CONDENSATION	Spo76p is conserved and related to the fungal proteins Pds5p and BIMD and the human AS3 prostate proliferative shutoff-associated protein. Spo76p localizes to mitotic and meiotic chromosomes, except at metaphase(s) and anaphase(s). During meiotic prophase, Spo76p assembles into strong lines in correlation with axial element formation. As inferred from spo76-1 mutant phenotypes, Spo76p is required for sister chromatid cohesiveness, chromosome axis morphogenesis, and chromatin condensation during critical transitions at mitotic prometaphase and meiotic midprophase. Spo76p is also required for meiotic interhomolog recombination, likely at postinitiation stage(s). We propose that a disruptive force coordinately promotes chromosomal axial compaction and destabilization of sister connections and that Spo76p restrains and channels the effects of this force into appropriate morphogenetic mitotic and meiotic outcomes.	Univ Paris Sud, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France; Ruhr Univ Bochum, Lehrstuhl Allgemeine Bot, D-44780 Bochum, Germany	UDICE-French Research Universities; Universite Paris Saclay; Ruhr University Bochum	van Heemst, D (corresponding author), Univ Paris Sud, Inst Genet & Microbiol, UMR 8621, F-91405 Orsay, France.	zickler@igmors.u-psud.fr	Berteaux-Lecellier, Veronique/O-4767-2018; BERTEAUX-LECELLIER, Veronique/P-6456-2019	Berteaux-Lecellier, Veronique/0000-0003-2152-6231; BERTEAUX-LECELLIER, Veronique/0000-0003-2152-6231	NIGMS NIH HHS [R37 GM25326] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1985, MOL CELL BIOL, V5, P2272, DOI 10.1128/MCB.5.9.2272; Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; Bickel SE, 1997, GENETICS, V146, P1319; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DAWE RK, 1994, CELL, V76, P901, DOI 10.1016/0092-8674(94)90364-6; DENISON SH, 1993, GENETICS, V134, P1085; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Geck P, 1999, J STEROID BIOCHEM, V68, P41, DOI 10.1016/S0960-0760(98)00165-4; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; Holt CL, 1996, GENETICS, V142, P777; HUYNH AD, 1986, CURR GENET, V10, P545, DOI 10.1007/BF00447389; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; LECELLIER G, 1994, CURR GENET, V25, P122, DOI 10.1007/BF00309536; MAGUIRE MP, 1993, GENOME, V36, P797, DOI 10.1139/g93-105; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; Moore DP, 1998, J CELL BIOL, V140, P1003, DOI 10.1083/jcb.140.5.1003; MOREAU PJF, 1985, MOL GEN GENET, V198, P189, DOI 10.1007/BF00382995; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; OSIEWACZ HD, 1994, CURR GENET, V26, P87, DOI 10.1007/BF00326309; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Poggeler S, 1997, GENETICS, V147, P567; PUKKILA PJ, 1995, CAN J BOT, V73, pS215; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/0968-0004(96)10031-1; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSENTHAL A, 1993, NUCLEIC ACIDS RES, V21, P173, DOI 10.1093/nar/21.1.173; Schwacha A, 1997, CELL, V90, P1123, DOI 10.1016/S0092-8674(00)80378-5; SLONIMSKI PP, 1993, YEAST, V9, P941, DOI 10.1002/yea.320090902; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407; Tang TTL, 1998, GENE DEV, V12, P3843, DOI 10.1101/gad.12.24.3843; THOMPSONCOFFE C, 1994, DEV BIOL, V165, P257, DOI 10.1006/dbio.1994.1251; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; TURCQ B, 1990, CURR GENET, V17, P297, DOI 10.1007/BF00314876; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; VONWETTSTEIN D, 1984, ANNU REV GENET, V18, P331, DOI 10.1146/annurev.ge.18.120184.001555; Zickler D, 1998, ANNU REV GENET, V32, P619, DOI 10.1146/annurev.genet.32.1.619; ZICKLER D, 1992, GENETICS, V132, P135	45	104	106	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					261	271		10.1016/S0092-8674(00)81020-X	http://dx.doi.org/10.1016/S0092-8674(00)81020-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428037	Bronze			2022-12-24	WOS:000081632300015
J	Dieckmann, U; Doebeli, M				Dieckmann, U; Doebeli, M			On the origin of species by sympatric speciation	NATURE			English	Article							ADAPTIVE RADIATION; NATURAL-SELECTION; SEXUAL SELECTION; MODEL; DYNAMICS; ANIMALS	Understanding speciation is a fundamental biological problem. It is believed that many species originated through allopatric divergence, where new species arise from geographically isolated populations of the same ancestral species(1-3). In contrast, the possibility of sympatric speciation (in which new species arise without geographical isolation) has often been dismissed, partly because of theoretical difficulties(2,3). Most previous models analysing sympatric speciation concentrated on particular aspects of the problem while neglecting others(4-10). Here we present a model that integrates a novel combination of different features and show that sympatric speciation is a likely outcome of competition for resources. We use multilocus genetics to describe sexual reproduction in an individual-based model, and we consider the evolution of assortative mating (where individuals mate preferentially with like individuals) depending either on an ecological character affecting resource use or on a selectively neutral marker trait. In both cases, evolution of assortative mating often leads to reproductive isolation between ecologically diverging subpopulations. When assortative mating depends on a marker trait, and is therefore not directly linked to resource competition, speciation occurs when genetic drift breaks the linkage equilibrium between the marker and the ecological trait. Our theory conforms well with mounting empirical evidence for the-sympatric origin of many species(10-18).	Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria; Univ Basel, Inst Zool, CH-4051 Basel, Switzerland	International Institute for Applied Systems Analysis (IIASA); University of Basel	Dieckmann, U (corresponding author), Int Inst Appl Syst Anal, Adapt Dynam Network, A-2361 Laxenburg, Austria.		Gilbert, Marcus TP/A-8936-2013; Dieckmann, Ulf/E-1424-2011; Doebeli, Michael/D-5391-2012	Gilbert, Marcus TP/0000-0002-5805-7195; Dieckmann, Ulf/0000-0001-7089-0393; 				BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Dieckmann U, 1996, J MATH BIOL, V34, P579, DOI 10.1007/BF02409751; Dieckmann U, 1997, TRENDS ECOL EVOL, V12, P128, DOI 10.1016/S0169-5347(97)01004-5; Doebeli M, 1997, EVOLUTION, V51, P1730, DOI 10.1111/j.1558-5646.1997.tb05097.x; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Geritz SAH, 1998, EVOL ECOL, V12, P35, DOI 10.1023/A:1006554906681; Johannesson K, 1995, EVOLUTION, V49, P1180, DOI 10.1111/j.1558-5646.1995.tb04445.x; Johnson PA, 1996, EVOL ECOL, V10, P187, DOI 10.1007/BF01241784; KNOX EB, 1995, P NATL ACAD SCI USA, V92, P10349, DOI 10.1073/pnas.92.22.10349; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; KONDRASHOV AS, 1986, THEOR POPUL BIOL, V29, P1, DOI 10.1016/0040-5809(86)90002-X; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; Mayr E., 1963, ANIMAL SPECIES EVOLU; MEYER A, 1990, NATURE, V347, P550, DOI 10.1038/347550a0; MEZ JAJ, 1996, STOCHASTIC SPATIAL S, P183; Nagel L, 1998, EVOLUTION, V52, P209, DOI 10.1111/j.1558-5646.1998.tb05154.x; Orr MR, 1998, TRENDS ECOL EVOL, V13, P502, DOI 10.1016/S0169-5347(98)01511-0; RICE WR, 1993, EVOLUTION, V47, P1637, DOI 10.1111/j.1558-5646.1993.tb01257.x; ROSENZWEIG ML, 1978, BIOL J LINN SOC, V10, P275, DOI 10.1111/j.1095-8312.1978.tb00016.x; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; SCHLUTER D, 1993, TRENDS ECOL EVOL, V8, P197, DOI 10.1016/0169-5347(93)90098-A; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; SEGER J, 1985, EVOLUTOIN ESSAYS HON; Taylor EB, 1999, BIOL J LINN SOC, V66, P271, DOI 10.1111/j.1095-8312.1999.tb01891.x; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093	30	1199	1234	8	631	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					354	357		10.1038/22521	http://dx.doi.org/10.1038/22521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432112	Green Submitted			2022-12-24	WOS:000081590000047
J	Ely, EW; Evans, GW; Haponik, EF				Ely, EW; Evans, GW; Haponik, EF			Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	95th International Conference of the American-Thoracic-Society	APR 23-29, 1999	SAN DIEGO, CA	Amer Thorac Soc		respiration, artificial; age factors; intensive care units; outcome and process assessment (health care); health resources	ILL HOSPITALIZED ADULTS; NEW-YORK-STATE; RESPIRATORY-FAILURE; AGE; MORTALITY; SURVIVAL; SUPPORT; IMPACT; LIFE; PREFERENCES	Background: It has been argued that life support for the elderly should be limited to conserve resources. As this population increases, so will the importance of evaluating appropriate use of mechanical ventilation in this group. Objective: To determine whether age has an independent effect on the outcomes of patients treated with mechanical ventilation after admission to an intensive care unit (ICU). Design: Prospective cohort study. Setting: University-based tertiary care medical center. Patients: 63 patients 75 years of age or older and 237 patients younger than 75 years of age enrolled from medical and coronary ICUs. Measurements: In-hospital mortality rate, duration of mechanical ventilation, lengths of stay in the ICU and in the hospital, and cost of care. Results: Median duration of mechanical ventilation was 4.2 days (interquartile range, 2.1 to 9.3 days) for patients 75 years of age or older and 6.4 days (interquartile range, 3.4 to 11.4 days) for patients younger than 75 years of age (P = 0.14). When the length of time required to "pass" a daily screening test of weaning variables was used as an indicator of recovery from respiratory failure, elderly patients passed earlier than younger patients (risk ratio, 1.58 [95% CI, 1.13 to 2.22]; P = 0.03). The cost of ICU care was lower for older ($12 822 [CI, $9821 to $26 313] than for younger ($19 316 [CI, $9699 to $39 950]) patients (P = 0.03). Median hospital costs tended to be lower in the older group ($21 292 compared with $29 049; P = 0.17). After adjustment for ethnicity, sex, and severity of illness in a multivariate logistic regression analysis, patient age of 75 years or older was predictive of 1 less day on the ventilator (CI, -2.8 to 1.2 days). Lengths of stay in the ICU (beta-coefficient, -0.5 days [CI, -3.0 to 2.7 days]) and in the hospital (beta-coefficient, 0.3 days [CI, -3.7 to 5.5 days]) did not differ for persons 75 years of age or older after these adjustments (P > 0.1). Intensive care unit and hospital costs, however, were lower for elderly persons (P = 0.02). The in-hospital mortality rate was 38.1% among elderly patients and 38.8% among younger patients (P > 0.2); Cox proportional hazards analysis confirmed that survival did not differ between the two groups (relative risk for older patients, 0.82 [CI, 0.52 to 1.29]). Conclusions: After adjustment for severity of illness, elderly patients spent similar time on mechanical ventilation and in the ICU and hospital but had a lower cost of care than younger patients. These outcomes are not explained by differences in mortality rate and suggest that mechanical ventilation should not be restricted in elderly patients with respiratory failure on the basis of chronologic age.	Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA	Vanderbilt University; Wake Forest University	Ely, EW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Allergy Pulm & Crit Care Med, 913 Oxford House, Nashville, TN 37232 USA.		Ely, E. Wesley/Z-2018-2019	Ely, E. Wesley/0000-0003-3957-2172				Baltussen R, 1996, HEALTH ECON, V5, P227, DOI 10.1002/(SICI)1099-1050(199605)5:3<227::AID-HEC198>3.3.CO;2-P; Barrett-Connor E, 1998, JAMA-J AM MED ASSOC, V279, P622, DOI 10.1001/jama.279.8.622; Blouin AS, 1996, J NURS ADMIN, V26, P3, DOI 10.1097/00005110-199611000-00001; BOULT C, 1993, J AM GERIATR SOC, V41, P811, DOI 10.1111/j.1532-5415.1993.tb06175.x; Campion EW, 1998, NEW ENGL J MED, V338, P1064, DOI 10.1056/NEJM199804093381512; CAMPION EW, 1981, JAMA-J AM MED ASSOC, V246, P2052, DOI 10.1001/jama.246.18.2052; CHELLURI L, 1992, CRIT CARE MED, V20, P757, DOI 10.1097/00003246-199206000-00010; COHEN IL, 1995, CHEST, V107, P1673, DOI 10.1378/chest.107.6.1673; COHEN IL, 1993, JAMA-J AM MED ASSOC, V269, P1025, DOI 10.1001/jama.269.8.1025; COX DR, 1972, J R STAT SOC B, V34, P187; CURTIS JR, 1995, JAMA-J AM MED ASSOC, V273, P124, DOI 10.1001/jama.273.2.124; DARDAINE V, 1995, AGING-CLIN EXP RES, V7, P221, DOI 10.1007/BF03324339; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; ELPERN EH, 1989, CHEST, V96, P1120, DOI 10.1378/chest.96.5.1120; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Fried TR, 1996, J GEN INTERN MED, V11, P257, DOI 10.1007/BF02598264; Giugliano RP, 1998, ARCH INTERN MED, V158, P1113, DOI 10.1001/archinte.158.10.1113; GOLDBERG AI, 1988, CHEST, V94, P1277, DOI 10.1378/chest.94.6.1277; GRACEY DR, 1992, CHEST, V101, P211, DOI 10.1378/chest.101.1.211; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HEUSER MD, 1992, ARCH INTERN MED, V152, P1683, DOI 10.1001/archinte.152.8.1683; Hobbs FB, 1995, 65 PLUS US; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kurek CJ, 1998, CHEST, V114, P214, DOI 10.1378/chest.114.1.214; Kurek CJ, 1997, CRIT CARE MED, V25, P983, DOI 10.1097/00003246-199706000-00015; MCLEAN RF, 1985, CRIT CARE MED, V13, P625, DOI 10.1097/00003246-198508000-00002; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NUCKTON TJ, 1995, ARCH INTERN MED, V155, P1087, DOI 10.1001/archinte.155.10.1087; NUNN JF, 1979, BRIT MED J, V1, P1525, DOI 10.1136/bmj.1.6177.1525; ODONNELL A, 1991, CHEST, V100, P295; PAPADAKIS MA, 1993, WESTERN J MED, V159, P659; PESAU B, 1992, CRIT CARE MED, V20, P489, DOI 10.1097/00003246-199204000-00010; SAGE WM, 1987, J AM GERIATR SOC, V35, P312, DOI 10.1111/j.1532-5415.1987.tb04637.x; Shaw AB, 1996, DRUG AGING, V9, P403, DOI 10.2165/00002512-199609060-00003; SINGER PA, 1992, ARCH INTERN MED, V152, P478, DOI 10.1001/archinte.152.3.478; STAUFFER JL, 1993, CHEST, V104, P1222, DOI 10.1378/chest.104.4.1222; Steiner T, 1997, STROKE, V28, P711, DOI 10.1161/01.STR.28.4.711; SWINBURNE AJ, 1993, ARCH INTERN MED, V153, P1657, DOI 10.1001/archinte.153.14.1657; TENO JM, 1995, J GEN INTERN MED, V10, P179, DOI 10.1007/BF02600252; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; Vita AJ, 1998, NEW ENGL J MED, V338, P1035, DOI 10.1056/NEJM199804093381506; WITEK TJ, 1985, ARCH INTERN MED, V145, P235, DOI 10.1001/archinte.145.2.235; Yuen E J, 1995, Am J Med Qual, V10, P76, DOI 10.1177/0885713X9501000203; Zilberberg MD, 1998, AM J RESP CRIT CARE, V157, P1159, DOI 10.1164/ajrccm.157.4.9704088	54	132	138	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					96	+		10.7326/0003-4819-131-2-199907200-00004	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	217QD	10419447				2022-12-24	WOS:000081509700003
J	Selam, JL				Selam, JL			Implantable insulin pumps	LANCET			English	Editorial Material							INTRAPERITONEAL; MULTICENTER; INFUSION; GLUCOSE		Univ Paris 06, CHU Broussais Hotel Dieu, INSERM,U341, Serv Diabetol, F-75181 Paris 04, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Selam, JL (corresponding author), Univ Paris 06, CHU Broussais Hotel Dieu, INSERM,U341, Serv Diabetol, F-75181 Paris 04, France.							ABRAIRA C, 1995, DIABETES CARE, V18, P1112; ALBISSER AM, 1974, DIABETES, V23, P397, DOI 10.2337/diab.23.5.397; BLACKSHEAR P J, 1970, Surgical Forum (Chicago), V21, P136; BLACKSHEAR PJ, 1979, DIABETES, V28, P634, DOI 10.2337/diabetes.28.7.634; BROUSSOLLE C, 1994, LANCET, V343, P514, DOI 10.1016/S0140-6736(94)91462-1; Duckworth WC, 1998, DIABETES CARE, V21, P1596, DOI 10.2337/diacare.21.10.1596; DUCKWORTH WC, 1992, DIABETES, V41, P657, DOI 10.2337/diabetes.41.6.657; HAARDT MJ, 1994, DIABETES CARE, V17, P847, DOI 10.2337/diacare.17.8.847; HANAIREBROUTIN H, 1995, DIABETES CARE, V18, P388, DOI 10.2337/diacare.18.3.388; LassmannVague V, 1997, DIABETES METAB, V23, P234; Laube BL, 1998, CHEST, V114, P1734, DOI 10.1378/chest.114.6.1734; Saudek CD, 1996, JAMA-J AM MED ASSOC, V276, P1322, DOI 10.1001/jama.276.16.1322; Selam JL, 1995, DIABETIC MED, V12, P1102, DOI 10.1111/j.1464-5491.1995.tb00428.x	13	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					178	179		10.1016/S0140-6736(99)90034-X	http://dx.doi.org/10.1016/S0140-6736(99)90034-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421296				2022-12-24	WOS:000081504200006
J	Shlomchik, WD; Couzens, MS; Tang, CB; McNiff, J; Robert, ME; Liu, JL; Shlomchik, MJ; Emerson, SG				Shlomchik, WD; Couzens, MS; Tang, CB; McNiff, J; Robert, ME; Liu, JL; Shlomchik, MJ; Emerson, SG			Prevention of graft versus host disease by inactivation of host antigen-presenting cells	SCIENCE			English	Article							BONE-MARROW TRANSPLANTATION; CD8+ T-CELLS; HISTOCOMPATIBILITY ANTIGEN; DENDRITIC CELLS; LYMPHOCYTES; DEFICIENT; TOLERANCE; PROTEINS; MICE	Craft versus host disease, an alloimmune attack on host tissues mounted by donor T cells, is the most important toxicity of allogeneic bone marrow transplantation. The mechanism by which allogeneic T cells are initially stimulated is unknown. In a murine allogeneic bone marrow transplantation model it was found that, despite the presence of numerous donor antigen-presenting cells, only host-derived antigen-presenting cells initiated graft versus host disease. Thus, strategies for preventing graft versus host disease could be developed that are based on inactivating host antigen-presenting cells. Such strategies could expand the safety and application of allogeneic bone marrow transplantation in treatment of common genetic and neoplastic diseases.	Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA	University of Pennsylvania; University of Pennsylvania; Yale University; Yale University; Yale University; Yale University	Emerson, SG (corresponding author), Univ Penn, Sch Med, Dept Med, Div Hematol & Oncol, Philadelphia, PA 19104 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959	NHLBI NIH HHS [P50HL-54516] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054516] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; BEVAN MJ, 1995, J EXP MED, V182, P639, DOI 10.1084/jem.182.3.639; BIX M, 1991, NATURE, V349, P329, DOI 10.1038/349329a0; CHAO NJ, 1996, GRAFT VS HOST DIS, P639; DEEG HJ, 1996, GRAFT VS HOST DIS, P311; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; FERRARA JLM, 1994, BONE MARROW TRANSPL, V14, P183; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HOROWITZ MM, 1990, BLOOD, V75, P555; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; KORNGOLD R, 1982, J EXP MED, V155, P872, DOI 10.1084/jem.155.3.872; KOSAKA H, 1992, J EXP MED, V176, P1291, DOI 10.1084/jem.176.5.1291; Kurts C, 1998, J EXP MED, V188, P409, DOI 10.1084/jem.188.2.409; MAIER T, 1996, GRAFT VS HOST DIS, P75; MATZINGER P, 1977, CELL IMMUNOL, V33, P92, DOI 10.1016/0008-8749(77)90137-X; METLAY JP, 1990, J EXP MED, V171, P1753, DOI 10.1084/jem.171.5.1753; SRIVASTAVA PK, 1994, IMMUNOGENETICS, V39, P93; STREILEIN JW, 1970, J EXP MED, V132, P163, DOI 10.1084/jem.132.1.163; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; TRUITT RL, 1991, BLOOD, V77, P2515; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640; WEIDEN PL, 1976, J IMMUNOL, V116, P1212	23	957	988	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					412	415		10.1126/science.285.5426.412	http://dx.doi.org/10.1126/science.285.5426.412			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411505				2022-12-24	WOS:000081465900056
J	Peng, JR; Richards, DE; Hartley, NM; Murphy, GP; Devos, KM; Flintham, JE; Beales, J; Fish, LJ; Worland, AJ; Pelica, F; Sudhakar, D; Christou, P; Snape, JW; Gale, MD; Harberd, NP				Peng, JR; Richards, DE; Hartley, NM; Murphy, GP; Devos, KM; Flintham, JE; Beales, J; Fish, LJ; Worland, AJ; Pelica, F; Sudhakar, D; Christou, P; Snape, JW; Gale, MD; Harberd, NP			'Green revolution' genes encode mutant gibberellin response modulators	NATURE			English	Article							WHEAT; MAIZE; TRANSDUCTION; EVOLUTION; DWARFISM; GENETICS; ALLELES; PATHWAY; DNA; SH2	World wheat grain yields increased substantially in the 1960s and 1970s because farmers rapidly adopted the new varieties and cultivation methods of the so-called 'green revolution(1-4). The new varieties are shorter, increase grain yield at the expense of straw biomass, and are more resistant to damage by wind and rain(3,4). These wheats are short because they respond abnormally to the plant growth hormone gibberellin, This reduced response to gibberellin is conferred by mutant dwarfing alleles at one of two Reduced height-1 (Rht-B1 and Rht-D1) loci(4,5), Here we show that Rht-B1/Rht-D1 and maize dwarf-8 (d8)(6,7) are orthologues of the Arabidopsis Gibberellin Insensitive (GAI) gene(8,9). These genes encode proteins that resemble nuclear transcription factors and contain an SH2-like(10) domain, indicating that phosphotyrosine may participate in gibberellin signalling. Six different orthologous dwarfing mutant alleles encode proteins that are altered in a conserved amino-terminal gibberellin signalling domain, Transgenic rice plants containing a mutant GAI allele give reduced responses to gibberellin and are dwarfed, indicating that mutant GAI orthologues could be used to increase yield in a wide range of crop species.	John Innes Ctr Plant Sci Res, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Harberd, NP (corresponding author), John Innes Ctr Plant Sci Res, Norwich Res Pk,Colney Lane, Norwich NR4 7UH, Norfolk, England.	harberd@bbsrc.ac.uk	Christou, Paul/C-8645-2011; Devos, Katrien M/B-1380-2014	Christou, Paul/0000-0001-6358-7396; Snape, john/0000-0002-9241-3931; Peng, Jinrong/0000-0002-0793-4848	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000583] Funding Source: researchfish	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Borner A, 1996, EUPHYTICA, V89, P69, DOI 10.1007/BF00015721; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Conway G., 1997, DOUBLY GREEN REVOLUT; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVOS KM, 1995, THEOR APPL GENET, V91, P282, DOI 10.1007/BF00220890; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; Dyson T, 1996, POPULATION FOOD GLOB; Evans LT., 1993, CROP EVOLUTION ADAPT; FUJIOKA S, 1988, P NATL ACAD SCI USA, V85, P9031, DOI 10.1073/pnas.85.23.9031; Futterer J, 1996, PLANT MOL BIOL, V32, P159, DOI 10.1007/BF00039382; Gale M. D., 1985, Progress in plant breeding - 1, P1; GALE MD, 1976, HEREDITY, V37, P283, DOI 10.1038/hdy.1976.88; HARBERD NP, 1989, GENETICS, V121, P827; HOOLEY R, 1994, PLANT MOL BIOL, V26, P1529, DOI 10.1007/BF00016489; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOORNNEEF M, 1985, PHYSIOL PLANTARUM, V65, P33, DOI 10.1111/j.1399-3054.1985.tb02355.x; KURATA N, 1994, NAT GENET, V8, P365, DOI 10.1038/ng1294-365; MOORE G, 1995, CURR BIOL, V5, P737, DOI 10.1016/S0960-9822(95)00148-5; PENG JR, 1993, PLANT CELL, V5, P351, DOI 10.1105/tpc.5.3.351; Peng JR, 1997, GENE DEV, V11, P3194, DOI 10.1101/gad.11.23.3194; Peng JR, 1999, PLANT PHYSIOL, V119, P1199, DOI 10.1104/pp.119.4.1199; Sambrook JFE, 1989, MOL CLONING LAB MANU; Schumacher K, 1999, P NATL ACAD SCI USA, V96, P290, DOI 10.1073/pnas.96.1.290; Silverstone AL, 1998, PLANT CELL, V10, P155, DOI 10.1105/tpc.10.2.155; Sudhakar D, 1998, TRANSGENIC RES, V7, P289, DOI 10.1023/A:1008870012568; Webb SE, 1998, PHYTOCHEMISTRY, V47, P671, DOI 10.1016/S0031-9422(97)00684-5; WINKLER RG, 1994, PLANTA, V193, P341, DOI 10.1007/BF00201811; Winkler RG, 1993, MAIZE GENET COOP NEW, V67, P110	30	1380	1661	40	583	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					256	261		10.1038/22307	http://dx.doi.org/10.1038/22307			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421366				2022-12-24	WOS:000081503800042
J	Martinez-Menarguez, JA; Geuze, HJ; Slot, JW; Klumperman, J				Martinez-Menarguez, JA; Geuze, HJ; Slot, JW; Klumperman, J			Vesicular tubular clusters between the ER and Golgi mediate concentration of soluble secretory proteins by exclusion front COPI-coated vesicles	CELL			English	Article							PANCREATIC ACINAR CELL; ENDOPLASMIC-RETICULUM; TRANSPORT VESICLES; INTERMEDIATE COMPARTMENT; SELECTIVE TRANSPORT; EXOCRINE PANCREAS; THIN-SECTIONS; LIVING CELLS; BULK FLOW; CARGO	We have determined the concentrations of the secretory proteins amylase and chymotrypsinogen and the membrane proteins KDELr and rBet1 in COPII- and COPI-coated pre-Golgi compartments of pancreatic cells by quantitative immunoelectron microscopy. COPII was confined to ER membrane buds and adjacent vesicles. COPI occurred on vesicular tubular clusters (VTCs), Golgi cisternae, the trans-Golgi network, and immature secretory granules. Both secretory proteins exhibited a first, significant concentration step in noncoated segments of VTC tubules and were excluded from COPI-coated tips. By contrast, KDELr and rBet1 showed a first, significant concentration in COPII-coated ER buds and vesicles and were prominently present in COPI-coated tips of VTC tubules. These data suggest an important role of VTCs in soluble cargo concentration by exclusion from COPI-coated domains.	Univ Utrecht, Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Univ Utrecht, Inst Biomembranes, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University	Klumperman, J (corresponding author), Univ Utrecht, Univ Med Ctr, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands.							Aridor M, 1996, TRENDS CELL BIOL, V6, P315, DOI 10.1016/0962-8924(96)10027-1; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1998, HISTOCHEM CELL BIOL, V109, P463, DOI 10.1007/s004180050248; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BENDAYAN M, 1984, HISTOCHEM J, V16, P85, DOI 10.1007/BF01003438; Bonfanti L, 1998, CELL, V95, P993, DOI 10.1016/S0092-8674(00)81723-7; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; DIJKHOF J, 1978, BIOCHIM BIOPHYS ACTA, V543, P167, DOI 10.1016/0304-4165(78)90062-4; Dominguez M, 1998, J CELL BIOL, V140, P751, DOI 10.1083/jcb.140.4.751; FARQUHAR MG, 1997, GOLGI APPARATUS, P63; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; GEUZE HJ, 1980, EUR J CELL BIOL, V21, P93; GEUZE JJ, 1979, J CELL BIOL, V82, P697, DOI 10.1083/jcb.82.3.697; GRIFFITHS G, 1995, TRENDS CELL BIOL, V5, P9, DOI 10.1016/S0962-8924(00)88926-6; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; Kaiser C, 1998, CURR OPIN CELL BIOL, V10, P477, DOI 10.1016/S0955-0674(98)80062-8; Kappeler F, 1997, J BIOL CHEM, V272, P31801, DOI 10.1074/jbc.272.50.31801; Klumperman J, 1998, J CELL SCI, V111, P3411; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; Kuehn MJ, 1998, NATURE, V391, P187, DOI 10.1038/34438; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Majoul I, 1998, J CELL BIOL, V143, P601, DOI 10.1083/jcb.143.3.601; MartinezMenarguez JA, 1996, EUR J CELL BIOL, V71, P137; Nickel W, 1998, J CELL SCI, V111, P3081; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1985, CELL, V42, P671, DOI 10.1016/0092-8674(85)90124-2; Orci L, 1997, CELL, V90, P335, DOI 10.1016/S0092-8674(00)80341-4; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PELHAM HRB, 1995, CURR OPIN CELL BIOL, V7, P530, DOI 10.1016/0955-0674(95)80010-7; POSTHUMA G, 1987, J HISTOCHEM CYTOCHEM, V35, P405, DOI 10.1177/35.4.2434559; POSTHUMA G, 1984, J HISTOCHEM CYTOCHEM, V32, P1028, DOI 10.1177/32.10.6207220; POSTHUMA G, 1988, EUR J CELL BIOL, V46, P327; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SALAMA NR, 1995, CURR OPIN CELL BIOL, V7, P536, DOI 10.1016/0955-0674(95)80011-5; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; SCHEELE G, 1985, J BIOL CHEM, V260, P926; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SESSO A, 1994, J CELL SCI, V107, P517; SLOT JW, 1985, EUR J CELL BIOL, V38, P87; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Tang BL, 1997, MOL CELL BIOL, V17, P256, DOI 10.1128/MCB.17.1.256; TOOZE J, 1986, J CELL BIOL, V103, P839, DOI 10.1083/jcb.103.3.839; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Zhang T, 1997, J CELL BIOL, V139, P1157, DOI 10.1083/jcb.139.5.1157	55	247	251	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					81	90		10.1016/S0092-8674(00)80608-X	http://dx.doi.org/10.1016/S0092-8674(00)80608-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412983	Bronze			2022-12-24	WOS:000081451000010
J	Visscher, K; Schnitzer, MJ; Block, SM				Visscher, K; Schnitzer, MJ; Block, SM			Single kinesin molecules studied with a molecular force clamp	NATURE			English	Article							STOCHASTIC-MODEL; MYOSIN MOLECULE; ATP HYDROLYSIS; OPTICAL TRAPS; MOTOR; MECHANICS; KINETICS; MOVEMENT; MICROTUBULES; STEPS	Kinesin is a two-headed, ATP-driven motor protein that moves processively along microtubules in discrete steps of 8 nm, probably by advancing each of its heads alternately in sequence(1-4). Molecular details of how the chemical energy stored in ATP is coupled to mechanical displacement remain obscure. To shed light on this question, a force clamp was constructed, based on a feedback-driven optical trap capable of maintaining constant loads on single kinesin motors(5). The instrument provides unprecedented resolution of molecular motion and permits mechanochemical studies under controlled external loads. Analysis of records of kinesin motion under variable ATP concentrations and loads revealed several new features. First, kinesin stepping appears to be tightly coupled to ATP hydrolysis over a wide range of forces, with a single hydrolysis per 8-nm mechanical advance. Second, the kinesin stall force depends on the ATP concentration. Third, increased loads reduce the maximum velocity as expected, but also raise the apparent Michaelis-Menten constant. The kinesin cycle therefore contains at least one load-dependent transition affecting the rate at which ATP molecules bind and subsequently commit to hydrolysis, It is likely that at least one other load-dependent rate exists, affecting turnover number. Together, these findings will necessitate revisions to our understanding of how kinesin motors function.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University; Princeton University; Princeton University	Schnitzer, MJ (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.							Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Coppin CM, 1996, P NATL ACAD SCI USA, V93, P1913, DOI 10.1073/pnas.93.5.1913; Derenyi I, 1996, P NATL ACAD SCI USA, V93, P6775, DOI 10.1073/pnas.93.13.6775; Duke T, 1996, BIOPHYS J, V71, P1235, DOI 10.1016/S0006-3495(96)79323-2; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HIGUCHI H, 1998, CELL STRUCT FUNCT S, V23, P198; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1995, BIOPHYS J, V68, pS245; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; LEIBLER S, 1993, J CELL BIOL, V121, P1357, DOI 10.1083/jcb.121.6.1357; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; PESKIN CS, 1995, BIOPHYS J, V68, pS202; Samuel ADT, 1996, BIOPHYS J, V71, P918, DOI 10.1016/S0006-3495(96)79295-0; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; SVOBODA K, 1994, P NATL ACAD SCI USA, V91, P11782, DOI 10.1073/pnas.91.25.11782; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0	32	804	818	0	110	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					184	189		10.1038/22146	http://dx.doi.org/10.1038/22146			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408448				2022-12-24	WOS:000081324900059
J	Hayakawa, K; Asano, M; Shinton, SA; Gui, M; Allman, D; Stewart, CL; Silver, J; Hardy, RR				Hayakawa, K; Asano, M; Shinton, SA; Gui, M; Allman, D; Stewart, CL; Silver, J; Hardy, RR			Positive selection of natural autoreactive B cells	SCIENCE			English	Article							REGION GENE-EXPRESSION; TRANSGENIC MICE; AUTOIMMUNE-DISEASE; CLONAL SELECTION; NORMAL MOUSE; IMMUNOGLOBULIN; ANTIGEN; AUTOANTIBODIES; ANTIBODY; LINEAGE	Lymphocyte development is critically influenced by self-antigens. T cells are subject to both positive and negative selection, depending on their degree of seif-reactivity. Although B cells are subject to negative selection, it has been difficult to test whether self-antigen plays any positive role in B cell development. A murine model system of naturally generated autoreactive B cells with a germ Line gene-encoded specificity for the Thy-1 (CD90) glycoprotein was developed, in which the presence of self-antigen promotes B cell accumulation and serum autoantibody secretion. Thus, B cells can be subject to positive selection, generated, and maintained on the basis of their autoreactivity.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; NCI, Lab Canc & Dev Biol, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Cornell Univ Med Coll, N Shore Univ Hosp, Div Mol Med, Manhasset, NY 11030 USA	Fox Chase Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Cornell University; Northwell Health; North Shore University Hospital	Hayakawa, K (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.							ARNOLD LW, 1994, J EXP MED, V179, P1585, DOI 10.1084/jem.179.5.1585; BOYDEN S, 1964, NATURE, V201, P200, DOI 10.1038/201200a0; BRILES DE, 1981, J EXP MED, V153, P694, DOI 10.1084/jem.153.3.694; CUNNINGHAM AJ, 1974, NATURE, V252, P749, DOI 10.1038/252749a0; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; DIGHIERO G, 1985, J IMMUNOL, V134, P765; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hannum LG, 1996, J EXP MED, V184, P1269, DOI 10.1084/jem.184.4.1269; HARDY RR, 1994, ADV IMMUNOL, V55, P297; HARDY RR, 1994, IMMUNOL REV, V137, P91, DOI 10.1111/j.1600-065X.1994.tb00660.x; HARTLEY SB, 1994, INT IMMUNOL, V6, P1417, DOI 10.1093/intimm/6.9.1417; HAUGHTON G, 1986, IMMUNOL REV, V93, P35, DOI 10.1111/j.1600-065X.1986.tb01501.x; HAYAKAWA K, 1990, J EXP MED, V172, P869, DOI 10.1084/jem.172.3.869; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Kearney J F, 1992, Curr Top Microbiol Immunol, V182, P81; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; MACLENNAN ICM, 1986, IMMUNOL REV, V91, P61, DOI 10.1111/j.1600-065X.1986.tb01484.x; MARTIN WJ, 1974, NATURE, V249, P564, DOI 10.1038/249564a0; MURAKAMI M, 1992, NATURE, V357, P77, DOI 10.1038/357077a0; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; Page DM, 1997, J IMMUNOL, V159, P5285; PENNELL CA, 1989, EUR J IMMUNOL, V19, P1289, DOI 10.1002/eji.1830190721; PENNELL CA, 1988, J IMMUNOL, V141, P2788; POTTER M, 1982, MOL IMMUNOL, V19, P1619, DOI 10.1016/0161-5890(82)90273-5; SCHLESINGER M, 1965, NATURE, V207, P429, DOI 10.1038/207429b0	33	462	473	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					113	116		10.1126/science.285.5424.113	http://dx.doi.org/10.1126/science.285.5424.113			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390361				2022-12-24	WOS:000081199800043
J	Sadetzki, S; Modan, B				Sadetzki, S; Modan, B			Epidemiology as a basis for legislation: how far should epidemiology go?	LANCET			English	Editorial Material							RADIATION		Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Stanley Steyer Inst Canc Epidemiol, IL-69978 Tel Aviv, Israel	Chaim Sheba Medical Center; Tel Aviv University	Modan, B (corresponding author), Chaim Sheba Med Ctr, Dept Clin Epidemiol, IL-52621 Tel Hashomer, Israel.							BROWN WMC, 1955, LANCET, V1, P1283; CRAWFORD GM, 1951, NEW ENGL J MED, V245, P726, DOI 10.1056/NEJM195111082451904; DAMESHEK W, 1957, JAMA-J AM MED ASSOC, V163, P838, DOI 10.1001/jama.1957.02970450040010; HARDER D, 1995, DIGNITY DISCOVERY RA; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; *ICRP, 1992, ICRP PUBL, V59; KAPLAN I I, 1957, Can Med Assoc J, V76, P43; LANGE RD, 1954, BLOOD, V9, P574, DOI 10.1182/blood.V9.6.574.574; LEVIN ML, 1950, JAMA-J AM MED ASSOC, V143, P336, DOI 10.1001/jama.1950.02910390008002; MARCH HC, 1950, AM J MED SCI, V220, P282, DOI 10.1097/00000441-195022030-00007; March HC., 1944, RADIOLOGY, V43, P275, DOI DOI 10.1148/43.3.275; Modan B, 1975, Harefuah, V88, P541; MODAN B, 1974, LANCET, V1, P277; MODAN B, 1987, MED ONCOL TUMOR PHAR, V4, P141; MOLONEY WC, 1995, SCIENCE, V121, P308; RON E, 1984, ISRAEL J MED SCI, V20, P1164; RON E, 1988, NEW ENGL J MED, V319, P1033, DOI 10.1056/NEJM198810203191601; RON E, 1982, AM J EPIDEMIOL, V16, P149; *US DHEW, 1964, PHS PUBL; VETTER RJ, 1993, HEALTH PHYS, V64, P115; WERNER A, 1968, PHYS MED BIOL, V13, P247, DOI 10.1088/0031-9155/13/2/310; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P320	22	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2238	2239		10.1016/S0140-6736(98)12327-9	http://dx.doi.org/10.1016/S0140-6736(98)12327-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10393003				2022-12-24	WOS:000081091300045
J	Duchamp-Viret, P; Chaput, MA; Duchamp, A				Duchamp-Viret, P; Chaput, MA; Duchamp, A			Odor response properties of rat olfactory receptor neurons	SCIENCE			English	Article							HOMEOTIC TRANSFORMATION; TARGETED DISRUPTION; BRANCHIAL REGION; CHICK HINDBRAIN; CRANIAL NERVES; MOTOR-NEURONS; NEURAL CREST; MUTANT MICE; HOX CODE; SYSTEM	Molecular biology studies of olfaction have identified a multigene family of molecular receptors that are Likely to be involved in odor transduction mechanisms. However, because previous functional data on peripheral coding were mainly collected from inferior vertebrates, it has been difficult to document the degree of specificity of odor interaction mechanisms. As a matter of fact, studies of the functional expression of olfactory receptors have not demonstrated the Low or high specificity of olfactory receptors. In this study, the selectivity of olfactory receptor neurons was investigated in the rat at the cellular Level under physiological conditions by unitary extracellular recordings. Individual olfactory receptor neurons were broadly responsive to qualitatively distinct odor compounds. We conclude that peripheral coding is based on activated arrays of olfactory receptor cells with overlapping tuning profiles.	Univ Lyon 1, CNRS, Lab Neurosci & Syst Sensoriels, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Duchamp-Viret, P (corresponding author), Univ Lyon 1, CNRS, Lab Neurosci & Syst Sensoriels, 43 Blvd 11 Novembre 1918, F-69622 Villeurbanne, France.	pduchamp@olfac.univ-lyon1.fr	Duchamp-Viret, Patricia/N-9827-2017	Duchamp-Viret, Patricia/0000-0002-7730-266X				Alexandre D, 1996, DEVELOPMENT, V122, P735; Bateson W., 1894, MAT STUDY VARIATION, DOI 10.5962/bhl.title.88017; BELL E, IN PRESS MECH DEV; BUCK L, 1993, CHEM SENSES, V18, P203, DOI 10.1093/chemse/18.2.203; Burke AC, 1996, DEV BIOL, V178, P192, DOI 10.1006/dbio.1996.0210; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; DUCHAMPVIRET P, 1989, J NEUROPHYSIOL, V61, P1085, DOI 10.1152/jn.1989.61.5.1085; DuchampViret P, 1997, PROG NEUROBIOL, V53, P561, DOI 10.1016/S0301-0082(97)00049-X; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Goddard JM, 1996, DEVELOPMENT, V122, P3217; Goulding M, 1998, NEURON, V21, P943, DOI 10.1016/S0896-6273(00)80612-1; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; PATA I, UNPUB; POURQUIE O, 1990, DEVELOPMENT, V109, P743; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RIJLI FM, 1993, CELL, V75, P1333, DOI 10.1016/0092-8674(93)90620-6; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Tiret L, 1998, DEVELOPMENT, V125, P279; VASSAR R, 1994, CELL, V79, P981, DOI 10.1016/0092-8674(94)90029-9; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	35	220	226	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2171	2174		10.1126/science.284.5423.2171	http://dx.doi.org/10.1126/science.284.5423.2171			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381881	Green Submitted			2022-12-24	WOS:000081099300050
J	Lynch, KR; O'Neill, GP; Liu, QY; Im, DS; Sawyer, N; Metters, KM; Coulombe, N; Abramovitz, M; Figueroa, DJ; Zeng, ZZ; Connolly, BM; Bai, C; Austin, CP; Chateauneuf, A; Stocco, R; Greig, GM; Kargman, S; Hooks, SB; Hosfield, E; Williams, DL; Ford-Hutchinson, AW; Caskey, CT; Evans, JF				Lynch, KR; O'Neill, GP; Liu, QY; Im, DS; Sawyer, N; Metters, KM; Coulombe, N; Abramovitz, M; Figueroa, DJ; Zeng, ZZ; Connolly, BM; Bai, C; Austin, CP; Chateauneuf, A; Stocco, R; Greig, GM; Kargman, S; Hooks, SB; Hosfield, E; Williams, DL; Ford-Hutchinson, AW; Caskey, CT; Evans, JF			Characterization of the human cysteinyl leukotriene CysLT(1) receptor	NATURE			English	Article							DOUBLE-BLIND TRIAL; GUINEA-PIG LUNG; CHRONIC ASTHMA; ANTAGONIST; MONTELUKAST; POTENT; PHARMACOLOGY; MULTICENTER; EXPRESSION; RESPONSES	The cysteinyl leukotrienes-leukotriene C-4(LTC4), leukotriene D-4(LTD4) and leukotriene E-4(LTE4)-are important mediators of human bronchial asthma(1-3). Pharmacological studies have determined that cysteinyl leukotrienes activate at least two receptors, designated CysLT(1) and CysLT(2) (refs 4-6). The CysLT(1)-selective antagonists, such as montelukast (Singulair)(7-10), zafirlukast (Accolate)(11) and pranlukast (Onon)(12), are important in the treatment of asthma. Previous biochemical characterization of CysLT(1) antagonists and the CysLT(1) receptor has been in membrane preparations from tissues enriched for this receptor(13). Here we report the molecular and pharmacological characterization of the cloned human CysLT(1) receptor. We describe the functional activation (calcium mobilization) of this receptor by LTD4 and LTC4, and competition for radiolabelled LTD4 binding to this receptor by the cysteinyl leukotrienes and three structurally distinct classes of CysLT(1)-receptor antagonists. We detected CysLT(1)-receptor messenger RNA in spleen, peripheral blood leukocytes and lung. In normal human lung, expression of the CysLT(1)-receptor mRNA was confined to smooth muscle cells and tissue macrophages. Finally, we mapped the human CysLT(1)-receptor gene to the X chromosome.	Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA; Merck Frosst Canada & Co, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck & Co Inc, Dept Pharmacol, West Point, PA 19486 USA; Merck & Co Inc, Dept Human Genet, West Point, PA 19486 USA	University of Virginia; Merck & Company; Merck & Company; Merck & Company	Evans, JF (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pharmacol, Charlottesville, VA 22908 USA.	jilly_evans@merck.com		IM, DONG-SOON/0000-0001-8054-8946				CHAN CC, 1994, J PHARMACOL EXP THER, V269, P891; CHARETTE L, 1987, BRIT J PHARMACOL, V91, P179, DOI 10.1111/j.1476-5381.1987.tb08997.x; COLEMAN RA, 1995, ADV PROSTAG THROMB L, V23, P283; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DURIEUX ME, 1993, AM J PHYSIOL, V264, pC1360, DOI 10.1152/ajpcell.1993.264.5.C1360; ELLIS C, 1998, Patent No. 0874047; FREY EA, 1993, EUR J PHARM-MOLEC PH, V244, P239, DOI 10.1016/0922-4106(93)90149-4; Grossman J, 1997, J ASTHMA, V34, P321, DOI 10.3109/02770909709067222; Hooks SB, 1998, MOL PHARMACOL, V53, P188, DOI 10.1124/mol.53.2.188; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191, DOI 10.1139/y95-028; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Kolakowski LF, 1998, J NEUROCHEM, V71, P2239; LABAT C, 1992, J PHARMACOL EXP THER, V263, P800; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Martin V, 1999, J BIOL CHEM, V274, P8597, DOI 10.1074/jbc.274.13.8597; McClintock TS, 1996, J CELL PHYSIOL, V167, P1; METTERS KM, 1993, J BIOL CHEM, V268, P6487; METTERS KM, 1995, J LIPID MEDIAT CELL, V12, P413, DOI 10.1016/0929-7855(95)00027-N; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIPER PJ, 1984, PHYSIOL REV, V64, P744, DOI 10.1152/physrev.1984.64.2.744; POTENZA MN, 1994, J NEUROSCI, V14, P1463, DOI 10.1523/JNEUROSCI.14-03-01463.1994; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Suissa S, 1997, ANN INTERN MED, V126, P177, DOI 10.7326/0003-4819-126-3-199702010-00001; UNGRIN MD, IN PRESS ANAL BIOCH; Wright DH, 1998, BRIT J PHARMACOL, V123, P1317; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	28	801	826	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					789	793						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391245				2022-12-24	WOS:000081101600055
J	Carr, A; Samaras, K; Thorisdottir, A; Kaufmann, GR; Chisholm, DJ; Cooper, DA				Carr, A; Samaras, K; Thorisdottir, A; Kaufmann, GR; Chisholm, DJ; Cooper, DA			Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; X-RAY ABSORPTIOMETRY; MYOCARDIAL-INFARCTION; DENSITY-LIPOPROTEIN; INSULIN-RESISTANCE; INFECTED PATIENTS; BODY-COMPOSITION; HDL-CHOLESTEROL; RISK; TRIGLYCERIDE	Background The prevalence and severity of lipodystrophy syndrome with long-term therapy for HIV-1 infection that includes a protease inhibitor is unknown. We studied the natural course of the syndrome to develop diagnostic criteria and identifying markers that. predict its severity. Methods We assessed 113 patients who were receiving HIV-1 protease inhibitors (mean 21 months) and 45 HIV-1-infected patients (28 with follow-up) never treated with a protease inhibitor. Lipodystrophy was assessed by questionnaire (including patients' rating of severity), physical examination, and dual-energy x-ray absorptiometry. Body composition and lasting lipid and glycaemic variables were compared with data obtained 8 months previously. Oral glucose tolerance was investigated. Findings There was 98% concordance between patients' reports of the presence or absence of lipodystrophy (reported by 83% of protease-inhibitor recipients and 4% of treatment-naive patients; p=0.0001) and physical examination. Patients' ratings of lipodystrophy were significantly associated with declining total body fat (p=0.02). Lower body fat was independently associated with longer duration of protease inhibitor therapy and lower bodyweight before therapy, and more severe lipodystrophy was associated with higher previous (p<0.03) and current (p less than or equal to 0.01) triglyceride and C-peptide concentrations, and less peripheral and greater central fat (p=0.005 and 0.09, respectively). Body fat declined a mean 1.2 kg over 8 months in protease-inhibitor recipients (p=0.05). The prevalence of hyperlipidaemia remained stable over time (74% of treated patients vs 28% of naive patients; p=0.0001). Impaired glucose tolerance occurred in 16% of protease-inhibitor recipients and diabetes mellitus in 7%; in all but three patients these abnormalities were detected on 2 h post-glucose load values. Interpretation Diagnosis and rating severity of lipodystrophy is aided by the combination of physical examination, patient's rating, and measurement of body fat, fasting triglycerides, and C-peptide. Weight before therapy, fasting triglyceride, and C-peptide concentrations early in therapy, and therapy duration seem to predict lipodystrophy severity. Lipodystrophy was common and progressive after almost 2 years of protease inhibitor therapy, but. was not usually severe. Hyperlipidaemia and impaired glucose tolerance were also common.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia; Univ New S Wales, Garvan Inst Med Res, Div Metab, Sydney, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute; Garvan Institute of Medical Research; University of New South Wales Sydney	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au	Chisholm, Donald J/J-9332-2013	Chisholm, Donald J/0000-0002-5349-5735				BURCHFIEL CM, 1995, CIRCULATION, V92, P1430, DOI 10.1161/01.CIR.92.6.1430; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Carr A, 1998, LANCET, V351, P1881, DOI 10.1016/S0140-6736(98)03391-1; CHIDIAC C, 1995, AIDS, V9, P215, DOI 10.1097/00002030-199502000-00022; Coyle P, 1996, MED J AUSTRALIA, V165, P587, DOI 10.5694/j.1326-5377.1996.tb138654.x; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; Dube MP, 1997, LANCET, V350, P713, DOI 10.1016/S0140-6736(05)63513-1; FULLER JH, 1980, LANCET, V1, P1373; Gavin JR, 1999, DIABETES CARE, V22, pS5; Gaziano JM, 1997, CIRCULATION, V96, P2520, DOI 10.1161/01.CIR.96.8.2520; HAARBO J, 1991, CLIN PHYSIOL, V11, P331, DOI 10.1111/j.1475-097X.1991.tb00662.x; Herry I, 1997, CLIN INFECT DIS, V25, P937, DOI 10.1086/597649; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Jeppesen J, 1998, CIRCULATION, V97, P1029, DOI 10.1161/01.CIR.97.11.1029; KERULY JE, 1998, 5 C RETR OPP INF FEB; Lamarche B, 1996, ATHEROSCLEROSIS, V119, P235, DOI 10.1016/0021-9150(95)05653-X; Lo JC, 1998, LANCET, V351, P867, DOI 10.1016/S0140-6736(97)11443-X; LUMPKIN MM, 1997, FDA PUBLIC HLTH 0611; MARKOWITZ M, 1995, NEW ENGL J MED, V333, P1534, DOI 10.1056/NEJM199512073332304; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; MAZESS RB, 1990, AM J CLIN NUTR, V51, P1106, DOI 10.1093/ajcn/51.6.1106; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Miller KK, 1998, CLIN INFECT DIS, V27, P68, DOI 10.1086/514638; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; OSULLIVAN AJ, 1994, J CLIN ENDOCR METAB, V78, P381, DOI 10.1210/jc.78.2.381; ROSENBURG HE, 1998, 5 C RETR OPP INF FEB; Roth VR, 1998, CLIN INFECT DIS, V27, P65, DOI 10.1086/514639; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Striker R, 1998, CLIN INFECT DIS, V27, P218, DOI 10.1086/517682; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Viraben R, 1998, AIDS, V12, pF37, DOI 10.1097/00002030-199806000-00001; Welborn TA, 1997, METABOLISM, V46, P35, DOI 10.1016/S0026-0495(97)90315-2	33	1221	1251	3	36	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2093	2099		10.1016/S0140-6736(98)08468-2	http://dx.doi.org/10.1016/S0140-6736(98)08468-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382692				2022-12-24	WOS:000080969300008
J	Newell-Price, J; Grossman, A				Newell-Price, J; Grossman, A			Diagnosis and management of Cushing's syndrome	LANCET			English	Editorial Material							CORTICOTROPIN-RELEASING HORMONE; DIFFERENTIAL-DIAGNOSIS; SERUM CORTISOL; DISEASE		St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England	University of London; Queen Mary University London	Newell-Price, J (corresponding author), St Bartholomews Hosp, Dept Endocrinol, London EC1A 7BE, England.							CRAPO L, 1979, METABOLISM, V28, P955, DOI 10.1016/0026-0495(79)90097-0; Dickstein G, 1996, J CLIN ENDOCR METAB, V81, P2934, DOI 10.1210/jc.81.8.2934; HALL WA, 1994, ANN INTERN MED, V120, P817, DOI 10.7326/0003-4819-120-10-199405150-00001; Invitti C, 1999, J CLIN ENDOCR METAB, V84, P440, DOI 10.1210/jc.84.2.440; KENNEDY L, 1984, BRIT MED J, V289, P1188, DOI 10.1136/bmj.289.6453.1188; LIDDLE GW, 1960, J CLIN ENDOCR METAB, V20, P1539, DOI 10.1210/jcem-20-12-1539; McCance DR, 1996, CLIN ENDOCRINOL, V44, P1, DOI 10.1046/j.1365-2265.1996.614436.x; MILLER DL, 1992, RADIOLOGY, V185, P143, DOI 10.1148/radiology.185.1.1523298; Newell-Price J, 1998, ENDOCR REV, V19, P647, DOI 10.1210/er.19.5.647; NEWELLPRICE J, 1995, CLIN ENDOCRINOL, V43, P545, DOI 10.1111/j.1365-2265.1995.tb02918.x; NewellPrice J, 1997, J CLIN ENDOCR METAB, V82, P176, DOI 10.1210/jc.82.1.176; NIEMAN LK, 1993, J CLIN ENDOCR METAB, V77, P1308, DOI 10.1210/jc.77.5.1308; OLDFIELD EH, 1991, NEW ENGL J MED, V325, P897, DOI 10.1056/NEJM199109263251301; TRAINER PJ, 1995, J CLIN ENDOCR METAB, V80, P412, DOI 10.1210/jc.80.2.412; TRAINER PJ, 1993, CLIN ENDOCRINOL, V38, P73, DOI 10.1111/j.1365-2265.1993.tb00975.x	15	19	20	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2087	2088		10.1016/S0140-6736(99)99091-8	http://dx.doi.org/10.1016/S0140-6736(99)99091-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382687				2022-12-24	WOS:000080969300003
J	Taylor, B; Miller, E; Farrington, CP; Petropoulos, MC; Favot-Mayaud, I; Li, J; Waight, PA				Taylor, B; Miller, E; Farrington, CP; Petropoulos, MC; Favot-Mayaud, I; Li, J; Waight, PA			Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; ADVERSE EVENTS; CASE SERIES; PERTUSSIS; DISORDERS; CHILDREN	Background. We undertook an epidemiological study to investigate whether measles, mumps, and rubella (MMR) vaccine may be causally associated with autism. Methods. Children with autism born since 1979 were identified from special needs/disability registers and special schools in eight North Thames health districts, UK. Information from clinical records was linked to immunisation data held on the child health computing system. We looked for evidence of a change in trend in incidence or age at diagnosis associated with the introduction of MR IR vaccination to the UK in 1988. Clustering of onsets within defined postvaccination periods was investigated by the case-series method. Findings. We identified 498 cases of autism (261 of core autism, 166 of atypical autism, and 71 of Asperger's syndrome). In 293 cases the diagnosis could be confirmed by the criteria of the International Classification of Diseases, tenth revision (ICD10: 214 [82%] core autism, 52 [31%] atypical autism. 27 [38%] Asperger's syndrome). There was a steady increase in cases by year of birth with no sudden "step-up" or change in the trend line after the introduction of MMR vaccination. There was no difference in age at diagnosis between the cases vaccinated before or after 18 months of age and those never vaccinated. There was no temporal association between onset of autism within 1 or 2 years after vaccination with MMR (relative incidence compared with control period 0.94 [95% Cl 0.60-1.47] and 1.09 [0.79-1.52]). Developmental regression was not clustered in the months after vaccination (relative incidence within 2 months and 4 months after MMR vaccination 0.92 [0.38-2.21] and 1.00 [0.52-1.95]). No significant temporal clustering for age at onset of parental concern was seen far cases of core autism or atypical autism with the exception of a single interval within 6 months of MMR vaccination. This appeared to be an artifact related to the difficulty of defining precisely the onset of symptoms in this disorder. Interpretation. Our analyses do not support a causal association between MMR vaccine and autism. If such an association occurs, it is so rare that it could not be identified in this large regional sample.	UCL, Royal Free & Univ Coll Med Sch, Dept Community Child Hlth, London NW3 2QG, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Immunisat Div, London NW9 5EQ, England; Open Univ, Dept Stat, Milton Keynes, Bucks, England	University of London; University College London; Public Health England; Open University - UK	Taylor, B (corresponding author), UCL, Royal Free & Univ Coll Med Sch, Dept Community Child Hlth, Royal Free Campus, London NW3 2QG, England.			Farrington, Conor Patrick/0000-0002-7148-2612; Petropoulos, Maria-Christina/0000-0003-0618-7016				Bedford H, 1998, LANCET, V351, P907, DOI 10.1016/S0140-6736(05)70320-2; *CDSC, 1998, COMMUN DIS REP CDR W, V8, P345; Chadwick N, 1998, J MED VIROL, V55, P305, DOI 10.1002/(SICI)1096-9071(199808)55:4&lt;305::AID-JMV9&gt;3.0.CO;2-4; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; Farrington CP, 1996, AM J EPIDEMIOL, V143, P1165; FARRINGTON CP, 1995, BIOMETRICS, V51, P228, DOI 10.2307/2533328; FARRINGTON P, 1995, LANCET, V345, P567, DOI 10.1016/S0140-6736(95)90471-9; Fombonne E, 1997, J AM ACAD CHILD PSY, V36, P1561, DOI 10.1016/S0890-8567(09)66566-7; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; GILLBERG C, 1998, AUTISM, V2, P423; Lee JW, 1998, LANCET, V351, P905, DOI 10.1016/S0140-6736(98)26012-0; Morrell JM, 1997, AM J PRIMATOL, V41, P37, DOI 10.1002/(SICI)1098-2345(1997)41:1<37::AID-AJP3>3.0.CO;2-0; NICHOLL A, 1998, BMJ-BRIT MED J, V316, P715; SIEGEL B, 1988, J DEV BEHAV PEDIATR, V9, P199; THOMPSON NP, 1995, EUR J GASTROEN HEPAT, V7, P385; THOMPSON NP, 1995, LANCET, V345, P1071, DOI 10.1016/S0140-6736(95)90816-1; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; Wing L, 1996, BRIT MED J, V312, P327	19	461	473	0	519	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2026	2029		10.1016/S0140-6736(99)01239-8	http://dx.doi.org/10.1016/S0140-6736(99)01239-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376617	Green Accepted			2022-12-24	WOS:000080812200012
J	Haggard, M				Haggard, M			Commentary: Plausible candidates for treatment of glue ear - is one issue really three?	BRITISH MEDICAL JOURNAL			English	Editorial Material									MRC, Inst Hearing Res, Nottingham NG7 2RD, England		Haggard, M (corresponding author), MRC, Inst Hearing Res, Univ Pk, Nottingham NG7 2RD, England.							Buxton M, 1996, J Health Serv Res Policy, V1, P35; Haggard MP, 1991, SCREENING CHILDRENS	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 1	1999	318	7192					1178	1178						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	195XR	10383203				2022-12-24	WOS:000080277900030
J	Harnden, P; Mahmood, N; Southgate, J				Harnden, P; Mahmood, N; Southgate, J			Expression of cytokeratin 20 redefines urothelial papillomas of the bladder	LANCET			English	Article							CARCINOMA; CANCER	Background Most non-invasive urothelial tumours of the bladder are diagnosed as papillary carcinomas in accordance with the WHO classification and because the identification of papillomas is difficult by routine histology; some patients are therefore misdiagnosed. This practice is associated with psychological morbidity for the patient and may also skew cancer statistics. Cytokeratin 20 (CK20) is a sensitive marker of urothelial differentiation. We investigated whether this marker could be used in the identification of urothelial papillomas and used the rate of recurrence as an indicator to assess the biological behaviour of such tumours. Methods In a prospective study, immunocytochemistry for CK20 was done on tumours of all patients who presented for the first time with non-invasive papillary bladder tumours. We classified the expression pattern of CK20 as normal or abnormal at the time of initial diagnosis. We recorded time to first biopsy-proven recurrence or length of follow-up when no recurrence was observed. Findings Of 58 consecutive patients, ten had tumours with a normal pattern of CK20 expression. No patients developed further tumours during the follow-up (median 18 [range 13-28] months). By contrast, 30 (73%) of the 41 evaluable patients with tumours that showed abnormal CK20 expression developed further tumours; the median time to a second tumour was 6 (2-24) months. The only factor that had a significant effect on the outcome of patients in terms of recurrence was expression of CK20 (p<0.0001). Interpretation Normal urothelial differentiation, as evidenced by a normal pattern of CK20 expression, is retained in a proportion of non-invasive papillary urothelial tumours and thus justifies use of the term urothelial papilloma. A large-scale study is needed to investigate the outcome of patients with such tumours.	Gen Infirm, Leeds LS1 3EX, W Yorkshire, England; St James Univ Hosp, Imperial Canc Res Fund, Canc Med Res Unit, Leeds LS9 7TF, W Yorkshire, England	Leeds General Infirmary; Saint James's University Hospital	Harnden, P (corresponding author), St James Univ Hosp, Dept Histopathol, Leeds LS9 7TF, W Yorkshire, England.		Southgate, Jennifer/AAJ-9089-2021	Southgate, Jennifer/0000-0002-0135-480X				DEMING CL, 1950, J UROLOGY, V63, P815, DOI 10.1016/S0022-5347(17)68833-5; GREENE LF, 1973, J UROLOGY, V110, P205, DOI 10.1016/S0022-5347(17)60161-7; HALL RR, 1994, BMJ-BRIT MED J, V308, P257, DOI 10.1136/bmj.308.6923.257; Harnden P, 1996, BRIT J UROL, V78, P870, DOI 10.1046/j.1464-410X.1996.23511.x; HARNDEN P, 1996, CURR DIAGN PATHOL, V3, P109; HARNDEN P, 1995, HISTOPATHOLOGY, V27, P167; JORDAN AM, 1987, CANCER, V60, P2766, DOI 10.1002/1097-0142(19871201)60:11<2766::AID-CNCR2820601129>3.0.CO;2-0; KIEMENEY LALM, 1994, EUR J CANCER, V30A, P1134, DOI 10.1016/0959-8049(94)90472-3; KURTH KH, 1995, EUR J CANCER, V31A, P1840, DOI 10.1016/0959-8049(95)00287-S; Murphy WM, 1994, TUMORS KIDNEY BLADDE; OOMS ECM, 1983, HUM PATHOL, V14, P140, DOI 10.1016/S0046-8177(83)80242-1; PROUT GR, 1992, J UROLOGY, V148, P1413, DOI 10.1016/S0022-5347(17)36924-0; READING J, 1995, BRIT J UROL, V75, P604, DOI 10.1111/j.1464-410X.1995.tb07417.x; REUTER VE, 1994, DIAGNOSTIC SURG PATH; *WHO, 1973, HIST TYP UR BLADD TU, V10; [No title captured]	16	95	98	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					974	977		10.1016/S0140-6736(98)05383-5	http://dx.doi.org/10.1016/S0140-6736(98)05383-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459907				2022-12-24	WOS:000079421600013
J	Mofenson, LM				Mofenson, LM			Short-course zidovudine for prevention of perinatal infection	LANCET			English	Editorial Material							CLINICAL-TRIAL; TRANSMISSION; AFRICA		NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Mofenson, LM (corresponding author), NICHHD, Pediat Adolescent & Maternal AIDS Branch, Ctr Res Mothers & Children, NIH, Rockville, MD 20852 USA.		Mofenson, Lynne/P-9631-2019	Mofenson, Lynne/0000-0002-2818-9808				Biggar RJ, 1996, LANCET, V347, P1647, DOI 10.1016/S0140-6736(96)91486-5; Bobat R, 1997, AIDS, V11, P1627, DOI 10.1097/00002030-199713000-00012; Cartoux M, 1998, AIDS, V12, P2489, DOI 10.1097/00002030-199818000-00019; Cartoux M, 1998, AIDS, V12, P2337, DOI 10.1097/00002030-199817000-00016; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; Downing RG, 1998, J ACQ IMMUN DEF SYND, V18, P384, DOI 10.1097/00042560-199808010-00011; Fawzi WW, 1998, LANCET, V351, P1477, DOI 10.1016/S0140-6736(98)04197-X; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; MOFENSON LM, IN PRESS AIDS; Rouse DJ, 1997, AM J OBSTET GYNECOL, V176, P617, DOI 10.1016/S0002-9378(97)70557-X; Scholl TO, 1997, AM J EPIDEMIOL, V146, P134, DOI 10.1093/oxfordjournals.aje.a009244; SEMBA R, 1998, 3 INT S GLOB STRAT P; Taha TE, 1998, AIDS, V12, P197, DOI 10.1097/00002030-199802000-00010; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; World Health Organization, 1997, COV MAT CAR LIST AV	16	50	51	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					766	767		10.1016/S0140-6736(99)90028-4	http://dx.doi.org/10.1016/S0140-6736(99)90028-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459952				2022-12-24	WOS:000079089100002
J	Lenski, RE; Ofria, C; Collier, TC; Adami, C				Lenski, RE; Ofria, C; Collier, TC; Adami, C			Genome complexity, robustness and genetic interactions in digital organisms	NATURE			English	Article							DELETERIOUS MUTATIONS; EVOLUTION; FITNESS; POPULATIONS; ADAPTATION	Digital organisms are computer programs that self-replicate, mutate and adapt by natural selection(1-3). They offer an opportunity to test generalizations about living systems that may extend beyond the organic life that biologists usually study. Here we have generated two classes of digital organism: simple programs selected solely for rapid replication, and complex programs selected to perform mathematical operations that accelerate replication through a set of defined 'metabolic' rewards., To examine the differences in their genetic architecture, we introduced millions of single and multiple mutations into each organism and measured the effects on the organism's fitness. The complex organisms are more robust than the simple ones with respect to the average effects of single mutations. Interactions among mutations are common and usually yield higher fitness than predicted from the component mutations assuming multiplicative effects; such interactions are especially important in the complex organisms. Frequent interactions among mutations have also been seen in bacteria, fungi and fruitflies(4-6). Our findings support the view that interactions are a general feature of genetic systems(7-9).	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; CALTECH, Kellogg Radiat Lab, Pasadena, CA 91125 USA; Univ Calif Los Angeles, Dept Organism Biol Ecol & Evolut, Los Angeles, CA 90095 USA	Michigan State University; California Institute of Technology; University of California System; University of California Los Angeles	Lenski, RE (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.	lenski@pilot.msu.edu; chalres@krl.caltech.edu	Adami, Chris/A-9675-2011; Adami, Christoph/A-5181-2009	Adami, Chris/0000-0002-2915-9504; Lenski, Richard/0000-0002-1064-8375; Ofria, Charles/0000-0003-2924-1732				ADAMI C, 1995, PHYSICA D, V80, P154, DOI 10.1016/0167-2789(95)90073-X; Adami C., 1998, INTRO ARTIFICIAL LIF; Burch CL, 1999, GENETICS, V151, P921; Clark AG, 1997, GENETICS, V147, P157; de Visser JAGM, 1999, SCIENCE, V283, P404, DOI 10.1126/science.283.5400.404; deVisser JAGM, 1997, EVOLUTION, V51, P1499, DOI 10.1111/j.1558-5646.1997.tb01473.x; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Eyre-Walker A, 1999, NATURE, V397, P344, DOI 10.1038/16915; Frank Steven A., 1996, P451; Holland JH, 1992, ADAPTATION NATURAL A, DOI DOI 10.7551/MITPRESS/1090.001.0001; Hurst Laurence D., 1996, Trends in Ecology and Evolution, V11, P46, DOI 10.1016/0169-5347(96)81041-X; KAUFFMAN S, 1987, J THEOR BIOL, V128, P11, DOI 10.1016/S0022-5193(87)80029-2; Kauffman S. A., 1993, ORIGINS ORDER; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; KOZA JR, 1998, EVOLUTIONARY ROBOTIC, P37; Koza JR, 1992, GENETIC PROGRAMMING; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Maynard Smith J., 1978, EVOLUTION SEX; Otto SP, 1997, THEOR POPUL BIOL, V51, P134, DOI 10.1006/tpbi.1997.1301; PAQUIN CE, 1983, NATURE, V306, P368, DOI 10.1038/306368a0; Rainey PB, 1998, NATURE, V394, P69, DOI 10.1038/27900; RAY T., 1992, ARTIF LIFE, P371, DOI DOI 10.1016/S0040-4039(01)97473-8; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SMITH JM, 1992, NATURE, V355, P772; SOKAL RR, 1994, BIOMETRY; TRAVISANO M, 1995, SCIENCE, V267, P87, DOI 10.1126/science.7809610; Turner PE, 1999, NATURE, V398, P441, DOI 10.1038/18913; Wright S., 1977, EVOLUTION GENETICS P, V3	29	197	198	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 12	1999	400	6745					661	664		10.1038/23245	http://dx.doi.org/10.1038/23245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458160				2022-12-24	WOS:000082032900052
J	Ehresman, K; Lynfield, R; Danila, R; Black, S; Shinefield, H; Fireman, B; Cordova, S				Ehresman, K; Lynfield, R; Danila, R; Black, S; Shinefield, H; Fireman, B; Cordova, S			Intussusception among recipients of rotavirus vaccine - United States, 1998-1999 (Reprinted from MMWR, vol 48, pg 577, 1999)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Reprint									Minnesota Dept Hlth, Minneapolis, MN 55414 USA; Kaiser Permanente, Vaccine Study Ctr, Oakland, CA USA; US FDA, Div Biostat & Epidemiol, Rockville, MD 20857 USA; Natl Ctr Infect Dis, Viral Gastroenteritis Sect, Resp & Enter Viruses Br, Atlanta, GA USA; Natl Ctr Infect Dis, Off Director, Div Viral & Rickettsial Dis, Atlanta, GA USA; CDC, Vaccine Safety Datalink Team, Atlanta, GA 30333 USA; CDC, Stat Anal Br, Data Management Div, Atlanta, GA 30333 USA; CDC, Vaccine Safety & Dev Activ, Atlanta, GA 30333 USA; CDC, Child Vaccine Prevent Dis Br, Epidemiol & Surveillance Div, Natl Immunizat Program, Atlanta, GA 30333 USA	Minnesota Department of Health (MHD); Kaiser Permanente; US Food & Drug Administration (FDA); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Ehresman, K (corresponding author), Minnesota Dept Hlth, Minneapolis, MN 55414 USA.							Ehresman K., 1999, Morbidity and Mortality Weekly Report, V48, P577	1	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					520	521						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450702				2022-12-24	WOS:000081919100010
J	Chen, CH; von Kessler, DP; Park, WJ; Beachy, PA				Chen, CH; von Kessler, DP; Park, WJ; Beachy, PA			Nuclear trafficking of cubitus interruptus in the transcriptional regulation of hedgehog target gene expression	CELL			English	Article							KINESIN-RELATED PROTEIN; SIGNAL-TRANSDUCTION; DROSOPHILA EMBRYOS; KINASE-A; WINGLESS; PROTEOLYSIS; PATHWAYS; COMPLEX; PHOSPHORYLATION; PROTEASOME	Transcriptional activation of Hedgehog (Hh) target genes requires Cubitus interruptus, a 155 kDa cytoplasmic zinc finger protein (Ci155), which in the absence of Hh signaling is processed to form a nuclear repressor (Ci75). We show that Hh signaling reduces phosphorylation of Ci155, and this reduction in turn appears to decrease processing. Blocking processing with proteasome inhibitors or altered Ci proteins, however, is insufficient for activation of Hh targets. We find that Hh signaling increases the rate of Ci155 nuclear import, resulting in significant nuclear accumulation. Even in the absence of signaling, nuclear accumulation of Ci155 suffices for significant induction of Hh targets, and active nuclear export of Ci155 is an essential mechanism for maintenance of the unstimulated state.	Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Howard Hughes Medical Institute; Johns Hopkins University	Beachy, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Howard Hughes Med Inst, Baltimore, MD 21205 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Alexandre C, 1996, GENE DEV, V10, P2003, DOI 10.1101/gad.10.16.2003; Alves G, 1998, MECH DEVELOP, V78, P17, DOI 10.1016/S0925-4773(98)00130-0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; CAPDEVILA J, 1994, DEVELOPMENT, V120, P987; CAPDEVILA J, 1994, EMBO J, V13, P71, DOI 10.1002/j.1460-2075.1994.tb06236.x; Chen Y, 1998, P NATL ACAD SCI USA, V95, P2349, DOI 10.1073/pnas.95.5.2349; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; FORBES AJ, 1993, DEVELOPMENT, P115; Hepker J, 1997, DEVELOPMENT, V124, P549; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Krishnan V, 1997, SCIENCE, V278, P1947, DOI 10.1126/science.278.5345.1947; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Methot N, 1999, CELL, V96, P819, DOI 10.1016/S0092-8674(00)80592-9; Monnier V, 1998, CURR BIOL, V8, P583, DOI 10.1016/S0960-9822(98)70227-1; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Ohlmeyer JT, 1998, NATURE, V396, P749, DOI 10.1038/25533; Ohlmeyer JT, 1997, GENE DEV, V11, P2250, DOI 10.1101/gad.11.17.2250; ORENIC TV, 1990, GENE DEV, V4, P1053, DOI 10.1101/gad.4.6.1053; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; POLLARD TD, 1984, J CELL BIOL, V99, P1970, DOI 10.1083/jcb.99.6.1970; PORTER JA, 1995, NATURE, V374, P363, DOI 10.1038/374363a0; Robbins DJ, 1997, CELL, V90, P225, DOI 10.1016/S0092-8674(00)80331-1; Sisson JC, 1997, CELL, V90, P235, DOI 10.1016/S0092-8674(00)80332-3; SLUSARSKI DC, 1995, GENETICS, V139, P229; Theodosiou NA, 1998, DEVELOPMENT, V125, P3411; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; ZHANG J, 1991, J BIOL CHEM, V266, P2290	35	213	219	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					305	316		10.1016/S0092-8674(00)81960-1	http://dx.doi.org/10.1016/S0092-8674(00)81960-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458606	hybrid			2022-12-24	WOS:000081950300006
J	Miyashita-Lin, EM; Hevner, R; Wassarman, KM; Martinez, S; Rubenstein, JLR				Miyashita-Lin, EM; Hevner, R; Wassarman, KM; Martinez, S; Rubenstein, JLR			Early neocortical regionalization in the absence of thalamic innervation	SCIENCE			English	Article							CEREBRAL-CORTEX; NERVOUS-SYSTEM; CALRETININ IMMUNOREACTIVITY; EXPRESSION PATTERN; CORTICAL AREAS; MUTANT MICE; FOREBRAIN; GENE; RAT; SPECIFICATION	There is a Long-standing controversy regarding the mechanisms that generate the functional subdivisions of the cerebral neocortex. One model proposes that thalamic axonal input specifies these subdivisions; the competing model postulates that patterning mechanisms intrinsic to the dorsal telencephalon generate neocortical regions. Gbx-2 mutant mice, whose thalamic differentiation is disrupted, were investigated. Despite the Lack of cortical innervation by thalamic axons, neocortical region-specific gene expression (Cadherin-6, EphA-7, Id-2, and RZR-beta) developed normally. This provides evidence that patterning mechanisms intrinsic to the neocortex specify the basic organization of its functional subdivisions.	Univ Calif San Francisco, Sch Med, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Program Dev Biol, San Francisco, CA 94143 USA; Univ Miguel Hernandez, Univ Murcia, Inst Neurosci, Fac Med,Dept Morphol Sci, Alicante, Spain	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidad Miguel Hernandez de Elche; University of Murcia	Rubenstein, JLR (corresponding author), Univ Calif San Francisco, Sch Med, Dept Psychiat, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA.		Mratinez, Salvador/L-4896-2014	Mratinez, Salvador/0000-0002-9320-4103; Martinez, Salvador/0000-0002-2910-8926	NIMH NIH HHS [R01 MH51561-01A1, R01 MH49428-01] Funding Source: Medline; NINDS NIH HHS [NS34661-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051561, R01MH049428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034661] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Acampora D, 1997, DEVELOPMENT, V124, P3639; ARIMATSU Y, 1992, P NATL ACAD SCI USA, V89, P8879, DOI 10.1073/pnas.89.19.8879; BULFONE A, 1993, J NEUROSCI, V13, P3155; BULFONE A, 1995, NEURON, V15, P63, DOI 10.1016/0896-6273(95)90065-9; Bulfone A, 1998, NEURON, V21, P1273, DOI 10.1016/S0896-6273(00)80647-9; COHENTANNOUDJI M, 1994, NATURE, V368, P460, DOI 10.1038/368460a0; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P5212, DOI 10.1210/en.136.11.5212; FERRI RT, 1993, CEREB CORTEX, V3, P187, DOI 10.1093/cercor/3.3.187; FONSECA M, 1995, J COMP NEUROL, V361, P177, DOI 10.1002/cne.903610114; FRANZ T, 1994, ACTA ANAT, V150, P38; Frassoni C, 1998, NEUROSCIENCE, V83, P1203, DOI 10.1016/S0306-4522(97)00443-0; Furuta Y, 1997, DEVELOPMENT, V124, P2203; GITTON Y, IN PRESS CEREB; Golden JA, 1999, P NATL ACAD SCI USA, V96, P2439, DOI 10.1073/pnas.96.5.2439; Grove EA, 1998, DEVELOPMENT, V125, P2315; HEVNER RF, UNPUB; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Lebrand C, 1996, NEURON, V17, P823, DOI 10.1016/S0896-6273(00)80215-9; MIYASHITALIN EM, UNPUB; Monaghan AP, 1997, NATURE, V390, P515, DOI 10.1038/37364; MORI T, 1995, MOL BRAIN RES, V34, P154, DOI 10.1016/0169-328X(95)00154-K; Nothias F, 1998, CURR BIOL, V8, P459, DOI 10.1016/S0960-9822(98)70189-7; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; Pellegrini M, 1996, DEVELOPMENT, V122, P3893; Qiu MS, 1996, DEV BIOL, V178, P174, DOI 10.1006/dbio.1996.0207; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RIECHMANN V, 1994, NUCLEIC ACIDS RES, V22, P749, DOI 10.1093/nar/22.5.749; Rubenstein JLR, 1998, CURR OPIN NEUROBIOL, V8, P18, DOI 10.1016/S0959-4388(98)80004-4; RUBENSTEIN JLR, IN PRESS CEREB CORTE; Schaeren-Wiemers N, 1997, EUR J NEUROSCI, V9, P2687, DOI 10.1111/j.1460-9568.1997.tb01698.x; Stoykova A, 1996, DEVELOPMENT, V122, P3453; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Wassarman KM, 1997, DEVELOPMENT, V124, P2923; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yoshida M, 1997, DEVELOPMENT, V124, P101	36	264	269	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					906	909		10.1126/science.285.5429.906	http://dx.doi.org/10.1126/science.285.5429.906			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436162				2022-12-24	WOS:000081860900054
J	Bowman, S; Lawson, D; Basham, D; Brown, D; Chillingworth, T; Churcher, CM; Craig, A; Davies, RM; Devlin, K; Feltwell, T; Gentles, S; Gwilliam, R; Hamlin, N; Harris, D; Holroyd, S; Hornsby, T; Horrocks, P; Jagels, K; Jassal, B; Kyes, S; McLean, J; Moule, S; Mungall, K; Murphy, L; Oliver, K; Quail, MA; Rajandream, MA; Rutter, S; Skelton, J; Squares, R; Squares, S; Sulston, JE; Whitehead, S; Woodward, JR; Newbold, C; Barrell, BG				Bowman, S; Lawson, D; Basham, D; Brown, D; Chillingworth, T; Churcher, CM; Craig, A; Davies, RM; Devlin, K; Feltwell, T; Gentles, S; Gwilliam, R; Hamlin, N; Harris, D; Holroyd, S; Hornsby, T; Horrocks, P; Jagels, K; Jassal, B; Kyes, S; McLean, J; Moule, S; Mungall, K; Murphy, L; Oliver, K; Quail, MA; Rajandream, MA; Rutter, S; Skelton, J; Squares, R; Squares, S; Sulston, JE; Whitehead, S; Woodward, JR; Newbold, C; Barrell, BG			The complete nucleotide sequence of chromosome 3 of Plasmodium falciparum	NATURE			English	Article							MALARIA; GENE; DNA; GENOME; CENTROMERE; DOMAINS; CONSTRUCTION; EXPRESSION; LIBRARIES; PROTEINS	Analysis of Plasmodium falciparum chromosome 3, and comparison with chromosome 2, highlights novel features of chromosome organization and gene structure. The sub-telomeric regions of chromosome 3 show a conserved order of features, including repetitive DNA sequences, members of multigene families involved in pathogenesis and antigenic variation, a number of conserved pseudogenes, and several genes of unknown function. A putative centromere has been identified that has a core region of about 2 kilobases with an extremely high (adenine + thymidine) composition and arrays of tandem repeats. We have predicted 215 protein-coding genes and two transfer RNA genes In the 1,060,106-base-pair chromosome sequence. The predicted protein-coding genes can be divided into three main classes: 52.6% are not spliced, 45.1% have a large exon with short additional 5' or 3' exons, and 2.3% have a multiple exon structure more typical of higher eukaryotes.	Sanger Ctr, Pathogen Sequencing Unit, Hinxton CB10 1SA, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England	Wellcome Trust Sanger Institute; University of Oxford	Bowman, S (corresponding author), Sanger Ctr, Pathogen Sequencing Unit, Wellcome Trust Genome Campus, Hinxton CB10 1SA, England.	sharen@sanger.ac.uk	Quail, michael/ABE-6131-2020; Horrocks, Paul/C-2615-2009	Horrocks, Paul/0000-0003-3981-0732; Jassal, Bijay/0000-0002-5039-5405; Lawson, Daniel/0000-0001-7765-983X; Murphy, Lee/0000-0001-6467-7449; Craig, Alister/0000-0003-0914-6164; Newbold, Chris/0000-0002-9274-3789; Davies, Robert/0000-0002-9983-1378	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Aston C, 1999, TRENDS BIOTECHNOL, V17, P297, DOI 10.1016/S0167-7799(99)01326-8; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; Berriman M, 1998, BIOCHEM J, V334, P437, DOI 10.1042/bj3340437; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; CARCY B, 1997, MOL BIOCHEM PARASIT, V68, P221; Cheng Q, 1998, MOL BIOCHEM PARASIT, V97, P161, DOI 10.1016/S0166-6851(98)00144-3; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; Clarke L, 1998, CURR OPIN GENET DEV, V8, P212, DOI 10.1016/S0959-437X(98)80143-3; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DEBRUIN D, 1994, P NATL ACAD SCI USA, V91, P619, DOI 10.1073/pnas.91.2.619; ENEA V, 1984, SCIENCE, V225, P628, DOI 10.1126/science.6204384; Fischer K, 1997, MOL CELL BIOL, V17, P3679, DOI 10.1128/MCB.17.7.3679; Garcia A, 1999, PARASITOL TODAY, V15, P90, DOI 10.1016/S0169-4758(99)01393-9; Gardiner K, 1995, SOMAT CELL MOLEC GEN, V21, P399, DOI 10.1007/BF02310207; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Hoffman SL, 1997, NATURE, V387, P647, DOI 10.1038/42571; HOLT DC, IN PRESS INT J PARAS; Horrocks P, 1998, MOL BIOCHEM PARASIT, V95, P171, DOI 10.1016/S0166-6851(98)00110-8; KYES S, IN PRESS P NATL ACAD; LANZER M, 1992, EMBO J, V11, P1949, DOI 10.1002/j.1460-2075.1992.tb05248.x; LEECH JH, 1984, J EXP MED, V159, P1567, DOI 10.1084/jem.159.6.1567; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; McMurray AA, 1998, GENOME RES, V8, P562, DOI 10.1101/gr.8.5.562; Mott R, 1997, COMPUT APPL BIOSCI, V13, P477; Newbold CI, 1997, ANN TROP MED PARASIT, V91, P551, DOI 10.1080/00034989760923; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; Soldati D, 1999, PARASITOL TODAY, V15, P5, DOI 10.1016/S0169-4758(98)01363-5; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; Thompson JK, 1997, MOL BIOCHEM PARASIT, V90, P537, DOI 10.1016/S0166-6851(97)00203-X; Thompson JK, 1997, MOL BIOCHEM PARASIT, V87, P49, DOI 10.1016/S0166-6851(97)00041-8; TRIGLIA T, 1991, MOL BIOCHEM PARASIT, V44, P207, DOI 10.1016/0166-6851(91)90006-R; Trottein F, 1995, MOL BIOCHEM PARASIT, V74, P129, DOI 10.1016/0166-6851(95)02489-1; VAUDIN M, 1995, NUCLEIC ACIDS RES, V23, P670, DOI 10.1093/nar/23.4.670; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; White NJ, 1996, NEW ENGL J MED, V335, P800, DOI 10.1056/NEJM199609123351107; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; Wootton JC, 1996, METHOD ENZYMOL, V266, P554; World Health Organization, 1993, GLOB STRAT MAL CONTR	45	269	297	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					532	538		10.1038/22964	http://dx.doi.org/10.1038/22964			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448855				2022-12-24	WOS:000081854800046
J	Rosner, F				Rosner, F			Can an amulet cure leukemia?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		PREUSS J, 1993, BIBLICAL TALMUDIC ME, P146; Rosner F, 1999, MT SINAI J MED, V66, P102; ZIMMELS HJ, 1952, MAGICIANS THEOLOGIAN, P135	3	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1999	282	4					307	307		10.1001/jama.282.4.307	http://dx.doi.org/10.1001/jama.282.4.307			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219FG	10432013				2022-12-24	WOS:000081596800001
J	Franklyn, JA; Maisonneuve, P; Sheppard, M; Betteridge, J; Boyle, P				Franklyn, JA; Maisonneuve, P; Sheppard, M; Betteridge, J; Boyle, P			Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study	LANCET			English	Article							I-131 THERAPY; FOLLOW-UP; RADIOACTIVE IODINE; BREAST-CANCER; THYROTOXICOSIS; RISK	Background Radioiodine is used increasingly as first-line treatment for hyperthyroidism, but concerns remain about subsequent risk of cancer, especially in those treated at a young age, We investigated cancer incidence and mortality in patients treated with radioiodine for hyperthyroidism, Methods We did a population-based study in 7417 patients treated in Birmingham, UK, between 1950 and 1991. We compared details of all cancer diagnoses and deaths in 1971-91 from the UK Office for National Statistics with data on cancer incidence and mortality for England and Wales specific for age, sex, and period. Findings During 72 073 person-years of follow-up, 634 cancer diagnoses were made, compared with an expected number of 761 (standardised incidence ratio [SIR] 0.83 [95% CI 0.77-0.90]), The relative risk of cancer mortality was also decreased (observed cancer deaths 448, expected 499; standardised mortality ratio [SMR] 0.90 [0.82-0.98]). Incidence of cancers of the pancreas, bronchus, trachea, bladder, and lymphatic and haemopoietic systems was lowered. Mortality from cancers at all these sites was also reduced but findings were significant only for bronchus and trachea. There were significant increases in incidence and mortality for cancers of the small bowel (SIR 4.81 [2.16-10.72], SMR 7.03 [3.16-15.66]) and thyroid (SIR 3.25 [1.69-6.25], SMR 2.78 [1.16- 6.77]), although absolute risk of these cancers was small. Interpretation The decrease in overall cancer incidence and mortality in those treated for hyperthyroidism with radioiodine is reassuring. The absolute risk of cancers of the small bower and thyroid remain low, but the increased relative risk shows the need for long-term vigilance in those receiving radioiodine.	Univ Birmingham, Dept Med, Birmingham, W Midlands, England; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy	University of Birmingham; IRCCS European Institute of Oncology (IEO)	Franklyn, JA (corresponding author), Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.		Boyle, Peter/A-4380-2014; Maisonneuve, Patrick/U-9789-2018	Boyle, Peter/0000-0001-6251-0610; Maisonneuve, Patrick/0000-0002-5309-4704				BARBER SG, 1977, LANCET, V2, P967; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; BAXTER MA, 1993, Q J MED, V86, P495, DOI 10.1093/qjmed/86.8.495; Boyle P, 1997, LUNG CANCER, V17, P1, DOI 10.1016/S0169-5002(97)00648-X; DOBYNS BM, 1974, J CLIN ENDOCR METAB, V38, P976, DOI 10.1210/jcem-38-6-976; FRANKLYN JA, 1991, CLIN ENDOCRINOL, V34, P71, DOI 10.1111/j.1365-2265.1991.tb01738.x; Franklyn JA, 1998, NEW ENGL J MED, V338, P712, DOI 10.1056/NEJM199803123381103; FRANKLYN JA, 1994, NEW ENGL J MED, V330, P1731; GOLDMAN MB, 1988, AM J EPIDEMIOL, V127, P969, DOI 10.1093/oxfordjournals.aje.a114900; HALL P, 1992, LANCET, V340, P1; HALL P, 1992, INT J CANCER, V50, P886, DOI 10.1002/ijc.2910500611; HOFFMAN DA, 1982, AM J EPIDEMIOL, V115, P243, DOI 10.1093/oxfordjournals.aje.a113296; HOFFMAN DA, 1982, INT J EPIDEMIOL, V11, P218, DOI 10.1093/ije/11.3.218; HOFFMAN DA, 1983, J NATL CANCER I, V70, P63; HOLM LE, 1991, JNCI-J NATL CANCER I, V83, P1072, DOI 10.1093/jnci/83.15.1072; KERBER RA, 1993, JAMA-J AM MED ASSOC, V270, P2076; MUIR CS, 1987, IARC SCI PUBLICATION, V88; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; PARKIN DM, 1992, IARC SCI PUBLICATION, V120; PARKIN DM, 1997, IARC SCI PUBLICATION, V143; Ron E, 1998, JAMA-J AM MED ASSOC, V280, P347, DOI 10.1001/jama.280.4.347; SHORE RE, 1985, J NATL CANCER I, V74, P1177; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; Waterhouse J., 1976, IARC SCI PUBLICATION, V15; Waterhouse JA, 1982, IARC SCI PUBLICATION, VIV; *WHO, 1977, INT CLASS DIS MAN IN, V1	26	165	172	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2111	2115		10.1016/S0140-6736(98)12295-X	http://dx.doi.org/10.1016/S0140-6736(98)12295-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382695				2022-12-24	WOS:000080969300011
J	Pauker, SG; Rothberg, M				Pauker, SG; Rothberg, M			Commentary: Resist jumping to conclusions	BRITISH MEDICAL JOURNAL			English	Editorial Material									New England Med Ctr, Boston, MA 02111 USA	Tufts Medical Center	Pauker, SG (corresponding author), New England Med Ctr, Box 302,750 Washington St, Boston, MA 02111 USA.							CHOW JW, 1991, ANN INTERN MED, V115, P585, DOI 10.7326/0003-4819-115-8-585; GOLDRATT F, 1992, GOAL; Levy Stuart B., 1992, ANTIBIOTIC PARADOX M; Wiener J, 1999, JAMA-J AM MED ASSOC, V281, P517, DOI 10.1001/jama.281.6.517; 1999, ALLIANCE PRUDENT USE	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1616	1617						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428553				2022-12-24	WOS:000080913100038
J	Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, B				Clarke, WL; Cox, DJ; Gonder-Frederick, LA; Kovatchev, B			Hypoglycemia and the decision to drive a motor vehicle by persons with diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MODERATE HYPOGLYCEMIA; AWARENESS; ADULTS; IDDM	Context Laboratory studies have shown impairments in driving performance among subjects with type 1 diabetes mellitus when their blood glucose (BG) level is between 2.6 and 3.6 mmol/L (47-65 mg/dL), However, to our knowledge, no data exist examining subjects' decisions to drive at various BC levels during their daily routine, Objective To examine type 1 diabetic subjects' decisions to drive during their daily routine based on perception of BG levels compared with actual measured BC; levels. Design and Setting Two separate groups of patients were recruited 2 years apart from 4 academic medical centers. Participants All subjects were adults with type 1 diabetes who were drivers and who performed at least 2 BC tests per day. Group 1 (initial) subjects (n = 65) had a mean (SD) age of 38.6 (8.9) years with a mean (SD) diabetes duration of 20.5 (10.6) years, were taking 38.8 (16.8) U/d of insulin, and had a mean (SD) glycosylated hemoglobin (HbA(1)) level of 10.0% (1.9%), Group 2 (replication) subjects (n = 93) were 35.8 (8.0) years old with a mean diabetes duration of 17.0 (10.6) years, were taking 40.0 (15.5) U/d of insulin, and had a mean (SD) HbA(1) level of 8.5% (1.6%). Each subject used a handheld computer to record data on symptoms, cognitive function, insulin dosage, food, activity, estimated and actual BC levels, and whether he/she would drive. Data were entered 3 to 6 times per day for a total of 50 to 70 collections per subject during a 3- to 4-week period. Main outcome Measures Decisions to drive when subjects estimated their BC level to be less than 2.2 mmol/L (40 mg/dL), 2.2 to 2.8 mmol/L (40-50 mg/dL), 2.8 to 3.3 mmol/L (50-60 mg/dL), 3.3 to 3.9 mmol/L (60-70 mg/dL), 3.9 to 10 mmol/L (70-180 mg/dL), and more than 10 mmol/L (>180 mg/dL), and driving decisions when actual BG levels were in these ranges. Results Subjects stated they would drive 43% to 44% of the time when they estimated their BG level to be 3.3 to 3.9 mmol/L (60-70 mg/dL), and 38% to 47% of the time when their actual BC level was less than 2.2 mmol/L (40 mg/dL), Logistic regression analysis demonstrated that number of autonomic symptoms, degree of impairment on cognitive function tests, and BC level estimate predicted 76% to 80% of decisions to drive (P < .01 for all). Approximately 50% of subjects in each group decided to drive at least 50% of the time when their BG level was less than 3.9 mmol/L (70 mg/dL), Conclusions Our data suggest that persons with type 1 diabetes may not judge correctly when their BC level is too low to permit safe driving and may consider driving with a low BC level even when they are aware of the low level. Health care professionals should counsel their patients about the risk of driving with hypoglycemia and the importance of measuring BG level before driving.	Univ Virginia, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Dept Psychiat Med, Behav Med Ctr, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Clarke, WL (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Pediat, Div Pediat Endocrinol, Box 386, Charlottesville, VA 22908 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK028288] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00847] Funding Source: Medline; NIDDK NIH HHS [R01-DK-28288] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM DIAB ASS NAT C, 1996, PROV REC PROGR; Clarke WL, 1997, DIABETES EDUCATOR, V23, P55, DOI 10.1177/014572179702300107; COX D, 1995, DIABETES CARE, V18, P523, DOI 10.2337/diacare.18.4.523; COX D, IN PRESS DIABETES CA; COX DJ, 1993, DIABETES CARE, V16, P519, DOI 10.2337/diacare.16.2.519; COX DJ, 1993, DIABETES, V42, P239, DOI 10.2337/diabetes.42.2.239; COX DJ, 1994, DIABETES CARE, V17, P1, DOI 10.2337/diacare.17.1.1; Kovatchev B, 1998, HEALTH PSYCHOL, V17, P277, DOI 10.1037/0278-6133.17.3.277; QUILLIAN WC, 1994, DIABETES CARE, V17, P1367, DOI 10.2337/diacare.17.11.1367	9	50	51	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					750	754		10.1001/jama.282.8.750	http://dx.doi.org/10.1001/jama.282.8.750			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463710				2022-12-24	WOS:000082118800026
J	Musaro, A; McCullagh, KJA; Naya, FJ; Olson, EN; Rosenthal, N				Musaro, A; McCullagh, KJA; Naya, FJ; Olson, EN; Rosenthal, N			IGF-1 induces skeletal myocyte hypertrophy through calcineurin in association with GATA-2 and NF-ATc1	NATURE			English	Article							DEPENDENT TRANSCRIPTIONAL PATHWAY; NF-AT; MYOGENIC DIFFERENTIATION; GENE-EXPRESSION; TRANSGENIC MICE; GROWTH-FACTORS; MUSCLE-CELLS; ACTIVATION; MORPHOGENESIS	Localized synthesis of insulin-like growth factors (IGFs) has been broadly implicated in skeletal muscle growth, hypertrophy and regeneration(1). Virally delivered IGF-1 genes induce local skeletal muscle hypertrophy and attenuate age-related skeletal muscle atrophy, restoring and improving muscle mass and strength in mice(2), Here we show that the molecular pathways underlying the hypertrophic action of IGF-1 in skeletal muscle are similar to those responsible for cardiac hypertrophy, Transfected IGF-1 gene expression in postmitotic skeletal myocytes activates calcineurin-mediated calcium signalling by inducing calcineurin transcripts and nuclear localization of calcineurin protein. Expression of activated calcineurin mimics the effects of IGF-1, whereas expression of a dominant-negative calcineurin mutant or addition of cyclosporin, a calcineurin inhibitor, represses myocyte differentiation and hypertrophy. Either IGF-1 or activated calcineurin induces expression of the transcription factor GATA-2, which accumulates in a subset of myocyte nuclei, where it associates with calcineurin and a specific dephosphorylated isoform of the transcription factor NF-ATc1. Thus, IGF-1 induces calcineurin-mediated signalling and activation of GATA-2, a marker of skeletal muscle hypertrophy, which cooperates with selected NF-ATc isoforms to activate gene expression programs.	Massachusetts Gen Hosp E, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75225 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rosenthal, N (corresponding author), Massachusetts Gen Hosp E, Cardiovasc Res Ctr, 149 13th St, Charlestown, MA 02129 USA.		Musaro, Antonio/P-2953-2019; Musarò, Antonio/K-9598-2016	Musaro, Antonio/0000-0002-2944-9739; Musarò, Antonio/0000-0002-2944-9739; Rosenthal, Nadia/0000-0002-7599-7365				Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bruton JD, 1999, P NATL ACAD SCI USA, V96, P3281, DOI 10.1073/pnas.96.6.3281; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Engert JC, 1996, J CELL BIOL, V135, P431, DOI 10.1083/jcb.135.2.431; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; Hogan PG, 1999, NATURE, V398, P200, DOI 10.1038/18327; KINCAID RL, 1990, J BIOL CHEM, V265, P11312; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MANALAN AS, 1983, P NATL ACAD SCI-BIOL, V80, P4291, DOI 10.1073/pnas.80.14.4291; MITSUMOTO Y, 1992, FEBS LETT, V301, P94, DOI 10.1016/0014-5793(92)80217-5; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Muramatsu T, 1996, BIOCHEM BIOPH RES CO, V218, P466, DOI 10.1006/bbrc.1996.0083; Musaro A, 1999, MOL CELL BIOL, V19, P3115; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; SHIMATSU A, 1987, J BIOL CHEM, V262, P7894; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Wang ZM, 1999, J PHYSIOL-LONDON, V516, P331, DOI 10.1111/j.1469-7793.1999.0331v.x; WILSON CM, 1995, FEBS LETT, V368, P19, DOI 10.1016/0014-5793(95)00589-2; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	30	530	547	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					581	585		10.1038/23060	http://dx.doi.org/10.1038/23060			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448862				2022-12-24	WOS:000081854800060
J	Norman, TC; Smith, DL; Sorger, PK; Drees, BL; O'Rourke, SM; Hughes, TR; Roberts, CJ; Friend, SH; Fields, S; Murray, AW				Norman, TC; Smith, DL; Sorger, PK; Drees, BL; O'Rourke, SM; Hughes, TR; Roberts, CJ; Friend, SH; Fields, S; Murray, AW			Genetic selection of peptide inhibitors of biological pathways	SCIENCE			English	Article							SPINDLE ASSEMBLY CHECKPOINT; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; STAPHYLOCOCCAL NUCLEASE; RESPONSE PATHWAY; PROTEIN; KINASE; IDENTIFICATION; ACTIVATION; PHEROMONE	Genetic selections were used to find peptides that inhibit biological pathways in budding yeast. The peptides were presented inside cells as peptamers, surface loops on a highly expressed and biologically inert carrier protein, a catalytically inactive derivative of staphylococcal nuclease, Peptamers that inhibited the pheromone signaling pathway, transcriptional silencing, and the spindle checkpoint were isolated. Putative targets for the inhibitors were identified by a combination of two-hybrid analysis and genetic dissection of the target pathways. This analysis identified Ydr517w as a component of the spindle checkpoint and reinforced earlier indications that Ste50 has both positive and negative roles in pheromone signaling. Analysis of transcript arrays showed that the peptamers were highly specific in their effects, which suggests that they may be useful reagents in organisms that lack sophisticated genetics as well as for identifying components of existing biological pathways that are potential targets for drug discovery.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Rosetta Pharmaceut, Kirkland, WA 98034 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Norman, TC (corresponding author), Microbia Inc, 840 Mem Dr, Cambridge, MA 02139 USA.			Sorger, Peter/0000-0002-3364-1838	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR11823] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Cao YX, 1997, MOL CELL BIOL, V17, P3323, DOI 10.1128/MCB.17.6.3323; Caponigro G, 1998, P NATL ACAD SCI USA, V95, P7508, DOI 10.1073/pnas.95.13.7508; CHAMBERS A, 1988, NUCLEIC ACIDS RES, V16, P8245, DOI 10.1093/nar/16.17.8245; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; COTTON FA, 1979, P NATL ACAD SCI USA, V76, P2551, DOI 10.1073/pnas.76.6.2551; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Hardwick KG, 1998, TRENDS GENET, V14, P1, DOI 10.1016/S0168-9525(97)01340-1; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; Henchoz S, 1997, GENE DEV, V11, P3046, DOI 10.1101/gad.11.22.3046; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hwang LH, 1998, SCIENCE, V279, P1041, DOI 10.1126/science.279.5353.1041; James P, 1996, GENETICS, V144, P1425; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; Marton MJ, 1998, NAT MED, V4, P1293, DOI 10.1038/3282; NORMAN TC, UNPUB; O'Rourke SM, 1998, GENE DEV, V12, P2874, DOI 10.1101/gad.12.18.2874; ONEIL KT, 1992, PROTEINS, V14, P509, DOI 10.1002/prot.340140411; Posas F, 1998, MOL CELL BIOL, V18, P5788, DOI 10.1128/MCB.18.10.5788; RAD MR, 1992, MOL GEN GENET, V236, P145; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SERPERSU EH, 1987, BIOCHEMISTRY-US, V26, P1289, DOI 10.1021/bi00379a014; SHARP PM, 1987, NUCLEIC ACIDS RES, V15, P1281, DOI 10.1093/nar/15.3.1281; Singer MS, 1998, GENETICS, V150, P613; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75	36	153	170	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					591	595		10.1126/science.285.5427.591	http://dx.doi.org/10.1126/science.285.5427.591			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417390				2022-12-24	WOS:000081609500040
J	Weliky, M; Katz, LC				Weliky, M; Katz, LC			Correlational structure of spontaneous neuronal activity in the developing lateral geniculate nucleus in vivo	SCIENCE			English	Article							ORIENTATION PREFERENCE MAPS; OCULAR DOMINANCE COLUMNS; RETINAL GANGLION-CELLS; CAT VISUAL-CORTEX; STRIATE CORTEX; IN-VITRO; PERIGENICULATE NUCLEUS; ORDERED ARRANGEMENT; BURSTING ACTIVITY; MAMMALIAN RETINA	The properties of spontaneous activity in the developing visual pathway beyond the retina are unknown. Multielectrode recordings in the lateral geniculate nucleus (LGN) of awake behaving ferrets, before eye opening, revealed patterns of spontaneous activity that reflect a reshaping of retinal drive within higher visual stages. Significant binocular correlations were present only when corticothalamic feedback was intact. In the absence of retinal drive, cortico-thalamic feedback was required to sustain correlated LGN bursting. Activity originating from the contralateral eye drove thalamic activity far more strongly than that originating from the ipsilateral eye. Thus, in vivo patterns of LGN spontaneous activity emerge from interactions between retina, thalamus, and cortex.	Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Weliky, M (corresponding author), Univ Rochester, Dept Brain & Cognit Sci, Meljora Hall, Rochester, NY 14627 USA.							BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Contreras D, 1996, SCIENCE, V274, P771, DOI 10.1126/science.274.5288.771; COULTER DA, 1993, BRAIN RES, V631, P137, DOI 10.1016/0006-8993(93)91199-3; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; Erwin E, 1998, J NEUROSCI, V18, P9870; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Godwin DW, 1996, J NEUROSCI, V16, P8181; HOLLANDER H, 1972, BRAIN RES, V41, P464, DOI 10.1016/0006-8993(72)90516-1; Horton JC, 1996, J NEUROSCI, V16, P1791; HU B, 1989, NEUROSCIENCE, V31, P13, DOI 10.1016/0306-4522(89)90027-4; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; Kao CQ, 1997, J NEUROPHYSIOL, V77, P2661, DOI 10.1152/jn.1997.77.5.2661; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; LO FS, 1994, EXP BRAIN RES, V100, P365; LU SM, 1993, VISUAL NEUROSCI, V10, P631, DOI 10.1017/S0952523800005332; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MILLER KD, 1994, J NEUROSCI, V14, P409; Mooney R, 1996, NEURON, V17, P863, DOI 10.1016/S0896-6273(00)80218-4; Murphy PC, 1996, J NEUROSCI, V16, P1180; MURPHY PC, 1994, VISUAL NEUROSCI, V11, P781, DOI 10.1017/S0952523800003084; PETTIGREW JD, 1974, J PHYSIOL-LONDON, V237, P49, DOI 10.1113/jphysiol.1974.sp010469; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SWINDALE NV, 1980, PROC R SOC SER B-BIO, V208, P243, DOI 10.1098/rspb.1980.0051; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P978, DOI 10.1152/jn.1963.26.6.978; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	37	207	210	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					599	604		10.1126/science.285.5427.599	http://dx.doi.org/10.1126/science.285.5427.599			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417392				2022-12-24	WOS:000081609500042
J	Stapleton, JA; Lowin, A; Russell, MAH				Stapleton, JA; Lowin, A; Russell, MAH			Prescription of transdermal nicotine patches for smoking cessation in general practice: evaluation of cost-effectiveness	LANCET			English	Article							RANDOMIZED TRIAL; ADJUNCT	Background The 1998 UK government White Paper Smoking Kills emphasises that normal practice should be for general practitioners (GPs), practice nurses, and others to offer advice and support to smokers in their efforts to stop. However, GPs are not allowed to write NHS prescriptions for nicotine-replacement therapy, even though this is the only effective pharmceutical treatment available in the UK. We estimated the cost-effectiveness, for the NHS, of allowing GPs to prescribe transdermal nicotine patches for up to 12 weeks. Methods We used data from a randomised, placebo-controlled efficacy trial of nicotine patches and a survey of associated resource use in 30 GP surgeries in 15 English counties. We calculated the health benefit of nicotine-patch treatment in number of life years that would be saved by stopping smoking at various ages, and used an abstinence-contingent treatment model to calculate the incremental cost per life year saved by GP counselling with nicotine-patch treatment over GP counselling alone. Cost effectiveness was assessed on the basis that GPs would provide repeat NHS prescriptions for up to 12 weeks if the treatment was proving successful. Findings If GPs were allowed to prescribe transdermal nicotine patches on the NHS, for up to 12 weeks, the incremental cost per life year saved would be: pound 398 per person younger than 35 years; pound 345 for those aged 35-44 years; pound 432 for those aged 45-54 years; and pound 785 for those aged 55-65 years. Interpretation The low cost per life year saved would make GP intervention against smoking a cost-effective life-saving treatment. The priniciples of the government White Paper could be cost-effectively extended into general practice to reduce smoking and smoking-related illnesses.	Inst Psychiat, Tobacco Res Sect, London SE5 8AF, England; Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; Univ Sydney, Ctr Hlth Econ & Evaluat, Sydney, NSW 2006, Australia	University of London; King's College London; University of London; King's College London; University of Sydney	Stapleton, JA (corresponding author), Inst Psychiat, Tobacco Res Sect, London SE5 8AF, England.		Stapleton, John A/I-6550-2012					Akehurst R, 1994, BR J MED EC, V7, P115; Blondal T, 1999, BRIT MED J, V318, P285, DOI 10.1136/bmj.318.7179.285; BURKE P, 1994, BRIT MED J, V308, P1476; Cromwell J, 1997, JAMA-J AM MED ASSOC, V278, P1759, DOI 10.1001/jama.278.21.1759; *DEP HLTH, 1995, HLTH NAT POL APPR HL; Department of Health, 1998, SMOK KILLS WHIT PAP; Department of Physical Education Teaching Materials Compilation Committee the writing group calisthenics teaching, 1990, BLOOD CHOL TEST COST, P1; Dey P, 1999, BRIT J GEN PRACT, V49, P127; DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901; Fiscella K, 1996, JAMA-J AM MED ASSOC, V275, P1247, DOI 10.1001/jama.275.16.1247; HAM C, 1995, BR J HLTH CARE MANAG, V1, P27; JARVIS M, 1988, BRIT J ADDICT, V83, P323; JARVIS MJ, 1996, COMMUNICATION; KENFORD SL, 1994, JAMA-J AM MED ASSOC, V271, P589, DOI 10.1001/jama.271.8.589; Mikkelsen K, 1994, J SMOK REL DIS, V5, P95; Netten A, 1998, UNIT COSTS HLTH SOCI; *OFF NAT STAT, 1998, LIV BRIT RES 1996 GE; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PARROTS S, 1999, THORAX S5, V53, pS1; PETO R, 1994, BRIT MED J, V309, P937, DOI 10.1136/bmj.309.6959.937; PETO R, 1994, MORTALITY TOBACCO DE; RUSSELL MAH, 1993, BRIT MED J, V306, P1308, DOI 10.1136/bmj.306.6888.1308; SILAGY C, 1999, COCHRANE LIBRARY; STAPLETON JA, 1995, ADDICTION, V90, P31, DOI 10.1046/j.1360-0443.1995.901316.x; Stapleton JA, 1998, BRIT MED J, V316, P830, DOI 10.1136/bmj.316.7134.830; Tonnesen P, 1999, EUR RESPIR J, V13, P238, DOI 10.1034/j.1399-3003.1999.13b04.x; Torrance GW, 1987, METHODS EC EVALUATIO; Wasley MA, 1997, PREV MED, V26, P264, DOI 10.1006/pmed.1996.0127; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207; Yudkin PL, 1996, BRIT J GEN PRACT, V46, P145	30	64	64	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					210	215		10.1016/S0140-6736(99)90001-6	http://dx.doi.org/10.1016/S0140-6736(99)90001-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421303				2022-12-24	WOS:000081504200013
J	Kosunen, E; Vikat, A; Rimpela, M; Rimpela, A; Huhtala, H				Kosunen, E; Vikat, A; Rimpela, M; Rimpela, A; Huhtala, H			Questionnaire study of use of emergency contraception among teenagers	BMJ-BRITISH MEDICAL JOURNAL			English	Article							KNOWLEDGE	Easy accessibility and availability of emergency contraception raises contradictory opinions. Education about emergency contraception is resisted because of a fear that it might lead to irresponsible sexual behaviour and repeated use of emergency contraception instead of regular contraception.(1) In Finland, sales of emergency contraception (the Yuzpe method) increased 10-fold from 1987 to the mid-1990s. In 1994 a national survey among 18-44 year old women showed that knowledge and use of the method was concentrated in the youngest respondents.(2) Reports from other countries confirm that young women and even teenagers are well aware of the method.(3) (4) However, only a few reports have been published on use of emergency contraception among adolescents. We studied knowledge of emergency contraception and frequency of use among teenagers.	Tampere Univ, Sch Med, Dept Gen Practice, FIN-33101 Tampere, Finland; Tampere Univ, Sch Publ Hlth, FIN-33101 Tampere, Finland; Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland	Tampere University; Tampere University	Kosunen, E (corresponding author), Tampere Univ, Sch Med, Dept Gen Practice, POB 607, FIN-33101 Tampere, Finland.	meelko@uta.fi	Rimpela, Arja/J-3910-2014					Graham A, 1996, BRIT MED J, V312, P1567, DOI 10.1136/bmj.312.7046.1567; Kosunen E, 1997, CONTRACEPTION, V55, P153, DOI 10.1016/S0010-7824(97)00022-X; RIMPELA M, 1996, INT J HLTH PROMOTION, V3, P28; Smith BH, 1996, BRIT J OBSTET GYNAEC, V103, P1109, DOI 10.1111/j.1471-0528.1996.tb09592.x; Stubblefield P, 1998, NEW ENGL J MED, V339, P41, DOI 10.1056/NEJM199807023390108	5	25	27	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					91	91		10.1136/bmj.319.7202.91	http://dx.doi.org/10.1136/bmj.319.7202.91			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398631	Bronze, Green Published			2022-12-24	WOS:000081438200030
J	Sandvik, H				Sandvik, H			Health information and interaction on the internet: a survey of female urinary incontinence	BRITISH MEDICAL JOURNAL			English	Article							WORLD-WIDE-WEB; MEDICAL INFORMATION; ADVICE; CONTINENCE; REQUESTS; QUALITY; WOMEN	Objective To evaluate the internet as a source of information about urinary incontinence and to explore interactive facilities. Design Limited survey of internet resources. Subjects 75 websites providing information about incontinence and an opportunity for interactivity, 25 web doctors, and two news groups. Main outcome measures Quality scores according to predefined general and specific criteria. Internet popularity indexes according to number of links to websites. Correlation between quality scores and popularity indexes. Results Few sites provided comprehensive information, but the information actually provided was mostly correct Internet popularity indexes did not correlate with quality scores. The most informative site was easily found xith general internet search engines but was not found in any of the medical index sites investigated. Sixty six per cent of sites responded to an email request for advice from a fictitious incontinent woman, half of them within 24 hours. Twelve responders provided vital information that the woman might suffer from drug induced incontinence. Conclusions Excellent information about urinary incontinence was found on the internet, but the number of links to a site did not reflect quality of content. Patients may get valuable advice and comfort from using interactive services.	Univ Bergen, Dept Publ Hlth & Primary Care, N-5009 Bergen, Norway	University of Bergen	Sandvik, H (corresponding author), Univ Bergen, Dept Publ Hlth & Primary Care, Ulriksdal 8C, N-5009 Bergen, Norway.							Borowitz SM, 1998, JAMA-J AM MED ASSOC, V280, P1321, DOI 10.1001/jama.280.15.1321; Eysenbach G, 1998, BRIT MED J, V317, P1496, DOI 10.1136/bmj.317.7171.1496; Eysenbach G, 1998, JAMA-J AM MED ASSOC, V280, P1333, DOI 10.1001/jama.280.15.1333; Fonda D, 1997, EUR UROL, V32, P28; Goldstein M, 1992, J Gerontol Nurs, V18, P15; Impicciatore P, 1997, BMJ-BRIT MED J, V314, P1875, DOI 10.1136/bmj.314.7098.1875; Lim PHC, 1997, NEUROUROL URODYNAM, V16, P609, DOI 10.1002/(SICI)1520-6777(1997)16:6<609::AID-NAU10>3.0.CO;2-9; Marshall HJ, 1996, BRIT J CLIN PHARMACO, V42, P507, DOI 10.1046/j.1365-2125.1996.45217.x; NEWMAN DK, 1999, ACCT ACCESS CONTINEN; NORTON PA, 1988, BRIT MED J, V297, P1187, DOI 10.1136/bmj.297.6657.1187; Sandvik H, 1995, Fam Med, V27, P388; SANDVIK H, 1999, FEMALE URINARY INCON; Seim A, 1996, BRIT MED J, V312, P1459, DOI 10.1136/bmj.312.7044.1459; Silberg WM, 1997, JAMA-J AM MED ASSOC, V277, P1244, DOI 10.1001/jama.1997.03540390074039; Widman LE, 1997, ARCH INTERN MED, V157, P209, DOI 10.1001/archinte.157.2.209	15	109	113	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					29	32		10.1136/bmj.319.7201.29	http://dx.doi.org/10.1136/bmj.319.7201.29			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390457	Green Published, Bronze			2022-12-24	WOS:000081326500031
J	Taylor, DR; Shi, ST; Romano, PR; Barber, GN; Lai, MMC				Taylor, DR; Shi, ST; Romano, PR; Barber, GN; Lai, MMC			Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein	SCIENCE			English	Article							HEPATITIS-C VIRUS; NONSTRUCTURAL 5A PROTEIN; RNA-BINDING; HUMAN-CELLS; DAI; LOCALIZATION; ORGANIZATION; ACTIVATION; SITES	Most isolates of hepatitis C virus (HCV) infections are resistant to interferon, the only available therapy, but the mechanism underlying this resistance has not been defined. Here it is shown that the HCV envelope protein E2 contains a sequence identical with phosphorylation sites of the interferon-inducible protein kinase PKR and the translation initiation factor eIF2 alpha, a target of PKR. E2 inhibited the kinase activity of PKR and blocked its inhibitory effect on protein synthesis and cell growth. This interaction of E2 and PKR may be one mechanism by which HCV circumvents the antiviral effect of interferon.	Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90089 USA; Small Mol Therapeut, Monmouth Junction, NJ 08852 USA; Univ Miami, Sch Med, Miami, FL 33136 USA	University of Southern California; Howard Hughes Medical Institute; University of Southern California; University of Miami	Lai, MMC (corresponding author), Univ So Calif, Sch Med, Dept Mol Microbiol & Immunol, Los Angeles, CA 90089 USA.		Lai, Michael M. C./I-7001-2012; Yang, Chen/G-1379-2010		NIAID NIH HHS [AI 40038] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI040038] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Besse S, 1998, EXP CELL RES, V239, P379, DOI 10.1006/excr.1997.3908; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; CLEMENS MJ, 1996, TRANSLATIONAL CONTRO, P575; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; DEVER TE, 1993, P NATL ACAD SCI USA, V90, P4616, DOI 10.1073/pnas.90.10.4616; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Gale M, 1998, MOL CELL BIOL, V18, P5208, DOI 10.1128/MCB.18.9.5208; Gale MJ, 1997, VIROLOGY, V230, P217, DOI 10.1006/viro.1997.8493; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 1999, NATURE, V398, P90, DOI 10.1038/18057; Hsieh TY, 1998, J BIOL CHEM, V273, P17651, DOI 10.1074/jbc.273.28.17651; JIMENEZGARCIA LF, 1993, J CELL SCI, V106, P11; KATZE MG, 1991, MOL CELL BIOL, V11, P5497, DOI 10.1128/MCB.11.11.5497; LAURENT AG, 1985, P NATL ACAD SCI USA, V82, P4341, DOI 10.1073/pnas.82.13.4341; MATHEWS MB, 1991, J VIROL, V65, P5657, DOI 10.1128/JVI.65.11.5657-5662.1991; MATHEWS MB, 1996, TRANSLATIONAL CONTRO, P505; Raine DA, 1998, FEBS LETT, V436, P343, DOI 10.1016/S0014-5793(98)01163-6; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; TAYLOR DSC, UNPUB; Thomas HC, 1999, HEPATOLOGY, V29, P1333, DOI 10.1002/hep.510290453; Zhang XL, 1998, ANAL CHEM, V70, P2050, DOI 10.1021/ac971207m	23	588	632	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					107	110		10.1126/science.285.5424.107	http://dx.doi.org/10.1126/science.285.5424.107			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390359				2022-12-24	WOS:000081199800041
J	Jimenez, GS; Bryntesson, F; Torres-Arzayus, MI; Priestley, A; Beeche, M; Saito, S; Sakaguchi, K; Appella, E; Jeggo, PA; Taccioli, GE; Wahl, GM; Hubank, M				Jimenez, GS; Bryntesson, F; Torres-Arzayus, MI; Priestley, A; Beeche, M; Saito, S; Sakaguchi, K; Appella, E; Jeggo, PA; Taccioli, GE; Wahl, GM; Hubank, M			DNA-dependent protein kinase is not required for the p53-dependent response to DNA damage	NATURE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; CELL-CYCLE ARREST; V(D)J RECOMBINATION; P53; GROWTH; MICE; GENE; PK	Damage to DNA in the cell activates the tumour-suppressor protein p53 (ref. 1), and failure of this activation leads to genetic instability and a predisposition to cancer, It is therefore crucial to understand the signal transduction mechanisms that connect DNA damage with p53 activation. The enzyme known as DNA-dependent protein kinase (DNA-PK) has been proposed to be an essential activator of p53 (refs 2, 3), but the evidence for its involvement in this pathway is controversial(3,4). We now show that the p53 response is fully functional in primary mouse embryonic fibroblasts lacking DNA-PK: irradiation-induced DNA damage in these defective fibroblasts induces a normal response of p53 accumulation, phosphorylation of a p53 serine residue at position 15, nuclear localization and binding to DNA of p53. The upregulation of p53-target genes and cell-cycle arrest also occur normally. The DNA-PR-deficient cell line SCGR11 contains a homozygous mutation in the DNA-binding domain of p53, which may explain the defective response by p53 reported in this line(3), Our results indicate that DNA-PK activity is not required for cells to mount a p53-dependent response to DNA damage.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Univ Sussex, Trafford Ctr, Brighton BN1 9RY, E Sussex, England; Boston Univ, Sch Med, Dept Microbiol, Boston, MA 02118 USA; Univ Sussex, MRC, Cell Mutat Unit, Brighton BN1 9RR, E Sussex, England; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	Salk Institute; University of Brighton; University of Sussex; Boston University; University of Sussex; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wahl, GM (corresponding author), Salk Inst Biol Studies, Gene Express Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Hubank, Michael JF/C-1837-2008	Hubank, Michael JF/0000-0002-2901-0742; Sakaguchi, Kazuyasu/0000-0002-8434-4171	NATIONAL CANCER INSTITUTE [Z01BC005599, ZIABC005599] Funding Source: NIH RePORTER; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Huang LC, 1996, CANCER RES, V56, P2940; Jeggo PA, 1997, MUTAT RES-DNA REPAIR, V384, P1, DOI 10.1016/S0921-8777(97)00009-8; Jongmans W, 1996, ONCOGENE, V13, P1133; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Rathmell WK, 1997, CANCER RES, V57, P68; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	19	113	116	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					81	83		10.1038/21913	http://dx.doi.org/10.1038/21913			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403253				2022-12-24	WOS:000081255700055
J	Bohni, R; Riesgo-Escovar, J; Oldham, S; Brogiolo, W; Stocker, H; Andruss, BF; Beckingham, K; Hafen, E				Bohni, R; Riesgo-Escovar, J; Oldham, S; Brogiolo, W; Stocker, H; Andruss, BF; Beckingham, K; Hafen, E			Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS1-4	CELL			English	Article							INSULIN-RECEPTOR SUBSTRATE-1; PHOSPHOINOSITIDE 3-KINASE; TYROSINE KINASE; GROWTH-FACTORS; C-ELEGANS; LIFE-SPAN; MICE; GENE; CYCLE; DIVISION	The control of growth is fundamental to the developing metazoan. Here, we show that CHICO, a Drosophila homolog of vertebrate IRS1-4, plays an essential role in the control of cell size and growth. Animals mutant for chico are less than half the size of wild-type flies, owing to fewer and smaller cells. In mosaic animals, chico homozygous cells grow slower than their heterozygous siblings, show an autonomous reduction in cell size, and form organs of reduced size. Although chico flies are smaller, they show an almost P-fold increase in lipid levels. The similarities of the growth defects caused by mutations in chico and the insulin receptor gene in Drosophila and by perturbations of the insulin/IGF1 signaling pathway in vertebrates suggest that this pathway plays a conserved role in the regulation of overall growth by controling cell size, cell number, and metabolism.	Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich	Hafen, E (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hafen@zool.unizh.ch	Stoecker, Horst/F-8382-2012	Stoecker, Horst/0000-0002-3282-3664				Abe H, 1998, J CLIN INVEST, V101, P1784, DOI 10.1172/JCI1594; Apfeld J, 1998, CELL, V95, P199, DOI 10.1016/S0092-8674(00)81751-1; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/0092-8674(93)90680-O; BASLER K, 1988, CELL, V54, P299; BERG CA, 1991, GENETICS, V127, P515; Britton JS, 1998, DEVELOPMENT, V125, P2149; BRYANT PJ, 1984, Q REV BIOL, V59, P387, DOI 10.1086/414040; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Chen C, 1996, ENDOCRINOLOGY, V137, P846, DOI 10.1210/en.137.3.846; Chou TB, 1996, GENETICS, V144, P1673; Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEVALOIR T, 1991, P NATL ACAD SCI USA, V88, P2113, DOI 10.1073/pnas.88.6.2113; EDGAR BA, 1994, DEVELOPMENT, V120, P3131; FERNANDEZ R, 1995, EMBO J, V14, P3373, DOI 10.1002/j.1460-2075.1995.tb07343.x; Follette PJ, 1997, CELL, V88, P309, DOI 10.1016/S0092-8674(00)81869-3; Gallant P, 1996, SCIENCE, V274, P1523, DOI 10.1126/science.274.5292.1523; Hekimi S, 1998, TRENDS GENET, V14, P14, DOI 10.1016/S0168-9525(97)01299-7; Ilic D, 1998, J CELL BIOL, V143, P547; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MINARI O, 1963, ANAL BIOCHEM, V6, P320, DOI 10.1016/0003-2697(63)90156-8; MOLLER DE, 1991, NEW ENGL J MED, V325, P938; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Neufeld TP, 1998, CELL, V93, P1183, DOI 10.1016/S0092-8674(00)81462-2; Nurse P., 1985, P185; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; Riddle DL., 1988, NEMATODE CAENORHABDI, P393; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; ROBERTSON FW, 1963, GENET RES, V4, P74, DOI 10.1017/S001667230000344X; SANTAMARIA P, 1983, DEV BIOL, V96, P285, DOI 10.1016/0012-1606(83)90165-3; SCHMIDT A, 1998, EMBO J, V17, P101; SIMPSON P, 1979, DEV BIOL, V69, P182, DOI 10.1016/0012-1606(79)90284-7; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stern DL, 1999, DEVELOPMENT, V126, P1091; Stewart CEH, 1996, PHYSIOL REV, V76, P1005, DOI 10.1152/physrev.1996.76.4.1005; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VANHANDEL E, 1988, J AM MOSQUITO CONTR, V4, P549; Weigmann K, 1997, DEVELOPMENT, V124, P3555; Weinkove D, 1997, J BIOL CHEM, V272, P14606, DOI 10.1074/jbc.272.23.14606; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; XU T, 1993, DEVELOPMENT, V117, P1223; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Yenush L, 1996, MOL CELL BIOL, V16, P2509; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	50	656	669	0	36	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					865	875		10.1016/S0092-8674(00)80799-0	http://dx.doi.org/10.1016/S0092-8674(00)80799-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399915	Bronze			2022-12-24	WOS:000081162800008
J	Tai, AW; Chuang, JZ; Bode, C; Wolfrum, U; Sung, CH				Tai, AW; Chuang, JZ; Bode, C; Wolfrum, U; Sung, CH			Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1	CELL			English	Article							DOMINANT RETINITIS-PIGMENTOSA; PHOTORECEPTOR CELLS; ROD PHOTORECEPTORS; VESICLE TRANSPORT; OUTER SEGMENT; RETINAL RODS; IN-VIVO; COMPLEX; LOCALIZATION; GENE	The interaction of cytoplasmic dynein with its cargoes is thought to be indirectly mediated by dynactin, a complex that binds to the dynein intermediate chain. However, the roles of other dynein subunits in cargo binding have been unknown. Here we demonstrate that dynein translocates rhodopsin-bearing vesicles along microtubules. This interaction occurs directly between the C-terminal cytoplasmic tail of rhodopsin and Tctex-1, a dynein light chain. C-terminal rhodopsin mutations responsible for retinitis pigmentosa inhibit this interaction. Our results point to an alternative docking mechanism for cytoplasmic dynein, provide novel insights into the role of motor proteins in the polarized transport of post-Golgi vesicles, and shed light on the molecular basis of retinitis pigmentosa.	Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Ophthalmol, Margaret M Dyson Vis Res Inst, New York, NY 10021 USA; Johannes Gutenberg Univ Mainz, Inst Zool, D-55099 Mainz, Germany	Cornell University; Cornell University; Johannes Gutenberg University of Mainz	Sung, CH (corresponding author), Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA.	chsung@mail.med.cornell.edu	Tai, Andrew W./M-8380-2017	Tai, Andrew W./0000-0002-6877-450X	NATIONAL EYE INSTITUTE [R01EY011307] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY011307, EY11307] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ADAMUS G, 1988, Peptide Research, V1, P42; Bauch A, 1998, EUR J IMMUNOL, V28, P2167, DOI 10.1002/(SICI)1521-4141(199807)28:07<2167::AID-IMMU2167>3.0.CO;2-L; Beech PL, 1996, J CELL SCI, V109, P889; BESHARSE JC, 1995, J NEUROCYTOL, V24, P371, DOI 10.1007/BF01189064; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; Campbell KS, 1998, J IMMUNOL, V161, P1728; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; Chuang JZ, 1998, J CELL BIOL, V142, P1245, DOI 10.1083/jcb.142.5.1245; COLLINS CA, 1987, J CELL BIOL, V105, P2847, DOI 10.1083/jcb.105.6.2847; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DEETIC D, 1998, P NATL ACAD SCI USA, V95, P10620; DERETIC D, 1991, J CELL BIOL, V113, P1281, DOI 10.1083/jcb.113.6.1281; DILLMAN JF, 1994, J CELL BIOL, V127, P1671, DOI 10.1083/jcb.127.6.1671; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; DRYJA TP, 1990, NEW ENGL J MED, V323, P1302, DOI 10.1056/NEJM199011083231903; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; Echeverri CJ, 1996, J CELL BIOL, V132, P617, DOI 10.1083/jcb.132.4.617; GILL SR, 1994, MOL BIOL CELL, V5, P645, DOI 10.1091/mbc.5.6.645; HARGRAVE PA, 1982, METHOD ENZYMOL, V81, P251; Harrison A, 1998, J CELL BIOL, V140, P1137, DOI 10.1083/jcb.140.5.1137; HYMAN AA, 1991, J CELL SCI, P125; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; King SM, 1996, J BIOL CHEM, V271, P19358, DOI 10.1074/jbc.271.32.19358; King SM, 1996, J BIOL CHEM, V271, P32281, DOI 10.1074/jbc.271.50.32281; King SM, 1998, BIOCHEMISTRY-US, V37, P15033, DOI 10.1021/bi9810813; KREBS W, 1977, EXP EYE RES, V25, P511, DOI 10.1016/0014-4835(77)90180-4; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LADER E, 1989, CELL, V58, P969, DOI 10.1016/0092-8674(89)90948-3; Li ZY, 1998, INVEST OPHTH VIS SCI, V39, P808; Liu XR, 1997, CELL MOTIL CYTOSKEL, V37, P240, DOI 10.1002/(SICI)1097-0169(1997)37:3<240::AID-CM6>3.3.CO;2-2; MACKE JP, 1993, AM J HUM GENET, V53, P80; MCGRAIL M, 1995, J CELL BIOL, V131, P411, DOI 10.1083/jcb.131.2.411; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; Mou T, 1998, FEBS LETT, V435, P275, DOI 10.1016/S0014-5793(98)01069-2; Muresan V, 1996, J CELL BIOL, V135, P383, DOI 10.1083/jcb.135.2.383; Nagano F, 1998, J BIOL CHEM, V273, P30065, DOI 10.1074/jbc.273.46.30065; PAPERMASTER DS, 1986, J HISTOCHEM CYTOCHEM, V34, P5, DOI 10.1177/34.1.2934469; PASCHAL BM, 1987, J CELL BIOL, V105, P1273, DOI 10.1083/jcb.105.3.1273; Pfister KK, 1996, MOL BIOL CELL, V7, P331, DOI 10.1091/mbc.7.2.331; PLAMANN M, 1994, J CELL BIOL, V127, P139, DOI 10.1083/jcb.127.1.139; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; ROHLICH P, 1975, CELL TISSUE RES, V161, P421; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; SPENCER M, 1988, INVEST OPHTH VIS SCI, V29, P1012; Steffen W, 1997, MOL BIOL CELL, V8, P2077, DOI 10.1091/mbc.8.10.2077; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P6481, DOI 10.1073/pnas.88.15.6481; SUNG CH, 1991, P NATL ACAD SCI USA, V88, P8840, DOI 10.1073/pnas.88.19.8840; SUNG CH, 1993, J BIOL CHEM, V268, P26645; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tai AW, 1998, J BIOL CHEM, V273, P19639, DOI 10.1074/jbc.273.31.19639; TROUTT LL, 1988, J NEUROSCI, V8, P2371; Vallee RB, 1995, COLD SPRING HARB SYM, V60, P803, DOI 10.1101/SQB.1995.060.01.086; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; Watanabe TK, 1996, CYTOGENET CELL GENET, V73, P153, DOI 10.1159/000134329; WEISS ER, 1995, BIOCHEM BIOPH RES CO, V216, P755, DOI 10.1006/bbrc.1995.2686; WOLFRUM U, 1995, CELL MOTIL CYTOSKEL, V32, P55, DOI 10.1002/cm.970320107; YOUNG RW, 1976, INVEST OPHTH VISUAL, V15, P700	62	388	398	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					877	887		10.1016/S0092-8674(00)80800-4	http://dx.doi.org/10.1016/S0092-8674(00)80800-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399916	hybrid			2022-12-24	WOS:000081162800009
J	Miyata, T; Asami, N; Uragami, T				Miyata, T; Asami, N; Uragami, T			A reversibly antigen-responsive hydrogel	NATURE			English	Article							PHASE-TRANSITIONS; POLYMER GEL; RELEASE; GLUCOSE; COLLAPSE; PH	Stimuli-responsive hydrogels that undergo abrupt changes in volume in response to external stimuli such as pH, temperature and solvent composition have potential applications in biomedicine and the creation of 'intelligent' materials systems, for example as media for drug delivery, separation processes and protein immobilization. Hydrogels have been reported that respond to pH(1-3), temperature(4-13), electric fields(14-16) and saccharides(17-22). For some biomedical applications it would be very useful to have a material whose swelling response was dictated by a specific protein. Here we report such a material, which swells reversibly in a buffer solution in response to a specific antigen. The hydrogel was prepared by grafting the antigen and corresponding antibody to the polymer network, so that binding between the two introduces crosslinks in the network. Competitive binding of the free antigen triggers a change in gel volume owing to breaking of these non-covalent crosslinks. In addition, we show that the hydrogel displays shape-memory behaviour, and that stepwise changes in antigen concentration can induce pulsatile permeation of a protein through the network.	Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan; Kansai Univ, High Technol Res Ctr, Osaka 5648680, Japan	Kansai University; Kansai University	Miyata, T (corresponding author), Kansai Univ, Fac Engn, Chem Branch, Osaka 5648680, Japan.							AOKI T, 1994, MACROMOLECULES, V27, P947, DOI 10.1021/ma00082a010; BAE YH, 1987, MAKROMOL CHEM-RAPID, V8, P481; BAE YH, 1988, MAKROMOL CHEM-RAPID, V9, P185; CHEN GH, 1995, NATURE, V373, P49, DOI 10.1038/373049a0; FEIL H, 1991, J MEMBRANE SCI, V64, P283, DOI 10.1016/0376-7388(91)80099-R; Flory P. J, 1953, PRINCIPLES POLYM CHE; HIROKAWA Y, 1984, J CHEM PHYS, V81, P6379, DOI 10.1063/1.447548; HOFFMAN A S, 1987, Journal of Controlled Release, V6, P297, DOI 10.1016/0168-3659(87)90083-6; Kataoka K, 1998, J AM CHEM SOC, V120, P12694, DOI 10.1021/ja982975d; KOKUFATA E, 1991, NATURE, V351, P302, DOI 10.1038/351302a0; KWON IC, 1991, NATURE, V354, P291, DOI 10.1038/354291a0; Lee SJ, 1996, J MOL RECOGNIT, V9, P549, DOI 10.1002/(SICI)1099-1352(199634/12)9:5/6<549::AID-JMR299>3.0.CO;2-C; Miyata T, 1996, MACROMOL CHEM PHYSIC, V197, P1135, DOI 10.1002/macp.1996.021970330; MIYATA T, 1994, MACROMOL CHEM PHYSIC, V195, P1111, DOI 10.1002/macp.1994.021950401; MURAI N, 1995, J BIOL CHEM, V270, P19957, DOI 10.1074/jbc.270.34.19957; NATSUME T, 1994, J BIOL CHEM, V269, P31224; OBIDAT AA, 1996, PHARMACEUT RES, V13, P989; OBIDAT AA, 1997, BIOMATERIALS, V18, P801; OSADA Y, 1992, NATURE, V355, P242, DOI 10.1038/355242a0; SHOEMAKER SG, 1987, APPL BIOCHEM BIOTECH, V15, P11, DOI 10.1007/BF02798503; SIEGEL RA, 1988, MACROMOLECULES, V21, P3254, DOI 10.1021/ma00189a021; STAYTON PS, 1995, NATURE, V378, P472, DOI 10.1038/378472a0; TANAKA T, 1978, PHYS REV LETT, V40, P820, DOI 10.1103/PhysRevLett.40.820; TANAKA T, 1982, SCIENCE, V218, P467, DOI 10.1126/science.218.4571.467; TANAKA T, 1980, PHYS REV LETT, V45, P1636, DOI 10.1103/PhysRevLett.45.1636; YOSHIDA R, 1995, NATURE, V374, P240, DOI 10.1038/374240a0	26	934	971	16	676	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					766	769		10.1038/21619	http://dx.doi.org/10.1038/21619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391240				2022-12-24	WOS:000081101600049
J	Ascherio, A; Rimm, EB; Hernan, MA; Giovannucci, E; Kawachi, I; Stampfer, MJ; Willett, WC				Ascherio, A; Rimm, EB; Hernan, MA; Giovannucci, E; Kawachi, I; Stampfer, MJ; Willett, WC			Relation of consumption of vitamin E, vitamin C, and carotenoids to risk for stroke among men in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; CORONARY HEART-DISEASE; BETA-CAROTENE; LOGISTIC-REGRESSION; VEGETABLES PROTECT; FOLLOW-UP; DIETARY; PLASMA; ANTIOXIDANT; MORTALITY	Background: Antioxidants increase the resistance of low-density lipoprotein to oxidation and may thereby reduce risk for atherosclerosis. Objective: To determine whether intake of vitamin E, vitamin C, or carotenoids predict risk for total or ischemic stroke. Design: Prospective observational study. Setting: The Health Professionals Follow-up Study. Participants: 43 738 men 40 to 75 years of age who did not have cardiovascular disease or diabetes. Measurements: Repeated and validated dietary assessments were done by using a self-administered 131-item food-frequency questionnaire, which included questions on dose and duration of vitamin supplement use. The follow-up period was 8 years. Results: A total of 328 strokes occurred: 210 ischemic, 70 hemorrhagic, and 48 unclassified. After adjustment for age, smoking, hypertension, hypercholesterolemia, body mass index, physical activity, parental history of myocardial infarction, alcohol consumption, and total energy intake, the relative risk for ischemic stroke in the top quintile of vitamin E intake (median, 411 IU/d) compared with the bottom quintile (5.4 IU/d) was 1.18 (95% Cl, 0.77 to 1.82). The relative risk for ischemic stroke in the top quintile of vitamin C intake (1167 mg/d) compared with the bottom quintile (95 mg/d) was 1.03 (Cl, 0.66 to 1.59). Results for total stroke were similar. Associations of vitamin intake with hemorrhagic stroke were also nonsignificant, but the Cls were wide. Neither dose nor duration of vitamin E or vitamin C supplement use was related to risk for total or ischemic stroke. The relative risk for ischemic stroke was 1.16 (Cl, 0.81 to 1.67) in men using 250 IU or more of vitamin E supplementation per day compared with men who used no vitamin E supplements and was 0.93 (Cl, 0.60 to 1.45) in men using 700 mg or more of vitamin C supplementation per day compared with men who used no vitamin C supplements. A significant inverse relation between lutein intake and risk for ischemic stroke was seen but was not independent of other dietary factors. Conclusions: Vitamin E and vitamin C supplements and specific carotenoids did not seem to substantially reduce risk for stroke in this cohort. Modest effects, however, cannot be excluded.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	alberto.ascherio@channing.harvard.edu			NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACHESON RM, 1983, LANCET, V1, P1191; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; Azen SP, 1996, CIRCULATION, V94, P2369, DOI 10.1161/01.CIR.94.10.2369; BENDICH A, 1989, J NUTR, V119, P135, DOI 10.1093/jn/119.1.135; BOSCOBOINIK D, 1991, J BIOL CHEM, V266, P6188; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Daviglus ML, 1997, NEUROEPIDEMIOLOGY, V16, P69, DOI 10.1159/000109673; DI MASCIO P, 1989, ARCH BIOCHEM BIOPHYS, V274, P532, DOI 10.1016/0003-9861(89)90467-0; DONNAN PT, 1993, AM J CLIN NUTR, V57, P917, DOI 10.1093/ajcn/57.6.917; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GEY KF, 1993, AM J CLIN NUTR, V57, P787; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KRITCHEVSKY SB, 1995, CIRCULATION, V92, P2142, DOI 10.1161/01.CIR.92.8.2142; Kushi LH, 1996, AM J EPIDEMIOL, V144, P165, DOI 10.1093/oxfordjournals.aje.a008904; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Mark SD, 1998, EPIDEMIOLOGY, V9, P9, DOI 10.1097/00001648-199801000-00005; Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; Ross RK, 1997, CIRCULATION, V96, P50; Rothman K., 1998, MODERN EPIDEMIOLOGY; SHEKELLE RB, 1982, AM J EPIDEMIOL, V115, P506, DOI 10.1093/oxfordjournals.aje.a113332; STAMPFER MJ, 1995, AM J CLIN NUTR, V62, P1365, DOI 10.1093/ajcn/62.6.1365S; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINER M, 1991, J AM COLL NUTR, V10, P466; STEINER M, 1995, AM J CLIN NUTR, V62, P1381, DOI 10.1093/ajcn/62.6.1381S; VOLLSET SE, 1983, LANCET, V2, P742; WALKER AM, 1981, LANCET, V1, P13; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366	42	152	157	0	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					963	970		10.7326/0003-4819-130-12-199906150-00003	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383366				2022-12-24	WOS:000080894700002
J	Connelly, MT; Ferrari, N; Hagen, N; Inui, TS				Connelly, MT; Ferrari, N; Hagen, N; Inui, TS			Patient-identified needs for hormone replacement therapy counseling: A qualitative study	ANNALS OF INTERNAL MEDICINE			English	Article							WOMEN	Background: Numerous medical organizations, including the American College of Physicians, have recommended that women be counseled about postmenopausal hormone replacement therapy (HRT). Patients' perspectives on their counseling needs, however, have not been integrated into most counseling guides. Objective: To use patient self-reports to identify needs for HRT counseling. Design: Individual, in-depth patient interviews. Setting: Managed care organization. Patients: 26 women who had received an initial prescription for HRT. Measurements: Qualitative, consensus review of the content of interview transcripts. Results: On average, women reported 15 factors (range, 6 to 24 factors) as critical to their decision-making process. Although most women cited their physician's opinion (96%), reports in the media (81%), and experiences and opinions of friends (77%) as critical to their decisions about HRT, counseling recommendations address none of these concerns. Conclusions: Many women in a managed care organization who accepted a prescription for HRT identified counseling needs that are not included in widely used HRT guidelines.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Hlth Publicat Grp, Boston, MA 02215 USA; Brown & Toland Phys Serv Org, San Francisco, CA 94109 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Harvard Medical School	Connelly, MT (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 203, Boston, MA 02215 USA.				AHRQ HHS [1F32HS00107-01] Funding Source: Medline; BHP HRSA HHS [2T32PE11001-06, 5T32PE11001-07] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		*AM COLL OBST GYN, 1998, AM COLL OBST GYN ED, V247, P1; Barry M.J., 1997, DIS MANAG CLIN OUTCO, V1, P5, DOI DOI 10.1016/S1088-3371(96)00004-6; Chan ECY, 1998, AM J MED, V105, P266, DOI 10.1016/S0002-9343(98)00257-5; CRABTREE BF, 1992, DOING QUALITATIVE RE, P41; Daley J, 1999, ANN INTERN MED, V130, P602, DOI 10.7326/0003-4819-130-7-199904060-00021; FEASLEY J, 1996, HLTH OUTCOMES OLDER; GRADY D, 1992, ANN INTERN MED, V117, P1038; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; Liao L, 1996, J GEN INTERN MED, V11, P373, DOI 10.1007/BF02600051; LIVINGSTON WW, 1994, J GEN INTERN MED, V9, P385, DOI 10.1007/BF02629518; MANSFIELD PK, 1998, HEALTH CARE WOMEN IN, V18, P55; Newton KM, 1997, J WOMENS HEALTH, V6, P459, DOI 10.1089/jwh.1997.6.459; O'Connor AM, 1998, MED DECIS MAKING, V18, P295, DOI 10.1177/0272989X9801800307; ROTHERT M, 1994, EXP GERONTOL, V29, P463, DOI 10.1016/0531-5565(94)90026-4; Saver BG, 1997, AM J PREV MED, V13, P358, DOI 10.1016/S0749-3797(18)30155-7; Seto TB, 1996, J GEN INTERN MED, V11, P197, DOI 10.1007/BF02642475; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P829	18	37	37	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					265	268		10.7326/0003-4819-131-4-199908170-00005	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454947				2022-12-24	WOS:000082012500004
J	Silvian, LF; Wang, JM; Steitz, TA				Silvian, LF; Wang, JM; Steitz, TA			Insights into editing from an Ile-tRNA synthetase structure with tRNA(Ile) and mupirocin	SCIENCE			English	Article							TRANSFER-RNA-SYNTHETASE; DNA-POLYMERASE-I; ESCHERICHIA-COLI; KLENOW FRAGMENT; AMINOACYLATION; REFINEMENT; MECHANISM; SITES; GENE	Isoleucyl-transfer RNA (tRNA) synthetase (IleRS) joins Ire to tRNA(Ile) at its synthetic active site and hydrolyzes incorrectly acylated amino acids at its editing active site. The 2.2 angstrom resolution crystal structure of Staphylococcus aureus IleRS complexed with tRNA(Ile) and Mupirocin shows the acceptor strand of the tRNA(Ile) in the continuously stacked, A-form conformation with the 3' terminal nucleotide in the editing active site. To position the 3' terminus in the synthetic active site, the acceptor strand must adopt the hairpinned conformation seen in tRNA(Gln) complexed with its synthetase, The amino acid editing activity of the IleRS may result from the incorrect products shuttling between the synthetic and editing active sites, which is reminiscent of the editing mechanism of DNA polymerases.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Yale University; Howard Hughes Medical Institute	Silvian, LF (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		Steitz, Thomas A./C-6559-2009	Silvian, Laura/0000-0002-5299-5201	NIGMS NIH HHS [GM22778] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; CHALKER AF, 1994, GENE, V141, P103, DOI 10.1016/0378-1119(94)90135-X; Fersht AR, 1998, SCIENCE, V280, P541, DOI 10.1126/science.280.5363.541; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P1238, DOI 10.1021/bi00574a019; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FRIEDMAN AM, 1994, AM CRYST ASS ANN M A; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; HECK JD, 1988, J BIOL CHEM, V263, P868; JONES TA, 1994, O MANUAL; JOYCE CM, 1989, J BIOL CHEM, V264, P10858; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Rath VL, 1998, STRUCT FOLD DES, V6, P439, DOI 10.1016/S0969-2126(98)00046-X; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SILVIAN LF, UNPUB; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; SUDDATH FL, 1974, NATURE, V248, P20, DOI 10.1038/248020a0; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; WANG JC, UNPUB	28	344	358	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1074	1077		10.1126/science.285.5430.1074	http://dx.doi.org/10.1126/science.285.5430.1074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446055				2022-12-24	WOS:000082033100048
J	Veenstra, DL; Saint, S; Sullivan, SD				Veenstra, DL; Saint, S; Sullivan, SD			Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-STREAM INFECTION; PROSPECTIVE RANDOMIZED TRIAL; PULMONARY-ARTERY CATHETERS; CRITICALLY ILL PATIENTS; BACTERIAL-COLONIZATION; INTENSIVE-CARE; SILVER-SULFADIAZINE; MORTALITY; SEPSIS; CHLORHEXIDINE	Context A recent randomized controlled trial and meta-analysis indicated that central venous catheters impregnated with an antiseptic combination of chlorhexidine and silver sulfadiazine are efficacious in reducing the incidence of catheter-related bloodstream infection (CR-BSI); however, the ultimate clinical and economic consequences of their use have not been formally evaluated. Objective To estimate the incremental clinical and economic outcomes associated with the use of antiseptic-impregnated vs standard catheters. Design Decision analytic model using data from randomized controlled trials, meta-analyses, and case-control studies, as well as safety data from the US Food and Drug Administration. Setting and Patients A hypothetical cohort of hospitalized patients at high risk for catheter-related infections leg, patients in intensive care units, immunosuppressed patients, and patients receiving total parenteral nutrition) requiring use of a central venous catheter. Intervention Short-term use (2-10 days) of chlorhexidine-silver sulfadiazine-impregnated multilumen central venous catheters and nonimpregnated catheters. Main Outcome Measures Expected incidence of CR-BSI and death attributable to antiseptic-impregnated and standard catheter use; direct medical costs for both types of catheters. Results In the base-case analysis, use of antiseptic-impregnated catheters resulted in a decrease in the incidence of CR-BSI of 2.2% (5.2% for standard vs 3.0% for antiseptic-impregnated catheters), a decrease in the incidence of death of 0.33% (0.78% for standard vs 0.45% for antiseptic-impregnated), and a decrease in costs of $196 per catheter used ($532 for standard vs $336 for antiseptic-impregnated). The decrease in CR-BSI ranged from 1.2% to 3.4%, the decrease in death ranged from 0.09% to 0.78%, and the costs saved ranged from $68 to $391 in a multivariate sensitivity analysis. Conclusion Our analyses suggest that use of chlorhexidine-silver sulfadiazine-impregnated central venous catheters in patients at high risk for catheter-related infections reduces the incidence of CR-BSI and death and provides significant saving in costs. Use of these catheters should be considered as part of a comprehensive nosocomial infection control program.	Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; Univ Washington, Sch Pharm, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Washington, Sch Pharm, Dept Pharm, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle	Veenstra, DL (corresponding author), Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, POB 357630, Seattle, WA 98195 USA.		Saint, Sanjay/AAF-5126-2019		AHRQ HHS [HS/HL08368-01A1, HS07834-03S1] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Appavu S. K., 1994, Chest, V106, p176S; ARNOW PM, 1993, CLIN INFECT DIS, V16, P778, DOI 10.1093/clind/16.6.778; Bach A, 1996, J ANTIMICROB CHEMOTH, V37, P315, DOI 10.1093/jac/37.2.315; Bach A, 1995, ZBL BAKT-INT J MED M, V283, P208; BACH A, 1994, ANESTHESIOLOGY, V81, pA261; BOOTH FVM, 1996, CRIT CARE MED S1, V24, pA45; *BUR LAB STAT, 1998, CONS PRIC IND MED CA; *CDCP, 1996, EPI INF COMP PROGR V; Ciresi DL, 1996, AM SURGEON, V62, P641; Civetta JM, 1996, CRIT CARE MED, V24, P1660, DOI 10.1097/00003246-199610000-00010; COBB DK, 1992, NEW ENGL J MED, V327, P1062, DOI 10.1056/NEJM199210083271505; Collin GR, 1999, CHEST, V115, P1632, DOI 10.1378/chest.115.6.1632; CRITCHFIELD GC, 1986, MED DECIS MAKING, V6, P85, DOI 10.1177/0272989X8600600205; *CTR DEV RAD HLTH, 1998, POT HYP REACT CHLORH; Darouiche RO, 1999, NEW ENGL J MED, V340, P1, DOI 10.1056/NEJM199901073400101; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Drummond MF, 2015, METHODS EC EVALUATIO; EYER S, 1990, CRIT CARE MED, V18, P1073, DOI 10.1097/00003246-199010000-00005; FLOWERS RH, 1989, JAMA-J AM MED ASSOC, V261, P878, DOI 10.1001/jama.261.6.878; George SJ, 1997, EUR J ANAESTH, V14, P428, DOI 10.1046/j.1365-2346.1997.00168.x; GILLUM BS, 1998, VITAL HLTH STAT, V13, P133; Hannan M, 1996, CLIN INTENSIVE CARE, V7, P56; Hasaniya NWMA, 1996, CHEST, V109, P1030, DOI 10.1378/chest.109.4.1030; Heard SO, 1998, ARCH INTERN MED, V158, P81, DOI 10.1001/archinte.158.1.81; *HLTH CAR FIN ADM, 1998, PROSP PAYM SYST STAN; HOFFMANN KK, 1992, JAMA-J AM MED ASSOC, V267, P2072, DOI 10.1001/jama.267.15.2072; Jarvis WR, 1998, AM J INFECT CONTROL, V26, P522; KAMAL GD, 1991, JAMA-J AM MED ASSOC, V265, P2364, DOI 10.1001/jama.265.18.2364; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; Logghe C, 1997, J HOSP INFECT, V37, P145, DOI 10.1016/S0195-6701(97)90184-5; Maki Dennis G., 1994, P155; MAKI DG, 1991, LANCET, V338, P339, DOI 10.1016/0140-6736(91)90479-9; MAKI DG, 1994, CRIT CARE MED, V22, P1729; Maki DG, 1997, ANN INTERN MED, V127, P257, DOI 10.7326/0003-4819-127-4-199708150-00001; MARTIN MA, 1989, ANN INTERN MED, V110, P9, DOI 10.7326/0003-4819-110-1-9; Mimoz O, 1996, CRIT CARE MED, V24, P1818, DOI 10.1097/00003246-199611000-00010; MODAK SM, 1992, COMPLICATION SURG, V11, P23; Naglie G, 1997, MED DECIS MAKING, V17, P136, DOI 10.1177/0272989X9701700203; NYSTROM B, 1994, INFECT CONT HOSP EP, V15, P435; Oda T, 1997, ANESTHESIOLOGY, V87, P1242, DOI 10.1097/00000542-199711000-00031; Pearson ML, 1996, AM J INFECT CONTROL, V24, P262; Pearson ML, 1997, ANN INTERN MED, V127, P304, DOI 10.7326/0003-4819-127-4-199708150-00009; Pemberton LB, 1996, ARCH SURG-CHICAGO, V131, P986; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; Pittet D, 1994, JAMA-J AM MED ASSOC, V272, P1819; Raad I, 1997, ANN INTERN MED, V127, P267, DOI 10.7326/0003-4819-127-4-199708150-00002; Raad I, 1998, LANCET, V351, P893, DOI 10.1016/S0140-6736(97)10006-X; RAAD II, 1992, CLIN INFECT DIS, V15, P197, DOI 10.1093/clinids/15.2.197; Ramsay J, 1994, CRIT CARE MED, V22, pA115; SMITH RL, 1991, CHEST, V100, P164, DOI 10.1378/chest.100.1.164; Tennenberg S, 1997, ARCH SURG-CHICAGO, V132, P1348; Torrance GW., 1996, COST EFFECTIVENESS H, P54; TRAZZERA S, 1995, CRIT CARE MED, V23, pA152; vanHeerden PV, 1996, ANAESTH INTENS CARE, V24, P330, DOI 10.1177/0310057X9602400305; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V281, P261, DOI 10.1001/jama.281.3.261; *WHO, 1997, INF EXCH SYST	57	194	202	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					554	560		10.1001/jama.282.6.554	http://dx.doi.org/10.1001/jama.282.6.554			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450717				2022-12-24	WOS:000081919100029
J	Lin, L; Faraco, J; Li, R; Kadotani, H; Rogers, W; Lin, XY; Qiu, XH; de Jong, PJ; Nishino, S; Mignot, E				Lin, L; Faraco, J; Li, R; Kadotani, H; Rogers, W; Lin, XY; Qiu, XH; de Jong, PJ; Nishino, S; Mignot, E			The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene	CELL			English	Article							RNA SPLICE JUNCTIONS; MESSENGER-RNA; DROSOPHILA PERIOD; SEQUENCE; CATAPLEXY; SYSTEMS; SUSCEPTIBILITY; HYPOTHALAMUS; CHROMOSOMES; EXPRESSION	Narcolepsy is a disabling sleep disorder affecting humans and animals. It is characterized by daytime sleepiness, cataplexy, and striking transitions from wakefulness into rapid eye movement (REM) sleep. In this study, we used positional cloning to identify an autosomal recessive mutation responsible for this sleep disorder in a well-established canine model. We have determined that canine narcolepsy is caused by disruption of the hypocretin (orexin) receptor 2 gene (Hcrtr2). This result identifies hypocretins as major sleep-modulating neurotransmitters and opens novel potential therapeutic approaches for narcoleptic patients.	Stanford Univ, Sch Med, Dept Psychiat, Ctr Narcolepsy, Stanford, CA 94305 USA; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA	Stanford University; Roswell Park Cancer Institute	Mignot, E (corresponding author), Stanford Univ, Sch Med, Dept Psychiat, Ctr Narcolepsy, Stanford, CA 94305 USA.		Kadotani, Hiroshi/A-7908-2015	Kadotani, Hiroshi/0000-0001-7474-3315	NHLBI NIH HHS [HL59601] Funding Source: Medline; NINDS NIH HHS [NS23724, NS33797] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059601] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS033797, P50NS023724, P01NS023724, R01NS033797] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aldrich MS, 1998, NEUROLOGY, V50, pS2, DOI 10.1212/WNL.50.2_Suppl_1.S2; ALDRICH MS, 1993, PROG NEUROBIOL, V41, P533, DOI 10.1016/0301-0082(93)90042-Q; ALDRICH MS, 1989, NEUROLOGY, V39, P1505, DOI 10.1212/WNL.39.11.1505; Baker TL, 1985, BRAIN MECH SLEEP, P199; Barch MJ, 1997, AGT CYTOGENETICS LAB; Beck B, 1999, BIOCHEM BIOPH RES CO, V258, P119, DOI 10.1006/bbrc.1999.0605; Borbely AA, 1994, PRINCIPLES PRACTICE, P309; Broberger C, 1998, J COMP NEUROL, V402, P460; Cederberg R, 1998, VET REC, V142, P31, DOI 10.1136/vr.142.2.31; COLTMAN DW, 1994, NUCLEIC ACIDS RES, V22, P2726, DOI 10.1093/nar/22.14.2726; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Date Y, 1999, P NATL ACAD SCI USA, V96, P748, DOI 10.1073/pnas.96.2.748; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dement VV, 1994, PRINCIPLES PRACTICE, P3; Dutra AS, 1996, CYTOGENET CELL GENET, V74, P113, DOI 10.1159/000134395; Edwards CMB, 1999, J ENDOCRINOL, V160, pR7, DOI 10.1677/joe.0.160R007; FOUTZ AS, 1979, SLEEP, V1, P413; Francisco LV, 1996, MAMM GENOME, V7, P359, DOI 10.1007/s003359900104; Green E D, 1991, PCR Methods Appl, V1, P77; Honda Y., 1990, HDB SLEEP DISORDERS, P217; Horvath TL, 1999, J NEUROSCI, V19, P1072; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Ida T, 1999, BRAIN RES, V821, P526, DOI 10.1016/S0006-8993(99)01131-2; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kastin AJ, 1999, J PHARMACOL EXP THER, V289, P219; Kazazian HH, 1999, NAT GENET, V22, P130, DOI 10.1038/9638; KILDUFF TS, 1986, SLEEP, V9, P102, DOI 10.1093/sleep/9.1.102; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KRAWCZAK M, 1992, HUM GENET, V90, P41; Li R, 1999, GENOMICS, V58, P9, DOI 10.1006/geno.1999.5772; Lin L, 1997, TISSUE ANTIGENS, V50, P507, DOI 10.1111/j.1399-0039.1997.tb02907.x; Lubkin M, 1998, BIOCHEM BIOPH RES CO, V253, P241, DOI 10.1006/bbrc.1998.9750; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MATSUKI K, 1992, LANCET, V339, P1052, DOI 10.1016/0140-6736(92)90571-J; McGrory J, 1999, CLIN GENET, V55, P118, DOI 10.1034/j.1399-0004.1999.550208.x; MIGNOT E, 1993, PSYCHOPHARMACOLOGY, V113, P76, DOI 10.1007/BF02244337; MIGNOT E, 1995, ADV NEUROIMMUNOL, V5, P23, DOI 10.1016/0960-5428(94)00043-N; MIGNOT E, 1993, J NEUROSCI, V13, P1057; MIGNOT E, 1994, SLEEP, V17, pS60, DOI 10.1093/sleep/17.suppl_8.S60; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; MIGNOT E, 1991, P NATL ACAD SCI USA, V88, P3475, DOI 10.1073/pnas.88.8.3475; MIGNOT E, 1994, SLEEP, V17, pS68, DOI 10.1093/sleep/17.suppl_8.S68; MILLER JD, 1990, BRAIN RES, V509, P169, DOI 10.1016/0006-8993(90)90328-9; MINNICK MF, 1992, GENE, V110, P235, DOI 10.1016/0378-1119(92)90654-8; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; Moore RY, 1998, CHRONOBIOL INT, V15, P475, DOI 10.3109/07420529808998703; Moriguchi T, 1999, NEUROSCI LETT, V264, P101, DOI 10.1016/S0304-3940(99)00177-9; Nambu T, 1999, BRAIN RES, V827, P243, DOI 10.1016/S0006-8993(99)01336-0; Neff MW, 1999, GENETICS, V151, P803; Nishino S, 1997, PROG NEUROBIOL, V52, P27, DOI 10.1016/S0301-0082(96)00070-6; OSTRANDER EA, 1995, MAMM GENOME, V6, P192, DOI 10.1007/BF00293011; Ott J., 1991, ANAL HUMAN GENETIC L; Peyron C, 1998, J NEUROSCI, V18, P9996; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; RECHTSCHAFFEN A, 1983, SCIENCE, V221, P182, DOI 10.1126/science.6857280; REED R, 1988, GENE DEV, V2, P1268, DOI 10.1101/gad.2.10.1268; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; Reid MS, 1996, BRAIN RES, V733, P83, DOI 10.1016/0006-8993(96)00541-0; Riehl J, 1998, EXP NEUROL, V152, P292, DOI 10.1006/exnr.1998.6847; Ryder EJ, 1999, ANIM GENET, V30, P63, DOI 10.1046/j.1365-2052.1999.00424.x; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; Soderlund C, 1997, COMPUT APPL BIOSCI, V13, P523; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Sweet DC, 1999, BRAIN RES, V821, P535, DOI 10.1016/S0006-8993(99)01136-1; Teraoka SN, 1999, AM J HUM GENET, V64, P1617, DOI 10.1086/302418; Trivedi P, 1998, FEBS LETT, V438, P71, DOI 10.1016/S0014-5793(98)01266-6; van den Pol AN, 1999, J NEUROSCI, V19, P3171; Wakefield MJ, 1996, MAMM GENOME, V7, P715, DOI 10.1007/s003359900221; Yamamoto Y, 1999, MOL BRAIN RES, V65, P14, DOI 10.1016/S0169-328X(98)00320-9	73	1892	1991	5	162	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					365	376		10.1016/S0092-8674(00)81965-0	http://dx.doi.org/10.1016/S0092-8674(00)81965-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458611	Bronze			2022-12-24	WOS:000081950300011
J	Skuse, D				Skuse, D			Survival after being born too soon, but at what cost?	LANCET			English	Editorial Material							LOW-BIRTH-WEIGHT; EARLY INTERVENTION; PREMATURE-INFANTS; RISK-FACTORS; AGE; ADJUSTMENT; OUTCOMES; CHILDREN; SCHOOL		Inst Child Hlth, Behav Sci Unit, London WC1N 1EH, England	University of London; University College London	Skuse, D (corresponding author), Inst Child Hlth, Behav Sci Unit, 30 Guilford St, London WC1N 1EH, England.							BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BLAIR C, 1995, AM J MENT RETARD, V99, P542; Breslau N, 1996, BIOL PSYCHIAT, V40, P389, DOI 10.1016/0006-3223(95)00399-1; Finnstrom O, 1998, ACTA PAEDIATR, V87, P1055, DOI 10.1080/080352598750031374; FORFAR JO, 1994, DEV MED CHILD NEUROL, V36, P1037; Hack M, 1999, EARLY HUM DEV, V53, P193, DOI 10.1016/S0378-3782(98)00052-8; HILLE ETM, 1994, J PEDIATR-US, V125, P426, DOI 10.1016/S0022-3476(05)83290-1; Horwood LJ, 1998, ARCH DIS CHILD-FETAL, V79, pF12, DOI 10.1136/fn.79.1.F12; Kaufman AS., 2004, KAUFMAN BRIEF INTELL, V2nd; Lucas A, 1998, BRIT MED J, V317, P1481, DOI 10.1136/bmj.317.7171.1481; McCarton CM, 1997, JAMA-J AM MED ASSOC, V277, P126, DOI 10.1001/jama.277.2.126; PERLMAN M, 1995, J PEDIATR-US, V126, P75, DOI 10.1016/S0022-3476(95)70507-4; Schendel DE, 1997, AM J EPIDEMIOL, V146, P740; Sykes DH, 1997, J CHILD PSYCHOL PSYC, V38, P315, DOI 10.1111/j.1469-7610.1997.tb01516.x; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201	15	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					354	355		10.1016/S0140-6736(99)00150-6	http://dx.doi.org/10.1016/S0140-6736(99)00150-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437859				2022-12-24	WOS:000081764900004
J	Carmeliet, P; Lampugnani, MG; Moons, L; Breviario, F; Compernolle, V; Bono, F; Balconi, G; Spagnuolo, R; Oosthuyse, B; Dewerchin, M; Zanetti, A; Angellilo, A; Mattot, V; Nuyens, D; Lutgens, E; Clotman, F; de Ruiter, MC; Gittenberger-de Groot, A; Poelmann, R; Lupu, F; Herbert, JM; Collen, D; Dejana, E				Carmeliet, P; Lampugnani, MG; Moons, L; Breviario, F; Compernolle, V; Bono, F; Balconi, G; Spagnuolo, R; Oosthuyse, B; Dewerchin, M; Zanetti, A; Angellilo, A; Mattot, V; Nuyens, D; Lutgens, E; Clotman, F; de Ruiter, MC; Gittenberger-de Groot, A; Poelmann, R; Lupu, F; Herbert, JM; Collen, D; Dejana, E			Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis	CELL			English	Article							BLOOD-VESSEL DEVELOPMENT; GROWTH-FACTOR RECEPTOR; CELL-CELL CONTACTS; BETA-CATENIN; N-CADHERIN; NEURONAL APOPTOSIS; EMBRYOS LACKING; IN-VITRO; EXPRESSION; ACTIVATION	Vascular endothelial cadherin, VE-cadherin, mediates adhesion between endothelial cells and may affect vascular morphogenesis via intracellular signaling, but the nature of these signals remains unknown. Here, targeted inactivation (VEC-/-) or truncation of the beta-catenin-binding cytosolic domain (VECdelta C/delta C) Of the VE-cadherin gene was found not to affect assembly of endothelial cells in vascular plexi, but to impair their subsequent remodeling and maturation, causing lethality at 9.5 days of gestation. Deficiency or truncation of VE-cadherin induced endothelial apoptosis and abolished transmission of the endothelial survival signal by VEGF-A to Akt kinase and Bc12 via reduced complex formation with VEGF receptor-2, beta-catenin, and phosphoinositide 3 (PI3)-kinase. Thus, VE-cadherin/beta-catenin signaling controls endothelial survival.	Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium; Mario Negri Inst Pharmacol Res, I-20157 Milan, Italy; Sanofi Rech, Dept Haematol, F-31036 Toulouse, France; Leiden Univ, Med Ctr, Dept Anat & Embryol, Leiden, Netherlands; Thrombosis Res Inst, Vasc Biol Lab, Weston Expt Res Ctr, London SW3 6LR, England; Univ Insubria, Dept Clin & Biol Sci, Sch Med, Varese, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Sanofi-Aventis; Sanofi France; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Thrombosis Research Institute; University of Insubria	Carmeliet, P (corresponding author), Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium.		Lutgens, Esther/E-2919-2010; Lupu, Florea/AAV-3257-2021; Carmeliet, Peter/AAQ-5140-2020; Lupu, Florea/C-3162-2009; adriana, zanetti/ABA-1189-2020	Lutgens, Esther/0000-0002-2609-5744; Lupu, Florea/0000-0003-1249-9278; Carmeliet, Peter/0000-0001-7961-1821; Lupu, Florea/0000-0003-1249-9278; adriana, zanetti/0000-0002-5825-9707; Moons, Lieve (Godelieve)/0000-0003-0186-1411; Nuyens, Dieter/0000-0001-9390-3273; Lampugnani, Maria Grazia/0000-0002-4802-7064; Angelillo-Scherrer, Anne/0000-0003-2872-4863; DEJANA, ELISABETTA/0000-0002-0007-0426				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Breier G, 1996, BLOOD, V87, P630, DOI 10.1182/blood.V87.2.630.bloodjournal872630; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; BUSSOLINO F, 1991, J IMMUNOL, V147, P2122; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 1999, NAT MED, V5, P495, DOI 10.1038/8379; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Caveda L, 1996, J CLIN INVEST, V98, P886, DOI 10.1172/JCI118870; CORADA M, 1999, IN PRESS P NATL ACAD; Dejana E, 1996, J CLIN INVEST, V98, P1949, DOI 10.1172/JCI118997; Esser S, 1998, J CELL SCI, V111, P1853; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hogers B, 1999, CARDIOVASC RES, V41, P87, DOI 10.1016/S0008-6363(98)00218-1; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Hynes RO, 1992, CURR OPIN GENET DEV, V2, P621, DOI 10.1016/S0959-437X(05)80182-0; Kemler R, 1992, Semin Cell Biol, V3, P149; Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; MCCLANAHAN T, 1993, BLOOD, V81, P2903; Meili R, 1998, ONCOGENE, V16, P903, DOI 10.1038/sj.onc.1201605; Navarro P, 1998, J CELL BIOL, V140, P1475, DOI 10.1083/jcb.140.6.1475; Nieset JE, 1997, J CELL SCI, V110, P1013; Nunez G, 1998, CURR OPIN NEUROBIOL, V8, P613, DOI 10.1016/S0959-4388(98)80089-5; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Radice GL, 1997, DEV BIOL, V181, P64, DOI 10.1006/dbio.1996.8443; Rosen ED, 1997, NATURE, V390, P290, DOI 10.1038/36862; SALOMON D, 1992, J CELL SCI, V102, P7; Stromblad S, 1996, J CLIN INVEST, V98, P426, DOI 10.1172/JCI118808; vanMaeleFabry G, 1997, INT J DEV BIOL, V41, P365; Vittet D, 1997, P NATL ACAD SCI USA, V94, P6273, DOI 10.1073/pnas.94.12.6273; Vittet D, 1996, BLOOD, V88, P3424, DOI 10.1182/blood.V88.9.3424.bloodjournal8893424; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208	40	980	1013	1	46	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					147	157		10.1016/S0092-8674(00)81010-7	http://dx.doi.org/10.1016/S0092-8674(00)81010-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428027	Bronze			2022-12-24	WOS:000081632300005
J	Finnerty, GT; Roberts, LSE; Connors, BW				Finnerty, GT; Roberts, LSE; Connors, BW			Sensory experience modifies the short-term dynamics of neocortical synapses	NATURE			English	Article							RAT VISUAL-CORTEX; PYRAMIDAL NEURONS; BARREL CORTEX; POSTSYNAPTIC POTENTIALS; CORTICAL PLASTICITY; RELEASE PROBABILITY; SYNAPTIC PLASTICITY; REORGANIZATION; DEPRESSION; MOUSE	Many representations of sensory stimuli in the neocortex are arranged as topographic maps. These cortical maps are not fixed, but show experience-dependent plasticity(1,2). For instance, sensory deprivation causes the cortical area representing the deprived sensory input to shrink, and neighbouring spared representations to enlarge, in somatosensory(3), auditory(4) or visual cortex(5). In adolescent and adult animals, changes in cortical maps are most noticeable in the supragranular layers at the junction of deprived and spared cortex(6-9). However, the cellular mechanisms of this experience-dependent plasticity are unclear. Long-term potentiation and depression have been implicated(10-12), but have not been proven to be necessary or sufficient for cortical map reorganization. Short-term synaptic dynamics have not been considered. We developed a brain slice preparation involving rat whisker barrel cortex in vitro. Here we report that sensory deprivation alters short-term synaptic dynamics in both vertical and horizontal excitatory pathways within the supragranular cortex. Moreover, modifications of horizontal pathways amplify changes in the vertical inputs. Our findings help to explain the functional cortical reorganization that follows persistent changes of sensory experience.	Brown Univ, Dept Neurosci, Providence, RI 02912 USA	Brown University	Connors, BW (corresponding author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA.		Finnerty, Gerald/E-5292-2010; Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ARMSTRONGJAMES M, 1994, J NEUROSCI, V14, P6978; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; CARVELL GE, 1990, J NEUROSCI, V10, P2638; Cash S, 1998, J NEUROSCI, V18, P10; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; Dobrunz LE, 1997, NEURON, V18, P995, DOI 10.1016/S0896-6273(00)80338-4; Florence SL, 1998, SCIENCE, V282, P1117, DOI 10.1126/science.282.5391.1117; FOX K, 1992, J NEUROSCI, V12, P1826; Garraghty PE, 1996, J COMP NEUROL, V367, P319, DOI 10.1002/(SICI)1096-9861(19960401)367:2<319::AID-CNE12>3.0.CO;2-L; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; Glazewski S, 1996, SCIENCE, V272, P421, DOI 10.1126/science.272.5260.421; Glazewski S, 1996, J NEUROPHYSIOL, V75, P1714, DOI 10.1152/jn.1996.75.4.1714; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Kirkwood A, 1996, NATURE, V381, P526, DOI 10.1038/381526a0; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MASON A, 1991, J NEUROSCI, V11, P72; MCCASLAND JS, 1988, J COMP NEUROL, V278, P555, DOI 10.1002/cne.902780407; Merzbacher L., 1910, Z F R GESAMTE NEUROL, V3, P1, DOI [10.1007/BF02893591, DOI 10.1007/BF02893591]; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; ROBERTSON D, 1989, J COMP NEUROL, V282, P456, DOI 10.1002/cne.902820311; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; VOLGUSHEV M, 1995, EUR J NEUROSCI, V7, P1751, DOI 10.1111/j.1460-9568.1995.tb00695.x; WELKER C, 1974, J COMP NEUROL, V158, P437, DOI 10.1002/cne.901580405	29	207	208	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					367	371		10.1038/22553	http://dx.doi.org/10.1038/22553			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432115				2022-12-24	WOS:000081590000051
J	Wu, W; Wong, K; Chen, JH; Jiang, ZH; Dupuls, S; Wu, JY; Rao, Y				Wu, W; Wong, K; Chen, JH; Jiang, ZH; Dupuls, S; Wu, JY; Rao, Y			Directional guidance of neuronal migration in the olfactory system by the protein Slit	NATURE			English	Article							SUBVENTRICULAR ZONE CELLS; NEURAL CREST MIGRATION; FETAL MONKEY NEOCORTEX; POLYSIALIC ACID; NERVOUS-SYSTEM; AXON GUIDANCE; GENE ENCODES; C-ELEGANS; GLIA; PRECURSORS	Although cell migration is crucial for neural development, molecular mechanisms guiding neuronal migration have remained unclear. Here we report that the secreted protein Slit repels neuronal precursors migrating from the anterior subventricular zone in the telencephalon to the olfactory bulb. Our results provide a direct demonstration of a molecular cue whose concentration gradient guides the direction of migrating neurons. They also support a common guidance mechanism for axon projection and neuronal migration and suggest that Slit may provide a molecular tool with potential therapeutic applications in controlling and directing cell migration.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Shanghai Res Ctr Life Sci, Mol Neurobiol Lab, Shanghai, Peoples R China; Chinese Acad Sci, Natl Inst Neurosci, Shanghai, Peoples R China	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences	Wu, JY (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, Box 8108,660 S Euclid Ave, St Louis, MO 63110 USA.		Chen, Jinhui/A-7138-2009	Chen, Jinhui/0000-0002-6864-7121	NCI NIH HHS [R01 CA114197-01A2, R01 CA114197] Funding Source: Medline; NEI NIH HHS [R01 EY014576, R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02, R01 GM070967] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; ALTMAN J, 1966, J COMP NEUROL, V126, P337, DOI 10.1002/cne.901260302; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANGEVINE JB, 1961, NATURE, V192, P766, DOI 10.1038/192766b0; Ba-Charvet KTN, 1999, NEURON, V22, P463, DOI 10.1016/S0896-6273(00)80702-3; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Frotscher M, 1998, CURR OPIN NEUROBIOL, V8, P570, DOI 10.1016/S0959-4388(98)80082-2; Getchell TV., 1991, SMELL TASTE HLTH DIS, P19; Gordon N, 1996, DEV MED CHILD NEUROL, V38, P1131; GRAY GE, 1990, EXPERIENTIA, V46, P929, DOI 10.1007/BF01939386; Hardesty I, 1904, AM J ANAT, V3, P229, DOI 10.1002/aja.1000030303; HATTEN ME, 1984, J CELL BIOL, V98, P193, DOI 10.1083/jcb.98.1.193; HATTEN ME, 1981, J CELL BIOL, V90, P622, DOI 10.1083/jcb.90.3.622; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HINDS JW, 1968, J COMP NEUROL, V134, P305, DOI 10.1002/cne.901340305; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Hu HY, 1996, NEURON, V16, P735, DOI 10.1016/S0896-6273(00)80094-X; Hu HY, 1996, NEURON, V16, P933, DOI 10.1016/S0896-6273(00)80116-6; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; KLEINMAN HK, 1982, BIOCHEMISTRY-US, V21, P6188, DOI 10.1021/bi00267a025; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; LEVIMONTALCINI R, 1950, J MORPHOL, V86, P253, DOI 10.1002/jmor.1050860203; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Norman M, 1995, CONGENITAL MALFORMAT; ONO K, 1994, NEURON, V13, P595, DOI 10.1016/0896-6273(94)90028-0; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1990, EXPERIENTIA, V46, P882, DOI 10.1007/BF01939380; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; Ramon y Cajal S., 1897, HISTOLOGY NERVOUS SY, V1; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; ROUSSELOT P, 1995, J COMP NEUROL, V351, P51, DOI 10.1002/cne.903510106; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Smith A, 1997, CURR BIOL, V7, P561, DOI 10.1016/S0960-9822(06)00255-7; TILNEY FREDERICK, 1933, BULL NEUROL INST NEW YORK, V3, P252; WALSH C, 1990, EXPERIENTIA, V46, P940, DOI 10.1007/BF01939387; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZHU Y, IN PRESS NEURON; Zigova T, 1996, DEV BIOL, V173, P459, DOI 10.1006/dbio.1996.0040	50	451	505	3	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					331	336		10.1038/22477	http://dx.doi.org/10.1038/22477			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432110	Green Accepted			2022-12-24	WOS:000081590000040
J	Orphanides, G; Wu, WH; Lane, WS; Hampsey, M; Reinberg, D				Orphanides, G; Wu, WH; Lane, WS; Hampsey, M; Reinberg, D			The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins	NATURE			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; CELL-PROLIFERATION; HISTONE OCTAMER; IN-VITRO; YEAST; CDC68; REPRESSION; MUTATIONS; BINDING	The regulation of gene expression depends critically upon chromatin structure(1). Transcription of protein-coding genes can be reconstituted on naked DNA with only the general transcription factors and RNA polymerase II (ref. 2), This minimal system cannot transcribe DNA packaged into chromatin, indicating that accessory factors may facilitate access to DNA. Two classes of accessory factor, ATP-dependent chromatin-remodelling enzymes(3) and histone acetyltransferases(4), facilitate transcription initiation from chromatin templates. FACT (for facilitates chromatin transcription) is a chromatin-specific elongation factor required for transcription of chromatin templates in vitro(5,6) Here we show that FACT comprises a new human homologue of the Saccharomyces cerevisiae Spt16/Cdc68 protein and the high-mobility group-1-like protein structure-specific recognition protein-1. Yeast SPT16/CDC68 is an essential gene that has been implicated in transcription and cell-cycle regulation. Consistent with our biochemical analysis of FACT, we provide evidence that Spt16/Cdc68 is involved in transcript elongation in vivo. Moreover, FACT specifically interacts with nucleosomes and histone H2A/H2B dimers, indicating that it may work by promoting nucleosome disassembly upon transcription. In support of this model, we show that FACT activity is abrogated by covalently crosslinking nucleasomal histones.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acids Enzymol, Piscataway, NJ 08854 USA; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Reinberg, Danny/0000-0003-4288-2016				BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; Brewster NK, 1998, J BIOL CHEM, V273, P21972, DOI 10.1074/jbc.273.34.21972; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Evans DRH, 1998, GENETICS, V150, P1393; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HANSEN JC, 1994, P NATL ACAD SCI USA, V91, P2339, DOI 10.1073/pnas.91.6.2339; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LYCAN D, 1994, MOL CELL BIOL, V14, P7455, DOI 10.1128/MCB.14.11.7455; MALONE EA, 1991, MOL CELL BIOL, V11, P5710, DOI 10.1128/MCB.11.11.5710; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; Powell W, 1996, J BIOL CHEM, V271, P6866, DOI 10.1074/jbc.271.12.6866; PRENDERGAST JA, 1990, GENETICS, V124, P81; ROWLEY A, 1991, MOL CELL BIOL, V11, P5718, DOI 10.1128/MCB.11.11.5718; Santisteban MS, 1997, EMBO J, V16, P2493, DOI 10.1093/emboj/16.9.2493; SHIRAKATA M, 1991, MOL CELL BIOL, V11, P4528, DOI 10.1128/MCB.11.9.4528; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; WALTER PP, 1995, MOL CELL BIOL, V15, P6178; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; XU QL, 1995, MOL CELL BIOL, V15, P6025	29	429	438	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					284	288		10.1038/22350	http://dx.doi.org/10.1038/22350			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421373				2022-12-24	WOS:000081503800049
J	Choy, E; Chiu, VK; Silletti, J; Feoktistov, M; Morimoto, T; Michaelson, D; Ivanov, IE; Philips, MR				Choy, E; Chiu, VK; Silletti, J; Feoktistov, M; Morimoto, T; Michaelson, D; Ivanov, IE; Philips, MR			Endomembrane trafficking of Ras: The CAAX motif targets proteins to the ER and Golgi	CELL			English	Article							PRENYLCYSTEINE CARBOXYL METHYLTRANSFERASE; ENDOPLASMIC-RETICULUM MEMBRANE; MURINE SARCOMA-VIRUS; PLASMA-MEMBRANE; LOCALIZATION; GENE; CELLS; PALMITOYLATION; PURIFICATION; PROTEOLYSIS	We show that Nras is transiently localized in the Golgi prior to the plasma membrane (PM). Moreover, green fluorescent protein (GFP)-tagged Nras illuminated motile, peri-Golgi vesicles, and prolonged BFA treatment blocked PM expression. GFP-Hras colocalized with GFP-Nras, but GFP-Kras4B revealed less Golgi and no vesicular fluorescence. Whereas a secondary membrane targeting signal was required for PM expression, the CAAX motif alone was necessary and sufficient to target proteins to the endomembrane where they were methylated, a modification required for efficient membrane association. Thus, prenylated CAAX proteins do not associate directly with the PM but instead associate with the endomembrane and are subsequently transported to the PM, a process that requires a secondary targeting motif.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Philips, MR (corresponding author), NYU, Sch Med, Dept Med, New York, NY 10016 USA.			Mark, Philips/0000-0002-1179-8156	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000096] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036224, R01AI036224] Funding Source: NIH RePORTER; NCRR NIH HHS [M01 RR00096] Funding Source: Medline; NIAID NIH HHS [R01 AI036224, AI36224] Funding Source: Medline; NIGMS NIH HHS [GM55279] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyartchuk VL, 1997, SCIENCE, V275, P1796, DOI 10.1126/science.275.5307.1796; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; CROZE E, 1989, J CELL BIOL, V108, P1597, DOI 10.1083/jcb.108.5.1597; Dai Q, 1998, J BIOL CHEM, V273, P15030, DOI 10.1074/jbc.273.24.15030; ESMANN M, 1988, METHOD ENZYMOL, V156, P105; FLECK A, 1962, BIOCHIM BIOPHYS ACTA, V55, P571; FLEISCHER B, 1969, J CELL BIOL, V43, P59, DOI 10.1083/jcb.43.1.59; FujimuraKamada K, 1997, J CELL BIOL, V136, P271, DOI 10.1083/jcb.136.2.271; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GRAND RJA, 1987, ONCOGENE, V1, P305; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HANCOCK JF, 1991, EMBO J, V10, P4033, DOI 10.1002/j.1460-2075.1991.tb04979.x; HANCOCK JF, 1991, EMBO J, V10, P641, DOI 10.1002/j.1460-2075.1991.tb07992.x; KASINATHAN C, 1990, J BIOL CHEM, V265, P5139; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MARCIANO D, 1995, J MED CHEM, V38, P1267, DOI 10.1021/jm00008a004; MARCUS S, 1991, MOL CELL BIOL, V11, P3603, DOI 10.1128/MCB.11.7.3603; PHILIPS MR, 1995, METHOD ENZYMOL, V256, P49; PILLINGER MH, 1994, J BIOL CHEM, V269, P1486; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; SAPPERSTEIN S, 1994, MOL CELL BIOL, V14, P1438, DOI 10.1128/MCB.14.2.1438; Schmidt WK, 1998, P NATL ACAD SCI USA, V95, P11175, DOI 10.1073/pnas.95.19.11175; SILVIUS JR, 1994, BIOCHEMISTRY-US, V33, P3014, DOI 10.1021/bi00176a034; Thissen JA, 1997, J BIOL CHEM, V272, P30362, DOI 10.1074/jbc.272.48.30362; ULSH LS, 1984, MOL CELL BIOL, V4, P1647, DOI 10.1128/MCB.4.8.1647; vantHof W, 1997, J CELL BIOL, V136, P1023, DOI 10.1083/jcb.136.5.1023; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; Willumsen BM, 1996, ONCOGENE, V13, P1901	36	602	609	1	36	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					69	80		10.1016/S0092-8674(00)80607-8	http://dx.doi.org/10.1016/S0092-8674(00)80607-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412982	hybrid			2022-12-24	WOS:000081451000009
J	Sym, M; Robinson, N; Kenyon, C				Sym, M; Robinson, N; Kenyon, C			MIG-13 positions migrating cells along the anteroposterior body axis of C. elegans	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; NEMATODE CAENORHABDITIS-ELEGANS; DROSOPHILA EMBRYO; ACTIVITY GRADIENT; GENE-EXPRESSION; NERVOUS-SYSTEM; AXON OUTGROWTH; MESSENGER-RNA; LDL-RECEPTOR; PROTEINS	The C. elegans Q neuroblasts and their descendants migrate along the anteroposterior (A/P) body axis to positions that are not associated with any obvious landmarks. We find that a novel protein, MIG-13, is required to position these cells correctly. MIG-13 is a transmembrane protein whose expression is restricted to the anterior and central body regions by Hox gene activity. MIG-13 functions non-cell autonomously within these regions to promote migration toward the anterior: loss of mig-13 activity shifts the Q descendants toward the posterior, whereas increasing the level of MIG-13 shifts them anteriorly in a dose-dependent manner. Our findings suggest that MIG-13 is a component of a global A/P migration system, and that the level of MIG-13 determines where along the body axis these migrating cells stop.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kenyon, C (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.							BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Battye R, 1999, DEVELOPMENT, V126, P2475; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRENNER S, 1974, GENETICS, V77, P71; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; Burdine RD, 1998, DEVELOPMENT, V125, P1083; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CLARK SG, 1993, CELL, V74, P43, DOI 10.1016/0092-8674(93)90293-Y; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; Harris J, 1996, DEVELOPMENT, V122, P3117; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1995, GENETICS, V141, P989; HUNTER CP, 1995, NATURE, V377, P229, DOI 10.1038/377229a0; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; Maloof JN, 1999, DEVELOPMENT, V126, P37; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller LM, 1996, GENETICS, V143, P1181; MITANI S, 1993, DEVELOPMENT, V119, P773; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SALSER SJ, 1993, GENE DEV, V7, P1714, DOI 10.1101/gad.7.9.1714; SALSER SJ, 1992, NATURE, V355, P255, DOI 10.1038/355255a0; SALSER SJ, 1995, THESIS U CALIFORNIA; SCHONBAUM CP, 1995, P NATL ACAD SCI USA, V92, P1485, DOI 10.1073/pnas.92.5.1485; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VarelaEchavarria A, 1997, GENE DEV, V11, P545, DOI 10.1101/gad.11.5.545; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WHARTON KA, 1993, DEVELOPMENT, V117, P807; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wightman B, 1996, DEVELOPMENT, V122, P671; Wolf FW, 1998, NEURON, V20, P655, DOI 10.1016/S0896-6273(00)81006-5; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	50	57	63	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					25	36		10.1016/S0092-8674(00)80603-0	http://dx.doi.org/10.1016/S0092-8674(00)80603-0			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412978	Bronze			2022-12-24	WOS:000081451000005
J	Culleton, BF; Larson, MG; Kannel, WB; Levy, D				Culleton, BF; Larson, MG; Kannel, WB; Levy, D			Serum uric acid and risk for cardiovascular disease and death: The Framingham Heart Study	ANNALS OF INTERNAL MEDICINE			English	Article						uric acid; cardiovascular diseases; outcome assessment (health care); diuretics; risk factors	DIABETES-MELLITUS; FOLLOW-UP; HYPERTENSIVE PATIENTS; GLUCOSE-TOLERANCE; XANTHINE-OXIDASE; FREE-RADICALS; HYPERURICEMIA; WOMEN; POPULATION; INSULIN	Background: Hyperuricemia is associated with risk for cardiovascular disease and death. However, the role of uric acid independent of established risk factors is uncertain. Objective: To examine the relation of serum uric acid level to incident coronary heart disease, death from cardiovascular disease, and death from all causes. Design: Community-based, prospective observational study. Setting: Framingham, Massachusetts. Patients: 6763 Framingham Heart Study participants (mean age, 47 years). Measurements: Serum uric acid level at baseline (1971 to 1976); event rates per 1000 person-years by sex-specific uric acid quintile. Results: During 117 376 person-years of follow-up, 617 coronary heart disease events, 429 cardiovascular disease deaths, and 1460 deaths from all causes occurred. In men, after adjustment for age, elevated serum uric acid level was not associated with increased risk for an adverse outcome. In women, after adjustment for age, uric acid level was predictive of coronary heart disease (P = 0.002), death from cardiovascular disease (P = 0.009), and death from all causes (P = 0.03). After additional adjustment for cardiovascular disease risk factors, uric acid level was no longer associated with coronary heart disease, death from cardiovascular disease, or death from ail causes. in a stepwise Cox model, diuretic use was identified as the covariate responsible for rendering serum uric acid a statistically nonsignificant predictor of outcomes. Conclusions: These findings indicate that uric acid does not have a causal role in the development of coronary heart disease, death from cardiovascular disease, or death from all causes. Any apparent association with these outcomes is probably due to the association of uric acid level with other risk factors.	Boston Univ, Sch Med, Boston, MA 02118 USA; NHLBI, Framingham Heart Study, Framingham, MA 01702 USA	Boston University; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Levy, D (corresponding author), NHLBI, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.	Dan@fram.nhlbi.nih.gov	Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021	Levy, Daniel/0000-0003-1843-8724; Larson, Martin/0000-0002-9631-1254	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; Alderman MH, 1998, J HYPERTENS, V16, pS5; ALDERMAN MH, 1998, AM J HYPERTENS, V11, P16; Anker SD, 1997, HEART, V78, P39, DOI 10.1136/hrt.78.1.39; [Anonymous], 1981, LANCET, V2, P539; ASHRAF M, 1993, J SUBMICR CYTOL PATH, V25, P193; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; BENGTSSON C, 1988, ACTA MED SCAND, V224, P549; BOLLI R, 1988, J AM COLL CARDIOL, V12, P239, DOI 10.1016/0735-1097(88)90381-6; BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; CAPPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354, DOI 10.1001/jama.270.3.354; COX DR, 1972, J R STAT SOC B, V34, P187; CROWLEY LV, 1964, CLIN CHEM, V10, P838; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEFRONZO RA, 1975, J CLIN INVEST, V55, P845, DOI 10.1172/JCI107996; EMMERSON BT, 1979, AUST NZ J MED, V9, P451, DOI 10.1111/j.1445-5994.1979.tb04180.x; FREEDMAN DS, 1995, AM J EPIDEMIOL, V141, P637, DOI 10.1093/oxfordjournals.aje.a117479; FRIEDL HP, 1990, AM J PATHOL, V136, P491; GALVAN AQ, 1995, AM J PHYSIOL-ENDOC M, V268, pE1, DOI 10.1152/ajpendo.1995.268.1.E1; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; GINSBERG MH, 1977, J CLIN INVEST, V60, P999, DOI 10.1172/JCI108880; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HAYABUCHI Y, 1993, EUR J PEDIATR, V152, P873, DOI 10.1007/BF01957519; HUIZER T, 1989, J MOL CELL CARDIOL, V21, P691, DOI 10.1016/0022-2828(89)90610-X; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KEIL U, 1988, ACTA MED SCAND, P119; KLEIN R, 1973, ARCH INTERN MED, V132, P401, DOI 10.1001/archinte.132.3.401; LAZZARINO G, 1994, CIRCULATION, V90, P291, DOI 10.1161/01.CIR.90.1.291; Lehto S, 1998, STROKE, V29, P635, DOI 10.1161/01.STR.29.3.635; LEVINE W, 1989, J CLIN EPIDEMIOL, V42, P257, DOI 10.1016/0895-4356(89)90061-9; LEWIS PJ, 1976, LANCET, V1, P564; Leyva F, 1997, EUR HEART J, V18, P858; Liese AD, 1998, CIRCULATION, V97, P822; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MONTOR SG, 1987, EUR J PHARMACOL, V140, P203, DOI 10.1016/0014-2999(87)90806-5; MURPHY MB, 1982, LANCET, V2, P1293; Newland H, 1975, Med Hypotheses, V1, P152, DOI 10.1016/0306-9877(75)90011-0; PERSKY VW, 1979, CIRCULATION, V59, P969, DOI 10.1161/01.CIR.59.5.969; PORTER KB, 1992, OBSTET GYNECOL, V79, P394, DOI 10.1097/00006250-199203000-00014; *PROGR COOP RES GR, 1985, PREV MED, V14, P312; Rathmann W, 1998, ANN EPIDEMIOL, V8, P250, DOI 10.1016/S1047-2797(97)00204-4; REAVEN GM, 1994, J INTERN MED, V236, P13; REUNANEN A, 1982, ACTA MED SCAND, P49; Sahebjami H, 1998, CHEST, V113, P1604, DOI 10.1378/chest.113.6.1604; *SAS STAT SOFTW, 1996, CHANG ENH REL 6 11 C; SAUGSTAD OD, 1975, PEDIATR RES, V9, P158, DOI 10.1203/00006450-197504000-00002; SHURTLEFF D, 1974, FRAMINGHAM STUDY, P17; Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617; STETTEN D, 1959, SCIENCE, V129, P1737, DOI 10.1126/science.129.3365.1737; VasquezVivar J, 1996, BIOCHEM J, V314, P869, DOI 10.1042/bj3140869; Wannamethee SG, 1997, HEART, V78, P147, DOI 10.1136/hrt.78.2.147; Ward HJ, 1998, LANCET, V352, P670, DOI 10.1016/S0140-6736(05)60816-1; WILSON PWF, 1991, AM HEART J, V121, P586, DOI 10.1016/0002-8703(91)90729-2; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; ZWEIER JL, 1988, P NATL ACAD SCI USA, V85, P4046, DOI 10.1073/pnas.85.11.4046; 1997, ARCH INTERN MED, V157, P2413	57	927	1004	4	59	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					7	+		10.7326/0003-4819-131-1-199907060-00003	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391820				2022-12-24	WOS:000081345200002
J	Hayashi, T; Tsumura, K; Suematsu, C; Okada, K; Fujii, S; Endo, G				Hayashi, T; Tsumura, K; Suematsu, C; Okada, K; Fujii, S; Endo, G			Walking to work and the risk for hypertension in men: The Osaka Health Survey	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; walking; exercise; middle age; cardiovascular disease	CORONARY HEART-DISEASE; TIME PHYSICAL-ACTIVITY; BLOOD-PRESSURE; COLLEGE ALUMNI; OLDER WOMEN; ATTACK RISK; EXERCISE; TREAT; TRIAL; DEATH	Background: It is not known whether physical activity is effective in reducing the risk for hypertension. Objective: To investigate the association of the duration of the walk to work and leisure-time physical activity with the risk for hypertension. Design: Prospective cohort study. Setting: Work site in Osaka, Japan. Participants: 6017 Japanese men 35 to 60 years of age with systolic blood pressure less than 140 mm Hg, diastolic blood pressure less than 90 mm Hg, normal glucose intolerance, and no history of hypertension or diabetes at baseline. Measurements: Data on physical activity were obtained by using questionnaires. Blood pressure was measured by using a standard technique; a value of at least 160/95 mm Hg was used to diagnose hypertension. Results: During 59 784 person-years of follow-up, 626 cases of hypertension were confirmed. The duration of the walk to work was associated with a reduction in the risk for incident hypertension; multivariate-adjusted relative risks were 1.00 for a walk of 10 minutes or less (reference category), 0.88 (95% CI, 0.75 to 1.04) for an 11- to 20-minute walk, and 0.71 (CI, 0.52 to 0.97) for a walk of 21 minutes or more (P for trend = 0.02). For every 26.3 men who walk more than 20 minutes to work, one case of hypertension will be prevented. Conclusions: Walking to work and other types of physical activity decreased the risk for hypertension in Japanese men. Regular exercise can prevent hypertension.	Osaka City Univ, Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, Osaka 5458585, Japan; Osaka Gas Co Ltd, Med Ctr Employees Hlth, Nishi Ku, Osaka 5500023, Japan; Environm & Publ Hlth Bur, Kita Ku, Osaka 5300005, Japan	Osaka Metropolitan University; Osaka Gas Co., Ltd.	Hayashi, T (corresponding author), Osaka City Univ, Sch Med, Dept Prevent Med & Environm Hlth, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.		Hayashi, Tomoshige/N-8508-2015					Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ARROLL B, 1992, J CLIN EPIDEMIOL, V45, P439, DOI 10.1016/0895-4356(92)90093-3; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; FAGARD R, 1990, HYPERTENSION PATHOPH, P1985; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAGBERG JM, 1989, AM J CARDIOL, V64, P348, DOI 10.1016/0002-9149(89)90533-X; KINGWELL BA, 1993, MED J AUSTRALIA, V158, P234, DOI 10.5694/j.1326-5377.1993.tb121740.x; LAPORTE RE, 1983, J GERONTOL, V38, P394, DOI 10.1093/geronj/38.4.394; LEON AS, 1985, MED CLIN N AM, V69, P3, DOI 10.1016/S0025-7125(16)31055-0; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; PAFFENBARGER RS, 1991, ANN MED, V23, P319, DOI 10.3109/07853899109148067; PAFFENBARGER RS, 1995, AM J EPIDEMIOL, V142, P889, DOI 10.1093/oxfordjournals.aje.a117736; PAFFENBARGER RS, 1983, AM J EPIDEMIOL, V117, P245, DOI 10.1093/oxfordjournals.aje.a113537; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; REAVEN PD, 1991, CIRCULATION, V83, P559, DOI 10.1161/01.CIR.83.2.559; SEALS DR, 1991, HYPERTENSION, V18, P583, DOI 10.1161/01.HYP.18.5.583; SICONOLFI SF, 1985, AM J EPIDEMIOL, V122, P101, DOI 10.1093/oxfordjournals.aje.a114068; SLATTERY ML, 1989, CIRCULATION, V79, P304, DOI 10.1161/01.CIR.79.2.304; STAMLER J, 1989, HYPERTENSION, V14, P570, DOI 10.1161/01.HYP.14.5.570; WASHBURN RA, 1990, AM J EPIDEMIOL, V132, P107, DOI 10.1093/oxfordjournals.aje.a115622; WASHBURN RA, 1987, PREV MED, V16, P636, DOI 10.1016/0091-7435(87)90047-8; WILLIAMS RR, 1991, HYPERTENSION, V18, P29, DOI 10.1161/01.HYP.18.3_Suppl.I29; World Health Organization, 1978, WHO TECH REP SER, P7; ZANCHETTI A, 1993, HYPERTENSION, V22, P392	28	148	158	0	19	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					21	+		10.7326/0003-4819-131-1-199907060-00005	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391811				2022-12-24	WOS:000081345200004
J	Jordan, BA; Devi, LA				Jordan, BA; Devi, LA			G-protein-coupled receptor heterodimerization modulates receptor function	NATURE			English	Article							DELTA-OPIOID RECEPTOR; SIGNAL-TRANSDUCTION; CROSS-TALK; INTERNALIZATION; DIMERIZATION; COEXPRESSION; PEPTIDES; SUBTYPES; AGONIST; POTENT	The opioid system modulates several physiological processes, including analgesia, the stress response, the immune response and neuroendocrine function(1). Pharmacological and molecular cloning studies have identified three opioid-receptor types, delta, kappa and mu, that mediate these diverse effects(2,3). Little is known about the ability of the receptors to interact to form new functional structures, the simplest of which would be a dimer, Structural and biochemical studies show that other G-protein-coupled receptors (GPCRs) interact to form homodimers(4,5), Moreover, two nonfunctional receptors heterodimerize to form a functional receptor, suggesting that dimerization is crucial for receptor function(6-11). However, heterodimerization between two fully functional receptors has not been documented. Here we provide biochemical and pharmacological evidence for the heterodimerization of two fully functional opioid receptors, kappa and delta. This results in a new receptor that exhibits ligand binding and functional properties that are distinct from those of either receptor. Furthermore, the kappa-delta heterodimer synergistically binds highly selective agonists and potentiates signal transduction. Thus, heterodimerization of these GPCRs represents a novel mechanism that modulates their function.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA	New York University	Devi, LA (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Jordan, Bryen/0000-0002-4967-444X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K05DA019521, R01DA008863] Funding Source: NIH RePORTER; NIDA NIH HHS [K05 DA019521-08, K05 DA019521, R01 DA008863-17, R01 DA008863] Funding Source: Medline; NINDS NIH HHS [R01 NS026880-22, R01 NS026880] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Cvejic S, 1996, J BIOL CHEM, V271, P4073; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1998, BIOCHEM CELL BIOL, V76, P1, DOI 10.1139/bcb-76-1-1; Herz A., 1993, OPIOIDS; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan B, 1998, BRIT J ANAESTH, V81, P12, DOI 10.1093/bja/81.1.12; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Keith DE, 1996, J BIOL CHEM, V271, P19021, DOI 10.1074/jbc.271.32.19021; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; LAHTI RA, 1985, EUR J PHARMACOL, V109, P281, DOI 10.1016/0014-2999(85)90431-5; LORD JAH, 1977, NATURE, V267, P495, DOI 10.1038/267495a0; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MIOTTO K, 1995, PHARM OPIOID PEPTIDE, P57; Monnot C, 1996, J BIOL CHEM, V271, P1507, DOI 10.1074/jbc.271.3.1507; Nock B.U., 1995, PHARM OPIOID PEPTIDE, P29; Polakiewicz RD, 1998, J BIOL CHEM, V273, P12402, DOI 10.1074/jbc.273.20.12402; PORTOGHESE PS, 1987, LIFE SCI, V40, P1287, DOI 10.1016/0024-3205(87)90585-6; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; ROTH G, 1990, J MED CHEM, V258, P299; SCHILLER PW, 1993, J MED CHEM, V36, P3182, DOI 10.1021/jm00073a020; Trapaidze N, 1996, J BIOL CHEM, V271, P29279, DOI 10.1074/jbc.271.46.29279; TRAYNOR JR, 1993, TRENDS PHARMACOL SCI, V14, P84, DOI 10.1016/0165-6147(93)90068-U; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Zaki PA, 1996, ANNU REV PHARMACOL, V36, P379; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061	30	918	987	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					697	700		10.1038/21441	http://dx.doi.org/10.1038/21441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385123	Green Accepted			2022-12-24	WOS:000080932800063
J	Oparka, KJ; Roberts, AG; Boevink, P; Santa Cruz, S; Roberts, L; Pradel, KS; Imlau, A; Kotlizky, G; Sauer, N; Epel, B				Oparka, KJ; Roberts, AG; Boevink, P; Santa Cruz, S; Roberts, L; Pradel, KS; Imlau, A; Kotlizky, G; Sauer, N; Epel, B			Simple, but not branched, plasmodesmata allow the nonspecific trafficking of proteins in developing tobacco leaves	CELL			English	Article							CELL-TO-CELL; GREEN FLUORESCENT PROTEIN; VIRUS MOVEMENT PROTEIN; SIZE-EXCLUSION LIMIT; MOSAIC-VIRUS; ENDOPLASMIC-RETICULUM; NICOTIANA-CLEVELANDII; SETCREASEA-PURPUREA; MOLECULAR-CLONING; SIEVE ELEMENTS	Leaves undergo a sink-source transition during which a physiological change occurs from carbon import to export. In sink leaves, biolistic bombardment of plasmids encoding GFP-fusion proteins demonstrated that proteins with an M-r up to 50 kDa could move freely through plasmodesmata. During the sink-source transition, the capacity to traffic proteins decreased substantially and was accompanied by a developmental switch from simple to branched forms of plasmodesmata. inoculation of sink leaves with a movement protein-defective virus showed that virally expressed GFP, but not viral RNA, was capable of trafficking between sink cells during infection. Contrary to dogma that plasmodesmata have a size exclusion limit below 1 kDa, the data demonstrate that nonspecific "macromolecular trafficking" is a general feature of simple plasmodesmata in sink leaves.	Scottish Crop Res Inst, Cell Biol Unit, Dundee DD2 5DA, Scotland; Univ Erlangen Nurnberg, Lehrstuhl Bot 2, D-91058 Erlangen, Germany; Tel Aviv Univ, Dept Plant Sci, IL-69978 Tel Aviv, Israel	James Hutton Institute; University of Erlangen Nuremberg; Tel Aviv University	Oparka, KJ (corresponding author), Scottish Crop Res Inst, Cell Biol Unit, Dundee DD2 5DA, Scotland.	kopark@scri.sari.ac.uk	Roberts, Alison/G-6305-2012; Boevink, Petra/AAO-6498-2021	Boevink, Petra/0000-0002-7021-9097				Angell SM, 1996, VIROLOGY, V216, P197, DOI 10.1006/viro.1996.0046; Balachandran S, 1997, P NATL ACAD SCI USA, V94, P14150, DOI 10.1073/pnas.94.25.14150; BECK DL, 1991, VIROLOGY, V183, P695, DOI 10.1016/0042-6822(91)90998-Q; Blackman LM, 1998, PLANT CELL, V10, P525, DOI 10.1105/tpc.10.4.525; Boevink P, 1996, PLANT J, V10, P935, DOI 10.1046/j.1365-313X.1996.10050935.x; BOEVINK PB, 1999, IN PRESS PLANTA; BURNELL JN, 1988, J EXP BOT, V39, P1575, DOI 10.1093/jxb/39.11.1575; CARRINGTON JC, 1990, J VIROL, V64, P1590, DOI 10.1128/JVI.64.4.1590-1597.1990; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; CLELAND RE, 1994, PROTOPLASMA, V178, P81, DOI 10.1007/BF01404123; Cook ME, 1997, AM J BOT, V84, P1169, DOI 10.2307/2446040; Cruz SS, 1998, PLANT CELL, V10, P495, DOI 10.1105/tpc.10.4.495; Cruz SS, 1996, P NATL ACAD SCI USA, V93, P6286, DOI 10.1073/pnas.93.13.6286; DEOM CM, 1990, P NATL ACAD SCI USA, V87, P3284, DOI 10.1073/pnas.87.9.3284; Ding B, 1996, PLANT J, V10, P157, DOI 10.1046/j.1365-313X.1996.10010157.x; DING B, 1992, PLANT CELL, V4, P915, DOI 10.1105/tpc.4.8.915; Ding B., 1996, MEMBRANES SPECIALIZE, P489; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; Dopf J, 1996, GENE, V173, P39, DOI 10.1016/0378-1119(95)00692-3; Ehlers K, 1996, PLANTA, V199, P126; Epel BL, 1996, GENE, V173, P75, DOI 10.1016/0378-1119(95)00678-8; ERWEE MG, 1985, PLANTA, V163, P9, DOI 10.1007/BF00395891; FENCZIK CA, 1996, PLANT GEN R, P249; FRANCESCHI VR, 1994, PLANTA, V192, P347; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; GalOn A, 1997, J VIROL METHODS, V64, P103, DOI 10.1016/S0166-0934(96)02146-5; GAMALEI YV, 1994, PLANTA, V194, P443, DOI 10.1007/BF00714455; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; GOODWIN PB, 1983, PLANTA, V157, P124, DOI 10.1007/BF00393645; GUNNING BES, 1978, PLANTA, V143, P121, DOI 10.1007/BF00387786; HATTORI T, 1985, PLANT MOL BIOL, V5, P313, DOI 10.1007/BF00020629; HEPLER PK, 1982, PROTOPLASMA, V111, P121, DOI 10.1007/BF01282070; Imlau A, 1999, PLANT CELL, V11, P309, DOI 10.1105/tpc.11.3.309; Ishiwatari Y, 1998, PLANTA, V205, P12, DOI 10.1007/s004250050291; Itaya A, 1998, PLANT PHYSIOL, V118, P373, DOI 10.1104/pp.118.2.373; Itaya A, 1997, PLANT J, V12, P1223, DOI 10.1046/j.1365-313X.1997.12051223.x; Jackson D, 1997, CURR OPIN GENET DEV, V7, P495, DOI 10.1016/S0959-437X(97)80076-7; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; KIKUYAMA M, 1992, PLANT CELL PHYSIOL, V33, P413; KOLLMANN R, 1985, PROTOPLASMA, V126, P19, DOI 10.1007/BF01287669; KOLLMANN R, 1985, PROTOPLASMA, V124, P224, DOI 10.1007/BF01290774; Kragler F, 1998, ANN BOT-LONDON, V81, P1, DOI 10.1006/anbo.1997.0522; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; LUCAS WJ, 1995, CURR OPIN CELL BIOL, V7, P673, DOI 10.1016/0955-0674(95)80109-X; Mezitt LA, 1996, PLANT MOL BIOL, V32, P251, DOI 10.1007/BF00039385; MIZUHIRA V, 1972, ACTA HISTOCHEM CYTOC, V1, P233; OPARKA KJ, 1981, PLANTA, V151, P561, DOI 10.1007/BF00387436; Oparka KJ, 1997, PLANT J, V12, P781, DOI 10.1046/j.1365-313X.1997.12040781.x; Oparka KJ, 1996, TRENDS PLANT SCI, V1, P412, DOI 10.1016/S1360-1385(96)10043-1; OVERALL RL, 1982, PROTOPLASMA, V111, P134, DOI 10.1007/BF01282071; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PETTY ITD, 1990, VIROLOGY, V179, P712, DOI 10.1016/0042-6822(90)90138-H; Raven JA, 1997, EUR J PHYCOL, V32, P95; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Roberts AG, 1997, PLANT CELL, V9, P1381, DOI 10.1105/tpc.9.8.1381; Ryabov EV, 1998, VIROLOGY, V242, P303, DOI 10.1006/viro.1997.9025; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHULZ A, 1995, PROTOPLASMA, V188, P22, DOI 10.1007/BF01276793; SEAGULL RW, 1983, PLANTA, V159, P497, DOI 10.1007/BF00409138; Siemering KR, 1996, CURR BIOL, V6, P1653, DOI 10.1016/S0960-9822(02)70789-6; SIMIONESCU N, 1976, J CELL BIOL, V70, P608, DOI 10.1083/jcb.70.3.608; STIEKEMA WJ, 1988, PLANT MOL BIOL, V11, P255, DOI 10.1007/BF00027383; TERRY BR, 1987, PLANTA, V171, P145, DOI 10.1007/BF00391090; TILNEY LG, 1991, J CELL BIOL, V112, P739, DOI 10.1083/jcb.112.4.739; TOMENIUS K, 1987, VIROLOGY, V160, P363, DOI 10.1016/0042-6822(87)90007-9; TUCKER EB, 1993, PROTOPLASMA, V174, P45, DOI 10.1007/BF01404041; TUCKER EB, 1982, PROTOPLASMA, V113, P193, DOI 10.1007/BF01280907; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; WAIGMANN E, 1994, P NATL ACAD SCI USA, V91, P1433, DOI 10.1073/pnas.91.4.1433; WANG HL, 1995, PLANT CELL ENVIRON, V18, P373, DOI 10.1111/j.1365-3040.1995.tb00373.x; WANG N, 1994, PLANT PHYSIOL, V104, P17, DOI 10.1104/pp.104.1.17; WOLF S, 1989, SCIENCE, V246, P377, DOI 10.1126/science.246.4928.377; WOLF S, 1991, PLANT CELL, V3, P593, DOI 10.1105/tpc.3.6.593; Wright KM, 1997, J EXP BOT, V48, P1807, DOI 10.1093/jexbot/48.315.1807; Zhu T, 1998, PROTOPLASMA, V203, P35, DOI 10.1007/BF01280585	77	343	357	2	40	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					743	754		10.1016/S0092-8674(00)80786-2	http://dx.doi.org/10.1016/S0092-8674(00)80786-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380926	Bronze			2022-12-24	WOS:000080886300012
J	Bromberg, JF; Wrzeszczynska, MH; Devgan, G; Zhao, YX; Pestell, RG; Albanese, C; Darnell, JE				Bromberg, JF; Wrzeszczynska, MH; Devgan, G; Zhao, YX; Pestell, RG; Albanese, C; Darnell, JE			Stat3 as an oncogene	CELL			English	Article							TRANSCRIPTIONALLY ACTIVE STAT1; EPIDERMAL GROWTH-FACTOR; DNA-BINDING ACTIVITY; ACUTE-PHASE REACTION; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; INTERFERON-GAMMA; GENE-REGULATION	STATs are latent transcription factors that mediate cytokine- and growth factor-directed transcription. In many human cancers and transformed cell lines, Stat3 is persistently activated, and in cell culture, active Stat3 is either required for transformation, enhances transformation, or blocks apoptosis. We report that substitution of two cysteine residues within the C-terminal loop of the SH2 domain of Stat3 produces a molecule that dimerizes spontaneously, binds to DNA, and activates transcription. The Stat3-C molecule in immortalized fibroblasts causes cellular transformation scored by colony formation in soft agar and tumor formation in nude mice. Thus, the activated Stat3 molecule by itself can mediate cellular transformation and the experiments focus attention on the importance of constitutive Stat3 activation in human tumors.	Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Biophys, New York, NY 10021 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Rockefeller University; Rockefeller University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Darnell, JE (corresponding author), Rockefeller Univ, Mol Cell Biol Lab, 1230 York Ave, New York, NY 10021 USA.			Zhao, Yanxiang/0000-0002-9408-9979	NATIONAL CANCER INSTITUTE [R01CA070897, R01CA075503] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA70897, R01CA75503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALEXANDER WS, 1995, EMBO J, V14, P5569, DOI 10.1002/j.1460-2075.1995.tb00244.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; Besser D, 1999, MOL CELL BIOL, V19, P1401; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Cory S, 1999, CANCER RES, V59, p1685S; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Garcia R, 1998, J BIOMED SCI, V5, P79, DOI 10.1159/000025316; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haspel RL, 1996, EMBO J, V15, P6262, DOI 10.1002/j.1460-2075.1996.tb01016.x; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; Heinrich PC, 1998, Z ERNAHRUNGSWISS, V37, P43; Horvath CM, 1996, J VIROL, V70, P647, DOI 10.1128/JVI.70.1.647-650.1996; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LODISH H, 1995, MOL CELL BIOL, P1247; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schulteis CT, 1996, BIOCHEMISTRY-US, V35, P12133, DOI 10.1021/bi961083s; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Takeda K, 1998, J IMMUNOL, V161, P4652; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; Thierfelder WE, 1996, NATURE, V382, P171, DOI 10.1038/382171a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; Weber-Nordt RM, 1998, LEUKEMIA LYMPHOMA, V28, P459, DOI 10.3109/10428199809058353; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; Zong C, 1996, EMBO J, V15, P4515, DOI 10.1002/j.1460-2075.1996.tb00829.x	49	2410	2593	3	157	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					295	303		10.1016/S0092-8674(00)81959-5	http://dx.doi.org/10.1016/S0092-8674(00)81959-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458605	Bronze			2022-12-24	WOS:000081950300005
J	Cotzias, CS; Paterson-Brown, S; Fisk, NM				Cotzias, CS; Paterson-Brown, S; Fisk, NM			Prospective risk of unexplained stillbirth in singleton pregnancies at term: population based analysis	BRITISH MEDICAL JOURNAL			English	Article									Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, Imperial Coll, Sch Med, Inst Obstet & Gynaecol, London W6 0XG, England.		Fisk, Nicholas M/B-2126-2009	Fisk, Nicholas M/0000-0003-0031-7975				FELDMAN GB, 1992, OBSTET GYNECOL, V79, P547; Hilder L, 1998, BRIT J OBSTET GYNAEC, V105, P169, DOI 10.1111/j.1471-0528.1998.tb10047.x; *STAT OFF, 1996, CONF ENQ STILLB DEAT; THORNTON JG, 1989, J OBSTET GYNAECOL, V9, P283, DOI 10.3109/01443618909151065; YUDKIN PL, 1987, LANCET, V1, P1192	5	83	85	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					287	288		10.1136/bmj.319.7205.287	http://dx.doi.org/10.1136/bmj.319.7205.287			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426736	Bronze, Green Published			2022-12-24	WOS:000081909100020
J	Annunen, S; Paassilta, P; Lohiniva, J; Perala, M; Pihlajamaa, T; Karppinen, J; Tervonen, O; Kroger, H; Lahde, S; Vanharanta, H; Ryhanen, L; Goring, HHH; Ott, J; Prockop, DJ; Ala-Kokko, L				Annunen, S; Paassilta, P; Lohiniva, J; Perala, M; Pihlajamaa, T; Karppinen, J; Tervonen, O; Kroger, H; Lahde, S; Vanharanta, H; Ryhanen, L; Goring, HHH; Ott, J; Prockop, DJ; Ala-Kokko, L			An allele of COL9A2 associated with intervertebral disc disease	SCIENCE			English	Article							COLLAGEN TYPE-IX; CROSS-LINKING SITES; LINKAGE ANALYSIS; MOLECULAR-CLONING; LUMBAR SPINE; II COLLAGEN; CARTILAGE; DEGENERATION; CHAIN; GENE	Intervertebral disc disease is one of the most common musculoskeletal disorders. A number of environmental and anthropometric risk factors may contribute to it, and recent reports have suggested the importance of genetic factors as well. The COL9A2 gene, which codes for one of the polypeptide chains of collagen IX that is expressed in the intervertebral disc, was screened for sequence variations in individuals with intervertebral disc disease. The analysis identified a putative disease-causing sequence variation that converted a codon for glutamine to one for tryptophan in six out of the 157 individuals but in none of 174 controls. The tryptophan allele cosegregated with the disease phenotype in the four families studied, giving a lod score (Logarithm of odds ratio) for linkage of 4.5, and subsequent linkage disequilibrium analysis conditional on linkage gave an additional lod score of 7.1.	Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland; Univ Oulu, Dept Biochem Med, SF-90220 Oulu, Finland; Univ Oulu, Dept Phys Med & Rehabil, SF-90220 Oulu, Finland; Univ Oulu, Dept Diagnost Radiol, SF-90220 Oulu, Finland; Univ Oulu, Dept Internal Med, SF-90220 Oulu, Finland; Univ Kuopio, Dept Surg, Kuopio 70211, Finland; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; MCP Hahnemann Univ, Ctr Gene Therapy, Philadelphia, PA 19102 USA	University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Oulu; University of Eastern Finland; Columbia University; Rockefeller University; Drexel University	Ala-Kokko, L (corresponding author), Univ Oulu, Bioctr, Collagen Res Unit, SF-90220 Oulu, Finland.	leena.ala-kokko@oulu.fi			NHGRI NIH HHS [HG00008] Funding Source: Medline; NIAMS NIH HHS [AR39740] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Battie MC, 1995, SPINE, V20, P2601, DOI 10.1097/00007632-199512150-00001; Becker A, 1998, HUM HERED, V48, P49, DOI 10.1159/000022781; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BUCKWALTER JA, 1995, SPINE, V20, P1307, DOI 10.1097/00007632-199506000-00022; CHOTAI J, 1984, ANN HUM GENET, V48, P359, DOI 10.1111/j.1469-1809.1984.tb00849.x; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; Diab M, 1996, BIOCHEM J, V314, P327, DOI 10.1042/bj3140327; EYRE DR, 1977, BIOCHIM BIOPHYS ACTA, V492, P29, DOI 10.1016/0005-2795(77)90211-2; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; GORING HHH, UNPUB; GORKING HHH, UNPUB; HELIOVAARA M, 1989, ANN MED, V21, P254, DOI 10.3109/07853898909149202; HELIOVAARA M, 1987, J EPIDEMIOL COMMUN H, V41, P251, DOI 10.1136/jech.41.3.251; HELLSTEN E, 1993, GENOMICS, V16, P720, DOI 10.1006/geno.1993.1253; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Kainulainen K, 1999, HYPERTENSION, V33, P844, DOI 10.1161/01.HYP.33.3.844; Kielty Cay M., 1993, P103; Kimura T, 1996, INT ORTHOP, V20, P177, DOI 10.1007/s002640050058; Korkko J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; MATSUI H, 1992, SPINE, V17, P1323, DOI 10.1097/00007632-199211000-00011; MORTON NE, 1955, AM J HUM GENET, V7, P277; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; Nelson C L, 1972, Clin Orthop Relat Res, V88, P142, DOI 10.1097/00003086-197210000-00025; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; PERALA M, 1993, FEBS LETT, V319, P177, DOI 10.1016/0014-5793(93)80062-Y; PERALA M, 1994, J BIOL CHEM, V269, P5064; Pihlajamaa T, 1998, MATRIX BIOL, V17, P237, DOI 10.1016/S0945-053X(98)90063-4; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; ROKOS I, 1994, MATRIX BIOL, V14, P1, DOI 10.1016/0945-053X(94)90024-8; Scapinelli R, 1993, Acta Orthop Belg, V59, P371; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; Terwilliger J., 1994, HDB HUMAN GENETIC LI; TIENARI PJ, 1994, GENOMICS, V19, P320, DOI 10.1006/geno.1994.1064; URBAN JPG, 1993, MUSCULOSKELETAL SOFT-TISSUE AGING: IMPACT ON MOBILITY, P391; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VARLOTTA GP, 1991, J BONE JOINT SURG AM, V73A, P124, DOI 10.2106/00004623-199173010-00016; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; Watanabe H, 1997, P NATL ACAD SCI USA, V94, P6943, DOI 10.1073/pnas.94.13.6943; Weishaupt D, 1998, RADIOLOGY, V209, P661, DOI 10.1148/radiology.209.3.9844656; WILLIAMSON JA, 1990, GENET EPIDEMIOL, V7, P309, DOI 10.1002/gepi.1370070502; WU JJ, 1992, J BIOL CHEM, V267, P23007	45	241	271	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					409	412		10.1126/science.285.5426.409	http://dx.doi.org/10.1126/science.285.5426.409			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411504				2022-12-24	WOS:000081465900055
J	Linthicum, KJ; Anyamba, A; Tucker, CJ; Kelley, PW; Myers, MF; Peters, CJ				Linthicum, KJ; Anyamba, A; Tucker, CJ; Kelley, PW; Myers, MF; Peters, CJ			Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya	SCIENCE			English	Article							DIFFERENCE VEGETATION INDEX; SEA-SURFACE TEMPERATURE; NEAR-INFRARED CHANNELS; DOMESTIC-ANIMALS; EL-NINO; RAINFALL; AVHRR; CALIBRATION; AFRICA; VIRUS	All known Rift Valley fever virus outbreaks in East Africa from 1950 to May 1998, and probably earlier, followed periods of abnormally high rainfall. Analysis of this record and Pacific and Indian Ocean sea surface temperature anomalies, coupled with satellite normalized difference vegetation index data, shows that prediction of Rift Valley fever outbreaks may be made up to 5 months in advance of outbreaks in East Africa. Concurrent near-real-time monitoring with satellite normalized difference vegetation data may identify actual affected areas.	Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Def, Washington, DC 20307 USA; NASA, Goddard Space Flight Ctr, Earth Sci Directorate, Greenbelt, MD 20771 USA; Ctr Dis Control & Prevent, Special Pathogens Branch, Atlanta, GA 30333 USA	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Centers for Disease Control & Prevention - USA	Anyamba, A (corresponding author), Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Def, Washington, DC 20307 USA.		Ibrahim, Essam Hassan/G-1960-2018	Ibrahim, Essam Hassan/0000-0003-0130-2257; Anyamba, Assaf/0000-0003-0932-9585				Anyamba A, 1996, INT J REMOTE SENS, V17, P2533, DOI 10.1080/01431169608949091; CANE MA, 1986, ANNU REV EARTH PL SC, V14, P43, DOI 10.1146/annurev.ea.14.050186.000355; CANE MA, 1994, NATURE, V370, P204, DOI 10.1038/370204a0; CHAGAS C, 1986, PERSISTENT METEOOCEA, P1; CHE N, 1992, REMOTE SENS ENVIRON, V41, P19, DOI 10.1016/0034-4257(92)90057-Q; Daubney R, 1931, J PATHOL BACTERIOL, V34, P545, DOI 10.1002/path.1700340418; DAVIES FG, 1985, B WORLD HEALTH ORGAN, V63, P941; FARMER G, 1988, J CLIMATOL, V8, P489, DOI 10.1002/joc.3370080505; Glantz M. H, 1991, TELECONNECTIONS LINK, P1; HOLBEN BN, 1990, INT J REMOTE SENS, V11, P1511, DOI 10.1080/01431169008955109; Lauenroth W. K., 1979, Perspectives in grassland ecology., P3; LEHOUEROU HN, 1977, J RANGE MANAGE, V30, P181; Linthicum K.J., 1994, SISTEMA TERRA, V3, P44; LINTHICUM KJ, 1985, J HYG-CAMBRIDGE, V95, P197, DOI 10.1017/S0022172400062434; LINTHICUM KJ, 1987, SCIENCE, V235, P1656, DOI 10.1126/science.3823909; LOGAN TM, 1990, J AM MOSQUITO CONTR, V6, P736; LOGAN TM, 1992, T ROY SOC TROP MED H, V86, P202, DOI 10.1016/0035-9203(92)90571-S; LOGAN TM, 1991, J MED ENTOMOL, V28, P293, DOI 10.1093/jmedent/28.2.293; LOS SO, 1993, INT J REMOTE SENS, V14, P1907, DOI 10.1080/01431169308954011; MALO AR, 1990, J ARID ENVIRON, V19, P1; Myneni RB, 1996, GEOPHYS RES LETT, V23, P729, DOI 10.1029/96GL00266; Nicholls N., 1991, TELECONNECTIONS LINK, P493; Nichols, 1991, TELECONNECTIONS LINK, P309; Nicholson SE, 1997, INT J CLIMATOL, V17, P345, DOI 10.1002/(SICI)1097-0088(19970330)17:4<345::AID-JOC127>3.0.CO;2-3; NICHOLSON SE, 1990, CLIMATIC CHANGE, V17, P209, DOI 10.1007/BF00138369; POPE KO, 1992, REMOTE SENS ENVIRON, V40, P185, DOI 10.1016/0034-4257(92)90002-2; ROPELEWSKI C. F., 1987, MON WEA REV, V115, P2352; TUCKER CJ, 1994, INT J REMOTE SENS, V15, P3547, DOI 10.1080/01431169408954344; TUCKER CJ, IN PRESS AMBIO; VERMOTE E, 1995, INT J REMOTE SENS, V16, P2317, DOI 10.1080/01431169508954561	30	402	419	4	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					397	400		10.1126/science.285.5426.397	http://dx.doi.org/10.1126/science.285.5426.397			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411500				2022-12-24	WOS:000081465900051
J	Zou, H; McGarry, TJ; Bernal, T; Kirschner, MW				Zou, H; McGarry, TJ; Bernal, T; Kirschner, MW			Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis	SCIENCE			English	Article							FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ANAPHASE TRANSITION; NUCLEAR DIVISION; BUDDING YEAST; METAPHASE; COMPLEX; MITOSIS; SPINDLE; PDS1P	A vertebrate securin (vSecurin) was identified on the basis of its biochemical analogy to the Pds1p protein of budding yeast and the Cut2p protein of fission yeast. The vSecurin protein bound to a vertebrate homolog of yeast separins Esp1p and Cut1p and was degraded by proteolysis mediated by an anaphase-promoting complex in a manner dependent on a destruction motif. Furthermore, expression of a stable Xenopus securin mutant protein blocked sister-chromatid separation but did not block the embryonic cell cycle. The vSecurin proteins share extensive sequence similarity with each other but show no sequence similarity to either of their yeast counterparts. Human securin is identical to the product of the gene called pituitary tumor-transforming gene (PTTG), which is overexpressed in some tumors and exhibits transforming activity in NIH 3T3 cells. The oncogenic nature of increased expression of vSecurin may result from chromosome gain or loss, produced by errors in chromatid separation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026875, R01GM026875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Dominguez A, 1998, ONCOGENE, V17, P2187, DOI 10.1038/sj.onc.1202140; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; Funabiki H, 1997, EMBO J, V16, P5977, DOI 10.1093/emboj/16.19.5977; Harlow E, 1988, ANTIBODIES LAB MANUA; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1997, SCIENCE, V277, P973, DOI 10.1126/science.277.5328.973; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kroll KL, 1998, DEVELOPMENT, V125, P3247; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; ZOU H, UNPUB	29	655	691	1	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					418	422		10.1126/science.285.5426.418	http://dx.doi.org/10.1126/science.285.5426.418			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411507				2022-12-24	WOS:000081465900058
J	Kerem, E; Bistritzer, T; Hanukoglu, A; Hofmann, T; Zhou, ZQ; Bennett, W; MacLaughlin, E; Barker, P; Nash, M; Quittell, L; Boucher, R; Knowles, MR				Kerem, E; Bistritzer, T; Hanukoglu, A; Hofmann, T; Zhou, ZQ; Bennett, W; MacLaughlin, E; Barker, P; Nash, M; Quittell, L; Boucher, R; Knowles, MR			Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTIC-FIBROSIS; I PSEUDOHYPOALDOSTERONISM; MUCOCILIARY CLEARANCE; ION-TRANSPORT; GENE; DISEASE; METHACHOLINE; MUTATIONS; CHILDREN; INFANTS	Background Active sodium absorption is the dominant mechanism of ion transport in airway epithelium, but its role in pulmonary physiology and airway host defense is unknown. To address this question, we studied the function of airway epithelial cells and determined the frequency of pulmonary symptoms in patients with systemic pseudohypoaldosteronism, a salt-losing disorder caused by loss-of-function mutations in the genes for the epithelial sodium channel. Methods In nine patients 1.5 to 22 years of age who had systemic pseudohypoaldosteronism, we tested for mutations in the genes for the epithelial sodium channel, estimated the rate of sodium transport in the airway, determined the volume and ion composition of airway surface liquid, reviewed clinical features, collected laboratory data pertinent to pulmonary function, and, in three adults, measured mucociliary clearance. Results The patients with systemic pseudohypoaldosteronism had loss-of-function mutations in the genes for the epithelial sodium-channel subunits, no sodium absorption from airway surfaces, and a volume of airway surface liquid that was more than twice the normal value. The mean (+/-SE) mucociliary transport rate was higher in the 3 adult patients than in 12 normal subjects (2.0+/-0.7 vs. 0.5+/-0.3 percent per minute, P=0.009). Young patients (those five years of age or less) all had recurrent episodes of chest congestion, coughing, and wheezing, but no airway infections with Staphylococcus aureus or Pseudomonas aeruginosa. Older patients (those more than five years of age) had less frequent respiratory symptoms. Conclusions Patients with systemic pseudohypoaldosteronism fail to absorb liquid from airway surfaces; the result is an increased volume of liquid in the airways. These results demonstrate that sodium transport has a role in regulating the volume of liquid on airway surfaces. (N Engl J Med 1999;341: 156-62.) (C) 1999, Massachusetts Medical Society.	Univ N Carolina, Cystic Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Sch Med, Pediat Resp Med & Cyst Fibrosis Ctr, Jerusalem, Israel; Assaf Harofeh Med Ctr, Dept Pediat, IL-70300 Zerifin, Israel; Wolfson Med Ctr, Dept Pediat, Holon, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; Univ Giessen, Kinderklin, Giessen, Germany; Univ N Carolina, Ctr Environm Med, Chapel Hill, NC 27599 USA; Univ So Calif, Los Angeles, CA USA; Childrens Hosp Los Angeles, Div Pediat Pulm, Los Angeles, CA 90027 USA; Columbia Presbyterian Med Ctr, Pediat Nephrol Div, New York, NY 10032 USA; Columbia Presbyterian Med Ctr, Pediat Pulm Div, New York, NY 10032 USA	University of North Carolina; University of North Carolina Chapel Hill; Hebrew University of Jerusalem; Shaare Zedek Medical Center; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Justus Liebig University Giessen; University of North Carolina; University of North Carolina Chapel Hill; University of Southern California; Children's Hospital Los Angeles; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital	Knowles, MR (corresponding author), Univ N Carolina, Cystic Fibrosis Pulm Res & Treatment Ctr, 7011 Thurston Bowles Bldg,CB 7248, Chapel Hill, NC 27599 USA.	knowles@med.unc.edu	Hanukoglu, Aaron/L-4892-2016; MacLaughlin, Eric J/L-7316-2019	Hanukoglu, Aaron/0000-0003-1486-6641; MacLaughlin, Eric J/0000-0002-1460-445X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00046] Funding Source: Medline; NHLBI NIH HHS [P01 HL34322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVITAL A, 1988, J PEDIATR-US, V112, P591, DOI 10.1016/S0022-3476(88)80177-X; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P581, DOI 10.1164/ajrccm.150.2.8049852; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Clark JC, 1997, AM J RESP CELL MOL, V16, P46, DOI 10.1165/ajrcmb.16.1.8998078; Geller DS, 1998, NAT GENET, V19, P279, DOI 10.1038/966; GERHARDT T, 1985, PEDIATR RES, V19, P1165, DOI 10.1203/00006450-198511000-00010; GILLIGAN PH, 1991, CLIN MICROBIOL REV, V4, P35, DOI 10.1128/CMR.4.1.35-51.1991; HANUKOGLU A, 1994, J PEDIATR-US, V125, P752, DOI 10.1016/S0022-3476(94)70071-0; HANUKOGLU A, 1991, J CLIN ENDOCR METAB, V73, P936, DOI 10.1210/jcem-73-5-936; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HIGHSMITH WE, 1994, NEW ENGL J MED, V331, P974, DOI 10.1056/NEJM199410133311503; KILBURN KH, 1968, AM REV RESPIR DIS, V98, P449; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; Knowles MR, 1998, J CLIN INVEST, V101, P285; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; Knowles MR, 1997, J CLIN INVEST, V100, P2588, DOI 10.1172/JCI119802; LI XJ, 1995, MOL PHARMACOL, V47, P1133; LODRUPCARLSEN KC, 1993, EUR RESPIR J, V6, P1496; Marthinsen L, 1998, ACTA PAEDIATR, V87, P472; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MITCHELL I, 1978, J PEDIATR-US, V93, P744, DOI 10.1016/S0022-3476(78)81070-1; OBERFIELD SE, 1979, J CLIN ENDOCR METAB, V48, P228, DOI 10.1210/jcem-48-2-228; Olivier KN, 1996, AM J RESP CRIT CARE, V154, P217, DOI 10.1164/ajrccm.154.1.8680683; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; SANCHEZ I, 1993, AM REV RESPIR DIS, V147, P705, DOI 10.1164/ajrccm/147.3.705; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Smith JJ, 1996, CELL, V87, pU25; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; VANDENPLAS Y, 1992, J PEDIATR GASTR NUTR, V14, P467; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868, DOI 10.1164/ajrccm.154.6.8970383; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222; YAGER D, 1989, J APPL PHYSIOL, V66, P2873, DOI 10.1152/jappl.1989.66.6.2873; Zar JH, 1996, BIOSTATISTICAL ANAL	35	263	278	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 15	1999	341	3					156	162		10.1056/NEJM199907153410304	http://dx.doi.org/10.1056/NEJM199907153410304			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215YV	10403853	Green Published			2022-12-24	WOS:000081413800004
J	Grakoui, A; Bromley, SK; Sumen, C; Davis, MM; Shaw, AS; Allen, PM; Dustin, ML				Grakoui, A; Bromley, SK; Sumen, C; Davis, MM; Shaw, AS; Allen, PM; Dustin, ML			The immunological synapse: A molecular machine controlling T cell activation	SCIENCE			English	Article							II PEPTIDE COMPLEXES; LIPID-LINKED FORM; ANTIGEN-RECEPTOR; PHOTOBLEACHING RECOVERY; SIGNAL-TRANSDUCTION; PLANAR BILAYERS; ADHESION; RECOGNITION; MEMBRANES; AFFINITY	The specialized junction between a T lymphocyte and an antigen-presenting cell, the immunological synapse, consists of a central cluster of T cell receptors surrounded by a ring of adhesion molecules. Immunological synapse formation is now shown to be an active and dynamic mechanism that allows T cells to distinguish potential antigenic Ligands, initially, T cell receptor ligands were engaged in an outermost ring of the nascent synapse. Transport of these complexes into the central cluster was dependent on T cell receptor-ligand interaction kinetics. Finally, formation of a stable central cluster at the heart of the synapse was a determinative event for T cell proliferation.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA	Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Stanford University	Dustin, ML (corresponding author), Washington Univ, Sch Med, Dept Pathol, 660 S Euclid Ave,Campus Box 8118, St Louis, MO 63110 USA.	dustin@immunology.wustl.edu	Dustin, Michael/AAM-4611-2020	Dustin, Michael/0000-0003-4983-6389; Davis, Mark/0000-0001-6868-657X				Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; Alam SM, 1999, IMMUNITY, V10, P227, DOI 10.1016/S1074-7613(00)80023-0; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Baldwin KK, 1999, J EXP MED, V189, P13, DOI 10.1084/jem.189.1.13; Boniface JJ, 1998, IMMUNITY, V9, P459, DOI 10.1016/S1074-7613(00)80629-9; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; Dustin ML, 1996, J IMMUNOL, V157, P2014; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; ELSON EL, 1989, METHOD CELL BIOL, V30, P307; Felsenfeld DP, 1996, NATURE, V383, P438, DOI 10.1038/383438a0; GAY D, 1986, J IMMUNOL, V136, P2026; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1989, COLD SH Q B, V54, P657; Kersh EN, 1998, SCIENCE, V281, P572, DOI 10.1126/science.281.5376.572; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KUPFER A, 1987, P NATL ACAD SCI USA, V84, P5888, DOI 10.1073/pnas.84.16.5888; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; Negulescu PA, 1996, IMMUNITY, V4, P421, DOI 10.1016/S1074-7613(00)80409-4; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Reich Z, 1997, NATURE, V387, P617, DOI 10.1038/42500; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; UNANUE ER, 1984, ANNU REV IMMUNOL, V2, P395, DOI 10.1146/annurev.iy.02.040184.002143; VAFUTUTTI S, 1995, NATURE, V375, P148; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WADE WF, 1989, J CELL BIOL, V109, P3325, DOI 10.1083/jcb.109.6.3325; WADE WF, 1994, INT IMMUNOL, V6, P1457, DOI 10.1093/intimm/6.10.1457; Wang W, 1997, J IMMUNOL, V158, P5797; WEISS A, 1987, J IMMUNOL, V138, P2169; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; Wulfing C, 1998, P NATL ACAD SCI USA, V95, P6302, DOI 10.1073/pnas.95.11.6302; Wulfing C, 1998, SCIENCE, V282, P2266, DOI 10.1126/science.282.5397.2266	47	2443	2544	3	217	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					221	227		10.1126/science.285.5425.221	http://dx.doi.org/10.1126/science.285.5425.221			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398592				2022-12-24	WOS:000081346000032
J	Dalgaard, LZ; Klar, AJS				Dalgaard, LZ; Klar, AJS			Orientation of DNA replication establishes mating-type switching pattern in S-pombe	NATURE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; GENETIC-ANALYSIS; INITIATION; CELLS; TRANSPOSITION; ASYMMETRY; STRANDS; BREAKS	The fission yeast Schizosaccharomyces pombe normally has haploid cells of two mating types, which differ at the chromosomal locus mat1. After two consecutive asymmetric cell divisions, only one in four 'grand-daughter' cells undergoes a 'mating-type switch', in which genetic information is transferred to mat1 from the mat2-P or mat3-M donor loci(1-4). This switching pattern probably results from an imprinting event at mat1 that marks one sister chromatid in a strand-specific manner(3-5), and is related to a site-specific, double-stranded DNA break at mat1(6,7). Here we show that the genetic imprint is a strand-specific, alkali-labile DNA modification at mat1. The DNA break is an artefact, created from the imprint during DNA purification. We also propose and test the model that mat1 is preferentially replicated by a centromere-distal origin(s), so that the strand-specific imprint occurs only during lagging-strand synthesis. Altering the origin of replication, by inverting mat1 or introducing an origin of replication, affects the imprinting and switching efficiencies in predicted ways. Two-dimensional gel analysis confirmed that mat1 is preferentially replicated by a centromere-distal origin(s). Thus, the DNA replication machinery may confer different developmental potential to sister cells.	NCI, Gene Regulat & Chromosome Biol Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Klar, AJS (corresponding author), NCI, Gene Regulat & Chromosome Biol Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA.	klar@mail.ncifcrf.gov		Dalgaard, Jacob/0000-0001-9545-7254				Arcangioli B, 1998, EMBO J, V17, P4503, DOI 10.1093/emboj/17.15.4503; ARCANGIOLI B, 1991, EMBO J, V10, P3025, DOI 10.1002/j.1460-2075.1991.tb07853.x; BEACH DH, 1983, NATURE, V305, P682, DOI 10.1038/305682a0; BRESCH C, 1968, MOL GEN GENET, V102, P301, DOI 10.1007/BF00433721; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CADDLE MS, 1994, MOL CELL BIOL, V14, P1796, DOI 10.1128/MCB.14.3.1796; Clyne RK, 1995, EMBO J, V14, P6348, DOI 10.1002/j.1460-2075.1995.tb00326.x; EGEL R, 1984, P NATL ACAD SCI-BIOL, V81, P3481, DOI 10.1073/pnas.81.11.3481; EGEL R, 1987, CURR GENET, V12, P429, DOI 10.1007/BF00434820; Egel R., 1989, MOL BIOL FISSION YEA, P31; GERRING S L, 1991, P57; KLAR AJS, 1990, EMBO J, V9, P1407, DOI 10.1002/j.1460-2075.1990.tb08256.x; KLAR AJS, 1987, NATURE, V326, P466, DOI 10.1038/326466a0; KLAR AJS, 1993, COLD SPRING HARB SYM, V58, P457, DOI 10.1101/SQB.1993.058.01.052; Klar AJS, 1998, CIBA F SYMP, V214, P87; KLAR AJS, 1993, CURR OPIN GENET DEV, V3, P745, DOI 10.1016/S0959-437X(05)80093-0; KLAR AJS, 1986, CELL, V46, P725, DOI 10.1016/0092-8674(86)90348-X; MCDONELL MW, 1977, J MOL BIOL, V110, P119, DOI 10.1016/S0022-2836(77)80102-2; MIYATA H, 1981, J GEN APPL MICROBIOL, V27, P365, DOI 10.2323/jgam.27.365; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NIELSEN O, 1989, EMBO J, V8, P269, DOI 10.1002/j.1460-2075.1989.tb03373.x; Sambrook JFE, 1989, MOL CLONING LAB MANU; SINGH J, 1993, NATURE, V361, P271, DOI 10.1038/361271a0; STYRKARSDOTTIR U, 1993, CURR GENET, V23, P184, DOI 10.1007/BF00352020	24	113	116	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					181	184		10.1038/22139	http://dx.doi.org/10.1038/22139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408447				2022-12-24	WOS:000081324900058
J	Roux, B; MacKinnon, R				Roux, B; MacKinnon, R			The cavity and pore helices the KcsA K+ channel: Electrostatic stabilization of monovalent cations	SCIENCE			English	Article							MOLECULAR-DYNAMICS; POTASSIUM CHANNEL; PROTEINS; DIPOLES; ENERGY	The electrostatic influence of the central cavity and pore alpha helices in the potassium ion channel from Streptomyces lividans (KcsA K+ channel) was analyzed by solving the finite difference Poisson equation. The cavity and helices overcome the destabilizing influence of the membrane and stabilize a cation at the membrane center. The electrostatic effect of the pore helices is large compared to that described for water-soluble proteins because of the low dielectric membrane environment. The combined contributions of the ion self-energy and the helix electrostatic field give rise to selectivity for monovalent cations in the water-filled cavity. Thus, the K+ channel uses simple electrostatic principles to solve the fundamental problem of ion destabilization by the cell membrane lipid bilayer.	Univ Montreal, Dept Phys, GRTM, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Chim, GRTM, Montreal, PQ H3C 3J7, Canada; Rockefeller Univ, Lab Mol Neurobiol & Biophys, Howard Hughes Med Inst, New York, NY 10021 USA	Universite de Montreal; Universite de Montreal; Howard Hughes Medical Institute; Rockefeller University	Roux, B (corresponding author), Univ Montreal, Dept Phys, GRTM, Case Postal 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Born M, 1920, Z PHYS, V1, P45, DOI 10.1007/BF01881023; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; *CCP4 PROGR, 1994, ACTA CRYSTALLOGR D, V50, P60; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; HE JJ, 1993, PROTEIN SCI, V2, P1643, DOI 10.1002/pro.5560021010; HOL WGJ, 1985, PROG BIOPHYS MOL BIO, V45, P149, DOI 10.1016/0079-6107(85)90001-X; HOL WGJ, 1978, NATURE, V273, P5662; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; Nina M, 1997, J PHYS CHEM B, V101, P5239, DOI 10.1021/jp970736r; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARSEGIAN A, 1969, NATURE, V221, P844, DOI 10.1038/221844a0; Simonson T, 1996, J AM CHEM SOC, V118, P8452, DOI 10.1021/ja960884f; WARWICKER J, 1982, J MOL BIOL, V157, P671, DOI 10.1016/0022-2836(82)90505-8; WIBBLE BA, 1994, NATURE, V371, P246	17	371	379	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					100	102		10.1126/science.285.5424.100	http://dx.doi.org/10.1126/science.285.5424.100			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390357				2022-12-24	WOS:000081199800039
J	Scally, G				Scally, G			Tackling teenage pregnancy in the UK	LANCET			English	Editorial Material									Natl Hlth Serv Execut, Bristol BS34 8SR, Avon, England		Scally, G (corresponding author), Natl Hlth Serv Execut, South West Reg, Bristol BS34 8SR, Avon, England.							Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; *DEP HLTH, 1992, HLTH NAT; JONES EF, 1986, TEENAGE PREGNANCY IN; MCKITTRICK D, 1993, BRIT MED J, V306, P229; Scally G, 1993, Midwives Chron, V106, P232; *SOC EXCL UN, 1999, TEEN PREGN; The Expert Advisory Group on Cancer to the Chief Medical Officers of England and Wales, 1995, POL FRAM COMM CANC S; WELLINGS K, 1995, BRIT MED J, V311, P417, DOI 10.1136/bmj.311.7002.417; 1999, DAILY TELEGRAPH 0615, P23	9	3	3	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2178	2178		10.1016/S0140-6736(99)00208-1	http://dx.doi.org/10.1016/S0140-6736(99)00208-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392980				2022-12-24	WOS:000081091300008
J	Kahana, MJ; Sekuler, R; Caplan, JB; Kirschen, M; Madsen, JR				Kahana, MJ; Sekuler, R; Caplan, JB; Kirschen, M; Madsen, JR			Human theta oscillations exhibit task dependence during virtual maze navigation	NATURE			English	Article							HUMAN HIPPOCAMPAL-FORMATION; RHYTHM; MODULATION; RAT	Theta oscillations (electroencephalographic activity with a frequency of 4-8 Hz) have long been implicated in spatial navigation in rodents(1-3); however, the role of theta oscillators in human spatial navigation has not been explored. Here we describe subdural recordings from epileptic patients learning to navigate computer-generated mazes. Visual inspection of the raw intracranial signal revealed striking episodes of high-amplitude slow-wave oscillations at a number of areas of the cortex, including temporal cortex. Spectral analysis showed that these oscillations were in the theta band. These episodes of theta activity, which typically last several cycles, are dependent on task characteristics. Theta oscillations occur more frequently in more complex mazes; they are also more frequent during recall trials than during learning trials.	Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA; Childrens Hosp, Dept Neurosurg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA	Brandeis University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Kahana, MJ (corresponding author), Brandeis Univ, Volen Ctr Complex Syst, Waltham, MA 02454 USA.							Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; [Anonymous], 1983, CANADIAN PSYCHOL; ARNOLDS DEAT, 1980, ELECTROEN CLIN NEURO, V50, P324, DOI 10.1016/0013-4694(80)90160-1; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BORST JGG, 1987, BRAIN RES, V407, P81, DOI 10.1016/0006-8993(87)91221-2; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Epstein R, 1998, NATURE, V392, P598, DOI 10.1038/33402; GROSSMANN A, 1985, MATH PLUS PHYSICS, V1; HALGREN E, 1978, ELECTROEN CLIN NEURO, V44, P778, DOI 10.1016/0013-4694(78)90212-2; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; Jensen O, 1998, J NEUROSCI, V18, P10688; LISMAN JE, 1995, SCIENCE, V267, P1512, DOI 10.1126/science.7878473; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1997, J NEUROSCI, V17, P7103; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; ROUTTENBERG A, 1973, BEHAV BIOL, V8, P801, DOI 10.1016/S0091-6773(73)80122-1; Skaggs WE, 1996, HIPPOCAMPUS, V6, P149, DOI 10.1002/(SICI)1098-1063(1996)6:2<149::AID-HIPO6>3.0.CO;2-K; SLAWINSKA U, 1995, BRAIN RES, V678, P117, DOI 10.1016/0006-8993(95)00174-O; Sohal VS, 1998, HIPPOCAMPUS, V8, P171, DOI 10.1002/(SICI)1098-1063(1998)8:2<171::AID-HIPO9>3.0.CO;2-O; Sperling MR, 1997, EPILEPSIA, V38, pS6, DOI 10.1111/j.1528-1157.1997.tb04541.x; STEWART M, 1991, BRAIN RES, V538, P59, DOI 10.1016/0006-8993(91)90376-7; Talairach J., 1988, COPLANAR STEREOTAXIC; Tesche CD, 1997, BRAIN RES, V749, P53, DOI 10.1016/S0006-8993(96)01286-3; WINSON J, 1978, SCIENCE, V201, P160, DOI 10.1126/science.663646	27	454	460	2	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					781	784		10.1038/21645	http://dx.doi.org/10.1038/21645			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391243				2022-12-24	WOS:000081101600053
J	Whiten, A; Goodall, J; McGrew, WC; Nishida, T; Reynolds, V; Sugiyama, Y; Tutin, CEG; Wrangham, RW; Boesch, C				Whiten, A; Goodall, J; McGrew, WC; Nishida, T; Reynolds, V; Sugiyama, Y; Tutin, CEG; Wrangham, RW; Boesch, C			Cultures in chimpanzees	NATURE			English	Article							CHILDREN HOMO-SAPIENS; PAN-TROGLODYTES; WILD CHIMPANZEES; EVOLUTION; IMITATION	As an increasing number of field studies of chimpanzees (Pan troglodytes) have achieved long-term status across Africa, differences in the behavioural repertoires described have become apparent that suggest there is significant cultural variation(1-7). Here we present a systematic synthesis of this information from the seven most long-term studies, which together have accumulated 151 years of chimpanzee observation. This comprehensive analysis reveals patterns of variation that are far more extensive than have previously been documented for any animal species except humans(8-11). We find that 39 different behaviour patterns, including tool usage, grooming and courtship behaviours, are customary or habitual in some communities but are absent in others where ecological explanations have been discounted. Among mammalian and avian species, cultural variation has previously been identified only for single behaviour patterns, such as the local dialects of song-birds(12,13). The extensive, multiple variations now documented for chimpanzees are thus without parallel. Moreover, the combined repertoire of these behaviour patterns in each chimpanzee community is itself highly distinctive, a phenomenon characteristic of human cultures(14) but previously unrecognised in non-human species.	Univ St Andrews, Scottish Primate Res Grp, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland; Gombe Stream Res Ctr, Kigoma, Tanzania; Miami Univ, Dept Zool, Oxford, OH 45056 USA; Miami Univ, Dept Sociol Gerontol & Anthropol, Oxford, OH 45056 USA; Kyoto Univ, Human Evolut Studies Lab, Kyoto 60601, Japan; Univ Oxford, Inst Biol Anthropol, Oxford OX2 6QS, England; Kyoto Univ, Primate Res Inst, Inuyama, Aichi 4848506, Japan; Ctr Int Rech Med Franceville, Franceville, Gabon; Univ Stirling, Dept Biol Sci, Stirling FK9 4LA, Scotland; Harvard Univ, Dept Anthropol, Cambridge, MA 02138 USA; Max Planck Inst Evolutionary Anthropol, D-04301 Leipzig, Germany	University of St Andrews; University System of Ohio; Miami University; University System of Ohio; Miami University; Kyoto University; University of Oxford; Kyoto University; University of Stirling; Harvard University; Max Planck Society	Whiten, A (corresponding author), Univ St Andrews, Scottish Primate Res Grp, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland.							BLOCH M, 1991, MAN, V26, P183, DOI 10.2307/2803828; BOESCH C, 1994, J HUM EVOL, V26, P325, DOI 10.1006/jhev.1994.1020; Boesch Christophe, 1996, Proceedings of the British Academy, V88, P251; BONNER JT, 1980, EVOLUTION CULTURE AN; Galef B G, 1992, Hum Nat, V3, P157, DOI 10.1007/BF02692251; Goodall J., 1986, CHIMPANZEES GOMBE PA; Huffman Michael A., 1996, P267, DOI 10.1016/B978-012273965-1/50014-5; Imanishi K., 1957, Primates, V1, P1, DOI 10.1007/BF01667196; Kroeber A.L., 1963, CULTURE; Lefebvre L., 1988, P141; MARLER P, 1964, SCIENCE, V146, P1483, DOI 10.1126/science.146.3650.1483; McGrew W.C., 1992, CHIMPANZEE MAT CULTU; McGrew WC, 1998, ANNU REV ANTHROPOL, V27, P301, DOI 10.1146/annurev.anthro.27.1.301; MCGREW WC, 1978, MAN, V13, P234, DOI 10.2307/2800247; MUNDINGER PC, 1980, ETHOL SOCIOBIOL, V1, P183, DOI 10.1016/0162-3095(80)90008-4; Murdock G.P., 1967, ETHNOGRAPHIC ATLAS; NAGELL K, 1993, J COMP PSYCHOL, V107, P174, DOI 10.1037/0735-7036.107.2.174; Nishida T., 1987, P462; Nishida T., 1990, CHIMPANZEES MAHALE M; Paquette D., 1992, Human Evolution, V7, P17, DOI 10.1007/BF02436257; Slater T.L.B., 1995, BIRD SONG THEMES VAR; Spence KW, 1937, PSYCHOL BULL, V34, P806, DOI 10.1037/h0061498; Sugiyama Yukimaru, 1993, P175; SUMITA K, 1985, Primates, V26, P168, DOI 10.1007/BF02382016; TOMASELLO M, 1993, BEHAV BRAIN SCI, V16, P495, DOI 10.1017/S0140525X0003123X; Tomasello M., 1987, HUM EVOL, V2, P175, DOI DOI 10.1007/BF02436405; WHITEN A, 1992, ADV STUD BEHAV, V21, P239, DOI 10.1016/S0065-3454(08)60146-1; Whiten A, 1998, J COMP PSYCHOL, V112, P270, DOI 10.1037/0735-7036.112.3.270; Whiten A, 1996, J COMP PSYCHOL, V110, P3, DOI 10.1037/0735-7036.110.1.3; Wrangham R. W., 1994, CHIMPANZEE CULTURES	30	1411	1461	6	429	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					682	685		10.1038/21415	http://dx.doi.org/10.1038/21415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	207JB	10385119				2022-12-24	WOS:000080932800058
J	Li, XY; Virbasius, A; Zhu, XC; Green, MR				Li, XY; Virbasius, A; Zhu, XC; Green, MR			Enhancement of TBP binding by activators and general transcription factors	NATURE			English	Article							RNA-POLYMERASE-II; IN-VIVO; SACCHAROMYCES-CEREVISIAE; PROMOTER SELECTIVITY; TATA-ELEMENT; YEAST; PROTEIN; COMPLEX; MOT1; CORE	Eukaryotic transcriptional activators function, at least in part, by promoting assembly of the preinitiation complex(1-3), which comprises RNA polymerase II and its general transcription factors (GTFs). Activator-mediated stimulation of the assembly of the preinitiation complex has been studied in vitro but has been relatively refractory to in vivo analysis, Here we use a DNA-crosslinking/immunoprecipitation assay to study in living cells the first step in the assembly of the preinitiation complex, the interaction between the TATA-box-binding protein (TBP) and its binding site, the TATA box. Analysis of a variety of endogenous yeast genes, and of a series of activators of differing strength, reveals a general correlation between TBP binding and transcriptional activity. Using mutant yeast strains, we show that Mot1 prevents the binding of TBP to inactive promoters and that activator-mediated stimulation of TBP binding requires additional GTFs, including TFIIB and Srb4. Taken together, our results indicate that TBP binding in vivo is stringently controlled, and that the ability of activators to stimulate this step in the assembly of the preinitiation complex is a highly cooperative process involving multiple transcription factors.	Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.	michael.green@ummed.edu						AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Collart MA, 1996, MOL CELL BIOL, V16, P6668; DAVIS JL, 1992, MOL CELL BIOL, V12, P1879, DOI 10.1128/MCB.12.4.1879; GIARDINA C, 1995, MOL CELL BIOL, V15, P2737; Halle JP, 1996, TRENDS GENET, V12, P161, DOI 10.1016/0168-9525(96)30035-8; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; Lee M, 1997, MOL CELL BIOL, V17, P1336, DOI 10.1128/MCB.17.3.1336; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LUE NF, 1989, P NATL ACAD SCI USA, V86, P486, DOI 10.1073/pnas.86.2.486; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SELLECK SB, 1988, P NATL ACAD SCI USA, V85, P5399, DOI 10.1073/pnas.85.15.5399; Shen WC, 1997, CELL, V90, P615, DOI 10.1016/S0092-8674(00)80523-1; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; Verrijzer CP, 1996, TRENDS BIOCHEM SCI, V21, P338, DOI 10.1016/0968-0004(96)10044-X	28	201	203	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					605	609		10.1038/21232	http://dx.doi.org/10.1038/21232			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376604				2022-12-24	WOS:000080778400061
J	Bammer, G; Dobler-Mikola, A; Fleming, PM; Strang, J; Uchtenhagen, A				Bammer, G; Dobler-Mikola, A; Fleming, PM; Strang, J; Uchtenhagen, A			Drug abuse - The heroin prescribing debate: Integrating science and politics	SCIENCE			English	Editorial Material							PRESCRIPTION; MAINTENANCE; PROGRAM; ENGLAND; TRIAL; WALES		Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; Res Inst Addict, CH-8005 Zurich, Switzerland; Portsmouth City Drugs & Alcohol Serv, Portsmouth PO5 1LR, Hants, England; Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England	Australian National University; University of London; King's College London	Bammer, G (corresponding author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Bammer, Gabriele/0000-0001-9098-0951				Bammer G, 1996, MED J AUSTRALIA, V164, P690, DOI 10.5694/j.1326-5377.1996.tb122243.x; Bammer G, 1999, CNS DRUGS, V11, P253, DOI 10.2165/00023210-199911040-00002; BAMMER G, 1994, 9 AUSTR NAT U AUSTR; BAMMER G, 1995, REPORT RECOMMENDATIO; *CENTR COMM TREATM, 1997, INV MED PRESCR HER R; DOBLERMIKOLA A, IN PRESS HEROIN METH; FLEMING PM, 1997, FEASIBILITY RES CONT, P1; HARTNOLL RL, 1980, ARCH GEN PSYCHIAT, V37, P877; *INT COMMD RUG ADD, 1965, DRUG ADD 2 REP; Metrebian N, 1998, MED J AUSTRALIA, V168, P596, DOI 10.5694/j.1326-5377.1998.tb141444.x; Minist. Health, 1926, ROLL REP DEP COMM MO; Perneger TV, 1998, BMJ-BRIT MED J, V317, P13, DOI 10.1136/bmj.317.7150.13; Sell L, 1997, DRUG ALCOHOL REV, V16, P221, DOI 10.1080/09595239800187401; SPEAR HB, 1994, HEROIN ADDICTION DRU, P3; Strang J, 1997, DRUG ALCOHOL REV, V16, P7, DOI 10.1080/09595239700186281; THORLEY A, 1981, DRUG PROBLEMS BRITAI, P117; Uchtenhagen A, 1997, EUR ADDICT RES, V3, P160, DOI 10.1159/000259173; UCHTENHAGEN A, IN PRESS PRESCRIPTIO; United Nations International Drug Control Programme, 1997, WORLD DRUG REP; Ward J., 1998, METHADONE MAINTENANC; 1977, SINGL CONV NARC DRUG, P19	21	57	57	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1277	1278		10.1126/science.284.5418.1277	http://dx.doi.org/10.1126/science.284.5418.1277			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	198NN	10383306				2022-12-24	WOS:000080430600024
J	Gleissberg, V				Gleissberg, V			The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?	LANCET			English	Article									Newham Healthcare NHS Trust, Shrrewsbury Ctr, London E7, England		Gleissberg, V (corresponding author), Newham Healthcare NHS Trust, Shrrewsbury Ctr, Shrewsbury Rd, London E7, England.	ginig@ibm.net						BENNETT DE, 1996, THORAX S3, V51, pSA32; Breathnach AS, 1998, J HOSP INFECT, V39, P111, DOI 10.1016/S0195-6701(98)90324-3; *DEP HLTH NT WORK, 1996, PREV CONTR TUB UK RE; FARMER F, 1998, BRIT MED J, V317, P671; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; HAYWARD A, 1998, TUBERCULOSIS CONTROL; KENT JH, 1993, MED CLIN N AM, V77, P1391, DOI 10.1016/S0025-7125(16)30200-0; SKINNER C, 1994, THORAX, V49, P1193, DOI 10.1136/thx.49.12.1193; Snider DE, 1998, NEW ENGL J MED, V338, P1689, DOI 10.1056/NEJM199806043382309; TURETT GS, 1995, CLIN INFECT DIS, V21, P1238, DOI 10.1093/clinids/21.5.1238; WHO, 1997, TREATM TUB GUID NAT, V2; *WHO, 1997, ANT DRUG RES WORLD W	12	14	16	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					998	999		10.1016/S0140-6736(99)01439-7	http://dx.doi.org/10.1016/S0140-6736(99)01439-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459924				2022-12-24	WOS:000079421600045
J	Salonen, JT; Malin, R; Tuomainen, TP; Nyyssonen, K; Lakka, TA; Lehtimaki, T				Salonen, JT; Malin, R; Tuomainen, TP; Nyyssonen, K; Lakka, TA; Lehtimaki, T			Polymorphism in high density lipoprotein paraoxonase gene and risk of acute myocardial infarction in men: prospective nested case-control study	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		Univ Kuopio, Res Inst Publ Hlth, Kuopio 70211, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, Kuopio 70211, Finland	University of Eastern Finland; University of Eastern Finland	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, POB 1627, Kuopio 70211, Finland.		Lehtimäki, Terho/AAD-1094-2022	Lehtimäki, Terho/0000-0002-2555-4427; Lakka, Timo/0000-0002-9199-2871	NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Garin MCB, 1997, J CLIN INVEST, V99, P62, DOI 10.1172/JCI119134; HUMBERT R, 1993, NAT GENET, V3, P73, DOI 10.1038/ng0193-73; SALONEN JT, 1991, CIRCULATION, V84, P129, DOI 10.1161/01.CIR.84.1.129; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; Sanghera DK, 1998, ATHEROSCLEROSIS, V136, P217, DOI 10.1016/S0021-9150(97)00206-2	5	58	59	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					487	488		10.1136/bmj.319.7208.487	http://dx.doi.org/10.1136/bmj.319.7208.487			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454401	Bronze, Green Published			2022-12-24	WOS:000082199600020
J	Yakshinskiy, BV; Madey, TE				Yakshinskiy, BV; Madey, TE			Photon-stimulated desorption as a substantial source of sodium in the lunar atmosphere	NATURE			English	Article							MERCURY; SURFACE; POTASSIUM; ATOMS; EXOSPHERE; DISCOVERY; ORIGIN; IONS; MOON	Mercury and the Moon both have tenuous atmospheres that contain atomic sodium and potassium. These chemicals must be continuously resupplied, as neither body can retain the atoms for more than a few hours (refs 1-6). The mechanisms proposed to explain the resupply include sputtering of the surface by the solar wind(3,4), micrometeorite impacts(5), thermal desorption(6-8) and photon-stimulated desorption(6-10). But there are few data and no general agreement about which processes. dominate(5,10-14). Here we report laboratory studies of photon-stimulated desorption of sodium from Surfaces that simulate lunar silicates. We find that bombardment of such surfaces at temperatures of similar to 250 K by ultraviolet photons (wavelength lambda < 300 nm) causes very efficient desorption of sodium atoms, induced by electronic excitations rather than by thermal processes or momentum transfer. The flux at the lunar surface of ultraviolet photons from the Sun is sufficient to ensure that photon-stimulated desorption of sodium contributes substantially to the Moon's atmosphere. On Mercury, solar heating of the surface implies that thermal desorption(7) will also be an important source of atmospheric sodium.	Rutgers State Univ, Dept Phys & Astron, Piscataway, NJ 08854 USA; Rutgers State Univ, Surface Modificat Lab, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick	Madey, TE (corresponding author), Rutgers State Univ, Dept Phys & Astron, POB 849, Piscataway, NJ 08854 USA.							AGEEV VN, 1995, NUCL INSTRUM METH B, V101, P69, DOI 10.1016/0168-583X(95)00286-3; Ageev VN, 1998, PHYS REV B, V58, P2248, DOI 10.1103/PhysRevB.58.2248; FLYNN B, 1995, J GEOPHYS RES-PLANET, V100, P23271, DOI 10.1029/95JE01747; HEATH DF, 1977, SOLAR OUTPUT ITS VAR, P193; Hellsing B, 1997, J CHEM PHYS, V106, P982, DOI 10.1063/1.473177; Hunten DM, 1997, ADV SPACE RES-SERIES, V19, P1551, DOI 10.1016/S0273-1177(97)00368-2; IP WH, 1986, GEOPHYS RES LETT, V13, P423, DOI 10.1029/GL013i005p00423; KIVELSON MG, 1995, INTRO SPACE PHYSICS, V92; KNOTEK ML, 1983, SPRINGER SER CHEM PH, V24, P139; KOZLOWSKI RWH, 1990, GEOPHYS RES LETT, V17, P2253, DOI 10.1029/GL017i012p02253; Madey TE, 1998, J GEOPHYS RES-PLANET, V103, P5873, DOI 10.1029/98JE00230; MASCHHOFF BL, 1991, SURF SCI, V259, P190, DOI 10.1016/0039-6028(91)90537-3; MCGRATH MA, 1986, NATURE, V323, P694, DOI 10.1038/323694a0; MENDILLO M, 1995, NATURE, V377, P404, DOI 10.1038/377404a0; Mendillo M, 1999, ICARUS, V137, P13, DOI 10.1006/icar.1998.6042; MENDILLO M, 1997, ADV SPACE RES, V19, P1557; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; POTTER A, 1985, SCIENCE, V229, P651, DOI 10.1126/science.229.4714.651; POTTER AE, 1988, SCIENCE, V241, P675, DOI 10.1126/science.241.4866.675; POTTER AE, 1987, ICARUS, V71, P472, DOI 10.1016/0019-1035(87)90041-8; Potter AE, 1998, J GEOPHYS RES-PLANET, V103, P8581, DOI 10.1029/98JE00059; POTTER AE, 1994, GEOPHYS RES LETT, V21, P2263, DOI 10.1029/94GL01702; Sprague AL, 1997, ICARUS, V129, P506, DOI 10.1006/icar.1997.5784; SPRAGUE AL, 1990, SCIENCE, V249, P1140, DOI 10.1126/science.249.4973.1140; SPRAGUE AL, 1992, ICARUS, V96, P7; Verani S, 1998, PLANET SPACE SCI, V46, P1003, DOI 10.1016/S0032-0633(98)00024-5; Wilde M, 1997, SURF SCI, V390, P186, DOI 10.1016/S0039-6028(97)00547-5; XU XP, 1993, SURF SCI, V282, P323, DOI 10.1016/0039-6028(93)90937-F; ZHOU XL, 1991, SURF SCI REP, V13, P73, DOI 10.1016/0167-5729(91)90009-M	29	138	138	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					642	644		10.1038/23204	http://dx.doi.org/10.1038/23204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458159				2022-12-24	WOS:000082032900045
J	Mehta, AD; Rock, RS; Rief, M; Spudich, JA; Mooseker, MS; Cheney, RE				Mehta, AD; Rock, RS; Rief, M; Spudich, JA; Mooseker, MS; Cheney, RE			Myosin-V is a processive actin-based motor	NATURE			English	Article							SINGLE KINESIN MOLECULES; MOVEMENT; FORCE; TRANSPORT; MECHANICS; STEPS; ATP	Class-V myosins, one of 15 known classes of actin-based molecular motors, have been implicated in several forms of organelle transport(1-5), perhaps working with microtubule-based motors such as kinesin(2-4,6). Such movements may require a motor with mechanochemical properties distinct from those of myosin-II, which operates in large ensembles to drive high-speed motility as in muscle contraction(7). Based on its function and biochemistry, it has been suggested that myosin-V may be a processive motor(7,8) like kinesing(9,10). Processivity means that the motor undergoes multiple catalytic cycles and coupled mechanical advances for each diffusional encounter with its track. This allows single motors to support movement of an organelle along its track Here we provide direct evidence that myosin-V is indeed a processive actin-based motor that can move in large steps approximating the 36-nm pseudo-repeat of the actin filament.	Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA	Stanford University; Yale University; University of North Carolina; University of North Carolina Chapel Hill	Mehta, AD (corresponding author), Stanford Univ, Med Ctr, Dept Biochem, Stanford, CA 94305 USA.			Cheney, Richard/0000-0001-6565-7888	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003299] Funding Source: NIH RePORTER; NIDCD NIH HHS [R29 DC003299] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bertrand E, 1998, MOL CELL, V2, P437, DOI 10.1016/S1097-2765(00)80143-4; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; Cheney RE, 1998, METHOD ENZYMOL, V298, P3, DOI 10.1016/S0076-6879(98)98003-X; CHENEY RE, 1993, CELL, V75, P13, DOI 10.1016/0092-8674(93)90675-G; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; Evans LL, 1998, J CELL SCI, V111, P2055; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Howard J, 1996, Proc Natl Acad Sci U S A, V93, P4462; Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Huang JD, 1999, NATURE, V397, P267, DOI 10.1038/16722; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Mehta AD, 1998, METHOD ENZYMOL, V298, P436, DOI 10.1016/S0076-6879(98)98039-9; Mehta AD, 1998, ADV STR BIO, V5, P229; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MEYHOFER E, 1995, P NATL ACAD SCI USA, V92, P574, DOI 10.1073/pnas.92.2.574; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; Nascimento AAC, 1996, J BIOL CHEM, V271, P17561, DOI 10.1074/jbc.271.29.17561; Reck-Peterson SL, 1999, MOL BIOL CELL, V10, P1001, DOI 10.1091/mbc.10.4.1001; Rogers SL, 1998, CURR BIOL, V8, P161, DOI 10.1016/S0960-9822(98)70063-6; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tabb JS, 1998, J CELL SCI, V111, P3221; Veigel C, 1999, NATURE, V398, P530, DOI 10.1038/19104; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; Wu XF, 1998, J CELL BIOL, V143, P1899, DOI 10.1083/jcb.143.7.1899	30	648	663	1	77	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					590	593		10.1038/23072	http://dx.doi.org/10.1038/23072			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448864				2022-12-24	WOS:000081854800062
J	Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V				Frank, MW; Bauer, HM; Arican, N; Fincanci, SK; Iacopino, V			Virginity examinations in turkey - Role of forensic physicians in controlling female sexuality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HYMEN; GIRLS	Context Although the Turkish Medical Association has deemed "virginity examinations" a form of gender-based violence, women in Turkey are often subjected to such examinations by forensic physicians for both legal and social reasons. Little is known about these physicians' role and attitudes in this practice. Objectives To assess forensic physicians' experiences and attitudes regarding virginity examinations in Turkey and suggest potential solutions to the problems identified, Design Cross-sectional self-administered survey. Setting Surveys were completed during the Forensic Science Congress held in Kusadasi in April 1998 as well as in urban academic and medical practice settings between April and October 1998. Participants Of 158 physicians who practice, are formally trained in, or are in training for forensic medicine, 118 completed the survey (response rate, 74.7%). Main Outcome Measures Frequency and circumstances of conducting virginity examinations, opinions regarding beneficial and adverse consequences of these examinations, and recommendations for changing the practice, as measured by a 100-item questionnaire. Results Overall, survey respondents reported conducting 5901 examinations in the previous 12 months; 4045 were conducted because of alleged sexual assault and 1856 for social reasons, Although 68% of forensic physicians indicated that they believed virginity examinations are inappropriate in the absence of an allegation of sexual assault, 45% had conducted examinations for social reasons. The majority of the respondents (93%) agreed that the examinations are psychologically traumatic for the patient. In addition, more than half (58%) reported that at least 50% of patients undergo examinations against their will. Conclusions Nearly half of forensic physicians in Turkey conduct virginity examinations for social reasons despite beliefs that such examinations are inappropriate, traumatic to the patient, and often performed against the patient's will. Physicians' participation in such practices is inconsistent with principles of bioethics and international human rights.	Phys Human Rights, Boston, MA 02116 USA; Columbia Univ, Ctr Populat & Family Hlth, Joseph L Mailman Sch Publ Hlth, Program Forced Migrat & Hlth, New York, NY 10027 USA; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Univ Istanbul, Dept Forens Med, Istanbul, Turkey	Columbia University; University of California System; University of California San Francisco; Istanbul University	Iacopino, V (corresponding author), Phys Human Rights, 100 Boylston St,Suite 702, Boston, MA 02116 USA.		Fincanci, Sebnem Korur/F-6684-2010; ARICAN, Nadir/G-2778-2012	Fincanci, Sebnem Korur/0000-0003-4484-4961; ARICAN, Nadir/0000-0002-9736-0277				BERENSON AB, 1992, PEDIATRICS, V89, P387; BERENSON AB, 1994, CURR OPIN OBSTET GYN, V6, P526; BUROSU E, 1992, CUMHURIYET      0509; Copelon Rhonda, 1998, WOMEN WAR READER, P63; Das V, 1996, DAEDALUS, V125, P67; FAHRI I, 1984, TOPLUMUMUZDA KADIN C, P152; Finkel MA, 1994, CHILD ABUSE MED DIAG, P185; GIARDINO AP, 1992, PRACTICAL GUIDE EVAL; GODDARD V, 1987, CULTURAL CONSTRUCTIO; Goodyear-Smith FA, 1998, FORENSIC SCI INT, V94, P147, DOI 10.1016/S0379-0738(98)00053-X; ISLAMI U, 1992, TURKIYE KAD N OLGUSU, P131; MATTHEWS CD, 1994, REPROD FERT DEVELOP, V6, P1; Onderoglu Selda, 1993, Okajimas Folia Anatomica Japonica, V70, P35; ORTNER SB, 1978, FEMINIST STUD, V4, P19; OZBAY F, 1992, TURKIYE KAD N OLGUSU, P151; OZUGURLU K, 1985, EVLILIK RAPORU ALTIN, P46; PETERSON VS, 1998, WOMEN WAR READER, P44; Reich, 1990, ORIGINS TERRORISM PS, P161; SCHEGEL A, 1991, AM ETHNOL, V18, P719; *SPSS INC, 1998, SPSS BAS 8 0 WIND; Staub E., 1990, PSYCHOL TORTURE, P49; XIAO Z, 1989, FEMINIST STUD, V15, P279; YUKSEL S, 1992, TURKIYE KAD N OLGUSU, P115; 1994, CUMHURIYET      0325; 1999, LOS ANGELES TIM 0106; [No title captured]	26	19	20	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					485	490		10.1001/jama.282.5.485	http://dx.doi.org/10.1001/jama.282.5.485			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222KP	10442667				2022-12-24	WOS:000081784900029
J	Garfield, R				Garfield, R			Malaria control in Nicaragua: social and political influences on disease transmission and control activities	LANCET			English	Article							HEALTH	Throughout Central America, a traditional malaria control strategy (depending on heavy use of organic pesticides) became less effective during the 1970s. In Nicaragua, an alternative strategy, based on frequent local epidemiological assessments and community participation, was developed in the 1980s. Despite war-related social instability, and continuing vector resistance, this approach was highly successful. By the end of the contra wart there finally existed organisational and ecological conditions that favoured improved malaria control. Yet the expected improvements did not occur. In the 1990s, Nicaragua experienced its worst recorded malaria epidemics. This situation was partly caused by the country's macroeconomic structural adjustment programme. Volunteers now take fewer slides and provide less treatment, malaria control workers are less motivated by the spirit of public service, and some malaria control stations charge for diagnosis or treatment. To "roll back malaria", In Nicaragua at least, will require the roll-back of some erroneous aspects of structural adjustment.	Columbia Univ, Sch Nursing, New York, NY 10032 USA	Columbia University	Garfield, R (corresponding author), Columbia Univ, Sch Nursing, Box 6,630 W 168th St, New York, NY 10032 USA.							BRUCECHWATT LJ, 1966, B WORLD HEALTH ORGAN, V35, P405; BRUCECHWATT LJ, 1983, LANCET, V2, P688; Curtis E, 1998, LANCET, V352, P1622, DOI 10.1016/S0140-6736(98)03248-6; GABALDON A, 1978, AM J TROP MED HYG, V24, P653; GARFIELD R, 1993, JAMA-J AM MED ASSOC, V270, P989, DOI 10.1001/jama.270.8.989; GARFIELD RM, 1983, LANCET, V2, P500; GARFIELD RM, 1987, AM J PUBLIC HEALTH, V77, P615, DOI 10.2105/AJPH.77.5.615; GARFIELD RM, 1984, AM J PUBLIC HEALTH, V74, P1138, DOI 10.2105/AJPH.74.10.1138; GARFIELD RM, 1986, SOC SCI MED, V8, P869; GEORGHIOU GP, 1972, AM J TROP MED HYG, V21, P797, DOI 10.4269/ajtmh.1972.21.797; Harrison G, 1978, MOSQUITOES MALARIA M; MACDONALD G, 1968, B WORLD HEALTH ORGAN, V38, P743; *MIN SAL, 1982, EV IMP MOV NAC ANT N; *PAN AM HLTH ORG, 1985, STAT MAL CONTR PROGR; WERNSDORFER WH, 1980, MALARIA, V1; WHO, 1973, WHO TECH REP SER, V529; *WHO, 1974, WHO TECH REP SER, V537	17	26	27	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					414	418		10.1016/S0140-6736(99)02226-6	http://dx.doi.org/10.1016/S0140-6736(99)02226-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222CB	10437886				2022-12-24	WOS:000081764900044
J	Zygmunt, PM; Petersson, J; Andersson, DA; Chuang, HH; Sorgard, M; Di Marzo, V; Julius, D; Hogestatt, ED				Zygmunt, PM; Petersson, J; Andersson, DA; Chuang, HH; Sorgard, M; Di Marzo, V; Julius, D; Hogestatt, ED			Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide	NATURE			English	Article							ENDOTHELIUM-DEPENDENT RELAXATION; ISOLATED MESENTERIC-ARTERY; GENE-RELATED PEPTIDE; RAT HEPATIC-ARTERY; CANNABINOID RECEPTOR; CAPSAICIN RECEPTOR; CB1; NEUROTRANSMITTER; ANTAGONIST; INHIBITION	The endogenous cannabinoid receptor agonist anandamide(1) is a powerful vasodilator of isolated vascular preparations(2-4), but its mechanism of action is unclear. Here we show that the vasodilator response to anandamide in isolated arteries is capsaicin-sensitive and accompanied by release of calcitonin-gene-related peptide (CGRP), The selective CGRP-receptor antagonist 8-37 CGRP (ref. 5), but not the cannabinoid CB1 receptor blocker SR141716A (ref. 7), inhibited the vasodilator effect of anandamide, Other endogenous (2-arachidonylglycerol, palmitylethanolamide) and synthetic (HU 210, WIN 55,212-2, CP 55,940) CB1 and CB2 receptor agonists' could not mimic the action of anandamide. The selective 'vanilloid receptor' antagonist capsazepine(6,7) inhibited anandamide-induced vasodilation and release of CGRP. In patch-clamp experiments on cells expressing the cloned vanilloid receptor (VR1)(8), anandamide induced a capsazepine-sensitive current in whale cells and isolated membrane patches. Our results indicate that anandamide induces vasodilation by activating: vanilloid receptors on perivascular sensory nerves and causing release of CGRP. The vanilloid receptor may thus be another molecular target for endogenous anandamide, besides cannabinoid receptors, in the nervous and cardiovascular systems.	Univ Lund, Inst Lab Med, Dept Clin Pharmacol, S-22185 Lund, Sweden; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; CNR, Ist Chim Mol Interesse Biol, I-80072 Arco Felice, Napoli, Italy	Lund University; University of California System; University of California San Francisco; Consiglio Nazionale delle Ricerche (CNR)	Hogestatt, ED (corresponding author), Univ Lund, Inst Lab Med, Dept Clin Pharmacol, S-22185 Lund, Sweden.		Andersson, David A/C-3435-2008; Petersson, Jesper/I-2546-2016; Di Marzo, Vincenzo/AAD-7742-2019	Andersson, David A/0000-0001-7451-8548; Di Marzo, Vincenzo/0000-0002-1490-3070; Zygmunt, Peter/0000-0002-5102-8199				BEVAN S, 1992, BRIT J PHARMACOL, V107, P544, DOI 10.1111/j.1476-5381.1992.tb12781.x; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Chyb S, 1999, NATURE, V397, P255, DOI 10.1038/16703; Deutsch DG, 1997, J CLIN INVEST, V100, P1538, DOI 10.1172/JCI119677; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 1998, FEBS LETT, V436, P449, DOI 10.1016/S0014-5793(98)01175-2; diMarzo V, 1996, BIOCHEM J, V316, P977, DOI 10.1042/bj3160977; EDVINSSON L, 1987, J CEREBR BLOOD F MET, V7, P720, DOI 10.1038/jcbfm.1987.126; Geppert M, 1998, J BIOL CHEM, V273, P1705, DOI 10.1074/jbc.273.3.1705; HAN SP, 1990, BIOCHEM BIOPH RES CO, V168, P786, DOI 10.1016/0006-291X(90)92390-L; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Ishac EJN, 1996, BRIT J PHARMACOL, V118, P2023, DOI 10.1111/j.1476-5381.1996.tb15639.x; KAWASAKI H, 1988, NATURE, V335, P164, DOI 10.1038/335164a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; Petersson J, 1998, J VASC RES, V35, P285, DOI 10.1159/000025595; Plane F, 1997, BRIT J PHARMACOL, V121, P1509, DOI 10.1038/sj.bjp.0701361; Pratt PF, 1998, AM J PHYSIOL-HEART C, V274, pH375, DOI 10.1152/ajpheart.1998.274.1.H375; Sugiura T, 1998, BIOCHEM BIOPH RES CO, V243, P838, DOI 10.1006/bbrc.1998.8187; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Varga K, 1998, FASEB J, V12, P1035, DOI 10.1096/fasebj.12.11.1035; Varga K, 1996, HYPERTENSION, V28, P682, DOI 10.1161/01.HYP.28.4.682; Wagner JA, 1997, NATURE, V390, P518, DOI 10.1038/37371; Wagner JA, 1999, HYPERTENSION, V33, P429, DOI 10.1161/01.HYP.33.1.429; White R, 1998, BRIT J PHARMACOL, V125, P533, DOI 10.1038/sj.bjp.0702111; White R, 1998, BRIT J PHARMACOL, V125, P689, DOI 10.1038/sj.bjp.0702127; ZYGMENT PM, 1996, BRIT J PHARMACOL, V118, P1149; ZYGMUNT PM, 1994, ACTA PHYSIOL SCAND, V152, P107, DOI 10.1111/j.1748-1716.1994.tb09789.x; Zygmunt PM, 1997, BRIT J PHARMACOL, V122, P1679, DOI 10.1038/sj.bjp.0701601	30	1729	1796	4	92	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					452	457		10.1038/22761	http://dx.doi.org/10.1038/22761			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440374				2022-12-24	WOS:000081715000051
J	Melville, M; Brown, N; Gray, D; Young, T; Hampton, J				Melville, M; Brown, N; Gray, D; Young, T; Hampton, J			Outcome and use of health services four years after admission for acute myocardial infarction: case record follow up study	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England; Univ Nottingham, Dept Math, British Heart Fdn, Cardiovasc Stat Unit, Nottingham NG7 2RH, England	University of Nottingham; University of Nottingham	Melville, M (corresponding author), Univ Nottingham Hosp, Dept Cardiovasc Med, Nottingham NG7 2UH, England.		Young, Tracey A/A-4543-2010	Young, Tracey/0000-0001-8467-0471				*BRIT CARD SOC, 1998, STRAT PLANN CARD SER; DEBONO DP, 1994, J ROY COLL PHYS LOND, V28, P312; GRAY D, 1993, LANCET, V341, P654, DOI 10.1016/0140-6736(93)90420-L; GREENWOOD D, 1995, SOC SCI MED, V40, P639, DOI 10.1016/0277-9536(94)00147-L; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706	5	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					230	231		10.1136/bmj.319.7204.230	http://dx.doi.org/10.1136/bmj.319.7204.230			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	221HB	10417086	Bronze, Green Published			2022-12-24	WOS:000081720300025
J	Sanson, B; Alexandre, C; Fascetti, N; Vincent, JP				Sanson, B; Alexandre, C; Fascetti, N; Vincent, JP			Engrailed and hedgehog make the range of wingless asymmetric in Drosophila embryos	CELL			English	Article							MORPHOGEN GRADIENT; GENE-EXPRESSION; CELL FATE; EPIDERMIS; PROTEIN; ARMADILLO; EMBRYOGENESIS; BOUNDARIES; SECRETION; INDUCTION	In many instances, remote signaling involves the transport of secreted molecules. Here, we examine the spread of Wingless within the embryonic epidermis of Drosophila. Using two assays for Wingless activity (specification of naked cuticle and repression of rhomboid transcription), we found that Wingless acts at a different range in the anterior and posterior directions. We show that this asymmetry follows in part from differential distribution of the Wingless protein. Transport or stability is reduced within engrailed-expressing cells, and farther posteriorward Wingless movement is blocked at the presumptive segment boundary and perhaps beyond. We demonstrate the role of hedgehog in the formation of this barrier.	Natl Inst Med Res, London NW7 1AA, England; Univ Cambridge, Dept Genet, Cambridge CB2 3EH, England; MRC, LMB, Cambridge CB2 2QH, England	MRC National Institute for Medical Research; University of Cambridge; MRC Laboratory Molecular Biology	Vincent, JP (corresponding author), Natl Inst Med Res, Mill Hill, London NW7 1AA, England.	jp.vincent@nimr.mrc.ac.uk		Sanson, Benedicte/0000-0002-2782-4195				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BIER E, 1990, GENE DEV, V4, P190, DOI 10.1101/gad.4.2.190; BRAND AH, 1993, DEVELOPMENT, V118, P401; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; Dierick HA, 1998, DEVELOPMENT, V125, P4729; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; FIETZ MJ, 1995, CURR BIOL, V5, P643, DOI 10.1016/S0960-9822(95)00129-1; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; Hepker J, 1997, DEVELOPMENT, V124, P549; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; Jowett T., 1997, TISSUE IN SITU HYBRI; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Martinez Arias Alfonso, 1993, P517; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Orsulic S, 1996, J CELL BIOL, V134, P1283, DOI 10.1083/jcb.134.5.1283; PAYRE F, 1999, IN PRESS NATURE; PFEIFFER S, 1999, IN PRESS SEMIN DEV B; Pignoni F, 1997, DEVELOPMENT, V124, P271; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Szuts D, 1997, DEVELOPMENT, V124, P3209; VINCENT JP, 1994, CELL, V77, P909, DOI 10.1016/0092-8674(94)90139-2; WIESCHAUS E, 1987, CELL, V49, P177, DOI 10.1016/0092-8674(87)90558-7; WILDER EL, 1995, DEVELOPMENT, V121, P477; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	39	67	70	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					207	216		10.1016/S0092-8674(00)81015-6	http://dx.doi.org/10.1016/S0092-8674(00)81015-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428032	Bronze			2022-12-24	WOS:000081632300010
J	Dawson, DW; Volpert, OV; Gillis, P; Crawford, SE; Xu, HJ; Benedict, W; Bouck, NP				Dawson, DW; Volpert, OV; Gillis, P; Crawford, SE; Xu, HJ; Benedict, W; Bouck, NP			Pigment epithelium-derived factor: A potent inhibitor of angiogenesis	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC ACTIVITY; DIABETIC-RETINOPATHY; FACTOR VEGF; NEOVASCULARIZATION; EXPRESSION; OXYGEN; GENE; BETA; IDENTIFICATION	In the absence of disease, the vasculature of the mammalian eye is quiescent, in part because of the action of angiogenic inhibitors that prevent vessels from invading the cornea and vitreous. Here, an inhibitor responsible for the avascularity of these ocular compartments is identified as pigment epithelium-derived factor (PEDF), a protein previously shown to have neurotrophic activity. The amount of inhibitory PEDF produced by retinal cells was positively correlated with oxygen concentrations, suggesting that its loss plays a permissive role in ischemia-driven retinal neovascularization. These results suggest that PEDF may be of therapeutic use, especially in retinopathies where pathological neovascularization compromises vision and leads to blindness.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Northwestern University; Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Bouck, NP (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	n-bouck@nwu.edu	Dawson, David/I-5917-2014	Volpert, Olga/0000-0003-1381-5543				ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010; AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Becerra SP, 1997, ADV EXP MED BIOL, V425, P223; BECERRA SP, 1993, J BIOL CHEM, V268, P23148; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; CONNOLLY SE, 1988, MICROVASC RES, V36, P275, DOI 10.1016/0026-2862(88)90028-3; DAWSON D, UNPUB; DIPAOLO BR, 1995, EXP CELL RES, V220, P178, DOI 10.1006/excr.1995.1304; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J., 1995, MOL BASIS CANC, P206; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; Gulledge CJ, 1996, ANTICANCER RES, V16, P741; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hayasaka K, 1998, LIFE SCI, V63, P1089, DOI 10.1016/S0024-3205(98)00205-7; HENKIND P, 1978, AM J OPHTHALMOL, V85, P287, DOI 10.1016/S0002-9394(14)77719-0; KAMINSKA GM, 1993, INVEST OPHTH VIS SCI, V34, P222; KLINTWORTH GK, 1991, CORNEAL ANGIOGENESIS; Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Pierce EA, 1996, ARCH OPHTHALMOL-CHIC, V114, P1219, DOI 10.1001/archopht.1996.01100140419009; PIGNOLO RJ, 1993, J BIOL CHEM, V268, P8949; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; PREIS I, 1977, AM J OPHTHALMOL, V84, P323; Provis JM, 1997, EXP EYE RES, V65, P555, DOI 10.1006/exer.1997.0365; SCHACHAT A, 1994, RETINA; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526; Sugita Y, 1997, J NEUROSCI RES, V49, P710, DOI 10.1002/(SICI)1097-4547(19970915)49:6<710::AID-JNR5>3.0.CO;2-A; TANAWAKI T, 1995, J NEUROCHEM, V64, P2509; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D; Vinores SA, 1998, J NEUROIMMUNOL, V89, P43, DOI 10.1016/S0165-5728(98)00075-7; Wu YQ, 1996, INVEST OPHTH VIS SCI, V37, P1984; XU HJ, 1991, CANCER RES, V51, P4481	36	1260	1384	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					245	248		10.1126/science.285.5425.245	http://dx.doi.org/10.1126/science.285.5425.245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398599				2022-12-24	WOS:000081346000039
J	Carazo-Salas, RE; Guarguaglini, G; Gruss, OJ; Segref, A; Karsenti, E; Mattaj, IW				Carazo-Salas, RE; Guarguaglini, G; Gruss, OJ; Segref, A; Karsenti, E; Mattaj, IW			Generation of GTP-bound Ran by RCC1 is required for chromatin-induced mitotic spindle formation	NATURE			English	Article							XENOPUS EGG EXTRACTS; MICROTUBULE-ASSOCIATED PROTEIN; SELF-ORGANIZATION; RESPECTIVE ROLES; IMPORT; CENTROSOMES; TRANSPORT; RANGAP1; NUCLEUS; MUTANTS	Chromosomes are segregated by two antiparallel arrays of microtubules arranged to form the spindle apparatus. During cell division, the nucleation of cytosolic microtubules is prevented and spindle microtubules nucleate from centrosomes (in mitotic animal cells) or around chromosomes (in plants and some meiotic cells)(1,2). The molecular mechanism by which chromosomes induce local microtubule nucleation in the absence of centrosomes is unknown(3-5), but it can be studied by adding chromatin beads to Xenopus egg extracts(6). The beads nucleate microtubules that eventually reorganize into a bipolar spindle. RCC1, the guanine-nucleotide-exchange factor for the GTPase protein Ran, is a component of chromatin. Using the chromatin bead assay, we show here that the activity of chromosome-associated RCC1 protein is required for spindle formation. Ran itself, when in the GTP-bound state (Ran-GTP), induces microtubule nucleation and spindle-like structures in M-phase extract. We propose that RCC1 generates a high local concentration of Ran-GTP around chromatin which in turn induces the local nucleation of microtubules.	European Mol Biol Lab, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Mattaj, IW (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Segref, Alexandra/C-8325-2011	Carazo-Salas, Rafael E/0000-0002-5943-3981; Segref, Alexandra/0000-0001-8095-4469; Mattaj, Iain/0000-0002-5537-8284				Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; CLARKE PR, 1995, J CELL SCI, V108, P1217; DASSO M, 1994, EMBO J, V13, P5732, DOI 10.1002/j.1460-2075.1994.tb06911.x; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DOMINGUEZ JE, 1994, J CELL SCI, V107, P601; Gorlich D, 1998, EMBO J, V17, P2721, DOI 10.1093/emboj/17.10.2721; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Heald R, 1997, J CELL BIOL, V138, P615, DOI 10.1083/jcb.138.3.615; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hoyt MA, 1996, ANNU REV GENET, V30, P7, DOI 10.1146/annurev.genet.30.1.7; Hyman A, 1998, J CELL SCI, V111, P2077; Izaurralde E, 1997, EMBO J, V16, P6535, DOI 10.1093/emboj/16.21.6535; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; Koepp DM, 1996, CELL, V87, P1, DOI 10.1016/S0092-8674(00)81315-X; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LEPAULT J, 1986, METHOD ENZYMOL, V127, P719; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MURRAY AW, 1991, XENOPUS LAEVIS PRACT, P581; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nicolas FJ, 1997, J CELL SCI, V110, P3019; Palacios I, 1996, J CELL BIOL, V133, P485, DOI 10.1083/jcb.133.3.485; Pu RT, 1997, MOL BIOL CELL, V8, P1955, DOI 10.1091/mbc.8.10.1955; Saitoh H, 1997, P NATL ACAD SCI USA, V94, P3736, DOI 10.1073/pnas.94.8.3736; Ullrich O, 1996, J CELL BIOL, V135, P913, DOI 10.1083/jcb.135.4.913; Walczak CE, 1998, CURR BIOL, V8, P903, DOI 10.1016/S0960-9822(07)00370-3; Weis K, 1996, EMBO J, V15, P7120, DOI 10.1002/j.1460-2075.1996.tb01103.x; Wittmann T, 1998, J CELL BIOL, V143, P673, DOI 10.1083/jcb.143.3.673	30	386	392	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					178	181		10.1038/22133	http://dx.doi.org/10.1038/22133			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408446				2022-12-24	WOS:000081324900057
J	Tomitani, A; Okada, K; Miyashita, H; Matthijs, HCP; Ohno, T; Tanaka, A				Tomitani, A; Okada, K; Miyashita, H; Matthijs, HCP; Ohno, T; Tanaka, A			Chlorophyll b and phycobilins in the common ancestor of cyanobacteria and chloroplasts	NATURE			English	Article							MULTIPLE EVOLUTIONARY ORIGINS; A/B; PROCHLOROPHYTES; PROTEINS; PLANTS; ANTENNA; ALGA	Photosynthetic organisms have a variety of accessory pigments, on which their classification has been based. Despite this variation, it is generally accepted that all chloroplasts are derived from a single cyanobacterial ancestor(1-3). How the pigment diversity has arisen is the key to revealing their evolutionary history. Prochlorophytes are prokaryotes which perform oxygenic photosynthesis using chlorophyll b, like land plants and green algae (Chlorophyta), and were proposed to be the ancestors of chlorophyte chloroplasts(4,5). However, three known prochlorophytes (Prochloron didemni, Prochlorothrix hollandica and Prochlorococcus marinus) have been shown to be not the specific ancestors of chloroplasts, but only diverged members of the cyanobacteria, which contain phycobilins but lack chlorophyll b(6,7). Consequently it has been proposed that the ability to synthesize chlorophyll b developed independently several times in prochlorophytes and in the ancestor of chlorophytes. Here we have isolated the chlorophyll b synthesis genes (chlorophyll a oxygenase)(8) from two prochlorophytes and from major groups of chlorophytes. Phylogenetic analyses show that these genes share a common evolutionary origin. This indicates that the progenitors of oxygenic photosynthetic bacteria, including the ancestor of chloroplasts, had both chlorophyll b and phycobilins.	Kyoto Univ, Grad Sch Sci, Dept Geol & Mineral, Kyoto 6068502, Japan; Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan; Kamaishi Labs, Marine Biotechnol Inst, Kamaishi, Iwate 0260001, Japan; Univ Amsterdam, Dept Microbiol, NL-1018 WS Amsterdam, Netherlands; Kyoto Univ, Kyoto Univ Museum, Kyoto 6068502, Japan	Kyoto University; Hokkaido University; Kyoto University; University of Amsterdam; Kyoto University	Tomitani, A (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Geol & Mineral, Kyoto 6068502, Japan.	tomitani@terra.kueps.kyoto-u.ac.jp	Matthijs, Hans/B-4503-2009; Tanaka, Ayumi/D-9003-2012					Adachi J., 1996, COMPUTER SCI MONOGRA, V28; Ausubel F.M., 1987, CURRENT PROTOCOLS MO; Bhattacharya D, 1998, PLANT PHYSIOL, V116, P9, DOI 10.1104/pp.116.1.9; BHATTACHARYYA A, 1995, PHYS ESSAYS, V8, P3, DOI 10.4006/1.3036517; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; DELWICHE CF, 1997, ORIGINS ALGAE THEIR, P53; DOLGANOV NAM, 1995, P NATL ACAD SCI USA, V92, P636, DOI 10.1073/pnas.92.2.636; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Gray J, 1997, CELL, V89, P25, DOI 10.1016/S0092-8674(00)80179-8; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; Hess WR, 1996, P NATL ACAD SCI USA, V93, P11126, DOI 10.1073/pnas.93.20.11126; Kaneko T, 1996, DNA Res, V3, P109; KISHINO H, 1990, J MOL EVOL, V31, P151, DOI 10.1007/BF02109483; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; LEWIN RA, 1975, NATURE, V256, P735, DOI 10.1038/256735a0; LEWIN RA, 1976, NATURE, V261, P697, DOI 10.1038/261697b0; MORDEN CW, 1989, NATURE, V337, P382, DOI 10.1038/337382a0; PALENIK B, 1992, NATURE, V355, P265, DOI 10.1038/355265a0; Rudiger W, 1999, NATO ASI 3 HIGH TECH, V64, P185; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Tan S, 1997, PLANT MOL BIOL, V33, P157, DOI 10.1023/A:1005715528297; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; URBACH E, 1992, NATURE, V355, P267, DOI 10.1038/355267a0; WOLFE GR, 1994, NATURE, V367, P566, DOI 10.1038/367566a0	25	154	172	3	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					159	162		10.1038/22101	http://dx.doi.org/10.1038/22101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408441				2022-12-24	WOS:000081324900052
J	Haan, MN; Shemanski, L; Jagust, WJ; Manolio, TA; Kuller, L				Haan, MN; Shemanski, L; Jagust, WJ; Manolio, TA; Kuller, L			The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E EPSILON-4; DEPENDENT DIABETIC-PATIENTS; ALZHEIMERS-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR HEALTH; E GENOTYPE; POPULATION; DEMENTIA; OLDER; ASSOCIATION	Context Cognitive decline in elderly persons is often an early predictor of dementia. Subclinical cardiovascular disease (CVD) and diabetes mellitus may contribute to substantial decline in cognitive function in the elderly. These risks may be modified by gene-environment interactions between apolipoprotein E (APOE) genotype and CVD risk factors or subclinical CVD. Objectives To examine the association between subclinical CVD and decline in cognitive functioning in the elderly and to examine effect modification by the APOE genotype of the association between subclinical disease and cognitive decline. Design The Cardiovascular Health Study, a population-based, prospective cohort study. Setting and Population A total of 5888 randomly selected Medicare-eligible participants from Sacramento County, California; Forsyth County, North Carolina; Washington County, Maryland; and Pittsburgh, Pa, aged 65 years or older, who were recruited in 1989-1990 (n = 5201) and in 1992-1993 (n = 687) and who were followed up for 7 and 5 years, respectively. Main Outcome Measures Change over time in scores on the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test as a function of APOE genotype, subclinical CVD, and diabetes mellitus. Results Seventy percent of participants had no significant decline on the Modified Mini-Mental State Examination. Systolic blood pressure, the ankle-arm brachial index, atherosclerosis of the internal carotid artery, diabetes mellitus, and several diagnoses of prevalent CVD were significantly associated with declines in scores on the Modified Mini-Mental State Examination and the Digit Symbol Substitution Test. The rate of cognitive decline associated with peripheral vascular disease, atherosclerosis of the common and internal carotid arteries, or diabetes mellitus was increased by the presence of any APOE epsilon 4 allele. Conclusions Most healthy elderly people did not experience cognitive decline. Measures of subclinical CVD were modest predictors of cognitive decline. Those with any APOE epsilon 4 allele in combination with atherosclerosis, peripheral vascular disease, or diabetes mellitus were at substantially higher risk of cognitive decline than those without the APOE epsilon 4 allele or subclinical CVD. High levels of atherosclerosis increased cognitive decline independently of APOE genotype.	Univ Calif Davis, Sch Med, Dept Epidemiol & Prevent Med, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Neurol, Davis, CA 95616 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; NHLBI, Dept Epidemiol, Bethesda, MD 20892 USA; NHLBI, Dept Biometry, Bethesda, MD 20892 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	University of California System; University of California Davis; University of California System; University of California Davis; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Haan, MN (corresponding author), Univ Calif Davis, Sch Med, Dept Epidemiol & Prevent Med, 1 Shields Ave, Davis, CA 95616 USA.	mnhaan@ucdavis.edu	Jagust, William/ABE-6426-2020; Haan, Mary N/Y-9354-2018	Haan, Mary N/0000-0001-9312-4501	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060753] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R03AG033751] Funding Source: NIH RePORTER; NIA NIH HHS [R03 AG033751] Funding Source: Medline; NIDDK NIH HHS [R01 DK060753] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allen JB, 1996, NEUROPSYCHOLOGIA, V34, P459, DOI 10.1016/0028-3932(95)00115-8; APPLEGATE WB, 1994, ARCH INTERN MED, V154, P2154, DOI 10.1001/archinte.154.19.2154; BERES CA, 1981, J GERONTOL, V36, P591, DOI 10.1093/geronj/36.5.591; Berr C, 1996, NEUROSCI LETT, V218, P9, DOI 10.1016/S0304-3940(96)13059-7; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; BRETELER MMB, 1994, NEUROLOGY, V44, P1246, DOI 10.1212/WNL.44.7.1246; Cattin L, 1997, ARTERIOSCL THROM VAS, V17, P91, DOI 10.1161/01.ATV.17.1.91; Chandra V, 1998, NEUROEPIDEMIOLOGY, V17, P225, DOI 10.1159/000026175; Crawford JG, 1998, MED HYPOTHESES, V50, P25, DOI 10.1016/S0306-9877(98)90173-6; Curb JD, 1999, NEUROLOGY, V52, P971, DOI 10.1212/WNL.52.5.971; Dey J, 1997, DIABETES CARE, V20, P32, DOI 10.2337/diacare.20.1.32; Evans DA, 1997, JAMA-J AM MED ASSOC, V277, P822, DOI 10.1001/jama.277.10.822; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; Finch CE, 1997, EXP NEUROL, V143, P82, DOI 10.1006/exnr.1996.6339; Fujishima M, 1995, Hypertens Res, V18, P111, DOI 10.1291/hypres.18.111; FURBERG CD, 1992, AM J CARDIOL, V69, P1329, DOI 10.1016/0002-9149(92)91231-R; Glynn RJ, 1999, JAMA-J AM MED ASSOC, V281, P438, DOI 10.1001/jama.281.5.438; Guo ZC, 1997, AM J PUBLIC HEALTH, V87, P623, DOI 10.2105/AJPH.87.4.623; Heckbert SR, 1997, J AM GERIATR SOC, V45, P1423, DOI 10.1111/j.1532-5415.1997.tb03191.x; Helkala EL, 1996, NEUROSCI LETT, V204, P177, DOI 10.1016/0304-3940(96)12348-X; Hyman BT, 1996, ANN NEUROL, V40, P55, DOI 10.1002/ana.410400111; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; KALMIJN S, 1995, DIABETOLOGIA, V38, P1096, DOI 10.1007/BF00402181; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; KURITA A, 1995, ACTA NEUROL SCAND, V92, P319; Kurita A, 1996, DIABETES CARE, V19, P361, DOI 10.2337/diacare.19.4.361; KUUSISTO J, 1993, HYPERTENSION, V22, P771, DOI 10.1161/01.HYP.22.5.771; Kuusisto J, 1997, BRIT MED J, V315, P1045, DOI 10.1136/bmj.315.7115.1045; LAUNER LJ, 1995, JAMA-J AM MED ASSOC, V274, P1846, DOI 10.1001/jama.274.23.1846; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Messier C, 1996, BEHAV BRAIN RES, V75, P1, DOI 10.1016/0166-4328(95)00153-0; MOORADIAN AD, 1988, ARCH INTERN MED, V148, P2369, DOI 10.1001/archinte.148.11.2369; MORTEL KF, 1994, ANGIOLOGY, V45, P171, DOI 10.1177/000331979404500301; Myers RH, 1996, NEUROLOGY, V46, P673, DOI 10.1212/WNL.46.3.673; Naor M, 1997, J DIABETES COMPLICAT, V11, P40, DOI 10.1016/1056-8727(95)00106-9; O'Hara R, 1998, J AM GERIATR SOC, V46, P1493, DOI 10.1111/j.1532-5415.1998.tb01532.x; OLEARY DH, 1992, STROKE, V23, P1752, DOI 10.1161/01.STR.23.12.1752; Ott A, 1996, DIABETOLOGIA, V39, P1392, DOI 10.1007/s001250050588; PEREZMUNOZ M, 1995, ACTAS LUSO ESPANOLES, V24, P332; Perlmuter L C, 1988, J Diabet Complications, V2, P210, DOI 10.1016/S0891-6632(88)80011-4; Phillips NA, 1997, STROKE, V28, P777, DOI 10.1161/01.STR.28.4.777; Price T R, 1993, Ann Epidemiol, V3, P504; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; REAVEN GM, 1990, DIABETES CARE, V13, P16, DOI 10.2337/diacare.13.1.16; ROSES AD, 1977, INT PSYCHOLOGERIA S1, V9, P277; RYAN CM, 1993, J CLIN EXP NEUROPSYC, V15, P685, DOI 10.1080/01688639308402589; *SAS I INC, 1999, SAS STAT COMP PROGR; Skoog I, 1998, J NEUROL NEUROSUR PS, V64, P37, DOI 10.1136/jnnp.64.1.37; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Slooter AJC, 1998, ARCH NEUROL-CHICAGO, V55, P964, DOI 10.1001/archneur.55.7.964; Small BJ, 1998, PSYCHOL AGING, V13, P80, DOI 10.1037/0882-7974.13.1.80; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tun P A, 1990, Clin Geriatr Med, V6, P731; UREN RC, 1990, J AM GERIATR SOC, V38, P505, DOI 10.1111/j.1532-5415.1990.tb02398.x; WORRALL G, 1993, J FAM PRACTICE, V36, P639; Worrall GJ, 1996, J DIABETES COMPLICAT, V10, P320, DOI 10.1016/1056-8727(94)00078-6	59	364	370	1	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					40	46		10.1001/jama.282.1.40	http://dx.doi.org/10.1001/jama.282.1.40			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212BE	10404910				2022-12-24	WOS:000081195800027
J	Heaney, LG; McAllister, D; MacMahon, J				Heaney, LG; McAllister, D; MacMahon, J			Cost minimisation analysis of provision of oxygen at home: Are the Drug Tariff guidelines cost effective?	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To determine the level of oxygen cylinder use at which it becomes more cost effective to provide oxygen by concentrator at home in Northern Ireland, and to examine potential cost savings if cylinder use above this level had been replaced by concentrator in 1996. Design Cost minimisation analysis. Setting Area health boards in Northern Ireland. Main outcome measures Cost effective cut off point for switch to provision of oxygen from cylinder to concentrator. Potential maximum and minimum savings in Northern Ireland (sensitivity analysis) owing to switch to more cost effective strategy on the basis of provision of cylinders in 1996. Results In Northern Ireland it is currently cost effective to provide oxygen by concentrator when the patient is using three or more cylinders per month independent of the duration of the prescription. More widespread use of concentrators at this level of provision is likely to lead to a cost saving. Conclusions The Drug Tariff prescribing guidelines, advocating that provision of oxygen by concentrator becomes cheaper when 21 cylinders are being used per month-are currently inaccurate in Northern Ireland, Regional health authorities should review their current arrangements for provision of oxygen at home and perform a cost analysis to determine at what level it becomes more cost effective to provide oxygen by concentrator.	Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland; Univ Ulster, Sch Publ Policy & Law, Jordanstown, North Ireland	Belfast City Hospital; Ulster University	Heaney, LG (corresponding author), Belfast City Hosp, Dept Resp Med, Belfast BT9 7AB, Antrim, North Ireland.	LiamHeaney@ukgateway.net						[Anonymous], 1980, ANN INTERN MED, V93, P391; *DEP HLTH, 1996, DRUG TAR 10; Drummond MF, 2015, METHODS EC EVALUATIO; FLENLEY DC, 1981, LANCET, V1, P681; Rees P. J., 1998, BMJ, V317, P935	5	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					19	23		10.1136/bmj.319.7201.19	http://dx.doi.org/10.1136/bmj.319.7201.19			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390453	Bronze, Green Published			2022-12-24	WOS:000081326500024
J	Cacciola, I; Pollicino, T; Squadrito, G; Cerenzia, G; Orlando, ME; Raimondo, G				Cacciola, I; Pollicino, T; Squadrito, G; Cerenzia, G; Orlando, ME; Raimondo, G			Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SURFACE-ANTIGEN; HEPATOCELLULAR-CARCINOMA; POSITIVE PATIENTS; CHRONIC CARRIERS; DNA; REACTIVATION; REPLICATION; HBSAG; GENE; TRANSPLANTATION	Background Hepatitis B virus (HBV) infections in patients who lack detectable hepatitis B surface antigen (HBsAg) are called occult infections. Although such infections have been identified in patients with chronic hepatitis C liver disease, their prevalence and clinical significance are not known. Methods With the polymerase chain reaction, we searched for HBV DNA in liver and serum samples from 200 HBsAg-negative patients with hepatitis C virus (HCV)-related liver disease (147 with chronic hepatitis, 48 with cirrhosis, and 5 with minimal histologic changes). One hundred of the patients had detectable antibodies to the HBV core antigen (anti-HBc); 100 were negative for all HBV markers. Eighty-three were treated with interferon alfa. We also studied 50 patients with liver disease who were negative both for HBsAg and for HCV markers. In six patients found to have occult HBV infection, we evaluated possible genomic rearrangements through cloning or direct sequencing procedures. Results Sixty-six of the 200 patients with chronic hepatitis C liver disease (33 percent) had HBV sequences, as did 7 of the 50 patients with liver disease unrelated to hepatitis C (14 percent, P = 0.01). Among the 66 patients, 46 were anti-HBc-positive and 20 were negative for all HBV markers (P<0.001). Twenty-two of these 66 patients (33 percent) had cirrhosis, as compared with 26 of the 134 patients with hepatitis C infection but no HBV sequences (19 percent, P = 0.04). HBV sequences were detected in 26 of the 55 patients in whom interferon therapy was ineffective and 7 of the 28 patients in whom interferon therapy was effective (P = 0.06). None of the sequenced HBV genomes had changes known to interfere with viral activity and gene expression. Conclusions Occult hepatitis B infection occurs frequently in patients with chronic hepatitis C liver disease and may have clinical significance. (N Engl J Med 1999;341:22-6.) (C)1999, Massachusetts Medical Society.	Univ Messina, Policlin Univ, Dipartimento Med Interna, I-98100 Messina, Italy	AOU Policlinico Gaetano Martino; University of Messina	Raimondo, G (corresponding author), Univ Messina, Policlin Univ, Dipartimento Med Interna, I-98100 Messina, Italy.		Cacciola, Irene/K-1174-2019; Pollicino, Teresa/HDN-3708-2022; Pollicino, Teresa/K-5790-2016	Cacciola, Irene/0000-0001-7721-6799; Pollicino, Teresa/0000-0001-6602-3035				ALBERTI A, 1995, J HEPATOL, V22, P38; Armitage P., 2001, STAT METHODS MED RES; BLUM HE, 1991, J VIROL, V65, P1836, DOI 10.1128/JVI.65.4.1836-1842.1991; BRECHOT C, 1981, P NATL ACAD SCI-BIOL, V78, P3906, DOI 10.1073/pnas.78.6.3906; Brunetto MR, 1998, LANCET, V351, P1535; Carman WF, 1997, HEPATOLOGY, V26, P1658, DOI 10.1002/hep.510260640; CHAZOUILLERES O, 1994, LANCET, V343, P142, DOI 10.1016/S0140-6736(94)90934-2; CRESPO J, 1994, AM J GASTROENTEROL, V89, P1147; FATTOVICH G, 1991, J INFECT DIS, V163, P400, DOI 10.1093/infdis/163.2.400; FERAY C, 1992, J CLIN INVEST, V89, P1361, DOI 10.1172/JCI115723; GROTZINGER T, 1992, VIROLOGY, V187, P383, DOI 10.1016/0042-6822(92)90332-J; GRUMAYER ER, 1989, J HEPATOL, V8, P232, DOI 10.1016/0168-8278(89)90012-3; HOOFNAGLE JH, 1982, ANN INTERN MED, V96, P447, DOI 10.7326/0003-4819-96-4-447; Huo TI, 1998, HEPATOLOGY, V28, P231, DOI 10.1002/hep.510280130; Koike K, 1998, J MED VIROL, V54, P249, DOI 10.1002/(SICI)1096-9071(199804)54:4&lt;249::AID-JMV3&gt;3.0.CO;2-4; KORBA BE, 1989, HEPATOLOGY, V9, P461, DOI 10.1002/hep.1840090321; LIANG TJ, 1991, HEPATOLOGY, V13, P1044, DOI 10.1002/hep.1840130607; LIANG TJ, 1990, HEPATOLOGY, V12, P204, DOI 10.1002/hep.1840120205; LOK ASF, 1991, GASTROENTEROLOGY, V100, P182, DOI 10.1016/0016-5085(91)90599-G; MARCELLIN P, 1991, GASTROENTEROLOGY, V100, P1432; MARION PL, 1991, MOL BIOL HEPATITIS B, P39; MICHALAK TI, 1994, J CLIN INVEST, V93, P230, DOI 10.1172/JCI116950; MICHALAK TI, 1994, J CLIN INVEST, V94, pA905; PATERLINI P, 1995, HEPATOLOGY, V21, P313, DOI 10.1002/hep.1840210208; PATERLINI P, 1993, HEPATOLOGY, V17, P20, DOI 10.1016/0270-9139(93)90186-Q; PATERLINI P, 1990, NEW ENGL J MED, V323, P80, DOI 10.1056/NEJM199007123230202; Penna A, 1996, J CLIN INVEST, V98, P1185, DOI 10.1172/JCI118902; Pollicino T, 1997, HEPATOLOGY, V26, P495, DOI 10.1002/hep.510260235; Pollicino T, 1996, J GEN VIROL, V77, P1833, DOI 10.1099/0022-1317-77-8-1833; POLLICINO T, 1995, VIROLOGY, V208, P672, DOI 10.1006/viro.1995.1198; SATO S, 1994, J HEPATOL, V21, P159, DOI 10.1016/S0168-8278(05)80389-7; Schepis F, 1997, J HEPATOL, V26, P765, DOI 10.1016/S0168-8278(97)80240-1; SHAFRITZ DA, 1981, NEW ENGL J MED, V305, P1067, DOI 10.1056/NEJM198110293051807; SHEEN IS, 1992, J INFECT DIS, V165, P831, DOI 10.1093/infdis/165.5.831; SHEU JC, 1992, GASTROENTEROLOGY, V103, P1322, DOI 10.1016/0016-5085(92)91523-7; SHIH CM, 1993, J VIROL, V67, P5823, DOI 10.1128/JVI.67.10.5823-5832.1993; Siegel S., 1998, NONPARAMETRIC STAT B; THIERS V, 1988, LANCET, V2, P1273; VILLA E, 1993, LANCET, V341, P1413, DOI 10.1016/0140-6736(93)90980-U; VILLARI D, 1989, J CLIN PATHOL, V42, P689, DOI 10.1136/jcp.42.7.689; WAITE J, 1988, AIDS, V2, P443, DOI 10.1097/00002030-198812000-00006; YAMAMOTO K, 1994, J VIROL, V68, P2671, DOI 10.1128/JVI.68.4.2671-2676.1994; Yotsuyanagi H, 1998, HEPATOLOGY, V27, P1377, DOI 10.1002/hep.510270526; Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0; ZHANG YY, 1993, HEPATOLOGY, V17, P538, DOI 10.1002/hep.1840170403; Zignego AL, 1997, J MED VIROL, V51, P313, DOI 10.1002/(SICI)1096-9071(199704)51:4&lt;313::AID-JMV9&gt;3.0.CO;2-8	46	517	544	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					22	26		10.1056/NEJM199907013410104	http://dx.doi.org/10.1056/NEJM199907013410104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387938				2022-12-24	WOS:000081195600004
J	Gilon, D; Buonanno, FS; Joffe, MM; Leavitt, M; Marshall, JE; Kistler, JP; Levine, RA				Gilon, D; Buonanno, FS; Joffe, MM; Leavitt, M; Marshall, JE; Kistler, JP; Levine, RA			Lack of evidence of an association between mitral-valve prolapse and stroke in young patients	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBRAL ISCHEMIC EVENTS; LEAFLET PROLAPSE; EMBOLIC STROKE; RISK-FACTORS; PREVALENCE; DIAGNOSIS; CLASSIFICATION; REGURGITATION; POPULATION	Background Previous studies have reported a high prevalence of mitral-valve prolapse among patients with embolic stroke (28 to 40 percent), especially among young patients (those less than or equal to 45 years old); this finding has practical implications for prophylaxis. However, diagnostic criteria for prolapse have changed and are now based on three-dimensional analysis of the shape of the valve; use of the current criteria reduces markedly the frequency of such a diagnosis and increases its specificity. Previously described complications must therefore be reconsidered. Methods In a case-control study, we reviewed data on 213 consecutive patients 45 years of age or younger with documented ischemic stroke or transient ischemic attack between 1985 and 1995; they underwent complete neurologic and echocardiographic evaluations. The prevalence of prolapse in these patients was compared with that in 263 control subjects without known heart disease, who were referred to our institution for assessment of ventricular function before receiving chemotherapy. Results Mitral-valve prolapse was present in 4 of the 213 young patients with stroke (1.9 percent), as compared with 7 of the 263 controls (2.7 percent); prolapse was present in 2 of 71 patients (2.8 percent) with otherwise unexplained stroke. The crude odds ratio for mitral-valve prolapse among the patients who had strokes, as compared with those who did not have strokes, was 0.70 (95 percent confidence interval, 0.15 to 2.80; P = 0.80); after adjustment for age and sex, the odds ratio was 0.59 (95 percent confidence interval, 0.12 to 2.50; P = 0.62). Conclusions Mitral-valve prolapse is considerably less common than previously reported among young patients with stroke or transient ischemic attack, including unexplained stroke, and no more common than among controls. Using more specific and currently accepted echocardiographic criteria, therefore, we could not demonstrate an association between the presence of mitral-valve prolapse and acute ischemic neurologic events in young people. (N Engl J Med 1999;341:8-13.) (C)1999, Massachusetts Medical Society.	Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Neurol, Stroke Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Levine, RA (corresponding author), Massachusetts Gen Hosp, Cardiac Ultrasound Lab, VBK-508,32 Fruit St, Boston, MA 02114 USA.				NHLBI NIH HHS [HL53702, HL38176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053702, R29HL038176, R01HL038176] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARLETTA G A, 1984, Journal of Cardiovascular Ultrasonography, V3, P147; BARNETT HJM, 1980, NEW ENGL J MED, V302, P139, DOI 10.1056/NEJM198001173020303; BOUGHNER DR, 1985, STROKE, V16, P175, DOI 10.1161/01.STR.16.2.175; BRAUNWALD E, 1992, HEART DIS TXB CARDIO, V2, P1029; BUSCH EH, 1986, CHEST, V90, P454, DOI 10.1378/chest.90.3.454; DEBONO DP, 1981, LANCET, V1, P343; DEVEREUX RB, 1987, AM HEART J, V113, P1265, DOI 10.1016/0002-8703(87)90955-0; EGEBLAD H, 1984, ACTA MED SCAND, V216, P385; EGEBLAD H, 1987, AM HEART J, V114, P648, DOI 10.1016/0002-8703(87)90765-4; Freed LA, 1999, NEW ENGL J MED, V341, P1, DOI 10.1056/NEJM199907013410101; Gross C M, 1989, J Am Soc Echocardiogr, V2, P94; HECK AF, 1989, ANGIOLOGY, V40, P743, DOI 10.1177/000331978904000810; JONES HR, 1982, STROKE, V13, P451, DOI 10.1161/01.STR.13.4.451; KELLEY RE, 1988, STROKE, V19, P443, DOI 10.1161/01.STR.19.4.443; KISTLER JP, 1994, NEW ENGL J MED, V331, P1517, DOI 10.1056/NEJM199412013312211; KISTLER JP, 1994, HARRISONS PRINCIPLES, P2233; KOUVARAS G, 1985, Q J MED, V56, P387; KRIWISKY M, 1987, AM J CARDIOL, V59, P1149, DOI 10.1016/0002-9149(87)90864-2; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; MARKIEWICZ W, 1978, AM HEART J, V96, P555, DOI 10.1016/0002-8703(78)90172-2; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; NIDORF SM, 1993, J AM SOC ECHOCARDIOG, V6, pS8; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P1305, DOI 10.1056/NEJM198511213132101; PERLOFF JK, 1982, NEW ENGL J MED, V307, P369, DOI 10.1056/NEJM198208053070609; PERLOFF JK, 1989, CIRCULATION, V80, P710, DOI 10.1161/01.CIR.80.3.710; PETTY GW, 1994, MAYO CLIN PROC, V69, P632, DOI 10.1016/S0025-6196(12)61338-X; RANGANATHAN N, 1973, CIRCULATION, V48, P514, DOI 10.1161/01.CIR.48.3.514; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; ROTHROCK J, 1993, NEUROLOGY, V43, P2473, DOI 10.1212/WNL.43.12.2473; SAHN DJ, 1977, AM J CARDIOL, V39, P422, DOI 10.1016/S0002-9149(77)80100-8; SANDOK BA, 1982, STROKE, V13, P448, DOI 10.1161/01.STR.13.4.448; SCHARF RE, 1982, STROKE, V13, P454, DOI 10.1161/01.STR.13.4.454; THARAKAN J, 1982, ACTA NEUROL SCAND, V66, P295; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WILSON LA, 1977, BRIT MED J, V2, P86, DOI 10.1136/bmj.2.6079.86; WOLF PA, 1983, STROKE, V14, P1010, DOI 10.1161/01.STR.14.6.1010; WOOLEY CF, 1988, MITRAL VALVE PROLAPS, P149	40	96	99	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					8	13		10.1056/NEJM199907013410102	http://dx.doi.org/10.1056/NEJM199907013410102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387936				2022-12-24	WOS:000081195600002
J	Heeb, P; Werner, I; Mateman, AC; Kolliker, M; Brinkhof, MWG; Lessells, CM; Richner, H				Heeb, P; Werner, I; Mateman, AC; Kolliker, M; Brinkhof, MWG; Lessells, CM; Richner, H			Ectoparasite infestation and sex-biased local recruitment of hosts	NATURE			English	Article							GREAT-TITS; NATAL DISPERSAL; PARUS-MAJOR; BIRDS; PHILOPATRY; COMPETITION; ADAPTATION; EVOLUTION; SURVIVAL; SYSTEMS	Dispersal patterns of organisms are a fundamental aspect of their ecology, modifying the genetic and social structure of local populations(1-4). Parasites reduce the reproductive success and survival of hosts and thereby exert selection pressure on host life-history traits(4-6), possibly affecting host dispersal(7-9). Here we test experimentally whether infestation by hen fleas, Ceratophyllus gallinae, affects sex-related recruitment of great tit, Parus major, fledglings. Using sex-specific DNA markers, we show that flea infestation led to a higher proportion of male fledglings recruiting in the local population in one year. In infested broods, the proportion of male recruits increased with brood size over a three year period, whereas the proportion of male recruits from uninfested broods decreased with brood size. Natal dispersal distances of recruits from infested nests were shorter than those from uninfested nests(10). To our knowledge, this study provides the first evidence for parasite-mediated host natal dispersal and local recruitment in relation to sex. Current theory needs to consider parasites as potentially important factors shaping life-history traits associated with host dispersal.	Univ Bern, Dept Zool, Ctr Behav & Evolut, CH-3032 Hinterkappelen, Switzerland; Netherlands Inst Ecol, NL-6666 ZG Heteren, Netherlands	University of Bern; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW)	Heeb, P (corresponding author), Univ Bern, Dept Zool, Ctr Behav & Evolut, CH-3032 Hinterkappelen, Switzerland.	philipp.heeb@esh.unibe.ch	Mateman, Christa/C-9380-2012; Richner, Heinz/B-1659-2008; Lessells, C.M./B-3891-2011	Mateman, Christa/0000-0002-9832-5780; Richner, Heinz/0000-0001-7390-0526; van der Heijden, Marianne/0000-0002-0795-3619; Brinkhof, Martin/0000-0002-9319-665X				Belthoff JR, 1998, ANIM BEHAV, V55, P405, DOI 10.1006/anbe.1997.0625; Brown CR, 1995, P ROY SOC B-BIOL SCI, V262, P313, DOI 10.1098/rspb.1995.0211; BROWN CR, 1992, ECOLOGY, V73, P1718, DOI 10.2307/1940023; Christe P, 1996, BEHAV ECOL, V7, P127, DOI 10.1093/beheco/7.2.127; Clarke AL, 1997, OIKOS, V79, P429, DOI 10.2307/3546885; Clayton DH., 1997, HOST PARASITE EVOLUT; Crawley M.J., 1993, GLIM ECOLOGISTS; Danchin E, 1998, ECOLOGY, V79, P2415, DOI 10.2307/176832; DHONDT AA, 1968, BIRD STUDY, V15, P127, DOI 10.1080/00063656809476192; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; GEBHARDTHENRICH SG, 1991, J EVOLUTION BIOL, V4, P341, DOI 10.1046/j.1420-9101.1991.4030341.x; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; HAMILTON WD, 1977, NATURE, V269, P578, DOI 10.1038/269578a0; HAMILTON WD, 1967, SCIENCE, V156, P477, DOI 10.1126/science.156.3774.477; Heeb P, 1998, P ROY SOC B-BIOL SCI, V265, P51, DOI 10.1098/rspb.1998.0263; Heeb P, 1996, J ANIM ECOL, V65, P474, DOI 10.2307/5782; HEEB P, IN PRESS ECOLOGY; HERRE EA, 1993, SCIENCE, V259, P1442, DOI 10.1126/science.259.5100.1442; JOHNSON ML, 1990, ANNU REV ECOL SYST, V21, P449, DOI 10.1146/annurev.ecolsys.21.1.449; KACELNIK A, 1995, P ROY SOC B-BIOL SCI, V259, P259, DOI 10.1098/rspb.1995.0038; Kaltz O, 1998, HEREDITY, V81, P361, DOI 10.1046/j.1365-2540.1998.00435.x; Lessells CM, 1998, MOL ECOL, V7, P187, DOI 10.1046/j.1365-294x.1998.00331.x; Poulin R, 1996, AM NAT, V147, P287, DOI 10.1086/285851; RICHNER H, 1993, J ANIM ECOL, V62, P703, DOI 10.2307/5390; Richner H, 1998, ZOOL-ANAL COMPLEX SY, V101, P333; SMITH HG, 1989, J ANIM ECOL, V58, P383, DOI 10.2307/4837; SORCI G, 1994, AM NAT, V144, P153, DOI 10.1086/285666; TINBERGEN JM, 1990, J ANIM ECOL, V59, P1113, DOI 10.2307/5035; Verhulst S, 1997, ECOLOGY, V78, P864, DOI 10.1890/0012-9658(1997)078[0864:NDOGTI]2.0.CO;2; WEATHERHEAD PJ, 1994, BEHAV ECOL, V5, P426, DOI 10.1093/beheco/5.4.426	30	65	65	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1999	400	6739					63	65		10.1038/21881	http://dx.doi.org/10.1038/21881			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403248				2022-12-24	WOS:000081255700050
J	Mankoo, BS; Collins, NS; Ashby, P; Grigorieva, E; Pevny, LH; Candia, A; Wright, CVE; Rigby, PWJ; Pachnis, V				Mankoo, BS; Collins, NS; Ashby, P; Grigorieva, E; Pevny, LH; Candia, A; Wright, CVE; Rigby, PWJ; Pachnis, V			Mox2 is a component of the genetic hierarchy controlling limb muscle development	NATURE			English	Article							SKELETAL MYOGENESIS; PAX-3 EXPRESSION; MET RECEPTOR; MOUSE; CELLS; MIGRATION; MYOD; MUSCULATURE; EMBRYOS; DEFINE	The skeletal muscles of the limbs develop from myogenic progenitors that originate in the paraxial mesoderm and migrate into the limb-bud mesenchyme(1). Among the genes known to be important for muscle development in mammalian embryos are those encoding the basic helix-loop-helix (bHLH) myogenic regulatory factors (MRFs; MyoD, Myf5, myogenin and MRF4)(2-4) and Pax3, a paired-type homeobox gene that is critical for the development of limb musculature(5-7). Mox1 and Mox2 are closely related homeobox genes that are expressed in overlapping patterns in the paraxial mesoderm and its derivatives(8,9), Here we show that mice homozygous for a null mutation of Mox2 have a developmental defect of the limb musculature, characterized by an overall reduction in muscle mass and elimination of specific muscles. Mox2 is not needed for the migration of myogenic precursors into the limb bud, but it is essential for normal appendicular muscle formation and for the normal regulation of myogenic genes, as demonstrated by the downregulation of Pax3 and Myf5 but not MyoD in Mox2-deficient limb buds. Our findings show that the MOX2 homeoprotein is an important regulator of vertebrate limb myogenesis.	Natl Inst Med Res, MRC, Div Dev Neurobiol, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Eukaryot Mol Genet, London NW7 1AA, England; Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Vanderbilt Univ Sch Med, Nashville, TN 37232 USA	MRC National Institute for Medical Research; MRC National Institute for Medical Research; MRC National Institute for Medical Research; Vanderbilt University	Pachnis, V (corresponding author), Natl Inst Med Res, MRC, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.	v-pachni@nimr.mrc.ac.uk		Pachnis, Vassilis/0000-0001-9733-7686				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOBER E, 1994, DEVELOPMENT, V120, P603; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; Candia AF, 1996, INT J DEV BIOL, V40, P1179; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; Daston G, 1996, DEVELOPMENT, V122, P1017; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; GOULDING M, 1994, DEVELOPMENT, V120, P957; GRIM M, 1991, ANAT EMBRYOL, V183, P67; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; Jacob HJ, 1980, TERATOLOGY LIMBS, P89; JAGLA K, 1995, MECH DEVELOP, V53, P345, DOI 10.1016/0925-4773(95)00450-5; Kardon G, 1998, DEVELOPMENT, V125, P4019; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; RUDNICKI MA, 1995, BIOESSAYS, V17, P203, DOI 10.1002/bies.950170306; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Wachtler F, 1986, Bibl Anat, P24; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; Yamamoto M, 1998, DEVELOPMENT, V125, P1325; YEE SP, 1993, GENE DEV, V7, P1277, DOI 10.1101/gad.7.7a.1277	26	144	147	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1999	400	6739					69	73		10.1038/21892	http://dx.doi.org/10.1038/21892			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403250				2022-12-24	WOS:000081255700052
J	Pierani, A; Brenner-Morton, S; Chiang, C; Jessell, TM				Pierani, A; Brenner-Morton, S; Chiang, C; Jessell, TM			A sonic hedgehog-independent, retinoid-activated pathway of neurogenesis in the ventral spinal cord	CELL			English	Article							FLOOR PLATE DIFFERENTIATION; MOTOR-NEURON INDUCTION; EXPRESSION PATTERN; PARAXIAL MESODERM; HOMEOBOX GENES; CELL FATE; PAX GENES; MOUSE; SPECIFICATION; IDENTITY	Sonic hedgehog (Shh) is thought to control the generation of motor neurons and interneurons in the ventral CNS. We show here that a Shh-independent pathway of interneuron generation also operates in the ventral spinal cord. Evidence for this parallel pathway emerged from an analysis of the induction of ventral progenitors that express the Dbx homeodomain proteins and of Evx1/2 (V0) and En1 (V1) neurons. Shh signaling is sufficient to induce Dbx cells and V0 and V1 neurons but is not required for their generation in vitro or in vivo. Retinoids appear to mediate this parallel pathway. These findings reveal an unanticipated Shh-independent signaling pathway that controls progenitor cell identity and interneuron diversity in the ventral spinal cord.	Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA; Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA	Columbia University; Howard Hughes Medical Institute; Vanderbilt University	Jessell, TM (corresponding author), Columbia Univ, Dept Biochem & Mol Biophys, Howard Hughes Med Inst, New York, NY 10032 USA.		Pierani, Alessandra/O-6136-2017	Pierani, Alessandra/0000-0002-4872-4791				Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Burrill JD, 1997, DEVELOPMENT, V124, P4493; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ericson J, 1997, COLD SPRING HARB SYM, V62, P451; Gould A, 1998, NEURON, V21, P39, DOI 10.1016/S0896-6273(00)80513-9; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GrapinBotton A, 1997, DEVELOPMENT, V124, P849; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOGAN BLM, 1992, NATURE, V359, P237, DOI 10.1038/359237a0; Itasaki N, 1996, NEURON, V16, P487, DOI 10.1016/S0896-6273(00)80069-0; JOSTES B, 1990, MECH DEVELOP, V33, P27, DOI 10.1016/0925-4773(90)90132-6; LEBER SM, 1995, J NEUROSCI, V15, P1236; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; LU S, 1992, P NATL ACAD SCI USA, V89, P8053, DOI 10.1073/pnas.89.17.8053; LU SW, 1994, MECH DEVELOP, V47, P187, DOI 10.1016/0925-4773(94)90089-2; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; Lumsden A, 1995, CURR BIOL, V5, P1347, DOI 10.1016/S0960-9822(95)00266-1; Maden M, 1998, DEVELOPMENT, V125, P4133; Mansouri A, 1998, MECH DEVELOP, V78, P171, DOI 10.1016/S0925-4773(98)00168-3; Mansouri A, 1996, CURR OPIN CELL BIOL, V8, P851, DOI 10.1016/S0955-0674(96)80087-1; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1997, J NEUROSCI, V17, P7805; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pituello F, 1999, DEVELOPMENT, V126, P587; Pourquie O, 1996, CELL, V84, P461, DOI 10.1016/S0092-8674(00)81291-X; RANGINI Z, 1991, MECH DEVELOP, V35, P13, DOI 10.1016/0925-4773(91)90037-7; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; Shoji H, 1996, MECH DEVELOP, V56, P25, DOI 10.1016/0925-4773(96)00509-6; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; Tremblay P, 1996, DEVELOPMENT, V122, P2555; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; WAGNER M, 1992, DEVELOPMENT, V116, P55; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	50	274	277	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					903	915		10.1016/S0092-8674(00)80802-8	http://dx.doi.org/10.1016/S0092-8674(00)80802-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399918	hybrid			2022-12-24	WOS:000081162800011
J	Thompson, JN				Thompson, JN			The evolution of species interactions	SCIENCE			English	Editorial Material							COEVOLUTION; HOSTS; MODEL	Interactions between species are as evolutionarily malleable as the species themselves and have played a central role in the diversification and organization of life. This malleability creates complex geographic mosaics in interspecific interactions that can evolve rapidly over decades, blurring the distinction between evolutionary time and ecological time and making the study of coevolution crucial for human health and welfare.	Washington State Univ, Dept Bot, Pullman, WA 99164 USA; Washington State Univ, Dept Zool, Pullman, WA 99164 USA	Washington State University; Washington State University	Thompson, JN (corresponding author), Washington State Univ, Dept Bot, Pullman, WA 99164 USA.		Thompson, Jessica/GXW-0323-2022					BENKMAN CW, IN PRESS AM NAT; Berenbaum MR, 1998, P NATL ACAD SCI USA, V95, P13743, DOI 10.1073/pnas.95.23.13743; Brown JM, 1997, MOL ECOL, V6, P215, DOI 10.1046/j.1365-294X.1997.t01-1-00171.x; BURDON JJ, IN PRESS AM NAT; DAVIES NB, 1989, J ANIM ECOL, V58, P225, DOI 10.2307/4996; DWYER G, 1990, ECOL MONOGR, V60, P423, DOI 10.2307/1943014; Gandon S, 1996, P ROY SOC B-BIOL SCI, V263, P1003, DOI 10.1098/rspb.1996.0148; Hochberg ME, 1998, AM NAT, V152, P620, DOI 10.1086/286194; JANZEN DH, 1984, CRAWFORD LECT R SWED, V3, P1; Kearns CA, 1998, ANNU REV ECOL SYST, V29, P83, DOI 10.1146/annurev.ecolsys.29.1.83; LIVELY CM, IN PRESS AM NAT; Margulis L., 1991, SYMBIOSISOURCE EVO; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; Nuismer SL, 1999, P ROY SOC B-BIOL SCI, V266, P605, DOI 10.1098/rspb.1999.0679; PARKER MA, IN PRESS AM NAT; Pellmyr O, 1996, AM NAT, V148, P827, DOI 10.1086/285958; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; Smith J. M., 1995, MAJOR TRANSITIONS EV; SOLTIS DE, 1992, SYST BOT, V17, P607, DOI 10.2307/2419730; Thompson J. N., 1994, COEVOLUTIONARY PROCE, DOI 10.7208/chicago/9780226797670.001.0001; Thompson J. O. F., UNPUB; Thompson JN, 1998, TRENDS ECOL EVOL, V13, P329, DOI 10.1016/S0169-5347(98)01378-0	22	272	287	3	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2116	2118		10.1126/science.284.5423.2116	http://dx.doi.org/10.1126/science.284.5423.2116			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381869				2022-12-24	WOS:000081099300038
J	Goodwin, AW				Goodwin, AW			Sensorimotor coordination in cerebral palsy	LANCET			English	Editorial Material							CHILDREN		Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3054, Australia	University of Melbourne	Goodwin, AW (corresponding author), Univ Melbourne, Dept Anat & Cell Biol, Parkville, Vic 3054, Australia.							ELIASSON AC, 1991, DEV MED CHILD NEUROL, V33, P661; Gordon A.M., 1997, NEUROPHYSIOLOGY NEUR, P214; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P176, DOI 10.1017/S0012162299000365; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P166, DOI 10.1017/S0012162299000353; Johansson RS, 1996, NATO ADV SCI I D-BEH, V85, P205; NEILSON PD, 1990, DEV MED CHILD NEUROL, V32, P778; WESTLING G, 1984, EXP BRAIN RES, V53, P277; YEKUTIEL M, 1994, DEV MED CHILD NEUROL, V36, P619	8	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2090	2091		10.1016/S0140-6736(99)00136-1	http://dx.doi.org/10.1016/S0140-6736(99)00136-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382689				2022-12-24	WOS:000080969300005
J	Stephens, DS				Stephens, DS			Uncloaking the meningococcus: dynamics of carriage and disease	LANCET			English	Editorial Material							NEISSERIA-MENINGITIDIS; POPULATION; SPREAD		Emory Univ, Sch Med, Dept Med & Microbiol & Immunol, Atlanta, GA 30303 USA; Vet Affairs Med Ctr, Res Serv, Atlanta, GA 30033 USA	Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System	Stephens, DS (corresponding author), Emory Univ, Sch Med, Dept Med & Microbiol & Immunol, Atlanta, GA 30303 USA.		Stephens, David S/A-8788-2012					ACHTMAN M, 1994, MOL MICROBIOL, V11, P15, DOI 10.1111/j.1365-2958.1994.tb00285.x; Andersen J, 1998, EPIDEMIOL INFECT, V121, P85, DOI 10.1017/S0950268898008930; [Anonymous], 1805, J MED CHIR PHARM; CARTWRIGHT KAV, 1987, EPIDEMIOL INFECT, V99, P591, DOI 10.1017/S0950268800066449; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; CAUGANT DA, 1988, INFECT IMMUN, V56, P2060, DOI 10.1128/IAI.56.8.2060-2068.1988; GOLDSCHNEIDER I, 1969, J EXP MED, V129, P1327, DOI 10.1084/jem.129.6.1327; Jones GR, 1998, J INFECT DIS, V178, P451, DOI 10.1086/515622; Maiden MCJ, 1998, P NATL ACAD SCI USA, V95, P3140, DOI 10.1073/pnas.95.6.3140; NORTH E, 1980, REV INFECT DIS, V2, P811; Raymond NJ, 1997, J INFECT DIS, V176, P1277, DOI 10.1086/514123; Swartley JS, 1997, P NATL ACAD SCI USA, V94, P271, DOI 10.1073/pnas.94.1.271; Vogel U, 1998, J CLIN MICROBIOL, V36, P2465, DOI 10.1128/JCM.36.9.2465-2470.1998	14	132	139	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					941	942		10.1016/S0140-6736(98)00279-7	http://dx.doi.org/10.1016/S0140-6736(98)00279-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459897				2022-12-24	WOS:000079421600003
J	Haucke, V; De Camilli, P				Haucke, V; De Camilli, P			AP-2 recruitment to synaptotagmin stimulated by tyrosine-based endocytic motifs	SCIENCE			English	Article							COATED VESICLE FORMATION; SORTING SIGNALS; SYNAPTIC VESICLES; RECEPTOR; MEMBRANE; PROTEINS; BINDING; DOMAIN; COMPLEXES; LIPOSOMES	Clathrin-mediated endocytosis is initiated by the recruitment of the clathrin adaptor protein AP-2 to the plasma membrane where the membrane protein synaptotagmin is thought to act as a docking site. AP-2 also interacts with endocytic motifs present in other cargo proteins. Peptides with a tyrosine-based endocytic motif stimulated binding of AP-2 to synaptotagmin and enhanced AP-2 recruitment to the plasma membrane of neuronal and non-neuronal cells. This suggests a mechanism by which nucleation of clathrin-coated pits is stimulated by the loading of cargo proteins.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA	Yale University; Howard Hughes Medical Institute; Yale University	De Camilli, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 295 Congress Ave, New Haven, CT 06510 USA.			Haucke, Volker/0000-0003-3119-6993	NCI NIH HHS [CA46128] Funding Source: Medline; NINDS NIH HHS [NS36252] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R41NS036252, R42NS036252] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Chapman ER, 1998, J BIOL CHEM, V273, P32966, DOI 10.1074/jbc.273.49.32966; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Gaidarov I, 1996, J BIOL CHEM, V271, P20922, DOI 10.1074/jbc.271.34.20922; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; IACOPETTA BJ, 1988, CELL, V54, P485, DOI 10.1016/0092-8674(88)90069-4; JACOBSON BS, 1977, SCIENCE, V195, P302, DOI 10.1126/science.831278; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Kibbey RG, 1998, J CELL BIOL, V142, P59, DOI 10.1083/jcb.142.1.59; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; MAHAFFEY DT, 1990, J BIOL CHEM, V265, P1651; Matsuoka K, 1998, CELL, V93, P263, DOI 10.1016/S0092-8674(00)81577-9; MILLER K, 1991, CELL, V65, P621, DOI 10.1016/0092-8674(91)90094-F; Nesterov A, 1999, EMBO J, V18, P2489, DOI 10.1093/emboj/18.9.2489; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rapoport I, 1997, EMBO J, V16, P2240, DOI 10.1093/emboj/16.9.2240; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Springer S, 1998, SCIENCE, V281, P698, DOI 10.1126/science.281.5377.698; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; West MA, 1997, J CELL BIOL, V138, P1239, DOI 10.1083/jcb.138.6.1239; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	26	145	149	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1268	1271		10.1126/science.285.5431.1268	http://dx.doi.org/10.1126/science.285.5431.1268			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455054				2022-12-24	WOS:000082130200044
J	Burkle, FM				Burkle, FM			Fortnightly review - Lessons learnt and future expectations of complex emergencies	BRITISH MEDICAL JOURNAL			English	Review							PUBLIC-HEALTH; WAR		Univ Hawaii, John A Burns Sch Med, Ctr Excellence Disaster Med & Humanitarian Assist, WHO,Collaborating Ctr, Honolulu, HI 96826 USA	University of Hawaii System; World Health Organization	Burkle, FM (corresponding author), Univ Hawaii, John A Burns Sch Med, Ctr Excellence Disaster Med & Humanitarian Assist, WHO,Collaborating Ctr, Honolulu, HI 96826 USA.		Burkle, Frederick/AAE-5423-2020					[Anonymous], 1997, REFUGEE HLTH APPROAC; BLECHMAN BM, 1994, TRAINING PEACEKEEPIN, P1; Borton J, 1996, DISASTERS, V20, P305, DOI 10.1111/j.1467-7717.1996.tb01046.x; BRADSHAW AL, 1998, INT ENV SECURITY REG; BURKHOLDER BT, 1995, LANCET, V346, P1012, DOI 10.1016/S0140-6736(95)91694-6; Burkle F M Jr, 1995, Prehosp Disaster Med, V10, P48; BURKLE FM, 1999, HUMANITARIAN CRISES, P293; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; *DIV EM HUM ACT, 1999, APPL HLTH RES EM SET; Garshnek V, 1998, SPACE POLICY, V14, P223, DOI 10.1016/S0265-9646(98)00023-X; *INT FED RED CROSS, 1997, WORLD DIS REP 1997; KANE H, 1995, WORLDWATCH       JUN, P18; MINEAR L, 1991, HUMANITARIANISM WAR; *NAT DEF COUNC FDN, 1998, NAT DEF COUNC FDN WO; Palmer CA, 1998, DISASTERS, V22, P236, DOI 10.1111/1467-7717.00089; Perrin P., 1996, HDB WAR PUBLIC HLTH; *PUBL BROADC SYST, 1997, ALL THINGS CONS CULT; *REPR HLTH REF CON, 1998, REF REPR HLTH CAR NE; *SPHER PROJ, 1998, HUM CHART MIN STAND, pCH6; THAROOR S, 1998, WASHINGTON POST 0216, P34; TOOLE MJ, 1993, LANCET, V341, P1193, DOI 10.1016/0140-6736(93)91013-C; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; *UN HIGH COMM REF, 1999, STAT WORLDS REF HUM; ZWI A, 1991, HEALTH POLICY PLANN, V6, P203, DOI 10.1093/heapol/6.3.203; 1998, ECONOMIST       0502, P21	25	48	49	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					422	426		10.1136/bmj.319.7207.422	http://dx.doi.org/10.1136/bmj.319.7207.422			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	227UT	10445925	Green Published			2022-12-24	WOS:000082098900020
J	Sakakibara, H; Kojima, H; Sakai, Y; Katayama, E; Oiwa, K				Sakakibara, H; Kojima, H; Sakai, Y; Katayama, E; Oiwa, K			Inner-arm dynein c of Chlamydomonas flagella is a single-headed processive motor	NATURE			English	Article							KINESIN MOLECULES; MICROTUBULES; PROTEINS; PURIFICATION; MICROSCOPY; MOVEMENT; MUTANTS; TUBULIN; DOMAIN; ASSAY	Axonemal dyneins are force-generating ATPases that produce movement of eukaryotic cilia and flagella(1,2). Several studies indicate that inner-arm dyneins mainly produce bending moments in flagella(3,4) and that these motors have inherent oscillations in force and motility(5-8). Processive motors such as kinesins have high duty ratios of attached to total ATPase cycle (attached plus detached) times(9) compared to sliding motors such as myosin(10). Here we provide evidence that subspecies-c, a single-headed axonemal inner-arm dynein, is processive but has a low duty ratio. Ultrastructurally it is similar to other dyneins(11-14), with a single globular head, long stem and a slender stalk that attaches to microtubules. In vitro studies of microtubules sliding over surfaces coated with subspecies-c at low densities (measured by single-molecule fluorescence) show that a single molecule is sufficient to move a microtubule more than 1 mu m at 0.7 mu m s(-1). When many motors interact the velocity is 5.1 mu m s(-1), fitting a duty ratio of 0.14. Using optical trap nanometry, we show that beads carrying a single subspecies-c motor move processively along the microtubules in 8-nm steps but slip backwards under high loads. These results indicate that dynein subspecies-c functions in a very different way from conventional motor proteins, and has properties that could produce self-oscillation in vivo.	Kansai Adv Res Ctr, Commun Res Lab, Kobe, Hyogo 6512401, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan	National Institute of Information & Communications Technology (NICT) - Japan; University of Tokyo	Oiwa, K (corresponding author), Kansai Adv Res Ctr, Commun Res Lab, Kobe, Hyogo 6512401, Japan.	oiwa@crl.go.jp	Oiwa, Kazuhiro/D-7721-2011	Oiwa, Kazuhiro/0000-0002-1281-113X				AMOS LA, 1989, J CELL SCI, V93, P19; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BROKAW CJ, 1987, CELL MOTIL CYTOSKEL, V8, P68, DOI 10.1002/cm.970080110; Cole DG, 1998, J CELL BIOL, V141, P993, DOI 10.1083/jcb.141.4.993; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Gee MA, 1997, NATURE, V390, P636, DOI 10.1038/37663; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1987, J MOL BIOL, V194, P481, DOI 10.1016/0022-2836(87)90676-0; Hancock WO, 1998, J CELL BIOL, V140, P1395, DOI 10.1083/jcb.140.6.1395; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; HOWARD J, 1993, METHOD CELL BIOL, V39, P105, DOI 10.1016/S0091-679X(08)60164-8; Jameson DM, 1997, METHOD ENZYMOL, V278, P363; KAGAMI O, 1992, J CELL SCI, V103, P653; KAMIMURA S, 1989, NATURE, V340, P476, DOI 10.1038/340476a0; KAMIYA R, 1995, CELL MOTIL CYTOSKEL, V32, P98, DOI 10.1002/cm.970320205; KATAYAMA E, 1989, J BIOCHEM-TOKYO, V106, P751, DOI 10.1093/oxfordjournals.jbchem.a122928; KING SM, 1986, METHOD ENZYMOL, V134, P291; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Oiwa K., 1997, Biophysical Journal, V72, pA180; OIWA K, 1988, CELL STRUCT FUNCT, V13, P193, DOI 10.1247/csf.13.193; PASCHAL BM, 1989, NATURE, V342, P569, DOI 10.1038/342569a0; Samso M, 1998, J MOL BIOL, V276, P927, DOI 10.1006/jmbi.1997.1584; Shingyoji C, 1998, NATURE, V393, P711, DOI 10.1038/31520; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; TAKAHASHI K, 1983, J SUBMICR CYTOL PATH, V15, P1; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89	28	149	152	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					586	590		10.1038/23066	http://dx.doi.org/10.1038/23066			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448863				2022-12-24	WOS:000081854800061
J	O'Neill, J				O'Neill, J			A peaceful death	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					327	327		10.1136/bmj.319.7205.327	http://dx.doi.org/10.1136/bmj.319.7205.327			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426772	Green Published			2022-12-24	WOS:000081909100069
J	Corrie, JET; Brandmeier, BD; Ferguson, RE; Trentham, DR; Kendrick-Jones, I; Hopkins, SC; van der Heide, UA; Goldman, YE; Sabido-David, C; Dale, RE; Criddle, S; Irving, M				Corrie, JET; Brandmeier, BD; Ferguson, RE; Trentham, DR; Kendrick-Jones, I; Hopkins, SC; van der Heide, UA; Goldman, YE; Sabido-David, C; Dale, RE; Criddle, S; Irving, M			Dynamic measurement of myosin light-chain-domain tilt and twist in muscle contraction	NATURE			English	Article							SKELETAL-MUSCLE; FLUORESCENCE POLARIZATION; FORCE GENERATION; STRIATED-MUSCLE; SCALLOP MYOSIN; MOTOR DOMAIN; LEVER-ARM; FIBERS; ORIENTATION; ACTIN	A new method is described for measuring motions of protein domains in their native environment on the physiological timescale. pairs of cysteines are introduced Into the domain at sites chosen from its static structure and are crosslinked by a bifunctional rhodamine. Domain orientation in a reconstituted macromolecular complex is determined by combining fluorescence polarization data from a small number of such labelled cysteine pairs. This approach bridges the gap between in vitro studies of protein structure and cellular studies of protein function and is used here to measure the tilt and twist of the myosin light-chain domain with respect to actin filaments in single muscle cells. The results reveal the structural basis for the lever-arm action of the light-chain domain of the myosin motor during force generation in muscle.	Univ London Kings Coll, Randall Inst, London WC2B 5RL, England; Natl Inst Med Res, London NW7 1AA, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA	University of London; King's College London; MRC National Institute for Medical Research; MRC Laboratory Molecular Biology; University of Pennsylvania	Irving, M (corresponding author), Univ London Kings Coll, Randall Inst, 26-29 Drury Lane, London WC2B 5RL, England.			, Seth/0000-0003-3999-2281	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Anson M, 1996, EMBO J, V15, P6069, DOI 10.1002/j.1460-2075.1996.tb00995.x; Baker JE, 1998, P NATL ACAD SCI USA, V95, P2944, DOI 10.1073/pnas.95.6.2944; CHANTLER PD, 1980, J MOL BIOL, V138, P473, DOI 10.1016/S0022-2836(80)80013-1; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; COOKE R, 1982, NATURE, V300, P776, DOI 10.1038/300776a0; Corrie JET, 1998, BIOCONJUGATE CHEM, V9, P160, DOI 10.1021/bc970174e; Dale RE, 1999, BIOPHYS J, V76, P1606, DOI 10.1016/S0006-3495(99)77320-0; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Hopkins SC, 1998, BIOPHYS J, V74, P3093, DOI 10.1016/S0006-3495(98)78016-6; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; JANSCO A, 1994, P NATL ACAD SCI USA, V91, P8762; KABASCH W, 1990, NATURE, V347, P37; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Linari M, 1998, BIOPHYS J, V74, P2459, DOI 10.1016/S0006-3495(98)77954-8; Ling N, 1996, BIOPHYS J, V70, P1836, DOI 10.1016/S0006-3495(96)79749-7; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MOSS RL, 1982, J BIOL CHEM, V257, P8588; OKI M, 1983, TOP STEREOCHEM, V14, P1; PENZKOFER A, 1980, OPT COMMUN, V35, P81, DOI 10.1016/0030-4018(80)90364-8; Press W., 1992, NUMERICAL RECIPES FO; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; ROWE T, 1992, EMBO J, V11, P4715, DOI 10.1002/j.1460-2075.1992.tb05576.x; Sabido-David C, 1998, BIOPHYS J, V74, P3083, DOI 10.1016/S0006-3495(98)78015-4; Sabido-David C, 1998, J MOL BIOL, V279, P387, DOI 10.1006/jmbi.1998.1771; SIMMONS RM, 1980, NATURE, V286, P626, DOI 10.1038/286626a0; Uyeda TQP, 1996, P NATL ACAD SCI USA, V93, P4459, DOI 10.1073/pnas.93.9.4459; Warshaw DM, 1998, P NATL ACAD SCI USA, V95, P8034, DOI 10.1073/pnas.95.14.8034; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	44	172	173	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					425	430		10.1038/22704	http://dx.doi.org/10.1038/22704			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440371				2022-12-24	WOS:000081715000043
J	Muers, MF				Muers, MF			Quitting smoking and lungs	LANCET			English	Editorial Material							DECLINE; FEV(1)		Gen Infirm Leeds, Resp Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary	Muers, MF (corresponding author), Gen Infirm Leeds, Resp Unit, Leeds LS1 3EX, W Yorkshire, England.							ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; CALLUM C, 1998, UK SMOKING EPIDEMIC; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794, DOI 10.1164/arrd.1987.135.4.794; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270, DOI 10.1001/jama.1996.03530400058039; Fletcher CM, 1976, NATURAL HIST CHRONIC; GOLDING JF, 1995, SMOKING RESP MED, P531; Murray RP, 1998, J CLIN EPIDEMIOL, V51, P1317, DOI 10.1016/S0895-4356(98)00120-6; Raw M, 1998, THORAX, V53, pS1, DOI 10.1136/thx.53.2008.S1; Sherrill DL, 1996, CHEST, V109, P1001, DOI 10.1378/chest.109.4.1001; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802, DOI 10.1164/ajrccm.153.6.8665038; *U YORK NHS CTR RE, 1998, EFFECTIVENESS MATTER, V3, P1; XU X, 1994, EUR RESPIR J, V7, P1056; XU XP, 1992, AM REV RESPIR DIS, V146, P1345, DOI 10.1164/ajrccm/146.5_Pt_1.1345	13	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					177	178		10.1016/S0140-6736(99)90021-1	http://dx.doi.org/10.1016/S0140-6736(99)90021-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421295				2022-12-24	WOS:000081504200005
J	Streeten, DHP				Streeten, DHP			What test for hypothalamic-pituitary-adrenocortical insufficiency?	LANCET			English	Editorial Material							NORMAL CORTISOL RESPONSE; ADRENAL AXIS; CORTICOTROPIN; ACTH; CELLS		SUNY Hlth Sci Ctr, Dept Med, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Streeten, DHP (corresponding author), SUNY Hlth Sci Ctr, Dept Med, 750 E Adams St, Syracuse, NY 13210 USA.							Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Agwu JC, 1999, ARCH DIS CHILD, V80, P330, DOI 10.1136/adc.80.4.330; BORST GC, 1982, NEW ENGL J MED, V306, P1462, DOI 10.1056/NEJM198206173062405; Clark PM, 1998, CLIN ENDOCRINOL, V49, P287; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; DONALD RA, 1993, CLIN ENDOCRINOL, V38, P609, DOI 10.1111/j.1365-2265.1993.tb02142.x; LANDON J, 1967, LANCET, V2, P697; LEBRETHON MC, 1994, J CLIN INVEST, V93, P1828, DOI 10.1172/JCI117168; MASTORAKOS G, 1993, J CLIN ENDOCR METAB, V77, P1690, DOI 10.1210/jc.77.6.1690; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; RESCHINI E, 1982, J ENDOCRINOL INVEST, V5, P259, DOI 10.1007/BF03348333; SIMPSON ER, 1988, ANNU REV PHYSIOL, V50, P427, DOI 10.1146/annurev.ph.50.030188.002235; Streeten DHP, 1999, J CLIN ENDOCR METAB, V84, P835, DOI 10.1210/jc.84.3.835; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; STREETEN DHP, 1984, ENDOCR REV, V5, P371, DOI 10.1210/edrv-5-3-371	16	34	39	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 17	1999	354	9174					179	180		10.1016/S0140-6736(98)00318-3	http://dx.doi.org/10.1016/S0140-6736(98)00318-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421297				2022-12-24	WOS:000081504200007
J	Payre, F; Vincent, A; Carreno, S				Payre, F; Vincent, A; Carreno, S			Ovo/svb integrates Wingless and DER pathways to control epidermis differentiation	NATURE			English	Article							DROSOPHILA EGF RECEPTOR; OVO GENE; ARMADILLO; EXPRESSION; PROTEIN; ROLES; MORPHOGENESIS; SHAVENBABY; ENCODES; CUTICLE	In Drosophila, as in mammals, epidermal differentiation is controlled by signalling cascades' that include Wnt proteins(2,3) and the ovo/shavenbaby (svb) family of zinc-finger transcription factor(4-6) Ovo/svb is a complex gene with two genetic functions corresponding to separate control regions: ovo is required for female germline development and svb for epidermal morphogenesis(7,8). In the Drosophila embryo, the ventral epidermis consists of the segmental alternance of two major cell types that produce either naked cuticle or cytoplasmic extrusions known as denticles. Wingless signalling specifies smooth cells that produce naked cuticle(9), whereas the activation of the Drosophila epidermal growth factor (EGF) receptor (DER) leads to the production of denticles(10). Here we show that expression of the ovo/svb gene controls the choice between these cell fates. We find that svb is a key selector gene that, cell autonomously, directs cytoskeletal modifications producing the denticle. The DER pathway promotes denticle formation by activating svb expression. Conversely, Wingless promotes the smooth cell fate through the transcriptional repression of svb by the bipartite nuclear factor Armadillo/dTcf. Ou data indicate that transcriptional regulation of svb integrates inputs fi om the Wingless and DER pathways and controls epidermal differentiation.	Ctr Dev Biol, F-31062 Toulouse, France		Payre, F (corresponding author), Ctr Dev Biol, UMR5547,Bat IVR3,118 Route Narbonne, F-31062 Toulouse, France.		Vincent, Alain/AAE-4712-2019	PAYRE, Francois/0000-0002-8144-6711; Carreno, Sebastien/0000-0002-5839-2102				Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cadigan KM, 1998, CELL, V93, P767, DOI 10.1016/S0092-8674(00)81438-5; Dai X, 1998, GENE DEV, V12, P3452, DOI 10.1101/gad.12.21.3452; Dickinson WJ, 1997, CELL MOTIL CYTOSKEL, V38, P9; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GARFINKEL MD, 1994, MOL CELL BIOL, V14, P6809, DOI 10.1128/MCB.14.10.6809; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Lawrence PA, 1996, DEVELOPMENT, V122, P4095; Lee T, 1996, DEVELOPMENT, V122, P409; Lu JN, 1998, DEV GENES EVOL, V208, P213, DOI 10.1007/s004270050175; MEVELNINIO M, 1991, EMBO J, V10, P2259, DOI 10.1002/j.1460-2075.1991.tb07762.x; MEVELNINIO M, 1995, MECH DEVELOP, V49, P83, DOI 10.1016/0925-4773(94)00305-7; MevelNinio M, 1996, DEVELOPMENT, V122, P4131; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; O'Keefe L, 1997, DEVELOPMENT, V124, P4837; Oro AE, 1998, CELL, V95, P575, DOI 10.1016/S0092-8674(00)81624-4; Pai LM, 1997, DEVELOPMENT, V124, P2255; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; SCHWEITZER R, 1995, GENE DEV, V9, P1518, DOI 10.1101/gad.9.12.1518; Szuts D, 1997, DEVELOPMENT, V124, P3209; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yu X, 1998, EMBO J, V17, P7021, DOI 10.1093/emboj/17.23.7021	30	171	177	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					271	275		10.1038/22330	http://dx.doi.org/10.1038/22330			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421370				2022-12-24	WOS:000081503800046
J	Moore, PA; Belvedere, O; Orr, A; Pieri, K; LaFleur, DW; Feng, P; Soppet, D; Charters, M; Gentz, R; Parmelee, D; Li, YL; Galperina, O; Giri, J; Roschke, V; Nardelli, B; Carrell, J; Sosnovtseva, S; Greenfield, W; Ruben, SM; Olsen, HS; Fikes, J; Hilbert, DM				Moore, PA; Belvedere, O; Orr, A; Pieri, K; LaFleur, DW; Feng, P; Soppet, D; Charters, M; Gentz, R; Parmelee, D; Li, YL; Galperina, O; Giri, J; Roschke, V; Nardelli, B; Carrell, J; Sosnovtseva, S; Greenfield, W; Ruben, SM; Olsen, HS; Fikes, J; Hilbert, DM			BLyS: Member of the tumor necrosis factor family and B lymphocyte stimulator	SCIENCE			English	Article							MOLECULAR-CLONING; CD40 LIGAND; CELL GROWTH; EXPRESSION; DIFFERENTIATION; IMMUNOGLOBULIN; INTERLEUKIN-5; LYMPHOTOXIN; BSF-2; CDNA	The tumor necrosis factor (INF) superfamily of cytokines includes both soluble and membrane-bound proteins that regulate immune responses. A member of the human TNF family, BLyS (B Lymphocyte stimulator), was identified that induced B cell proliferation and immunoglobulin secretion. BLyS expression on human monocytes could be up-regulated by interferon-gamma. Soluble BLyS functioned as a potent B cell growth factor in costimulation assays. Administration of soluble recombinant BLyS to mice disrupted splenic B and T cell zones and resulted in elevated serum immunoglobulin concentrations. The B cell tropism of BLyS is consistent with its receptor expression on B-Lineage cells. The biological profile of BLyS suggests it is involved in monocyte-driven B cell activation.	Human Genome Sci, Rockville, MD 20850 USA	GlaxoSmithKline; Human Genome Sciences Inc	Hilbert, DM (corresponding author), Human Genome Sci, 9410 Key W Ave, Rockville, MD 20850 USA.		Carrell, Jeffrey/AAV-7361-2020	Carrell, Jeffrey/0000-0001-7484-4407				AKERSTROM B, 1985, J IMMUNOL, V135, P2589; ARMITAGE RJ, 1995, J IMMUNOL, V154, P483; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARMITAGE RJ, 1991, ADV EXP MED BIOL, V292, P121; BERTOLINI JN, 1993, EUR J IMMUNOL, V23, P398, DOI 10.1002/eji.1830230215; COSMAN D, 1994, STEM CELLS, V12, P440, DOI 10.1002/stem.5530120501; GEFTER ML, 1977, SOMAT CELL GENET, V3, P231, DOI 10.1007/BF01551818; GOODWIN RG, 1989, P NATL ACAD SCI USA, V86, P302, DOI 10.1073/pnas.86.1.302; GRABSTEIN KH, 1993, J IMMUNOL, V150, P3141; GRAY PW, 1984, NATURE, V312, P721, DOI 10.1038/312721a0; Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185; HILBERT DM, 1995, P NATL ACAD SCI USA, V92, P649, DOI 10.1073/pnas.92.3.649; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; HILBERT DM, 1993, EUR J IMMUNOL, V23, P2412, DOI 10.1002/eji.1830231006; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; Lens SMA, 1998, SEMIN IMMUNOL, V10, P491, DOI 10.1006/smim.1998.0154; Metzger DW, 1995, RES IMMUNOL, V146, P499, DOI 10.1016/0923-2494(96)83023-9; MOORE PS, UNPUB; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; Oshima H, 1998, INT IMMUNOL, V10, P517, DOI 10.1093/intimm/10.4.517; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; POUPART P, 1987, EMBO J, V6, P1219, DOI 10.1002/j.1460-2075.1987.tb02357.x; PUNNONEN J, 1994, ALLERGY, V49, P576, DOI 10.1111/j.1398-9995.1994.tb00122.x; RINGDEN O, 1977, SCAND J IMMUNOL, V6, P1159; SIECKMANN DG, 1978, J EXP MED, V147, P814, DOI 10.1084/jem.147.3.814; TAKATSU K, 1987, P NATL ACAD SCI USA, V84, P4234, DOI 10.1073/pnas.84.12.4234; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; vanKooten C, 1997, INT ARCH ALLERGY IMM, V113, P393, DOI 10.1159/000237614; YOKOTA T, 1986, P NATL ACAD SCI USA, V83, P5894, DOI 10.1073/pnas.83.16.5894	29	934	1117	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					260	263		10.1126/science.285.5425.260	http://dx.doi.org/10.1126/science.285.5425.260			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398604				2022-12-24	WOS:000081346000044
J	Hindie, E; Urena, P; Jeanguillaume, C; Melliere, D; Berthelot, JM; Menoyo-Calonge, V; Chiappini-Briffa, D; Janin, A; Galle, P				Hindie, E; Urena, P; Jeanguillaume, C; Melliere, D; Berthelot, JM; Menoyo-Calonge, V; Chiappini-Briffa, D; Janin, A; Galle, P			Preoperative imaging of parathyroid glands with technetium-99m-labelled sestamibi and iodine-123 subtraction scanning in secondary hyperparathyroidism	LANCET			English	Article							CHRONIC-RENAL-FAILURE; TECHNETIUM 99M SESTAMIBI; SURGICAL-TREATMENT; SUBTOTAL PARATHYROIDECTOMY; TC-99M SESTAMIBI; DOUBLE-PHASE; LOCALIZATION; TECHNETIUM-99M-SESTAMIBI; SURGERY; PATHOGENESIS	Background Parathyroidectomy is unsuccessful in 10-30% of uraemic patients operated on for secondary hyperparathyroidism, We investigated the usefulness of preoperative radionuclide imaging, with simultaneous recording of the distribution images of iodine-123 and technetium-99m-labelled sestamibi. Methods 11 patients with secondary hyperparathyroidism underwent prospective imaging and parathyroidectomy. Plasma concentrations of intact parathyroid hormone (PTH) were measured in all patients before and 6 months after subtotal parathyroidectomy. Findings Preoperative scanning showed 42 hot-spots suggesting enlarged parathyroid glands, 45 glands were discovered at surgery, and the parathyroidectomy was deemed successful in ten patients. Among the latter, one patient had a supernumerary parathyroid gland detected by scanning and resected from the left thymus. Another patient showed ectopic uptake corresponding to a large parathyroid gland in the upper mediastinum, and another had a parathyroid gland well above the thyroid. No false-positive scan findings were documented. In the patient for whom parathyroidectomy failed, preoperative scanning suggested five enlarged parathyroid glands, though the surgeon found only four glands, in their normal positions. Hyperparathyroidism persisted (intact PTH 527 ng/L, 6 months after surgery). A second scan confirmed the preoperative scan, showing a fifth parathyroid gland in the middle of the right thyroid lobe. Interpretation Simultaneous recording of Tc-99m-sestamibi and I-123 improved the imaging of parathyroid glands in secondary hyperparathyroidism. The technique can identify ectopic and supernumerary parathyroid glands.	Hop Henri Mondor, Dept Nucl Med & Biophys, F-94010 Creteil, France; Hop Henri Mondor, Dept Endocrine Surg, F-94010 Creteil, France; Clin LOrangerie, Nephrol Unit, Aubervilliers, France; Ctr Henri Kuntziger, Haemodyalysis Unit, Paris, France; Hop St Louis, Dept Pathol, Paris, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Hindie, E (corresponding author), Univ Paris 12, Fac Med, Biophys Lab, 8 Rue Gen Sarrail, F-94000 Creteil, France.	hindie@univ-paris12.fr	Galle, Peter R/T-5292-2018; JEANGUILLAUME, Christian/A-1070-2008	Galle, Peter R/0000-0001-8294-0992; Jeanguillaume, Christian/0000-0002-8335-4255				AKERSTROM G, 1984, SURGERY, V95, P14; AKERSTROM G, 1992, WORLD J SURG, V16, P562, DOI 10.1007/BF02067321; ARNOLD A, 1995, J CLIN INVEST, V95, P2047, DOI 10.1172/JCI117890; BLAKE DP, 1983, SURG GYNECOL OBSTET, V157, P325; Borley NR, 1996, BRIT J SURG, V83, P989, DOI 10.1002/bjs.1800830734; Chesser AMS, 1997, NEPHROL DIAL TRANSPL, V12, P97, DOI 10.1093/ndt/12.1.97; COAKLEY AJ, 1989, NUCL MED COMMUN, V10, P791, DOI 10.1097/00006231-198911000-00003; DRUEKE TB, 1995, KIDNEY INT, V48, P259, DOI 10.1038/ki.1995.292; FRAKER DL, 1990, WORLD J SURG, V14, P342, DOI 10.1007/BF01658522; Fukagawa M, 1997, SEMIN SURG ONCOL, V13, P73, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<73::AID-SSU2>3.0.CO;2-Z; GAGNE ER, 1992, J AM SOC NEPHROL, V3, P1008; GAZ RD, 1987, SURGERY, V102, P949; GIANGRANDE A, 1992, NEPHROL DIAL TRANSPL, V7, P412; Hindie E, 1998, J NUCL MED, V39, P1100; HINDIE E, 1995, J CLIN ENDOCR METAB, V80, P302, DOI 10.1210/jc.80.1.302; Hindie E, 1997, RADIOLOGY, V204, P221, DOI 10.1148/radiology.204.1.9205251; Hines OJ, 1998, J CLIN ENDOCR METAB, V83, P2384, DOI 10.1210/jc.83.7.2384; Jeanguillaume C, 1998, RADIOLOGY, V207, P207, DOI 10.1148/radiology.207.1.9580138; Johnston LB, 1996, J CLIN ENDOCR METAB, V81, P346, DOI 10.1210/jc.81.1.346; KESSLER M, 1991, NEPHROL DIAL TRANSPL, V6, P176, DOI 10.1093/ndt/6.3.176; Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598; ODOHERTY MJ, 1992, J NUCL MED, V33, P313; Parfitt AM, 1997, KIDNEY INT, V52, P3, DOI 10.1038/ki.1997.297; Piga M, 1996, J NUCL MED, V37, P565; Pons F, 1997, EUR J NUCL MED, V24, P1494, DOI 10.1007/s002590050179; PUNCH JD, 1995, ARCH SURG-CHICAGO, V130, P538; ROTHMUND M, 1988, ANN SURG, V207, P310, DOI 10.1097/00000658-198803000-00014; ROTHMUND M, 1990, WORLD J SURG, V14, P393, DOI 10.1007/BF01658536; RUDBERG C, 1986, SURGERY, V99, P643; RUSSELL CF, 1981, ANN SURG, V193, P805, DOI 10.1097/00000658-198106000-00016; SLATOPOLSKY E, 1994, AM J KIDNEY DIS, V23, P229, DOI 10.1016/S0272-6386(12)80977-2; TAILLEFER R, 1992, J NUCL MED, V33, P1801; TAKAGI H, 1986, WORLD J SURG, V10, P605, DOI 10.1007/BF01655536; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<78::AID-SSU3>3.0.CO;2-Z; Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P87, DOI 10.1002/(SICI)1098-2388(199703/04)13:2<87::AID-SSU4>3.0.CO;2-Y; WANG M, 1995, AM J KIDNEY DIS, V26, P836, DOI 10.1016/0272-6386(95)90453-0; WEBER CJ, 1993, SURGERY, V114, P1011; WEI JP, 1992, SURGERY, V112, P1111	38	55	56	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2200	2204		10.1016/S0140-6736(98)09089-8	http://dx.doi.org/10.1016/S0140-6736(98)09089-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392985				2022-12-24	WOS:000081091300013
J	Alonso, JM; Hirayama, T; Roman, G; Nourizadeh, S; Ecker, JR				Alonso, JM; Hirayama, T; Roman, G; Nourizadeh, S; Ecker, JR			EIN2, a bifunctional transducer of ethylene and stress responses in Arabidopsis	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; SIGNAL-TRANSDUCTION; SACCHAROMYCES-CEREVISIAE; GENETIC-ANALYSIS; PROTEIN-KINASES; ROOT-GROWTH; THALIANA; YEAST; PATHWAY; TRANSPORTER	Ethylene regulates plant growth, development, and responsiveness to a variety of stresses. Cloning of the Arabidopsis EIN2 gene identifies a central component: of the ethylene signaling pathway. The amino-terminal integral membrane domain of EIN2 shows similarity to the disease-related Nramp family of metal-ion transporters. Expression of the EIN2 CEND is sufficient to constitutively activate ethylene responses and restores responsiveness to jasmonic acid and paraquat-induced oxygen radicals to mutant plants. EIN2 is thus recognized as a molecular link between previously distinct hormone response pathways. plants may use a combinatorial mechanism for assessing various stresses by enlisting a common set of signaling molecules.	Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA	University of Pennsylvania	Ecker, JR (corresponding author), Univ Penn, Dept Biol, Inst Plant Sci, Philadelphia, PA 19104 USA.		Roman, Gregg/W-1586-2019; Bruening, Stefan/B-8505-2011; Alonso, Jose M/K-6826-2014; HIRAYAMA, Takashi/B-2496-2011; Ecker, Joseph R/B-9144-2008	Roman, Gregg/0000-0003-1519-4699; Alonso, Jose M/0000-0001-7087-1571; HIRAYAMA, Takashi/0000-0002-3868-2380; Ecker, Joseph R/0000-0001-5799-5895				BALCOMBE D, 1986, NATURE, V321, P446; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BLEECKER AB, 1988, SCIENCE, V241, P1086, DOI 10.1126/science.241.4869.1086; BURG SP, 1967, PLANT PHYSIOL, V42, P144, DOI 10.1104/pp.42.1.144; Chao QM, 1997, CELL, V89, P1133, DOI 10.1016/S0092-8674(00)80300-1; CHEN QHG, 1995, PLANT PHYSIOL, V108, P597, DOI 10.1104/pp.108.2.597; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; Fleet JC, 1998, NUTR REV, V56, P88, DOI 10.1111/j.1753-4887.1998.tb01701.x; Fujita H, 1996, PLANT CELL PHYSIOL, V37, P1094, DOI 10.1093/oxfordjournals.pcp.a029059; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; Hirayama T, 1999, CELL, V97, P383, DOI 10.1016/S0092-8674(00)80747-3; Hua J, 1998, CELL, V94, P261, DOI 10.1016/S0092-8674(00)81425-7; Johnson PR, 1998, ANNU REV GENET, V32, P227, DOI 10.1146/annurev.genet.32.1.227; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)90126-7; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Matallana E., 1992, Methods in Arabidopsis research., P144; NOURIZADEH S, UNPUB; Oh SA, 1997, PLANT J, V12, P527, DOI 10.1046/j.1365-313X.1997.00527.x; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; PELECH SL, 1992, TRENDS BIOCHEM SCI, V17, P233, DOI 10.1016/S0968-0004(00)80005-5; Penninckx IAMA, 1998, PLANT CELL, V10, P2103, DOI 10.1105/tpc.10.12.2103; Pinner E, 1997, J BIOL CHEM, V272, P28933, DOI 10.1074/jbc.272.46.28933; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RODRIGUES V, 1995, EMBO J, V14, P3007, DOI 10.1002/j.1460-2075.1995.tb07303.x; Rodriguez FI, 1999, SCIENCE, V283, P996, DOI 10.1126/science.283.5404.996; ROMAN G, 1995, GENETICS, V139, P1393; ROTHENBERG M, UNPUB SCIENCE; Sakai H, 1998, P NATL ACAD SCI USA, V95, P5812, DOI 10.1073/pnas.95.10.5812; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Smalle J, 1997, P NATL ACAD SCI USA, V94, P2756, DOI 10.1073/pnas.94.6.2756; Solano R, 1998, GENE DEV, V12, P3703, DOI 10.1101/gad.12.23.3703; SU WP, 1992, PLANT PHYSIOL, V99, P1569, DOI 10.1104/pp.99.4.1569; Supek F, 1997, J EXP BIOL, V200, P321; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VAN DER STRAETEN D, 1993, PLANT PHYSIOL, V102, P401, DOI 10.1104/pp.102.2.401; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WEST AH, 1992, J BIOL CHEM, V267, P24625	43	928	997	14	189	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2148	2152		10.1126/science.284.5423.2148	http://dx.doi.org/10.1126/science.284.5423.2148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381874				2022-12-24	WOS:000081099300043
J	Jablonski, D				Jablonski, D			The future of the fossil record	SCIENCE			English	Editorial Material							MASS EXTINCTION; EVOLUTION; DIVERSITY; REORGANIZATION; LIMBS	The fossil record provides a powerful basis for analyzing the controlling factors and impact of biological evolution over a wide range of temporal and spacial scales and in the context of an evolving Earth. An increasingly interdisciplinary paleontology has begun to formulate the next generation of questions, drawing on a wealth of new data, and on methodological advances ranging from high-resolution geochronology to simulation of morphological evolution. Key issues related to evolutionary biology include the biotic and physical factors that govern biodiversity dynamics, the developmental and ecological basis for the nonrandom introduction of evolutionary innovations in time and space, rules of biotic response to environmental perturbations, and the dynamic feedbacks between life and the Earth's surface processes. The sensitivity of evolutionary processes to rates, magnitudes, and spatial scales of change in the physical and biotic environment will be important in all these areas.	Univ Chicago, Dept Geophys Sci, Chicago, IL 60637 USA	University of Chicago	Jablonski, D (corresponding author), Univ Chicago, Dept Geophys Sci, 5734 S Ellis Ave, Chicago, IL 60637 USA.	djablons@midway.uchicago.edu						Benton Michael J., 1996, P185; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; Coates MI, 1998, BIOESSAYS, V20, P371, DOI 10.1002/(SICI)1521-1878(199805)20:5<371::AID-BIES4>3.0.CO;2-R; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; Droser ML, 1997, GEOLOGY, V25, P167, DOI 10.1130/0091-7613(1997)025<0167:ETEAOM>2.3.CO;2; FLESSE KW, 1999, GEOBIOLOGY EARTH SCI; Foote M, 1997, ANNU REV ECOL SYST, V28, P129, DOI 10.1146/annurev.ecolsys.28.1.129; Foote M, 1999, NATURE, V398, P415, DOI 10.1038/18872; Gould SJ, 1998, PHILOS T R SOC B, V353, P307, DOI 10.1098/rstb.1998.0211; Holland SM, 1999, GEOLOGY, V27, P491, DOI 10.1130/0091-7613(1999)027<0491:MFSTFR>2.3.CO;2; Jablonski D, 1998, SCIENCE, V279, P1327, DOI 10.1126/science.279.5355.1327; Jackson JBC, 1999, TRENDS ECOL EVOL, V14, P72, DOI 10.1016/S0169-5347(98)01504-3; Kidwell Susan M., 1996, P290; Kirschvink JL, 1997, SCIENCE, V277, P541, DOI 10.1126/science.277.5325.541; LANE HR, 1997, PALEONTOLOGY 21 CENT, V25, P1; LOGAN GA, 1995, NATURE, V376, P53, DOI 10.1038/376053a0; Lupia R, 1999, PALEOBIOLOGY, V25, P1, DOI 10.1666/0094-8373(1999)25[1:MDITER]2.0.CO;2; MALEY C, 1997, GEOL SOC AM ABSTR, V29, pA31; Marshall CR, 1996, SCIENCE, V274, P1360, DOI 10.1126/science.274.5291.1360; McGhee GR, 1999, PERS PALEOB; McKinney ML, 1997, ANNU REV ECOL SYST, V28, P495, DOI 10.1146/annurev.ecolsys.28.1.495; Miller AI, 1998, SCIENCE, V281, P1157, DOI 10.1126/science.281.5380.1157; Morris SC, 1998, PHILOS T R SOC B, V353, P327, DOI 10.1098/rstb.1998.0213; Roy K, 1996, PALEOBIOLOGY, V22, P436, DOI 10.1017/S0094837300016389; Sepkoski J. John Jr, 1996, P211; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P43, DOI 10.1017/S0094837300012306; SEPKOSKI JJ, 1993, PALEOBIOLOGY, V19, P168, DOI 10.1017/S0094837300015852; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Stanley SM, 1998, PALAEOGEOGR PALAEOCL, V144, P3, DOI 10.1016/S0031-0182(98)00109-6; STANLEY SM, 1997, GEOBIOLOGY CRITICAL; Valentine JW, 1999, DEVELOPMENT, V126, P851; VANVALEN L, 1973, SCIENCE, V180, P516	32	36	38	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2114	2116		10.1126/science.284.5423.2114	http://dx.doi.org/10.1126/science.284.5423.2114			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381868				2022-12-24	WOS:000081099300037
J	Agami, R; Blandino, G; Oren, M; Shaul, Y				Agami, R; Blandino, G; Oren, M; Shaul, Y			Interaction of c-Abl and p73 alpha and their collaboration to induce apoptosis	NATURE			English	Article							FUNCTIONAL DOMAIN; DNA-DAMAGE; P53; PROTEIN; GENE; IDENTIFICATION; LIBRARIES; LIGANDS; REGION; P73	c-Abl, a non-receptor tyrosine kinase, is activated by agents that damage DNA. This activation results in either arrest of the cell cycle in phase G1 or apoptotic cell death, both of which are dependent on the kinase activity of c-Abl(1). p73, a member of the p53 family of tumour-suppressor proteins(2,3), can also induce apoptosis(3), Here we show that the apoptotic activity of p73 alpha requires the presence of functional, kinase-competent c-Abl. Furthermore, p73 and c-Abl can associate with each other, and this binding is mediated by a PxxP motif in p73 and the SH3 domain of c-Abl. We find that p73 is a substrate of the c-Abl kinase and that the ability of c-Abl to phosphorylate p73 is markedly increased by gamma-irradiation. Moreover, p73 is phosphorylated in vivo in response to ionizing radiation. These findings define a pro-apoptotic signalling pathway involving p73 and c-Abl.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Shaul, Y (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.	Ivshaul@weizmann.weizmann.ac.il	Blandino, Giovanni/B-1137-2013; agami, reuven/GOG-8289-2022	Blandino, Giovanni/0000-0002-6970-2241; Agami, Reuven/0000-0002-2848-2473; Oren, Moshe/0000-0003-4311-7172	Telethon [596] Funding Source: Medline	Telethon(Fondazione Telethon)		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; DAI ZH, 1995, GENE DEV, V9, P2569, DOI 10.1101/gad.9.21.2569; HONIGWACHS J, 1989, J VIROL, V63, P919, DOI 10.1128/JVI.63.2.919-924.1989; Jiang W, 1998, BIOTECHNIQUES, V24, P349; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHI YG, 1995, GENE DEV, V9, P2583, DOI 10.1101/gad.9.21.2583; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Zhu JH, 1998, CANCER RES, V58, P5061	23	489	499	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					809	813						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391250				2022-12-24	WOS:000081101600060
J	Dimmeler, S; Fleming, I; Fisslthaler, B; Hermann, C; Busse, R; Zeiher, AM				Dimmeler, S; Fleming, I; Fisslthaler, B; Hermann, C; Busse, R; Zeiher, AM			Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation	NATURE			English	Article							PROTEIN-KINASE-B; FLUID SHEAR-STRESS; SIGNAL-TRANSDUCTION; CALCIUM; SUPPRESSION; EXPRESSION; APOPTOSIS; PATHWAY; ANGIOGENESIS; CALMODULIN	Nitric oxide (NO) produced by the endothelial NO synthase (eNOS) is a fundamental determinant of cardiovascular homesotasis: it regulates systemic blood pressure, vascular remodelling and angiogenesis(1-3). Physiologically, the most important stimulus for the continuous formation of NO is the viscous drag (shear stress) generated by the streaming blood on the endothelial layer(4-8). Although shear-stress-mediated phosphorylation of eNOS is thought to regulate enzyme activity(9,10), the mechanism of activation of eNOS is not yet known. Here we demonstrate that the serine/threonine protein kinase Akt/PKB (11-13) mediates the activation of eNOS, leading to increased NO production. Inhibition of the phosphatidylinositol-3-OH kinase/Akt pathway or mutation of the Akt site on eNOS protein (at serine 1177) attenuates the serine phosphorylation and prevents the activation of eNOS, Mimicking the phosphorylation of Ser1177 directly enhances enzyme activity and alters the sensitivity of the enzyme to Ca2+, rendering its activity maximal at sub-physiological concentrations of Ca2+. Thus, phosphorylation of eNOS by Akt represents a novel Ca2+-independent regulatory mechanism for activation of eNOS.	Univ Frankfurt, Dept Internal Med 4, D-60590 Frankfurt, Germany; Univ Frankfurt, Inst Cardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Zeiher, AM (corresponding author), Univ Frankfurt, Dept Internal Med 4, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Dimmeler, Stefanie/0000-0002-1045-2436				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUSSE R, 1990, FEBS LETT, V265, P133, DOI 10.1016/0014-5793(90)80902-U; Busse R, 1998, J VASC RES, V35, P73, DOI 10.1159/000025568; COPPER JA, 1983, METHOD ENZYMOL, V99, P387; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, SCIENCE, V279, P673, DOI 10.1126/science.279.5351.673; FLEMING L, 1996, CIRC RES, V79, P984; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moroi M, 1998, J CLIN INVEST, V101, P1225, DOI 10.1172/JCI1293; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; vanderZee R, 1997, CIRCULATION, V95, P1030; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeiher AM, 1996, LANCET, V348, pS10, DOI 10.1016/S0140-6736(96)98004-6; ZEIHER AM, 1995, CIRC RES, V76, P980, DOI 10.1161/01.RES.76.6.980; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	29	2897	2986	11	211	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					601	605		10.1038/21224	http://dx.doi.org/10.1038/21224			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376603				2022-12-24	WOS:000080778400060
J	Smith, O				Smith, O			Biomedicine - Pain-killer genes	SCIENCE			English	Editorial Material																		FINEGOLD AA, IN PRESS HUM GENE TH; Wilson SP, 1999, P NATL ACAD SCI USA, V96, P3211, DOI 10.1073/pnas.96.6.3211	2	2	4	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1634	1634		10.1126/science.284.5420.1634	http://dx.doi.org/10.1126/science.284.5420.1634			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383343				2022-12-24	WOS:000080668300033
J	McLafferty, FW; Fridriksson, EK; Horn, DM; Lewis, MA; Zubarev, RA				McLafferty, FW; Fridriksson, EK; Horn, DM; Lewis, MA; Zubarev, RA			Biochemistry - Biomolecule mass spectrometry	SCIENCE			English	Article							PROTEIN CHARACTERIZATION; ELECTROPHORESIS; IDENTIFICATION; PEPTIDE		Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	McLafferty, FW (corresponding author), Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.		Zubarev, Roman A/W-7891-2018	Zubarev, Roman A/0000-0001-9839-2089; Lewis Ph.D., Mark/0000-0002-2273-3729				BIEMANN K, 1995, PROTEIN SCI, V4, P1920, DOI 10.1002/pro.5560040926; CHAIT BT, UNPUB; CHENG XH, 1995, J AM CHEM SOC, V117, P8859, DOI 10.1021/ja00139a023; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; FORET F, 1995, J CHROMATOGR A, V716, P157, DOI 10.1016/0021-9673(95)00621-S; HORN D, UNPUB; Jensen ON, 1997, ANAL CHEM, V69, P1706, DOI 10.1021/ac961189t; Jensen ON, 1998, PROTEINS, P74; Jorgensen TJD, 1998, ANAL CHEM, V70, P4427, DOI 10.1021/ac980563h; Kelleher NL, 1998, PROTEIN SCI, V7, P1796, DOI 10.1002/pro.5560070815; Kelleher NL, 1999, J AM CHEM SOC, V121, P806, DOI 10.1021/ja973655h; Kelleher NL, 1997, J BIOL CHEM, V272, P32215, DOI 10.1074/jbc.272.51.32215; KELLEHER NL, UNPUB; Little DP, 1996, J AM CHEM SOC, V118, P9352, DOI 10.1021/ja9533611; McLafferty FW, 1998, J AM CHEM SOC, V120, P4732, DOI 10.1021/ja9728076; McLafferty FW, 1997, INT J MASS SPECTROM, V165, P457, DOI 10.1016/S0168-1176(97)00171-7; Mortz E, 1996, P NATL ACAD SCI USA, V93, P8264, DOI 10.1073/pnas.93.16.8264; Schnier PD, 1998, J AM CHEM SOC, V120, P9605, DOI 10.1021/ja973534h; Schuhmacher M, 1996, ELECTROPHORESIS, V17, P848, DOI 10.1002/elps.1150170506; Senko MW, 1997, J AM SOC MASS SPECTR, V8, P970, DOI 10.1016/S1044-0305(97)00126-8; SHABANOWITZ J, 1999, MASS SPECTROMETRY BI; Valaskovic GA, 1996, SCIENCE, V273, P1199, DOI 10.1126/science.273.5279.1199; Yang LY, 1998, ANAL CHEM, V70, P3235, DOI 10.1021/ac980224o; Zubarev RA, 1999, J AM CHEM SOC, V121, P2857, DOI 10.1021/ja981948k	24	168	184	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1289	1290		10.1126/science.284.5418.1289	http://dx.doi.org/10.1126/science.284.5418.1289			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383309				2022-12-24	WOS:000080430600031
J	Barakat, K; Wilkinson, P; Deaner, A; Fluck, D; Ranjadayalan, K; Timmis, A				Barakat, K; Wilkinson, P; Deaner, A; Fluck, D; Ranjadayalan, K; Timmis, A			How should age affect management of acute myocardial infarction? A prospective cohort study	LANCET			English	Article							THROMBOLYTIC THERAPY; RISK; SURVIVAL; TRIAL	Background About 75% of patients with acute myocardial infarction are older than 70 years, but patients in this age group are commonly treated less vigorously than younger patients. This differential treatment may partly reflect clinicians' misconceptions about the outlook of such patients, and the importance of age in clinical decisions. We examined how age does and should affect the management of patients and risk stratification in acute myocardial infarction. Methods In this prospective cohort study, we recruited 1225 consecutive patients admitted with acute myocardial infarction to a district general hospital in east London. The primary endpoint was death. We used tabulation and regression methods to analyse the association between age group and clinical variables. Findings Patients aged 70 years or older took a longer time to arrive in hospital and were less likely to receive thrombolysis or discharge beta-blockers than patients younger than 60 years: odds ratio 0.63 (95% CI 9.45-0.88) for thrombolysis and 0.25 (0.16-0.37) for beta-blockade, adjusted for sex, diabetes, previous acute myocardial infarction, Q wave infarction, and left-ventricular failure. Left-ventricular failure was the strongest independent predictor of death within 1 year of infarction with a hazard ratio of 4.76 (3.53-6.43), adjusted for age, sex, diabetes, and Q wave infarction. Patients aged 70 years or older without left-ventricular failure had significantly better survival at 1 year after acute myocardial infarction than patients under 60 years with left-ventricular failure. 70.8% (62.2-78.2) of the older patients who survived to hospital discharge were still alive 3 years later. Interpretation Elderly patients with acute myocardial infarction were treated less vigorously than younger patients. The prognosis of acute myocardial infarction, however, was substantially affected by the development of left-ventricular failure and other clinical indices, such that many older patients had a better outlook than younger patients with adverse clinical factors. In planning risk-based management, consideration of age independently of clinical status is inappropriate.	London Chest Hosp, Royal Hosp NHS Trust, Dept Cardiol, London E2 9JX, England; Newman Healthcare Trust, London, England; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England	University of London; Queen Mary University London; University of London; London School of Hygiene & Tropical Medicine	Timmis, A (corresponding author), London Chest Hosp, Royal Hosp NHS Trust, Dept Cardiol, London E2 9JX, England.	adam@timmis-lch.demon.co.uk		Wilkinson, Paul/0000-0001-7456-259X				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; COLEMAN MP, 1989, 89006 INT AG RES CAN; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; HAMMERMEISTER KE, 1979, CIRCULATION, V59, P421, DOI 10.1161/01.CIR.59.3.421; HANNAFORD PC, 1994, BRIT MED J, V309, P573, DOI 10.1136/bmj.309.6954.573; HAWKINS CM, 1983, CIRCULATION, V67, P94; HILLIS LD, 1990, J AM COLL CARDIOL, V16, P313, DOI 10.1016/0735-1097(90)90579-E; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; McMechan SR, 1998, BMJ-BRIT MED J, V317, P1334, DOI 10.1136/bmj.317.7169.1334; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NORRIS RM, 1969, LANCET, V1, P274; *OFF NAT STAT, 1997, MORT STAT DH2, V22; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; STEVENSON R, 1993, BMJ-BRIT MED J, V307, P349, DOI 10.1136/bmj.307.6900.349; White HD, 1996, CIRCULATION, V94, P1826, DOI 10.1161/01.CIR.94.8.1826; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; WILCOX RG, 1988, LANCET, V2, P525	23	103	109	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					955	959		10.1016/S0140-6736(98)07114-1	http://dx.doi.org/10.1016/S0140-6736(98)07114-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459903				2022-12-24	WOS:000079421600009
J	Lindegren, ML; Byers, RH; Thomas, P; Davis, SF; Caldwell, B; Rogers, M; Gwinn, M; Ward, JW; Fleming, PL				Lindegren, ML; Byers, RH; Thomas, P; Davis, SF; Caldwell, B; Rogers, M; Gwinn, M; Ward, JW; Fleming, PL			Trends in perinatal transmission of HIV/AIDS in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTION; PREGNANT-WOMEN; VERTICAL TRANSMISSION; ZIDOVUDINE TREATMENT; CHILDREN; AIDS; PREVALENCE; REDUCTION; TYPE-1	Context Since 1994, the US Public Health Service (PHS) has recommended routine, voluntary prenatal human immunodeficiency virus (HIV)testing and zidovudine therapy to reduce perinatal HIV transmission. Objective To describe trends in incidence of perinatal AIDS and factors contributing to these trends, particularly the effect of PHS perinatal HIV recommendations. Design, Setting, and Participants Analysis of nationwide AIDS surveillance data and data from HIV-reporting states through June 1998. Main Outcome Measures Trends in AIDS by year of diagnosis, incidence rates of AIDS and Pneumocystis carinii pneumonia (PCP) among infants younger than 1 year from US natality data for birth cohorts 1988 to 1996; expected number of infants with AIDS from national serosurvey data; and zidovudine use data from selected HIV-reporting states. Results Perinatal AIDS cases peaked in 1992 and then declined 67% from 1992 through 1997, including an 80% decline in infants and a 66% decline in children aged 1 to 5 years. Rates of AIDS among infants (per 100 000 births) declined 69%, from 8.9 in 1992 to 2.8 in 1996 compared with a 17% decline in births to HIV-infected women from 1992 (n = 6990) to 1995 (n = 5797). Among infants, PCP rates per 100 000 declined 67% (from 4.5 in 1992 to 1,5 in 1996), similar to the decline in other AIDS conditions. The percentage of perinatally exposed children born from 1993 through 1997 whose mothers were tested for HIV before giving birth increased from 70% to 94%; the percentage who received zidovudine increased from 7% to 91%. Conclusions According to these data, substantial declines in AIDS incidence were temporally associated with an increase in zidovudine use to reduce perinatal HIV transmission, demonstrating substantial success in implementing PHS guidelines. Reductions in the numbers of births and effects of therapy in delaying AIDS do not explain the decline.	New York City Dept Hlth, New York, NY 10013 USA; Ctr Dis Control & Prevent, Off Genet & Dis Prevent, Atlanta, GA USA; Ctr Dis Control & Prevent, Program Epidemiol, Off Sci & Hlth Commun, Atlanta, GA USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Lindegren, ML (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent Sueveillance & Epidemiol, Natl Ctr HIV STD & TB Prevent, Mailstop E-47,1600 Clifton Rd, Atlanta, GA 30333 USA.	mll3@cdc.gov						Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; AUGER I, 1988, NATURE, V336, P575, DOI 10.1038/336575a0; Barnhart HX, 1996, PEDIATRICS, V97, P710; Blanche S, 1997, J ACQ IMMUN DEF SYND, V14, P442, DOI 10.1097/00042560-199704150-00008; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; BUEHLER JW, 1992, J ACQ IMMUN DEF SYND, V5, P257; Byers RH, 1998, STAT MED, V17, P169, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;169::AID-SIM759&gt;3.0.CO;2-8; BYERS RH, 1993, 9 INT AIDS C JUN 6 1; *CDCP, 1985, MMWR-MORBID MORTAL W, V34, P731; *CDCP, 1998, HIV AIDS SURVEILLANC, V10, P1; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P43; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P861; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1086; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P688; Centers for Disease Control (CDC), 1987, MMWR Suppl, V36, p1S; Centers for Disease Control (CDC), 1985, MMWR Morb Mortal Wkly Rep, V34, P721; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR EM, 1993, PEDIATR INFECT DIS J, V12, P513, DOI 10.1097/00006454-199306000-00011; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; Culnane M, 1999, JAMA-J AM MED ASSOC, V281, P151, DOI 10.1001/jama.281.2.151; Davis SF, 1998, J ACQ IMMUN DEF SYND, V19, P158, DOI 10.1097/00042560-199810010-00009; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; Englund JA, 1997, NEW ENGL J MED, V336, P1704, DOI 10.1056/NEJM199706123362403; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gindler J. S., 1995, Morbidity and Mortality Weekly Report, V44, P1; Green TA, 1998, STAT MED, V17, P143, DOI 10.1002/(SICI)1097-0258(19980130)17:2&lt;143::AID-SIM757&gt;3.0.CO;2-Y; *I MED NAT RES COU, 1999, RED ODDS PREV PER TR; Karon JM, 1996, JAMA-J AM MED ASSOC, V276, P126, DOI 10.1001/jama.276.2.126; KARON JM, 1989, LECTURE NOTES BIOMAT, V83, P58; KROGSTAD P, 1998, 5 C RETR OPP INF FEB; Lansky A, 1998, J ACQ IMMUN DEF SYND, V18, P289, DOI 10.1097/00042560-199807010-00014; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; Minkoff H, 1997, AM J OBSTET GYNECOL, V176, P478, DOI 10.1016/S0002-9378(97)70519-2; MUELLER BU, 1997, 4 C RETR OPP INF JAN; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; SIMONDS RJ, 1995, NEW ENGL J MED, V332, P786, DOI 10.1056/NEJM199503233321206; Simonds RJ, 1998, AIDS, V12, P301, DOI 10.1097/00002030-199803000-00008; Simpson BJ, 1997, J ACQ IMMUN DEF SYND, V14, P145, DOI 10.1097/00042560-199702010-00007; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201; Stiehm ER, 1999, J INFECT DIS, V179, P567, DOI 10.1086/314637; WANG MC, 1992, J AM STAT ASSOC, V87, P397, DOI 10.2307/2290270; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9; Wilfert C, 1998, PEDIATRICS, V101, P315, DOI 10.1542/peds.101.2.315; WORTLEY P, 1997, JAMA-J AM MED ASSOC, V298, P911	48	197	204	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					531	538		10.1001/jama.282.6.531	http://dx.doi.org/10.1001/jama.282.6.531			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450714	Bronze			2022-12-24	WOS:000081919100026
J	Geissler, PE; McEwen, AS; Ip, W; Belton, MJS; Johnson, TV; Smyth, WH; Ingersoll, AP				Geissler, PE; McEwen, AS; Ip, W; Belton, MJS; Johnson, TV; Smyth, WH; Ingersoll, AP			Galileo imaging of atmospheric emissions from Io	SCIENCE			English	Article							PLASMA TORUS; ELECTRON-IMPACT; ULTRAVIOLET; JUPITER; TEMPERATURE; VOLCANISM; SO2	The Galileo spacecraft has detected diffuse optical emissions from to in high-resolution images acquired while the satellite was eclipsed by Jupiter. Three distinct components make up lo's visible emissions. Bright blue glows of more than 300 kilorayleighs emanate from volcanic plumes, probably due to electron impact on molecular sulfur dioxide. Weaker red emissions, possibly due to atomic oxygen, are seen along the Limbs, brighter on the pole closest to the plasma torus. A faint green glow appears concentrated on the night side of to, possibly produced by atomic sodium. to's disk-averaged emission diminishes with time after entering eclipse, whereas the localized blue glows brighten instead.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA; Natl Cent Univ, Astron Inst, Chungli 320, Taiwan; Natl Opt Astron Observ, Tucson, AZ 85719 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Atmospher & Environm Res Inc, Cambridge, MA 02139 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA	University of Arizona; National Central University; National Optical Astronomy Observatory; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Atmospheric & Environmental Research; California Institute of Technology	Geissler, PE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85711 USA.							AJELLO JM, 1992, J GEOPHYS RES-SPACE, V97, P10501, DOI 10.1029/92JA00295; AUSTIN JV, 1998, B AM ASTRON SOC, V30, P1121; BAGENAL F, 1994, J GEOPHYS RES-SPACE, V99, P11043, DOI 10.1029/93JA02908; BALLESTER GE, 1997, B AM ASTRON SOC, V29, P980; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BRENEMAN H, 1993, D5880 JET PROP LAB; BROWN MA, UNPUB; Brown R. A., 1974, EXPLORATION PLANETAR, P527; BROWN RA, 1981, ASTROPHYS J, V244, P1072, DOI 10.1086/158777; CLARK REH, 1982, ASTROPHYS J, V254, P412, DOI 10.1086/159746; CLARKE JT, 1994, J GEOPHYS RES-PLANET, V99, P8387, DOI 10.1029/93JE02547; Combi MR, 1998, J GEOPHYS RES-SPACE, V103, P9071, DOI 10.1029/98JA00073; COOK AF, 1981, SCIENCE, V211, P1419, DOI 10.1126/science.211.4489.1419; DURRANCE ST, 1983, ASTROPHYS J, V267, pL125, DOI 10.1086/184016; Frank LA, 1996, SCIENCE, V274, P394, DOI 10.1126/science.274.5286.394; Gold T, 1979, Science, V206, P1071, DOI 10.1126/science.206.4422.1071; GOLDREICH P, 1969, ASTROPHYS J, V156, P59, DOI 10.1086/149947; Gurnett DA, 1996, SCIENCE, V274, P391, DOI 10.1126/science.274.5286.391; Hendrix AR, 1999, J GEOPHYS RES-PLANET, V104, P11817, DOI 10.1029/1999JE900009; Ingersoll AP, 1998, ICARUS, V135, P251, DOI 10.1006/icar.1998.5971; Klaasen KP, 1997, OPT ENG, V36, P3001, DOI 10.1117/1.601525; Lellouch E, 1996, ICARUS, V124, P1, DOI 10.1006/icar.1996.0186; Linker JA, 1998, J GEOPHYS RES-PLANET, V103, P19867, DOI 10.1029/98JE00632; McEwen AS, 1998, ICARUS, V135, P181, DOI 10.1006/icar.1998.5972; McEwen AS, 1998, SCIENCE, V281, P87, DOI 10.1126/science.281.5373.87; MILLER K, 1987, CAN J PHYS, V65, P530, DOI 10.1139/p87-074; PEARL J, 1979, NATURE, V280, P757; PERATT AL, 1988, ASTROPHYS SPACE SCI, V144, P451; Roesler FL, 1999, SCIENCE, V283, P353, DOI 10.1126/science.283.5400.353; SAUER J, IN PRESS J GEOPHYS R; SCHERB F, 1993, J GEOPHYS RES-PLANET, V98, P18729, DOI 10.1029/93JE00539; SITTLER EC, 1987, J GEOPHYS RES, V92, P5741, DOI 10.1029/JA092iA06p05741; STROM RG, 1982, SATELLITES JUPITER, pCH16; TRAFTON L, 1975, NATURE, V258, P690, DOI 10.1038/258690a0; TRAUGER JT, 1976, B AM ASTRON SOC, V8, P468; TRAUGER JT, 1997, B AM ASTRON SOC, V29, P1002; Volwerk M, 1997, GEOPHYS RES LETT, V24, P1147, DOI 10.1029/97GL00966; WONG MC, 1998, B AM ASTRON SOC, V30, P1117	38	64	64	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					870	874		10.1126/science.285.5429.870	http://dx.doi.org/10.1126/science.285.5429.870			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436151				2022-12-24	WOS:000081860900043
J	Best, D; Noble, A; Finch, E; Gossop, M; Sidwell, C; Strang, J				Best, D; Noble, A; Finch, E; Gossop, M; Sidwell, C; Strang, J			Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment	BRITISH MEDICAL JOURNAL			English	Article							DRUG-USERS; VIRUS-INFECTION; RISK		Maudsley Hosp, Natl Addict Ctr, London SE5 8AF, England; Inst Psychiat, London SE5 8AF, England	South London & Maudsley NHS Trust; University of London; King's College London; University of London; King's College London	Best, D (corresponding author), Maudsley Hosp, Natl Addict Ctr, London SE5 8AF, England.		Strang, John/H-5460-2011	Strang, John/0000-0002-5413-2725; Best, David/0000-0002-6792-916X				Crofts N, 1997, ADDICTION, V92, P999, DOI 10.1111/j.1360-0443.1997.tb02979.x; DOW BC, 1993, J MED VIROL, V41, P215, DOI 10.1002/jmv.1890410309; MAJID A, 1995, J MED VIROL, V46, P48, DOI 10.1002/jmv.1890460111; Rhodes T, 1996, ADDICTION, V91, P1457, DOI 10.1111/j.1360-0443.1996.tb02250.x; Serfaty MA, 1997, DRUG ALCOHOL REV, V16, P339, DOI 10.1080/09595239700186721	5	77	78	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					290	291		10.1136/bmj.319.7205.290	http://dx.doi.org/10.1136/bmj.319.7205.290			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	224QE	10426739	Bronze, Green Published			2022-12-24	WOS:000081909100023
J	Aliprantis, AO; Yang, RB; Mark, MR; Suggett, S; Devaux, B; Radolf, JD; Klimpel, GR; Godowski, P; Zychlinsky, A				Aliprantis, AO; Yang, RB; Mark, MR; Suggett, S; Devaux, B; Radolf, JD; Klimpel, GR; Godowski, P; Zychlinsky, A			Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2	SCIENCE			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; SYNTHETIC LIPOPEPTIDE ANALOGS; TREPONEMA-PALLIDUM; CYTOKINE PRODUCTION; PATHWAY DISTINCT; MONOCYTIC CELLS; LIPOPOLYSACCHARIDE; GENE; FAMILY	Apoptosis is implicated in the generation and resolution of inflammation in response to bacterial pathogens. All bacterial pathogens produce lipoproteins (BLPs), which trigger the innate immune response. BLPs were found to induce apoptosis in THP-1 monocytic cells through human Toll-like receptor-2 (hTLR2). BLPs also initiated apoptosis in an epithelial cell line transfected with hTLR2. In addition, BLPs stimulated nuclear factor-kappa B, a transcriptional activator of multiple host defense genes, and activated the respiratory burst through hTLR2. Thus, hTLR2 is a molecular link between microbial products, apoptosis, and host defense mechanisms.	NYU, Sch Med, Skirball Inst, New York, NY 10016 USA; NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; Genentech Inc, Antibody Technol Grp, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA	New York University; New York University; Roche Holding; Genentech; Roche Holding; Genentech; University of Connecticut; University of Texas System; University of Texas Medical Branch Galveston	Zychlinsky, A (corresponding author), NYU, Sch Med, Skirball Inst, 540 1st Ave, New York, NY 10016 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714	NIAID NIH HHS [AI 37720-04, AI-38894] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALIPRANTIS AO, UNPUB; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bessler WG, 1997, INT J IMMUNOPHARMACO, V19, P547, DOI 10.1016/S0192-0561(97)00054-4; BESSLER WG, 1985, J IMMUNOL, V135, P1900; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Henderson B, 1996, MICROBIOL REV, V60, P316, DOI 10.1128/MMBR.60.2.316-341.1996; HEUMANN D, 1992, J IMMUNOL, V148, P3505; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kreutz M, 1997, IMMUNOLOGY, V92, P396, DOI 10.1046/j.1365-2567.1997.00365.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Moss JE, 1999, INT REV CYTOL, V187, P203, DOI 10.1016/S0074-7696(08)62419-5; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; RADOLF JD, 1995, J IMMUNOL, V154, P2866; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Segal AW, 1997, ANN NY ACAD SCI, V832, P215, DOI 10.1111/j.1749-6632.1997.tb46249.x; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Vidal V, 1998, NAT MED, V4, P1416, DOI 10.1038/4007; Williams MJ, 1997, EMBO J, V16, P6120, DOI 10.1093/emboj/16.20.6120; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG RG, UNPUB; Zhang HW, 1997, J IMMUNOL, V159, P4868; Zychlinsky A, 1997, J CLIN INVEST, V100, P493, DOI 10.1172/JCI119557	29	1228	1287	0	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					736	739		10.1126/science.285.5428.736	http://dx.doi.org/10.1126/science.285.5428.736			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426996				2022-12-24	WOS:000081765100055
J	Edmonds, ME				Edmonds, ME			Progress in care of the diabetic foot	LANCET			English	Editorial Material							ULCERS		Univ London Kings Coll Hosp, Kings Diabet Ctr, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Edmonds, ME (corresponding author), Univ London Kings Coll Hosp, Kings Diabet Ctr, Denmark Hill, London SE5 9RS, England.							APELQVIST J, 1993, J INTERN MED, V233, P485, DOI 10.1111/j.1365-2796.1993.tb01003.x; Armstrong D G, 1998, Clin Podiatr Med Surg, V15, P95; Edmonds M, 1994, FOOT DIABETES; EMBONDS M, 1996, DIABET MED S4, V13, pS27; Eneroth M, 1997, FOOT ANKLE INT, V18, P716, DOI 10.1177/107110079701801107; LARSSON J, 1995, DIABETIC MED, V12, P770, DOI 10.1111/j.1464-5491.1995.tb02078.x; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; Naughton G, 1997, ARTIF ORGANS, V21, P1203; PAPA J, 1993, J BONE JOINT SURG AM, V75A, P1056, DOI 10.2106/00004623-199307000-00012; POMPOSELLI FB, 1995, J VASC SURG, V21, P375, DOI 10.1016/S0741-5214(95)70279-2; Wieman TJ, 1998, AM J SURG, V176, P436, DOI 10.1016/S0002-9610(98)00235-9	11	35	35	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					270	272		10.1016/S0140-6736(99)90012-0	http://dx.doi.org/10.1016/S0140-6736(99)90012-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440300				2022-12-24	WOS:000081646000006
J	Yang, YM; Bauer, C; Strasser, G; Wollman, R; Julien, JP; Fuchs, E				Yang, YM; Bauer, C; Strasser, G; Wollman, R; Julien, JP; Fuchs, E			Integrators of the cytoskeleton that stabilize microtubules	CELL			English	Article							NEUROLOGIC DEGENERATION; INTERMEDIATE FILAMENTS; NERVOUS-SYSTEM; LIVING CELLS; MUTANT MICE; TAU-PROTEIN; ORGANIZATION; GENE; EXPRESSION; PLECTIN	Sensory neurodegeneration occurs in mice defective in BPAG1, a gene encoding cytoskeletal linker proteins capable of anchoring neuronal intermediate filaments to actin cytoskeleton. While BPAG1 null mice fail to anchor neurofilaments (NFs), BPAG1/NF null mice still degenerate in the absence of NFs. We report a novel neural splice form that lacks the actin-binding domain and instead binds and stabilizes microtubules. This interaction is functionally important; in mice and in vitro, neurons lacking BPAG1 display short, disorganized, and unstable microtubules defective in axonal transport. Ironically, BPAG1 neural isoforms represent microtubule-associated proteins that when absent lead to devastating consequences. Moreover, BPAG1 can functionally account for the extraordinary stability of axonal microtubules necessary for transport over long distances. Its isoforms interconnect all three cytoskeletal networks, a feature apparently central to neuronal survival.	Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Neurol, Chicago, IL 60637 USA; McGill Univ, Neurosci Res Ctr, Montreal, PQ H3G 1A4, Canada	Howard Hughes Medical Institute; University of Chicago; Howard Hughes Medical Institute; University of Chicago; McGill University	Fuchs, E (corresponding author), Univ Chicago, Pritzker Sch Med, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA.	nliptak@midway.uchicago.edu	Fuchs, Elaine/G-1565-2016		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR27883] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andra K, 1998, GENE DEV, V12, P3442, DOI 10.1101/gad.12.21.3442; BAAS PW, 1994, J CELL SCI, V107, P135; BARLOW S, 1994, J CELL BIOL, V126, P1017, DOI 10.1083/jcb.126.4.1017; Bernier G, 1995, MOL CELL NEUROSCI, V6, P509, DOI 10.1006/mcne.1995.0003; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; COFFEY RL, 1995, J BIOL CHEM, V270, P1035, DOI 10.1074/jbc.270.3.1035; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; Dalpe G, 1998, MOL CELL NEUROSCI, V10, P243, DOI 10.1006/mcne.1997.0660; Dowling J, 1997, DEV BIOL, V187, P131, DOI 10.1006/dbio.1997.8567; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Edelmann W, 1996, P NATL ACAD SCI USA, V93, P1270, DOI 10.1073/pnas.93.3.1270; Eyer J, 1998, NATURE, V391, P584, DOI 10.1038/35378; Gimona M, 1998, CURR BIOL, V8, pR674; Gregory SL, 1998, J CELL BIOL, V143, P1271, DOI 10.1083/jcb.143.5.1271; Guillaud L, 1998, J CELL BIOL, V142, P167, DOI 10.1083/jcb.142.1.167; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HARADA A, 1994, NATURE, V369, P488, DOI 10.1038/369488a0; HIROKAWA N, 1994, CURR OPIN CELL BIOL, V6, P74, DOI 10.1016/0955-0674(94)90119-8; Leung CL, 1999, J CELL BIOL, V144, P435, DOI 10.1083/jcb.144.3.435; LEWIS SA, 1989, NATURE, V342, P498, DOI 10.1038/342498a0; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MORRIS JR, 1982, J CELL BIOL, V92, P192, DOI 10.1083/jcb.92.1.192; NAGELE RG, 1988, BRAIN RES, V474, P279, DOI 10.1016/0006-8993(88)90441-6; Prokop A, 1998, J CELL BIOL, V143, P1283, DOI 10.1083/jcb.143.5.1283; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; SEIFERT GJ, 1992, EUR J CELL BIOL, V59, P138; Strumpf D, 1998, J CELL BIOL, V143, P1259, DOI 10.1083/jcb.143.5.1259; Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991; Takei Y, 1997, J CELL BIOL, V137, P1615, DOI 10.1083/jcb.137.7.1615; Togel M, 1998, J CELL BIOL, V143, P695, DOI 10.1083/jcb.143.3.695; WALLIS KT, 1993, J BIOL CHEM, V268, P15158; WEBB BC, 1980, BIOCHEMISTRY-US, V19, P1993, DOI 10.1021/bi00550a041; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5; Zhu QZ, 1997, EXP NEUROL, V148, P299, DOI 10.1006/exnr.1997.6654	36	157	162	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					229	238		10.1016/S0092-8674(00)81017-X	http://dx.doi.org/10.1016/S0092-8674(00)81017-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428034	Bronze			2022-12-24	WOS:000081632300012
J	Huang, JT; Welch, JS; Ricote, M; Binder, CJ; Willson, TM; Kelly, C; Witztum, JL; Funk, CD; Conrad, D; Glass, CK				Huang, JT; Welch, JS; Ricote, M; Binder, CJ; Willson, TM; Kelly, C; Witztum, JL; Funk, CD; Conrad, D; Glass, CK			Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase	NATURE			English	Article							ACTIVATED RECEPTOR-GAMMA; LOW-DENSITY-LIPOPROTEIN; MAMMALIAN LIPOXYGENASES; PERITONEAL-MACROPHAGES; HUMAN 15-LIPOXYGENASE; TRANSCRIPTION FACTOR; GENE-EXPRESSION; OXIDIZED LDL; CD36; FIBROBLASTS	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-dependent nuclear receptor that has been implicated in the modulation of critical aspects of development and homeostasis, including adipocyte differentiation(1), glucose metabolism(2,3) and macrophage development and function(4-6). PPAR-gamma is activated by a range of synthetic and naturally occurring substances, including antidiabetic thiazolidinediones(2,3), polyunsaturated fatty acids(7), 15-deoxy-Delta(12,14)prostaglandin J(2) (refs 8, 9) and components of oxidized low-density lipoprotein, such as 13-hydroxyoctadecadienoic acid (13-HODE) and 15-hydroxyeicosatetraenoic acid (15-HETE)(10), However, the identities of endogenous ligands for PPAR-gamma and their means of production in vivo have not been established. In monocytes and macrophages, 13-HODE and 15-HETE can be generated from linoleic and arachidonic acids, respectively, by a 12/15-lipoxygenase that is upregulated by the T(H)2-derived cytokine interleukin-4 (ref. 11). Here we show that interleukin-4 also induces the expression of PPAR-gamma and provide evidence that the coordinate induction of PPAR-gamma and 12/15-lipoxygenase mediates interleukin-4-dependent transcription of the CD36 gene in macrophages. These findings reveal a physiological role of 12/15-lipoxygenase in the generation of endogenous ligands for PPAR-gamma, and suggest a paradigm for the regulation of nuclear receptor function by cytokines.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Nephrol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; GlaxoSmithKline; University of Pennsylvania	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Ricote, Mercedes/L-4615-2014; Glass, Christopher/AAI-3933-2021; Funk, Colin D/A-9518-2010; feinstein, doug/M-9414-2019	Ricote, Mercedes/0000-0002-8090-8902; Glass, Christopher/0000-0003-4344-3592; Binder, Christoph J./0000-0001-8313-7050; Funk, Colin/0000-0001-7029-4233				BENZ DJ, 1995, J BIOL CHEM, V270, P5191, DOI 10.1074/jbc.270.10.5191; BOGDAN C, 1994, J LEUKOCYTE BIOL, V55, P227, DOI 10.1002/jlb.55.2.227; CONRAD DJ, 1992, P NATL ACAD SCI USA, V89, P217, DOI 10.1073/pnas.89.1.217; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Funk CD, 1996, BBA-LIPID LIPID MET, V1304, P65, DOI 10.1016/S0005-2760(96)00107-5; Heydeck D, 1998, BLOOD, V92, P2503, DOI 10.1182/blood.V92.7.2503.2503_2503_2510; Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184; KILEWER SA, 1995, CELL, V83, P813; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kuhn H, 1996, PROG LIPID RES, V35, P203, DOI 10.1016/S0163-7827(96)00008-2; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; RANKIN SM, 1991, J LIPID RES, V32, P449; Ricote M, 1998, P NATL ACAD SCI USA, V95, P7614, DOI 10.1073/pnas.95.13.7614; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; Sun DX, 1996, J BIOL CHEM, V271, P24055, DOI 10.1074/jbc.271.39.24055; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; van Leyen K, 1998, NATURE, V395, P392, DOI 10.1038/26500; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Yamada Y, 1998, CELL MOL LIFE SCI, V54, P628, DOI 10.1007/s000180050191; YAMAMOTO S, 1992, BIOCHIM BIOPHYS ACTA, V1128, P117, DOI 10.1016/0005-2760(92)90297-9; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	30	740	774	0	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					378	382		10.1038/22572	http://dx.doi.org/10.1038/22572			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432118				2022-12-24	WOS:000081590000054
J	Lowrie, DB; Tascon, RE; Bonato, VLD; Lima, VMF; Faccioli, LH; Stavropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K; Silva, CL				Lowrie, DB; Tascon, RE; Bonato, VLD; Lima, VMF; Faccioli, LH; Stavropoulos, E; Colston, MJ; Hewinson, RG; Moelling, K; Silva, CL			Therapy of tuberculosis in mice by DNA vaccination	NATURE			English	Article							MYCOBACTERIUM-TUBERCULOSIS; T-CELLS; INTERLEUKIN-12; EXPRESSION; INFECTION; IMMUNITY; IL-12; RESISTANCE; ANTIGEN; MPT70	Mycobacterium tuberculosis continues to kill about 3 million people every year(1), more than any other single infectious agent, This is attributed primarily to an inadequate immune response towards infecting bacteria, which suffer growth inhibition rather than death and subsequently multiply catastrophically. Although the bacillus Calmette-Guerin (BCG) vaccine is widely used, it has major limitations as a preventative measure(2), In addition, effective treatment requires that patients take large doses of antibacterial drug combinations for at least 6 months after diagnosis(3), which is difficult to achieve in many parts of the world and is further restricted by the emergence of multidrug-resistant strains of M. tuberculosis, In these circumstances, immunotherapy to boost the efficiency of the immune system in infected patients could be a valuable adjunct to antibacterial chemotherapy(4), Here we show in mice that DNA vaccines, initially designed to prevent infection, can also have a pronounced therapeutic action, In heavily infected mice, DNA vaccinations can switch the immune response from one that is relatively inefficient and gives bacterial stasis to one that kills bacteria, Application of such immunotherapy in conjunction with conventional chemotherapeutic antibacterial drugs might result in faster or more certain cure of the disease in humans.	Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, BR-14049900 Ribeirao Preto, SP, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, BR-14049900 Ribeirao Preto, SP, Brazil; Natl Inst Med Res, Mycobacteriol Res Lab, London NW7 1AA, England; Cent Vet Lab, Addlestone KT15 3NB, Surrey, England; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Universidade de Sao Paulo; Universidade de Sao Paulo; MRC National Institute for Medical Research; University of Zurich	Silva, CL (corresponding author), Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto, Dept Clin Anal, BR-14049900 Ribeirao Preto, SP, Brazil.	clsilva@beverly.fmrp.usp.br	Hewinson, Glyn/AAA-2364-2019; Silva, Celio/C-4639-2012; Hewinson, Glyn/J-1902-2014; Lowrie, Douglas/B-8151-2013; Hewinson, Glyn/F-7077-2010; Lucia, Faccioli/G-8976-2015; de Lima, Valéria M.F./B-7867-2013; Bonato, Vania LD/C-3509-2015; Faccioli, Lúcia Helena/AGH-5297-2022	Silva, Celio/0000-0002-0043-4568; Lowrie, Douglas/0000-0003-2689-9627; Lucia, Faccioli/0000-0002-4999-8305; de Lima, Valéria M.F./0000-0002-0954-5045; Bonato, Vania LD/0000-0003-4189-2685; Faccioli, Lúcia Helena/0000-0002-4999-8305; Hewinson, Glyn/0000-0002-5517-4281				ALLAN WGL, 1982, TUBERCLE, V63, P89; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Bloom Barry R., 1994, P531; Bonato VLD, 1998, INFECT IMMUN, V66, P169, DOI 10.1128/IAI.66.1.169-175.1998; CHAPMAN BS, 1991, NUCLEIC ACIDS RES, V19, P3979, DOI 10.1093/nar/19.14.3979; Cooper AM, 1997, J EXP MED, V186, P39, DOI 10.1084/jem.186.1.39; de Jong R, 1998, SCIENCE, V280, P1435; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; FLYNN JL, 1995, J IMMUNOL, V155, P2515; Hewinson RG, 1996, SCAND J IMMUNOL, V43, P490, DOI 10.1046/j.1365-3083.1996.d01-78.x; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; Johnston SA, 1997, VACCINE, V15, P808, DOI 10.1016/S0264-410X(96)00276-9; KOCHI A, 1994, LANCET, V344, P608; Krieg AM, 1998, J IMMUNOL, V161, P2428; Lai WC, 1997, J IMMUNOL, V158, P2513; Lowrie DB, 1997, VACCINE, V15, P834, DOI 10.1016/S0264-410X(97)00073-X; MATSUMOTO S, 1995, SCAND J IMMUNOL, V41, P281, DOI 10.1111/j.1365-3083.1995.tb03565.x; MCCUNE RM, 1966, J EXP MED, V123, P445, DOI 10.1084/jem.123.3.445; MITCHISON DA, 1985, TUBERCLE, V66, P219, DOI 10.1016/0041-3879(85)90040-6; ORME IM, 1993, J IMMUNOL, V151, P518; SCHULTZ J, IN PRESS HUM GENE TH; Smith P. G., 1994, P47; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Tascon RE, 1997, NATO ADV SCI I A-LIF, V293, P181; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; Trinchieri G, 1998, IMMUNOL RES, V17, P269, DOI 10.1007/BF02786451; WIEGESHAUS E, 1989, INFECT IMMUN, V57, P3671, DOI 10.1128/IAI.57.12.3671-3676.1989; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; ZHANG M, 1995, INFECT IMMUN, V63, P3231, DOI 10.1128/IAI.63.8.3231-3234.1995; Zhu XJ, 1997, J IMMUNOL, V158, P5921	30	372	425	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					269	271		10.1038/22326	http://dx.doi.org/10.1038/22326			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421369				2022-12-24	WOS:000081503800045
J	Kadir, RA; Sabin, C; Whitlow, B; Brockbank, E; Economides, D				Kadir, RA; Sabin, C; Whitlow, B; Brockbank, E; Economides, D			Neural tube defects and periconceptional folic acid in England and Wales: retrospective study	BRITISH MEDICAL JOURNAL			English	Article								The risks of a first occurrence and a recurrence of neural tube defects have been shown to be reduced by periconceptional folic acid supplementation-that is by taking folic acid from 3 months before conception to 3 months after conception.(1 2) The Expert Advisory Group in the United Kingdom recommended in 1992 that women who were trying to conceive should take 0.4 mg folic acid per day.(3) We assessed whether there had been any change in the incidence of neural tube defects since this recommendation was made.	UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, London NW3 2QG, England; UCL Royal Free & Univ Coll Med Sch, Dept Epidemiol & Populat Sci, London, England	University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School	Economides, D (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Obstet & Gynaecol, London NW3 2QG, England.		Abdulkadir, Rezan/C-5589-2008; Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; *DEP HLTH SCOTT OF, 1992, REP EXP ADV GROUP FO; McGovern E, 1997, BRIT J GEN PRACT, V47, P635; WALD N, 1991, LANCET, V338, P131	4	40	40	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					92	93		10.1136/bmj.319.7202.92	http://dx.doi.org/10.1136/bmj.319.7202.92			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398632	Bronze, Green Published			2022-12-24	WOS:000081438200031
J	Nightingale, SL				Nightingale, SL			Trovafloxacin public health advisory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					19	19		10.1001/jama.282.1.19	http://dx.doi.org/10.1001/jama.282.1.19			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404896				2022-12-24	WOS:000081195800007
J	Dyer, C				Dyer, C			Doctors as gods	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					64	64		10.1136/bmj.319.7201.64	http://dx.doi.org/10.1136/bmj.319.7201.64			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390489	Green Published			2022-12-24	WOS:000081326500072
J	Todd, JA				Todd, JA			Interpretation of results from genetic studies of multifactorial diseases	LANCET			English	Article							ALZHEIMER-DISEASE; INSULIN GENE		Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 2XY, England	University of Cambridge	Todd, JA (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Wellcome Trust-MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.		Todd, John/A-3542-2010	Todd, John/0000-0003-2740-8148	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altshuler D, 1998, NEW ENGL J MED, V338, P1626, DOI 10.1056/NEJM199805283382214; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Blacker D, 1998, ARCH NEUROL-CHICAGO, V55, P294, DOI 10.1001/archneur.55.3.294; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; Bonn D, 1999, LANCET, V353, P1684, DOI 10.1016/S0140-6736(05)76995-6; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; CUCCA F, 1996, HLA MHC GENES MOL FU, P3483; DAY N, IN PRESS BR J CANC S; Dow DJ, 1999, NAT GENET, V22, P16, DOI 10.1038/8724; Golding J, 1990, West Engl Med J, V105, P80; Rogaeva EA, 1999, NAT GENET, V22, P19, DOI 10.1038/8729; Rudrasingham V, 1999, NAT GENET, V22, P17, DOI 10.1038/8726; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; SUAREZ BK, 1994, GENETIC APPROACHES M, P23; TODD JA, IN PRESS METABOLIC M; 1999, NAT GENET, V22, P1	17	21	21	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI15	SI16						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437850				2022-12-24	WOS:000081825900005
J	Glaser, R; Rabin, B; Chesney, M; Cohen, S				Glaser, R; Rabin, B; Chesney, M; Cohen, S			Stress-induced immunomodulation - Implications for infectious diseases?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CELLULAR IMMUNE-RESPONSES; HEPATITIS-B VACCINE; PSYCHOLOGICAL STRESS; COMMON COLD; ADRENERGIC-BLOCKADE; DEPRESSIVE SYMPTOMS; MENTAL STRESS; GAY MEN; SUSCEPTIBILITY		Ohio State Univ, Med Ctr, Dept Med Microbiol & Immunol, Columbus, OH 43210 USA; Univ Pittsburgh, Med Ctr, Dept Pathol, Clin Immunopathol CLSI, Pittsburgh, PA USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, E Orange, NJ USA	University System of Ohio; Ohio State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; Carnegie Mellon University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Glaser, R (corresponding author), Ohio State Univ, Med Ctr, Dept Med Microbiol & Immunol, 2175 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.	glaser.1@postbox.acs.ohio-state.edu	Glaser, Ronald/E-3124-2011	Cohen, Sheldon/0000-0003-2248-4600	NIMH NIH HHS [MH00721] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACHEN EA, 1995, PSYCHOSOM MED, V57, P366, DOI 10.1097/00006842-199507000-00008; BENSCHOP RJ, 1994, CIRCULATION, V89, P762, DOI 10.1161/01.CIR.89.2.762; BURACK JH, 1993, JAMA-J AM MED ASSOC, V270, P2568, DOI 10.1001/jama.270.21.2568; Cohen S, 1997, JAMA-J AM MED ASSOC, V277, P1940; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214; Cole SW, 1996, PSYCHOSOM MED, V58, P219, DOI 10.1097/00006842-199605000-00005; Glaser R, 1998, ANN NY ACAD SCI, V840, P649, DOI 10.1111/j.1749-6632.1998.tb09603.x; GLASER R, 1992, PSYCHOSOM MED, V54, P22, DOI 10.1097/00006842-199201000-00005; Glaser R., 1994, HUMAN HERPESVIRUS IN, P245; GRAVENSTEIN S, 1994, J AM GERIATR SOC, V42, P245, DOI 10.1111/j.1532-5415.1994.tb01746.x; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364, DOI 10.1097/00006842-199307000-00004; Ironson G, 1994, Int J Behav Med, V1, P90, DOI 10.1207/s15327558ijbm0101_6; JABAAIJ L, 1993, J PSYCHOSOM RES, V37, P361, DOI 10.1016/0022-3999(93)90138-6; Kiecolt-Glaser JK, 1998, AM PSYCHOL, V53, P1209, DOI 10.1037/0003-066X.53.11.1209; KIECOLTGLASER JK, 1995, LANCET, V346, P1194, DOI 10.1016/S0140-6736(95)92899-5; KiecoltGlaser JK, 1996, P NATL ACAD SCI USA, V93, P3043, DOI 10.1073/pnas.93.7.3043; LYKETSOS CG, 1993, JAMA-J AM MED ASSOC, V270, P2563, DOI 10.1001/jama.270.21.2563; Mayne TJ, 1996, ARCH INTERN MED, V156, P2233, DOI 10.1001/archinte.156.19.2233; Padgett DA, 1998, P NATL ACAD SCI USA, V95, P7231, DOI 10.1073/pnas.95.12.7231; Rabin B.S., 1999, STRESS IMMUNE FUNCTI; RASSNICK S, 1994, J NEUROSCI, V14, P6033; SOLOMON GF, 1991, PSYCHONEUROIMMUNOLOG, P1081; TOBACH E, 1956, AM J PHYSIOL, V187, P399, DOI 10.1152/ajplegacy.1956.187.2.399; Vedhara K, 1999, LANCET, V353, P627, DOI 10.1016/S0140-6736(98)06098-X; WETMORE L, 1991, EXP NEUROL, V113, P226, DOI 10.1016/0014-4886(91)90179-G	26	122	124	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2268	2270		10.1001/jama.281.24.2268	http://dx.doi.org/10.1001/jama.281.24.2268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207FN	10386538				2022-12-24	WOS:000080925600001
J	Rzany, B; Correia, O; Kelly, JP; Naldi, L; Auquier, A; Stern, R				Rzany, B; Correia, O; Kelly, JP; Naldi, L; Auquier, A; Stern, R		Study Grp Int Case-Control Study Sever	Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study	LANCET			English	Article							ERYTHEMA MULTIFORME; LAMOTRIGINE; APOPTOSIS; RADIATION; GERMANY; DEATH	Background There is still controversy about whether all antiepileptic drugs are associated with the severe cutaneous reactions Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). We have studied the role of antiepileptic drugs in SJS and TEN, taking into account potential cofactors that might confound or modify the risk. Methods The case-control study in France, Italy, Germany, and Portugal identified cases of SJS/TEN that developed when the patient was not in hospital and were validated by an expert committee. Controls were patients admitted to the same hospital as the case for an acute illness or an elective procedure. Findings 73 (21%) of the 352 SJS/TEN cases and 28 (2%) of the 1579 controls reported intake of antiepileptic drugs. Among the 73 exposed SJS and TEN patients, 36 reported intake of phenobarbital, 14 of phenytoin, 21 of carbamazepine, 13 of valproic acid, and three of lamotrigine. Risk was highest in the first 8 weeks after onset of treatment. For individual antiepileptic drugs the univariate relative risk of SJS/TEN for 8 weeks or less of use was 57 (95% CI 16-360; multivariate risk 59 [12-302]) for phenobarbital; 91(26-infinity) for phenytoin; 120 (34-infinity) for carbamazepine; 25 (5.6-infinity) for lamotrigine, and 24 (5.9-infinity) for valproic acid. The result for valproic acid was based on four case users, all of whom reported concurrent use of other associate drugs. The univariate relative risk for more than 8 weeks of use was 6.2 (2.4-17.0; multivariate risk 2.1 [0.5-9.3]) for phenobarbital, 1.2 (0-5.4) for phenytoin, 0.4 (0.02-2.1) for carbamazepine, and 7.0 (2.4-21.0; multivariate risk 2.0 [0.3-15.0]) for valproic acid. Interpretation SJS and TEN are associated with short-term therapy with phenytoin, phenobarbital, and carbamazepine. The association with valproic acid seems to be confounded by concomitant short-term therapy with other causal drugs. Lamotrigine also has the potential for severe skin reactions. The period of increased risk is largely confined to the first 8 weeks of treatment.	Univ Heidelberg, Fak Klin Med Mannheim, Dept Dermatol, D-6800 Mannheim, Germany; Fac Med, Inst Portugues Oncol & Immunol, Dept Dermatol & Immunol, Porto, Portugal; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Milan, Osped Riuniti, Dept Dermatol, Bergamo, Italy; Inst Gustave Roussy, Dept Biostat & Epidemiol, Villejuif, France; Harvard Univ, Sch Med, Beth Israel Deaconess Med CTr, Dept Dermatol, Boston, MA USA	Ruprecht Karls University Heidelberg; Universidade do Porto; Boston University; Ospedali Riuniti di Bergamo; University of Milan; UNICANCER; Gustave Roussy; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rzany, B (corresponding author), Univ Heidelberg, Klinikum Mannheim gGmbH, Fak Klin Med Mannheim, Hautklin, Theodor Kutzer Ufer, D-68135 Mannheim, Germany.		Naldi, Luigi/AFM-8982-2022; Naldi, Luigi/K-6343-2016	Naldi, Luigi/0000-0002-3160-2835; Naldi, Luigi/0000-0002-3160-2835				ASMARK H, 1990, ACTA NEUROL SCAND, V81, P131; BASTUJI S, 1993, ARCH DERMATOL, V125, P92; Borg M F, 1995, Australas Radiol, V39, P42, DOI 10.1111/j.1440-1673.1995.tb00230.x; Chaffin JJ, 1997, ANN PHARMACOTHER, V31, P720, DOI 10.1177/106002809703100609; CHAN HL, 1990, ARCH DERMATOL, V126, P43, DOI 10.1001/archderm.126.1.43; CHEN M, 1995, CANCER RES, V55, P991; DELATTRE JY, 1988, NEUROLOGY, V38, P194, DOI 10.1212/WNL.38.2.194; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; DUVAL X, 1995, LANCET, V345, P1301; Fogh K, 1997, SEIZURE, V6, P63, DOI 10.1016/S1059-1311(97)80055-6; GOODMAN LS, 1985, PHARMACOL BASIS THER, P446; Inachi S, 1997, ARCH DERMATOL, V133, P845, DOI 10.1001/archderm.133.7.845; KELLY JP, 1995, J CLIN EPIDEMIOL, V48, P1099, DOI 10.1016/0895-4356(95)00004-N; LEENUTAPHONG V, 1993, INT J DERMATOL, V32, P428, DOI 10.1111/j.1365-4362.1993.tb02814.x; MAICHE A, 1985, LANCET, V2, P45; MIETTINEN OS, 1976, AM J EPIDEMIOL, V109, P226; NAWALKHA PL, 1972, BRIT J RADIOL, V45, P768, DOI 10.1259/0007-1285-45-538-768; Paul C, 1996, BRIT J DERMATOL, V134, P710, DOI 10.1111/j.1365-2133.1996.tb06976.x; ROUJEAU JC, 1990, ARCH DERMATOL, V126, P37, DOI 10.1001/archderm.126.1.37; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; RUIZMALDONADO R, 1985, J AM ACAD DERMATOL, V13, P623, DOI 10.1016/S0190-9622(85)70207-1; Rzany B, 1996, J CLIN EPIDEMIOL, V49, P769, DOI 10.1016/0895-4356(96)00035-2; Sachs B, 1996, LANCET, V348, P1597, DOI 10.1016/S0140-6736(05)66227-7; SCHOPF E, 1991, ARCH DERMATOL, V127, P839, DOI 10.1001/archderm.127.6.839; STERKER M, 1995, INT J CLIN PHARM TH, V33, P595; STERN RS, 1989, J AM ACAD DERMATOL, V21, P317, DOI 10.1016/S0190-9622(89)70176-6; Sullivan J R, 1996, Australas J Dermatol, V37, P208, DOI 10.1111/j.1440-0960.1996.tb01057.x; Tennis P, 1997, NEUROLOGY, V49, P542, DOI 10.1212/WNL.49.2.542; Wadelius M, 1996, LANCET, V348, P1041, DOI 10.1016/S0140-6736(05)64979-3	29	222	226	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2190	2194		10.1016/S0140-6736(98)05418-X	http://dx.doi.org/10.1016/S0140-6736(98)05418-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392983				2022-12-24	WOS:000081091300011
J	Hong, KS; Hinck, L; Nishiyama, M; Poo, MM; Tessier-Lavigne, M; Stein, E				Hong, KS; Hinck, L; Nishiyama, M; Poo, MM; Tessier-Lavigne, M; Stein, E			A ligand-gated association between cytoplasmic domains of UNC5 and DCC family receptors converts netrin-induced growth cone attraction to repulsion	CELL			English	Article							C-ELEGANS; COLORECTAL-CANCER; AXON GUIDANCE; ENCODES; PROTEIN; GENES; IMMUNOGLOBULIN; EXPRESSION; MIGRATIONS; RESPONSES	Netrins are bifunctional: they attract some axons and repel others. Netrin receptors of the Deleted in Colorectal Cancer (DCC) family are implicated in attraction and those of the UNC5 family in repulsion, but genetic evidence also suggests involvement of the DCC protein UNC-40 in some cases of repulsion. To test whether these proteins form a receptor complex for repulsion, we studied the attractive responses of Xenopus spinal axons to netrin-1, which are mediated by DCC. Vie show that attraction is converted to repulsion by expression of UNC5 proteins in these cells, that this repulsion requires DCC function, that the UNC5 cytoplasmic domain is sufficient to effect the conversion, and that repulsion can be initiated by netrin-1 binding to either UNC5 or DCC. The isolated cytoplasmic domains of DCC and UNC5 proteins interact directly, but this interaction is repressed in the context of the full-length proteins. We provide evidence that netrin-1 triggers the formation of a receptor complex of DCC: and UNC5 proteins and simultaneously derepresses the interaction between their cytoplasmic domains, thereby converting DCC-mediated attraction to UNC5/DCC-mediated repulsion.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Tessier-Lavigne, M (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Stein, Elke/E-8107-2013	Stein, Elke/0000-0001-8965-5692; Hinck, Lindsay/0000-0002-4009-3913	NINDS NIH HHS [NS22764] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ackerman SL, 1997, NATURE, V386, P838, DOI 10.1038/386838a0; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; Bashaw GJ, 1999, CELL, V97, P917, DOI 10.1016/S0092-8674(00)80803-X; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CLARY DO, 1994, MOL BIOL CELL, V5, P549, DOI 10.1091/mbc.5.5.549; Colavita A, 1998, DEV BIOL, V194, P72, DOI 10.1006/dbio.1997.8790; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; Gong QZ, 1999, DEVELOPMENT, V126, P1451; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOFMANN K, 1995, FEBS LETT, V371, P321, DOI 10.1016/0014-5793(95)00931-X; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; Leonardo ED, 1997, NATURE, V386, P833, DOI 10.1038/386833a0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Mehlen P, 1998, NATURE, V395, P801, DOI 10.1038/27441; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Przyborski SA, 1998, DEVELOPMENT, V125, P41; Rose M, 1990, LAB COURSE MANUAL ME; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Tabti N., 1991, CULTURING NERVE CELL, P137; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Van Vactor D, 1999, NEURON, V22, P649, DOI 10.1016/S0896-6273(00)80723-0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wadsworth WG, 1996, BIOESSAYS, V18, P355, DOI 10.1002/bies.950180505; Wang XH, 1997, NEURON, V19, P825, DOI 10.1016/S0896-6273(00)80964-2; ZHANG JQ, 1994, NATURE, V368, P140	37	545	568	4	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					927	941		10.1016/S0092-8674(00)80804-1	http://dx.doi.org/10.1016/S0092-8674(00)80804-1			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399920	Bronze			2022-12-24	WOS:000081162800013
J	Izraeli, S; Lowe, LA; Bertness, VL; Good, DJ; Dorward, DW; Kirsch, IR; Kuehn, MR				Izraeli, S; Lowe, LA; Bertness, VL; Good, DJ; Dorward, DW; Kirsch, IR; Kuehn, MR			The SIL gene is required for mouse embryonic axial development and left-right specification	NATURE			English	Article							LEFT-RIGHT ASYMMETRY; SIGNALING PATHWAY; SONIC HEDGEHOG; TRANSCRIPTION FACTOR; NODAL EXPRESSION; NOTOCHORD; ZEBRAFISH; INDUCTION; PATTERN; PITX2	The establishment of the main body axis and the determination of left-right asymmetry are fundamental aspects of vertebrate embryonic development. A link between these processes has been revealed by the frequent finding of midline defects in humans with left-right anomalies(1). This association is also seen in a number of mutations in mouse(2-4) and zebrafish(1,5), and in experimentally manipulated Xenopus embryos(5). However, the severity of laterality defects accompanying abnormal midline development varies(6), and the molecular basis for this variation is unknown. Here we show that mouse embryos lacking the early-response gene SIL have axial midline defects, a block in midline Sonic hedgehog (Shh) signalling and randomized cardiac looping. Comparison with Shh mutant embryos(7), which have axial defects but normal cardiac looping, indicates that the consequences of abnormal midline development for left-right patterning depend on the time of onset, duration and severity of disruption of the normal asymmetric patterns of expression of nodal, lefty-2 and Pitx2.	NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; NCI, Dept Genet, Med Branch, NIH, Bethesda, MD 20889 USA; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; NIAID, Rocky Mt Labs, NIH, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Massachusetts System; University of Massachusetts Amherst; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kuehn, MR (corresponding author), NCI, Expt Immunol Branch, NIH, Bldg 10, Bethesda, MD 20892 USA.	kirshi@exchange.nih.gov; mkuehn@box-m.nih.gov	Kuehn, Michael R/A-4573-2014	Kuehn, Michael R/0000-0002-7703-9160	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC006579] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [Z01BC009297, ZIABC009297] Funding Source: NIH RePORTER	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; Campione M, 1999, DEVELOPMENT, V126, P1225; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CollazoGarcia N, 1995, GENOMICS, V30, P506, DOI 10.1006/geno.1995.1271; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Danos MC, 1996, DEV BIOL, V177, P96, DOI 10.1006/dbio.1996.0148; Goldstein AM, 1998, DEV GENET, V22, P278, DOI 10.1002/(SICI)1520-6408(1998)22:3<278::AID-DVG9>3.0.CO;2-3; Good DJ, 1997, NAT GENET, V15, P397, DOI 10.1038/ng0497-397; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Heymer J, 1997, MECH DEVELOP, V66, P5, DOI 10.1016/S0925-4773(97)00084-1; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; Izraeli S, 1997, CELL GROWTH DIFFER, V8, P1171; King T, 1998, MECH DEVELOP, V79, P29, DOI 10.1016/S0925-4773(98)00166-X; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Lohr JL, 1997, DEVELOPMENT, V124, P1465; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; Melloy PG, 1998, DEV BIOL, V193, P77, DOI 10.1006/dbio.1997.8787; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Motoyama J, 1998, NAT GENET, V20, P54, DOI 10.1038/1711; Oh SP, 1997, GENE DEV, V11, P1812, DOI 10.1101/gad.11.14.1812; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7	30	169	172	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					691	694		10.1038/21429	http://dx.doi.org/10.1038/21429			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385121				2022-12-24	WOS:000080932800061
J	Geng, Y; Whoriskey, W; Park, MY; Bronson, RT; Medema, RH; Li, TS; Weinberg, RA; Sicinski, P				Geng, Y; Whoriskey, W; Park, MY; Bronson, RT; Medema, RH; Li, TS; Weinberg, RA; Sicinski, P			Rescue of cyclin D1 deficiency by knockin cyclin E	CELL			English	Article							RETINOBLASTOMA PROTEIN; CELL-PROLIFERATION; S-PHASE; DEPENDENT KINASES; ESTROGEN-RECEPTOR; MAMMARY-GLAND; G1 CYCLIN; E GENE; TRANSCRIPTION; EXPRESSION	D-type cyclins and cyclin E represent two very distinct classes of mammalian G1 cyclins. We have generated a mouse strain in which the coding sequences of the cyclin D1 gene (Ccnd1) have been deleted and replaced by those of human cyclin E (CCNE). In the tissues and cells of these mice, the expression pattern of human cyclin E faithfully reproduces that normally associated with mouse cyclin D1. The replacement of cyclin D1 with cyclin E rescues all phenotypic manifestations of cyclin D1 deficiency and restores normal development in cyclin D1-dependent tissues. Thus, cyclin E can functionally replace cyclin D1. Our analyses suggest that cyclin E is the major downstream target of cyclin D1.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Tufts Univ, Sch Med & Vet Med, Boston, MA 02111 USA; Univ Utrecht, Med Ctr, Jordan Lab, Dept Hematol, NL-3584 CX Utrecht, Netherlands; Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Berman Gund Lab Study Retinal Degenerat, Boston, MA 02114 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Tufts University; Utrecht University; Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Sicinski, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.		Medema, Rene H/G-5415-2011; Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381	NATIONAL CANCER INSTITUTE [R35CA039826] Funding Source: NIH RePORTER; NCI NIH HHS [535CA39826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Botz J, 1996, MOL CELL BIOL, V16, P3401; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; Geng Y, 1996, ONCOGENE, V12, P1173; Gudas JM, 1999, MOL CELL BIOL, V19, P612; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Robinson GW, 1998, GENE DEV, V12, P1907, DOI 10.1101/gad.12.12.1907; SAVOURET JF, 1991, EMBO J, V10, P1875, DOI 10.1002/j.1460-2075.1991.tb07713.x; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Steinberg RH., 1991, PROGR RETINAL RES, V10, P121, DOI 10.1016/0278-4327(91)90011-P; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; Zariwala M, 1998, ONCOGENE, V17, P2787, DOI 10.1038/sj.onc.1202505; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	25	279	282	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					767	777		10.1016/S0092-8674(00)80788-6	http://dx.doi.org/10.1016/S0092-8674(00)80788-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380928	Bronze			2022-12-24	WOS:000080886300014
J	Rocheleau, CE; Yasuda, J; Shin, TH; Lin, RL; Sawa, H; Okano, H; Priess, JR; Davis, RJ; Mello, CC				Rocheleau, CE; Yasuda, J; Shin, TH; Lin, RL; Sawa, H; Okano, H; Priess, JR; Davis, RJ; Mello, CC			WRM-1 activates the LIT-1 protein kinase to transduce anterior posterior polarity signals in C-elegans	CELL			English	Article							ASYMMETRIC CELL DIVISIONS; CAENORHABDITIS-ELEGANS; BETA-CATENIN; DROSOPHILA EYE; GENE LIN-44; ENCODES; ADHESION; EMBRYOS; IDENTIFICATION; SPECIFICATION	During C. elegans development, Wnt/WG signaling is required for differences in cell fate between sister cells born from anterior/posterior divisions. A beta-catenin-related gene, wrm-1, and the lit-1 gene are effecters of this signaling pathway and appear to downregulate the activity of POP-1, a TCF/LEF-related protein, in posterior daughter cells. We show here that lit-1 encodes a serine/threonine protein kinase homolog related to the Drosophila tissue polarity protein Nemo. We demonstrate that the WRM-1 protein binds to LIT-1 in vivo and that WRM-1 can activate the LIT-1 protein kinase when coexpressed in vertebrate tissue culture cells. This activation leads to phosphorylation of POP-1 and to apparent changes in its subcellular-localization. Our findings provide evidence for novel regulatory avenues for an evolutionarily conserved Wnt/WG signaling pathway.	Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Japan Soc & Technol Corp, Dept Neuroanat, Ctr Biomed Res, Suita, Osaka 5650871, Japan; Japan Soc & Technol Corp, PRESTO, Suita, Osaka 5650871, Japan; Japan Soc & Technol Corp, CREST, Suita, Osaka 5650871, Japan; Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Zool, Seattle, WA 98195 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Mello, CC (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.		Okano, Hideyuki/I-7584-2019	Yasuda, Jun/0000-0002-3887-6871; Sawa, Hitoshi/0000-0001-9774-7976; Rocheleau, Christian/0000-0001-6738-5636				Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; BRENNER S, 1974, GENETICS, V77, P71; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Bullions Linda C., 1998, Current Opinion in Oncology, V10, P81, DOI 10.1097/00001622-199801000-00013; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo R, 1997, CURR OPIN GENET DEV, V7, P459, DOI 10.1016/S0959-437X(97)80071-8; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; Costa M, 1998, J CELL BIOL, V141, P297, DOI 10.1083/jcb.141.1.297; Eisenmann DM, 1998, DEVELOPMENT, V125, P3667; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; Han M, 1997, CELL, V90, P581, DOI 10.1016/S0092-8674(00)80517-6; HERMAN MA, 1994, DEVELOPMENT, V120, P1035; HERMAN MA, 1995, CELL, V83, P101, DOI 10.1016/0092-8674(95)90238-4; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KLYMKOWSKY MW, 1995, CELL, V83, P5, DOI 10.1016/0092-8674(95)90226-0; Kuhl M, 1997, BIOESSAYS, V19, P101, DOI 10.1002/bies.950190204; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; Mello C, 1995, METHOD CELL BIOL, V48, P451; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Muller HAJ, 1999, DEVELOPMENT, V126, P577; Novak A, 1998, P NATL ACAD SCI USA, V95, P4374, DOI 10.1073/pnas.95.8.4374; Papavassiliou Athanasios G., 1992, Methods in Molecular and Cellular Biology, V3, P149; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R., 1997, C ELEGANS, P361; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; Tournier C, 1999, MOL CELL BIOL, V19, P1569; VINSON CR, 1989, NATURE, V338, P263, DOI 10.1038/338263a0; VINSON CR, 1987, NATURE, V329, P549, DOI 10.1038/329549a0; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; ZHENG L, 1995, DEVELOPMENT, V121, P3045	42	216	228	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					717	726		10.1016/S0092-8674(00)80784-9	http://dx.doi.org/10.1016/S0092-8674(00)80784-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380924	Bronze			2022-12-24	WOS:000080886300010
J	Purnell, BA; Marx, J				Purnell, BA; Marx, J			Microbe management	SCIENCE			English	Editorial Material																			0	3	3	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1301	1301		10.1126/science.284.5418.1301	http://dx.doi.org/10.1126/science.284.5418.1301			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383311				2022-12-24	WOS:000080430600036
J	Meddings, DR; O'Connor, SM				Meddings, DR; O'Connor, SM			Circumstances around weapon injury in Cambodia after departure of a peacekeeping force: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							WAR; EPIDEMIOLOGY; INTERVENTION; HEALTH	Objective To examine the circumstances surrounding weapon injury and combatant status of those injured by weapons. Design Prospective cohort study Setting Northwestern Cambodia after departure of United Nations peacekeeping force, Subjects 863 people admitted to hospital for weapon injuries over 12 months. Main outcome measures Annual incidence of Weapon injury by time period; proportions of injuries inflicted as a result of interfactional combat (combat injuries) and outside such combat (non-combat injuries) by combatant status and weapon type. Results The annual incidence of weapon injuries was higher than the rate observed before the peacekeeping operation. 30%, of weapon injuries occurred in contexts other than inter-factional combat. Most commonly these were firearm injuries inflicted intentionally on civilians, Civilians accounted for 71% of those with non-combat injuries, 42% of those with combat related injuries, and 51% of those with weapon injuries of either type. Conclusions The incidence of weapon injuries remained high when the disarmament component of a peacekeeping operation achieved only limited success. Furthermore, injuries occurring outside the context of interfactional combat accounted for a substantial proportion of all weapon injuries, were experienced disproportionately by civilians, and were most likely to entail the intentional use of a firearm against a civilian.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Div Hlth Operat, CH-1202 Geneva, Switzerland		Meddings, DR (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							Aboutanos MB, 1997, J TRAUMA, V43, P719, DOI 10.1097/00005373-199710000-00031; ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; *AS WATCH PHYS HUM, 1991, LAND MIN CAMB COW WA; COBEY JC, 1993, JAMA-J AM MED ASSOC, V270, P632, DOI 10.1001/jama.270.5.632; COMNINELLIS N, 1994, TROP DOCT, V24, P1; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Coupland RM, 1999, BRIT MED J, V319, P410, DOI 10.1136/bmj.319.7207.410; Grossman Dave, 1995, KILLING PSYCHOL COST; Klare M. T., 1995, LETHAL COMMERCE GLOB; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; WANG J, 1996, MANAGING ARMS PEACE, P32; WEINBERG J, 1995, SOC SCI MED, V40, P1663, DOI 10.1016/0277-9536(95)00022-Y; Williams P., 1997, SOC SIEGE CRIME VIOL, P11; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	14	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					412	415		10.1136/bmj.319.7207.412	http://dx.doi.org/10.1136/bmj.319.7207.412			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445922	Bronze, Green Published			2022-12-24	WOS:000082098900016
J	Moszynski, P				Moszynski, P			United Nations estimates of HIV prevalence in Zambia under attack	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 7	1999	319	7206					338	338		10.1136/bmj.319.7206.338	http://dx.doi.org/10.1136/bmj.319.7206.338			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226CA	10435948	Green Published			2022-12-24	WOS:000082001700012
J	Zuber, ME; Perron, M; Philpott, A; Bang, A; Harris, WA				Zuber, ME; Perron, M; Philpott, A; Bang, A; Harris, WA			Giant eyes in Xenopus laevis by overexpression of XOptx2	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; HOMEOBOX GENE SIX3; S-PHASE; LENS INDUCTION; DROSOPHILA EYE; NERVOUS-SYSTEM; EYELESS GENE; SINE OCULIS; EXPRESSION; DIFFERENTIATION	Overexpression of XOptx2, a homeodomain-containing transcription factor expressed in the Xenopus embryonic eye field, results in a dramatic increase in eye size. An XOptx2-Engrailed repressor gives a similar phenotype, while an XOptx2-VP16 activator reduces eye size. XOptx2 stimulates bromodeoxyuridine incorporation, and XOptx2-induced eye enlargement is dependent on cellular proliferation. Moreover, retinoblasts transfected with XOptx2 produce clones of cells approximately twice as large as control clones. Pax6, which does not increase eye size alone, acts synergistically with XOptx2. Our results suggest that XOptx2, in combination with other genes expressed in the eye field, is crucially involved in the proliferative state of retinoblasts and thereby the size of the eye.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Dept Oncol, Cambridge CB3 2QQ, England; Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA	University of Cambridge; University of Cambridge; Salk Institute	Harris, WA (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.		Perron, Muriel/F-6795-2019	Perron, Muriel/0000-0002-1558-8236; Philpott, Anna/0000-0003-3789-2463	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altmann CR, 1997, DEV BIOL, V185, P119, DOI 10.1006/dbio.1997.8573; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; Casarosa S, 1997, MECH DEVELOP, V61, P187, DOI 10.1016/S0925-4773(96)00640-5; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; EAGLESON G, 1995, J NEUROBIOL, V28, P146, DOI 10.1002/neu.480280203; Faber J., 1994, NORMAL TABLE XENOPUS, P2; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Halder G, 1998, DEVELOPMENT, V125, P2181; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Harris W. A., 1979, SOC NEUROSCI S, V4, P228; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Hirsch N, 1997, J NEUROBIOL, V32, P45, DOI 10.1002/(SICI)1097-4695(199701)32:1<45::AID-NEU5>3.3.CO;2-V; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; Jean D, 1998, MECH DEVELOP, V76, P3, DOI 10.1016/S0925-4773(98)00117-8; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Kobayashi M, 1998, DEVELOPMENT, V125, P2973; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Li HS, 1997, DEVELOPMENT, V124, P603; Loosli F, 1999, GENE DEV, V13, P649, DOI 10.1101/gad.13.6.649; Lopez-Rios J, 1999, MECH DEVELOP, V83, P155, DOI 10.1016/S0925-4773(99)00017-9; MARDON G, 1994, DEVELOPMENT, V120, P3473; Mariani FV, 1998, DEVELOPMENT, V125, P5019; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Oliver G, 1996, MECH DEVELOP, V60, P233, DOI 10.1016/S0925-4773(96)00632-6; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; PITTACK C, 1991, DEVELOPMENT, V113, P577; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; ROTMANN ECKHARD, 1940, WILHELM ROUX ARCH ENTWICKLUNGSMECH ORGAN, V140, P124, DOI 10.1007/BF00576250; Rotmann Eckhard, 1939, Wilhelm Roux Arch Entwickl Mech Org, V139, P1, DOI 10.1007/BF00576382; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; Sakaguchi DS, 1997, DEV DYNAM, V209, P387, DOI 10.1002/(SICI)1097-0177(199708)209:4<387::AID-AJA6>3.0.CO;2-E; Shen WP, 1997, DEVELOPMENT, V124, P45; Sprenger F, 1997, CURR BIOL, V7, P488, DOI 10.1016/S0960-9822(06)00220-X; Stone LS, 1930, J EXP ZOOL, V55, P193, DOI 10.1002/jez.1400550112; Toy J, 1999, MECH DEVELOP, V83, P183, DOI 10.1016/S0925-4773(99)00049-0; Toy J, 1998, P NATL ACAD SCI USA, V95, P10643, DOI 10.1073/pnas.95.18.10643; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TWITTY V, 1955, ANAL DEV, P402; TWITTY VC, 1940, GROWTH, V4, P109	46	169	169	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					341	352		10.1016/S0092-8674(00)81963-7	http://dx.doi.org/10.1016/S0092-8674(00)81963-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458609	Bronze			2022-12-24	WOS:000081950300009
J	Clancy, CE; Rudy, Y				Clancy, CE; Rudy, Y			Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia	NATURE			English	Article							LONG-QT SYNDROME; DYNAMIC-MODEL; ION CHANNELS; MUTATIONS; HEART; AFTERDEPOLARIZATIONS; MECHANISM; MYOCYTES	Advances in genetics and molecular biology have provided an extensive body of information on the structure and function of the elementary building blocks of living systems. Genetic defects in membrane ion channels can disrupt the delicate balance of dynamic interactions between the ion channels and the cellular environment, leading to altered cell function(1-3). As ion-channel defects are typically studied in isolated expression systems, away from the cellular environment where they function physiologically, a connection between molecular findings and the physiology and pathophysiology of the cell is rarely established. Here we describe a single-channel-based Markovian modelling approach that bridges this gap. We achieve this by determining the cellular arrhythmogenic consequences of a mutation in the cardiac sodium channel that can lead to a clinical arrhythmogenic disorder (the long-QT syndrome) and sudden cardiac death.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Cardiac Bioelect Res & Training Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Rudy, Y (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA.	yxr@po.cwru.edu	Clancy, Colleen/B-2528-2010					Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; BALSER JR, 1990, BIOPHYS J, V57, P433, DOI 10.1016/S0006-3495(90)82560-1; Barinaga M, 1998, SCIENCE, V281, P32, DOI 10.1126/science.281.5373.32; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Chandra R, 1998, AM J PHYSIOL-HEART C, V274, pH1643, DOI 10.1152/ajpheart.1998.274.5.H1643; Dumaine R, 1996, CIRC RES, V78, P916, DOI 10.1161/01.RES.78.5.916; Hanck D. A., 1995, CARDIAC ELECTROPHYSI, P65; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; LUO CH, 1994, CIRC RES, V74, P1097, DOI 10.1161/01.RES.74.6.1097; LUO CH, 1994, CIRC RES, V74, P1071, DOI 10.1161/01.RES.74.6.1071; MITSUIYE T, 1995, J PHYSIOL-LONDON, V485, P581, DOI 10.1113/jphysiol.1995.sp020754; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; Wang DW, 1996, P NATL ACAD SCI USA, V93, P13200, DOI 10.1073/pnas.93.23.13200; Wang DW, 1997, J CLIN INVEST, V99, P1714, DOI 10.1172/JCI119335; WELSH MJ, 1995, NATURE, V376, P640, DOI 10.1038/376640a0; YUE DT, 1989, SCIENCE, V244, P349, DOI 10.1126/science.2540529; ZENG J, 1997, BIOMEDICAL ENG; ZENG JL, 1995, CIRC RES, V77, P140, DOI 10.1161/01.RES.77.1.140; ZENG JL, 1995, BIOPHYS J, V68, P949, DOI 10.1016/S0006-3495(95)80271-7	21	324	332	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1999	400	6744					566	569		10.1038/23034	http://dx.doi.org/10.1038/23034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448858				2022-12-24	WOS:000081854800056
J	Farrell, Z; O'Neill, D				Farrell, Z; O'Neill, D			Towards better screening and assessment of oropharyngeal swallow disorders in the general hospital	LANCET			English	Editorial Material							ASPIRATION; STROKE		Adelaide & Meath Hosp Dublin, Dept Speech & Language Therapy, Dublin 24, Ireland; Adelaide & Meath Hosp Dublin, Dept Age Related Hlth Care, Dublin 24, Ireland	Trinity College Dublin; Trinity College Dublin	Farrell, Z (corresponding author), Adelaide & Meath Hosp Dublin, Dept Speech & Language Therapy, Dublin 24, Ireland.		O'Neill, Desmond/D-1486-2013	O'Neill, Desmond/0000-0002-5542-9897				*AG HLTH CAR POL R, 1999, 99E023 ACHPR AG HLTH; Bastian Robert W., 1993, Dysphagia, V8, P359, DOI 10.1007/BF01321780; COLLINS DR, 1996, CLIN INTENSIVE CARE, V7, P315; Collins MJ, 1997, STROKE, V28, P1773, DOI 10.1161/01.STR.28.9.1773; DEPIPPO KL, 1994, ARCH PHYS MED REHAB, V75, P1284; Gresham GE, 1997, STROKE, V28, P1522, DOI 10.1161/01.STR.28.7.1522; Leder SB, 1997, DYSPHAGIA, V12, P21, DOI 10.1007/PL00009514; Linden P., 1993, Dysphagia, V8, P170, DOI 10.1007/BF01354535; Logemann J., 1997, EVALUATION TREATMENT; *SCOTT INT GUID NE, 1997, MAN PAT STROK 3; Selley W. G., 1994, Dysphagia, V9, P162, DOI 10.1007/BF00341260; Smith D., 1997, ROMANI CULTURE IDENT, P7; Smithard DG, 1998, AGE AGEING, V27, P99, DOI 10.1093/ageing/27.2.99; STROUD A, 1997, DYSPHAGIA, V12, P106; ZENNER PM, 1995, DYSPHAGIA, V10, P27, DOI 10.1007/BF00261276	15	12	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					355	356		10.1016/S0140-6736(98)90085-X	http://dx.doi.org/10.1016/S0140-6736(98)90085-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437860				2022-12-24	WOS:000081764900005
J	Goodman, CA; Coleman, PG; Mills, AJ				Goodman, CA; Coleman, PG; Mills, AJ			Cost-effectiveness of malaria control in sub-Saharan Africa	LANCET			English	Article							CHILDREN; HEALTH; CHEMOPROPHYLAXIS; CHLOROQUINE; STRATEGIES; MORBIDITY; EFFICACY; PROGRAM; WOMEN	Background Information on the cost-effectiveness of malaria control is needed for the WHO Roll Back Malaria campaign, but is sparse. We used mathematical models to calculate cost-effectiveness ratios for the main prevention and treatment interventions in sub-Saharan Africa. Methods We analysed interventions to prevent malaria in childhood (insecticide-treated nets, residual spraying of houses, and chemoprophylaxis) and pregnancy (chloroquine chemoprophylaxis and sulfadoxine-pyrimethamine intermittent treatment), and to improve malaria treatment (improved compliance, improved availability of second-line and third-line drugs, and changes in first-line drug). We developed models that included probabilistic sensitivity analysis to calculate ranges for the cost per disability-adjusted life year (DALY) averted for each intervention in three economic strata. Data were obtained from published and unpublished sources, and consultations with researchers and programme managers. Findings In a very-low-income country, for insecticide treatment of existing nets, the cost-effectiveness range was US$4-10 per DALY averted; for provision of nets and insecticide treatment $19-85; for residual spraying (two rounds per year) $32-58; for chemoprophylaxis for children $3-12 (assuming an existing delivery system); for intermittent treatment of pregnant women $4-29; and for improvement in case management $1-8. Although some interventions are inexpensive, achieving high coverage with an intervention to prevent childhood malaria would use a high proportion of current health-care expenditure. Interpretation Cost-effective interventions are available. A package of interventions:to decrease the bulk of the malaria burden is not, however, affordable in very-low-income countries. Coverage of the most vulnerable groups in Africa will require substantial assistance from external donors.	London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, Dis Control & Vector Biol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Goodman, CA (corresponding author), London Sch Hyg & Trop Med, Hlth Policy Unit, Dept Publ Hlth & Policy, London WC1E 7HT, England.			Goodman, Catherine/0000-0002-2241-3485; Mills, Anne/0000-0001-9863-9950				[Anonymous], DECADE PROGR MALARIA; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Barat LM, 1998, TROP MED INT HEALTH, V3, P535, DOI 10.1046/j.1365-3156.1998.00271.x; Barendregt JJ, 1996, B WORLD HEALTH ORGAN, V74, P439; Bloland PB, 1998, TROP MED INT HEALTH, V3, P543; BRINKMANN U, 1991, TROP MED PARASITOL, V42, P204; Coleman PG, 1999, TROP MED INT HEALTH, V4, P175, DOI 10.1046/j.1365-3156.1999.43382.x; Curtis CF, 1998, PHILOS T ROY SOC B, V353, P1769, DOI 10.1098/rstb.1998.0329; Curtis CF, 1998, TROP MED INT HEALTH, V3, P619, DOI 10.1046/j.1365-3156.1998.00281.x; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Eurostat, 2022, LIF TABL EUR COUNTR; Gilson L, 1998, SOC SCI MED, V47, P1891; GREENWOOD AM, 1992, T ROY SOC TROP MED H, V86, P483, DOI 10.1016/0035-9203(92)90078-Q; GREENWOOD BM, 1988, LANCET, V1, P1121; GULMEZOGLU AM, 1998, COCHRANE COLLABORATI; HILL JA, 1996, APPROACHES MALARIA 1; JAMISON DT, 1993, DIS CONTROL PRIORIRI; LENGELER C, 1998, COCHRANE LIB; *MAN SCI HLTH, 1996, INT DRUG PRIC IND GU; MCDERMOTT JM, 1996, AM J TROP MED HYG S1, V55, P1; MENON A, 1990, T ROY SOC TROP MED H, V84, P768, DOI 10.1016/0035-9203(90)90071-L; MOLINEAUX L, 1985, HLTH POLICY SOCIAL P, P13; Nabarro DN, 1998, SCIENCE, V280, P2067, DOI 10.1126/science.280.5372.2067; Pagnoni F, 1997, T ROY SOC TROP MED H, V91, P512, DOI 10.1016/S0035-9203(97)90006-7; Phillips MA., 1993, PEEM GUIDELINES SERI, V3; SCHAPIRA A, 1993, PARASITOL TODAY, V9, P168, DOI 10.1016/0169-4758(93)90140-B; SCHULTZ LJ, 1994, AM J TROP MED HYG, V51, P515, DOI 10.4269/ajtmh.1994.51.515; Shulman CE, 1999, LANCET, V353, P632, DOI 10.1016/S0140-6736(98)07318-8; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Steketee RW, 1996, AM J TROP MED HYG, V55, P95, DOI 10.4269/ajtmh.1996.55.95; WERNSDORFER WH, 1988, MALARIA PRINCIPLES P, V2, P1765; *WHO, 1998, ROLL BACK MAL GLOB P; *WHO, 1996, TDRGEN961 WHO; *WHO TDR, 1997, TDR NEWS, V54, P5; *WORLD BANK, 1994, TANZ ROL GOV PUBL EX, V1; World Bank, 1997, WORLD DEV REP STAT C	36	182	183	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					378	385		10.1016/S0140-6736(99)02141-8	http://dx.doi.org/10.1016/S0140-6736(99)02141-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437867				2022-12-24	WOS:000081764900013
J	Adachi-Yamada, T; Fujimura-Kamada, K; Nishida, Y; Matsumoto, K				Adachi-Yamada, T; Fujimura-Kamada, K; Nishida, Y; Matsumoto, K			Distortion of proximodistal information causes JNK-dependent apoptosis in Drosophila wing	NATURE			English	Article							LONG-RANGE ACTION; DECAPENTAPLEGIC GENE; MORPHOGEN GRADIENT; IMAGINAL DISKS; EXPRESSION; MELANOGASTER; SURVIVAL; COMPLEX; AXIS; HID	Distinct and evolutionarily conserved signal-transduction cascades mediate the survival or death of cells during development. The c-Jun amino-terminal kinases (JNKs) of the mitogen-activated protein kinase superfamily are involved in apoptotic signalling in various cultured cells(1), However, the role of the JNK pathway in development is less well understood In Drosophila, Decapentaplegic (Dpp; a homologue of transforming growth factor-beta) and Wingless (Wg; a Wnt homologue) proteins are secretory morphogens that act cooperatively to induce formation of the proximodistal axis of appendages(2-7). Here we show that either decreased Dpp signalling in the distal wing cells or increased Dpp signalling in the proximal wing cells causes apoptosis, Inappropriate levels of Dpp signalling lead to aberrant morphogenesis in the respective wing zones, and these apoptotic zones are also determined by the strength of the Wg signal. Our results indicate that distortion of the positional information determined by Dpp and Wg signalling gradients leads to activation of the JNK apoptotic pathway, and the consequent induction of cell death thereby maintains normal morphogenesis.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan	Nagoya University; Japan Science & Technology Agency (JST)	Adachi-Yamada, T (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan.		Tsai, Yu-Chen/B-5852-2008	Kamada, Konomi/0000-0002-2186-8728				Adachi-Yamada T, 1999, MOL CELL BIOL, V19, P2322; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; deCelis JF, 1997, DEVELOPMENT, V124, P1007; Goberdhan DCI, 1998, BIOESSAYS, V20, P1009, DOI 10.1002/(SICI)1521-1878(199812)20:12<1009::AID-BIES7>3.0.CO;2-D; Grimm S, 1996, SCIENCE, V271, P1601, DOI 10.1126/science.271.5255.1601; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito K, 1997, DEVELOPMENT, V124, P761; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; MASUCCI JD, 1990, GENE DEV, V4, P2011, DOI 10.1101/gad.4.11.2011; Milan M, 1997, P NATL ACAD SCI USA, V94, P5691, DOI 10.1073/pnas.94.11.5691; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Noselli S, 1998, TRENDS GENET, V14, P33, DOI 10.1016/S0168-9525(97)01320-6; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; SEGAL D, 1985, GENETICS, V109, P119; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; TERRAS V, 1994, SLAVIC E EUR J, V38, P165, DOI 10.2307/308553; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1	27	243	245	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					166	169		10.1038/22112	http://dx.doi.org/10.1038/22112			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408443				2022-12-24	WOS:000081324900054
J	Katzman, GL; Dagher, AP; Patronas, NJ				Katzman, GL; Dagher, AP; Patronas, NJ			Incidental findings on brain magnetic resonance imaging from 1000 asymptomatic volunteers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR HEALTH; SINUS ABNORMALITIES; PINEAL CYSTS; MRI	Context Previous reports have discussed incidental disease found on brain magnetic resonance imaging (MRI) scans that had been requested for an unrelated clinical concern or symptom, resulting in a selection bias for disease. However, the prevalence of unexpected abnormalities has not been studied in a healthy population. Objective To evaluate the prevalence of incidental findings on brain MRI scans obtained for a healthy, asymptomatic population without selection bias. Design, Setting, and Participants Retrospective analysis of brain MRI scans obtained between May 17, 1996, and July 25, 1997, from 1000 volunteers who participated as control subjects for various research protocols at the National Institutes of Health. All participants (age range, 3-83 years; 54.6% male) were determined to be healthy and asymptomatic by physician examination and participant history. Main Outcome Measure Prevalence of abnormalities on brain MRI by category of finding (no referral necessary, routine referral, urgent referral [within 1 week of study], and immediate referral [within 1 to several days of study]), Results Eighty-two percent of the MRI results were normal, Of the 18% demonstrating incidental abnormal findings, 15.1% required no referral; 1.8%, routine referral; 1.1%, urgent referral; and 0%, immediate referral. In subjects grouped for urgent referral, 2 confirmed primary brain tumors (and a possible but unconfirmed third) were found, demonstrating a prevalence of at least 0.2%. Conclusion Asymptomatic subjects present with a variety of abnormalities, providing valuable information on disease prevalence in a presumed healthy population, A small percentage of these findings require urgent medical attention and/or additional studies.	NIH, Dept Diagnost Radiol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Dagher, AP (corresponding author), NIH, Dept Diagnost Radiol, Bldg 10,Room 1C660, Bethesda, MD 20892 USA.							Baum KA, 1996, NEURORADIOLOGY, V38, P755, DOI 10.1007/s002340050342; BRYAN RN, 1994, AM J NEURORADIOL, V15, P1625; Davis FG, 1996, NEUROEPIDEMIOLOGY, V15, P103, DOI 10.1159/000109895; DICOSTANZO A, 1993, J NEUROL NEUROSUR PS, V56, P207, DOI 10.1136/jnnp.56.2.207; HUME AJ, 1984, GREENFIELDS NEUROPAT, P426; Iwabuchi Y, 1997, ARCH OTOLARYNGOL, V123, P602; MALY PV, 1995, NEURORADIOLOGY, V37, P471, DOI 10.1007/BF00600097; MORRIS P, 1997, PRACTICAL NEUROANGIO, P296; OSBORN AG, 1994, DIAGNOSTIC NEURORADI, P529; Patel K, 1996, J LARYNGOL OTOL, V110, P649, DOI 10.1017/S0022215100134516; PrestonMartin S, 1996, NEUROL CLIN, V14, P273, DOI 10.1016/S0733-8619(05)70256-5; ROBINSON JR, 1991, J NEUROSURG, V75, P709, DOI 10.3171/jns.1991.75.5.0709; Robinson R., 1971, PROGR NEUROLOGICAL S, P133, DOI 10.1159/000391818; Salonen O, 1997, NEURORADIOLOGY, V39, P537, DOI 10.1007/s002340050463; SAWAMURA Y, 1995, NEUROSURGERY, V37, P11, DOI 10.1227/00006123-199507000-00002; Yue NC, 1997, RADIOLOGY, V202, P41, DOI 10.1148/radiology.202.1.8988190	16	371	376	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					36	39		10.1001/jama.282.1.36	http://dx.doi.org/10.1001/jama.282.1.36			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404909	Bronze			2022-12-24	WOS:000081195800026
J	Williamson, LM; Lowe, S; Love, EM; Cohen, H; Soldan, K; McClelland, DBL; Skacel, P; Barbara, JAJ				Williamson, LM; Lowe, S; Love, EM; Cohen, H; Soldan, K; McClelland, DBL; Skacel, P; Barbara, JAJ			Serious hazards of transfusion (SHOT) initiative: analysis of the first two annual reports	BRITISH MEDICAL JOURNAL			English	Article							BLOOD-TRANSFUSION; SYSTEM; RISK	Objective To receive and collate reports of death or major complications of transfusion of blood or components. Design Haematologists were invited confidentially to report deaths and major complications after blood transfusion during October 1996 to September 1998. S etting Hospitals in United Kingdom and Ireland. Subjects Patients who died or experienced serious complications, as defined below; associated with transfusion of red cells, platelets, fresh frozen plasma or cryoprecipitate. Main outcome measures Death, "wrong" blood transfused to patient acute and delayed transfusion reactions, transfusion related acute lung injury, transfusion associated graft versus host disease, post-transfusion purpura, and infection transmitted by transfusion. Circumstances relating to these cases and relative frequency of complications. Results Over 24 months, 366 cases were reported of which 191 (52%) were "wrong blood to patient" episodes. Analysis of these revealed multiple errors of identification, often beginning when blood was collected from the blood bank. There were 22 deaths from all causes, including three from ABO incompatibility. There were 12 infections: four bacterial (one fatal), seven viral, and one fatal case of malaria. During die second 12 months, 164/424 hospitals (39%) submitted a "nil to report" return. Conclusions Transfusion is now extremely safe, but vigilance is needed to ensure correct identification of blood and patient Staff education should include an awareness of ABO incompatibility and bacterial contamination as causes of life threatening reactions to blood.	Univ E Anglia, Natl Blood Serv, Div Transfus Med, Cambridge CB2 2PT, England; Natl Blood Serv Manchester, Manchester M13 9LL, Lancs, England; UCL Hosp, London WC1E 6DB, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, Natl Blood Serv, London NW9 5EQ, England; Royal Infirm, Dept Transfus Med, Edinburgh & South East Scotland Blood Transfus Se, Edinburgh EH3 9HB, Midlothian, Scotland; Hammersmith Hosp, Royal Postgrad Med Sch, London W12 0HS, England; Natl Blood Serv, London NW9 5BG, England	University of East Anglia; University College London Hospitals NHS Foundation Trust; University of London; University College London; Public Health England; Royal Infirmary of Edinburgh; Imperial College London	Williamson, LM (corresponding author), Univ E Anglia, Natl Blood Serv, Div Transfus Med, Cambridge CB2 2PT, England.	lorna.williamson@nbs.nhs.uk		Soldan, Kate/0000-0002-0361-3174				AuBuchon JP, 1997, TRANSFUSION, V37, P1211, DOI 10.1046/j.1537-2995.1997.37111298088055.x; BLAJCHMAN MA, 1994, VOX SANG, V67, P25, DOI 10.1111/j.1423-0410.1994.tb04540.x; Calman KC, 1996, BRIT MED J, V313, P799; Chapman JF, 1996, TRANSFUSION MED, V6, P273, DOI 10.1111/j.1365-3148.1996.tb00079.x; *CTR NAT HEM, 1999, HEM ACT DOSS LETT IN; Ingrand P, 1998, TRANSFUSION, V38, P1030, DOI 10.1046/j.1537-2995.1998.38111299056312.x; Kaplan HS, 1998, TRANSFUSION, V38, P1071, DOI 10.1046/j.1537-2995.1998.38111299056319.x; Lumadue JA, 1997, TRANSFUSION, V37, P1169, DOI 10.1046/j.1537-2995.1997.37111298088047.x; MCCLELLAND DBL, 1994, BRIT MED J, V308, P1205, DOI 10.1136/bmj.308.6938.1205; McClelland DBL, 1998, TRANSFUSION, V38, P999, DOI 10.1046/j.1537-2995.1998.38111299056306.x; *NHS EX, 1999, BETT BLOOD TRANSF; SAZAMA K, 1985, TRANSFUSION, V30, P583; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; Shiba M, 1997, TRANSFUSION, V37, P457, DOI 10.1046/j.1537-2995.1997.37597293873.x; Williamson LM, 1996, BRIT MED J, V313, P1221, DOI 10.1136/bmj.313.7067.1221; WILLIAMSON LM, 1999, SHOT ANN REPORT 1997; WILLIAMSON LM, 1998, SHOT ANN REPORT 1996	17	233	241	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					16	19		10.1136/bmj.319.7201.16	http://dx.doi.org/10.1136/bmj.319.7201.16			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390452	Bronze, Green Published			2022-12-24	WOS:000081326500023
J	Chen, DG; Ma, H; Hong, H; Koh, SS; Huang, SM; Schurter, BT; Aswad, DW; Stallcup, MR				Chen, DG; Ma, H; Hong, H; Koh, SS; Huang, SM; Schurter, BT; Aswad, DW; Stallcup, MR			Regulation of transcription by a protein methyltransferase	SCIENCE			English	Article							ARGININE N-METHYLTRANSFERASE; HORMONE RECEPTORS; STEROID-RECEPTORS; COACTIVATOR; BINDING; DOMAINS; ACETYLTRANSFERASE; TRANSACTIVATION; ACETYLATION; SPECIFICITY	The p160 family of coactivators, SRC-1, GRIP1/TIF2, and p/CIP, mediate transcriptional activation by nuclear hormone receptors. Coactivator-associated arginine methyltransferase 1 (CARM1), a previously unidentified protein that binds to the carboxyl-terminal region of p160 coactivators, enhanced transcriptional activation by nuclear receptors, but only when GRIP1 or SRC-1a was coexpressed. Thus, CARM1 functions as a secondary coactivator through its association with p160 coactivators. CARM1 can methylate histone H3 in vitro, and a mutation in the putative S-adenosylmethionine binding domain of CARM 1 substantially reduced both methyltransferase and coactivator activities. Thus, coactivator-mediated methylation of proteins in the transcription machinery may contribute to transcriptional regulation.	Univ So Calif, Dept Pathol HMR 301, Los Angeles, CA 90033 USA; Univ Calif Irvine, Dept Biochem & Mol Biol, Irvine, CA USA	University of Southern California; University of California System; University of California Irvine	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol HMR 301, 2011 Zonal Ave, Los Angeles, CA 90033 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017269] Funding Source: NIH RePORTER; NIA NIH HHS [AG00093] Funding Source: Medline; NIDDK NIH HHS [DK43093] Funding Source: Medline; NINDS NIH HHS [NS17269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aleta JM, 1998, TRENDS BIOCHEM SCI, V23, P89, DOI 10.1016/S0968-0004(98)01185-2; ASWAD DW, UNPUB; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAMBERLIN JP, 1978, ANAL BIOCHEM, V98, P132; Chen D.-Y., UNPUB; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GARY JD, 1996, J BIOL CHEM, V271, P11585; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MA H, IN PRESS MOL CELL BI; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	32	956	995	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 25	1999	284	5423					2174	2177		10.1126/science.284.5423.2174	http://dx.doi.org/10.1126/science.284.5423.2174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381882				2022-12-24	WOS:000081099300051
J	Ishitani, T; Ninomiya-Tsuji, J; Nagai, S; Nishita, M; Meneghini, M; Barker, N; Waterman, M; Bowerman, B; Clevers, H; Shibuya, H; Matsumoto, K				Ishitani, T; Ninomiya-Tsuji, J; Nagai, S; Nishita, M; Meneghini, M; Barker, N; Waterman, M; Bowerman, B; Clevers, H; Shibuya, H; Matsumoto, K			The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF	NATURE			English	Article							XENOPUS-EMBRYOS; DROSOPHILA; GENE; WINGLESS; TRANSDUCTION; ARMADILLO; LEF-1; AXIS; IDENTIFICATION; ACTIVATION	The Wnt signalling pathway regulates many developmental processes through a complex of beta-catenin and the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of high-mobility-group transcription factors(1-5). Wnt stabilizes cytosolic beta-catenin, which then binds to TCF and activates gene transcription. This signalling cascade is conserved in vertebrates, Drosophila and Caenorhabditis elegans. In C. elegans, the proteins MOM-4 and LIT-I regulate Wnt signalling to polarize responding cells during embryogenesis(6). MOM-4 and LIT-1 are homologous to TAK1 (a kinase activated by transforming growth factor-beta) mitogen-activated protein-kinase-kinase kinase (MAP3K)(7) and MAP kinase (MAPK)-related NEMO-like kinase (NLK)(8,9), respectively, in mammalian cells. These results raise the possibility that TAK1 and NLK are also involved in Wnt signalling in mammalian cells. Here we show that TAK1 activation stimulates NLK activity and downregulates transcriptional activation mediated by beta-catenin and TCF. Injection of NLK suppresses the induction of axis duplication by microinjected beta-catenin in Xenopus embryos. NLK phosphorylates TCF/LEF factors and inhibits the interaction of the beta-catenin-TCF complex with DNA. Thus, the TAK1-NLK-MAPK-like pathway negatively regulates the Wnt signalling pathway.	Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Natl Inst Basic Biol, Dept Dev Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan; Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	Nagoya University; Japan Science & Technology Agency (JST); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of Oregon; Utrecht University; Utrecht University Medical Center; University of California System; University of California Irvine	Matsumoto, K (corresponding author), Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan.		Barker, Nick/AAS-2774-2020; Barker, Nick/A-5535-2011; Ishitani, Tohru/E-9781-2014; Barker, Nick/AAE-9833-2021	Barker, Nick/0000-0003-3566-4475; Ninomiya-Tsuji, Jun/0000-0002-5584-0176				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Blanco DR, 1997, EMERG INFECT DIS, V3, P11, DOI 10.3201/eid0301.970102; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CARDIGAN KM, 1997, GENE DEV, V11, P3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; Meneghini MD, 1999, NATURE, V399, P793, DOI 10.1038/21666; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1996, MOL CELL BIOL, V16, P745; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	491	521	0	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 24	1999	399	6738					798	802		10.1038/21674	http://dx.doi.org/10.1038/21674			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391247				2022-12-24	WOS:000081101600057
J	Barker, DJP				Barker, DJP			Intrauterine nutrition may be important - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England	University of Southampton	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.							ACHESON ED, 1986, P NUTR SOC, V45, P131, DOI 10.1079/PNS19860047; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; Barker DJP, 1998, MOTHERS BABIES HLTH; Dwork, 1987, WAR IS GOOD BABIES O; Fogel R., 1991, NUTR POVERTY	5	10	10	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1477	1478						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419294				2022-12-24	WOS:000080668200030
J	Gilbert, RE; Tookey, PA				Gilbert, RE; Tookey, PA			Perinatal mortality and morbidity among babies delivered in water: surveillance study and postal survey	BRITISH MEDICAL JOURNAL			English	Article							BIRTHING POOLS; TERM INFANTS; LABOR; ENCEPHALOPATHY; INFECTION	Aim To compare perinatal morbidity and mortality for babies delivered in water with rates for babies delivered conventionally (not in water). Design Surveillance study (of all consultant paediatricians) and postal survey (of all NHS maternity units). Setting British Isles (surveillance study); England and Wales (postal survey). Subjects Babies born in the British Isles between April 1994 and March 1996 who died perinatally or were admitted for special care within 48 hours of birth after delivery in water or after labour in water followed by conventional delivery (surveillance study); babies delivered in water in England and Wales in the same period (postal survey). Main outcome measures Number of deliveries in water in the British Isles that resulted in perinatal death or in admission to special care within 48 hours of birth; and proportions (of such deliveries) of all water births in England and Wales. Results 4032 deliveries (0.6% of all deliveries) in England and Wales occurred in water. Perinatal mortality was 1.2/1000 (95% confidence interval 0.4 to 2.9) live births; 8.4/1000 (5.8 to 11.8) live births were admitted for special care. No deaths were directly attributable to delivery in water, but 2 admissions were for water aspiration. UK reports of mortality and special care admission rates for babies of women considered to be at low risk of complications during delivery who delivered conventionally ranged from 0.8/1000 (0.2 to 4.2) to 4.6/1000 (0.1 to 25) live births and from 9.2 (1.1 to 33) to 64/1000 (58 to 10) live births respectively. Compared with regional data for low risk, spontaneous, normal vaginal deliveries at term, the relative risk for perinatal mortality associated with delivery in water was 0.9 (99% confidence interval 0.2 to 3.6). Conclusions Perinatal mortality is not substantially higher among babies delivered in water than among those born to low risk women who delivered conventionally. The data are compatible with a small increase or decrease in perinatal mortality for babies delivered in water.	Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England	University of London; University College London	Gilbert, RE (corresponding author), Inst Child Hlth, Dept Epidemiol & Publ Hlth, London WC1N 1EH, England.		Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387; Gilbert, Ruth/0000-0001-9347-2709				ALDERDICE F, 1995, BRIT MED J, V310, P837, DOI 10.1136/bmj.310.6983.837; ALDERDICE F, 1995, BRIT J MIDWIFERY, V3, P375; Arya R, 1996, ARCH DIS CHILD-FETAL, V75, pF97, DOI 10.1136/fn.75.2.F97; Barron SL, 1996, BRIT MED J, V313, P1306; BARRY CN, 1995, BRIT MED J, V310, P1602, DOI 10.1136/bmj.310.6994.1602b; CAMMU H, 1994, ACTA OBSTET GYN SCAN, V73, P468, DOI 10.3109/00016349409013433; CHURCH LK, 1989, J NURSE-MIDWIFERY, V34, P165, DOI 10.1016/0091-2182(89)90076-1; Cleary R, 1996, BRIT J OBSTET GYNAEC, V103, P223, DOI 10.1111/j.1471-0528.1996.tb09710.x; FORD C, 1991, BRIT MED J, V303, P1517, DOI 10.1136/bmj.303.6816.1517; HALL S, 1997, CHILD CARE HLTH DEV, V24, P129; HULL J, 1992, BRIT J OBSTET GYNAEC, V99, P386, DOI 10.1111/j.1471-0528.1992.tb13754.x; Johnson P, 1996, BRIT J OBSTET GYNAEC, V103, P202, DOI 10.1111/j.1471-0528.1996.tb09706.x; LEVENE ML, 1985, EARLY HUM DEV, V11, P21, DOI 10.1016/0378-3782(85)90115-X; Middle C, 1995, BRIT J OBSTET GYNAEC, V102, P970, DOI 10.1111/j.1471-0528.1995.tb10904.x; NIKODEM V, 1998, COCHRANE LIB; ODENT M, 1983, LANCET, V2, P1476, DOI 10.1016/S0140-6736(83)90816-4; PAGE L, 1995, MATERNAL CHILD H JAN, P22; Parker PC, 1997, PEDIATRICS, V99, P653, DOI 10.1542/peds.99.4.653a; RAWAL J, 1994, BRIT MED J, V309, P511, DOI 10.1136/bmj.309.6953.511; Roome APCH, 1996, LANCET, V348, P274, DOI 10.1016/S0140-6736(05)65590-0; ROSEVEAR SK, 1993, LANCET, V342, P1048, DOI 10.1016/0140-6736(93)92902-6; Rosser J, 1994, MIDIRS MIDWIFERY DIG, V4, P4; Rush J, 1996, BIRTH-ISS PERINAT C, V23, P136, DOI 10.1111/j.1523-536X.1996.tb00474.x; SCHORN MN, 1993, J NURSE-MIDWIFERY, V38, P336, DOI 10.1016/0091-2182(93)90014-8	24	64	68	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					483	487		10.1136/bmj.319.7208.483	http://dx.doi.org/10.1136/bmj.319.7208.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454400	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000082199600019
J	van Oudenaarden, A; Boxer, SG				van Oudenaarden, A; Boxer, SG			Brownian ratchets: Molecular separations in lipid bilayers supported on patterned arrays	SCIENCE			English	Article							PARTICLES; POLYELECTROLYTES; MACROMOLECULES; MEMBRANES; PROTEINS; MOTION; SIEVE	Brownian ratchets use a time-varying asymmetric potential that can be applied to separate diffusing particles or molecules. A new type of Brownian ratchet, a geometrical Brownian ratchet, has been realized, Charged, fluorescently labeled phospholipids in a two-dimensional fluid bilayer were driven in one direction by an electric field through a two-dimensional periodic array of asymmetric barriers to lateral diffusion fabricated from titanium oxide on silica, Diffusion spreads the phospholipid molecules in the orthogonal direction, and the asymmetric barriers rectify the Brownian motion, causing a directional transport of molecules. The geometrical ratchet can be used as a continuous molecular sieve to separate mixtures of membrane-associated molecules that differ in electrophoretic mobility and diffusion coefficient.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University	Boxer, SG (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		van Oudenaarden, Alexander/AAA-1705-2019	Boxer, Steven/0000-0001-9167-4286				AJDARI A, 1992, CR ACAD SCI II, V315, P1635; ASTUMIAN RD, 1994, PHYS REV LETT, V72, P1766, DOI 10.1103/PhysRevLett.72.1766; Astumian RD, 1997, SCIENCE, V276, P917, DOI 10.1126/science.276.5314.917; Astumian RD, 1998, CHAOS, V8, P533, DOI 10.1063/1.166334; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BAYERL TM, 1990, BIOPHYS J, V58, P357, DOI 10.1016/S0006-3495(90)82382-1; BRIAN AA, 1984, P NATL ACAD SCI-BIOL, V81, P6159, DOI 10.1073/pnas.81.19.6159; Cornell BA, 1997, NATURE, V387, P580, DOI 10.1038/42432; Derenyi I, 1998, PHYS REV E, V58, P7781, DOI 10.1103/PhysRevE.58.7781; Duke TAJ, 1998, PHYS REV LETT, V80, P1552, DOI 10.1103/PhysRevLett.80.1552; Ertas D, 1998, PHYS REV LETT, V80, P1548, DOI 10.1103/PhysRevLett.80.1548; FAUCHEUX LP, 1995, J CHEM SOC FARADAY T, V91, P3163, DOI 10.1039/ft9959103163; FAUCHEUX LP, 1995, PHYS REV LETT, V74, P1504, DOI 10.1103/PhysRevLett.74.1504; FEYNMAN RP, 1966, FEYNMAN LECT PHYSICS, V1; Groves JT, 1996, BIOPHYS J, V71, P2716, DOI 10.1016/S0006-3495(96)79462-6; Groves JT, 1995, BIOPHYS J, V69, P1972, DOI 10.1016/S0006-3495(95)80067-6; Groves JT, 1998, LANGMUIR, V14, P3347, DOI 10.1021/la9711701; Groves JT, 1997, SCIENCE, V275, P651, DOI 10.1126/science.275.5300.651; JOHNSON SJ, 1991, BIOPHYS J, V59, P289, DOI 10.1016/S0006-3495(91)82222-6; KONIG BW, 1996, LANGMUIR, V12, P1343; KUNG LA, UNPUB; MAGNASCO MO, 1993, PHYS REV LETT, V71, P1477, DOI 10.1103/PhysRevLett.71.1477; ROUSSELET J, 1994, NATURE, V370, P446, DOI 10.1038/370446a0; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Salafsky J, 1996, BIOCHEMISTRY-US, V35, P14773, DOI 10.1021/bi961432i; Shimizu S, 1997, SYNTHETIC MET, V85, P1337, DOI 10.1016/S0379-6779(97)80260-3; Slater GW, 1997, PHYS REV LETT, V78, P1170, DOI 10.1103/PhysRevLett.78.1170; Stora T, 1999, ANGEW CHEM INT EDIT, V38, P389, DOI 10.1002/(SICI)1521-3773(19990201)38:3<389::AID-ANIE389>3.0.CO;2-U; WELLS JA, 1993, ANNU REV BIOPH BIOM, V22, P329, DOI 10.1146/annurev.bb.22.060193.001553	29	209	212	2	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1046	1048		10.1126/science.285.5430.1046	http://dx.doi.org/10.1126/science.285.5430.1046			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446046				2022-12-24	WOS:000082033100039
J	Zhong, Q; Chen, CF; Li, S; Chen, YM; Wang, CC; Xiao, J; Chen, PL; Sharp, ZD; Lee, WH				Zhong, Q; Chen, CF; Li, S; Chen, YM; Wang, CC; Xiao, J; Chen, PL; Sharp, ZD; Lee, WH			Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response	SCIENCE			English	Article							BREAST-CANCER; PROTEIN; IDENTIFICATION; REPAIR; RAD50	BRCA1 encodes a tumor suppressor that is mutated in familiar breast and ovarian cancers. Here, it is shown that BRCA1 interacts in vitro and in vivo with hRad50, which forms a complex with hMre11 and p95/nibrin. Upon irradiation, BRCA1 was detected in discrete foci in the nucleus, which colocalize with hRad50. Formation of irradiation-induced foci positive for BRCA1, hRad50, hMre11, or p95 was dramatically reduced in HCC/1937 breast cancer cells carrying a homozygous mutation in BRCA1 but was restored by transfection of wild-type BRCA1. Ectopic expression of wild-type, but not mutated, BRCA1 in these cells rendered them less sensitive to the DNA damage agent, methyl methanesulfonate. These data suggest that BRCA1 is important for the cellular responses to DNA damage that are mediated by the hRad50-hMre11-p95 complex.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, Inst Biotechnol, 15355 Lambda Dr, San Antonio, TX 78245 USA.		Zhong, Qing/GLT-4858-2022; LI, SHANG/HII-4989-2022	Zhong, Qing/0000-0001-6979-955X; LI, SHANG/0000-0002-6226-3362; Chen, Chi-Fen/0000-0002-6391-821X	NCI NIH HHS [CA 30195, CA 58183] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, P01CA030195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; RAYMOND WE, 1993, NUCLEIC ACIDS RES, V21, P3851, DOI 10.1093/nar/21.16.3851; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhong Q, 1997, CANCER RES, V57, P4225	15	502	525	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					747	750		10.1126/science.285.5428.747	http://dx.doi.org/10.1126/science.285.5428.747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426999				2022-12-24	WOS:000081765100058
J	Ralph, SG; Rutherford, AJ; Wilson, JD				Ralph, SG; Rutherford, AJ; Wilson, JD			Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study	BRITISH MEDICAL JOURNAL			English	Article							PRETERM DELIVERY; GENITAL-TRACT; PREGNANCY; WOMEN; ENDOMETRITIS; ASSOCIATION; HORMONE; BIRTH	Objectives To assess whether bacterial vaginosis affects the rates of conception and miscarriage in the first trimester. Design Cohort study. Setting Assisted conception unit of a teaching hospital in Leeds. Participants 867 consecutive women undergoing in vitro fertilisation. Interventions Screening for bacterial vaginosis with a Gram stained vaginal smear before egg collection. Main outcome measures The presence of bacterial vaginosis or normal vaginal flora, and the rate of conception and miscarriage in the first trimester. Results 190 of 771 (24.6%) women had bacterial vaginosis. No difference in conception rate was found between those women with bacterial vaginosis and those with normal vaginal flora: 61 women (32.1%) and 146 of 493 women (29.6%) respectively (relative risk 1.08, 95% confidence interval 0.85 to 1.39; odds ratio 1.12, 0.77 to 1.64). However, 22 women (31.6%) with bacterial vaginosis who conceived had a significantly increased risk of miscarriage in the first trimester compared with 27 women (18.5%) with normal vaginal flora (crude relative risk 1.95, 1.11 to 3.42; crude odds ratio: 2.49; 1.21 to 5.12). This increased risk remained significant after adjustment for factors known to increase the rate of miscarriage: increasing maternal age, smoking, history of three or more miscarriages, no precious live birth and polycystic ovaries (adjusted relative risk 2.03, 1.09 to 3.78; adjusted odds ratio 2.67, 1.26 to 5.63). Conclusions Bacterial vaginosis does not affect conception but is associated with an increased risk of miscarriage in the first trimester in women undergoing in vitro fertilisation, independent of other risk factors.	Gen Infirm, Dept Genitourinary Med, Leeds LS1 3EX, W Yorkshire, England; Gen Infirm, Reprod Med Unit, Leeds LS1 3EX, W Yorkshire, England	Leeds General Infirmary; Leeds General Infirmary	Wilson, JD (corresponding author), Gen Infirm, Dept Genitourinary Med, Leeds LS1 3EX, W Yorkshire, England.							ASHKENAZI J, 1994, FERTIL STERIL, V61, P526; Curtis P, 1992, HUM REPROD, V7, P625; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; Hillier SL, 1995, NEW ENGL J MED, V333, P1737, DOI 10.1056/NEJM199512283332604; HOWE RS, 1988, FERTIL STERIL, V49, P726; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KURKI T, 1992, OBSTET GYNECOL, V80, P173; MCGREGOR JA, 1995, AM J OBSTET GYNECOL, V173, P157, DOI 10.1016/0002-9378(95)90184-1; RIDUAN JM, 1993, AM J OBSTET GYNECOL, V169, P175, DOI 10.1016/0002-9378(93)90157-E; RUTHERFORD AJ, 1988, BRIT MED J, V296, P1765, DOI 10.1136/bmj.296.6639.1765; SAUER MV, 1992, AM J OBSTET GYNECOL, V166, P148, DOI 10.1016/0002-9378(92)91850-A; STENMAN UH, 1987, J CLIN ENDOCR METAB, V64, P730, DOI 10.1210/jcem-64-4-730; WATTS DH, 1990, OBSTET GYNECOL, V75, P52; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401	15	164	174	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 24	1999	319	7204					220	223		10.1136/bmj.319.7204.220	http://dx.doi.org/10.1136/bmj.319.7204.220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417083	Green Published, Bronze			2022-12-24	WOS:000081720300022
J	Huang, J; Kim, LJ; Mealey, R; Marsh, HC; Zhang, Y; Tenner, AJ; Connolly, ES; Pinsky, DJ				Huang, J; Kim, LJ; Mealey, R; Marsh, HC; Zhang, Y; Tenner, AJ; Connolly, ES; Pinsky, DJ			Neuronal protection in stroke by an sLe(x)-glycosylated complement inhibitory protein	SCIENCE			English	Article							FOCAL CEREBRAL-ISCHEMIA; P-SELECTIN; RECEPTOR TYPE-1; NEUTROPHIL ADHESION; ALZHEIMERS-DISEASE; INFARCT VOLUME; BRAIN; REPERFUSION; C1Q; PLATELET	Glycoprotein adhesion receptors such as selectins contribute to tissue injury in stroke. Ischemic neurons strongly expressed C1q, which may target them for complement-mediated attack or C1qRp-mediated clearance. A hybrid molecule was used to simultaneously inhibit both complement activation and selectin-mediated adhesion. The extracellular domain of soluble complement receptor-1 (sCR1) was sialyl Lewis x glycosylated (sCR1sLe(x)) to inhibit complement activation and endothelial-platelet-Leukocyte interactions. sCR1 and sCR1sLe(x) colocalized to ischemic cerebral microvessels and C1q-expressing neurons, inhibited neutrophil and platelet accumulation, and reduced cerebral infarct volumes. Additional benefit was conferred by sialyl Lewis x glycosylation of the unmodified parent sCR1 molecule.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Avant Immunotherapeut Inc, Needham, MA 02494 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	Columbia University; University of California System; University of California Irvine	Pinsky, DJ (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.		Kim, Louis/F-1781-2011	Marsh, Henry/0000-0001-5637-6013; Huang, Judy/0000-0002-0675-1935	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059488, R01HL055397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035144] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL59488, R01 HL55397] Funding Source: Medline; NINDS NIH HHS [R01 NS35144] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Afagh A, 1996, EXP NEUROL, V138, P22, DOI 10.1006/exnr.1996.0043; CHAVEZCARTAYA RE, 1995, TRANSPLANTATION, V59, P1047, DOI 10.1097/00007890-199504150-00023; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; Choudhri TF, 1998, J CLIN INVEST, V102, P1301, DOI 10.1172/JCI3338; Choudhri TF, 1997, STROKE, V28, P2296, DOI 10.1161/01.STR.28.11.2296; Connolly ES, 1997, CIRC RES, V81, P304, DOI 10.1161/01.RES.81.3.304; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; Diacovo TG, 1996, BLOOD, V88, P146; Frijns CJM, 1997, STROKE, V28, P2214, DOI 10.1161/01.STR.28.11.2214; Fruchterman TM, 1998, SURGERY, V124, P782, DOI 10.1067/msy.1998.91489; FURIE B, 1995, THROMB HAEMOSTASIS, V74, P224; GILLINOV AM, 1993, ANN THORAC SURG, V55, P619, DOI 10.1016/0003-4975(93)90264-I; Haring HP, 1996, STROKE, V27, P1386, DOI 10.1161/01.STR.27.8.1386; HILL J, 1992, J IMMUNOL, V149, P1723; HUANG J, IN PRESS NEUROSURGER; JOHNSON SA, 1992, NEUROBIOL AGING, V13, P641, DOI 10.1016/0197-4580(92)90086-D; Klickstein LB, 1997, IMMUNITY, V7, P345, DOI 10.1016/S1074-7613(00)80356-8; KOROTZER AR, 1995, EXP NEUROL, V134, P214, DOI 10.1006/exnr.1995.1051; Kuijper PHM, 1996, BLOOD, V87, P3271, DOI 10.1182/blood.V87.8.3271.bloodjournal8783271; Lazar HL, 1998, ANN THORAC SURG, V65, P973, DOI 10.1016/S0003-4975(98)00021-6; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; MAKRIDES SC, 1992, J BIOL CHEM, V267, P24754; Naka Y, 1997, TRANSPLANTATION, V64, P1248, DOI 10.1097/00007890-199711150-00004; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; PEMBERTON M, 1993, J IMMUNOL, V150, P5104; PETRY F, 1991, J IMMUNOL, V147, P3988; Prestigiacomo CJ, 1999, STROKE, V30, P1110, DOI 10.1161/01.STR.30.5.1110; Rittershaus CW, 1999, J BIOL CHEM, V274, P11237, DOI 10.1074/jbc.274.16.11237; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; TENNER AJ, 1981, J IMMUNOL, V127, P648; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; YOUNG KR, 1991, J IMMUNOL, V146, P3356	32	278	295	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					595	599		10.1126/science.285.5427.595	http://dx.doi.org/10.1126/science.285.5427.595			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417391				2022-12-24	WOS:000081609500041
J	Lall, S; Francis-Lang, H; Flament, A; Norvell, A; Schupbach, T; Ish-Horowicz, D				Lall, S; Francis-Lang, H; Flament, A; Norvell, A; Schupbach, T; Ish-Horowicz, D			Squid hnRNP protein promotes apical cytoplasmic transport and localization of Drosophila pair-rule transcripts	CELL			English	Article							MESSENGER-RNA LOCALIZATION; CIS-ACTING SEQUENCES; BINDING PROTEIN; XENOPUS OOCYTES; FUSHI-TARAZU; BICOID RNA; ASYMMETRIC LOCALIZATION; EARLY EMBRYOGENESIS; NUCLEAR EXPORT; GENE	Drosophila melanogaster pair-rule segmentation gene transcripts localize apically of nuclei in blastoderm embryos. This might occur by asymmetric (vectorial) export from one side of the nucleus or by transport within the cytoplasm. We have followed fluorescently labeled pair-rule transcripts postinjection into Drosophila embryos. Naked, microinjected fushi tarazu (ftz) transcripts do not localize in blastoderm embryos, indicating that cytoplasmic mechanisms alone are insufficient for epical targeting. However, prior exposure of ftz to Drosophila or human embryonic nuclear extract leads to rapid, specific, microtubule-dependent transport, arguing against vectorial export. We present evidence that ftz transcript localization involves the Squid (Hrp40) hnRNP protein and that the activity of hnRNP proteins in promoting transcript localization is evolutionarily conserved. We propose that cytoplasmic localization machineries recognize transcripts in the context of nuclear partner proteins.	Imperial Canc Res Fund, Dev Genet Lab, London WC2A 3PX, England; Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA	Cancer Research UK; Howard Hughes Medical Institute; Princeton University	Ish-Horowicz, D (corresponding author), Imperial Canc Res Fund, Dev Genet Lab, Lincolns Inn Fields, London WC2A 3PX, England.			Ish-Horowicz, David/0000-0001-5684-7129				AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; Bashirullah A, 1998, ANNU REV BIOCHEM, V67, P335, DOI 10.1146/annurev.biochem.67.1.335; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; DAVIS I, 1993, COLD SPRING HARB SYM, V58, P793, DOI 10.1101/SQB.1993.058.01.086; DAVIS I, 1991, CELL, V67, P927, DOI 10.1016/0092-8674(91)90366-7; Deshler JO, 1998, CURR BIOL, V8, P489, DOI 10.1016/S0960-9822(98)70200-3; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; EDGAR BA, 1986, CELL, V47, P747, DOI 10.1016/0092-8674(86)90517-9; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; ERDELYI M, 1995, NATURE, V377, P524, DOI 10.1038/377524a0; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; FOE VE, 1983, J CELL SCI, V61, P31; FrancisLang H, 1996, EMBO J, V15, P640, DOI 10.1002/j.1460-2075.1996.tb00396.x; Gavis ER, 1996, DEV BIOL, V176, P36, DOI 10.1006/dbio.1996.9996; Glotzer JB, 1997, CURR BIOL, V7, P326, DOI 10.1016/S0960-9822(06)00156-4; HAFEN E, 1984, CELL, V37, P833, DOI 10.1016/0092-8674(84)90418-5; Havin L, 1998, GENE DEV, V12, P1593, DOI 10.1101/gad.12.11.1593; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; ISHHOROWICZ D, 1989, CELL, V57, P223, DOI 10.1016/0092-8674(89)90960-4; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; KELLEY RL, 1993, GENE DEV, V7, P948, DOI 10.1101/gad.7.6.948; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; Kim-Ha Jeongsil, 1993, Development (Cambridge), V119, P169; KIMHA J, 1991, CELL, V66, P23, DOI 10.1016/0092-8674(91)90136-M; KISLAUSKIS EH, 1993, J CELL BIOL, V123, P165, DOI 10.1083/jcb.123.1.165; KISLAUSKIS EH, 1994, J CELL BIOL, V127, P441, DOI 10.1083/jcb.127.2.441; Litman P, 1996, DEV BIOL, V176, P86, DOI 10.1006/dbio.1996.9992; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MATUNIS EL, 1994, P NATL ACAD SCI USA, V91, P2781, DOI 10.1073/pnas.91.7.2781; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; Norvell A, 1999, GENE DEV, V13, P864, DOI 10.1101/gad.13.7.864; PinolRoma S, 1997, SEMIN CELL DEV BIOL, V8, P57, DOI 10.1006/scdb.1996.0122; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POKRYWKA NJ, 1994, DEV BIOL, V166, P210, DOI 10.1006/dbio.1994.1308; POKRYWKA NJ, 1995, DEV BIOL, V167, P363, DOI 10.1006/dbio.1995.1030; POKRYWKA NJ, 1991, DEVELOPMENT, V113, P55; PONDEL MD, 1988, P NATL ACAD SCI USA, V85, P7612, DOI 10.1073/pnas.85.20.7612; Ross AF, 1997, MOL CELL BIOL, V17, P2158, DOI 10.1128/MCB.17.4.2158; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1985, NATURE, V318, P677, DOI 10.1038/318677a0; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SUNDELL CL, 1991, SCIENCE, V253, P1275, DOI 10.1126/science.1891715; TANEJA KL, 1992, J CELL BIOL, V119, P1245, DOI 10.1083/jcb.119.5.1245; Tetzlaff MT, 1996, EMBO J, V15, P1247, DOI 10.1002/j.1460-2075.1996.tb00466.x; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; Visa N, 1996, CELL, V84, P253, DOI 10.1016/S0092-8674(00)80980-0; Wallace CS, 1998, J NEUROSCI, V18, P26; YISRAELI JK, 1988, NATURE, V336, P592, DOI 10.1038/336592a0; YISRAELI JK, 1990, DEVELOPMENT, V108, P289; ZACHAR Z, 1993, J CELL BIOL, V121, P729, DOI 10.1083/jcb.121.4.729; ZALOKAR M, 1976, J MICROSC BIOL CELL, V25, P97	61	71	71	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					171	180		10.1016/S0092-8674(00)81012-0	http://dx.doi.org/10.1016/S0092-8674(00)81012-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428029	Bronze			2022-12-24	WOS:000081632300007
J	Vaccarino, V; Parsons, L; Every, NR; Barron, HV; Krumholz, HM				Vaccarino, V; Parsons, L; Every, NR; Barron, HV; Krumholz, HM		Natl Registry Myocardial Infarction 2 Participa	Sex-based differences in early mortality after myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; THROMBOLYTIC THERAPY; UNITED-STATES; CASE-FATALITY; SHORT-TERM; INTERVENTION REGISTRY; NATIONAL REGISTRY; DIABETES-MELLITUS; CLINICAL OUTCOMES; BYPASS-SURGERY	Background There is conflicting information about whether short-term mortality after myocardial infarction is higher among women than among men after adjustment for age and other prognostic factors. We hypothesized that younger, but not older, women have higher mortality rates during hospitalization than their male peers. Methods We analyzed data on 384,878 patients (155,565 women and 229,313 men) who were 30 to 89 years of age and who had been enrolled in the National Registry of Myocardial Infarction 2 between June 1994 and January 1998. Patients who had been transferred from or to other hospitals were excluded. Results The overall mortality rate during hospitalization was 16.7 percent among the women and 11.5 percent among the men. Sex-based differences in the rates varied according to age. Among patients less than 50 years of age, the mortality rate for the women was more than twice that for the men. The difference in the rates decreased with increasing age and was no longer significant after the age of 74 (P < 0.001 for the interaction between sex and age). Logistic-regression analysis showed that the odds of death were 11.1 percent greater for women than for men with every five-year decrease in age (95 percent confidence interval, 10.1 to 12.1 percent). Differences in medical history, the clinical severity of the infarction, and early management accounted for only about one third of the difference in the risk. After adjustment for these factors, women still had a higher risk of death for every five years of decreasing age (increase in the odds of death, 7.0 percent; 95 percent confidence interval, 5.9 to 8.1 percent). Conclusions After myocardial infarction, younger women, but not older women, have higher rates of death during hospitalization than men of the same age. The younger the age of the patients, the higher the risk of death among women relative to men. Younger women with myocardial infarction represent a high-risk group deserving of special study. (N Engl J Med 1999;341:217-25.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Med Cardiol, New Haven, CT 06520 USA; Univ Washington, Sch Med, Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res & Dev Field Program, Seattle, WA USA; Univ Washington, Sch Med, Div Cardiol, Cardiovasc Outcomes Res Ctr, Seattle, WA USA; Univ Calif San Francisco, Div Cardiol, San Francisco, CA 94143 USA; Genentech Inc, Div Med Affairs, San Francisco, CA 94080 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA	Yale University; Yale University; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; Roche Holding; Genentech; Yale University	Vaccarino, V (corresponding author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020					ABBOT RD, 1989, JAMA-J AM MED ASSOC, V261, P1884; ABBOTT RD, 1988, JAMA-J AM MED ASSOC, V260, P3456, DOI 10.1001/jama.260.23.3456; Albert CM, 1996, CIRCULATION, V93, P1170, DOI 10.1161/01.CIR.93.6.1170; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P3249; BARRETTCONNOR EL, 1991, JAMA-J AM MED ASSOC, V265, P627, DOI 10.1001/jama.265.5.627; Barron HV, 1998, J AM COLL CARDIOL, V32, P360, DOI 10.1016/S0735-1097(98)00225-3; Barron HV, 1998, CIRCULATION, V97, P1150, DOI 10.1161/01.CIR.97.12.1150; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BERGLUND U, 1988, THROMB HAEMOSTASIS, V60, P21; Breslow NE, 1980, IARC SCI PUBL, V32; BUENO H, 1995, CIRCULATION, V92, P1133, DOI 10.1161/01.CIR.92.5.1133; Burke AP, 1998, CIRCULATION, V97, P2110, DOI 10.1161/01.CIR.97.21.2110; Chambless L, 1997, CIRCULATION, V96, P3849; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; CIRAULO DA, 1983, CHEST, V2, P196; Coronado BE, 1997, J AM COLL CARDIOL, V29, P1490, DOI 10.1016/S0735-1097(97)00077-6; Cox DR., 1989, ANAL BINARY DATA; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; Every NR, 1999, J AM COLL CARDIOL, V33, P1886, DOI 10.1016/S0735-1097(99)00113-8; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; Friedman L. M., 1998, FUNDAMENTALS CLIN TR; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; Gurwitz JH, 1996, ANN INTERN MED, V124, P283, DOI 10.7326/0003-4819-124-3-199602010-00001; HAMMAR N, 1992, INT J EPIDEMIOL, V21, P1090, DOI 10.1093/ije/21.6.1090; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Herman B, 1997, EUR HEART J, V18, P963; HERRINGTON DM, 1997, WOMEN HEART DIS, P243; HEUPLER FA, 1980, AM J CARDIOL, V45, P873, DOI 10.1016/0002-9149(80)90134-4; JOHANSSON S, 1984, AM J EPIDEMIOL, V119, P610, DOI 10.1093/oxfordjournals.aje.a113778; KARLSON BW, 1994, AM HEART J, V128, P477, DOI 10.1016/0002-8703(94)90620-3; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KILLIP T, 1967, AM J CARDIOL, V20, P467; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MAGGIONI AP, 1993, NEW ENGL J MED, V329, P1442, DOI 10.1056/NEJM199311113292002; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; MARRUGAT J, 1998, NEW ENGL J MED, V338, P8; Maynard C, 1997, ARCH INTERN MED, V157, P1379, DOI 10.1001/archinte.157.12.1379; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MAYNARD C, 1993, CARDIOL ELDER, V1, P121; Nohria Anju, 1998, Cardiology Clinics, V16, P45, DOI 10.1016/S0733-8651(05)70383-0; PETER T, 1978, MED J AUSTRALIA, V1, P189, DOI 10.5694/j.1326-5377.1978.tb107829.x; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; Sonke GS, 1996, BRIT MED J, V313, P853; Sowers JR, 1998, ARCH INTERN MED, V158, P617, DOI 10.1001/archinte.158.6.617; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; Vaccarino V, 1996, J AM GERIATR SOC, V44, P1174, DOI 10.1111/j.1532-5415.1996.tb01366.x; Vaccarino V, 1998, ARCH INTERN MED, V158, P2054, DOI 10.1001/archinte.158.18.2054; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097; Woodfield SL, 1997, J AM COLL CARDIOL, V29, P35, DOI 10.1016/S0735-1097(96)00449-4	63	930	967	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					217	225		10.1056/NEJM199907223410401	http://dx.doi.org/10.1056/NEJM199907223410401			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413733				2022-12-24	WOS:000081528800001
J	Wolter, T				Wolter, T			If the fates allow	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Family Hlth Associates, Chippewa Falls, WI 54729 USA		Wolter, T (corresponding author), Family Hlth Associates, 2449 Cty Highway 1, Chippewa Falls, WI 54729 USA.	taran@execpc.com							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					148	149		10.7326/0003-4819-131-2-199907200-00014	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419433				2022-12-24	WOS:000081509700012
J	Mansi, JL; Gogas, H; Bliss, JM; Gazet, JC; Berger, U; Coombes, RC				Mansi, JL; Gogas, H; Bliss, JM; Gazet, JC; Berger, U; Coombes, RC			Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study	LANCET			English	Article							BONE-MARROW MICROMETASTASES; EPITHELIAL MEMBRANE ANTIGEN; MAMMARY-CARCINOMA CELLS; MONOCLONAL-ANTIBODIES; PROGNOSTIC-SIGNIFICANCE; MICRO-METASTESES; TUMOR-CELLS; METASTASES	Background Bone-marrow micrometastases have been found in patients with primary breast cancer. We report long-term follow-up of women with primary breast cancer, diagnosed between 1981 and 1986, who had multiple aspirates taken at the time of initial surgery. Methods 350 women with primary breast cancer were examined immunocytochemically with antibody to epithelial membrane antigen. We investigated associations with various prognostic factors as well as the effect of micrometastases on relapse-free survival and overall survival. Findings At median follow-up of 12.5 years, 151 patients had metastatic disease and 136 patients had died from breast cancer. 10-year relapse-free and overall survival were 43.9% (95% CI 33.4-54.7) and 44.9% (34.2-55.9) in patients with micrometastases, and 62.7% (56.5-68.6) and 65.7% (59.4-71.5) in patients without micrometastases at presentation (p<0.001). For relapse-free survival acid overall survival, allowing for tumour size, lymph-node Status, and vascular invasion, the effect of micrometastases decreased and was no longer significant, with a hazard ratio of 1.09 (0.74-1.61) for relapse-free survival and 1.21 (0.84-1.75) for overall survival. Interpretation The presence of bone-marrow micrometastases in patients with primary breast cancer is associated with a shorter relapse-free survival and overall survival, but is not all independent prognostic factor. This immunocytochemical technique may be of value in patients for whom pathological tumour size and lymph-node status are unavailable tie, patients receiving primary medical treatment).	Univ London St Georges Hosp, Dept Med Oncol, London SW17 0QT, England; Inst Canc Res, Surrey, England; Univ London St Georges Hosp, Dept Surg, London SW17 0QT, England; Charing Cross Hosp, Dept Oncol, London, England	St Georges University London; University of London; Institute of Cancer Research - UK; St Georges University London; Imperial College London	Mansi, JL (corresponding author), Univ London St Georges Hosp, Dept Med Oncol, London SW17 0QT, England.			Bliss, Judith/0000-0001-7957-7424; Coombes, Raoul Charles/0000-0002-4811-1100				BERGER U, 1988, AM J CLIN PATHOL, V90, P1; COTE RJ, 1991, J CLIN ONCOL, V9, P1749, DOI 10.1200/JCO.1991.9.10.1749; COTE RJ, 1988, AM J SURG PATHOL, V12, P333, DOI 10.1097/00000478-198805000-00001; COTE RJ, 1991, DIAGN ONCOL, V1, P37; DEARNALEY DP, 1983, J ROY SOC MED, V76, P359, DOI 10.1177/014107688307600506; DEARNALEY DP, 1981, BRIT J CANCER, V44, P85, DOI 10.1038/bjc.1981.152; DIEL IJ, 1992, J CLIN ONCOL, V10, P1534, DOI 10.1200/JCO.1992.10.10.1534; Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601; Diel IJ, 1996, JNCI-J NATL CANCER I, V88, P1652, DOI 10.1093/jnci/88.22.1652; ELLIS G, 1989, CANCER, V63, P2509, DOI 10.1002/1097-0142(19890615)63:12<2509::AID-CNCR2820631225>3.0.CO;2-K; Fields KK, 1996, J CLIN ONCOL, V14, P1868, DOI 10.1200/JCO.1996.14.6.1868; HARBECK N, 1994, BRIT J CANCER, V69, P566, DOI 10.1038/bjc.1994.103; HARBECK N, 1990, Journal of Cancer Research and Clinical Oncology, V116, P49; HERMANEK P, 1995, WORLD J SURG, V19, P184, DOI 10.1007/BF00308624; LINDEMANN F, 1992, LANCET, V340, P685, DOI 10.1016/0140-6736(92)92230-D; MANSI JL, 1988, J UROLOGY, V139, P545, DOI 10.1016/S0022-5347(17)42516-X; MANSI JL, 1989, J CLIN ONCOL, V7, P445, DOI 10.1200/JCO.1989.7.4.445; MANSI JL, 1991, EUR J CANCER, V27, P1552, DOI 10.1016/0277-5379(91)90413-8; MANSI JL, 1987, BRIT MED J, V295, P1093, DOI 10.1136/bmj.295.6606.1093; PASSOSCOELHO J, 1994, CANCER RES, V54, P2366; PINKUS GS, 1985, HUM PATHOL, V16, P929, DOI 10.1016/S0046-8177(85)80132-5; PORRO G, 1988, CANCER, V61, P2407, DOI 10.1002/1097-0142(19880615)61:12<2407::AID-CNCR2820611202>3.0.CO;2-G; REDDING WH, 1983, LANCET, V2, P1271; SHARP JG, 1992, INT J CELL CLONING, V10, P92, DOI 10.1002/stem.5530100731; THOMAS P, 1987, HUM PATHOL, V18, P728, DOI 10.1016/S0046-8177(87)80244-7; THOR A, 1988, BREAST CANCER RES TR, V11, P133, DOI 10.1007/BF01805837	26	233	245	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 17	1999	354	9174					197	202		10.1016/S0140-6736(98)10175-7	http://dx.doi.org/10.1016/S0140-6736(98)10175-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MU	10421301				2022-12-24	WOS:000081504200011
J	Reddel, H; Jenkins, C; Woolcock, A				Reddel, H; Jenkins, C; Woolcock, A			Diurnal variability - time to change asthma guidelines?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PEAK EXPIRATORY FLOW; SELF-MANAGEMENT PLANS; BRONCHIAL RESPONSIVENESS; POPULATION-SAMPLE; OBSTRUCTION		Royal Prince Alfred Hosp, Inst Resp Med, Camperdown, NSW 2050, Australia; Univ Sydney, Camperdown, NSW 2050, Australia	University of Sydney; University of Sydney	Reddel, H (corresponding author), Royal Prince Alfred Hosp, Inst Resp Med, POB M77, Camperdown, NSW 2050, Australia.	hkr@mail.med.usyd.edu.au	Reddel, Helen/AAC-3394-2020; Reddel, Helen/ABD-6338-2021	Reddel, Helen/0000-0002-6695-6350; Jenkins, Christine/0000-0003-2717-5647				Brand PLP, 1997, EUR RESPIR J, V10, P1242, DOI 10.1183/09031936.97.10061242; CLARK TJH, 1977, BRIT J DIS CHEST, V71, P87, DOI 10.1016/0007-0971(77)90087-0; CONNOLLY CK, 1994, RESP MED, V88, P453, DOI 10.1016/S0954-6111(05)80049-6; CONNOLLY CK, 1981, BRIT J DIS CHEST, V75, P197, DOI 10.1016/0007-0971(81)90053-X; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; DAHL R, 1991, EUR RESPIR J, V4, P1178; DALONZO GE, 1995, AM J RESP CRIT CARE, V152, P1097, DOI 10.1164/ajrccm.152.3.7663789; Fishwick D, 1996, EUR RESPIR J, V9, P861, DOI 10.1183/09031936.96.09050861; Gannon PFG, 1998, THORAX, V53, P790, DOI 10.1136/thx.53.9.790; *GLOB IN ASTHM, 1995, NIH PUBL; Grol R, 1998, BRIT MED J, V317, P858, DOI 10.1136/bmj.317.7162.858; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368, DOI 10.1164/ajrccm/140.5.1368; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588, DOI 10.1164/ajrccm/145.3.588; Lebowitz MD, 1997, EUR RESPIR J, V10, pS49; Meijer RJ, 1997, EUR RESPIR J, V10, P1163, DOI 10.1183/09031936.97.10051163; *NAT ASHM ED PREV, 1997, NIH PUBL; *NAT ASTHM CAMP AU, 1998, ASTHM MAN HDB; NEUKIRCH F, 1992, AM REV RESPIR DIS, V146, P71, DOI 10.1164/ajrccm/146.1.71; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel H, 1999, LANCET, V353, P758; REDDEL HK, 1995, AM J RESP CRIT CARE, V151, P1320, DOI 10.1164/ajrccm.151.5.7735580; Reddel HK, 1998, EUR RESPIR J, V12, P309, DOI 10.1183/09031936.98.12020309; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SALOME C, 1998, AM J RESP CRIT CARE, V157, pA631; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598, DOI 10.1164/ajrccm.149.3.8118624; Toogood JH, 1996, J ALLERGY CLIN IMMUN, V98, P555, DOI 10.1016/S0091-6749(96)70089-1; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; [No title captured], DOI DOI 10.1136/THX.52.2008.S1]	34	34	35	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					45	47		10.1136/bmj.319.7201.45	http://dx.doi.org/10.1136/bmj.319.7201.45			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390464	Green Published			2022-12-24	WOS:000081326500037
J	Doetsch, F; Caille, I; Lim, DA; Garcia-Verdugo, JM; Alvarez-Buylla, A				Doetsch, F; Caille, I; Lim, DA; Garcia-Verdugo, JM; Alvarez-Buylla, A			Subventricular zone astrocytes are neural stem cells in the adult mammalian brain	CELL			English	Article							CENTRAL-NERVOUS-SYSTEM; FIBRILLARY ACIDIC PROTEIN; MEDIATED GENE-TRANSFER; RAT CEREBRAL-CORTEX; NEURONAL PRECURSORS; VENTRICULAR ZONE; RADIAL GLIA; RECEPTOR IMMUNOREACTIVITY; RECOMBINANT RETROVIRUS; MONOCLONAL-ANTIBODY	Neural stem cells reside in the subventricular zone (SVZ) of the adult mammalian brain. This germinal region, which continually generates new neurons destined for the olfactory bulb, is composed of four cell types: migrating neuroblasts, immature precursors, astrocytes, and ependymal cells. Here we show that SVZ astrocytes, and not ependymal cells, remain labeled with proliferation markers after long survivals in adult mice. After elimination of immature precursors and neuroblasts by an antimitotic treatment, SVZ astrocytes divide to generate immature precursors and neuroblasts. Furthermore, in untreated mice, SVZ astrocytes specifically infected with a retrovirus give rise to new neurons in the olfactory bulb. Finally, we show that SVZ astrocytes give rise to cells that grow into multipotent neurospheres in vitro. We conclude that SVZ astrocytes act as neural stem cells in both the normal and regenerating brain.	Rockefeller Univ, New York, NY 10021 USA; Univ Valencia, E-46100 Burjassot, Spain	Rockefeller University; University of Valencia	Alvarez-Buylla, A (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	alvarez@rockvax.rockefeller.edu	García-Verdugo, José Manuel/L-8421-2017; Caillé, Isabelle/AAC-9575-2021	García-Verdugo, José Manuel/0000-0001-9872-6499; Lim, Daniel/0000-0001-7221-3425; Alvarez-Buylla, Arturo/0000-0003-4426-8925; Caille, Isabelle/0000-0002-9054-2641	NICHD NIH HHS [HD32116] Funding Source: Medline; NIGMS NIH HHS [GM07739] Funding Source: Medline; NINDS NIH HHS [NS28478] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028478, R01NS028478, R29NS028478] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 1998, J NEUROSCI, V18, P1020; ALVAREZBUYLLA A, 1990, NEURON, V5, P101, DOI 10.1016/0896-6273(90)90038-H; ALVAREZBUYLLA A, 1987, J COMP NEUROL, V264, P159, DOI 10.1002/cne.902640203; Baba H, 1997, DEV NEUROSCI-BASEL, V19, P49, DOI 10.1159/000111185; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; Blasco-Ibanez JM, 1998, EUR J NEUROSCI, V10, P1784, DOI 10.1046/j.1460-9568.1998.00190.x; Caille I, 1996, BRAIN RES, V730, P17, DOI 10.1016/0006-8993(96)00424-6; Calaora V, 1996, NEUROSCIENCE, V73, P581, DOI 10.1016/0306-4522(96)00042-5; CAVANAGH JB, 1970, J ANAT, V106, P471; CEPKO CL, 1992, CURRENT PROTOCOLS MO; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DIDIER M, 1986, CELL TISSUE RES, V245, P343; Doetsch F, 1997, J NEUROSCI, V17, P5046; Doetsch F, 1996, P NATL ACAD SCI USA, V93, P14895, DOI 10.1073/pnas.93.25.14895; ECKENHOFF MF, 1988, J NEUROSCI, V8, P2729; FEKETE DM, 1993, MOL CELL BIOL, V13, P2604, DOI 10.1128/MCB.13.4.2604; FIELDSBERRY SC, 1992, P NATL ACAD SCI USA, V89, P693, DOI 10.1073/pnas.89.2.693; FREDERIKSEN K, 1988, J NEUROSCI, V8, P1144; GAGE FH, 1995, ANNU REV NEUROSCI, V18, P159, DOI 10.1146/annurev.neuro.18.1.159; Garcia-Verdugo J, 1998, J NEUROBIOL, V36, P234, DOI 10.1002/(SICI)1097-4695(199808)36:2<234::AID-NEU10>3.0.CO;2-E; GOMEZPINILLA F, 1995, J NEUROSCI, V15, P2021, DOI 10.1523/JNEUROSCI.15-03-02021.1995; GRAY GE, 1992, DEVELOPMENT, V114, P271; GRITTI A, 1995, NEUROSCI LETT, V185, P151, DOI 10.1016/0304-3940(95)11247-T; Gritti A, 1999, J NEUROSCI, V19, P3287; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; HUNTER KE, 1995, P NATL ACAD SCI USA, V92, P2061, DOI 10.1073/pnas.92.6.2061; Jacobson M., 1991, DEV NEUROBIOLOGY; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; KISHI K, 1987, J COMP NEUROL, V258, P112, DOI 10.1002/cne.902580109; KORR H, 1973, J COMP NEUROL, V150, P169, DOI 10.1002/cne.901500205; LATOV N, 1979, DEV BIOL, V72, P381, DOI 10.1016/0012-1606(79)90127-1; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; LUSKIN MB, 1988, NEURON, V1, P635, DOI 10.1016/0896-6273(88)90163-8; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MESSIER B, 1958, EXP CELL RES, V14, P224, DOI 10.1016/0014-4827(58)90235-0; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Okada A, 1999, EXP NEUROL, V156, P394, DOI 10.1006/exnr.1999.7033; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; PATERSON JA, 1973, J COMP NEUROL, V149, P83, DOI 10.1002/cne.901490106; Peters A, 1991, FINE STRUCTURE NERVO; POTTEN CS, 1988, J CELL SCI, P45; PRICE J, 1988, DEVELOPMENT, V104, P473; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Qian XM, 1998, DEVELOPMENT, V125, P3143; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROUGON G, 1986, J CELL BIOL, V103, P2429, DOI 10.1083/jcb.103.6.2429; SCHMECHEL DE, 1979, ANAT EMBRYOL, V156, P115, DOI 10.1007/BF00300010; Shi JY, 1998, J NEUROSCI, V18, P4627; SMART I, 1961, J COMP NEUROL, V116, P325, DOI 10.1002/cne.901160306; SOTELO JR, 1958, Z ZELLFORSCH MIK ANA, V49, P1, DOI 10.1007/BF00335059; SPRANGRUDE GJ, 1988, SCIENCE, V241, P58; Temple S, 1999, CURR OPIN NEUROBIOL, V9, P135, DOI 10.1016/S0959-4388(99)80017-8; TEMPLE S, 1989, NATURE, V340, P471, DOI 10.1038/340471a0; VOIGT T, 1989, J COMP NEUROL, V289, P74, DOI 10.1002/cne.902890106; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Weiss S, 1996, J NEUROSCI, V16, P7599; Weiss S, 1996, TRENDS NEUROSCI, V19, P387, DOI 10.1016/S0166-2236(96)10035-7; Wichterle H, 1997, NEURON, V18, P779, DOI 10.1016/S0896-6273(00)80317-7; Wichterle H, 1999, NAT NEUROSCI, V2, P461, DOI 10.1038/8131; WILKIN GP, 1990, TRENDS NEUROSCI, V13, P43, DOI 10.1016/0166-2236(90)90065-I; YAZAKI N, 1994, J NEUROSCI RES, V37, P445, DOI 10.1002/jnr.490370403; Yoon SO, 1996, P NATL ACAD SCI USA, V93, P11974, DOI 10.1073/pnas.93.21.11974; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	73	2995	3140	6	172	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					703	716		10.1016/S0092-8674(00)80783-7	http://dx.doi.org/10.1016/S0092-8674(00)80783-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380923	Bronze			2022-12-24	WOS:000080886300009
J	Coffman, RL; Reiner, SL				Coffman, RL; Reiner, SL			Immunology - Instruction, selection, or tampering with the odds?	SCIENCE			English	Editorial Material							T-LYMPHOCYTES; EXPRESSION; CELLS; ACTIVATION; MECHANISM; ALLELES; LINEAGE		DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Chicago	Coffman, RL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.	Coffman@dnax.org; sreiner@midway.uchicago.edu						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bix M, 1998, SCIENCE, V281, P1352, DOI 10.1126/science.281.5381.1352; Chess A, 1998, ADV IMMUNOL, V69, P437, DOI 10.1016/S0065-2776(08)60613-6; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Enver T, 1998, CELL, V94, P9, DOI 10.1016/S0092-8674(00)81215-5; Fitzpatrick DR, 1998, J EXP MED, V188, P103, DOI 10.1084/jem.188.1.103; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347; Naramura M, 1998, IMMUNITY, V9, P209, DOI 10.1016/S1074-7613(00)80603-2; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Riviere I, 1998, IMMUNITY, V9, P217, DOI 10.1016/S1074-7613(00)80604-4; Takemoto N, 1998, INT IMMUNOL, V10, P1981, DOI 10.1093/intimm/10.12.1981; WEINTRAUB H, 1977, COLD SPRING HARB SYM, V42, P401, DOI 10.1101/SQB.1978.042.01.042; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	17	47	48	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 21	1999	284	5418					1283	+		10.1126/science.284.5418.1283	http://dx.doi.org/10.1126/science.284.5418.1283			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383307				2022-12-24	WOS:000080430600029
J	Coupland, R				Coupland, R			Clinical and legal significance of fragmentation of bullets in relation to size of wounds: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article							WAR WOUNDS; CLASSIFICATION; MANAGEMENT; DISRUPTION; BALLISTICS	Objective To examine the relation between fragmentation of bullets and size of wounds clinically and in the context of the Hague Declaration of 1899. Design Retrospective analysis of prospectively collected data on hospital admissions. Setting Hospitals of the International Committee of the Red Cross. Subjects 5215 people wounded by bullets in armed conflicts (5933 wounds). Main outcome measures Grade of wound computed from the Red Cross wound classification and presence of bullet fragments on radiography. Results Of the 347 wounds with fragmentation of bullets, 251 (72%) were large wounds (grade 2 or 3)that is, those with a clinically detectable cavity. Of the 5586 wounds without fragmentation of bullets, 2915 (52.1%) were large wounds. Only 7.9% (251/3166) of large wounds were associated with fragmentation of bullets. Conclusions Fragmentation of bullets is associated with large wounds, but most large wounds do not contain bullet fragments. In addition, bullet fragments may occur in wounds that are not defined as large. Fragmentation of bullets is neither a necessary nor sufficient cause of large wounds, and surgeons should not diagnose extensive tissue damage because of the presence of fragments on radiography Such findings also do not necessarily represent the use of bullets which contravene the law of war. Future legislation should take into account not only the construction of bullets but also their potential to transfer energy to the human body.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, R (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							BOWYER GW, 1995, J TRAUMA, V38, P64, DOI 10.1097/00005373-199501000-00018; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; Coupland R.M., 1991, RED CROSS WOUND CLAS, P18; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1992, LANCET, V339, P35, DOI 10.1016/0140-6736(92)90152-S; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; COUPLAND RM, 1994, RECENT ADV SURG, P121; Coupland RM, 1993, WAR WOUNDS LIMBS SUR; Coupland Robin, 1997, SIRUS PROJECT DETERM; Davis H J, 1897, Br Med J, V2, P1789; FACKLER ML, 1984, J TRAUMA, V24, P35, DOI 10.1097/00005373-198401000-00005; FACKLER ML, 1984, J TRAUMA, V24, P263, DOI 10.1097/00005373-198403000-00014; KNEUBUEHL BP, 1994, EXP M CERT WEAP SYST, P26; KNUDSEN PJT, 1993, INT J LEGAL MED, V106, P61, DOI 10.1007/BF01225042; LINDSEY D, 1980, J TRAUMA, V20, P1068, DOI 10.1097/00005373-198012000-00012; Ogston A, 1898, Br Med J, V2, P813; Ogston Alex, 1899, BMJ, V2, P278; SELLER KG, 1994, WOUND BALLISTICS; SMITH MSO, 1981, HIGH VELOCITY MISSIL; Spencer CG, 1908, GUNSHOT WOUNDS	20	14	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					403	406		10.1136/bmj.319.7207.403	http://dx.doi.org/10.1136/bmj.319.7207.403			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445917	Green Published, Bronze			2022-12-24	WOS:000082098900012
J	Coupland, RM; Samnegaard, HO				Coupland, RM; Samnegaard, HO			Effect of type and transfer of conventional weapons on civilian injuries: retrospective analysis of prospective data from Red Cross hospitals	BRITISH MEDICAL JOURNAL			English	Article							ANTIPERSONNEL MINES; LAND MINES; MOZAMBIQUE; MANAGEMENT; HEALTH	Objective To examine the link between different weapons used in modern wars and their potential to injury civilians. Design Retrospective analysis of prospectively collected data about hospital admissions. Setting Hospitals of the International Committee of the Red Cross. Subjects 18 877 people wounded by bullets, fragmentation munitions, or mines. Of these, 2012 had been admitted to the hospital in Kabul within six hours of injury. Main outcome measures Age and sex of wounded people according to cause of injury and whether they were civilians (women and girls, boys under 16 years old, or men of 50 or more). Results 18.7% of those injured by bullets, 34.1% of those injured by fragments, and 30.8% of those injured by mines were civilians. Of those admitted to the Red Cross hospital in Kabul within six hours of injury, 39.1% of those injured by bullets, 60.6% of those injured by fragments, and 55.0% of those injured by mines were civilians. Conclusions The proportion of civilians injured differs between weapon systems. The higher proportion injured by fragments and mines is explicable in terms of the military efficiency of weapons, the distance between user and victim, and the effect that the kind of weapon has on the psychology of the user.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland		Coupland, RM (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; Bowyer GW, 1997, ANN ROY COLL SURG, V79, P175; CARFIELD RM, 1991, JAMA-J AM MED ASSOC, V226, P688; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Coupland RM, 1996, LANCET, V347, P450, DOI 10.1016/S0140-6736(96)90017-3; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1993, JAMA-J AM MED ASSOC, V270, P624, DOI 10.1001/jama.270.5.624; Grossman Dave, 1995, KILLING PSYCHOL COST; *INT COMM RED CROS, 1996, MED PROF EFF WEAP S; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; Prokosch E., 1995, TECHNOLOGY KILLING; SELLIER KG, 1994, WOUND BALLISTICS; Sidel VW, 1995, BRIT MED J, V311, P1677, DOI 10.1136/bmj.311.7021.1677	14	29	33	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					410	412		10.1136/bmj.319.7207.410	http://dx.doi.org/10.1136/bmj.319.7207.410			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445921	Bronze, Green Published			2022-12-24	WOS:000082098900015
J	Andretic, R; Chaney, S; Hirsh, J				Andretic, R; Chaney, S; Hirsh, J			Requirement of circadian genes for cocaine sensitization in Drosophila	SCIENCE			English	Article							CLOCK GENE; BEHAVIORAL SENSITIZATION; PERIOD PROTEIN; DOUBLE-TIME; MELANOGASTER; ADDICTION; MUTANTS; RHYTHMS; TRANSCRIPTION; RESPONSES	The circadian clock consists of a feedback loop in which clock genes are rhythmically expressed, giving rise to cycling Levels of RNA and proteins. Four of the five circadian genes identified to date influence responsiveness to free-base cocaine in the fruit fly, Drosophila melanogaster, Sensitization to repeated cocaine exposures, a phenomenon also seen in humans and animal models and associated with enhanced drug craving, is eliminated in flies mutant for period, clock, cycle, and doubletime, but not in flies lacking the gene timeless. Flies that do not sensitize owing to lack of these genes do not show the induction of tyrosine decarboxylase normally seen after cocaine exposure. These findings indicate unexpected roles for these genes in regulating cocaine sensitization and indicate that they function as regulators of tyrosine decarboxylase.	Univ Virginia, Dept Biol, Charlottesville, VA 22903 USA	University of Virginia	Hirsh, J (corresponding author), Univ Virginia, Dept Biol, Gilmer Hall, Charlottesville, VA 22903 USA.		Andretic, Rozi/M-5666-2013; Jansen, Heiko T./A-5770-2008	Andretic, Rozi/0000-0003-0375-0520; Jansen, Heiko T./0000-0003-0178-396X; Chaney, Sarah/0000-0002-4734-7576	NIDA NIH HHS [DA05942] Funding Source: Medline; NIGMS NIH HHS [GM/DA 27318] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027318] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRETIC R, UNPUB; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; GOODMAN A, 1990, PHARMACOL BASIS THER, P417; Hamblen MJ, 1998, GENETICS, V149, P165; HENRY DJ, 1995, J NEUROSCI, V15, P6287; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Lee CG, 1998, NEURON, V21, P857, DOI 10.1016/S0896-6273(00)80601-7; McClung C, 1998, CURR BIOL, V8, P109, DOI 10.1016/S0960-9822(98)70041-7; MCCLUNG C, IN PRESS CURR BIOL; MCCLUNG C, UNPUB; MORSE AC, 1995, PHYSIOL BEHAV, V58, P891, DOI 10.1016/0031-9384(95)00144-8; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; NESTLER EJ, 1993, NEURON, V11, P995, DOI 10.1016/0896-6273(93)90213-B; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; RUTILA JE, 1992, J NEUROGENET, V8, P101, DOI 10.3109/01677069209084155; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; Strakowski SM, 1996, BIOL PSYCHIAT, V40, P872, DOI 10.1016/0006-3223(95)00497-1; TOLLIVER BK, 1994, J PHARMACOL EXP THER, V270, P1230; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; WHITE FJ, 1995, NEUROBIOLOGY COCAINE, P81; Yellman C, 1997, P NATL ACAD SCI USA, V94, P4131, DOI 10.1073/pnas.94.8.4131; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135	29	214	228	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1066	1068		10.1126/science.285.5430.1066	http://dx.doi.org/10.1126/science.285.5430.1066			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446052				2022-12-24	WOS:000082033100045
J	Hill, LL; Ouhtit, A; Loughlin, SM; Kripke, ML; Ananthaswamy, HN; Owen-Schaub, LB				Hill, LL; Ouhtit, A; Loughlin, SM; Kripke, ML; Ananthaswamy, HN; Owen-Schaub, LB			Fas ligand: A sensor for DNA damage critical in skin cancer etiology	SCIENCE			English	Article							P53 MUTATIONS; INDUCED APOPTOSIS; CELL CARCINOMA; MOUSE SKIN; ULTRAVIOLET; LYMPHOCYTES; ACTIVATION; SUNLIGHT; TUMORS; MICE	DNA-damaged cells can either repair the DNA or be eliminated through a homeostatic control mechanism termed "cellular proofreading." Elimination of DNA-damaged cells after ultraviolet radiation (UVR) through sunburn cell (apoptotic keratinocyte) formation is thought to be pivotal for the removal of precancerous skin cells. Sunburn cell formation was found to be dependent on Fas ligand (FasL), a pro-apoptotic protein induced by DNA damage. Chronic exposure to UVR caused 14 of 20 (70 percent) FasL-deficient mice and 1 of 20 (5 percent) wild-type mice to accumulate p53 mutations in the epidermis, Thus, Fast-mediated apoptosis is important for skin homeostasis, suggesting that the dysregulation of Fas-FasL interactions may be central to the development of skin cancer.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Owen-Schaub, LB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA.	lowensch@mdanderson.org			NCI NIH HHS [CA45623, CA52457] Funding Source: Medline; NIAID NIH HHS [F32 AI09351] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [F32AI009351] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ananthaswamy HN, 1998, PHOTOCHEM PHOTOBIOL, V67, P227, DOI 10.1562/0031-8655(1998)067<0227:MIHSHM>2.3.CO;2; Ananthaswamy HN, 1997, NAT MED, V3, P510, DOI 10.1038/nm0597-510; Brash DE, 1996, NAT MED, V2, P525, DOI 10.1038/nm0596-525; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; FISHER MS, 1982, SCIENCE, V216, P1133, DOI 10.1126/science.6210958; GALLE PR, 1995, J EXP MED, V182, P1223, DOI 10.1084/jem.182.5.1223; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; Gutierrez-Steil C, 1998, J CLIN INVEST, V101, P33, DOI 10.1172/JCI1165; Hill LL, 1999, J EXP MED, V189, P1285, DOI 10.1084/jem.189.8.1285; HILL LL, UNPUB; Jonason AS, 1996, P NATL ACAD SCI USA, V93, P14025, DOI 10.1073/pnas.93.24.14025; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KANJILAL S, 1993, CANCER RES, V53, P2961; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Li G, 1998, J INVEST DERMATOL, V110, P72, DOI 10.1046/j.1523-1747.1998.00090.x; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	20	206	207	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					898	900		10.1126/science.285.5429.898	http://dx.doi.org/10.1126/science.285.5429.898			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436160				2022-12-24	WOS:000081860900052
J	Summons, RE; Jahnke, LL; Hope, JM; Logan, GA				Summons, RE; Jahnke, LL; Hope, JM; Logan, GA			2-Methylhopanoids as biomarkers for cyanobacterial oxygenic photosynthesis	NATURE			English	Article							PROKARYOTIC TRITERPENOIDS; METHYLOBACTERIUM-ORGANOPHILUM; HOPANE SERIES; 2-BETA-METHYLHOPANOIDS; LOCALIZATION; BIOSYNTHESIS; ANTIQUITY; ORIGIN	Oxygenic photosynthesis is widely accepted as the most important bioenergetic process happening in Earth's surface environment(1). It is thought to have evolved within the cyanobacterial lineage, but it has been difficult to determine when it began. Evidence based on the occurrence and appearance of stromatolites(2) and microfossils' indicates that phototrophy occurred as long ago as 3,465 Myr although no definite physiological inferences can be he made from these objects. Carbon isotopes and other geological phenomena(4,5) provide clues but are also equivocal, Biomarkers are potentially useful because the three domains of extant life-Bacteria, Archaea and Eukarya-have signature membrane lipids with recalcitrant carbon skeletons. These lipids turn into hydrocarbons in sediments and can be found wherever the record is sufficiently well preserved. Here we show that 2-methylbacteriohopanepolyols occur in a high proportion of cultured cyanobacteria and cyanobacterial mats, Their 2-methylhopane hydrocarbon derivatives are abundant in organic-rich sediments as old as 2,500 Myr. These biomarkers may help constrain the age of the oldest cyanobacteria and the advent of oxygenic photosynthesis. They could also be used to quantify the ecological importance of cyanobacteria through geological time.	Australian Geol Survey Org, Canberra, ACT 2601, Australia; NASA, Ames Res Ctr, Exobiol Biol Branch, Moffett Field, CA 94035 USA	Geoscience Australia; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Summons, RE (corresponding author), Australian Geol Survey Org, GPO Box 378, Canberra, ACT 2601, Australia.		Summons, Roger Everett/AAL-3789-2020					[Anonymous], 1994, EARLY LIFE EARTH; Bauld J., 1984, MBL LECT BIOL, V3, P39; BISSERET P, 1985, EUR J BIOCHEM, V150, P29, DOI 10.1111/j.1432-1033.1985.tb08982.x; Blankenship RE, 1998, TRENDS BIOCHEM SCI, V23, P94, DOI 10.1016/S0968-0004(98)01186-4; BUICK R, 1992, SCIENCE, V255, P74, DOI 10.1126/science.11536492; Buick R, 1998, AAPG BULL, V82, P50; GOLUBIC S, 1994, EARLY LIFE EARTH, P220; Haug GH, 1998, PALEOCEANOGRAPHY, V13, P427, DOI 10.1029/98PA01976; HERMANN D, 1995, THESIS U HAUTE ALSAC; JURGENS UJ, 1992, FEMS MICROBIOL LETT, V92, P285; JW, 1992, PROTEROZOIC BIOSPHER, P81; KENIG F, 1995, GEOCHIM COSMOCHIM AC, V59, P2999, DOI 10.1016/0016-7037(95)00190-5; KNANI M, 1994, MICROBIOL-UK, V140, P2755, DOI 10.1099/00221287-140-10-2755; Llopiz P, 1996, FEMS MICROBIOL LETT, V140, P199; PETERS KE, 1992, BIOMARKER GUIDE INTE; PRICE LC, 1993, GEOCHIM COSMOCHIM AC, V57, P3261, DOI 10.1016/0016-7037(93)90539-9; RENOUX JM, 1985, EUR J BIOCHEM, V151, P405, DOI 10.1111/j.1432-1033.1985.tb09116.x; ROHMER M, 1984, J GEN MICROBIOL, V130, P1137; ROHMER M, 1993, PURE APPL CHEM, V65, P1293, DOI 10.1351/pac199365061293; SCHOPF J.W., 1992, PROTEROZOIC BIOSPHER; SCHOPF JW, 1993, SCIENCE, V260, P640, DOI 10.1126/science.260.5108.640; Simonin P, 1996, EUR J BIOCHEM, V241, P865, DOI 10.1111/j.1432-1033.1996.00865.x; SUMMONS RE, 1992, BIOLOGICAL MARKERS IN SEDIMENTS AND PETROLEUM, P182; Summons RE, 1996, CIBA F SYMP, V202, P174; SUMMONS RE, 1990, AM J SCI, V290A, P212; VILCHEZE C, 1994, MICROBIOLOGY, V140, P2794; ZHAO N, 1996, TETRAHEDRON, V52, P2772; ZUNDEL M, 1985, EUR J BIOCHEM, V150, P35, DOI 10.1111/j.1432-1033.1985.tb08984.x	28	679	732	5	125	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					554	557		10.1038/23005	http://dx.doi.org/10.1038/23005			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448856				2022-12-24	WOS:000081854800052
J	Ceriani, MF; Darlington, TK; Staknis, D; Mas, P; Petti, AA; Weitz, CJ; Kay, SA				Ceriani, MF; Darlington, TK; Staknis, D; Mas, P; Petti, AA; Weitz, CJ; Kay, SA			Light-dependent sequestration of TIMELESS by CRYPTOCHROME	SCIENCE			English	Article							DROSOPHILA CLOCK GENE; CIRCADIAN CLOCK; PROTEIN; PERIOD; TIM; PHOTORECEPTORS; TRANSCRIPTION; MELANOGASTER; ENTRAINMENT; HOMOLOG	Most organisms have circadian clocks consisting of negative feedback Loops of gene regulation that facilitate adaptation to cycles of light and darkness. In this study, CRYPTOCHROME (CRY), a protein involved in circadian photoperception in Drosophila, is shown to block the function of PERIOD/TIMELESS (PER/TIM) heterodimeric complexes in a light-dependent fashion. TIM degradation does not occur under these conditions: thus, TIM degradation is uncoupled from abrogation of its function by light, CRY and TIM are part of the same complex and directly interact in yeast in a light-dependent fashion. PER/TIM and CRY influence the subcellular distribution of these protein complexes, which reside primarily in the nucleus after the perception of a light signal. Thus, CRY acts as a circadian photoreceptor by directly interacting with core components of the circadian clock.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, NSF, Ctr Biol Timing, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Scripps Research Institute; National Science Foundation (NSF); NSF - Center for Biological Timing; Scripps Research Institute; Harvard University; Harvard Medical School	Kay, SA (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Kay, Steve A/F-6025-2011; Mas, Paloma/B-8215-2016	Kay, Steve A/0000-0002-0402-2878; Mas, Paloma/0000-0002-3780-8041; Ceriani, Maria/0000-0001-8945-3070	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH051573, R01MH059943] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-59943, MH-51573] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CERIANI MF, UNPUB; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Egan ES, 1999, J NEUROSCI, V19, P3665; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Hao HP, 1997, MOL CELL BIOL, V17, P3687, DOI 10.1128/MCB.17.7.3687; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kobayashi K, 1998, NUCLEIC ACIDS RES, V26, P5086, DOI 10.1093/nar/26.22.5086; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; Miyamoto Y, 1998, P NATL ACAD SCI USA, V95, P6097, DOI 10.1073/pnas.95.11.6097; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Okano S, 1999, PHOTOCHEM PHOTOBIOL, V69, P108; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; So WV, 1997, EMBO J, V16, P7146, DOI 10.1093/emboj/16.23.7146; Somers DE, 1998, SCIENCE, V282, P1488, DOI 10.1126/science.282.5393.1488; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; STAKNIS D, UNPUB; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323	36	430	445	4	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					553	556		10.1126/science.285.5427.553	http://dx.doi.org/10.1126/science.285.5427.553			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417378				2022-12-24	WOS:000081609500028
J	Liu, YY; Gao, JH; Liotti, M; Pu, YL; Fox, PT				Liu, YY; Gao, JH; Liotti, M; Pu, YL; Fox, PT			Temporal dissociation of parallel processing in the human subcortical outputs	NATURE			English	Article							BASAL GANGLIA; WORKING-MEMORY; MOTOR CONTROL; HUMAN BRAIN; DATA SETS; CEREBELLUM; CHANNELS	Many tasks require rapid and fine-tuned adjustment of motor performance based on incoming sensory information. This process of sensorimotor adaptation engages two parallel subcortico-cortical neural circuits, involving the cerebellum and basal ganglia, respectively(1-10), How these distributed circuits are functionally coordinated has not been shown in humans. The cerebellum and basal ganglia show very similar convergence of input-output organization(11,12), which presents an ideal neuroimaging model for the study of parallel processing at a systems level(13). Here we used functional magnetic resonance imaging to measure the temporal coherence of brain activity during a tactile discrimination task. We found that, whereas the prefrontal cortex maintained a high level of activation, output activities in the cerebellum and basal ganglia showed different phasic patterns. Moreover, cerebellar activity significantly correlated with the activity of the supplementary motor area but not with that of the primary motor cortex; in contrast, basal ganglia activity was more strongly associated with the activity of the primary motor cortex than with that of the supplementary motor area. These results demonstrate temporally partitioned activity in the cerebellum and basal ganglia, implicating functional independence in the parallel subcortical outputs. This further supports the idea of task-related dynamic reconfiguration of large-scale neural networks(14,15).	Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, San Antonio, TX 78284 USA; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Liu, YY (corresponding author), Univ Texas, Hlth Sci Ctr, Res Imaging Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.		Fox, Peter/B-4725-2010; anand, amit/A-7222-2009	Fox, Peter/0000-0002-0465-2028; LIOTTI, MARIO/0000-0003-3375-5488				ALLEN GI, 1974, PHYSIOL REV, V54, P957, DOI 10.1152/physrev.1974.54.4.957; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; BRESSLER SL, 1995, BRAIN RES REV, V20, P288, DOI 10.1016/0165-0173(94)00016-I; CHURCHLAND PS, 1988, SCIENCE, V242, P741, DOI 10.1126/science.3055294; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; FOX EM, 1995, PAC RIM L POLY J, V4, P1; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Gao JH, 1996, SCIENCE, V272, P545, DOI 10.1126/science.272.5261.545; Ghez C, 1991, PRINCIPLES NEURAL SC, P609; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HOOVER JE, 1993, SCIENCE, V259, P819, DOI 10.1126/science.7679223; Hoover JE, 1999, J NEUROSCI, V19, P1446; Houk JC, 1997, PROG BRAIN RES, V114, P543; HOUK JC, 1993, TRENDS NEUROSCI, V16, P27, DOI 10.1016/0166-2236(93)90049-R; HOUK JC, 1995, CEREB CORTEX, V5, P95, DOI 10.1093/cercor/5.2.95; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LIU Y, 1998, P INT SOC MAGN RESON, V6, P110; MARSDEN CD, 1982, NEUROLOGY, V32, P514, DOI 10.1212/WNL.32.5.514; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Middleton FA, 1997, PROG BRAIN RES, V114, P553; OGAWA S, 1993, BIOPHYS J, V64, P803, DOI 10.1016/S0006-3495(93)81441-3; ROLAND PE, 1988, EUR J NEUROSCI, V1, P3; Rouiller Eric M., 1996, P99, DOI 10.1016/B978-012759440-8/50009-8; Van Essen D. C., 1994, LARGE SCALE NEURONAL, P271; Voogd J, 1997, PROG BRAIN RES, V114, P21; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	28	61	65	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					364	367		10.1038/22547	http://dx.doi.org/10.1038/22547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432114				2022-12-24	WOS:000081590000050
J	Batista, AP; Buneo, CA; Snyder, LH; Andersen, RA				Batista, AP; Buneo, CA; Snyder, LH; Andersen, RA			Reach plans in eye-centered coordinates	SCIENCE			English	Article							POSTERIOR PARIETAL CORTEX; PREMOTOR CORTEX; VISUAL SPACE; NEURONAL-ACTIVITY; MACAQUE MONKEY; MOVEMENTS; AREAS; GAZE	The neural events associated with visually guided reaching begin with an image on the retina and end with impulses to the muscles, In between, a reaching plan is formed, This plan could be in the coordinates of the arm, specifying the direction and amplitude of the movement, or it could be in the coordinates of the eye because visual information is initially gathered in this reference frame. In a reach-planning area of the posterior parietal cortex, neural activity was found to be more consistent with an eye-centered than an arm-centered coding of reach targets. Coding of arm movements in an eye-centered reference frame is advantageous because obstacles that affect planning as well as errors in reaching are registered in this reference frame. Also, eye movements are planned in eye coordinates, and the use of similar coordinates for reaching may facilitate hand-eye coordination.	CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Mail Code 216-76, Pasadena, CA 91125 USA.		Snyder, Lawrence H/A-4593-2017	Batista, Aaron/0000-0002-1719-0061				BALLARD DH, 1992, PHILOS T R SOC B, V337, P331, DOI 10.1098/rstb.1992.0111; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; Boussaoud D, 1998, J NEUROPHYSIOL, V80, P1132, DOI 10.1152/jn.1998.80.3.1132; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Clower DM, 1996, NATURE, V383, P618, DOI 10.1038/383618a0; COLBY CL, 1991, NEUROPSYCHOLOGIA, V29, P517, DOI 10.1016/0028-3932(91)90008-V; Colby CL, 1998, NEURON, V20, P15, DOI 10.1016/S0896-6273(00)80429-8; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; Fogassi L, 1996, J NEUROPHYSIOL, V76, P141, DOI 10.1152/jn.1996.76.1.141; Galletti C, 1997, EUR J NEUROSCI, V9, P410, DOI 10.1111/j.1460-9568.1997.tb01410.x; GEORGOPOULOS AP, 1983, EXP BRAIN RES, V49, P327; GNADT JW, 1988, EXP BRAIN RES, V70, P216; GRAZIANO MSA, 1994, SCIENCE, V266, P1054, DOI 10.1126/science.7973661; Graziano MSA, 1997, SCIENCE, V277, P239, DOI 10.1126/science.277.5323.239; Hein A, 1958, PERCEPT MOTOR SKILL, V8, P87, DOI [DOI 10.2466/PMS.1958.8.3.87, 10.2466/pms.1958.8.3.87]; Henriques DYP, 1998, J NEUROSCI, V18, P1583; Jeannerod M., 1988, NEURAL BEHAV ORG GOA; JOHNSON PB, 1996, CEREB CORTEX, V6, P1047; LACQUANITI F, 1995, CEREB CORTEX, V5, P391, DOI 10.1093/cercor/5.5.391; MAYS LE, 1980, J NEUROPHYSIOL, V43, P207, DOI 10.1152/jn.1980.43.1.207; McIntyre J, 1997, J NEUROPHYSIOL, V78, P1601, DOI 10.1152/jn.1997.78.3.1601; Murata A, 1996, J NEUROPHYSIOL, V75, P2180, DOI 10.1152/jn.1996.75.5.2180; Mushiake H, 1997, J NEUROPHYSIOL, V78, P567, DOI 10.1152/jn.1997.78.1.567; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; Sabes PN, 1997, J NEUROSCI, V17, P7119; SCOTT DW, 1985, ANN STAT, V13, P1024, DOI 10.1214/aos/1176349654; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; Soechting J F, 1990, J Cogn Neurosci, V2, P32, DOI 10.1162/jocn.1990.2.1.32; Vetter P, 1999, J NEUROPHYSIOL, V81, P935, DOI 10.1152/jn.1999.81.2.935; WALKER MF, 1995, J NEUROPHYSIOL, V73, P1988, DOI 10.1152/jn.1995.73.5.1988; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	32	523	530	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					257	260		10.1126/science.285.5425.257	http://dx.doi.org/10.1126/science.285.5425.257			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398603				2022-12-24	WOS:000081346000043
J	Perozo, E; Cortes, DM; Cuello, LG				Perozo, E; Cortes, DM; Cuello, LG			Structural rearrangements underlying K+-channel activation gating	SCIENCE			English	Article							PARAMAGNETIC-RESONANCE DATA; STREPTOMYCES-LIVIDANS; SECONDARY STRUCTURE; SPIN-LABELS; CIRCULAR-DICHROISM; POTASSIUM CHANNEL; PROTEIN-STRUCTURE; RECEPTOR CHANNEL; ION-CHANNEL; T4 LYSOZYME	The intramembrane molecular events underlying activation gating in the Streptomyces K+ channel were investigated by site-directed spin-labeling methods and electron paramagnetic resonance spectroscopy. A comparison of the closed and open conformations of the channel revealed periodic changes in spin-label mobility and intersubunit spin-spin interaction consistent with rigid-body movements of the two transmembrane helices TM1 and TM2. These changes involve translations and counterclockwise rotations of both helices relative to the center of symmetry of the channel. The movement of TM2 increases the diameter of the permeation pathway along the point of convergence of the four subunits, thus opening the pore, Although the extracellular residues flanking the selectivity filter remained immobile during gating, small movements were detected at the C-terminal end of the pore helix. with possible implications to the gating mechanism.	Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Ctr Struct Biol, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Perozo, E (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22906 USA.				NIGMS NIH HHS [GM57846, GM54690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057846, R01GM054690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Aidley D.J., 1996, ION CHANNELS MOL ACT; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ANDERSON CS, 1988, J GEN PHYSIOL, V91, P317, DOI 10.1085/jgp.91.3.317; ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Chapman ML, 1997, BIOPHYS J, V72, P708, DOI 10.1016/S0006-3495(97)78707-1; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; Cortes DM, 1997, BIOCHEMISTRY-US, V36, P10343, DOI 10.1021/bi971018y; CORTES DM, 1999, 43 ANN M BIOPH SOC B; Cuello LG, 1998, BIOCHEMISTRY-US, V37, P3229, DOI 10.1021/bi972997x; CUELLO LG, 1999, 43 ANN M BIOPH SOC B; DELEAGE G, 1993, COMPUT APPL BIOSCI, V9, P197; DONNELLY D, 1994, PROTEIN ENG, V7, P645, DOI 10.1093/protein/7.5.645; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; EATON GR, 1989, SPIN LABELING THEORY; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Heginbotham L, 1998, J GEN PHYSIOL, V111, P741, DOI 10.1085/jgp.111.6.741; Hille B., 1992, ION CHANNELS EXCITAB; Holmgren M, 1997, J GEN PHYSIOL, V109, P527, DOI 10.1085/jgp.109.5.527; Hubbell WL, 1998, CURR OPIN STRUC BIOL, V8, P649, DOI 10.1016/S0959-440X(98)80158-9; Hustedt EJ, 1997, BIOPHYS J, V72, P1861, DOI 10.1016/S0006-3495(97)78832-5; le Coutre J, 1998, P NATL ACAD SCI USA, V95, P6114, DOI 10.1073/pnas.95.11.6114; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Mchaourab HS, 1997, BIOCHEMISTRY-US, V36, P307, DOI 10.1021/bi962114m; Mchaourab HS, 1996, BIOCHEMISTRY-US, V35, P7692, DOI 10.1021/bi960482k; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Perozo E, 1998, NAT STRUCT BIOL, V5, P459, DOI 10.1038/nsb0698-459; RABENSTEIN MD, 1995, P NATL ACAD SCI USA, V92, P8239, DOI 10.1073/pnas.92.18.8239; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Steinhoff HJ, 1997, BIOPHYS J, V73, P3287, DOI 10.1016/S0006-3495(97)78353-X; Tatulian SA, 1998, FEBS LETT, V423, P205, DOI 10.1016/S0014-5793(98)00091-X; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; YELLEN G, IN PRESS Q REV BIOPH; ZAGOTTA WN, 1994, J GEN PHYSIOL, V103, P321, DOI 10.1085/jgp.103.2.321; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101	42	489	499	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					73	78		10.1126/science.285.5424.73	http://dx.doi.org/10.1126/science.285.5424.73			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390363				2022-12-24	WOS:000081199800030
J	Feneley, MR; Walsh, PC				Feneley, MR; Walsh, PC			Incontinence after radical prostatectomy	LANCET			English	Editorial Material							COLLAGEN INJECTION THERAPY; QUALITY-OF-LIFE; RETROPUBIC PROSTATECTOMY; URINARY-INCONTINENCE; FOLLOW-UP; CONTINENCE; SURGERY; CANCER		Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	Feneley, MR (corresponding author), Johns Hopkins Univ Hosp, James Buchanan Brady Urol Inst, Baltimore, MD 21287 USA.							APPELL RA, 1994, UROL CLIN N AM, V21, P177; Burnett AL, 1998, J UROLOGY, V160, P1301, DOI 10.1016/S0022-5347(01)62521-7; Eastham JA, 1996, J UROLOGY, V156, P1707, DOI 10.1016/S0022-5347(01)65488-0; Ficazzola MA, 1998, J UROLOGY, V160, P1317, DOI 10.1016/S0022-5347(01)62525-4; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; GEARY ES, 1995, UROLOGY, V45, P1000; Haab F, 1997, J UROLOGY, V158, P435, DOI 10.1016/S0022-5347(01)64496-3; MAATHEWSONCHAPM.M, 1997, J CANCER EDUC, V12, P218; SanchezOrtiz RF, 1997, J UROLOGY, V158, P2132, DOI 10.1016/S0022-5347(01)68177-1; STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9; Talcott JA, 1997, J NATL CANCER I, V89, P1117, DOI 10.1093/jnci/89.15.1117; Tefilli MV, 1998, UROLOGY, V52, P224, DOI 10.1016/S0090-4295(98)00151-4; Walsh Patrick C., 1999, Journal of Urology, V161, P387; WALSH PC, 1994, J UROLOGY, V152, P1831, DOI 10.1016/S0022-5347(17)32396-0; Walsh PC, 1998, J UROLOGY, V160, P2418, DOI 10.1016/S0022-5347(01)62202-X; WEIN AJ, 1995, UROL CLIN N AM, V22, P557	16	12	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2091	2092		10.1016/S0140-6736(98)00355-9	http://dx.doi.org/10.1016/S0140-6736(98)00355-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382690				2022-12-24	WOS:000080969300006
J	Weinberg, JR; Duerden, BI				Weinberg, JR; Duerden, BI			Commentary: A matter of good clinical practice	BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Lab Serv, London NW9 5EQ, England	Public Health England	Duerden, BI (corresponding author), Publ Hlth Lab Serv, London NW9 5EQ, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1617	1618						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428554				2022-12-24	WOS:000080913100039
J	Zhu, HT; Kavsak, P; Abdollah, S; Wrana, JL; Thomsen, GH				Zhu, HT; Kavsak, P; Abdollah, S; Wrana, JL; Thomsen, GH			A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation	NATURE			English	Article							TGF-BETA SUPERFAMILY; PROTEIN LIGASE; SIGNALING PATHWAYS; XENOPUS EMBRYO; C2 DOMAIN; DEGRADATION; RECEPTOR; ENCODES; SYSTEM; ACTS	The TGF-beta superfamily of proteins regulates many different biological processes, including cell growth, differentiation and embryonic pattern formation(1-3). TGF-beta-like factors signal across cell membranes through complexes of transmembrane receptors known as type I and type II serine/threonine-kinase receptors, which in turn activate the SMAD signalling pathway(4,5). On the inside of the cell membrane, a receptor-regulated class of SMADs are phosphorylated by the type-I-receptor kinase. In this way, receptors for different factors are able to pass on specific signals along the pathway: for example, receptors for bone morphogenetic protein (BMP) target SMADs 1, 5 and 8, whereas receptors for activin and TGF-beta target SMADs 2 and 3. Phosphorylation of receptor-regulated SMADs induces their association with Smad4, the 'common-partner' SMAD, and stimulates accumulation of this complex in the nucleus, where it regulates transcriptional responses. Here we describe Smurf1, a new member of the Hect family of E3 ubiquitin ligases. Smurf1 selectively interacts with receptor-regulated SMADs specific for the BMP pathway in order to trigger their ubiquitination and degradation, and hence their inactivation. In the amphibian Xenopus laevis, Smurf1 messenger RNA is localized to the animal pole of the egg; in Xenopus embryos, ectopic Smurf1 inhibits the transmission of BMP signals and thereby affects pattern formation. Smurf1 also enhances cellular responsiveness to the Smad2 (activin/TGF-beta) pathway. Thus, targeted ubipuitination of SMADs may serve to control both embryonic development and a wide variety of cellular responses to TGF-beta signals.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5G 1X8, Canada	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Thomsen, GH (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.		Kavsak, Pete/K-8089-2019; zhu, HAITAO/GVL-0589-2022; Wrana, Jeffrey/F-8857-2013		NICHD NIH HHS [R01 HD032429, R01 HD032429-04, R01 HD032429-05] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD032429] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Candia AF, 1997, DEVELOPMENT, V124, P4467; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HEIN C, 1995, MOL MICROBIOL, V18, P77, DOI 10.1111/j.1365-2958.1995.mmi_18010077.x; HEMMATIBRIVANLOU A, 1995, DEV GENET, V17, P78, DOI 10.1002/dvg.1020170109; HemmatiBrivanlou A, 1997, CELL, V88, P13, DOI 10.1016/S0092-8674(00)81853-X; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoodless PA, 1999, DEV BIOL, V207, P364, DOI 10.1006/dbio.1998.9168; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P5249, DOI 10.1073/pnas.92.11.5249-a; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Macias-Silva M, 1998, J BIOL CHEM, V273, P25628, DOI 10.1074/jbc.273.40.25628; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; Nefsky B, 1996, EMBO J, V15, P1301, DOI 10.1002/j.1460-2075.1996.tb00472.x; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; Nishimatsu S, 1998, MECH DEVELOP, V74, P75, DOI 10.1016/S0925-4773(98)00070-7; Plant PJ, 1997, J BIOL CHEM, V272, P32329, DOI 10.1074/jbc.272.51.32329; Rotin D, 1998, CURR TOP MICROBIOL, V228, P115; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Thomsen GH, 1996, DEVELOPMENT, V122, P2359; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; Wilson PA, 1997, DEVELOPMENT, V124, P3177	31	645	702	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					687	693		10.1038/23293	http://dx.doi.org/10.1038/23293			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458166				2022-12-24	WOS:000082032900059
J	Bell, AC; West, AG; Felsenfeld, G				Bell, AC; West, AG; Felsenfeld, G			The protein CTCF is required for the enhancer blocking activity of vertebrate insulators	CELL			English	Article							DNA-BINDING PROTEIN; ZINC-FINGER PROTEIN; HAIRY-WING PROTEIN; BETA-GLOBIN LOCUS; C-MYC GENE; DROSOPHILA-MELANOGASTER; CHROMATIN INSULATOR; TRANSCRIPTIONAL ACTIVITY; CHROMOSOMAL DOMAINS; PROMOTER	An insulator is a DNA sequence that can act as a barrier to the influences of neighboring cis-acting elements, preventing gene activation, for example, when located between an enhancer and a promoter. We have identified a 42 bp fragment of the chicken beta-globin insulator that is both necessary and sufficient for enhancer blocking activity in human cells. We show that this sequence is the binding site for CTCF, a previously identified eleven-zinc finger DNA-binding protein that is highly conserved in vertebrates. CTCF sites are present in all of the vertebrate enhancer-blocking elements we have examined. We suggest that directional enhancer blocking by CTCF is a conserved component of gene regulation in vertebrates.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Felsenfeld, G (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			West, Adam/0000-0003-3502-7804				ANDERSON GM, 1991, MOL CELL BIOL, V11, P1935, DOI 10.1128/MCB.11.4.1935; BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J; BRESNICK EH, 1994, P NATL ACAD SCI USA, V91, P1314, DOI 10.1073/pnas.91.4.1314; Bulger M, 1999, P NATL ACAD SCI USA, V96, P5129, DOI 10.1073/pnas.96.9.5129; Burcin M, 1997, MOL CELL BIOL, V17, P1281, DOI 10.1128/MCB.17.3.1281; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; DORSETT D, 1993, GENETICS, V134, P1135; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; Gdula DA, 1997, GENETICS, V145, P153; Georgiev P, 1996, GENETICS, V142, P425; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GEYER PK, 1992, GENE DEV, V6, P1865, DOI 10.1101/gad.6.10.1865; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HOLDRIDGE C, 1991, MOL CELL BIOL, V11, P1894, DOI 10.1128/MCB.11.4.1894; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; Klenova EM, 1997, NUCLEIC ACIDS RES, V25, P466, DOI 10.1093/nar/25.3.466; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; LABHART P, 1987, NUCLEIC ACIDS RES, V15, P3623, DOI 10.1093/nar/15.8.3623; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Ohtsuki S, 1998, GENE DEV, V12, P3325, DOI 10.1101/gad.12.21.3325; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; REITMAN M, 1990, MOL CELL BIOL, V10, P2774, DOI 10.1128/MCB.10.6.2774; Robinett CC, 1997, MOL CELL BIOL, V17, P2866, DOI 10.1128/MCB.17.5.2866; SPANA C, 1988, GENE DEV, V2, P1414, DOI 10.1101/gad.2.11.1414; UDVARDY A, 1985, J MOL BIOL, V185, P341, DOI 10.1016/0022-2836(85)90408-5; Udvardy A, 1999, EMBO J, V18, P1, DOI 10.1093/emboj/18.1.1; Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X; Zhong XP, 1997, P NATL ACAD SCI USA, V94, P5219, DOI 10.1073/pnas.94.10.5219; Zhou JM, 1996, GENE DEV, V10, P3195, DOI 10.1101/gad.10.24.3195	38	825	881	0	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					387	396		10.1016/S0092-8674(00)81967-4	http://dx.doi.org/10.1016/S0092-8674(00)81967-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458613	Bronze			2022-12-24	WOS:000081950300013
J	Koh, YH; Popova, E; Thomas, U; Griffith, LC; Budnik, V				Koh, YH; Popova, E; Thomas, U; Griffith, LC; Budnik, V			Regulation of DLG localization at synapses by CaMKII-dependent phosphorylation	CELL			English	Article							TUMOR-SUPPRESSOR GENE; LONG-TERM POTENTIATION; PROTEIN-KINASE-II; SYNAPTIC BOUTON STRUCTURE; FASCICLIN-II; FUNCTIONAL COMPONENTS; POSTSYNAPTIC DENSITY; ADHESION MOLECULE; K+ CHANNELS; IN-VIVO	Discs large (DLG) mediates the clustering of synaptic molecules. Here we demonstrate that synaptic localization of DLG itself is regulated by CaMKII. We show that DLG and CaMKII colocalize at synapses and exist in the same protein complex. Constitutively activated CaMKII phenocopied structural abnormalities of dig mutant synapses and dramatically increased extra-junctional DLG. Decreased CaMKII activity caused opposite alterations. In vitro, CaMKII phosphorylated a DLG fragment with a stoichiometry close to one. Moreover, expression of site-directed dig mutants that blocked or mimicked phosphorylation had effects similar to those observed upon inhibiting or constitutively activating CaMKII. We propose that CaMKII-dependent DLG phosphorylation regulates the association of DLG with the synaptic complex during development and plasticity, thus providing a link between synaptic activity and structure.	Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA; Brandeis Univ, Volen Ctr Complex Syst, Dept Biol, Waltham, MA 02454 USA	University of Massachusetts System; University of Massachusetts Amherst; Brandeis University	Budnik, V (corresponding author), Univ Massachusetts, Dept Biol, Amherst, MA 01003 USA.	vbudnik@bio.umass.edu		Griffith, Leslie/0000-0003-3164-9876	NIGMS NIH HHS [R01 GM54408, R01 GM054408] Funding Source: Medline; NINDS NIH HHS [KO4 NS01786, R01 NS030072, R01 NS30072] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054408] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001786, R01NS030072] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abel T, 1998, SCIENCE, V279, P338, DOI 10.1126/science.279.5349.338; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BRAND AH, 1993, DEVELOPMENT, V118, P401; Budnik V, 1996, NEURON, V17, P627, DOI 10.1016/S0896-6273(00)80196-8; BUDNIK V, 1990, J NEUROSCI, V10, P3754; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHO KO, 1991, NEURON, V7, P439, DOI 10.1016/0896-6273(91)90296-C; Davis GW, 1998, CURR OPIN NEUROBIOL, V8, P149, DOI 10.1016/S0959-4388(98)80018-4; ERONDU NE, 1985, J NEUROSCI, V5, P3270; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 1996, TRENDS CELL BIOL, V6, P429, DOI 10.1016/S0962-8924(96)10036-2; GORCZYCA M, 1993, J NEUROSCI, V13, P3692; Gramates LS, 1999, INT REV NEUROBIOL, V43, P93, DOI 10.1016/S0074-7742(08)60542-5; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GRIFFITH LC, 1993, J NEUROCHEM, V61, P1534, DOI 10.1111/j.1471-4159.1993.tb13650.x; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; Guan B, 1996, CURR BIOL, V6, P695, DOI 10.1016/S0960-9822(09)00451-5; GuptaRoy B, 1996, J NEUROCHEM, V66, P1282; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; Hsueh YP, 1999, J BIOL CHEM, V274, P532, DOI 10.1074/jbc.274.1.532; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jin R, 1998, J NEUROSCI, V18, P8955; KENNEDY M, 1997, TRENDS NEUROSCI, V20, P103; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; Kim E, 1997, J CELL BIOL, V136, P669, DOI 10.1083/jcb.136.3.669; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAHEY T, 1994, NEURON, V13, P823, DOI 10.1016/0896-6273(94)90249-6; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Roche KW, 1996, NEURON, V16, P1179, DOI 10.1016/S0896-6273(00)80144-0; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SODERLING TR, 1993, BIOTECHNOL APPL BIOC, V18, P185; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Takeuchi M, 1997, J BIOL CHEM, V272, P11943, DOI 10.1074/jbc.272.18.11943; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; Topinka JR, 1998, NEURON, V20, P125, DOI 10.1016/S0896-6273(00)80440-7; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; Wang Z, 1998, J NEUROCHEM, V71, P378; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	56	197	201	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					353	363		10.1016/S0092-8674(00)81964-9	http://dx.doi.org/10.1016/S0092-8674(00)81964-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458610	Green Accepted, Bronze			2022-12-24	WOS:000081950300010
J	Freedman, AL; Johnson, MP; Smith, CA; Gonzalez, R; Evans, MI				Freedman, AL; Johnson, MP; Smith, CA; Gonzalez, R; Evans, MI			Long-term outcome in children after antenatal intervention for obstructive uropathies	LANCET			English	Article							POSTERIOR URETHRAL VALVES; CONGENITAL HYDRONEPHROSIS INUTERO; FETAL RENAL-FUNCTION; PRUNE BELLY SYNDROME; PULMONARY HYPOPLASIA; GROWTH; BLADDER; OLIGOHYDRAMNIOS; BIOCHEMISTRY; THERAPY	Background Antenatal intervention has been done for fetal obstructive uropathy far over a decade, yet little is known about long-term outcomes. To assess the long-term implications of fetal intervention, we reviewed the outcomes of children who underwent vesicoamniotic shunt placement. Methods We reviewed the clinical outcomes of 14 children who underwent vesicoamniotic shunt placement at our institution and who survived beyond 2 years of age. Findings In 1987-96, 34 patients underwent vesicoamniotic shunt placement. 13 died and 21 survived, of whom 17 are now more than 2 years old. Three survivors were lost to follow-up. Mean age at follow-up was 54.3 months (range 25-114). Final diagnoses included prune belly syndrome (seven cases), posterior urethral valves (four), urethral atresia (one), vesicoureteral reflux (one), and megacystis (one). Height was below the 25th percentile in 12 (86%) with seven (50%) below the 5th percentile. Five (36%) had renal failure and had successful transplantation, three (21%) have renal insufficiency, and six (43%) have normal renal function. Seven (50%) are acceptably continent, five (36%) have not yet begun toilet-training, and two (14%) are incontinent. Three of four children with valves needed bladder augmentation. Interpretation Antenatal intervention may help those fetuses with the most severe forms of obstructive uropathy, usually associated with a fatal neonatal course. intervention achieves outcomes similar to less severe cases that are usually diagnosed postnatally.	Childrens Hosp Michigan, Dept Paediat Urol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Obstet & Gynaecol, Detroit, MI USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Mol Med & Geriatr, Detroit, MI USA; Wayne State Univ, Sch Med, Hutzel Hosp, Dept Pathol, Detroit, MI USA	Children's Hospital of Michigan; Wayne State University; Wayne State University; Wayne State University	Freedman, AL (corresponding author), 100 UCLA Med Plaza,Suite 690, Los Angeles, CA 90095 USA.							BAUER SB, 1979, J UROLOGY, V121, P769, DOI 10.1016/S0022-5347(17)56985-2; CAMPAIOLA JM, 1985, J UROLOGY, V134, P708, DOI 10.1016/S0022-5347(17)47400-3; CONNOR JP, 1990, J UROLOGY, V144, P1209, DOI 10.1016/S0022-5347(17)39695-7; CROMBLEHOLME TM, 1990, AM J OBSTET GYNECOL, V162, P1239, DOI 10.1016/0002-9378(90)90026-4; ELDER JS, 1990, J UROLOGY, V144, P574, DOI 10.1016/S0022-5347(17)39526-5; ELDER JS, 1987, LANCET, V2, P1007; FREEDMAN AL, 1997, J UROLOGY, V157, pA10; GEARY DF, 1986, J UROLOGY, V135, P324, DOI 10.1016/S0022-5347(17)45627-8; GLICK PL, 1985, J PEDIATR SURG, V20, P376, DOI 10.1016/S0022-3468(85)80223-2; GLICK PL, 1984, J PEDIATR SURG, V19, P649, DOI 10.1016/S0022-3468(84)80348-6; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HARRISON MR, 1982, J PEDIATR SURG, V17, P965, DOI 10.1016/S0022-3468(82)80476-4; HARRISON MR, 1983, J PEDIATR SURG, V18, P247, DOI 10.1016/S0022-3468(83)80094-3; JOHNSON MP, 1994, AM J OBSTET GYNECOL, V170, P1770; JOHNSON MP, 1995, AM J OBSTET GYNECOL, V173, P59, DOI 10.1016/0002-9378(95)90170-1; KRUEGER RP, 1980, UROL CLIN N AM, V7, P265; LIPITZ S, 1993, AM J OBSTET GYNECOL, V168, P174, DOI 10.1016/S0002-9378(12)90909-6; MANDELBROT L, 1991, J PERINAT MED, V19, P283; MANNING FA, 1986, NEW ENGL J MED, V315, P336, DOI 10.1056/NEJM198607313150532; MERGUERIAN PA, 1992, J UROLOGY, V148, P1499, DOI 10.1016/S0022-5347(17)36949-5; Mitchell M., 1982, DIAL PEDIAT UROL, V5, P8; MULLER F, 1993, OBSTET GYNECOL, V82, P813; NICOLAIDES KH, 1992, AM J OBSTET GYNECOL, V166, P932, DOI 10.1016/0002-9378(92)91367-J; PETERS CA, 1991, J UROLOGY, V146, P597, DOI 10.1016/S0022-5347(17)37865-5; PETERS CA, 1990, J UROLOGY, V144, P122, DOI 10.1016/S0022-5347(17)39388-6; PETERS CA, 1991, J UROLOGY, V146, P1178, DOI 10.1016/S0022-5347(17)38035-7; REINBERG Y, 1992, J UROLOGY, V148, P125, DOI 10.1016/S0022-5347(17)36532-1; REINBERG Y, 1992, J UROLOGY, V148, P532, DOI 10.1016/S0022-5347(17)36645-4; REINBERG Y, 1991, J UROLOGY, V145, P1017, DOI 10.1016/S0022-5347(17)38518-X; SCHWARTZ GJ, 1987, PEDIATR CLIN N AM, V34, P571; WARSHAW BL, 1985, J UROLOGY, V133, P240, DOI 10.1016/S0022-5347(17)48899-9	31	128	131	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					374	377		10.1016/S0140-6736(98)11006-1	http://dx.doi.org/10.1016/S0140-6736(98)11006-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437866				2022-12-24	WOS:000081764900012
J	Mackenzie, A; Hallam, N; Mitchell, E; Beattie, T				Mackenzie, A; Hallam, N; Mitchell, E; Beattie, T			Near patient testing for respiratory syncytial virus in paediatric accident and emergency: prospective pilot study	BRITISH MEDICAL JOURNAL			English	Article							INFECTIONS; DIAGNOSIS		City Hosp Edinburgh, Reg Clin Virol Lab, Edinburgh EH10 5SB, Midlothian, Scotland; Royal Hosp Sick Children, Edinburgh EH9 1LF, Midlothian, Scotland		Hallam, N (corresponding author), City Hosp Edinburgh, Reg Clin Virol Lab, Edinburgh EH10 5SB, Midlothian, Scotland.							*JOINT WORK GROUP, 1999, GUID NEAR PAT POINT; Langley JM, 1997, PEDIATRICS, V100, P943, DOI 10.1542/peds.100.6.943; TODD SJ, 1995, J CLIN MICROBIOL, V33, P1650, DOI 10.1128/JCM.33.6.1650-1651.1995; Wendt C H, 1995, Semin Respir Infect, V10, P224; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					289	290		10.1136/bmj.319.7205.289	http://dx.doi.org/10.1136/bmj.319.7205.289			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426738	Bronze, Green Published			2022-12-24	WOS:000081909100022
J	Wijnhoven, BPL; Pignatelli, M				Wijnhoven, BPL; Pignatelli, M			E-cadherin-catenin: more than a "sticky" molecular complex	LANCET			English	Editorial Material							ALPHA-CATENIN; BETA-CATENIN; EXPRESSION; CANCER		Univ Bristol, Bristol Royal Infirm, Dept Pathol & Microbiol, Div Histopathol, Bristol BS2 8HW, Avon, England	Bristol Royal Infirmary; University of Bristol	Wijnhoven, BPL (corresponding author), Univ Bristol, Bristol Royal Infirm, Dept Pathol & Microbiol, Div Histopathol, Bristol BS2 8HW, Avon, England.		Wijnhoven, Bas/AAF-4838-2020; Pignatelli, Massimo/ABA-2672-2020	Pignatelli, Massimo/0000-0001-9257-3567				Bailey T, 1998, AM J PATHOL, V152, P135; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Gofuku J, 1999, AM J CLIN PATHOL, V111, P29; GUMBINER BM, 1993, J CELL SCI, P155; Hugh TJ, 1999, BRIT J CANCER, V80, P1046, DOI 10.1038/sj.bjc.6690461; Krishnadath KK, 1997, J PATHOL, V182, P331; Liu D, 1997, LAB INVEST, V77, P557; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Richmond PJM, 1997, CANCER RES, V57, P3189; Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Valizadeh A, 1997, AM J PATHOL, V150, P1977	15	37	40	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					356	357		10.1016/S0140-6736(99)90055-7	http://dx.doi.org/10.1016/S0140-6736(99)90055-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437861				2022-12-24	WOS:000081764900006
J	Brustle, O; Jones, KN; Learish, RD; Karram, K; Choudhary, K; Wiestler, OD; Duncan, ID; McKay, RDG				Brustle, O; Jones, KN; Learish, RD; Karram, K; Choudhary, K; Wiestler, OD; Duncan, ID; McKay, RDG			Embryonic stem cell-derived glial precursors: A source of myelinating transplants	SCIENCE			English	Article							IN-VITRO DIFFERENTIATION; CENTRAL-NERVOUS-SYSTEM; NEURAL PRECURSORS; TARGETED MUTATION; PROGENITOR CELLS; NEURONS; BRAIN; ESTABLISHMENT; ASTROCYTE; LETHALITY	Self-renewing, totipotent embryonic stem (ES) cells may provide a virtually unlimited donor source for transplantation. A protocol that permits the in vitro generation of precursors for oligodendrocytes and astrocytes from ES cells was devised. Transplantation in a rat model of a human myelin disease shows that these ES cell-derived precursors interact with host neurons and efficiently myelinate axons in brain and spinal cord. Thus, ES cells can serve as a valuable source of cell type-specific somatic precursors for neural transplantation.	Univ Bonn, Med Ctr, Dept Neuropathol, D-53105 Bonn, Germany; NINDS, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA	University of Bonn; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Wisconsin System; University of Wisconsin Madison	Brustle, O (corresponding author), Univ Bonn, Med Ctr, Dept Neuropathol, Sigmund Freud Str 25, D-53105 Bonn, Germany.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033710] Funding Source: NIH RePORTER; NINDS NIH HHS [NS33710] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BLAKEMORE WF, 1995, BRAIN PATHOL, V5, P443, DOI 10.1111/j.1750-3639.1995.tb00623.x; BOGLER O, 1990, P NATL ACAD SCI USA, V87, P6368, DOI 10.1073/pnas.87.16.6368; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; Brustle O, 1995, NEURON, V15, P1275, DOI 10.1016/0896-6273(95)90007-1; Brustle O, 1998, NAT BIOTECHNOL, V16, P1040, DOI 10.1038/3481; BRUSTLE O, UNPUB; Campbell K, 1995, NEURON, V15, P1259, DOI 10.1016/0896-6273(95)90006-3; Deacon T, 1998, EXP NEUROL, V149, P28, DOI 10.1006/exnr.1997.6674; Dinsmore J, 1996, CELL TRANSPLANT, V5, P131, DOI 10.1016/0963-6897(95)02040-3; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Finley MFA, 1996, J NEUROSCI, V16, P1056; FISHELL G, 1995, DEVELOPMENT, V121, P803; FRAICHARD A, 1995, J CELL SCI, V108, P3181; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; Hammang JP, 1997, EXP NEUROL, V147, P84, DOI 10.1006/exnr.1997.6592; HODES ME, 1993, DEV NEUROSCI-BASEL, V15, P383, DOI 10.1159/000111361; KELLER GM, 1995, CURR OPIN CELL BIOL, V7, P862, DOI 10.1016/0955-0674(95)80071-9; LACHAPELLE F, 1995, BRAIN PATHOL, V5, P289, DOI 10.1111/j.1750-3639.1995.tb00606.x; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Shamblott MJ, 1998, P NATL ACAD SCI USA, V95, P13726, DOI 10.1073/pnas.95.23.13726; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0	32	737	852	1	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					754	756		10.1126/science.285.5428.754	http://dx.doi.org/10.1126/science.285.5428.754			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427001				2022-12-24	WOS:000081765100060
J	Norris, JD; Paige, LA; Christensen, DJ; Chang, CY; Huacani, MR; Fan, DJ; Hamilton, PT; Fowlkes, DM; McDonnell, DP				Norris, JD; Paige, LA; Christensen, DJ; Chang, CY; Huacani, MR; Fan, DJ; Hamilton, PT; Fowlkes, DM; McDonnell, DP			Peptide antagonists of the human estrogen receptor	SCIENCE			English	Article							HUMAN PROGESTERONE; ANTIESTROGENS; TAMOXIFEN; IDENTIFICATION; ACTIVATION; YEAST	Estrogen receptor a transcriptional activity is regulated by distinct conformational states that are the result of ligand binding. Phage display was used to identify peptides that interact specifically with either estradiol- or tamoxifen-activated estrogen receptor alpha. When these peptides were coexpressed with estrogen receptor alpha in cells, they functioned as ligand-specific antagonists, indicating that estradiol-agonist and tamoxifen-partial agonist activities do not occur by the same mechanism. The ability to regulate estrogen receptor a transcriptional activity by targeting sites outside of the ligand-binding pocket has implications for the development of estrogen receptor a antagonists for the treatment of tamoxifen-refractory breast cancers.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Novalon Pharmaceut Corp, Durham, NC 27703 USA	Duke University	McDonnell, DP (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Hamilton, Paul/0000-0003-4028-424X; Norris, John/0000-0001-6553-8053	NIDDK NIH HHS [DK48807] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048807, R37DK048807] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Chang C. H., UNPUB; DANA SL, 1994, MOL ENDOCRINOL, V8, P1193, DOI 10.1210/me.8.9.1193; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Imhof MO, 1996, MOL CELL BIOL, V16, P2594; Katzenellenbogen BS, 1997, BREAST CANCER RES TR, V44, P23, DOI 10.1023/A:1005835428423; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; Norris JD, 1996, MOL ENDOCRINOL, V10, P1605, DOI 10.1210/mend.10.12.8961270; NORRIS JR, UNPUB; Osborne CK, 1996, SCI MED, V3, P32; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Sato M, 1996, FASEB J, V10, P905, DOI 10.1096/fasebj.10.8.8666168; Scott JA, 1991, ENDOCRINE DEPENDENT, P179; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443	15	307	342	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					744	746		10.1126/science.285.5428.744	http://dx.doi.org/10.1126/science.285.5428.744			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426998				2022-12-24	WOS:000081765100057
J	Verkhovsky, MI; Jasaitis, A; Verkhovskaya, ML; Morgan, JE; Wikstrom, M				Verkhovsky, MI; Jasaitis, A; Verkhovskaya, ML; Morgan, JE; Wikstrom, M			Proton translocation by cytochrome c oxidase	NATURE			English	Article							PARACOCCUS-DENITRIFICANS; OXYGEN; PUMP	Cell respiration in mitochondria and some bacteria is catalysed by cytochrome c oxidase, which reduces O-2 to water, coupled with translocation of four protons across the mitochondrial or bacterial membrane. The enzyme's catalytic cycle consists of a reductive phase, in which the oxidized enzyme receives electrons from cytochrome c, and an oxidative phase, in which the reduced enzyme is oxidized by O-2. Previous studies indicated that proton translocation is coupled energetically only to the oxidative phase, but this has been challenged. Here, with the purified enzyme inlaid in liposomes, we report time-resolved measurements of membrane potential, which show that hall: of the electrical charges due to proton-pumping actually cross the membrane during reduction after a preceding oxidative phase. pH measurements confirm that proton translocation also occurs during reduction, but only when immediately preceded by an oxidative phase. We conclude that all the energy for proton translocation is conserved in the enzyme during its oxidation by O-2. One half of it is utilized for proton-pumping during oxidation, but the other half is unlatched for this purpose only during re-reduction of the enzyme.	Univ Helsinki, Inst Biomed Sci, Dept Med Chem, Helsinki Bioenerget Grp, FIN-00014 Helsinki, Finland; Univ Helsinki, Bioctr Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Wikstrom, M (corresponding author), Univ Helsinki, Inst Biomed Sci, Dept Med Chem, Helsinki Bioenerget Grp, POB 8, FIN-00014 Helsinki, Finland.		Wikstrom, Marten KF/A-4403-2008	Verkhovskaya, Marina/0000-0001-8950-5256				ARMSTRONG F, 1983, BIOCHIM BIOPHYS ACTA, V722, P61, DOI 10.1016/0005-2728(83)90157-3; BABCOCK GT, 1992, NATURE, V356, P301, DOI 10.1038/356301a0; DRACHEV LA, 1974, NATURE, V249, P321, DOI 10.1038/249321a0; Gennis RB, 1998, P NATL ACAD SCI USA, V95, P12747, DOI 10.1073/pnas.95.22.12747; Hinkle P, 1970, J Bioenerg, V1, P45, DOI 10.1007/BF01516088; Jasaitis A, 1999, BIOCHEMISTRY-US, V38, P2697, DOI 10.1021/bi982275l; Michel H, 1998, P NATL ACAD SCI USA, V95, P12819, DOI 10.1073/pnas.95.22.12819; MITCHELL R, 1992, BIOCHIM BIOPHYS ACTA, V1101, P188, DOI 10.1016/S0005-2728(05)80016-7; MITCHELL R, 1994, BBA-BIOENERGETICS, V1186, P19, DOI 10.1016/0005-2728(94)90130-9; OLIVEBERG M, 1991, BIOCHEMISTRY-US, V30, P436, DOI 10.1021/bi00216a019; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; SLATER EC, 1953, NATURE, V172, P975, DOI 10.1038/172975a0; SOLIOZ M, 1982, J BIOL CHEM, V257, P1579; VERKHOVSKY MI, IN PRESS BIOCH BIOPH; WIKSTROM M, 1989, NATURE, V338, P776, DOI 10.1038/338776a0; WIKSTROM MKF, 1977, NATURE, V266, P271, DOI 10.1038/266271a0; WILLIAMS RJP, 1961, J THEOR BIOL, V1, P1, DOI 10.1016/0022-5193(61)90023-6	17	193	197	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					480	483		10.1038/22813	http://dx.doi.org/10.1038/22813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440381				2022-12-24	WOS:000081715000058
J	Cormack, BP; Ghori, N; Falkow, S				Cormack, BP; Ghori, N; Falkow, S			An adhesin of the yeast pathogen Candida glabrata mediating adherence to human epithelial cells	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ANTIFUNGAL SUSCEPTIBILITY; ALBICANS GENE; RECEPTORS; EXPRESSION; VIRULENCE; INFECTION; PROTEINS; CLONING; VECTORS	Candida glabrata is an important fungal pathogen of humans that is responsible for about 15 percent of mucosal and systemic candidiasis. Candida glabrata adhered avidly to human epithelial cells in culture. By means of a genetic approach and a strategy allowing parallel screening of mutants, it was possible to clone a lectin from a Candida species. Deletion of this adhesin reduced adherence of C. glabrata to human epithelial cells by 95 percent. The adhesin, encoded by the EPA1 gene, is likely a glucan-cross-linked cell-wall protein and binds to host-cell carbohydrate, specifically recognizing asialo-lactosyl-containing carbohydrates.	Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; Prot Design Labs, Fremont, CA 94555 USA	Stanford University	Cormack, BP (corresponding author), Johns Hopkins Med Inst, Dept Mol Biol & Genet, 725 N Wolfe St, Baltimore, MD 21205 USA.	bcormack@jhmi.edu						Calderone R A, 1993, Arch Med Res, V24, P275; Cameron BJ, 1996, INFECT IMMUN, V64, P891, DOI 10.1128/IAI.64.3.891-896.1996; CLEMONS KV, 1994, J INFECT DIS, V169, P859, DOI 10.1093/infdis/169.4.859; Cormack BP, 1999, GENETICS, V151, P979; CRITCHLEY IA, 1987, J GEN MICROBIOL, V133, P637; Fidel PL, 1996, J INFECT DIS, V173, P425, DOI 10.1093/infdis/173.2.425; FONZI WA, 1993, GENETICS, V134, P717; Fu Y, 1998, INFECT IMMUN, V66, P1783, DOI 10.1128/IAI.66.4.1783-1786.1998; Gale CA, 1998, SCIENCE, V279, P1355, DOI 10.1126/science.279.5355.1355; Gaur NK, 1997, INFECT IMMUN, V65, P5289, DOI 10.1128/IAI.65.12.5289-5294.1997; *GENB, AF149048 GENB; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HOSTETTER MK, 1994, CLIN MICROBIOL REV, V7, P29, DOI 10.1128/CMR.7.1.29-42.1994; JIMENEZLUCHO V, 1990, INFECT IMMUN, V58, P2085, DOI 10.1128/IAI.58.7.2085-2090.1990; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Nguyen MH, 1996, AM J MED, V100, P617, DOI 10.1016/S0002-9343(95)00010-0; PASCOPELLA L, 1995, INFECT IMMUN, V63, P4329, DOI 10.1128/IAI.63.11.4329-4335.1995; PENDRAK ML, 1995, FEMS MICROBIOL LETT, V129, P103, DOI 10.1111/j.1574-6968.1995.tb07566.x; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V33, P217, DOI 10.1016/S0732-8893(98)00160-6; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V30, P121, DOI 10.1016/S0732-8893(97)00192-2; Pfaller MA, 1998, DIAGN MICR INFEC DIS, V31, P289, DOI 10.1016/S0732-8893(97)00245-9; SCHABERG DR, 1991, AM J MED S3B, V91, P725; Schuman P, 1998, CLIN INFECT DIS, V27, P1161, DOI 10.1086/514979; Sherman F., 1986, METHODS YEAST GENETI; Staab JF, 1999, SCIENCE, V283, P1535, DOI 10.1126/science.283.5407.1535; STANLEY P, 1977, SOMAT CELL GENET, V3, P391, DOI 10.1007/BF01542968; STGEME JW, 1994, INFECT IMMUN, V62, P3881, DOI 10.1128/IAI.62.9.3881-3889.1994; STRUHL K, 1983, NATURE, V305, P391, DOI 10.1038/305391a0; TEUNISSEN AWRH, 1993, YEAST, V9, P423, DOI 10.1002/yea.320090413; TOSH FD, 1992, INFECT IMMUN, V60, P4734, DOI 10.1128/IAI.60.11.4734-4739.1992; WATARI J, 1994, YEAST, V10, P211, DOI 10.1002/yea.320100208; WHELAN WL, 1987, CRC CR REV MICROBIOL, V14, P99, DOI 10.3109/10408418709104437; YU L, 1994, INFECT IMMUN, V62, P2843, DOI 10.1128/IAI.62.7.2843-2848.1994; YU L, 1994, INFECT IMMUN, V62, P5213, DOI 10.1128/IAI.62.12.5213-5219.1994	35	287	296	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1999	285	5427					578	582		10.1126/science.285.5427.578	http://dx.doi.org/10.1126/science.285.5427.578			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417386				2022-12-24	WOS:000081609500036
J	Sternlicht, MD; Lochter, A; Sympson, CJ; Huey, B; Rougler, JP; Gray, JW; Pinkel, D; Bissell, MJ; Werb, Z				Sternlicht, MD; Lochter, A; Sympson, CJ; Huey, B; Rougler, JP; Gray, JW; Pinkel, D; Bissell, MJ; Werb, Z			The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis	CELL			English	Article							TRANSGENIC MICE; MATRIX METALLOPROTEINASES; EPITHELIAL-CELLS; GENE-EXPRESSION; BREAST-CANCER; GROWTH-FACTOR; EXTRACELLULAR-MATRIX; JUVENILE POLYPOSIS; TUMOR PROGRESSION; STROMELYSIN-1	Matrix metalloproteinases (MMPs) are invariably upregulated in the stromal compartment of epithelial cancers and appear to promote invasion and metastasis. Here we report that phenotypically normal mammary epithelial cells with tetracycline-regulated expression of MMP3/stromelysin-1 (Str1) form epithelial glandular structures in vivo without Str1 but form invasive mesenchymal-like tumors with Str1. Once initiated, the tumors become independent of continued Str1 expression. Str1 also promotes spontaneous premalignant changes and malignant conversion in mammary glands of transgenic mice. These changes are blocked by coexpression of a TIMP1 transgene. The premalignant and malignant lesions have stereotyped genomic changes unlike those seen in other murine mammary cancer models. These data indicate that Str1 influences tumor initiation and alters neoplastic risk.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif San Francisco, Canc Genet Program, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Sternlicht, MD (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.				NCI NIH HHS [R01 CA057621, CA72006, P01 CA072006-020003, R01 CA064786-04A1, R37 CA064786, R01 CA064786, CA57621, P01 CA072006, CA64786, R01 CA057621-07] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057621, R01CA064786, R37CA064786, P01CA072006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADOLPH S, 1987, CYTOGENET CELL GENET, V44, P65, DOI 10.1159/000132345; Ahmad A, 1998, AM J PATHOL, V152, P721; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Bachman KE, 1999, CANCER RES, V59, P798; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Birchmeier C, 1996, ACTA ANAT, V156, P217; BORSI L, 1992, INT J CANCER, V52, P688, DOI 10.1002/ijc.2910520504; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Chin JR, 1997, DEVELOPMENT, V124, P1519; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7; DARMIENTO J, 1995, MOL CELL BIOL, V15, P5732; DEOME KB, 1959, CANCER RES, V19, P515; DOMAGALA W, 1990, AM J PATHOL, V136, P219; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; FISHER ER, 1975, CANCER, V36, P1, DOI 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GACK S, 1994, J BIOL CHEM, V269, P10363; GILLES C, 1996, BREAST J, V2, P83; Hay ED, 1995, ACTA ANAT, V154, P8; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Hsieh CJ, 1998, CANCER RES, V58, P3942; Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604; Jacoby RF, 1997, GASTROENTEROLOGY, V112, P1398, DOI 10.1016/S0016-5085(97)70156-2; Kataoka H, 1999, AM J PATHOL, V154, P457, DOI 10.1016/S0002-9440(10)65292-3; Kim KS, 1998, EXP CELL RES, V245, P79, DOI 10.1006/excr.1998.4238; Levin BR, 1996, EMERG INFECT DIS, V2, P93, DOI 10.3201/eid0202.960203; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Lochter A, 1999, MOL BIOL CELL, V10, P271, DOI 10.1091/mbc.10.2.271; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; Lund LR, 1996, DEVELOPMENT, V122, P181; Martorana AM, 1998, CANCER RES, V58, P4970; Masson R, 1998, J CELL BIOL, V140, P1535, DOI 10.1083/jcb.140.6.1535; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; Mehindate K, 1996, LAB INVEST, V75, P529; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; Noe V, 1999, J CELL SCI, V112, P127; OSTROWSKI LE, 1988, MOL CARCINOGEN, V1, P13, DOI 10.1002/mc.2940010106; Patterson BC, 1997, J BIOL CHEM, V272, P28823, DOI 10.1074/jbc.272.46.28823; Ritland SR, 1997, CANCER RES, V57, P3520; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; Rudolph-Owen LA, 1998, CANCER RES, V58, P5500; Rutter JL, 1998, CANCER RES, V58, P5321; SOMMERS CL, 1994, BREAST CANCER RES TR, V31, P325, DOI 10.1007/BF00666165; Squartini F, 1994, IARC Sci Publ, P47; Sternlicht M., 1999, GUIDEBOOK EXTRACELLU, P503; Sun DZ, 1998, INT J DEV BIOL, V42, P733; SUNDARRAJ N, 1992, CELL TISSUE RES, V267, P347, DOI 10.1007/BF00302973; Suzuki M, 1997, J BIOL CHEM, V272, P31730, DOI 10.1074/jbc.272.50.31730; SYMPSON CJ, 1994, J CELL BIOL, V125, P681, DOI 10.1083/jcb.125.3.681; SYMPSON CJ, 1996, J CELL BIOL, V132; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; TISTY TD, 1998, CURR OPIN CELL BIOL, V10, P647; WARGOTZ ES, 1989, HUM PATHOL, V20, P628, DOI 10.1016/0046-8177(89)90149-4; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; WITTY EP, 1995, MOL BIOL CELL, V6, P1287, DOI 10.1091/mbc.6.10.1287; Ye S, 1996, J BIOL CHEM, V271, P13055, DOI 10.1074/jbc.271.22.13055	62	711	728	3	35	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					137	146		10.1016/S0092-8674(00)81009-0	http://dx.doi.org/10.1016/S0092-8674(00)81009-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428026	Bronze, Green Accepted			2022-12-24	WOS:000081632300004
J	Hochman, JS; Tamis, JE; Thompson, TD; Weaver, WD; White, HD; Van de Werf, F; Aylward, P; Topol, EJ; Califf, RM				Hochman, JS; Tamis, JE; Thompson, TD; Weaver, WD; White, HD; Van de Werf, F; Aylward, P; Topol, EJ; Califf, RM		Global Use Strategies Open Occluded Coronary Ar	Sex, clinical presentation, and outcome in patients with acute coronary syndromes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; THROMBOLYTIC THERAPY; INTERVENTION REGISTRY; GENDER DIFFERENCES; HEART-DISEASE; RISK-FACTORS; SHORT-TERM; WOMEN; MEN; MORTALITY	Background Studies have reported that women with acute myocardial infarction have in-hospital and long-term outcomes that are worse than those of men. Methods To assess sex-based differences in presentation and outcome, we examined data from the Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb study, which enrolled 12,142 patients (3662 women and 8480 men) with acute coronary syndromes, including infarction with ST-segment elevation, infarction with no ST-segment elevation, and unstable angina. Results Overall, the women were older than the men and had significantly higher rates of diabetes, hypertension, and prior congestive heart failure. They had significantly lower rates of prior myocardial infarction and were less likely ever to have smoked. A smaller percentage of women than men had infarction with ST elevation (27.2 percent vs. 37.0 percent, P<0.001), and of the patients who presented with no ST elevation (those with myocardial infarction or unstable angina), fewer women than men had myocardial infarction (36.6 percent vs. 47.6 percent, P<0.001). Women had more complications than men during hospitalization and a higher mortality rate at 30 days (6.0 percent vs. 4.0 percent, P<0.001) but had similar rates of reinfarction at 30 days after presentation. However, there was a significant interaction between sex and the type of coronary syndrome at presentation (P=0.001). After stratification according to coronary syndrome and adjustment for base-line variables, there was a nonsignificant trend toward an increased risk of death or reinfarction among women as compared with men only in the group with infarction and ST elevation (odds ratio, 1.27; 95 percent confidence interval, 0.98 to 1.63; P=0.07). Among patients with unstable angina, female sex was associated with an independent protective effect (odds ratio for infarction or death, 0.65; 95 percent confidence interval, 0.49 to 0.87; P=0.003). Conclusions Women and men with acute coronary syndromes had different clinical profiles, presentation, and outcomes. These differences could not be entirely accounted for by differences in base-line characteristics and may reflect pathophysiologic and anatomical differences between men and women. (N Engl J Med 1999;341:226-32.) (C) 1999, Massachusetts Medical Society.	St Lukes Roosevelt Hosp Ctr, New York, NY 10025 USA; Columbia Univ, New York, NY USA; Duke Clin Res Inst, Durham, NC USA; Henry Ford Heart & Vasc Inst, Detroit, MI USA; Green Lane Hosp, Auckland 3, New Zealand; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Flinders Med Ctr, Adelaide, SA, Australia; Cleveland Clin Fdn, Cleveland, OH 44195 USA	Mount Sinai St. Luke's; Mount Sinai West; Columbia University; Duke University; Henry Ford Health System; KU Leuven; University Hospital Leuven; Flinders Medical Centre; Cleveland Clinic Foundation	Hochman, JS (corresponding author), St Lukes Roosevelt Hosp Ctr, 1111 Amsterdam Ave, New York, NY 10025 USA.			Aylward, Philip/0000-0002-5358-8552; Hochman, Judith/0000-0002-5889-5981				BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BEHAR S, 1994, AM J CARDIOL, V73, P438, DOI 10.1016/0002-9149(94)90672-6; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Braunwald E, 1994, AHCPR PUBLICATION, V94-0602, P1; CHIRIBOGA DE, 1993, AM J CARDIOL, V71, P268, DOI 10.1016/0002-9149(93)90789-F; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; Cucuianu M., 1993, Revue Roumaine de Medecine Interne, V31, P183; CUNNINGHAM MA, 1989, J GEN INTERN MED, V4, P392, DOI 10.1007/BF02599688; DAVIS KB, 1995, J AM COLL CARDIOL, V25, P1000, DOI 10.1016/0735-1097(94)00518-U; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; DITTRICH H, 1988, AM J CARDIOL, V62, P1, DOI 10.1016/0002-9149(88)91356-2; FIEBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092, DOI 10.1001/jama.263.8.1092; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; HARRELL FE, 1996, TRANSCAN S FUNCTION; HE J, 1994, AM J EPIDEMIOL, V139, P693, DOI 10.1093/oxfordjournals.aje.a117059; Hochman JS, 1997, J AM COLL CARDIOL, V30, P141, DOI 10.1016/S0735-1097(97)00107-1; HOCHMAN JS, IN PRESS AM HEART J; JOHANSSON S, 1984, EUR HEART J, V5, P374, DOI 10.1093/oxfordjournals.eurheartj.a061671; Kober L, 1996, AM J CARDIOL, V77, P1052, DOI 10.1016/S0002-9149(96)00129-4; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; Kudenchuk PJ, 1996, AM J CARDIOL, V78, P9, DOI 10.1016/S0002-9149(96)00218-4; LINCOFF AM, 1993, J AM COLL CARDIOL, V22, P1780, DOI 10.1016/0735-1097(93)90757-R; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MURABITO JM, 1993, CIRCULATION, V88, P2548, DOI 10.1161/01.CIR.88.6.2548; PULETTI M, 1984, AM HEART J, V108, P63, DOI 10.1016/0002-8703(84)90545-3; ROBINSON K, 1988, J AM COLL CARDIOL, V11, P932, DOI 10.1016/S0735-1097(98)90048-1; STEGNAR M, 1993, THROMB RES, V69, P81, DOI 10.1016/0049-3848(93)90005-9; STEGNAR M, 1993, THROMB RES, V72, P173, DOI 10.1016/0049-3848(93)90219-E; STONE GW, 1995, AM J CARDIOL, V75, P987, DOI 10.1016/S0002-9149(99)80709-7; TOFLER GH, 1987, J AM COLL CARDIOL, V9, P473, DOI 10.1016/S0735-1097(87)80038-4; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Tracy R P, 1992, Ann Epidemiol, V2, P509; TunstallPedoe H, 1996, CIRCULATION, V93, P1981, DOI 10.1161/01.CIR.93.11.1981; VACEK JL, 1993, AM HEART J, V126, P521, DOI 10.1016/0002-8703(93)90399-T; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; WEINBLATT E, 1973, AM J PUBLIC HEALTH, V63, P577, DOI 10.2105/AJPH.63.7.577; WHITE HD, 1993, CIRCULATION, V88, P2097, DOI 10.1161/01.CIR.88.5.2097	40	607	638	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					226	232		10.1056/NEJM199907223410402	http://dx.doi.org/10.1056/NEJM199907223410402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413734				2022-12-24	WOS:000081528800002
J	Moroney, JT; Tang, MX; Berglund, L; Small, S; Merchant, C; Bell, K; Stern, Y; Mayeux, R				Moroney, JT; Tang, MX; Berglund, L; Small, S; Merchant, C; Bell, K; Stern, Y; Mayeux, R			Low-density lipoprotein cholesterol and the risk of dementia with stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NORTHERN MANHATTAN STROKE; CARDIOVASCULAR-DISEASE; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; VASCULAR DEMENTIA; ISCHEMIC STROKE; E POLYMORPHISM; HEART-DISEASE; POPULATION; INFARCTION	Context Next to Alzheimer disease; vascular dementia is the second most common form of dementia in the elderly, yet few specific risk factors have been identified. Objective To investigate the relationship of plasma lipids and lipoproteins to dementia with stroke. Design and Setting Prospective longitudinal community-based study over a 7-year period (1991-1998). Participants A total of 1111 nondemented participants (mean [SD] age, 75.0 [5.9] years) were followed up for an average of 2.1 years (range, 1-7.8 years). Main Outcome Measure Incident dementia with stroke according to standardized criteria, by baseline levels of total plasma cholesterol and triglycerides, low-density lipoprotein (LDL)cholesterol, LDL levels corrected for lipoprotein(a), high-density lipoprotein cholesterol, lipoprotein(a), and apolipoprotein E genotype. Results Two hundred eighty-six (25.7%) of the 1111 subjects developed dementia during follow-up; 61 (21.3%) were classified as having dementia with stroke and 225 (78.7%) as having probable Alzheimer disease. Levels of LDC cholesterol were significantly associated with an increased risk of dementia with stroke. Compared with the lowest quartile, the highest quartile of LDL cholesterol was associated with an approximately 3-fold increase in risk of dementia with stroke, adjusting for vascular risk factors and demographic variables (relative risk [RR], 3.1; 95% confidence interval [CI], 1.5-6.1). Levels of LDL corrected for lipoprotein(a) were an even stronger predictor of dementia with stroke in the adjusted multivariate analysis. Compared with the lowest quartile, the RR of dementia with stroke for the highest quartile of lipoprotein(a)-corrected LDL cholesterol was 4.1 (95% CI, 1.8-9.6) after adjusting for vascular factors and demographic variables. Lipid or lipoprotein levels were not associated with the development of Alzheimer disease in-our cohort. Conclusions Elevated levels of LDL cholesterol were associated with the risk of dementia with stroke in elderly patients. Further study is needed to determine whether treatment of elevated LDL cholesterol levels will reduce the risk of dementia with stroke.	Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Taub Ctr Alzheimers Dis Res, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Biostat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University; Columbia University	Mayeux, R (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Mayeux, Richard/E-9788-2013	Mayeux, Richard/0000-0001-6519-9696; Berglund, Lars/0000-0001-6705-1791; Stern, Yaakov/0000-0001-7542-3241	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS002051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG010963, P01AG007232] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07232, AG 10963] Funding Source: Medline; NINDS NIH HHS [K08 NS 02051] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BRETELER MMB, 1994, BRIT MED J, V308, P1604, DOI 10.1136/bmj.308.6944.1604; Bruce-Keller AJ, 1999, ANN NEUROL, V45, P8, DOI 10.1002/1531-8249(199901)45:1<8::AID-ART4>3.0.CO;2-V; CARLETON RA, 1991, CIRCULATION, V83, P2154, DOI 10.1161/01.CIR.83.6.2154; CUTLER RG, 1991, ANN NY ACAD SCI, V621, P1; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Fujiwara Y, 1997, J Atheroscler Thromb, V4, P90; HATANO S, 1976, B WORLD HEALTH ORGAN, V54, P541; HIXSON J, 1991, J LIPID RES, V31, P545; Jorm AF, 1998, NEUROLOGY, V51, P728, DOI 10.1212/WNL.51.3.728; Kalmijn S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/oxfordjournals.aje.a009029; Kalmijn S, 1996, STROKE, V27, P2230, DOI 10.1161/01.STR.27.12.2230; Kalmijn S, 1997, ANN NEUROL, V42, P776, DOI 10.1002/ana.410420514; Kargman DE, 1998, ATHEROSCLEROSIS, V139, P391, DOI 10.1016/S0021-9150(98)00085-9; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MENDEZ I, 1987, NEUROLOGY, V37, P507, DOI 10.1212/WNL.37.3.507; NAUCK M, 1995, CLIN CHEM, V41, P1761; Pablos-Mendez A, 1997, ARTERIOSCL THROM VAS, V17, P3534, DOI 10.1161/01.ATV.17.12.3534; PEDROBOTET J, 1992, STROKE, V23, P1556, DOI 10.1161/01.STR.23.11.1556; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; SACCO RL, 1991, STROKE, V22, P1491, DOI 10.1161/01.STR.22.12.1491; SACCO RL, 1994, NEUROLOGY, V44, P626, DOI 10.1212/WNL.44.4.626; SHARRETT AR, 1994, ARTERIOSCLER THROMB, V14, P1098, DOI 10.1161/01.ATV.14.7.1098; Slooter AJC, 1997, JAMA-J AM MED ASSOC, V277, P818, DOI 10.1001/jama.277.10.818; Snowdon DA, 1997, JAMA-J AM MED ASSOC, V277, P813, DOI 10.1001/jama.277.10.813; SPARKS DL, 1994, EXP NEUROL, V126, P88, DOI 10.1006/exnr.1994.1044; STERN Y, 1992, ARCH NEUROL-CHICAGO, V49, P453, DOI 10.1001/archneur.1992.00530290035009; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; Tang MX, 1998, JAMA-J AM MED ASSOC, V279, P751, DOI 10.1001/jama.279.10.751; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; TATEMICHI TK, 1992, NEUROLOGY, V42, P1185, DOI 10.1212/WNL.42.6.1185; TATEMICHI TK, 1995, J NEUROL NEUROSUR PS, V58, P633, DOI 10.1136/jnnp.58.5.633; TOMLINSON BE, 1970, J NEUROL SCI, V11, P205, DOI 10.1016/0022-510X(70)90063-8; Tuck CH, 1997, ARTERIOSCL THROM VAS, V17, P1822, DOI 10.1161/01.ATV.17.9.1822; *US BUR CENS, 1991, CENS POP HOUS SUMM T; YOSHITAKE T, 1995, NEUROLOGY, V45, P1161, DOI 10.1212/WNL.45.6.1161; ZIMETBAUM P, 1992, ARTERIOSCLER THROMB, V12, P416, DOI 10.1161/01.ATV.12.4.416	40	152	161	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					254	260		10.1001/jama.282.3.254	http://dx.doi.org/10.1001/jama.282.3.254			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422994	Bronze, Green Published			2022-12-24	WOS:000081504400031
J	Shao, ZH; Raible, F; Mollaaghababa, R; Guyon, JR; Wu, CT; Bender, W; Kingston, RE				Shao, ZH; Raible, F; Mollaaghababa, R; Guyon, JR; Wu, CT; Bender, W; Kingston, RE			Stabilization of chromatin structure by PRC1, a polycomb complex	CELL			English	Article							POLYMERASE-II TRANSCRIPTION; DROSOPHILA BITHORAX COMPLEX; CHROMOSOME-BINDING-SITES; HOMEOTIC GENE-EXPRESSION; GROUP PROTEINS; CAENORHABDITIS-ELEGANS; MEDIATED REPRESSION; GROUP PRODUCTS; MELANOGASTER; DOMAIN	The Polycomb group (PcG) genes are required for maintenance of homeotic gene repression during development. Mutations in these genes can be suppressed by mutations in genes of the SWI/SNF family. We have purified a complex, termed PRC1 (Polycomb repressive complex 1), that contains the products of the PcG genes Polycomb, Posterior sex combs, polyhomeotic, Sex combs on midleg, and several other proteins. Preincubation of PRC1 with nucleosomal arrays blocked the ability of these arrays to be remodeled by SWI/SNF. Addition of PRC1 to arrays at the same time as SWI/SNF did not block remodeling. Thus, PRC1 and SWI/SNF might compete with each other for the nucleosomal template. Several different types of repressive complexes, including deacetylases, interact with histone tails. In contrast, PRC1 was active on nucleosomal arrays formed with tailless histones.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Kingston, RE (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Raible, Florian/G-6019-2011	Raible, Florian/0000-0002-4515-6485				Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; BIRD AP, 1995, TRENDS GENET, V11, P94, DOI 10.1016/S0168-9525(00)89009-5; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; Cavalli G, 1998, CURR OPIN CELL BIOL, V10, P354, DOI 10.1016/S0955-0674(98)80011-2; CHAN CS, 1994, EMBO J, V13, P2553, DOI 10.1002/j.1460-2075.1994.tb06545.x; CHIANG A, 1995, DEVELOPMENT, V121, P1681; Crosby MA, 1999, MOL CELL BIOL, V19, P1159; DECAMILLIS M, 1992, GENE DEV, V6, P223, DOI 10.1101/gad.6.2.223; DURA JM, 1987, CELL, V51, P829, DOI 10.1016/0092-8674(87)90106-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; GINDHART JG, 1995, GENETICS, V139, P797; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Guyon JR, 1999, MOL CELL BIOL, V19, P2088; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hodgson JW, 1997, MECH DEVELOP, V66, P69, DOI 10.1016/S0925-4773(97)00091-9; Holdeman R, 1998, DEVELOPMENT, V125, P2457; Jones CA, 1998, MOL CELL BIOL, V18, P2825, DOI 10.1128/MCB.18.5.2825; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KARESS RE, 1984, CELL, V38, P135, DOI 10.1016/0092-8674(84)90534-8; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; KENNISON JA, 1988, P NATL ACAD SCI USA, V85, P8136, DOI 10.1073/pnas.85.21.8136; KOGIE C, 1999, BIOCHEMISTRY-US, V38, P2514; Korf I, 1998, DEVELOPMENT, V125, P2469; Kyba M, 1998, MOL CELL BIOL, V18, P2712, DOI 10.1128/MCB.18.5.2712; LONIE A, 1994, DEVELOPMENT, V120, P2629; MARTIN EC, 1993, DEVELOPMENT, V117, P641; McCall K, 1996, EMBO J, V15, P569, DOI 10.1002/j.1460-2075.1996.tb00389.x; ORLANDO V, 1993, CELL, V75, P1187, DOI 10.1016/0092-8674(93)90328-N; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PARO R, 1990, TRENDS GENET, V6, P416, DOI 10.1016/0168-9525(90)90303-N; Peterson AJ, 1997, MOL CELL BIOL, V17, P6683, DOI 10.1128/MCB.17.11.6683; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Pirrotta V, 1997, TRENDS GENET, V13, P314, DOI 10.1016/S0168-9525(97)01178-5; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; SCHLOSSHERR J, 1994, MOL GEN GENET, V243, P453; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1993, DEV BIOL, V158, P131, DOI 10.1006/dbio.1993.1174; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; SOTO MC, 1995, GENETICS, V140, P231; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tie F, 1998, DEVELOPMENT, V125, P3483; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU CT, 1995, GENETICS, V140, P139; Yamamoto Y, 1997, DEVELOPMENT, V124, P3385; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511	53	648	666	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					37	46		10.1016/S0092-8674(00)80604-2	http://dx.doi.org/10.1016/S0092-8674(00)80604-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412979	Bronze			2022-12-24	WOS:000081451000006
J	Simon, DB; Lu, Y; Choate, KA; Velazquez, H; Al-Sabban, E; Praga, M; Casari, C; Bettinelli, A; Colussi, C; Rodriguez-Soriano, J; McCredie, D; Milford, D; Sanjad, S; Lifton, RP				Simon, DB; Lu, Y; Choate, KA; Velazquez, H; Al-Sabban, E; Praga, M; Casari, C; Bettinelli, A; Colussi, C; Rodriguez-Soriano, J; McCredie, D; Milford, D; Sanjad, S; Lifton, RP			Paracellin-1, a renal tight junction protein required for paracellular Mg2+ resorption	SCIENCE			English	Article							THICK ASCENDING LIMB; FAMILIAL HYPOMAGNESEMIA; MAGNESIUM TRANSPORT; COTRANSPORTER; PERMEABILITY; OCCLUDIN; RABBIT; LOOP	Epithelia permit selective and regulated flux from apical to basolateral surfaces by transcellular passage through cells or paracellular flux between cells. Tight junctions constitute the barrier to paracellular conductance; however, Little is known about the specific molecules that mediate paracellular permeabilities. Renal magnesium ion (Mg2+) resorption occurs predominantly through a paracellular conductance in the thick ascending limb of Henle (TAL), Here, positional cloning has identified a human gene, paracellin-1 (PCLN-1), mutations in which cause renal Mg2+ wasting. PCLN-1 is Located in tight junctions of the TAL and is related to the claudin family of tight junction proteins. These findings provide insight into Mg2+ homeostasis, demonstrate the role of a tight junction protein in human disease, and identify an essential component of a selective paracellular conductance.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA; King Faisal Specialist Hosp & Res Ctr, Dept Pediat, Riyadh 11211, Saudi Arabia; Hosp 12 Octubre, Serv Nefrol, E-28041 Madrid, Spain; Telethon Inst Genet & Med, I-20132 Milan, Italy; Univ Milan, Dept Pediat 2, Milan, Italy; Niguarda Ca Granda Hosp, Div Renal, Milan, Italy; Hosp Cruces, Dept Pediat, E-48903 Baracaldo, Spain; Royal Childrens Hosp, Dept Nephrol, Parkville, Vic 3052, Australia; Childrens Hosp, Dept Nephrol, Birmingham B16 8ET, W Midlands, England; American Univ, Dept Pediat, Beirut, Lebanon	Howard Hughes Medical Institute; Yale University; Yale University; Yale University; King Faisal Specialist Hospital & Research Center; Hospital Universitario 12 de Octubre; Fondazione Telethon; Telethon Institute of Genetics & Medicine (TIGEM); University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; Hospital Universitario Cruces; Royal Children's Hospital Melbourne; American University of Beirut	Lifton, RP (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.		Colussi, Giacomo/AFV-2812-2022; Casari, Giorgio/J-3070-2018	Colussi, Giacomo/0000-0001-6133-1899; Casari, Giorgio/0000-0002-0115-8980	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051696] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK51696] Funding Source: Medline; Telethon [F.1, TGM06S01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Telethon(Fondazione Telethon)		ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467, DOI 10.1152/ajpgi.1995.269.4.G467; Bonnet R, 1895, DEUT MED WOCHENSCHR, V21, P58; BRUNETTE MG, 1974, AM J PHYSIOL, V227, P891, DOI 10.1152/ajplegacy.1974.227.4.891; CLAUDE P, 1978, J MEMBRANE BIOL, V39, P219, DOI 10.1007/BF01870332; DEROUFFIGNAC C, 1994, PHYSIOL REV, V74, P305, DOI 10.1152/physrev.1994.74.2.305; DISTEFANO A, 1993, RENAL PHYSIOL BIOCH, V16, P157; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Friedman PA, 1998, ANNU REV PHYSIOL, V60, P179, DOI 10.1146/annurev.physiol.60.1.179; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Kelepouris E, 1998, SEMIN NEPHROL, V18, P58; KOKKO JP, 1974, FED PROC, V33, P25; Madara JL, 1998, ANNU REV PHYSIOL, V60, P143, DOI 10.1146/annurev.physiol.60.1.143; Meij IC, 1999, AM J HUM GENET, V64, P180, DOI 10.1086/302199; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; MORITA K, 1999, P NATL ACAD SCI USA, V78, P5759; PRAGA M, 1995, KIDNEY INT, V47, P1419, DOI 10.1038/ki.1995.199; QUAMME GA, 1980, AM J PHYSIOL, V238, P187; SHAREGHI GR, 1982, J CLIN INVEST, V69, P759, DOI 10.1172/JCI110514; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STEELE TH, 1968, J LAB CLIN MED, V71, P455; Velazquez H, 1998, KIDNEY INT, V54, P464, DOI 10.1046/j.1523-1755.1998.00036.x; Walder RY, 1997, HUM MOL GENET, V6, P1491, DOI 10.1093/hmg/6.9.1491	24	832	861	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					103	106		10.1126/science.285.5424.103	http://dx.doi.org/10.1126/science.285.5424.103			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390358				2022-12-24	WOS:000081199800040
J	Socie, G; Stone, JV; Wingard, JR; Weisdorf, D; Henslee-Downey, PJ; Bredeson, C; Cahn, JY; Passweg, JR; Rowlings, PA; Schouten, HC; Kolb, HJ; Klein, JP				Socie, G; Stone, JV; Wingard, JR; Weisdorf, D; Henslee-Downey, PJ; Bredeson, C; Cahn, JY; Passweg, JR; Rowlings, PA; Schouten, HC; Kolb, HJ; Klein, JP		Late Effects Working Comm Int Bone Marr	Long-term survival and late deaths after allogeneic bone marrow transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYELOGENOUS LEUKEMIA; SEVERE APLASTIC-ANEMIA; CHILDHOOD-CANCER; MYELOID-LEUKEMIA; UNRELATED DONORS; CHEMOTHERAPY; MORTALITY; BLOOD; CURE	Background and Methods It is uncertain whether mortality rates among patients who have undergone bone marrow transplantation return to the level of the mortality rates of the general population. We analyzed the characteristics of 6691 patients listed in the International Bone Marrow Transplant Registry. All the patients were free of their original disease two years after allogeneic bone marrow transplantation. Mortality rates in this cohort were compared with those of an age-, sex-, and nationality-matched general population. Cox proportional-hazards regression was used to identify risk factors for death more than two years after transplantation (late death). Results Among patients who were free of disease two yea rs after transplantation, the probability of living for five more years was 89 percent (95 percent confidence interval, 88 to 90 percent). Among patients who underwent transplantation for aplastic anemia, the risk of death by the sixth year after transplantation did not differ significantly from that of a normal population. Mortality remained significantly higher than normal throughout the study among patients who underwent transplantation for acute lymphoblastic leukemia or chronic myelogenous leukemia and through the ninth year among those who underwent transplantation for acute myelogenous leukemia. Recurrent leukemia was the chief cause of death among patients who received a transplant for leukemia, whereas chronic graft-versus-host disease was the chief cause among those who received a transplant for aplastic anemia. Advanced, long-standing disease before transplantation and active chronic graft-versus-host disease were important risk factors for late death. Conclusions In patients who receive an allogeneic bone marrow transplant as treatment for acute myelogenous or lymphoblastic leukemia, chronic myelogenous leukemia, or aplastic anemia and who are free of their original disease two years later, the disease is probably cured. However, for many years after transplantation, the mortality among these patients is higher than that in a normal population. (N Engl J Med 1999;341:14-21.) (C)1999, Massachusetts Medical Society.	Hop St Louis, Serv Hematol Greffe Moelle, Paris, France; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Hlth Policy Inst, Milwaukee, WI 53226 USA; Univ Florida, Coll Med, Gainesville, FL USA; Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA; Univ S Carolina, Div Transplantat Med, Columbia, SC 29208 USA; Univ Ottawa, Dept Med, Ottawa, ON, Canada; CHU Besancon, Serv Hematol, F-25030 Besancon, France; Kantonsspital Basel, Dept Med, Basel, Switzerland; Univ Hosp, Dept Internal Med, Maastricht, Netherlands; Univ Munich, Klinikum Grosshadern, Dept Hematol, D-8000 Munich, Germany; Univ Munich, Kinderpoliklin, Dept Hematol Oncol, Munich, Germany; Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Univ Miami, Sch Med, Div Pediat Hematol Oncol, Miami, FL USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Medical College of Wisconsin; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Ottawa; Universite de Franche-Comte; CHU Besancon; Maastricht University; University of Munich; University of Munich; Medical College of Wisconsin; University of Miami	Socie, G (corresponding author), Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Hlth Policy Inst, 8701 Watertown Plank Rd,POB 26509, Milwaukee, WI 53226 USA.		passweg, jakob/AAG-3911-2020	Passweg, Jakob R/0000-0001-7092-3351; Wingard, John/0000-0001-7478-5398	NCI NIH HHS [N01-CP-51028, U24-CA-76518, P01-CA-40053] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP051028] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [U24CA076518, P01CA040053] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSEN PK, 1989, BIOMETRICS, V45, P523, DOI 10.2307/2531494; [Anonymous], 2006, SURVIVAL ANAL TECHNI; Appelbaum FR, 1997, CANCER, V80, P2199; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BARRETT AJ, 1994, NEW ENGL J MED, V331, P1253, DOI 10.1056/NEJM199411103311902; Beatty PG, 1997, EXP HEMATOL, V25, P1195; Cella D F, 1995, Oncology (Williston Park), V9, P47; Collins RH, 1997, J CLIN ONCOL, V15, P433, DOI 10.1200/JCO.1997.15.2.433; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; Deeg HJ, 1998, BLOOD, V91, P3637; deLima M, 1997, BLOOD, V90, P4719, DOI 10.1182/blood.V90.12.4719.4719_4719_4724; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; Freireich EJ, 1997, CANCER, V80, P2215, DOI 10.1002/(SICI)1097-0142(19971201)80:11+<2215::AID-CNCR9>3.0.CO;2-G; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Goldman JM, 1997, NEW ENGL J MED, V337, P270, DOI 10.1056/NEJM199707243370410; Green DM, 1996, MED PEDIATR ONCOL, V26, P72, DOI 10.1002/(SICI)1096-911X(199601)26:1<72::AID-MPO13>3.0.CO;2-D; HAWKINS MM, 1990, ARCH DIS CHILD, V65, P1356, DOI 10.1136/adc.65.12.1356; HensleeDowney PJ, 1997, BLOOD, V89, P3864, DOI 10.1182/blood.V89.10.3864.3864_3864_3872; Horowitz M M, 1997, Curr Opin Hematol, V4, P395; Hudson MM, 1997, J CLIN ONCOL, V15, P2205, DOI 10.1200/JCO.1997.15.6.2205; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; NICHOLSON HS, 1994, CANCER, V73, P3094; Passweg JR, 1997, BLOOD, V90, P858; ROBERTSON CM, 1994, BRIT MED J, V309, P162, DOI 10.1136/bmj.309.6948.162; Storek J, 1997, AM J HEMATOL, V54, P131, DOI 10.1002/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y; SULLIVAN KM, 1994, BONE MARROW TRANSPL, P339; YOUNG NS, 1995, BLOOD, V85, P3367, DOI 10.1182/blood.V85.12.3367.bloodjournal85123367; ZITTOUN RA, 1995, NEW ENGL J MED, V332, P217, DOI 10.1056/NEJM199501263320403	29	526	537	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					14	21		10.1056/NEJM199907013410103	http://dx.doi.org/10.1056/NEJM199907013410103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387937	Bronze			2022-12-24	WOS:000081195600003
J	Tan, LJ; Williams, MA; Khan, MK; Champion, HC; Nielsen, NH				Tan, LJ; Williams, MA; Khan, MK; Champion, HC; Nielsen, NH		American Medical Association	Risk of transmission of bovine spongiform encephalopathy to humans in the United States - Report of the Council on Scientific Affairs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN GENE; AMYLOID PLAQUES; SCRAPIE PRION; VARIANT CJD; PRP GENE; BSE; MICE; EPIDEMIOLOGY; CATTLE	Context The risk of possible transmission of bovine spongiform encephalopathy (BSE) in the United States is a substantial public health concern. Objective To systematically review the current scientific literature and discuss legislation and regulations that have been implemented to prevent the disease. Methods Literature review using the MEDLINE, EMBASE, and Lexis/Nexis databases for 1975 through 1997 on the terms bovine spongiform encephalopathy, prion diseases, prions, and Creutzfeldt-Jakob syndrome. The Internet was used to identify regulatory actions and health surveillance. Data Extraction MEDLINE, EMBASE, and Lexis/Nexis databases were searched from 1975 through 1997 for English-language articles that provided information on assessment of transmission risk. Results Unique circumstances in the United Kingdom caused the emergence and propagation of BSE in cattle, including widespread use of meat and bonemeal cattle feed derived from scrapie-infected sheep and the adoption of a new type of processing that did not reduce the amount of infectious prions prior to feeding. Many of these circumstances do not exist in the United States. In the United Kingdom, new variant Creutzfeldt-Jakob disease probably resulted from the ingestion of BSE-contaminated processed beef. The United Kingdom and the European Union now have strong regulations in place to stop the spread of BSE, While BSE has not been observed in the United States, the US government has surveillance and response plans in effect. Conclusions Current risk of transmission of BSE in the United States is minimal because (1) BSE has not been shown to exist in this country; (2) adequate regulations exist to prevent entry of foreign sources of BSE into the United States; (3) adequate regulations exist to prevent undetected cases of BSE from uncontrolled amplification within the US cattle population; and (4) adequate preventive guidelines exist to prevent high-risk bovine materials from contaminating products intended for human consumption.	Amer Med Assoc, Chicago, IL 60610 USA	American Medical Association	Tan, LJ (corresponding author), Care of Dickinson B, Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.		Williams, Michael A./O-4075-2019	Williams, Michael A./0000-0002-7284-8014; Tan, Litjen/0000-0001-9054-6696				Almond J, 1997, NATURE, V389, P437, DOI 10.1038/38876; ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; BECK E, 1964, BRAIN, V87, P153, DOI 10.1093/brain/87.1.153; BERG LJ, 1994, P NATL ACAD SCI USA, V91, P429, DOI 10.1073/pnas.91.2.429; BOLTON DC, 1988, CIBA F SYMP, V135, P164; BROWN P, 1987, NEUROLOGY, V37, P895, DOI 10.1212/WNL.37.6.895; Brown P, 1998, TRANSFUSION, V38, P810, DOI 10.1046/j.1537-2995.1998.38998408999.x; Brown P, 1998, BMJ-BRIT MED J, V317, P1688, DOI 10.1136/bmj.317.7174.1688; Brown P, 1997, JAMA-J AM MED ASSOC, V278, P1008, DOI 10.1001/jama.278.12.1008; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUDKA H, 1995, BRAIN PATHOL, V5, P459, DOI 10.1111/j.1750-3639.1995.tb00625.x; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CARP RI, 1994, ANN NY ACAD SCI, V724, P221, DOI 10.1111/j.1749-6632.1994.tb38912.x; Chazot G, 1996, LANCET, V347, P1181, DOI 10.1016/S0140-6736(96)90638-8; Collee JG, 1997, LANCET, V349, P715, DOI 10.1016/S0140-6736(96)08496-6; Collee JG, 1997, LANCET, V349, P636, DOI 10.1016/S0140-6736(96)01310-4; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Collinge J, 1997, HUM MOL GENET, V6, P1699, DOI 10.1093/hmg/6.10.1699; Cousens SN, 1997, NATURE, V385, P197, DOI 10.1038/385197a0; CUTLIP RC, 1994, J INFECT DIS, V169, P814, DOI 10.1093/infdis/169.4.814; DLOUHY SR, 1992, NAT GENET, V1, P64, DOI 10.1038/ng0492-64; Dodelet V, 1996, CAN MED ASSOC J, V155, P549; DUFFY P, 1974, NEW ENGL J MED, V290, P692; ESMONDE TFG, 1993, LANCET, V341, P205, DOI 10.1016/0140-6736(93)90068-R; FRADKIN JE, 1991, JAMA-J AM MED ASSOC, V265, P880, DOI 10.1001/jama.265.7.880; GABIZON R, 1988, J BIOL CHEM, V263, P4950; GABIZON R, 1993, AM J HUM GENET, V53, P828; Gabizon R, 1997, TRENDS GENET, V13, P264, DOI 10.1016/S0168-9525(97)01116-5; GAJDUSEK DC, 1959, AM J MED, V26, P442, DOI 10.1016/0002-9343(59)90251-7; GAJDUSEK DC, 1985, HUMAN VIRAL INFECTIO, P1519; GIBBS CJ, 1994, J NEUROL NEUROSUR PS, V57, P757, DOI 10.1136/jnnp.57.6.757; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; GUIROY DC, 1993, ACTA NEUROPATHOL, V85, P437, DOI 10.1007/BF00334456; HARRIS DA, 1993, P NATL ACAD SCI USA, V90, P4309, DOI 10.1073/pnas.90.9.4309; HELLMAN KB, 1997, NAT MAN HLTH CAR C 2; Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Holman RC, 1996, EMERG INFECT DIS, V2, P333, DOI 10.3201/eid0204.960409; HONSTEAD JP, 1997, NAT MAN HLTH CAR C 2; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; Hsich G, 1996, NEW ENGL J MED, V335, P924, DOI 10.1056/NEJM199609263351303; HUESTON WD, 1997, NAT MAN HLTH CAR C 2; Ironside JW, 1996, BRAIN PATHOL, V6, P379, DOI 10.1111/j.1750-3639.1996.tb00869.x; KIMBERLIN RH, 1994, ANN NY ACAD SCI, V724, P210, DOI 10.1111/j.1749-6632.1994.tb38911.x; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; KITAMOTO T, 1986, ANN NEUROL, V20, P204, DOI 10.1002/ana.410200205; Korth C, 1997, NATURE, V390, P74, DOI 10.1038/36337; Lasmezas CI, 1996, J GEN VIROL, V77, P1601, DOI 10.1099/0022-1317-77-7-1601; MacKnight C, 1996, CAN MED ASSOC J, V155, P529; MARSH RF, 1991, J GEN VIROL, V72, P589, DOI 10.1099/0022-1317-72-3-589; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MEYER N, 1991, J GEN VIROL, V72, P37, DOI 10.1099/0022-1317-72-1-37; *MIN AGR FISH FOOD, 1998, MAFF BSE INF PUBL HL; *MIN AGR FISH FOOD, 1998, MAFF BSE INF SPEC RI; *MIN AGR FISH FOOD, 1998, MAFF BSE INF SEAC M; *MIN AGR FISH FOOD, 1998, MAFF BSE INF INC BSE; *MIN AGR FISH FOOD, 1998, MAFF BSE INF BON BEE; *MIN AGR FISH FOOD, 1998, MAFF BSE INF FEED BA; MURRAY I, 1999, SUNDAY LONDON TIMES; Narang H, 1996, P SOC EXP BIOL MED, V211, P306, DOI 10.3181/00379727-211-43975; Narang H, 1996, P SOC EXP BIOL MED, V212, P208, DOI 10.3181/00379727-212-44009; *NAT CJD SURV UN, 1999, MONTHL CREUTZF FIG; Nathanson N, 1997, AM J EPIDEMIOL, V145, P959, DOI 10.1093/oxfordjournals.aje.a009064; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; *OFF INT EP, 1998, BOV SPONG ENC; *OFF INT EP, 1998, INF REP BOV SPONG EN; Piccardo P, 1998, AM J PATHOL, V152, P1415; PORTER R, 1999, USDA RESTRICTS IMPOR; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1993, ARCH NEUROL-CHICAGO, V50, P1129, DOI 10.1001/archneur.1993.00540110011002; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Ricketts MN, 1997, EMERG INFECT DIS, V3, P155, DOI 10.3201/eid0302.970208; RIESNER D, 1992, E H S NEURO, P341; ROBAKIS NK, 1986, BIOCHEM BIOPH RES CO, V140, P758, DOI 10.1016/0006-291X(86)90796-5; ROGERS M, 1990, Glycobiology, V1, P101, DOI 10.1093/glycob/1.1.101; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; TATEISHI J, 1984, ANN NEUROL, V15, P278, DOI 10.1002/ana.410150313; U. S. Food and Drug Administration, 1997, FED REGISTER, V62, P30936; *US FDA, 1997, FED REGISTER, V62, P52345; *US FDA, 1997, FED REGISTER, V62, P49694; *US FDA, 1999, CHANG GUID ENT REV P; *USDA, 1991, FED REGISTER, V56, P63868; *USDA, 1999, USDA CONT EFF PREV B; *USDA, 1998, BOV SPONG ENC; VONRADOWITZ J, 1998, PA NEWS; WELLS GAH, 1987, VET REC, V121, P419, DOI 10.1136/vr.121.18.419; *WHO, 1999, WHOEMCZOO973; WILESMITH JW, 1991, VET REC, V128, P199, DOI 10.1136/vr.128.9.199; WILESMITH JW, 1988, VET REC, V123, P638; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; WILL RG, 1993, BRIT MED BULL, V49, P960, DOI 10.1093/oxfordjournals.bmb.a072655; Zeidler M, 1997, LANCET, V350, P908, DOI 10.1016/S0140-6736(97)03148-6; Zeidler M, 1997, LANCET, V350, P903, DOI 10.1016/S0140-6736(97)07472-2; Zhang SG, 1997, P NATL ACAD SCI USA, V94, P23, DOI 10.1073/pnas.94.1.23; 1997, MMWR MORB MORTAL WKL, V46, P1066; 1999, WASHINGTON DRUG 0201, P5	103	26	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2330	2339		10.1001/jama.281.24.2330	http://dx.doi.org/10.1001/jama.281.24.2330			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386559				2022-12-24	WOS:000080925600034
J	Gong, JG; Costanzo, A; Yang, HQ; Melino, G; Kaelin, WG; Levrero, M; Wang, JYJ				Gong, JG; Costanzo, A; Yang, HQ; Melino, G; Kaelin, WG; Levrero, M; Wang, JYJ			The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage	NATURE			English	Article							MISMATCH REPAIR DEFICIENCY; FLOW-CYTOMETRY; CELLS; PROTEIN; P53; RADIATION; STRESS; MICE	Cancer chemotherapeutic agents such as cisplatin exert their cytotoxic effect by inducing DNA damage and activating programmed cell death (apoptosis), The tumour-suppressor protein p53 is an important activator of apoptosis. Although p53-deficient cancer cells are less responsive to chemotherapy, their resistance is not complete, which suggests that other apoptotic pathways may exist. A p53-related gene, p73, which encodes several proteins as a result of alternative splicing(1,2), can also induce apoptosis(3). Here we show that the amount of p73 protein in the cell is increased by cisplatin. This induction of p73 is not seen in cells unable to carry out mismatch repair and in which the nuclear enzyme c-Abl tyrosine kinase is not activated by cisplatin, The half-life of p73 is prolonged by cisplatin and by co-expression with c-Abl tyrosine kinase; the apoptosis-inducing function of p73 is also enhanced by the c-Abl kinase, Mouse embryo fibroblasts deficient in mismatch repair or in c-Abl do not upregulate p73 and are more resistant to killing by cisplatin. Our results indicate that c-Abl and p73 are components ofa mismatch-repair-dependent apoptosis pathway which contributes to cisplatin-induced cytotoxicity.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92093 USA; Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy; Univ Roma Tor Vergata, Dept Expt Med, IRCCS, Ist Dermopatico Immacolata,Biochem Lab, I-00133 Rome, Italy; Howard Hughes Med Inst, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Sapienza University Rome; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Howard Hughes Medical Institute; Harvard University; Dana-Farber Cancer Institute	Wang, JYJ (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	jywang@ucsd.edu	Costanzo, Antonio/GZG-2433-2022; Costanzo, Antonio/D-3896-2012; Levrero, Massimo/G-5680-2016	Costanzo, Antonio/0000-0001-9697-2557; Levrero, Massimo/0000-0002-4978-0875; MELINO, GERRY/0000-0001-9428-5972	NATIONAL CANCER INSTITUTE [R01CA043054, R37CA043054] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA043054, R37 CA043054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; BOYER JC, 1995, CANCER RES, V55, P6063; Buermeyer AB, 1999, CANCER RES, V59, P538; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FINK D, 1995, CANCER RES, V57, P1841; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; Nehme A, 1997, CANCER RES, V57, P3253; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Toft NJ, 1999, P NATL ACAD SCI USA, V96, P3911, DOI 10.1073/pnas.96.7.3911; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	22	801	824	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					806	809						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391249				2022-12-24	WOS:000081101600059
J	Agnarsson, U; Thorgeirsson, G; Sigvaldason, H; Sigfusson, N				Agnarsson, U; Thorgeirsson, G; Sigvaldason, H; Sigfusson, N			Effects of leisure-time physical activity and ventilatory function on risk for stroke in men: The Reykjavik study	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; MONICA	Background: Stroke is a major ca use of illness, death, and health expenditures. Leisure-time physical activity may reduce the risk for stroke. Objective: To examine the association of leisure-time physical activity and pulmonary function with risk for stroke. Design: Prospective cohort study. Setting: Reykjavik, Iceland. Participants: 4484 men 45 to 80 yea rs of age followed for a mean (+/- SD) of 10.6 +/- 3.6 years. Measurements: Patients underwent physical examination, blood sampling, and spirometry and completed a questionnaire about health and exercise. Computerized hospital records were used to identify strokes, and the Icelandic National Registry was used to identify deaths. Results: New stroke developed in 249 men (5.6%) (hemorrhagic stroke in 44 [18%] and ischemic stroke in 205 [82%]). In a multivariable hazard analysis that controlled for known risk factors for cerebrovascular disease, leisure-time physical activity maintained after 40 years of age was associated with a reduced risk for stroke (relative risk, 0.69 [Cl, 0.47 to 1.01] for total stroke and 0.62 [Cl, 0.40 to 0.97] for ischemic stroke). Risk for stroke increased with diminished ventilatory function (FVC or FEV1) (relative risk, 1.9 [Cl, 1.06 to 3.25] for the lowest compared with the highest quintile). Conclusion: Middle-aged men who participate in leisure-time physical activity and have good pulmonary function seem to have a lower risk for stroke than men who are not active or have diminished pulmonary function.	Natl Univ Hosp Iceland, IS-101 Reykjavik, Iceland; Iceland Heart Assoc, Reykjavik, Iceland	Landspitali National University Hospital; Icelandic Heart Association	Agnarsson, U (corresponding author), Heart Prevent Clin, Lagmuli 9, IS-108 Reykjavik, Iceland.							ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; Eliasson M, 1996, INT J EPIDEMIOL, V25, P1182, DOI 10.1093/ije/25.6.1182; Eriksson KF, 1996, DIABETOLOGIA, V39, P573, DOI 10.1007/BF00403304; GEBSKI V, 1992, SPIDA USERS MANUAL V; Gillum RF, 1997, STROKE, V28, P1527, DOI 10.1161/01.STR.28.8.1527; KIELY DK, 1994, AM J EPIDEMIOL, V140, P608, DOI 10.1093/oxfordjournals.aje.a117298; KRAMSCH DM, 1981, NEW ENGL J MED, V305, P1483, DOI 10.1056/NEJM198112173052501; Lee IM, 1998, STROKE, V29, P2049, DOI 10.1161/01.STR.29.10.2049; Sacco RL, 1998, STROKE, V29, P380, DOI 10.1161/01.STR.29.2.380; SHINTON R, 1991, J EPIDEMIOL COMMUN H, V45, P138, DOI 10.1136/jech.45.2.138; SIGURDSSON E, 1993, EUR HEART J, V14, P584, DOI 10.1093/eurheartj/14.5.584; SIGURDSSON E, 1995, INT J EPIDEMIOL, V24, P58, DOI 10.1093/ije/24.1.58; STRACHAN DP, 1991, BMJ-BRIT MED J, V302, P84, DOI 10.1136/bmj.302.6768.84; Thorvaldsen P, 1997, STROKE, V28, P500, DOI 10.1161/01.STR.28.3.500; *US DEP HHS, 1996, PHYS ACT HLTH REP SU, P102; WANNAMETHEE G, 1992, BRIT MED J, V304, P597, DOI 10.1136/bmj.304.6827.597; Wei M, 1999, ANN INTERN MED, V130, P89, DOI 10.7326/0003-4819-130-2-199901190-00002; WELIN L, 1987, NEW ENGL J MED, V317, P521, DOI 10.1056/NEJM198708273170901; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025	20	54	54	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					987	990		10.7326/0003-4819-130-12-199906150-00006	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383369				2022-12-24	WOS:000080894700005
J	Owen, DJ; Vallis, Y; Noble, MEM; Hunter, JB; Dafforn, TR; Evans, PR; McMahon, HT				Owen, DJ; Vallis, Y; Noble, MEM; Hunter, JB; Dafforn, TR; Evans, PR; McMahon, HT			A structural explanation for the binding of multiple ligands by the alpha-adaptin appendage domain	CELL			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SYNAPTIC VESICLE ENDOCYTOSIS; COATED VESICLES; PROTEINS; EPS15; MEMBRANE; DYNAMIN; AP-2; AMPHIPHYSIN; COMPLEXES	The alpha subunit of the endocytotic AP2 adaptor complex contains a 30 kDa "appendage" domain, which is joined to the rest of the protein via a flexible linker. The 1.9 Angstrom resolution crystal structure of this domain reveals a single binding site for its ligands, which include amphiphysin, Eps15, and epsin. This domain when overexpressed in COS7 fibroblasts is shown to inhibit transferrin uptake, whereas mutants in which interactions with its binding partners are abolished do not. DPF/W motifs present in appendage domain-binding partners are shown to play a crucial role in their interactions with the domain. A single site for binding multiple ligands would allow for temporal and spatial regulation in the recruitment of components of the endocytic machinery.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England; Univ Cambridge, CIMR, Dept Haematol, Cambridge CB2 2XY, England	MRC Laboratory Molecular Biology; University of Oxford; University of Cambridge	Evans, PR (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	pre@mrc-lmb.cam.ac.uk; hmm@mrc-lmb.cam.ac.uk	; Dafforn, Tim/A-9072-2015	Noble, Martin/0000-0002-3595-9807; Dafforn, Tim/0000-0003-2257-6679				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Carbone R, 1997, CANCER RES, V57, P5498; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; CONNOLLY ML, 1985, J APPL CRYSTALLOGR, V18, P499, DOI 10.1107/S0021889885010779; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; de Beer T, 1998, SCIENCE, V281, P1357, DOI 10.1126/science.281.5381.1357; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; DeCamilli P, 1996, NEURON, V16, P481, DOI 10.1016/S0896-6273(00)80068-9; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Floyd S, 1998, TRENDS CELL BIOL, V8, P299, DOI 10.1016/S0962-8924(98)01316-6; GALLUSSER A, 1993, EMBO J, V12, P5237, DOI 10.1002/j.1460-2075.1993.tb06219.x; Goodford P, 1996, J CHEMOMETR, V10, P107; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; Iannolo G, 1997, CANCER RES, V57, P240; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; LINDNER R, 1992, J BIOL CHEM, V267, P16567; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Odorizzi G, 1998, TRENDS CELL BIOL, V8, P282, DOI 10.1016/S0962-8924(98)01295-1; ODRIDGE J, 1998, TRENDS CELL BIOL, V8, P302; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; PEARSE BMF, 1976, P NATL ACAD SCI USA, V73, P1255, DOI 10.1073/pnas.73.4.1255; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEELER JS, 1993, J CELL BIOL, V120, P47, DOI 10.1083/jcb.120.1.47; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; Robinson MS, 1997, TRENDS CELL BIOL, V7, P99, DOI 10.1016/S0962-8924(96)10048-9; ROTH TF, 1964, J CELL BIOL, V20, P313, DOI 10.1083/jcb.20.2.313; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Shih W, 1995, J BIOL CHEM, V270, P31083, DOI 10.1074/jbc.270.52.31083; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith CJ, 1998, EMBO J, V17, P4943, DOI 10.1093/emboj/17.17.4943; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Vallis Y, 1999, CURR BIOL, V9, P257, DOI 10.1016/S0960-9822(99)80114-6; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; YE W, 1995, J NEUROSCI RES, V41, P15, DOI 10.1002/jnr.490410104; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108; Zhang B, 1998, NEURON, V21, P1465, DOI 10.1016/S0896-6273(00)80664-9	54	241	252	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					805	815		10.1016/S0092-8674(00)80791-6	http://dx.doi.org/10.1016/S0092-8674(00)80791-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380931	Bronze			2022-12-24	WOS:000080886300017
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Dracula's wish	SCIENCE			English	Article									Mednav Com, Byfield, MA 01922 USA		Peters, R (corresponding author), Mednav Com, Byfield, MA 01922 USA.							McLean J, 1916, AM J PHYSIOL, V41, P250, DOI 10.1152/ajplegacy.1916.41.2.250; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Westerduin P, 1994, Bioorg Med Chem, V2, P1267, DOI 10.1016/S0968-0896(00)82078-7	3	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAY 21	1999	284	5418					1294	1294		10.1126/science.284.5418.1294	http://dx.doi.org/10.1126/science.284.5418.1294			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	198NN	10383310				2022-12-24	WOS:000080430600035
J	Kannus, P; Niemi, S; Parkkari, J; Palvanen, M; Vuori, I; Jarvinen, M				Kannus, P; Niemi, S; Parkkari, J; Palvanen, M; Vuori, I; Jarvinen, M			Hip fractures in Finland between 1970 and 1997 and predictions for the future	LANCET			English	Article							POSTMENOPAUSAL WOMEN; PROXIMAL FEMUR; EPIDEMIOLOGY; TRENDS; AGE; ENGLAND; RATES	Background Hip fractures in elderly people are common worldwide, and the predicted ageing of populations is increasing the burden of these fractures on health-care systems. However, prediction of the true increases in number of patients needing treatment requires exact knowledge of whether the number of hip fractures is rising more rapidly than can be accounted for by demographic changes alone. We aimed to make such a prediction for people aged 50 years or more in Finland. Methods All patients aged 50 years or more, who were admitted to hospitals in Finland during 1970-97 for primary treatment of first hip fracture were selected from the National Hospital Discharge Register. The age-specific and age-adjusted fracture incidences were expressed as the number of patients per 100 000 individuals per year, and predicton of the number, and incidence of hip fractures in Finland (population 5 million) until the year 2030 was calculated with a regression model. Findings The number of hip fractures in Finnish people aged 50 or more rose during the study period, from 1857 in 1970 to 7122 in 1997. The corresponding fracture incidence (per 100 000 people) increased from 163 to 438. The age-adjusted incidence of hip fractures also showed a steady increase from 1970 to 1997. in women, from 292 to 467, and in men, from 112 to 233. If this trend continues, the number of hip fractures in Finland will be almost three-fold higher in the year 2030 than in 1997. Interpretation The number of hip fractures in elderly Finnish men and women is increasing at a rate that cannot be explained merely by demographic changes. The precise reasons for this are not known, but deterioration in age-adjusted bone-mineral density and strength, with accompanying increase in the age-adjusted incidence of injurious falls of the elderly, could partly account for the development.	UKK Inst Hlth Promot Res, FIN-33500 Tampere, Finland; Tampere Res Ctr Sports Med, Tampere, Finland; Accid & Trauma Res Ctr, Tampere, Finland; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Surg, Tampere, Finland	UKK Institute; Tampere University; Tampere University; Tampere University Hospital	Kannus, P (corresponding author), UKK Inst Hlth Promot Res, Kaupinpuistonkatu 1, FIN-33500 Tampere, Finland.	klpeka@uta.fi						BOEREBOOM FTJ, 1992, OSTEOPOROSIS INT, V2, P279, DOI 10.1007/BF01623183; BOYCE WJ, 1985, LANCET, V1, P150; CUMMINGS SR, 1989, ARCH INTERN MED, V149, P2445, DOI 10.1001/archinte.149.11.2445; EISKJAER S, 1992, ACTA ORTHOP SCAND, V63, P293, DOI 10.3109/17453679209154785; Evans JG, 1997, J EPIDEMIOL COMMUN H, V51, P424, DOI 10.1136/jech.51.4.424; FENTONLEWIS A, 1981, BRIT MED J, V283, P1217; Gullberg B, 1997, OSTEOPOROSIS INT, V7, P407, DOI 10.1007/PL00004148; HOFFENBERG R, 1989, J ROY COLL PHYS LOND, V23, P8; HONKNEN R, 1990, HOSP DUE INJURIES FI; Jaglal SB, 1996, CAN J SURG, V39, P105; Kanis JA, 1993, OSTEOPOROSIS INT S1, V3, P10; Kannus P, 1996, BONE, V18, pS57, DOI 10.1016/8756-3282(95)00381-9; KEENE GS, 1993, BRIT MED J, V307, P1248, DOI 10.1136/bmj.307.6914.1248; Keskimaki I, 1991, INT J HLTH SCI, V2, P15, DOI DOI 10.1177/1403494812456637; LAU EMC, 1990, INT J EPIDEMIOL, V19, P1119, DOI 10.1093/ije/19.4.1119; LEE CM, 1993, ACTA ORTHOP SCAND, V64, P178, DOI 10.3109/17453679308994565; LEVY AR, 1995, AM J EPIDEMIOL, V142, P428, DOI 10.1093/oxfordjournals.aje.a117651; Lips Paul, 1997, American Journal of Medicine, V103, p3S, DOI 10.1016/S0002-9343(97)90021-8; LUTHJE P, 1995, ACTA ORTHOP SCAND, V66, P245; MARTIN AD, 1991, CLIN ORTHOP RELAT R, P111; Melton LJ, 1996, BONE, V18, pS121, DOI 10.1016/8756-3282(95)00492-0; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; OBRANT KJ, 1989, CALCIFIED TISSUE INT, V44, P157, DOI 10.1007/BF02556558; *OFF STAT FINL, 1998, STRUCT POP VIT STAT; *OFF STAT FINL, 1997, POP PROJ 1997 2030; PARKKARI J, 1994, CALCIFIED TISSUE INT, V55, P342, DOI 10.1007/BF00299311; SALMELA R, 1987, HOSPITAL, V79, P780; SPECTOR TD, 1990, BRIT MED J, V300, P1173, DOI 10.1136/bmj.300.6733.1173; Thorngren K G, 1994, Disabil Rehabil, V16, P119; WALLACE WA, 1983, LANCET, V1, P1413	30	236	240	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					802	805		10.1016/S0140-6736(98)04235-4	http://dx.doi.org/10.1016/S0140-6736(98)04235-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459962				2022-12-24	WOS:000079089100012
J	Michael, M; Meddings, DR; Ramez, S; Gutierrez-Fisac, JL				Michael, M; Meddings, DR; Ramez, S; Gutierrez-Fisac, JL			Incidence of weapon injuries not related to interfactional combat in Afghanistan in 1996: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							FIREARM	Objective To examine the descriptive epidemiology of weapon injuries not directly attributable to combat during armed conflict Design Prospective cohort study. Setting Nangarhar region of Afghanistan, which experienced effective peace, intense fighting, and then peace over six months in 1996, Subjects 608 people admitted to Jalalabad hospital because of weapon injuries. Main outcome measures Estimated incidence of injuries from combat or otherwise (non-combat injury) before, during, and after the fall of Kabul. Results Incidence of non-combat injury was initially 65 per 100 000, During the intense military campaign for Kabul the incidence declined dramatically and then differentially increased dependent on injury subcategory-that is, whether injuries were accidental or intentional and whether they were inflicted by firearms or fragmenting munitions. Non-combat injuries accounted for 51% of weapon injuries observed over the study period. Civilians were more likely to have non-combat injuries than combat injuries. Conclusions Weapon injuries that are not attributable to combat are common. Social changes accompanying conflict and widespread availability of weapons may be predictive of use of weapons that persists independently of conflict.	Int Comm Red Cross, Unit Chief Med Officer, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Hlth Operat Div, CH-1202 Geneva, Switzerland; Int Comm Red Cross, Peshawar, Pakistan; Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Madrid 28029, Spain	Autonomous University of Madrid	Meddings, DR (corresponding author), Int Comm Red Cross, Unit Chief Med Officer, 19 Ave Paix, CH-1202 Geneva, Switzerland.	dmeddings@icrc.org		Michael, Markus/0000-0003-0482-4325				ADENIJI O, 1998, MORATORIUM LIGHT WEA, P85; ANNEST JL, 1995, JAMA-J AM MED ASSOC, V273, P1749, DOI 10.1001/jama.273.22.1749; Bellah RN, 1995, BOST THEO I, V4, P1; BERMAN E, 1996, MANAGING ARMS PEACE, P57; CHACHIUA M, 1999, ARMS MANAGEMENT PROG; Coupland R. M., 1996, MED GLOBAL SURVIVAL, V3, P1; COUPLAND RM, 1994, BRIT MED J, V308, P1693, DOI 10.1136/bmj.308.6945.1693; Cukier W, 1998, Chronic Dis Can, V19, P25; HIGDON S, 1996, ANGOLA CONFLICT RESO; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; Klare M. T., 1995, LETHAL COMMERCE GLOB; Meddings DR, 1997, BRIT MED J, V315, P1417, DOI 10.1136/bmj.315.7120.1417; SLOAN JH, 1990, NEW ENGL J MED, V322, P369, DOI 10.1056/NEJM199002083220605; Smith C., 1995, LETHAL COMMERCE GLOB, P61; Williams P., 1997, SOC SIEGE CRIME VIOL, P11; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	16	19	20	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 14	1999	319	7207					415	417		10.1136/bmj.319.7207.415	http://dx.doi.org/10.1136/bmj.319.7207.415			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	227UT	10445923	Bronze, Green Published			2022-12-24	WOS:000082098900017
J	Peters, C; Andrews, PD; Stark, MJR; Cesaro-Tadic, S; Glatz, A; Podtelejnikov, A; Mann, M; Mayer, A				Peters, C; Andrews, PD; Stark, MJR; Cesaro-Tadic, S; Glatz, A; Podtelejnikov, A; Mann, M; Mayer, A			Control of the terminal step of intracellular membrane fusion by protein phosphatase 1	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SERINE/THREONINE PHOSPHATASES; YEAST VACUOLES; SEC18P NSF; T-SNARE; DOCKING; DISTINCT; KINASE; BINDS; ROLES	Intracellular membrane fusion is crucial for the biogenesis and maintenance of cellular compartments, for vesicular traffic between them, and for exo- and endocytosis. Parts of the molecular machinery underlying this process have been identified, but most of these components operate in mutual recognition of the membranes. Here it is shown that protein phosphatase 1 (PP1) is essential for bilayer mixing, the last step of membrane fusion, PP1 was also identified in a complex that contained calmodulin, the second known factor implicated in the regulation of bilayer mixing. The PP1-calmodulin complex was required at multiple sites of intracellular trafficking; hence, PP1 may be a general factor controlling membrane bilayer mixing.	Friedrich Miescher Lab, D-72076 Tubingen, Germany; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Univ So Denmark, Dept Mol Biol, Prot Interact Lab, DK-5230 Odense M, Denmark	Eberhard Karls University of Tubingen; University of Dundee; University of Southern Denmark	Mayer, A (corresponding author), Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.	andreas.mayer@tuebingen.mpg.de	Podtelejnikov, Alexandre/B-6120-2017; Mayer, Andreas/AAE-4315-2020; Mann, Matthias/A-3454-2013; Stark, Michael J. R./B-2815-2014	Podtelejnikov, Alexandre/0000-0002-8124-6584; Mayer, Andreas/0000-0001-6131-313X; Mann, Matthias/0000-0003-1292-4799; Stark, Michael J. R./0000-0001-9086-191X; Andrews, Paul/0000-0001-7699-5604	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDREWS PD, UNPUB; Ausubel F.A., 1997, CURRENT PROTOCOLS MO, DOI DOI 10.1.4; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JONES EW, 1977, GENETICS, V85, P23; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.0.CO;2-U; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MACKINTOSH RW, 1995, FEBS LETT, V371, P236, DOI 10.1016/0014-5793(95)00888-G; Mayer A, 1997, J CELL BIOL, V136, P307, DOI 10.1083/jcb.136.2.307; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; MAYER A, IN PRESS CURR OPIN C; MOORHEAD G, 1994, FEBS LETT, V356, P46, DOI 10.1016/0014-5793(94)01232-6; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Scepek S, 1998, EMBO J, V17, P4340, DOI 10.1093/emboj/17.15.4340; Shevchenko A, 1996, P NATL ACAD SCI USA, V93, P14440, DOI 10.1073/pnas.93.25.14440; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Xu ZY, 1997, J CELL BIOL, V136, P299, DOI 10.1083/jcb.136.2.299	29	138	142	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1999	285	5430					1084	1087		10.1126/science.285.5430.1084	http://dx.doi.org/10.1126/science.285.5430.1084			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446058				2022-12-24	WOS:000082033100051
J	Wichman, HA; Badgett, MR; Scott, LA; Boulianne, CM; Bull, JJ				Wichman, HA; Badgett, MR; Scott, LA; Boulianne, CM; Bull, JJ			Different trajectories of parallel evolution during viral adaptation	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RESISTANCE MUTATIONS; BENEFICIAL MUTATIONS; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; SELECTION; FITNESS; POPULATION; DRUG; DNA	The molecular basis of adaptation is a major focus of evolutionary biology, yet the dynamic process of adaptation has been explored only piecemeal. Experimental evolution of two bacteriophage lines under strong selection led to over a dozen nucleotide changes genomewide in each replicate. At Least 96 percent of the amino acid substitutions appeared to be adaptive, and half the changes in one line also occurred in the other. However, the order of these changes differed between replicates, and parallel substitutions did not reflect the changes with the largest beneficial effects or indicate a common trajectory of adaptation.	Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA; Univ Texas, Dept Zool, Austin, TX 78712 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Idaho; University of Idaho; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Wichman, HA (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83844 USA.	hwichman@uidaho.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057756, R01GM057755] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM057756, GM57755] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel F, 1989, MOL REPROD DEV, V1, P146; Borman AM, 1996, J GEN VIROL, V77, P419, DOI 10.1099/0022-1317-77-3-419; BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; Boyd EF, 1998, J MOL EVOL, V47, P258, DOI 10.1007/PL00006383; Bull JJ, 1997, GENETICS, V147, P1497; Canica MMM, 1997, J MOL EVOL, V44, P57, DOI 10.1007/PL00006121; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; DYKHUIZEN DE, 1987, GENETICS, V115, P25; Elena SF, 1996, SCIENCE, V272, P1802, DOI 10.1126/science.272.5269.1802; Elena SF, 1996, GENETICS, V142, P673; Gerrish PJ, 1998, GENETICA, V102-3, P127, DOI 10.1023/A:1017067816551; Hayashi M., 1988, BACTERIOPHAGES, V2, P1; HOLLAND JJ, 1979, CELL, V16, P495, DOI 10.1016/0092-8674(79)90024-2; KELLAM P, 1994, J GEN VIROL, V75, P341, DOI 10.1099/0022-1317-75-2-341; LAU PCK, 1985, GENE, V40, P273, DOI 10.1016/0378-1119(85)90050-2; LENSKI RE, 1994, P NATL ACAD SCI USA, V91, P6808, DOI 10.1073/pnas.91.15.6808; Li W-H, 1997, MOL EVOLUTION; MCDONALD JH, 1991, NATURE, V351, P652, DOI 10.1038/351652a0; Messler W, 1997, NATURE, V385, P151, DOI 10.1038/385151a0; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Nijhuis M, 1998, P NATL ACAD SCI USA, V95, P14441, DOI 10.1073/pnas.95.24.14441; NOVELLA IS, 1995, P NATL ACAD SCI USA, V92, P5841, DOI 10.1073/pnas.92.13.5841; ROSENZWEIG RF, 1994, GENETICS, V137, P903; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; SPENCER JH, 1978, SINGLE STRANDED DNA, P87; STEWART CB, 1987, NATURE, V330, P401, DOI 10.1038/330401a0; TAYLOR MFJ, 1995, SCIENCE, V270, P1497, DOI 10.1126/science.270.5241.1497; WARNER JC, 1978, SINGLE STRANDED DNA, P417	28	273	274	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 16	1999	285	5426					422	424		10.1126/science.285.5426.422	http://dx.doi.org/10.1126/science.285.5426.422			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411508				2022-12-24	WOS:000081465900059
J	Kovacs, A; Schluchter, M; Easley, K; Demmler, G; Shearer, W; La Russa, P; Pitt, J; Cooper, E; Goldfarb, J; Hodes, D; Kattan, M; McIntosh, K				Kovacs, A; Schluchter, M; Easley, K; Demmler, G; Shearer, W; La Russa, P; Pitt, J; Cooper, E; Goldfarb, J; Hodes, D; Kattan, M; McIntosh, K		Pediat Pulmonary Cardiovascular Complications	Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	XIth International Conference on AIDS	JUL 07-13, 1996	VANCOUVER, CANADA				HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; HOMOSEXUAL MEN; MULTIPLE IMPUTATION; AIDS PATIENTS; CMV DISEASE; TYPE-1; DNA; CHILDREN; MONONUCLEOSIS	Background and Methods Cytomegalovirus (CMV) has been implicated as a cofactor in the progression of human immunodeficiency virus type 1 (HIV-1) disease. We assessed 440 infants (75 of whom were HIV-1-infected and 365 of whom were not) whose CMV status was known, who were born to HIV-1-infected women, and who were followed prospectively. HIV-1 disease progression was defined as the presence of class C symptoms (according to the criteria of the Centers for Disease Control and Prevention [CDC]) or CD4 counts of less than 750 cells per cubic millimeter by 1 year of age and less than 500 cells per cubic millimeter by 18 months of age. Results At birth the frequency of CMV infection was similar in the HIV-1-infected and HIV-1-uninfected infants (4.3 percent and 4.5 percent, respectively), but the HIV-1-infected infants had a higher rate of CMV infection at six months of age (39.9 percent vs. 15.3 percent, P=0.001) and continued to have a higher rate of CMV infection through four years of age (P=0.04). By 18 months of age, the infants with both infections had higher rates of HIV-1 disease progression (70.0 percent vs. 30.4 percent, P=0.001), CDC class C symptoms or death (52.5 percent vs. 21.7 percent, P=0.008), and impaired brain growth or progressive motor deficits (35.6 percent vs. 8.7 percent, P=0.005) than infants infected only with HIV-1. In a Cox regression analysis, CMV infection was associated with an increased risk of HIV-1 disease progression (relative risk, 2.59; 95 percent confidence interval, 1.13 to 5.95). Among children infected with HIV-1 alone, but not among those infected with both viruses, children with rapid progression of HIV-1 disease had higher mean levels of HIV-1 RNA than those with slower or no progression of disease. Conclusions HIV-1-infected infants who acquire CMV infection in the first 18 months of life have a significantly higher rate of disease progression and central nervous system disease than those infected with HIV-1 alone. (N Engl J Med 1999;341:77-84.) (C) 1999, Massachusetts Medical Society.	Univ So Calif, Los Angeles Cty Med Ctr, Maternal Child HIV Management & Res Ctr, Los Angeles, CA 90033 USA; Univ So Calif, Div Pediat Invect Dis, Los Angeles, CA USA; Cleveland Clin Fdn, Dept Biostat & Epidemiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Div Pediat & Adolescent Med, Cleveland, OH 44195 USA; Baylor Coll Med, Dept Pediat, Sect Infect Dis, Houston, TX 77030 USA; Baylor Coll Med, Dept Allergy & Immunol, Houston, TX 77030 USA; Columbia Presbyterian Med Ctr, Dept Pediat, New York, NY 10032 USA; Bolston Med Ctr, Dept Pediat, Boston, MA USA; Mt Sinai Sch Med, Pediat Pulm & Crit Care Div, New York, NY USA; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; Mt Sinai Sch Med, Dept Pediat, Div Pediat Infect Dis, New York, NY USA	University of Southern California; University of Southern California; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Baylor College of Medicine; Baylor College of Medicine; Columbia University; NewYork-Presbyterian Hospital; Icahn School of Medicine at Mount Sinai; Harvard University; Boston Children's Hospital; Icahn School of Medicine at Mount Sinai	Kovacs, A (corresponding author), Hlth Res Associates Bldg,1640 Marengo St,3rd Fl, Los Angeles, CA 90033 USA.		Easley, Kirk A/K-6910-2015	Easley, Kirk A/0000-0003-4419-2617; Shearer, William/0000-0002-2483-2130	NCRR NIH HHS [M01 RR000188, M01 RR000071, M01 RR000645, M01 RR000533, M01 RR000043, M01 RR002172, K01 RR000188, M01 RR000865] Funding Source: Medline; NHLBI NIH HHS [N01 HR096037, N01-HR-96039, N01 HR096043, N01-HR-96038] Funding Source: Medline; DIVISION OF LUNG DISEASES [N01HR096037, N01HR096039, N01HR096038, N01HR096043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002172, M01RR000043, K01RR000188, M01RR000865, M01RR000533, M01RR000071, M01RR000645, M01RR000188] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF LUNG DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P1; BELMAN AL, 1988, AM J DIS CHILD, V142, P29, DOI 10.1001/archpedi.1988.02150010039017; BELMAN AL, 1988, AM J DIS CHILD, V142, P507; Carcaba V, 1991, An Med Interna, V8, P243; CARNEY WP, 1983, J IMMUNOL, V130, P390; Chandwani S, 1996, PEDIATR INFECT DIS J, V15, P310, DOI 10.1097/00006454-199604000-00006; COLLIER AC, 1987, AM J MED, V82, P593, DOI 10.1016/0002-9343(87)90105-7; COOPER ER, 1992, PEDIATR AIDS HIV INF, V3, P302; CURLESS RG, 1987, CHILD NERV SYST, V3, P255, DOI 10.1007/BF00274063; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DEMMLER GJ, 1991, REV INFECT DIS, V13, P315, DOI 10.1093/clinids/13.2.315; DEMMLER GJ, 1988, J INFECT DIS, V158, P1177, DOI 10.1093/infdis/158.6.1177; DETELS R, 1984, JAMA-J AM MED ASSOC, V251, P1719, DOI 10.1001/jama.251.13.1719; DOREY FJ, 1993, STAT MED, V12, P1589, DOI 10.1002/sim.4780121706; Doyle M, 1996, PEDIATR INFECT DIS J, V15, P1102, DOI 10.1097/00006454-199612000-00010; DREW WL, 1985, ANN INTERN MED, V103, P61, DOI 10.7326/0003-4819-103-1-61; DUDDING L, 1989, J IMMUNOL, V143, P3343; FRENKEL LD, 1990, REV INFECT DIS, V12, pS820; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GENDELMAN HE, 1986, P NATL ACAD SCI USA, V83, P9759, DOI 10.1073/pnas.83.24.9759; Gerard L, 1997, CLIN INFECT DIS, V24, P836, DOI 10.1093/clinids/24.5.836; GERNA G, 1994, J CLIN MICROBIOL, V32, P2709, DOI 10.1128/JCM.32.11.2709-2717.1994; HO DD, 1987, NEW ENGL J MED, V317, P278; JAULT FM, 1994, J VIROL, V68, P959, DOI 10.1128/JVI.68.2.959-973.1994; KALBFLEISCH JD, 1980, STAT ANAL FAILURE TI, P30; Kattan M, 1996, J CLIN EPIDEMIOL, V49, P1285; Kitchen BJ, 1997, PEDIATR INFECT DIS J, V16, P358, DOI 10.1097/00006454-199704000-00005; LANG DJ, 1989, J ACQ IMMUN DEF SYND, V2, P540; LATHEY JL, 1994, VIROLOGY, V199, P98, DOI 10.1006/viro.1994.1101; MCKEATING JA, 1990, NATURE, V343, P659, DOI 10.1038/343659a0; MOSCA JD, 1987, P NATL ACAD SCI USA, V84, P7408, DOI 10.1073/pnas.84.21.7408; Mussi-Pinhata MM, 1998, J PEDIATR-US, V132, P285, DOI 10.1016/S0022-3476(98)70446-9; NELSON JA, 1988, VIROLOGY, V165, P286, DOI 10.1016/0042-6822(88)90685-X; NGUYEN C, 1991, J INFECT DIS, V164, P219, DOI 10.1093/infdis/164.1.219; Nigro G, 1996, AIDS, V10, P1127, DOI 10.1097/00002030-199609000-00011; PASS RF, 1980, PEDIATRICS, V66, P758; POLK BF, 1987, NEW ENGL J MED, V316, P61, DOI 10.1056/NEJM198701083160201; QUINNAN GV, 1984, JAMA-J AM MED ASSOC, V252, P72, DOI 10.1001/jama.252.1.72; RABKIN CS, 1993, J INFECT DIS, V168, P1260, DOI 10.1093/infdis/168.5.1260; RAFFI F, 1990, ANN INTERN MED, V112, P234, DOI 10.7326/0003-4819-112-3-234; Rasmussen L, 1997, J INFECT DIS, V176, P1146, DOI 10.1086/514106; REYNOLDS DW, 1973, NEW ENGL J MED, V289, P1, DOI 10.1056/NEJM197307052890101; RINALDO CR, 1980, J INFECT DIS, V141, P488, DOI 10.1093/infdis/141.4.488; RUBIN DB, 1991, STAT MED, V10, P585, DOI 10.1002/sim.4780100410; SCHINDLER JM, 1990, KLIN WOCHENSCHR, V68, P237, DOI 10.1007/BF01662723; Shearer WT, 1997, NEW ENGL J MED, V336, P1337, DOI 10.1056/NEJM199705083361901; Shepp DH, 1996, J ACQ IMMUN DEF SYND, V11, P460, DOI 10.1097/00042560-199604150-00006; SKOLNIK PR, 1989, AM J OPHTHALMOL, V107, P361, DOI 10.1016/0002-9394(89)90659-4; SKOLNIK PR, 1988, J INFECT DIS, V157, P508, DOI 10.1093/infdis/157.3.508; Spector SA, 1998, J CLIN INVEST, V101, P497, DOI 10.1172/JCI1101; WEBSTER A, 1989, LANCET, V2, P63; WEBSTER A, 1991, J ACQ IMMUN DEF SYND, V4, pS47; WILEY CA, 1986, J NEUROPATH EXP NEUR, V45, P127, DOI 10.1097/00005072-198603000-00003	53	177	185	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					77	84		10.1056/NEJM199907083410203	http://dx.doi.org/10.1056/NEJM199907083410203			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214ET	10395631	Green Accepted			2022-12-24	WOS:000081316200003
J	Cranford, RE				Cranford, RE			Policy should be balanced with concern for the family	BRITISH MEDICAL JOURNAL			English	Article									Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA	Hennepin County Medical Center	Cranford, RE (corresponding author), Hennepin Cty Med Ctr, Dept Neurol, 701 Pk Ave, Minneapolis, MN 55415 USA.							Youngner S., 1999, DEFINITION DEATH CON	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1754	1755						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428563				2022-12-24	WOS:000081216900040
J	Hamiche, A; Sandaltzopoulos, R; Gdula, DA; Wu, C				Hamiche, A; Sandaltzopoulos, R; Gdula, DA; Wu, C			ATP-dependent histone octamer sliding mediated by the chromatin remodeling complex NURF	CELL			English	Article							NUCLEOSOME CORE PARTICLE; YEAST SWI/SNF COMPLEX; IN-VITRO; TRANSCRIPTIONAL ACTIVATION; MULTISUBUNIT COMPLEX; GENE-PRODUCTS; DNA; BINDING; ISWI; MOBILITY	Drosophila NURF is an ATP-dependent chromatin remodeling complex that contains ISWI, a member of the SW12/SNF2 family of ATPases. We demonstrate that NURF catalyzes the bidirectional redistribution of mononucleosomes reconstituted on hsp70 promoter DNA. In the presence of NURF, nucleosomes adopt one predominant position from an ensemble of possible locations within minutes. Movements occur in cis, with no transfer to competing DNA. Migrating intermediates trapped by fro III digestion reveal progressive nucleosome motion in increments of several base pairs. All four core histones are retained quantitatively during this process, indicating that the general integrity of the histone octamer is maintained. We suggest that NURF remodels nucleosomes by transiently decreasing the activation energy for short-range sliding of the histone octamer.	NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wu, C (corresponding author), NCI, Mol Cell Biol Lab, NIH, Bethesda, MD 20892 USA.							Arenhovel H., 1991, Few-Body Systems Supplementum, P1, DOI 10.1007/978-3-7091-6701-4_1; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BAXEVANIS AD, 1991, BIOCHEMISTRY-US, V30, P8817, DOI 10.1021/bi00100a013; Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BEARD P, 1978, CELL, V15, P955, DOI 10.1016/0092-8674(78)90279-9; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Cote J, 1998, P NATL ACAD SCI USA, V95, P4947, DOI 10.1073/pnas.95.9.4947; DUBANDGOULET I, 1992, J MOL BIOL, V224, P981, DOI 10.1016/0022-2836(92)90464-U; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; Flaus A, 1998, J MOL BIOL, V275, P427, DOI 10.1006/jmbi.1997.1464; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Georgel PT, 1997, EMBO J, V16, P4717, DOI 10.1093/emboj/16.15.4717; GLOTOV BO, 1982, BIOCHIM BIOPHYS ACTA, V696, P275, DOI 10.1016/0167-4781(82)90058-6; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; ITO T, 1999, IN PRESS GENES DEV; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KAMAKAKA RT, 1991, P NATL ACAD SCI USA, V88, P1024, DOI 10.1073/pnas.88.3.1024; KORNBERG RD, 1977, ANNU REV BIOCHEM, V46, P931, DOI 10.1146/annurev.bi.46.070177.004435; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Langst G, 1999, CELL, V97, P843, DOI 10.1016/S0092-8674(00)80797-7; LAURENT BC, 1993, GENE DEV, V7, P583, DOI 10.1101/gad.7.4.583; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Lorch Y, 1998, CELL, V94, P29, DOI 10.1016/S0092-8674(00)81218-0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Martinez-Balbas MA, 1998, P NATL ACAD SCI USA, V95, P132, DOI 10.1073/pnas.95.1.132; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Okada M, 1998, MOL CELL BIOL, V18, P2455, DOI 10.1128/MCB.18.5.2455; Papoulas O, 1998, DEVELOPMENT, V125, P3955; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PETERSON CL, 1994, P NATL ACAD SCI USA, V91, P2905, DOI 10.1073/pnas.91.8.2905; Pollard KJ, 1998, BIOESSAYS, V20, P771, DOI 10.1002/(SICI)1521-1878(199809)20:9<771::AID-BIES10>3.0.CO;2-V; Sandaltzopoulos R, 1999, METHOD ENZYMOL, V304, P757; Schnitzler G, 1998, CELL, V94, P17, DOI 10.1016/S0092-8674(00)81217-9; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1979, J BIOL CHEM, V254, P123; SPADAFORA C, 1979, EUR J BIOCHEM, V100, P225, DOI 10.1111/j.1432-1033.1979.tb02053.x; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Travers A, 1997, BIOPOLYMERS, V44, P423, DOI 10.1002/(SICI)1097-0282(1997)44:4<423::AID-BIP6>3.0.CO;2-M; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; van Holde KE., 1989, SPRINGER SERIES MOL; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEISCHET WO, 1978, NUCLEIC ACIDS RES, V5, P139, DOI 10.1093/nar/5.1.139; Widom J, 1998, ANNU REV BIOPH BIOM, V27, P285, DOI 10.1146/annurev.biophys.27.1.285; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Wu C, 1998, COLD SPRING HARB SYM, V63, P525, DOI 10.1101/sqb.1998.63.525; Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	75	277	281	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					833	842		10.1016/S0092-8674(00)80796-5	http://dx.doi.org/10.1016/S0092-8674(00)80796-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399912	Bronze			2022-12-24	WOS:000081162800005
J	DiSanti, MA; Mumma, MJ; Dello Russo, N; Magee-Sauer, K; Novak, R; Rettig, TW				DiSanti, MA; Mumma, MJ; Dello Russo, N; Magee-Sauer, K; Novak, R; Rettig, TW			Identification of two sources of carbon monoxide in comet Hale-Bopp	NATURE			English	Article							PLANETARY-ATMOSPHERES; HALLEY; P/HALLEY; MODEL; GAS; CO; EVOLUTION; TIME; DUST	The composition of ices in comets may reflect that of the molecular cloud in which the Sun formed, or it may show evidence of chemical processing in the pre-planetary accretion disk around the proto-Sun. As carbon monoxide (CO) is ubiquitous in molecular clouds(1,2), its abundance with respect to water could help to determine the degree to which pre-cometary material was processed, although variations in CO abundance may also be influenced by the distance from the Sun at which comets formed(3-5). Observations have not hitherto provided an unambiguous measure of CO in the cometary ice (native CO). Evidence for an extended source of CO associated with comet Halley was provided by the Giotto spacecraft(6-9), but alternative interpretations exist(10). Here we report observations of comet Hale-Bopp which show that about half of the CO in the comet comes directly from ice stored in the nucleus. The abundance of this CO with respect to water (12 per cent) is smaller than in quiescent regions of molecular clouds, but is consistent with that measured in proto-stellar envelopes(11), suggesting that the ices underwent some processing before their inclusion into Hale-Bopp. The remaining CO arises in the coma, probably through thermal destruction of more complex molecules.	Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA; NASA, Goddard Space Flight Ctr, Extraterr Phys Lab, Greenbelt, MD 20771 USA; Rowan Univ, Dept Chem & Phys, Glassboro, NJ 08028 USA; Iona Coll, Dept Phys, New Rochelle, NY 10801 USA; Univ Notre Dame, Dept Phys & Astron, Notre Dame, IN 46556 USA	Catholic University of America; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Rowan University; Iona College; University of Notre Dame	DiSanti, MA (corresponding author), Catholic Univ Amer, Dept Phys, Washington, DC 20064 USA.		mumma, michael j/I-2764-2013; Russo, Neil Dello/G-2727-2015; Magee-Sauer, Karen/K-6061-2015	mumma, michael j/0000-0003-4627-750X; Russo, Neil Dello/0000-0002-8379-7304; Magee-Sauer, Karen/0000-0002-4979-9875				Biver N, 1996, NATURE, V380, P137, DOI 10.1038/380137a0; Biver N, 1997, SCIENCE, V275, P1915, DOI 10.1126/science.275.5308.1915; BIVER N, IN PRESS EARTH MOON; BOICE DC, 1990, GEOPHYS RES LETT, V17, P1813, DOI 10.1029/GL017i011p01813; Chiar JE, 1998, ASTROPHYS J, V498, P716, DOI 10.1086/305569; Combi MR, 1996, ICARUS, V123, P207, DOI 10.1006/icar.1996.0150; CRIFO JF, 1995, ASTROPHYS J, V445, P470, DOI 10.1086/175712; CROVISIER J, 1987, ASTRON ASTROPHYS SUP, V68, P223; Dello Russo N, 1998, ICARUS, V135, P377, DOI 10.1006/icar.1998.5990; DELLORUSSO N, 1995, UNPUB ICARUS; EBERHARDT P, 1987, ASTRON ASTROPHYS, V187, P481; Green S.F., 1986, ESA SP250, VII, P81; Greenberg JM, 1998, ASTRON ASTROPHYS, V332, P374; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P311; Herzberg G., 1950, SPECTRA DIATOMIC MOL; HUEBNER WF, 1992, ASTROPHYS SPACE SCI, V195, P1, DOI 10.1007/BF00644558; HUEBNER WF, 1987, ASTROPHYS J, V320, pL149, DOI 10.1086/184992; HUNTRESS WT, 1991, NATURE, V352, P316, DOI 10.1038/352316a0; Jewitt D, 1999, ASTRON J, V117, P1056, DOI 10.1086/300743; KUNDE VG, 1974, J QUANT SPECTROSC RA, V14, P803, DOI 10.1016/0022-4073(74)90124-1; LAMMERZAHL P, 1987, ASTRON ASTROPHYS, V187, P169; MEIER R, 1993, ASTRON ASTROPHYS, V277, P677; Mumma M. J., 1997, Astronomical Society of the Pacific Conference Series, V122, P369; Mumma M. J., 1993, PROTOSTARS PLANETS, P1177; RANK DM, 1971, SCIENCE, V174, P1083, DOI 10.1126/science.174.4014.1083; ROTHMAN LS, 1992, J QUANT SPECTROSC RA, V48, P469, DOI 10.1016/0022-4073(92)90115-K; SANDFORD SA, 1988, ICARUS, V76, P201, DOI 10.1016/0019-1035(88)90069-3; TURNER BE, 1989, SPACE SCI REV, V51, P235, DOI 10.1007/BF00172023; WEAVER HA, IN PRESS EARTH MOON; Womack M, 1997, ASTRON J, V114, P2789, DOI 10.1086/118687; Xie XF, 1996, ASTROPHYS J, V464, P457, DOI 10.1086/177336; XIE XF, 1992, ASTROPHYS J, V386, P720, DOI 10.1086/171053	32	83	83	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					662	665		10.1038/21378	http://dx.doi.org/10.1038/21378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385117				2022-12-24	WOS:000080932800051
J	Kuras, L; Struhl, K				Kuras, L; Struhl, K			Binding of TBP to promoters in vivo is stimulated by activators and requires Pol II holoenzyme	NATURE			English	Article							RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; IN-VIVO; SACCHAROMYCES-CEREVISIAE; TATA BOXES; YEAST; RECRUITMENT; COMPLEXES; DNA; REPRESSOR	In eukaryotes, transcriptional activators have been proposed to function by recruiting the RNA polymerase II (Pol II) machinery(1-3), by altering the conformation of this machinery(4,5), or by affecting steps after initiation(6-8), but the evidence is not definitive. Genomic footprinting of yeast TATA-box elements reveals activator-dependent alterations of chromatin structure(9) and activator-independent protection(10), but little is known about the association of specific components of the Pol II machinery with promoters in vivo. Here we analyse TATA-box-binding-protein (TBP) occupancy of 30 yeast promoters in vivo. We find that TBP association with promoters is stimulated by activators and inhibited by the Cyc8-Tup1 repressor, and that transcriptional activity correlates strongly with the degree of TBP occupancy. In a small subset of promoters, TBP occupancy is higher than expected when gene activity is low, and the activator-dependent increase is modest. TBP association depends on the Pol II holoenzyme component Srb4, but not on the Kin28 subunit of the transcription factor TFIIH, even though both proteins are generally required for transcription. Thus in yeast cells, TBP association with promoters occurs in concert with the Pol II holoenzyme, activator-dependent recruitment of the Pol II machinery occurs at the vast majority of promoters, and Kin28 acts after the initial recruitment.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.			Kuras, Laurent/0000-0003-2932-0940				Akhtar A, 1996, EMBO J, V15, P4654, DOI 10.1002/j.1460-2075.1996.tb00842.x; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Blaiseau PL, 1998, EMBO J, V17, P6327, DOI 10.1093/emboj/17.21.6327; CHEN JJ, 1994, P NATL ACAD SCI USA, V91, P11909, DOI 10.1073/pnas.91.25.11909; Chi TH, 1996, GENE DEV, V10, P2540, DOI 10.1101/gad.10.20.2540; CISMOWSKI MJ, 1995, MOL CELL BIOL, V15, P2983; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; GonzalezCouto E, 1997, P NATL ACAD SCI USA, V94, P8036, DOI 10.1073/pnas.94.15.8036; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Patikoglou G, 1997, ANNU REV BIOPH BIOM, V26, P289, DOI 10.1146/annurev.biophys.26.1.289; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; ROUGVIE AE, 1990, MOL CELL BIOL, V10, P6041, DOI 10.1128/MCB.10.11.6041; SELLECK SB, 1987, NATURE, V325, P173, DOI 10.1038/325173a0; Stargell LA, 1996, MOL CELL BIOL, V16, P4456; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; THOMPSON CM, 1995, P NATL ACAD SCI USA, V92, P4587, DOI 10.1073/pnas.92.10.4587; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2	28	398	400	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					609	613		10.1038/21239	http://dx.doi.org/10.1038/21239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376605				2022-12-24	WOS:000080778400062
J	Paradis, K; Langford, G; Long, ZF; Heneine, W; Sandstrom, P; Switzer, WM; Chapman, LE; Lockey, C; Onions, D; Otto, E				Paradis, K; Langford, G; Long, ZF; Heneine, W; Sandstrom, P; Switzer, WM; Chapman, LE; Lockey, C; Onions, D; Otto, E		XEN 111 Study Grp	Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue	SCIENCE			English	Article							HUMAN-CELLS; NO EVIDENCE; INFECTION; XENOTRANSPLANTATION; CONNECTION; KIDNEYS; SAFETY	Pig organs may offer a solution to the shortage of human donor organs for transplantation, but concerns remain about possible cross-species transmission of porcine endogenous retrovirus (PERV). Samples were collected from 160 patients who had been treated with various Living pig tissues up to 12 years earlier. Reverse transcription-polymerase chain reaction (RT-PCR) and protein immunoblot analyses were performed on serum from all 160 patients. No viremia was detected in any patient. Peripheral blood mononuclear cells from 159 of the patients were analyzed by PCR using PERV-specific primers. No PERV infection was detected in any of the patients from whom sufficient DNA was extracted to allow complete PCR analysis (97 percent of the patients). Persistent microchimerism (presence of donor cells in the recipient) was observed in 23 patients for up to 8.5 years.	Imutran Ltd, Cambridge CB2 2YP, England; Genet Therapy Inc, Gaithersburg, MD 20878 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, HIV & Retrovirol Branch, Atlanta, GA 30333 USA; Q One Biotech Ltd, Glasgow G20 0XA, Lanark, Scotland; Univ Glasgow, Dept Vet Pathol, Glasgow G20 0XA, Lanark, Scotland; Circe Biomed, Lexington, KY 40501 USA; Novartis Pharma, Basel, Switzerland; CDC, Atlanta, GA 30333 USA	Novartis; Centers for Disease Control & Prevention - USA; University of Glasgow; Novartis; Centers for Disease Control & Prevention - USA	Paradis, K (corresponding author), Imutran Ltd, POB 399, Cambridge CB2 2YP, England.							ABOUNA GM, 1970, LANCET, V2, P391; Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; BENVENISTE RE, 1975, P NATL ACAD SCI USA, V72, P4090, DOI 10.1073/pnas.72.10.4090; BIGGAR RJ, 1985, LANCET, V2, P520; Breimer ME, 1996, XENOTRANSPLANTATION, V3, P328, DOI 10.1111/j.1399-3089.1996.tb00155.x; COZZI E, 1995, NAT MED, V1, P964, DOI 10.1038/nm0995-964; GRANT RF, 1995, VIROLOGY, V207, P292, DOI 10.1006/viro.1995.1080; Heneine W, 1998, LANCET, V352, P695, DOI 10.1016/S0140-6736(98)07145-1; HOOVER EA, 1991, J AM VET MED ASSOC, V199, P1392; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; Long ZF, 1998, HUM GENE THER, V9, P1165, DOI 10.1089/hum.1998.9.8-1165; Martin U, 1998, LANCET, V352, P692, DOI 10.1016/S0140-6736(98)07144-X; Matthews AL, 1999, TRANSPLANTATION, V67, P939, DOI 10.1097/00007890-199904150-00002; Mullon C, 1999, Expert Opin Investig Drugs, V8, P229, DOI 10.1517/13543784.8.3.229; NIKONOV S, 1991, GRUDN SERDECH SOSUDI, V2, P42; *NUFF COUNC BIOETH, 1996, AN HUM TRANSPL ETH X; Onions D, 1998, TRENDS MICROBIOL, V6, P430, DOI 10.1016/S0966-842X(98)01386-9; Patience C, 1998, LANCET, V352, P699, DOI 10.1016/S0140-6736(98)04369-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SONG IC, 1966, SURGERY, V59, P576; STARZL TE, 1993, HEPATOLOGY, V17, P1127; Stoye J, 1998, LANCET, V352, P666, DOI 10.1016/S0140-6736(98)22035-6; Switzer WM, 1999, TRANSPLANTATION, V68, P183, DOI 10.1097/00007890-199907270-00003; Takeuchi Y, 1998, J VIROL, V72, P9986, DOI 10.1128/JVI.72.12.9986-9991.1998; WHITE D, 1995, NATURE, V378, P434, DOI 10.1038/378434b0; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; 1997, Patent No. 40167	28	576	618	1	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1236	1241		10.1126/science.285.5431.1236	http://dx.doi.org/10.1126/science.285.5431.1236			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455044				2022-12-24	WOS:000082130200034
J	Weinberg, DS; Newschaffer, CJ; Topham, A				Weinberg, DS; Newschaffer, CJ; Topham, A			Risk for colorectal cancer after gynecologic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							OVARIAN-CANCER; COLON-CANCER; RECTUM; WOMEN; CARE	Background. Studies have suggested that women with previous diagnoses of gynecologic cancer (cervical, endometrial, or ovarian) have an increased risk for colorectal cancer. Objective: To quantify risk for colorectal cancer after gynecologic cancer, both overall and for subgroups defined by age at diagnosis, cancer stage at diagnosis, ethnicity, and duration of follow-up. Design: Retrospective cohort analysis of the Surveillance, Epidemiology, and End Results (SEER) program database from 1974 through 1995. Setting: U.S. cancer registry. Patients: 21 222 patients with cervical cancer, 51 680 patients with endometrial cancer, and 28 832 patients with ovarian cancer. Measurements: Standardized incidence ratios (SIRs) were calculated for each gynecologic cancer site and for subgroups to represent the relative risk for colorectal cancer in women with previously diagnosed gynecologic cancer compared with women without gynecologic cancer. Poisson regression methods adjusting simultaneously for all study variables were used to estimate relative risks for colorectal cancer across subgroups with each gynecologic cancer. Results: Overall, risk for colorectal cancer was elevated among women with previous ovarian cancer (SIR, 1.36 [95% CI, 1.21 to 1.53]). Risk was greatest in women who received a diagnosis before 50 years of age (SIR, 3.67 [CI, 2.74 to 4.80]) but was also elevated in women who received a diagnosis between 50 and 64 years of age (SIR, 1.52 [CI, 1.25 to 1.83]). The risk for colorectal cancer after endometrial cancer was also elevated substantially if endometrial cancer was diagnosed before the age of 50 (SIR, 3.39 [CI, 2.73 to 4.17]). No apparent risk elevation was associated with previous cervical cancer. Conclusions: Previous endometrial or ovarian cancer, particularly when diagnosed at an early age, increases subsequent risk for colorectal cancer. Greater emphasis on colorectal cancer screening in these populations may be necessary.	Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, Philadelphia, PA 19107 USA	Jefferson University	Weinberg, DS (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Div Gastroenterol & Hepatol, 480 Main Bldg,132 S 10th St, Philadelphia, PA 19107 USA.	david.weinberg@mail.tju.edu						BERGFELDT K, 1995, ACTA ONCOL, V34, P771, DOI 10.3109/02841869509127185; Boice J D Jr, 1985, Natl Cancer Inst Monogr, V68, P3; BOMAN B, 1999, P AM ASS CANC RES PH, V40, pA278; BRESLOW N, 1986, NATL CANC I MONOGR, V67, P149; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; CALLE EE, 1995, J NATL CANCER I, V87, P517, DOI 10.1093/jnci/87.7.517; Easton DF, 1996, INT J CANCER, V65, P284, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;284::AID-IJC2&gt;3.0.CO;2-W; Fontana SA, 1997, AM J PUBLIC HEALTH, V87, P1190, DOI 10.2105/AJPH.87.7.1190; HENDERSON B, 1997, CANC MED, V1, P277; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; Lynch HT, 1998, SEMIN ONCOL, V25, P265; McCredie M, 1997, CANCER EPIDEM BIOMAR, V6, P155; NELSON CL, 1993, GENET EPIDEMIOL, V10, P235, DOI 10.1002/gepi.1370100404; Potter J, 1996, PREVENTION EARLY DET; SANDLER RS, 1983, GASTROENTEROLOGY, V84, P51; *SEER CANC STAT RE, 1993, NIH PUBL; Travis LB, 1996, CANCER RES, V56, P1564; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; ZUMOFF B, 1982, CANCER RES, V42, P3289	20	42	42	1	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					189	193		10.7326/0003-4819-131-3-199908030-00005	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428735				2022-12-24	WOS:000081788700004
J	Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS				Jorgensen, HS; Nakayama, H; Kammersgaard, LP; Raaschou, HO; Olsen, TS			Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model	BRITISH MEDICAL JOURNAL			English	Article									Bispebjerg Hosp, Dept Neurol, DK-2400 Copenhagen NV, Denmark; Gentofte Hosp, Dept Neurol, DK-2900 Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Herlev & Gentofte Hospital	Jorgensen, HS (corresponding author), Bispebjerg Hosp, Dept Neurol, Bispebjerg Bakke 23, DK-2400 Copenhagen NV, Denmark.							Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; JORGENSEN HS, 1994, LANCET, V344, P156; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401	4	32	32	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					288	289		10.1136/bmj.319.7205.288	http://dx.doi.org/10.1136/bmj.319.7205.288			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426737	Bronze, Green Published			2022-12-24	WOS:000081909100021
J	Bisgaard, H; Moller, H				Bisgaard, H; Moller, H			Changes in risk of hospital readmission among asthmatic children in Denmark, 1978-93	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark; Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; Danmarks Grundforskningsfond	Bisgaard, H (corresponding author), Natl Univ Hosp, Rigshosp, Dept Paediat, DK-2100 Copenhagen, Denmark.	Bisgaard@RH.DK	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Moller, Henrik/0000-0001-8200-5929	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bisgaard H, 1997, PEDIATR PULM, P27; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Warner JO, 1998, PEDIATR PULM, V25, P1	4	25	25	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 24	1999	319	7204					229	230		10.1136/bmj.319.7204.229	http://dx.doi.org/10.1136/bmj.319.7204.229			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	221HB	10417085	Bronze, Green Published			2022-12-24	WOS:000081720300024
J	Barish, MA; Yucel, EK; Ferrucci, JT				Barish, MA; Yucel, EK; Ferrucci, JT			Current concepts - Magnetic resonance cholangiopancreatography	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; SPIN-ECHO TECHNIQUE; MR-CHOLANGIOPANCREATOGRAPHY; DUCT OBSTRUCTION; PANCREATIC DUCT; CHOLANGIOGRAPHY; CHOLEDOCHOLITHIASIS; DIAGNOSIS; ERCP		Boston Univ, Med Ctr, Dept Radiol, Boston, MA 02118 USA	Boston University	Barish, MA (corresponding author), Boston Univ, Med Ctr, Dept Radiol, 1 Boston Med Ctr Pl, Boston, MA 02118 USA.			Barish, Matthew/0000-0002-7521-8878				BARISH MA, 1995, AM J ROENTGENOL, V165, P295, DOI 10.2214/ajr.165.2.7618543; BARON RL, 1983, AM J ROENTGENOL, V140, P1173, DOI 10.2214/ajr.140.6.1173; BILBAO MK, 1976, GASTROENTEROLOGY, V70, P314; Bret PM, 1996, RADIOLOGY, V199, P99, DOI 10.1148/radiology.199.1.8633179; Chan YL, 1996, RADIOLOGY, V200, P85, DOI 10.1148/radiology.200.1.8657949; CRANLEY B, 1989, BRIT J SURG, V67, P869; CRONAN JJ, 1983, RADIOLOGY, V146, P467, DOI 10.1148/radiology.146.2.6849096; CUNNINGHAM JT, 1990, ADV THERAPEUTIC ENDO, P193; David V, 1998, AM J ROENTGENOL, V170, P1055, DOI 10.2214/ajr.170.4.9530058; DOWSETT JF, 1990, GUT, V31, P905, DOI 10.1136/gut.31.8.905; Ernst O, 1997, AM J ROENTGENOL, V168, P1115, DOI 10.2214/ajr.168.4.9124131; Ernst O, 1998, AM J ROENTGENOL, V171, P1027, DOI 10.2214/ajr.171.4.9762990; FORBES A, 1984, GUT, V25, P971, DOI 10.1136/gut.25.9.971; Fulcher AS, 1998, RADIOLOGY, V207, P21, DOI 10.1148/radiology.207.1.9530295; GROSS BH, 1983, RADIOLOGY, V146, P471, DOI 10.1148/radiology.146.2.6849097; Guibaud L, 1998, AM J ROENTGENOL, V170, P27, DOI 10.2214/ajr.170.1.9423592; GUIBAUD L, 1994, AM J ROENTGENOL, V163, P847, DOI 10.2214/ajr.163.4.8092021; GUIBAUD L, 1995, RADIOLOGY, V197, P109, DOI 10.1148/radiology.197.1.7568807; HAMILTON I, 1983, CLIN RADIOL, V34, P543, DOI 10.1016/S0009-9260(83)80156-1; JEFFREY RB, 1983, AM J ROENTGENOL, V140, P1179, DOI 10.2214/ajr.140.6.1179; Koito K, 1998, RADIOLOGY, V208, P231, DOI 10.1148/radiology.208.1.9646818; LAING FC, 1983, RADIOLOGY, V146, P475, DOI 10.1148/radiology.146.2.6849098; Lee MG, 1997, RADIOLOGY, V202, P663, DOI 10.1148/radiology.202.3.9051013; Lehman G A, 1995, Gastrointest Endosc Clin N Am, V5, P145; MACAULAY SE, 1995, RADIOLOGY, V196, P227, DOI 10.1148/radiology.196.1.7784572; Matos C, 1997, RADIOLOGY, V203, P435, DOI 10.1148/radiology.203.2.9114101; Onaya H, 1998, AM J ROENTGENOL, V171, P171, DOI 10.2214/ajr.171.1.9648782; OSNES M, 1986, GUT, V27, P1193, DOI 10.1136/gut.27.10.1193; PAVONE P, 1995, RADIOLOGY, V197, P312; PHILLIPS EH, 1994, SURG CLIN N AM, V74, P931, DOI 10.1016/S0039-6109(16)46395-4; Regan F, 1996, AM J ROENTGENOL, V167, P1441, DOI 10.2214/ajr.167.6.8956574; RIEGER R, 1995, GASTROINTEST ENDOSC, V42, P6, DOI 10.1016/S0016-5107(95)70235-0; SILVIS SE, 1985, BOCKUS GASTROENTEROL, V6, P3569; Soto JA, 1996, RADIOLOGY, V199, P91, DOI 10.1148/radiology.199.1.8633178; SOTO JA, 1995, RADIOLOGY, V196, P459, DOI 10.1148/radiology.196.2.7617861; Soto JA, 1996, GASTROENTEROLOGY, V110, P589, DOI 10.1053/gast.1996.v110.pm8566608; TAKEHARA Y, 1994, RADIOLOGY, V192, P73, DOI 10.1148/radiology.192.1.8208969; THOENI RF, 1990, GASTROINTEST RADIOL, V15, P291, DOI 10.1007/BF01888800; WALLNER BK, 1991, RADIOLOGY, V181, P805, DOI 10.1148/radiology.181.3.1947101; Yamataka A, 1997, J PEDIATR SURG, V32, P1560, DOI 10.1016/S0022-3468(97)90452-8	40	143	149	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					258	264		10.1056/NEJM199907223410407	http://dx.doi.org/10.1056/NEJM199907223410407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413739				2022-12-24	WOS:000081528800007
J	Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF				Steinbach, G; Ford, R; Glober, G; Sample, D; Hagemeister, FB; Lynch, PM; McLaughlin, PW; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A; Luthra, R; Manning, JT; Johnson, CM; Lahoti, S; Shen, Y; Lee, JE; Winn, RJ; Genta, RM; Graham, DY; Cabanillas, FF			Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue - An uncontrolled trial	ANNALS OF INTERNAL MEDICINE			English	Article						lymphoma, mucosa-associated lymphoid tissue; Helicobacter pylori; Helicobacter infections; antibiotics; neoplasm staging	HELICOBACTER-PYLORI INFECTION; MANTLE CELL LYMPHOMA; MALT LYMPHOMA; MALIGNANT-LYMPHOMA; CLASSIFICATION; REGRESSION; ERADICATION; THERAPY; SYSTEM; CURE	Background: Gastric lymphoma of mucosa-associated lymphoid tissue (MALT) is related to Helicobacter pylori infection and may depend on this infection for growth. Objective: To determine the response of gastric MALT lymphoma to antibiotic treatment. Design: Prospective, uncontrolled treatment trial. Setting: University hospital referral center and three collaborating university and community hospitals. Patients: 34 patients with stage I or stage II N1 gastric MALT lymphoma. Intervention: Two of three oral antibiotic regimens-1) amoxicillin, 750 mg three times daily, and clarithromycin, 500 mg three times daily; 2) tetracycline, 500 mg four times daily, and clarithromycin, 500 mg three times daily; or 3) tetracycline, 500 mg four times daily, and metronidazole, 500 mg three times daily-were administered sequentially (usually in the order written) for 21 days at baseline and at 8 weeks, along with a proton-pump inhibitor (lansoprazole or omeprazole) and bismuth subsalicylate. Measurements: Complete remission was defined as the absence of histopathologic evidence of lymphoma on endoscopic biopsy. Partial remission was defined as a reduction in endoscopic tumor stage or 50% reduction in the size of large tumors. Results: 34 patients were followed for a mean (+/-SD) of 41 +/- 16 months (range, 18 to 70 months) after antibiotic treatment. Of 28 H. pylori-positive patients, 14 (50% [95% CI, 31% to 69%]) achieved complete remission, 8 (29%) achieved partial remission (treatment eventually failed in 4 of the 8), and 10 (36% [CI, 19% to 56%]) did not respond to treatment. Treatment failed in all 6 (100% [CI, 54% to 100%]) H. pylori-negative patients. Patients with endoscopic appearance of gastritis (stage I T1 disease) were most likely to achieve complete remission within 18 months. Tumors in the distal stomach were associated with more favorable response than tumors in the proximal stomach. Conclusions: A subset of H. pylori-positive gastric MALT lymphomas, including infiltrative tumors, may respond to antibiotics. The likelihood of: early complete remission seems to be greatest for superficial and distal tumors.	Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Houston, TX 77030 USA; Vet Affairs Med Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Steinbach, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol & Digest Dis, Box 78,1515 Holcombe Blvd, Houston, TX 77030 USA.	gsteihb@aol.com	Graham, David/AAL-2165-2021	Shen, Yu/0000-0002-3899-7868; Steinbach, Gideon/0000-0001-7597-0544; Cabanillas, Fernando/0000-0001-9234-7893	NCI NIH HHS [CA-16672, R01 CA67540-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA067540, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAYERDORFFER E, 1995, LANCET, V345, P1591, DOI 10.1016/S0140-6736(95)90113-2; BLACKLEDGE G, 1979, CLIN ONCOL, V5, P209; Blum AL, 1998, NEW ENGL J MED, V339, P1875, DOI 10.1056/NEJM199812243392602; CHAN JKC, 1990, AM J PATHOL, V136, P1153; COGLIATTI SB, 1991, GASTROENTEROLOGY, V101, P1159, DOI 10.1016/0016-5085(91)90063-Q; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOGLIONI C, 1992, LANCET, V339, P834, DOI 10.1016/0140-6736(92)90280-G; GENTA RM, 1993, HUM PATHOL, V24, P577, DOI 10.1016/0046-8177(93)90235-9; GREINER A, 1994, LAB INVEST, V70, P572; HARRIS NL, 1994, BLOOD, V84, P1361; HUSSELL T, 1993, LANCET, V342, P571, DOI 10.1016/0140-6736(93)91408-E; ISAACSON P, 1983, CANCER, V52, P1410, DOI 10.1002/1097-0142(19831015)52:8<1410::AID-CNCR2820520813>3.0.CO;2-3; ISAACSON PG, 1987, HISTOPATHOLOGY, V11, P445, DOI 10.1111/j.1365-2559.1987.tb02654.x; KENNEDY BJ, 1987, SCAND J GASTROENTERO, V22, P11, DOI 10.3109/00365528709091007; LUTHRA R, 1995, DIAGN MOL PATHOL, V4, P4, DOI 10.1097/00019606-199503000-00003; McLaughlin P, 1996, ANN ONCOL, V7, P211; MONTALBAN C, 1995, ANN ONCOL, V6, P355, DOI 10.1093/oxfordjournals.annonc.a059184; MOUTSOPOULOS HM, 1994, CLIN IMMUNOL IMMUNOP, V72, P162, DOI 10.1006/clin.1994.1123; MUSSHOFF K, 1977, STRAHLENTHER ONKOL, V153, P218; NAKAMURA S, 1995, CANCER, V76, P1313, DOI 10.1002/1097-0142(19951015)76:8<1313::AID-CNCR2820760804>3.0.CO;2-1; NEGRINI R, 1991, GASTROENTEROLOGY, V101, P437, DOI 10.1016/0016-5085(91)90023-E; Neubauer A, 1997, JNCI-J NATL CANCER I, V89, P1350, DOI 10.1093/jnci/89.18.1350; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; RADASZKIEWICZ T, 1992, GASTROENTEROLOGY, V102, P1628, DOI 10.1016/0016-5085(92)91723-H; ROGGERO E, 1995, ANN INTERN MED, V122, P767, DOI 10.7326/0003-4819-122-10-199505150-00006; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; Sackmann M, 1997, GASTROENTEROLOGY, V113, P1087, DOI 10.1053/gast.1997.v113.pm9322502; SOBIN LH, 1988, CANCER, V61, P2310, DOI 10.1002/1097-0142(19880601)61:11<2310::AID-CNCR2820611127>3.0.CO;2-X; STEINBACH G, 1995, GASTROENTEROLOGY, V108, pA541; WEBER DM, 1994, GASTROENTEROLOGY, V107, P1835, DOI 10.1016/0016-5085(94)90828-1; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; WYATT JI, 1988, SCAND J GASTROENTERO, V23, P44, DOI 10.3109/00365528809091712	33	170	178	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					88	+		10.7326/0003-4819-131-2-199907200-00003	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419446				2022-12-24	WOS:000081509700002
J	Duff, SE; Wong, CKM; May, RE				Duff, SE; Wong, CKM; May, RE			Surgeons' and occupational health departments' awareness of guidelines on post-exposure prophylaxis for staff exposed to HIV: telephone survey	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CARE WORKERS; BLOOD; RISK		Frenchay Hosp, Dept Surg, Bristol BS16 1LE, Avon, England		Duff, SE (corresponding author), Royal Hampshire Cty Hosp, Winchester & Eastleigh Healthcare, Dept Surg, Winchester SO22 5DG, Hants, England.		Duff, Sarah E/AAW-3795-2021					Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; *DEP HLTH, 1997, GUID POST EXP PROPH; GERBERDING JL, 1994, J INFECT DIS, V170, P1410, DOI 10.1093/infdis/170.6.1410; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; TOKARS JI, 1993, ANN INTERN MED, V118, P913, DOI 10.7326/0003-4819-118-12-199306150-00001	5	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					162	163		10.1136/bmj.319.7203.162	http://dx.doi.org/10.1136/bmj.319.7203.162			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406752	Green Published, Bronze			2022-12-24	WOS:000081619300023
J	Morgan, K; Prothero, D; Frankel, S				Morgan, K; Prothero, D; Frankel, S			The rise in emergency admissions - crisis or artefact? Temporal analysis of health services data	BRITISH MEDICAL JOURNAL			English	Article									Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Avon Hlth Author, Bristol BS2 8EE, Avon, England	University of Bristol	Frankel, S (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.							Blatchford O, 1997, BRIT MED J, V315, P1322, DOI 10.1136/bmj.315.7119.1322; Capewell S, 1996, BRIT MED J, V312, P991; COAST J, 1995, J EPIDEMIOL COMMUN H, V49, P194, DOI 10.1136/jech.49.2.194; FRANKEL S, 1991, LANCET, V337, P1588, DOI 10.1016/0140-6736(91)93276-F; Kendrick S, 1996, Health Bull (Edinb), V54, P169	5	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					158	159		10.1136/bmj.319.7203.158	http://dx.doi.org/10.1136/bmj.319.7203.158			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406749	Green Published, Bronze			2022-12-24	WOS:000081619300020
J	Zheng, BH; Larkin, DW; Albrecht, U; Sun, ZS; Sage, M; Eichele, G; Lee, CC; Bradley, A				Zheng, BH; Larkin, DW; Albrecht, U; Sun, ZS; Sage, M; Eichele, G; Lee, CC; Bradley, A			The mPer2 gene encodes a functional component of the mammalian circadian clock	NATURE			English	Article							DROSOPHILA PERIOD GENE; SUPRACHIASMATIC NUCLEUS; TRANSCRIPTION; LIGHT; RHYTHMS; TIMELESS; HOMOLOG; PAS; REGULATORS; EXPRESSION	Circadian rhythms are driven by endogenous biological clocks that regulate many biochemical, physiological and behavioural professes in a wide range of life forms'. In mammals, there is a master circadian clock in the suprachiasmatic nucleus of the anterior hypothalamus. Three putative mammalian homologues (mPer1, mPer2 and mPer3) of the Drosophila circadian clock gene period (per) have been identified(2-8). The mPer genes share a conserved PAS domain (a dimerization domain found in Per, Amt and Sim) and show a circadian expression pattern in the suprachiasmatic nucleus. To assess the in vivo function of mPer2, we generated and characterized a deletion mutation in the PAS domain of the mouse mPer2 gene. Here we show that mice homozygous for this mutation display a shorter circadian period followed by a loss of circadian rhythmicity in constant darkness. The mutation also diminishes the oscillating expression of both mPer1 and mPer2 in the suprachiasmatic nucleus, indicating that mPer2 may regulate mPer1 in vivo. These data provide evidence that an mPer gene functions in the circadian clock, and define mPer2 as a component of the mammalian circadian oscillator.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.	ching@bcm.tmc.edu	Albrecht, Urs/A-9831-2011; Sun, Zhongsheng/AAS-4883-2020	Albrecht, Urs/0000-0002-0663-8676; Sun, Zhongsheng/0000-0002-7640-5026; Bradley, Allan/0000-0002-2349-8839				Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Aschoff J, 1981, HDB BEHAVIORAL NEURO, P3, DOI DOI 10.1007/978-1-4615-6552-9_1; Bae K, 1998, MOL CELL BIOL, V18, P6142, DOI 10.1128/MCB.18.10.6142; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Bracewell R. N., 1986, HARTLEY TRANSFORM; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; Dowse H.B., 1987, Journal of Biological Rhythms, V2, P65, DOI 10.1177/074873048700200106; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; IBUKA N, 1977, BRAIN RES, V122, P33, DOI 10.1016/0006-8993(77)90660-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RAMIREZSOLIS R, 1993, METHOD ENZYMOL, V225, P855; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Shearman LP, 1997, NEURON, V19, P1261, DOI 10.1016/S0896-6273(00)80417-1; SOKOLOVE PG, 1978, J THEOR BIOL, V72, P131, DOI 10.1016/0022-5193(78)90022-X; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Takumi T, 1998, EMBO J, V17, P4753, DOI 10.1093/emboj/17.16.4753; Takumi T, 1998, GENES CELLS, V3, P167, DOI 10.1046/j.1365-2443.1998.00178.x; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	30	563	577	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					169	173		10.1038/22118	http://dx.doi.org/10.1038/22118			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408444				2022-12-24	WOS:000081324900055
J	Dormann, P; Balbo, I; Benning, C				Dormann, P; Balbo, I; Benning, C			Arabidopsis galactolipid biosynthesis and lipid trafficking mediated by DGD1	SCIENCE			English	Article							CHLOROPLAST ENVELOPES; MONOGALACTOSYLDIACYLGLYCEROL SYNTHASE; MUTANT DEFICIENT; OUTER-MEMBRANE; THALIANA; DIGALACTOSYLDIACYLGLYCEROL; PLANTS; GALACTOSYLTRANSFERASE; DIACYLGLYCEROL; CLONING	The photosynthetic apparatus in plant cells is associated with membranes of the thylakoids within the chloroplast and is embedded into a highly specialized Lipid matrix. Diacylglycerol galactolipids are common in thylakoid membranes but are excluded from all others. Isolation of the gene DGD1, encoding a galactosyltransferase-like protein, now provides insights into assembly of the thylakoid Lipid matrix and subcellular Lipid trafficking in Arabidopsis thaliana.	Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Max Planck Inst Mol Pflanzenphysiol, D-14476 Golm, Germany	Michigan State University; Max Planck Society	Benning, C (corresponding author), Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA.	benning@pilot.msu.edu	Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667				ANDERSSON L, 1995, J LIPID RES, V36, P1392; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1990, NUCLEIC ACIDS RES, V18, P203, DOI 10.1093/nar/18.1.203; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BLOCK MA, 1983, J BIOL CHEM, V258, P3281; BROWSE J, 1986, BIOCHEM J, V235, P25, DOI 10.1042/bj2350025; BROWSE J, 1991, ANNU REV PLANT PHYS, V42, P467, DOI 10.1146/annurev.pp.42.060191.002343; BROWSE J, 1994, ARABIDOPSIS, P881; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; Chen LJ, 1998, PLANT J, V16, P33, DOI 10.1046/j.1365-313x.1998.00270.x; CLINE K, 1983, PLANT PHYSIOL, V71, P366, DOI 10.1104/pp.71.2.366; DORMANN P, 1995, PLANT CELL, V7, P1801, DOI 10.1105/tpc.7.11.1801; DORNE AJ, 1982, FEBS LETT, V145, P30, DOI 10.1016/0014-5793(82)81200-3; Hartel H, 1998, PLANT PHYSIOL BIOCH, V36, P407, DOI 10.1016/S0981-9428(98)80204-0; Hartel H, 1997, PLANT PHYSIOL, V115, P1175, DOI 10.1104/pp.115.3.1175; HEEMSKERK JWM, 1990, PLANT PHYSIOL, V93, P1286, DOI 10.1104/pp.93.4.1286; HEINZ E, 1983, PLANT PHYSIOL, V72, P273, DOI 10.1104/pp.72.2.273; Joyard J, 1998, PLANT PHYSIOL, V118, P715, DOI 10.1104/pp.118.3.715; KUNST L, 1988, P NATL ACAD SCI USA, V85, P4143, DOI 10.1073/pnas.85.12.4143; MARECHAL E, 1994, J BIOL CHEM, V269, P5788; MEYER K, 1996, GENOME MAPPING PLANT, P137; Mongrand S, 1998, PHYTOCHEMISTRY, V49, P1049, DOI 10.1016/S0031-9422(98)00243-X; Mozo T, 1998, MOL GEN GENET, V258, P562, DOI 10.1007/s004380050769; Ohlsson L, 1998, J NUTR, V128, P239, DOI 10.1093/jn/128.2.239; Reifarth F, 1997, BIOCHEMISTRY-US, V36, P11769, DOI 10.1021/bi9709654; Shimojima M, 1997, P NATL ACAD SCI USA, V94, P333, DOI 10.1073/pnas.94.1.333; TEUCHER T, 1991, PLANTA, V184, P319, DOI 10.1007/BF00195332; Uwer U, 1998, PLANT CELL, V10, P1277, DOI 10.1105/tpc.10.8.1277; VANBESOUW A, 1978, BIOCHIM BIOPHYS ACTA, V529, P44, DOI 10.1016/0005-2760(78)90102-9; VONSCHAEVEN A, 1989, THESIS FREIE U BERLI	32	162	168	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2181	2184		10.1126/science.284.5423.2181	http://dx.doi.org/10.1126/science.284.5423.2181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381884				2022-12-24	WOS:000081099300053
J	Langst, G; Bonte, EJ; Corona, DFV; Becker, PB				Langst, G; Bonte, EJ; Corona, DFV; Becker, PB			Nucleosome movement by CHRAC and ISWI without disruption or trans-displacement of the histone octamer	CELL			English	Article							REMODELING FACTOR; RNA-POLYMERASE; IN-VITRO; CHROMATIN ACCESSIBILITY; DNA; TRANSCRIPTION; COMPLEX; PROTEIN; YEAST; MOBILITY	The chromatin accessibility complex (CHRAC) belongs to the class of nucleosome remodeling factors that increase the accessibility of nucleosomal DNA in an ATP-dependent manner. We found that CHRAC induces movements of intact histone octamers to neighboring DNA segments without facilitating their displacement to competing DNA or histone chaperones in trans. CHRAC-induced energy-dependent nucleosome sliding may, in principle, explain nucleosome remodeling, nucleosome positioning, and nucleosome spacing reactions known to be catalyzed by CHRAC. The catalytic core of CHRAC, the ATPase ISWI, also mobilized nucleosomes at the expense of energy. However, the directionality of the CHRAC- and ISWI-induced nucleosome movements differed drastically, indicating that the geometry of the native complex modulates the activity of its catalytic core.	European Mol Biol Lab, Gene Express Programme, D-69117 Heidelberg, Germany	European Molecular Biology Laboratory (EMBL)	Becker, PB (corresponding author), European Mol Biol Lab, Gene Express Programme, Meyerhofstr 1, D-69117 Heidelberg, Germany.	becker@embl-heidelberg.de	Corona, Davide F.V./H-8467-2012; Längst, Gernot/G-5287-2015	Längst, Gernot/0000-0002-8232-1179; Becker, Peter/0000-0001-7186-0372				Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; BECKER PB, 1994, METHOD CELL BIOL, V44, P207, DOI 10.1016/S0091-679X(08)60915-2; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CHEN H, 1994, EMBO J, V13, P380, DOI 10.1002/j.1460-2075.1994.tb06272.x; Corona DFV, 1999, MOL CELL, V3, P239, DOI 10.1016/S1097-2765(00)80314-7; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ELFRING LK, 1994, MOL CELL BIOL, V14, P2225, DOI 10.1128/MCB.14.4.2225; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; Gdula DA, 1998, GENE DEV, V12, P3206, DOI 10.1101/gad.12.20.3206; Grigoriev M, 1998, MOL CELL, V2, P373, DOI 10.1016/S1097-2765(00)80281-6; Hamiche A, 1999, CELL, V97, P833, DOI 10.1016/S0092-8674(00)80796-5; Imbalzano AN, 1996, J BIOL CHEM, V271, P20726, DOI 10.1074/jbc.271.34.20726; Imbalzano AN, 1998, CRIT REV EUKAR GENE, V8, P225, DOI 10.1615/CritRevEukarGeneExpr.v8.i3-4.10; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Langst G, 1997, NUCLEIC ACIDS RES, V25, P511, DOI 10.1093/nar/25.3.511; Langst G, 1997, EMBO J, V16, P760, DOI 10.1093/emboj/16.4.760; Langst G, 1998, EMBO J, V17, P3135, DOI 10.1093/emboj/17.11.3135; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; LINXWEILER W, 1984, NUCLEIC ACIDS RES, V12, P9395, DOI 10.1093/nar/12.24.9395; Lorch Y, 1999, CELL, V96, P389, DOI 10.1016/S0092-8674(00)80551-6; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Marilley M, 1996, NUCLEIC ACIDS RES, V24, P2204, DOI 10.1093/nar/24.12.2204; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Pazin MJ, 1997, SCIENCE, V276, P809, DOI 10.1126/science.276.5313.809; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; RAMSPERGER U, 1995, EMBO J, V14, P3215, DOI 10.1002/j.1460-2075.1995.tb07324.x; ROTH SY, 1992, GENE DEV, V6, P411, DOI 10.1101/gad.6.3.411; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; STEIN A, 1979, P NATL ACAD SCI USA, V76, P5000, DOI 10.1073/pnas.76.10.5000; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; THOMA F, 1992, BIOCHIM BIOPHYS ACTA, V1130, P1, DOI 10.1016/0167-4781(92)90455-9; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Tsukiyama T, 1999, GENE DEV, V13, P686, DOI 10.1101/gad.13.6.686; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; VANHOLDE KE, 1985, STRUCTURE FUNCTION G; Varga-Weisz PD, 1999, METHOD ENZYMOL, V304, P742; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; WALL G, 1995, EMBO J, V14, P1727, DOI 10.1002/j.1460-2075.1995.tb07162.x; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Widom J, 1999, METH MOL B, V119, P61; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0	52	288	295	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					843	852		10.1016/S0092-8674(00)80797-7	http://dx.doi.org/10.1016/S0092-8674(00)80797-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399913	hybrid			2022-12-24	WOS:000081162800006
J	Clarkson, MJ; Wells, JRE; Gibson, F; Saint, R; Tremethick, DJ				Clarkson, MJ; Wells, JRE; Gibson, F; Saint, R; Tremethick, DJ			Regions of variant histone His2AvD required for Drosophila development	NATURE			English	Article							NUCLEOSOME	One way in which a distinct chromosomal domain could be established to carry out a specialized function is by the localized incorporation of specific histone variants into nucleosomes. H2AZ, one such variant of the histone protein H2A, is required for the survival of Drosophila melanogaster(1), Tetrahymena thermophila(2) and mice (R. Faast et al., in preparation). To search for the unique features of Drosophila H2AZ (His2AvD, also referred to as H2AvD) that are required for its essential function, we have performed amino-acid swap experiments in which residues unique to Drosophila His2AvD were replaced with equivalently positioned Drosophila H2A.1 residues. Mutated His2AvD genes encoding modified versions of this histone were transformed into Drosophila and tested for their ability to rescue null-mutant lethality. We show that the unique feature of His2AvD does not reside in its histone fold but in its carboxy-terminal domain. This C-terminal region maps to a short alpha-helix in H2A that is buried deep inside the nuceleosome core.	Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia; Univ Adelaide, Dept Biochem, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Genet, Adelaide, SA 5005, Australia	Australian National University; John Curtin School of Medical Research; University of Adelaide; University of Adelaide	Tremethick, DJ (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, POB 334, Canberra, ACT 2601, Australia.		Saint, Robert/A-4190-2008	Saint, Robert/0000-0002-7989-6043; Tremethick, David/0000-0001-5274-8078				HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Liu XW, 1996, MOL CELL BIOL, V16, P4305; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Ng KW, 1997, EMBO J, V16, P2072, DOI 10.1093/emboj/16.8.2072; PETERSON CL, 1995, TRENDS BIOCHEM SCI, V20, P143, DOI 10.1016/S0968-0004(00)88990-2; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593	8	158	163	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					694	697		10.1038/21436	http://dx.doi.org/10.1038/21436			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385122				2022-12-24	WOS:000080932800062
J	Das, A; Gilbert, CD				Das, A; Gilbert, CD			Topography of contextual modulations mediated by short-range interactions in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; FUNCTIONALLY CHARACTERIZED SITES; CROSS-CORRELATION ANALYSIS; HORIZONTAL CONNECTIONS; ORIENTATION SELECTIVITY; DIRECTION SELECTIVITY; INTRINSIC CONNECTIONS; CORTICAL DYNAMICS; CAT; SENSITIVITY	Neurons in primary visual cortex (V1) respond differently to a simple visual element presented in isolation from when it is embedded within a complex image. This difference, a specific modulation by surrounding elements in the image, is mediated by short- and long-range connections within V1 and by feedback from other areas. Here we study the role of short-range connections in this process, and relate it to the layout of local inhomogeneities in the cortical maps of orientation and space. By measuring correlation between neuron pairs located in optically imaged maps of V1 orientation columns we show that the strength of local connections between cells is a graded function of lateral separation across cortex, largely radially symmetrical and relatively independent of orientation preferences. We then show the contextual influence of flanking visual elements on neuronal responses varies systematically with a neuron's position within the cortical orientation map. The strength of this contextual influence on a neuron can be predicted from a model of local connections based on simple overlap with particular features of the orientation map. This Indicates that local Intracortical circuitry could endow neurons with a graded specialization for processing angular visual features such as corners and T functions, and this specialization could have its own functional cortical map, linked with the orientation map.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Gilbert, CD (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.	gilbert@rockvax.rockefeller.edu						AERTSEN AMHJ, 1985, BRAIN RES, V340, P341, DOI 10.1016/0006-8993(85)90931-X; Bauer U, 1999, VISION RES, V39, P613, DOI 10.1016/S0042-6989(98)00172-2; BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 1997, J NEUROSCI, V17, P2112; CRIST RE, 1997, ABSTR SOC NEUROSCI, V23, P1543; Crook JM, 1997, VISUAL NEUROSCI, V14, P141, DOI 10.1017/S095252380000883X; Crook JM, 1998, EUR J NEUROSCI, V10, P2056, DOI 10.1046/j.1460-9568.1998.00218.x; DAS A, 1995, J NEUROPHYSIOL, V74, P779, DOI 10.1152/jn.1995.74.2.779; Das A, 1997, NATURE, V387, P594, DOI 10.1038/42461; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Gawne TJ, 1996, CEREB CORTEX, V6, P482, DOI 10.1093/cercor/6.3.482; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1979, NATURE, V280, P120, DOI 10.1038/280120a0; GILBERT CD, 1992, NEURON, V9, P1, DOI 10.1016/0896-6273(92)90215-Y; Gilbert CD, 1998, PHYSIOL REV, V78, P467, DOI 10.1152/physrev.1998.78.2.467; GILBERT CD, 1983, J NEUROSCI, V3, P1116; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HATA Y, 1991, J PHYSIOL-LONDON, V441, P593, DOI 10.1113/jphysiol.1991.sp018769; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; HUBENER M, 1992, J COMP NEUROL, V324, P67, DOI 10.1002/cne.903240106; Ito M, 1999, NEURON, V22, P593, DOI 10.1016/S0896-6273(00)80713-8; Ito M, 1998, NEURON, V20, P1191, DOI 10.1016/S0896-6273(00)80499-7; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KATZ LC, 1989, J NEUROSCI, V9, P1389; KISVARDAY ZF, 1986, EXP BRAIN RES, V64, P541, DOI 10.1007/BF00340492; MALACH R, 1993, P NATL ACAD SCI USA, V90, P10469, DOI 10.1073/pnas.90.22.10469; MALACH R, 1994, TRENDS NEUROSCI, V17, P101, DOI 10.1016/0166-2236(94)90113-9; MALACH R, 1992, J COMP NEUROL, V315, P303, DOI 10.1002/cne.903150306; MCGUIRE BA, 1991, J COMP NEUROL, V305, P370, DOI 10.1002/cne.903050303; MELSSEN WJ, 1987, BIOL CYBERN, V57, P403, DOI 10.1007/BF00354985; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PERKEL DH, 1967, BIOPHYS J, V7, P391, DOI 10.1016/S0006-3495(67)86596-2; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; Shevelev IA, 1998, NEUROSCIENCE, V84, P713, DOI 10.1016/S0306-4522(97)00393-X; SHEVELEV IA, 1995, NEUROSCIENCE, V69, P51, DOI 10.1016/0306-4522(95)00188-O; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; TSO DY, 1989, J NEUROSCI, V9, P2432; ULLMAN S, 1990, COLD SH Q B, V55, P889; Wertheimer M., 1938, SOURCE BOOK GESTALT, P71, DOI 10.1037/11496-005	45	238	241	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 17	1999	399	6737					655	661		10.1038/21371	http://dx.doi.org/10.1038/21371			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385116				2022-12-24	WOS:000080932800050
J	Fambrough, D; McClure, K; Kazlauskas, A; Lander, ES				Fambrough, D; McClure, K; Kazlauskas, A; Lander, ES			Diverse signaling pathways activated by growth factor receptors induce broadly overlapping, rather than independent, sets of genes	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR-BETA-RECEPTOR; PHOSPHORYLATION SITES; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; PDGF RECEPTOR; AUTOPHOSPHORYLATION SITES; SERINE PHOSPHORYLATION; TRANSCRIPTION FACTOR; INTERFERON-GAMMA	We sought to explore the relationship between receptor tyrosine kinase (RTK) activated signaling pathways and the transcriptional induction of immediate early genes (IEGs). Using global expression monitoring, we identified 66 fibroblast IEGs induced by platelet-derived growth factor beta receptor (PDGFR beta) signaling. Mutant receptors lacking binding sites for activation of the PLC gamma, PI3K, SHP2, and RasGAP pathways still retain partial ability to induce 64 of these IEGs. Removal of the Grb2-binding site further broadly reduces induction. These results suggest that the diverse pathways exert broadly overlapping effects on IEG induction. Interestingly, a mutant receptor that restores the RasGAP-binding site promotes induction of an independent group of genes, normally induced by interferons. Finally, we compare the PDGFR beta and fibroblast growth factor receptor 1; each induces essentially identical IEGs in fibroblasts.	Schepens Eye Res Inst, Boston, MA 02114 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Schepens Eye Research Institute; Massachusetts Institute of Technology (MIT)	Lander, ES (corresponding author), Whitehead Inst Biomed Res, Cambridge Ctr 9, Cambridge, MA 02142 USA.	lander@wi.mit.edu						ARVIDSSON AK, 1994, MOL CELL BIOL, V14, P6715, DOI 10.1128/MCB.14.10.6715; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DeMali KA, 1997, J BIOL CHEM, V272, P9011; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Freeman M, 1996, CELL, V87, P651, DOI 10.1016/S0092-8674(00)81385-9; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; Iyer VR, 1999, SCIENCE, V283, P83, DOI 10.1126/science.283.5398.83; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KASHISHIAN A, 1993, MOL BIOL CELL, V4, P49, DOI 10.1091/mbc.4.1.49; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM L, 1995, MOL CELL BIOL, V15, P4553; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Montmayeur JP, 1997, J BIOL CHEM, V272, P32670, DOI 10.1074/jbc.272.51.32670; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Price MA, 1996, PHILOS T ROY SOC B, V351, P551, DOI 10.1098/rstb.1996.0054; Rani CSS, 1997, J BIOL CHEM, V272, P10777; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; ROLLINS BJ, 1989, ADV CANCER RES, V53, P1; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; STJOHNSTON D, 1992, CELL, V68, P201; Symes K, 1996, P NATL ACAD SCI USA, V93, P9641, DOI 10.1073/pnas.93.18.9641; TAMAYO P, 1999, IN PRESS P NATL ACAD; TAVERSE S, 1994, CURR BIOL, V4, P694; UENO H, 1993, J BIOL CHEM, V268, P22814; Vaillancourt RR, 1996, ONCOGENE, V13, P151; Valgeirsdottir S, 1998, ONCOGENE, V16, P505, DOI 10.1038/sj.onc.1201555; VALIUS M, 1995, MOL CELL BIOL, V15, P3058; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; WRIGHT TM, 1991, J EXP MED, V173, P417, DOI 10.1084/jem.173.2.417; Yamamoto H, 1996, EXP CELL RES, V222, P125, DOI 10.1006/excr.1996.0016; Yokote K, 1996, J BIOL CHEM, V271, P30942, DOI 10.1074/jbc.271.48.30942; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618; ZUBIAUR M, 1995, J BIOL CHEM, V270, P17221, DOI 10.1074/jbc.270.29.17221	59	381	395	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					727	741		10.1016/S0092-8674(00)80785-0	http://dx.doi.org/10.1016/S0092-8674(00)80785-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380925	Bronze			2022-12-24	WOS:000080886300011
J	Wu, Q; Maniatis, T				Wu, Q; Maniatis, T			A striking organization of a large family of human neural cadherin-like cell adhesion genes	CELL			English	Article							CLASSIC CADHERINS; STRUCTURAL BASIS; NERVOUS-SYSTEM; N-CADHERIN; EXPRESSION; SUPERFAMILY; MOLECULES; PROTEIN; PROTOCADHERINS; COMPLEX	We have identified 52 novel human cadherin-like genes organized into three closely linked clusters. Comparison of the genomic DNA sequences with those of representative cDNAs reveals a striking genomic organization similar to that of immunoglobulin and T cell receptor gene clusters. The N-terminal extracellular and transmembrane domains of each cadherin protein are encoded by a distinct and unusually large exon. These exons are organized in a tandem array. By contrast, the C-terminal cytoplasmic domain of each protein is identical and is encoded by three small exons located downstream from the cluster of N-terminal exons. This unusual organization has interesting implications regarding the molecular code required to establish complex networks of neuronal connections in the brain and the mechanisms of cell-specific cadherin-like gene expression.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Maniatis, T (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.		Wu, Qiang/A-6751-2009	Wu, Qiang/0000-0003-3841-3591	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042231] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Arndt K, 1998, MOL CELL NEUROSCI, V10, P211, DOI 10.1006/mcne.1998.0665; Black DL, 1998, NEURON, V20, P165, DOI 10.1016/S0896-6273(00)80444-4; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; Bradley RS, 1998, CURR BIOL, V8, P325, DOI 10.1016/S0960-9822(98)70132-0; BRUZIK JP, 1995, P NATL ACAD SCI USA, V92, P7056, DOI 10.1073/pnas.92.15.7056; Caudevilla C, 1998, P NATL ACAD SCI USA, V95, P12185, DOI 10.1073/pnas.95.21.12185; CHIARA MD, 1995, NATURE, V375, P510, DOI 10.1038/375510a0; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Chun J, 1999, NEURON, V22, P7, DOI 10.1016/S0896-6273(00)80671-6; Colman DR, 1997, MOL CELL NEUROSCI, V10, P1, DOI 10.1006/mcne.1997.0648; Fannon AM, 1996, NEURON, V17, P423, DOI 10.1016/S0896-6273(00)80175-0; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hagler DJ, 1998, NEURON, V20, P1059, DOI 10.1016/S0896-6273(00)80486-9; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; Hirano S, 1999, J NEUROSCI, V19, P995; Inoue A, 1997, SCIENCE, V276, P1428, DOI 10.1126/science.276.5317.1428; Iwai Y, 1997, NEURON, V19, P77, DOI 10.1016/S0896-6273(00)80349-9; Kohmura N, 1998, NEURON, V20, P1137, DOI 10.1016/S0896-6273(00)80495-X; MAHONEY PA, 1991, CELL, V67, P853, DOI 10.1016/0092-8674(91)90359-7; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Matsunami H, 1995, DEV BIOL, V172, P466, DOI 10.1006/dbio.1995.8029; MISHKEVICH F, 1998, MOL CELL NEUROSCI, V12, P240; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Nagase T, 1998, DNA Res, V5, P31, DOI 10.1093/dnares/5.1.31; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OBATA S, 1995, J CELL SCI, V108, P3765; Obata S, 1998, CELL ADHES COMMUN, V6, P323, DOI 10.3109/15419069809010791; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; SAGO H, 1995, GENOMICS, V29, P631, DOI 10.1006/geno.1995.9956; Sanes JR, 1999, CURR OPIN NEUROBIOL, V9, P79, DOI 10.1016/S0959-4388(99)80010-5; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Serafini T, 1997, TRENDS NEUROSCI, V20, P322; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1998, CURR OPIN NEUROBIOL, V8, P593, DOI 10.1016/S0959-4388(98)80086-X; Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467; Suzuki SC, 1997, MOL CELL NEUROSCI, V9, P433, DOI 10.1006/mcne.1997.0626; Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097-4644(19960616)61:4<531::AID-JCB6>3.0.CO;2-P; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tang LX, 1998, NEURON, V20, P1165, DOI 10.1016/S0896-6273(00)80497-3; Uchida N, 1996, J CELL BIOL, V135, P767, DOI 10.1083/jcb.135.3.767; Uemura T, 1998, CELL, V93, P1095, DOI 10.1016/S0092-8674(00)81452-X; YANCOPOULOS GD, 1986, ANNU REV IMMUNOL, V4, P339, DOI 10.1146/annurev.iy.04.040186.002011; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	55	545	620	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					779	790		10.1016/S0092-8674(00)80789-8	http://dx.doi.org/10.1016/S0092-8674(00)80789-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380929	Bronze			2022-12-24	WOS:000080886300015
J	Deuerling, E; Schulze-Specking, A; Tomoyasu, T; Mogk, A; Bukau, B				Deuerling, E; Schulze-Specking, A; Tomoyasu, T; Mogk, A; Bukau, B			Trigger factor and DnaK cooperate in folding of newly synthesized proteins	NATURE			English	Article							HEAT-SHOCK GENE; ESCHERICHIA-COLI; RECOGNITION; CHAPERONES; ISOMERASE; MUTATIONS	The role of molecular chaperones in assisting the folding of newly synthesized proteins in the cytosol is poorly understood. In Escherichia coli, GroEL assists folding of only a minority of proteins(1) and the Hsp70 homologue DnaK is not essential for protein folding or cell viability at intermediate growth temperatures(2). The major protein associated with nascent polypeptides is ribosome-bound trigger factor(3,4), which displays chaperone and prolyl isomerase activities in vitro(3,5,6). Here we show that Delta tig::kan mutants lacking trigger factor have no defects in growth or protein folding. However, combined Delta tig::kan and Delta dnaK mutations cause synthetic lethality. Depletion of DnaK in the Delta tig::kan mutant results in massive aggregation of cytosolic proteins. In Delta tig::kan cells, an increased amount of newly synthesized proteins associated transiently with DnaK. These findings show in vivo activity for a ribosome-associated chaperone, trigger factor, in general protein folding, and functional cooperation of this protein with a cytosolic Hsp70. Trigger factor and DnaK cooperate to promote proper folding of a variety of E. coli proteins, but neither is essential for folding and viability at intermediate growth temperatures.	Inst Biochem & Mol Biol, D-79104 Freiburg, Germany		Bukau, B (corresponding author), Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.			Bukau, Bernd/0000-0003-0521-7199				BARDWELL JCA, 1988, J BACTERIOL, V170, P2977, DOI 10.1128/jb.170.7.2977-2983.1988; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Gamer J, 1996, EMBO J, V15, P607, DOI 10.1002/j.1460-2075.1996.tb00393.x; Gross CA, 1996, ESCHERICHIA COLI SAL, P1382; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; KUMAMOTO CA, 1983, J BACTERIOL, V154, P253, DOI 10.1128/JB.154.1.253-260.1983; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; Tomoyasu T, 1998, MOL MICROBIOL, V30, P567, DOI 10.1046/j.1365-2958.1998.01090.x; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; ZEILSTRARYALLS J, 1993, J BACTERIOL, V175, P1134, DOI 10.1128/JB.175.4.1134-1143.1993	15	392	399	1	24	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					693	696		10.1038/23301	http://dx.doi.org/10.1038/23301			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458167	Green Published			2022-12-24	WOS:000082032900060
J	Hosfield, DJ; Guan, Y; Haas, BJ; Cunningham, RP; Tainer, JA				Hosfield, DJ; Guan, Y; Haas, BJ; Cunningham, RP; Tainer, JA			Structure of the DNA repair enzyme endonuclease IV and its DNA complex: Double-nucleotide flipping at abasic sites and three-metal-ion catalysis	CELL			English	Article							BASE EXCISION-REPAIR; MAJOR APURINIC ENDONUCLEASE; ESCHERICHIA-COLI K-12; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; BACILLUS-CEREUS; EXONUCLEASE-III; SUBSTRATE-ANALOG; POLYMERASE-BETA; STRANDED-DNA	Endonuclease IV is the archetype for a conserved apurinic/apyrimidinic (AP) endonuclease family that primes DNA repair synthesis by cleaving the DNA backbone 5' of AP sites. The crystal structures of Endonuclease IV and its AP-DNA complex at 1.02 and 1.55 Angstrom resolution reveal how an alpha(8)beta(8) TIM barrel fold can bind dsDNA. Enzyme loops intercalate side chains at the abasic site, compress the DNA backbone, bend the DNA similar to 90 degrees, and promote double-nucleotide flipping to sequester the extrahelical AP site in an enzyme pocket that excludes undamaged nucleotides. These structures suggest three Zn2+ ions directly participate in phosphodiester bond cleavage and prompt hypotheses that double-nucleotide flipping and sharp bending by AP endonucleases provide exquisite damage specificity while aiding subsequent base excision repair pathway progression.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; SUNY Albany, Dept Biol Sci, Ctr Biochem & Biophys, Albany, NY 12222 USA	Scripps Research Institute; Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Tainer, JA (corresponding author), Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046312] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM46312] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANNER DW, 1975, NATURE, V255, P609, DOI 10.1038/255609a0; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN E, 1987, P NATL ACAD SCI USA, V84, P3189, DOI 10.1073/pnas.84.10.3189; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; Demple B, 1997, ENVIRON HEALTH PERSP, V105, P931, DOI 10.2307/3433306; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; GETZOFF ED, 1992, NATURE, V358, P347, DOI 10.1038/358347a0; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Guan Y, 1998, NAT STRUCT BIOL, V5, P1058, DOI 10.1038/4168; Haas BJ, 1999, J BACTERIOL, V181, P2834, DOI 10.1128/JB.181.9.2834-2839.1999; HANSEN S, 1992, J MOL BIOL, V225, P543, DOI 10.1016/0022-2836(92)90938-G; HANSEN S, 1993, J MOL BIOL, V234, P179, DOI 10.1006/jmbi.1993.1572; HOUGH E, 1989, NATURE, V338, P357, DOI 10.1038/338357a0; IDE H, 1994, BIOCHEMISTRY-US, V33, P7842, DOI 10.1021/bi00191a011; KINGMA PS, 1995, J BIOL CHEM, V270, P21441, DOI 10.1074/jbc.270.37.21441; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Krokan HE, 1997, BIOCHEM J, V325, P1; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LEVIN JD, 1991, J BIOL CHEM, V266, P22893; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LOEB LA, 1985, CELL, V40, P483, DOI 10.1016/0092-8674(85)90191-6; Masson JY, 1996, GENE, V179, P291, DOI 10.1016/S0378-1119(96)00375-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOL CD, 1995, NATURE, V374, P381, DOI 10.1038/374381a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOL CD, 1998, NUCL ACID M, V12, P29; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Parikh Sudip S., 1999, Current Opinion in Structural Biology, V9, P37, DOI 10.1016/S0959-440X(99)80006-2; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POPOFF SC, 1990, P NATL ACAD SCI USA, V87, P4193, DOI 10.1073/pnas.87.11.4193; RAMOTAR D, 1991, MOL CELL BIOL, V11, P4537, DOI 10.1128/MCB.11.9.4537; Ramotar D, 1997, BIOCHEM CELL BIOL, V75, P327, DOI 10.1139/bcb-75-4-327; Ramotar D, 1998, BBA-GENE STRUCT EXPR, V1396, P15, DOI 10.1016/S0167-4781(97)00160-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; Romier C, 1998, PROTEINS, V32, P414, DOI 10.1002/(SICI)1097-0134(19980901)32:4<414::AID-PROT2>3.3.CO;2-5; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SAPORITO SM, 1988, J BACTERIOL, V170, P5141, DOI 10.1128/jb.170.11.5141-5145.1988; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SHELDRICK GM, 1997, HIGH RESOLUTION STRU; Shida T, 1996, NUCLEIC ACIDS RES, V24, P4572, DOI 10.1093/nar/24.22.4572; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; VOLBEDA A, 1991, EMBO J, V10, P1607, DOI 10.1002/j.1460-2075.1991.tb07683.x; WALKUP LKB, 1989, J BACTERIOL, V171, P1476, DOI 10.1128/jb.171.3.1476-1484.1989; WEISS B, 1976, J BIOL CHEM, V251, P1896; Zhong XJ, 1997, BIOCHEMISTRY-US, V36, P11891, DOI 10.1021/bi963181j	60	242	246	2	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					397	408		10.1016/S0092-8674(00)81968-6	http://dx.doi.org/10.1016/S0092-8674(00)81968-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458614	Bronze			2022-12-24	WOS:000081950300014
J	Busch, MA; Bomblies, K; Weigel, D				Busch, MA; Bomblies, K; Weigel, D			Activation of a floral homeotic gene in Arabidopsis	SCIENCE			English	Article							FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; MERISTEM IDENTITY; EXPRESSION; LEAFY; PLANTS; ANTIRRHINUM; FLORICAULA; TRANSCRIPTION; MORPHOGENESIS	The patterned expression of floral homeotic genes in Arabidopsis depends on the earlier action of meristem-identity genes such as LEAFY, which encodes a transcription factor that determines whether a meristem will generate flowers instead of Leaves and shoots. The LEAFY protein, which is expressed throughout the flower, participates in the activation of homeotic genes, which are expressed in specific regions of the flower. Analysis of a LEAFY-responsive enhancer in the homeotic gene AGAMOUS indicates that direct interaction of LEAFY with this enhancer is required for its activity in plants. Thus, LEAFY is a direct upstream regulator of floral homeotic genes.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/C-1418-2008; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/GSJ-0799-2022	Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Bomblies, Kirsten/0000-0002-2434-3863				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENFEY PN, 1990, SCIENCE, V250, P959, DOI 10.1126/science.250.4983.959; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Busch M., UNPUB; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; HANTKE SS, 1995, DEVELOPMENT, V121, P27; Hofer J, 1997, CURR BIOL, V7, P581, DOI 10.1016/S0960-9822(06)00257-0; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; KELLY AJ, 1995, PLANT CELL, V7, P225, DOI 10.1105/tpc.7.2.225; LIU ZC, 1995, DEVELOPMENT, V121, P975; MA H, 1994, GENE DEV, V8, P745, DOI 10.1101/gad.8.7.745; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; McSteen PCM, 1998, DEVELOPMENT, V125, P2359; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; Motte P, 1998, DEVELOPMENT, V125, P71; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PARCY F, UNPUB; Riechmann JL, 1997, BIOL CHEM, V378, P1079; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Souer E, 1998, DEVELOPMENT, V125, P733; Southerton SG, 1998, PLANT MOL BIOL, V37, P897, DOI 10.1023/A:1006056014079; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	36	290	336	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					585	587		10.1126/science.285.5427.585	http://dx.doi.org/10.1126/science.285.5427.585			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417388				2022-12-24	WOS:000081609500038
J	Socolovsky, M; Fallon, AEJ; Wang, S; Brugnara, C; Lodish, HF				Socolovsky, M; Fallon, AEJ; Wang, S; Brugnara, C; Lodish, HF			Fetal anemia and apoptosis of red cell progenitors in Stat5a(-/-)5b(-/-) mice: A direct role for Stat5 in Bcl-X-L induction	CELL			English	Article							GENE-EXPRESSION; ERYTHROID PROGENITORS; ERYTHROPOIETIN RECEPTOR; SEQUENCE SIMILARITY; FORMING-UNITS; S-PHASE; PROLIFERATION; ACTIVATION; DEATH; DIFFERENTIATION	The erythropoietin receptor (EpoR) is essential for production of red blood cells; a principal function of EpoR is to rescue committed erythroid progenitors from apoptosis. Stat5 is rapidly activated following EpoR stimulation, but its function in erythropoiesis has been unclear since adult Stat5a(-/-)5b(-/-) mice have normal steady-state hematocrit. Here we show that Stat5 is essential for the high erythropoietic rate during fetal development. Stat5a(-/-)5b(-/-) embryos are severely anemic; erythroid progenitors are present in low numbers, show higher levels of apoptosis, and are less responsive to Epo. These findings are explained by a crucial role for Stat5 in EpoR's antiapoptotic signaling: it mediates the immediate-early induction of Bcl-X-L in erythroid cells through direct binding to the Bcl-X promoter.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); Harvard University; Boston Children's Hospital; Harvard Medical School	Lodish, HF (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	lodish@wi.mit.edu	Brugnara, Carlo/A-8041-2010	Brugnara, Carlo/0000-0001-8192-8713; Socolovsky, Merav/0000-0001-6747-7960	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Azam M, 1997, IMMUNITY, V6, P691, DOI 10.1016/S1074-7613(00)80445-8; BRUGNARA C, 1994, AM J CLIN PATHOL, V102, P623, DOI 10.1093/ajcp/102.5.623; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Constantinescu SN, 1999, TRENDS ENDOCRIN MET, V10, P18, DOI 10.1016/S1043-2760(98)00101-5; CROIZAT H, 1990, BLOOD, V75, P1006; Erslev AF, 1995, WILLIAMS HEMATOLOGY, P441; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; Fujio Y, 1997, J CLIN INVEST, V99, P2898, DOI 10.1172/JCI119484; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; GREGORY T, 1999, IN PRESS BLOOD; Grillot DAM, 1997, J IMMUNOL, V158, P4750; GRONER B, 1995, CURR OPIN GENET DEV, V5, P587, DOI 10.1016/0959-437X(95)80027-1; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LANDSCHULZ KT, 1992, BLOOD, V79, P2749; LIN EY, 1993, J IMMUNOL, V151, P1979; Matsumoto A, 1997, BLOOD, V89, P3148, DOI 10.1182/blood.V89.9.3148; Matsumura I, 1999, EMBO J, V18, P1367, DOI 10.1093/emboj/18.5.1367; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Moritz KM, 1997, AM J PHYSIOL-REG I, V273, pR1829, DOI 10.1152/ajpregu.1997.273.6.R1829; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Onishi M, 1998, MOL CELL BIOL, V18, P3871, DOI 10.1128/MCB.18.7.3871; Palis J, 1998, BLOOD REV, V12, P106, DOI 10.1016/S0268-960X(98)90022-4; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; RUSSELL ELIZABETH S., 1966, P351; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Socolovsky M, 1997, J BIOL CHEM, V272, P14009, DOI 10.1074/jbc.272.22.14009; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Wu H, 1997, P NATL ACAD SCI USA, V94, P1806, DOI 10.1073/pnas.94.5.1806; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	42	593	606	0	22	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 23	1999	98	2					181	191		10.1016/S0092-8674(00)81013-2	http://dx.doi.org/10.1016/S0092-8674(00)81013-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428030	Bronze			2022-12-24	WOS:000081632300008
J	Uhlmann, F; Lottspeich, F; Nasmyth, K				Uhlmann, F; Lottspeich, F; Nasmyth, K			Sister-chromatid separation at anaphase onset is promoted by cleavage of the cohesin subunit Scc1	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; FISSION YEAST; BUDDING YEAST; CELL-CYCLE; STRUCTURAL MAINTENANCE; CUT2 PROTEOLYSIS; CHROMOSOMES; PROTEINS	Cohesion between sister chromatids is established during DNA replication and depends on a multiprotein complex called cohesin. Attachment of sister kinetochores to the mitotic spindle during mitosis generates forces that would immediately split sister chromatids were it not opposed by cohesion. Cohesion is essential for the alignment of chromosomes in metaphase but must be abolished for sister separation to start during anaphase. In the budding yeast Saccharomyces cerevisiae, loss of sister-chromatid cohesion depends on a separating protein (separin) called Esp 1 and is accompanied by dissociation from the chromosomes of the cohesion subunit Scc1. Here we show that Esp1 causes the dissooiation of Scc1 from chromosomes by stimulating its cleavage by proteolysis. A mutant Scc1 is described that is resistant to Esp1-dependent cleavage and which blocks both sister-chromatid separation and the dissociation of Scc1 from chromosomes. The evolutionary conservation of separins indicates that the proteolytic cleavage of cohesion proteins might be a general mechanism for triggering anaphase.	Res Inst Mol Pathol, A-1030 Vienna, Austria; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Max Planck Society	Nasmyth, K (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.			Nasmyth, Kim/0000-0001-7030-4403; Uhlmann, Frank/0000-0002-3527-6619				Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; Alexandru G, 1999, EMBO J, V18, P2707, DOI 10.1093/emboj/18.10.2707; Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; ECKERSKORN C, 1993, ELECTROPHORESIS, V14, P831, DOI 10.1002/elps.11501401133; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; Funabiki H, 1996, EMBO J, V15, P6617, DOI 10.1002/j.1460-2075.1996.tb01052.x; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GIMENEZABIAN JF, 1995, J CELL BIOL, V131, P7, DOI 10.1083/jcb.131.1.7; Groigno L, 1998, CELL, V92, P193, DOI 10.1016/S0092-8674(00)80914-9; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Kumada K, 1998, CURR BIOL, V8, P633, DOI 10.1016/S0960-9822(98)70250-7; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LIN Y, 1992, GENETICS, V132, P75; LOSADA A, 1998, GENE DEV, V12, P1003; MAY GS, 1992, J BIOL CHEM, V267, P15737; MCGREW JT, 1992, MOL BIOL CELL, V3, P1443, DOI 10.1091/mbc.3.12.1443; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; Nagase T, 1996, DNA Res, V3, P17, DOI 10.1093/dnares/3.1.17; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Peters JM, 1998, CURR OPIN CELL BIOL, V10, P759, DOI 10.1016/S0955-0674(98)80119-1; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Rose M, 1990, LAB COURSE MANUAL ME; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99	37	743	757	2	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					37	42		10.1038/21831	http://dx.doi.org/10.1038/21831			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403247				2022-12-24	WOS:000081255700042
J	Vidal, R; Frangione, B; Rostagno, A; Mead, S; Revesz, T; Plant, G; Ghiso, J				Vidal, R; Frangione, B; Rostagno, A; Mead, S; Revesz, T; Plant, G; Ghiso, J			A stop-codon mutation in the BRI gene associated with familial British dementia	NATURE			English	Article							CEREBRAL AMYLOID ANGIOPATHY; CREUTZFELDT-JAKOB DISEASE; ALZHEIMERS-DISEASE; PLAQUE-FORMATION; PROTEIN; VARIANT	Familial British dementia (FBD), previously designated familial cerebral amyloid angiopathy-British type(1), is an autosomal dominant disorder of undetermined origin characterized by progressive dementia, spasticity, and cerebellar ataxia, with onset at around the fifth decade of life. Cerebral amyloid angiopathy, non-neuritic and perivascular plaques and neurofibrillary tangles are the predominant pathological lesions(1-4). Here we report the identification of a unique 4K protein subunit named ABri from isolated amyloid fibrils. This highly insoluble peptide is a fragment of a putative type-II single-spanning transmembrane precursor that is encoded by a novel gene, BRI; located on chromosome 13. A single base substitution at the scop codon of this gene generates a longer open reading frame, resulting in a larger, 277-residue precursor. Release of the 34 carboxy-terminal amino acids from the mutated precursor generates the ABri amyloid subunit. The mutation creates a cutting site for the restriction enzyme XbaI, which is useful for detecting asymptomatic carriers. Antibodies against the amyloid or homologous synthetic peptides recognize both parenchymal and vascular lesions in FED patients. A point mutation at the stop codon of BRI therefore results in the generation of the ABri peptide, which is deposited as amyloid fibrils causing neuronal disfunction and dementia.	NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; UCL Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England; Inst Neurol, Dept Neuropathol, London WC1N 3BG, England	New York University; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London	Ghiso, J (corresponding author), NYU, Sch Med, Dept Pathol, 550 1st Ave, New York, NY 10016 USA.	ghisoj01@popmail.med.nyu.edu	Rostagno, Agueda/A-5801-2008; Revesz, Tamas/A-8732-2010; Mead, Simon/E-9414-2011	Revesz, Tamas/0000-0003-2501-0259; Mead, Simon/0000-0002-4326-1468; Rostagno, Agueda/0000-0002-6817-2074				AIKAWA H, 1985, ANN NEUROL, V17, P297, DOI 10.1002/ana.410170313; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baumann MH, 1996, BIOCHEM BIOPH RES CO, V219, P238, DOI 10.1006/bbrc.1996.0211; CORSELLIS JAN, 1954, BRAIN, V77, P571, DOI 10.1093/brain/77.4.571; COURTENMYERS G, 1987, NEUROLOGY, V37, P269; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Deleersnijder W, 1996, J BIOL CHEM, V271, P19475, DOI 10.1074/jbc.271.32.19475; Ghetti B, 1996, P NATL ACAD SCI USA, V93, P744, DOI 10.1073/pnas.93.2.744; GHISO J, 1995, J NEUROL SCI, V129, P74, DOI 10.1016/0022-510X(94)00274-R; GHISO J, 1994, MOL NEUROBIOL, V8, P49, DOI 10.1007/BF02778007; KEOHANE C, 1985, J NEUROL NEUROSUR PS, V48, P1175, DOI 10.1136/jnnp.48.11.1175; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MASTERS CL, 1981, BRAIN, V104, P535, DOI 10.1093/brain/104.3.535; PEARLMAN RL, 1988, NEUROLOGY, V38, P1249, DOI 10.1212/WNL.38.8.1249; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Vidal R, 1996, AM J PATHOL, V148, P361; VINTERS HV, 1987, STROKE, V18, P311, DOI 10.1161/01.STR.18.2.311; Worster-Drought C, 1940, BRAIN, V63, P237, DOI 10.1093/brain/63.3.237; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27; Worster-Drougt C, 1944, BRAIN, V67, P38, DOI 10.1093/brain/67.1.38	23	379	405	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					776	781						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391242				2022-12-24	WOS:000081101600052
J	Turner, BJ; Newschaffer, CJ; Zhang, DZ; Fanning, T; Hauck, WW				Turner, BJ; Newschaffer, CJ; Zhang, DZ; Fanning, T; Hauck, WW			Translating clinical trial results into practice: The effect of an AIDS clinical trial on prescribed antiretroviral therapy for HIV-infected pregnant women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	National Conference on Women and HIV	MAY 04-07, 1997	LOS ANGELES, CA				HUMAN-IMMUNODEFICIENCY-VIRUS; PRENATAL-CARE; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; ZIDOVUDINE USE; HEART-DISEASE; TRANSMISSION; COHORT; EXPERIENCE; TYPE-1	Background: The success of Pediatric AIDS Clinical Trials Group (PACTG) Protocol 076 in preventing vertical HIV transmission prompted intensive efforts to inform laypersons and professionals about the trial's results. Objective: To explore community responsiveness to these efforts by assessing temporal, maternal, and health care factors associated with prescribed antiretroviral therapy before and after PACTG Protocol 076, Design: Retrospective cohort study. Setting: New York State Medicaid program. Patients: 2607 HIV-infected women who delivered a living child between January 1993 and September 1996. Measurements: Adjusted odds of being prescribed antiretroviral treatment in the second or third trimester for women who delivered in period 1 (during the trial [January 1993 to February 1994]), period 2 (after the trial's end and announcement of the results to publication of the results [March 1994 to November 1994]), and period 3 (after publication of the trial results [December 1994 to September 1996]). Results: The adjusted odds of being prescribed antiretroviral therapy increased 21% per month in period 2 and decreased to 3% per month in period 3. In all time periods, the adjusted odds of being prescribed antiretroviral therapy were at least 60% greater (P < 0.05) for women who were treated at an institution that performed HIV clinical trials, received HIV-focused ambulatory care, or had adequate prenatal care visits. After the trial, women receiving methadone treatment had at least twofold (95% CI, 1.5- to 4.3-fold) greater adjusted odds of being prescribed antiretroviral therapy than women who did not take any illicit drugs. Latin-American women, older women, and women born in the United States had greater adjusted odds (P < 0.05) of being prescribed treatment in period 3. Conclusion: Community practice responded rapidly to efforts to disseminate the results of PACTG Protocol 076; however, the absolute increase in prescribed therapy was greatest for women who had adequate prenatal visits or were receiving HIV-focused care, care at a site that performed clinical trials, or methadone therapy.	Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA; New York State Dept Hlth, Albany, NY 12237 USA	Jefferson University; State University of New York (SUNY) System	Turner, BJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, 1025 Walnut St,Room 132, Philadelphia, PA 19107 USA.	barbara.turner@mail.tju.edu			NIDA NIH HHS [R01 DA07904] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007904] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		*AM PUBL HLTH ASS, 1998, AM PUBL HLTH ASS M; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; Avanzini F, 1997, EUR HEART J, V18, P1447; Bobat R, 1996, PEDIATR INFECT DIS J, V15, P604, DOI 10.1097/00006454-199607000-00009; Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Cooper ER, 1996, J INFECT DIS, V174, P1207, DOI 10.1093/infdis/174.6.1207; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P807, DOI 10.1001/jama.271.11.807; Fanning TR, 1995, AIDS PUBLIC POLICY J, V10, P39; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gwinn M, 1997, JAMA-J AM MED ASSOC, V277, P299, DOI 10.1001/jama.277.4.299a; Healton C, 1996, AM J PREV MED, V12, P47, DOI 10.1016/S0749-3797(18)30258-7; ISCOE NA, 1994, CAN MED ASSOC J, V150, P1109; KETLEY D, 1993, LANCET, V342, P891, DOI 10.1016/0140-6736(93)91945-I; Kitahata MM, 1996, NEW ENGL J MED, V334, P701, DOI 10.1056/NEJM199603143341106; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; Laine C, 1998, AIDS, V12, P417, DOI 10.1097/00002030-199804000-00011; MARKSON LE, 1994, ARCH INTERN MED, V154, P1497, DOI 10.1001/archinte.154.13.1497; McDermott J, 1997, PAEDIATR PERINAT EP, V11, P105, DOI 10.1046/j.1365-3016.1997.d01-4.x; *NY DEP HLTH MEM, 1993, HLTH FAC SER, V23; Phillips KA, 1997, J ACQ IMMUN DEF SYND, V14, P174, DOI 10.1097/00042560-199702010-00012; PSATY BM, 1995, JAMA-J AM MED ASSOC, V273, P1436, DOI 10.1001/jama.273.18.1436; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; Silverman NS, 1997, AM J PERINAT, V14, P341, DOI 10.1055/s-2007-994157; Singh N, 1996, AIDS CARE, V8, P261, DOI 10.1080/09540129650125696; Smith Sidney C. Jr., 1998, American Journal of Medicine, V104, p23S, DOI 10.1016/S0002-9343(98)00043-6; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; Turner BJ, 1998, J GEN INTERN MED, V13, P16, DOI 10.1046/j.1525-1497.1998.00003.x; Turner BJ, 1997, J ACQ IMMUN DEF SYND, V14, P327, DOI 10.1097/00042560-199704010-00004; TURNER BJ, 1995, J ACQ IMMUN DEF SYND, V9, P371; Turner BJ, 1996, J ACQ IMMUN DEF SYND, V12, P259, DOI 10.1097/00042560-199607000-00005; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; YUSUF S, 1988, JAMA-J AM MED ASSOC, V260, P2088, DOI 10.1001/jama.260.14.2088; 1989, N Y STATE J MED, V89, P542; 1998, MMWR MORB MORTAL WKL, V47, P688	37	31	31	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					979	986		10.7326/0003-4819-130-12-199906150-00005	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	206TE	10383368				2022-12-24	WOS:000080894700004
J	Yu, W; Misulovin, Z; Suh, H; Hardy, RR; Jankovic, M; Yannoutsos, N; Nussenzweig, MC				Yu, W; Misulovin, Z; Suh, H; Hardy, RR; Jankovic, M; Yannoutsos, N; Nussenzweig, MC			Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 5 ' of RAG2	SCIENCE			English	Article							V(D)J RECOMBINATION; ACTIVATING GENES; IMMUNE-SYSTEM; LIGASE-IV; IN-VIVO; MICE; PROMOTER; REPAIR; TRANSPOSITION; REARRANGEMENT	RAG1 and RAG2 are essential for V(D)J recombination and Lymphocyte development. These genes are thought to encode a transposase derived from a mobile genetic element that was inserted into the vertebrate genome 450 million years ago. The regulation of RAG1 and RAG2 was investigated in vivo with bacterial artificial chromosome (BAC) transgenes containing a fluorescent indicator. Coordinate expression of RAG1 and RAG2 in B and T cells was found to be regulated by distinct genetic elements found on the 5' side of the RAG2 gene. This observation suggests a mechanism by which asymmetrically disposed cis DNA elements could influence the expression of the primordial transposon and thereby capture RAGs for vertebrate evolution.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, New York, NY 10021 USA; Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Howard Hughes Medical Institute; Rockefeller University; Fox Chase Cancer Center	Nussenzweig, MC (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Immunol, 1230 York Ave, New York, NY 10021 USA.		Nussenzweig, Michel/AAE-7292-2019		NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; Allman D, 1999, J EXP MED, V189, P735, DOI 10.1084/jem.189.4.735; Besmer E, 1998, MOL CELL, V2, P817, DOI 10.1016/S1097-2765(00)80296-8; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Brown ST, 1997, J IMMUNOL, V158, P5071; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Fuller K, 1997, MOL IMMUNOL, V34, P939, DOI 10.1016/S0161-5890(97)00000-X; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Grawunder U, 1998, MOL CELL, V2, P477, DOI 10.1016/S1097-2765(00)80147-1; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Henikoff S, 1996, BIOESSAYS, V18, P401, DOI 10.1002/bies.950180510; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kioussis D, 1997, CURR OPIN GENET DEV, V7, P614, DOI 10.1016/S0959-437X(97)80008-1; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; Kitagawa T, 1996, BLOOD, V88, P3785, DOI 10.1182/blood.V88.10.3785.bloodjournal88103785; Kurioka H, 1996, MOL IMMUNOL, V33, P1059, DOI 10.1016/S0161-5890(96)00062-4; Lauring J, 1999, MOL CELL BIOL, V19, P2601; Lewis SM, 1997, CELL, V88, P159, DOI 10.1016/S0092-8674(00)81833-4; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; OETTINGER MA, 1992, IMMUNOGENETICS, V35, P97, DOI 10.1007/BF00189518; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; Shockett PE, 1999, MOL CELL BIOL, V19, P4159; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WAYNE J, 1994, IMMUNITY, V1, P95, DOI 10.1016/1074-7613(94)90103-1; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0; WONG Y, IN PRESS NATURE; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; YUESHENG L, 1996, IMMUNITY, V5, P527; ZARRIN AA, 1997, J IMMUNOL, V159, P4381; Zhu CM, 1996, CELL, V86, P379, DOI 10.1016/S0092-8674(00)80111-7	38	116	118	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1080	1084		10.1126/science.285.5430.1080	http://dx.doi.org/10.1126/science.285.5430.1080			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446057				2022-12-24	WOS:000082033100050
J	Li, X; Zhang, YL; Clarke, JD; Li, Y; Dong, XN				Li, X; Zhang, YL; Clarke, JD; Li, Y; Dong, XN			Identification and cloning of a negative regulator of systemic acquired resistance, SNlI1, through a screen for suppressors of npr1-1	CELL			English	Article							TOBACCO MOSAIC-VIRUS; SALICYLIC-ACID; RETINOBLASTOMA PROTEIN; DISEASE RESISTANCE; GENE-EXPRESSION; KAPPA-B; ARABIDOPSIS; MUTANT; SIGNAL; TRANSCRIPTION	Systemic acquired resistance (SAR) is a plant immune response induced after a local infection by necrotizing pathogens. The Arabidopsis NPR1 gene is a positive regulator of SAR, essential for transducing the SAR signal salicylic acid (SA). Mutations in the NPR1 gene abolish the SA-induced expression of pathogenesis-related (PR) genes and resistance to pathogens. To identify additional regulators of SAR, we screened for suppressors of npr1-1. In the npr1-1 background, the sni1 (suppressor of npr1-1, inducible 1) mutant shows near wild-type levels of PR1 expression and resistance to pathogens after induction. Restoration of SAR in npr1-1 by the recessive sni1 mutation indicates that wild-type SNI1 may function as a negative regulator of SAR. We cloned the SNI1 gene and found that it encodes a leucine-rich nuclear protein.	Duke Univ, Dept Bot, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA	Duke University	Dong, XN (corresponding author), Duke Univ, Dept Bot, Dev Cell & Mol Biol Grp, Durham, NC 27708 USA.	xdong@duke.edu						BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; Bowling SA, 1997, PLANT CELL, V9, P1573, DOI 10.1105/tpc.9.9.1573; Cao H, 1998, P NATL ACAD SCI USA, V95, P6531, DOI 10.1073/pnas.95.11.6531; Cao H, 1997, CELL, V88, P57, DOI 10.1016/S0092-8674(00)81858-9; CAO H, 1994, PLANT CELL, V6, P1583, DOI 10.1105/tpc.6.11.1583; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DELANEY TP, 1995, P NATL ACAD SCI USA, V92, P6602, DOI 10.1073/pnas.92.14.6602; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; FUNG YKT, 1993, ONCOGENE, V8, P2659; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Glazebrook J, 1996, GENETICS, V143, P973; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JEFFERSON RA, 1987, EMBO J, V6, P3901; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Lebel E, 1998, PLANT J, V16, P223, DOI 10.1046/j.1365-313x.1998.00288.x; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEE EYHP, 1994, GENE DEV, V8, P2008, DOI 10.1101/gad.8.17.2008; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; Metraux J. P., 1991, Advances in molecular genetics of plant-microbe interactions. Vol. 1. Proceedings of the 5th international symposium on the molecular genetics of plant-microbe interactions, Interlaken, Switzerland, September 9-14, 1990., P432; METRAUX JP, 1990, SCIENCE, V250, P1004, DOI 10.1126/science.250.4983.1004; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NEVINS JR, 1992, SCIENCE, V258, P424; RAIKHEL N, 1992, PLANT PHYSIOL, V100, P1627, DOI 10.1104/pp.100.4.1627; RASKIN I, 1989, P NATL ACAD SCI USA, V86, P2214, DOI 10.1073/pnas.86.7.2214; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; Riley DJ, 1997, MOL CELL BIOL, V17, P7342, DOI 10.1128/MCB.17.12.7342; Ryals J, 1997, PLANT CELL, V9, P425, DOI 10.1105/tpc.9.3.425; Ryals JA, 1996, PLANT CELL, V8, P1809, DOI 10.1105/tpc.8.10.1809; Shah J, 1997, MOL PLANT MICROBE IN, V10, P69, DOI 10.1094/MPMI.1997.10.1.69; Sokal RR, 1981, BIOMETRY PRINCIPLES; Stacey MG, 1999, PLANT CELL, V11, P349, DOI 10.1105/tpc.11.3.349; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; VONARNIM AG, 1994, CELL, V79, P1035, DOI 10.1016/0092-8674(94)90034-5; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; YALPANI N, 1991, PLANT CELL, V3, P809, DOI 10.1105/tpc.3.8.809; Zhang YL, 1999, P NATL ACAD SCI USA, V96, P6523, DOI 10.1073/pnas.96.11.6523	46	190	206	0	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	1999	98	3					329	339		10.1016/S0092-8674(00)81962-5	http://dx.doi.org/10.1016/S0092-8674(00)81962-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458608	Bronze			2022-12-24	WOS:000081950300008
J	de Walle, HEK; van der Pal, KM; de Jong-van den Berg, LTW; Jeeninga, W; Schouten, JSAG; de Rover, CM; Buitendijk, SE; Cornel, MC				de Walle, HEK; van der Pal, KM; de Jong-van den Berg, LTW; Jeeninga, W; Schouten, JSAG; de Rover, CM; Buitendijk, SE; Cornel, MC			Effect of mass media campaign to reduce socioeconomic differences in women's awareness and behaviour concerning use of folic acid: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands; Netherlands Org Appl Sci Res TNO Prevent & Hlth, NL-2301 CE Leiden, Netherlands; Groningen Inst Drug Studies, NL-9713 AW Groningen, Netherlands; Midden Brabent, Gemeenschappelylie Gezondheids dienst, NL-5003 DA Tilburg, Netherlands; GGD Reg Achterhock, NL-7005 AZ Doetinchem, Netherlands	University of Groningen; Netherlands Organization Applied Science Research; University of Groningen	Cornel, MC (corresponding author), Univ Groningen, Dept Med Genet, NL-9713 AW Groningen, Netherlands.		Cornel, Martina/AAE-8955-2020; Schouten, Johannes S.A.G./M-9376-2016	Cornel, Martina/0000-0002-5397-5544; Schouten, Johannes S.A.G./0000-0001-6495-7758				de Jong-van den Berg LTW, 1998, EUR J CLIN PHARMACOL, V54, P329, DOI 10.1007/s002280050468; GEERTS A, 1995, VOEDINGSMAGAZINE, V8, P3	2	36	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					291	292		10.1136/bmj.319.7205.291	http://dx.doi.org/10.1136/bmj.319.7205.291			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426740	Green Published, Bronze			2022-12-24	WOS:000081909100024
J	Lloyd, SA; Whitby, FG; Blair, DF; Hill, CP				Lloyd, SA; Whitby, FG; Blair, DF; Hill, CP			Structure of the C-terminal domain of FliG, a component of the rotor in the bacterial flagellar motor	NATURE			English	Article							SALMONELLA-TYPHIMURIUM; TORQUE GENERATION; ESCHERICHIA-COLI; PROTEIN FLIG; BASAL-BODY; COMPLEX; SWITCH; MUTATIONS; ROTATION; RESIDUES	Many motile species of bacteria are propelled by flagella, which are rigid helical filaments turned by rotary motors in the cell membrane(1-3). The motors are powered by the transmembrane gradient of protons or sodium ions. Although bacterial flagella contain many proteins, only three-MotA, MotB and FliG-participate closely in torque generation. MotA, and MotB are ion-conducting membrane proteins that: form the stator of the motor. FliG is a component of the rotor, present in about 25 copies per flagellum. It is composed of an amino-terminal domain that functions in flagellar assembly and a carboxy-terminal domain (FliG-C) that functions specifically in motor rotation. Here we report the crystal structure of FliG-C from the hyperthermophilic eubacterium Thermotoga maritima, Charged residues that are important for function, and which interact with the stator protein MotA(4,5), duster along a prominent ridge on FliG-C. On the basic; of the disposition of these residues, we present a hypothesis for the orientation of FliG-C domains in the flagellar motor, and propose a structural model for the part of the rotor that interacts with the stator.	Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Blair, DF (corresponding author), Univ Utah, Dept Biol, 257 South 1400 East, Salt Lake City, UT 84112 USA.							BLAIR DF, 1995, ANNU REV MICROBIOL, V49, P489, DOI 10.1146/annurev.mi.49.100195.002421; Braun TF, 1999, J BACTERIOL, V181, P3542, DOI 10.1128/JB.181.11.3542-3551.1999; BRUNGER AT, 1996, XPLOR VERSION 3 843; DeRosier DJ, 1998, CELL, V93, P17, DOI 10.1016/S0092-8674(00)81141-1; FRANCIS NR, 1992, P NATL ACAD SCI USA, V89, P6304, DOI 10.1073/pnas.89.14.6304; FRANCIS NR, 1994, J MOL BIOL, V235, P1261, DOI 10.1006/jmbi.1994.1079; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Garza AG, 1996, J MOL BIOL, V258, P270, DOI 10.1006/jmbi.1996.0249; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; Hutchinson EG, 1996, PROTEIN SCI, V5, P212; IRIKURA VM, 1993, J BACTERIOL, V175, P802, DOI 10.1128/JB.175.3.802-810.1993; JONES CJ, 1990, J MOL BIOL, V212, P377, DOI 10.1016/0022-2836(90)90132-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KHAN S, 1988, J MOL BIOL, V202, P575, DOI 10.1016/0022-2836(88)90287-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lloyd SA, 1997, J MOL BIOL, V266, P733, DOI 10.1006/jmbi.1996.0836; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; Marykwas DL, 1996, J BACTERIOL, V178, P1289, DOI 10.1128/jb.178.5.1289-1294.1996; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Tang H, 1996, J MOL BIOL, V261, P209, DOI 10.1006/jmbi.1996.0453; WELCH M, 1993, P NATL ACAD SCI USA, V90, P8787, DOI 10.1073/pnas.90.19.8787; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986; YAMAGUCHI S, 1986, J BACTERIOL, V166, P187, DOI 10.1128/jb.166.1.187-193.1986; Zhao RH, 1996, J MOL BIOL, V261, P195, DOI 10.1006/jmbi.1996.0452; Zhou JD, 1997, J MOL BIOL, V273, P428, DOI 10.1006/jmbi.1997.1316; Zhou JD, 1998, P NATL ACAD SCI USA, V95, P6436, DOI 10.1073/pnas.95.11.6436	30	96	97	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					472	475		10.1038/22794	http://dx.doi.org/10.1038/22794			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440379				2022-12-24	WOS:000081715000056
J	Price, CSC; Dyer, KA; Coyne, JA				Price, CSC; Dyer, KA; Coyne, JA			Sperm competition between Drosophila males involves both displacement and incapacitation	NATURE			English	Article							FEMALE RECEPTIVITY; MELANOGASTER; EVOLUTION	Females in almost all animal groups copulate with multiple males(1,2). This behaviour allows different males to compete for fertilization(3) and gives females the opportunity to mediate this competition(4). In many animals and most insects, the second male to copulate with a female typically sires most of her offspring(1,5,6). In Drosophila melanogaster, this second-male sperm precedence has long been studied(7-15) but, as in most species, its mechanism has remained unknown. Here we show, using labelled sperm in doubly mated females, that males can both physically displace and incapacitate stored sperm from earlier-mating males. Displacement occurs only if the second male transfers sperm to the female, and in only one of her three sperm-storage organs. Incapacitation can be caused by either fertile or spermless second males, but requires extended intervals between matings. Sperm from different males are not 'stratified' in the storage organs but mix freely. Many animal species may have multiple mechanisms of sperm competition like those observed here, and revealing these mechanisms is necessary to understand the genetic and evolutionary basis of second-male sperm precedence in animals.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Coyne, JA (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.	j-coyne@uchicago.edu						[Anonymous], [No title captured]; Birkhead TR, 1992, SPERM COMPETITION BI; Birkhead TR, 1998, SPERM COMPETITION SE; Clark AG, 1998, GENETICS, V149, P1487; Clark AG, 1999, SCIENCE, V283, P217, DOI 10.1126/science.283.5399.217; COYNE JA, 1991, GENETICS, V129, P791; Eberhard W. G., 1996, FEMALE CONTROL SEXUA; GILCHRIST AS, 1995, J INSECT PHYSIOL, V41, P1087, DOI 10.1016/0022-1910(95)00068-6; Gromko M.H., 1984, P371; GROMKO MH, 1993, ANIM BEHAV, V45, P253, DOI 10.1006/anbe.1993.1031; GROMKO MH, 1984, EVOLUTION, V38, P1273, DOI 10.1111/j.1558-5646.1984.tb05649.x; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; Imhof M, 1998, MOL ECOL, V7, P915, DOI 10.1046/j.1365-294x.1998.00382.x; INGMANBAKER J, 1980, BIOCHEM GENET, V18, P809, DOI 10.1007/BF00484595; Kaufmann P, 1942, AM NAT, V76, P445, DOI 10.1086/281068; KIEFER BI, 1966, GENETICS, V54, P1441; LEFEVRE G, 1962, GENETICS, V42, P1719; Lobashov ME, 1939, CR ACAD SCI URSS, V23, P827; NCHTSHEIM H, 1927, Z IND ABST VEREB S, V2, P1143; NEWPORT MEA, 1984, EVOLUTION, V38, P1261, DOI 10.1111/j.1558-5646.1984.tb05648.x; Nonidez JF, 1920, BIOL BULL-US, V39, P207, DOI 10.2307/1536488; PARKER GA, 1970, BIOL REV, V45, P525, DOI 10.1111/j.1469-185X.1970.tb01176.x; Price CSC, 1997, NATURE, V388, P663, DOI 10.1038/41753; Rice WR, 1996, NATURE, V381, P232, DOI 10.1038/381232a0; Santel A, 1997, MECH DEVELOP, V64, P19, DOI 10.1016/S0925-4773(97)00031-2; SCOTT D, 1990, J INSECT PHYSIOL, V36, P451, DOI 10.1016/0022-1910(90)90063-L; SCOTT D, 1993, J INSECT PHYSIOL, V39, P201, DOI 10.1016/0022-1910(93)90089-A; Simmons L.W., 1998, P341, DOI 10.1016/B978-012100543-6/50035-0; Snedecor G.W., 1967, STAT METHODS; Sokal RR., 1995, BIOMETRY, V3	30	135	140	0	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1999	400	6743					449	452		10.1038/22755	http://dx.doi.org/10.1038/22755			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440373				2022-12-24	WOS:000081715000050
J	Koshiya, N; Smith, JC				Koshiya, N; Smith, JC			Neuronal pacemaker for breathing visualized in vitro	NATURE			English	Article							RESPIRATORY RHYTHM GENERATION; PRE-BOTZINGER COMPLEX; SPINAL-CORD; MEDULLARY SLICES; MAMMALIAN BRAIN; MECHANISMS; CIRCUITRY; NETWORK; MOTOR; RAT	Breathing movements in mammals arise from a rhythmic pattern of neural activity, thought to originate in the pre-Botzinger complex(1) in the lower brainstem. The mechanisms generating the neural rhythm in this region are unknown(2-5). The central question is whether the rhythm is generated by a network of bursting pacemaker neurons coupled by excitatory synapses that synchronize pacemaker activity. Here we visualized the activity of inspiratory pacemaker neurons at single-cell and population levels with calcium-sensitive dye. We developed methods to label these neurons retrogradely with the dye in neonatal rodent brainstem slices that retain the rhythmically active respiratory network We simultaneously used infrared structural imaging to allow patch-damp recording from the identified neurons, After we pharmacologically blocked glutamatergic synaptic transmission, a subpopulation of inspiratory neurons continued to burst rhythmically but asynchronously. The intrinsic bursting frequency of these pacemaker neurons depended on the baseline membrane potential, providing a cellular mechanism for respiratory frequency control. These results provide evidence that the neuronal kernel for rhythm generation consists of a network of synaptically-coupled pacemaker neurons.	NINDS, Cellular & Syst Neurobiol Sect, Neural Control Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Koshiya, N (corresponding author), NINDS, Cellular & Syst Neurobiol Sect, Neural Control Lab, NIH, Bethesda, MD 20892 USA.	koshiya@nih.gov	Koshiya, Naohiro/ABA-8628-2020	Koshiya, Naohiro/0000-0002-2952-8779				BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; Butera RJ, 1999, J NEUROPHYSIOL, V82, P398, DOI 10.1152/jn.1999.82.1.398; Butera RJ, 1999, J NEUROPHYSIOL, V82, P382, DOI 10.1152/jn.1999.82.1.382; DODT HU, 1994, TRENDS NEUROSCI, V17, P453, DOI 10.1016/0166-2236(94)90130-9; FETCHO JR, 1995, J NEUROPHYSIOL, V73, P399, DOI 10.1152/jn.1995.73.1.399; FOSKETT JK, 1988, AM J PHYSIOL       S, pC566; FRIEDLANDER ML, 1992, INT J GYNECOL CANCER, V2, P2; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497, DOI 10.1152/jn.1993.70.4.1497; Inoue S., 1997, VIDEO MICROSCOPY FUN; JOHNSON SM, 1994, J NEUROPHYSIOL, V72, P2598, DOI 10.1152/jn.1994.72.6.2598; Koshiya N, 1996, J PHYSIOL-LONDON, V491, P859, DOI 10.1113/jphysiol.1996.sp021263; Koshiya N., 1997, Society for Neuroscience Abstracts, V23, P1252; LI YX, 1995, AM J PHYSIOL-CELL PH, V269, pC1079, DOI 10.1152/ajpcell.1995.269.5.C1079; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; ODONOVAN M, 1994, J NEUROSCI, V14, P6354; Ramirez JM, 1996, CURR OPIN NEUROBIOL, V6, P817, DOI 10.1016/S0959-4388(96)80033-X; Ramirez JM, 1998, J PHYSIOL-LONDON, V507, P895, DOI 10.1111/j.1469-7793.1998.895bs.x; Ramirez JM, 1996, J PHYSIOL-LONDON, V491, P799, DOI 10.1113/jphysiol.1996.sp021258; REGEHR WG, 1995, BIOPHYS J, V68, P2156, DOI 10.1016/S0006-3495(95)80398-X; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Richter D W, 1992, Curr Opin Neurobiol, V2, P788, DOI 10.1016/0959-4388(92)90135-8; Sabatini BL, 1996, NATURE, V384, P170, DOI 10.1038/384170a0; SCHWARZACHER SW, 1995, J NEUROPHYSIOL, V73, P1452, DOI 10.1152/jn.1995.73.4.1452; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; SMITH JC, 1995, LUNG BIOL HEALTH DIS, V82, P463; SMITH JC, 1997, NEURONS NETWORKS MOT, P97; Torrence C, 1998, B AM METEOROL SOC, V79, P61, DOI 10.1175/1520-0477(1998)079<0061:APGTWA>2.0.CO;2; Tsubokawa H, 1996, J NEUROPHYSIOL, V76, P2896, DOI 10.1152/jn.1996.76.5.2896; WILSON CG, 1998, SOC NEUR ABSTR, V23, P875	30	353	358	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					360	363		10.1038/22540	http://dx.doi.org/10.1038/22540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432113				2022-12-24	WOS:000081590000049
J	Valmadrid, CT; Klein, R; Moss, SE; Klein, BEK; Cruickshanks, KJ				Valmadrid, CT; Klein, R; Moss, SE; Klein, BEK; Cruickshanks, KJ			Alcohol intake and the risk of coronary heart disease mortality in persons with older-onset diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; US MALE PHYSICIANS; MYOCARDIAL-INFARCTION; INSULIN SENSITIVITY; 4-YEAR INCIDENCE; SHAPED CURVE; BRITISH MEN; CONSUMPTION; WISCONSIN; RETINOPATHY	Context Despite nutrition information and guidelines that advise against depriving diabetic patients of the potential benefit of moderate alcohol intake against cardiovascular events, the association between alcohol consumption and risk of cardiovascular outcomes in diabetic individuals has not been determined. Objective To examine the relationship between alcohol intake and coronary heart disease (CHD) mortality in persons with older-onset diabetes. Design Population-based, prospective cohort study conducted from 1984 through 1996, with a follow-up of up to 12.3 years. Setting and Participants A total of 983 older-onset diabetic individuals (mean [SD] age, 68.6 [11.0] years; 45.2% male; 98.5% white) were interviewed about their past-year intake of alcoholic beverages during the 1984-1986 follow-up examination of a population-based study of diabetic persons in southern Wisconsin. Main Outcome Measure Time to mortality from CHD by category alcohol intake. Results Alcohol use was inversely associated with risk of CHD mortality in older-onset diabetic subjects. The CHD mortality rates for never and former drinkers were 43.9 and 38.5 per 1000 person-years, respectively, while the rates for those with alcohol intakes of less than 2, 2 to 13, and 14 or more g/d were 25.3, 20.8, and 10.0 per 1000 person-years, respectively. Compared with never drinkers and controlling for age, sex, cigarette smoking, glycosylated hemoglobin level, insulin use, plasma C-peptide level, history of angina or myocardial infarction, digoxin use, and the presence and severity of diabetic retinopathy, former drinkers had a relative risk (RR) of 0.69 (95% confidence interval [CI], 0.43-1.12); for those who drank less than 2 g/d (less frequent than 1 drink a week), the RR was 0.54 (95% CI, 0.33-0.90); for 2 to 13 g/d, it was 0.44 (95% CI, 0.23-0.84); and for 14 or more g/d (about 1 drink or more a day), it was 0.21 (95% CI, 0.09-0.48). Further adjustments for blood pressure, body mass index, education, physical activity, diabetes duration, hypertension history, overt nephropathy, peripheral neuropathy, lipid measures, or intake of medications such as aspirin and antihypertensive agents did not change the associations observed. Conclusion Our results suggest an overall beneficial effect of alcohol consumption in decreasing the risk of death due to CHD in people with older-onset diabetes.	Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, Madison, WI 53705 USA	University of Wisconsin System; University of Wisconsin Madison	Klein, R (corresponding author), Univ Wisconsin, Sch Med, Dept Ophthalmol & Visual Sci, 610 N Walnut St,WARF 460, Madison, WI 53705 USA.	kleinr@epi.ophth.wisc.edu			NEI NIH HHS [EY03083] Funding Source: Medline; NHLBI NIH HHS [HL59259] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003083] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059259] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; *AM DIAB ASS, 1998, MED MAN TYP 2 DIAB, P48; Amer Diabet Assoc, 1999, DIABETES CARE, V22, pS42; [Anonymous], 1981, INVEST OPHTH VIS SCI, V21, P210; [Anonymous], 1991, Ophthalmology, V98, P823; [Anonymous], 1991, Ophthalmology, V98, P786; [Anonymous], 1995, DIABETES AM; Bell DSH, 1996, DIABETES CARE, V19, P509, DOI 10.2337/diacare.19.5.509; Camargo CA, 1997, ANN INTERN MED, V126, P372, DOI 10.7326/0003-4819-126-5-199703010-00005; Camargo CA, 1997, ARCH INTERN MED, V157, P79, DOI 10.1001/archinte.157.1.79; Cox D. R., 1984, ANAL SURVIVAL DATA; COX DR, 1972, J R STAT SOC B, V34, P187; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; FABER OK, 1978, DIABETES, V27, P170, DOI 10.2337/diab.27.1.S170; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FUCHS CS, 1995, NEW ENGL J MED, V332, P1245, DOI 10.1056/NEJM199505113321901; GOLDBERG RJ, 1994, CIRCULATION, V89, P651, DOI 10.1161/01.CIR.89.2.651; Hein HO, 1996, BRIT MED J, V312, P736, DOI 10.1136/bmj.312.7033.736; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; HULLEY SB, 1981, CIRCULATION, V64, P57; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; Kiechl S, 1996, BRIT MED J, V313, P1040; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; Kitamura A, 1998, AM J EPIDEMIOL, V147, P59; Klatsky AL, 1997, AM J CARDIOL, V80, P416, DOI 10.1016/S0002-9149(97)00388-3; KLEIN BEK, 1991, OPHTHALMOLOGY, V98, P1261; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P244, DOI 10.1001/archopht.1989.01070010250031; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P527, DOI 10.1001/archopht.1984.01040030405011; KLEIN R, 1984, AM J EPIDEMIOL, V119, P54, DOI 10.1093/oxfordjournals.aje.a113725; KLEIN R, 1989, ARCH OPHTHALMOL-CHIC, V107, P237, DOI 10.1001/archopht.1989.01070010243030; KLEIN R, 1984, ARCH OPHTHALMOL-CHIC, V102, P520, DOI 10.1001/archopht.1984.01040030398010; KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023; Lazarus R, 1997, AM J EPIDEMIOL, V145, P909, DOI 10.1093/oxfordjournals.aje.a009050; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; Malin H, 1983, DHHS PUBLICATION PHS, P490; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MOSS SE, 1994, ARCH INTERN MED, V154, P2473; MOSS SE, 1988, J CLIN EPIDEMIOL, V41, P645, DOI 10.1016/0895-4356(88)90116-3; MOSS SE, 1991, AM J PUBLIC HEALTH, V81, P1158, DOI 10.2105/AJPH.81.9.1158; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RUBIN R, 1994, ALCOHOL CLIN EXP RES, V18, P105, DOI 10.1111/j.1530-0277.1994.tb00888.x; SHAPER AG, 1988, LANCET, V2, P1267; The hypertension detection and follow-up program. Hypertension detetection and follow-up program cooperative group, 1976, PREV MED, V5, P207; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; *USDA, 1995, NUTR YOUR HLTH DIET, P40; Wannamethee SG, 1997, INT J EPIDEMIOL, V26, P523, DOI 10.1093/ije/26.3.523; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WIEBE DA, 1984, CLIN CHEM, V30, P352; World Health Organization, 1977, INT CLASS DIS	55	117	117	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					239	246		10.1001/jama.282.3.239	http://dx.doi.org/10.1001/jama.282.3.239			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422992	Bronze			2022-12-24	WOS:000081504400029
J	Lin, XH; Perrimon, N				Lin, XH; Perrimon, N			Daily cooperates with Drosophila Frizzled 2 to transduce Wingless signalling	NATURE			English	Article							LONG-RANGE ACTION; EXPRESSION; GENE; GLYCOSAMINOGLYCANS; PROTEOGLYCANS; MORPHOGEN; POLARITY	The Drosophila wingless gene (wg) encodes a protein of the Wnt family and is a critical regulator in many developmental processes(1). Biochemical studies have indicated that heparan sulphate proteoglycans, consisting of a protein core to which heparan sulphate glycosaminoglycans are attached(2), are important for Wg function(3). Here we show that, consistent with these findings, the Drosophila gene sulfateless (sfl), which encodes a homologue of vertebrate heparan sulphate N-deacetylase/N-sulphotransferase (an enzyme needed for the modification of heparan sulphate) is essential for Wg signalling. We have identified the product of division abnormally delayed (dally), a glycosyl-phosphatidyl inositol (GPI)-linked glypican, as a heparan sulphate proteoglycan molecule involved in Wg signalling, Our results indicate that Daily may act as a co-receptor for Wg, and that Daily, together with Drosophila Frizzled 2, modulates both short- and long-range activities of Wg.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Perrimon, N (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA.			Perrimon, Norbert/0000-0001-7542-472X				Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; CADIGAN KM, 1998, DEVELOPMENT, V125, P3075; Cumberledge S, 1997, TRENDS GENET, V13, P421, DOI 10.1016/S0168-9525(97)01275-4; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; Gustafson K, 1996, GENOME, V39, P174, DOI 10.1139/g96-023; HAECKER U, 1997, DEVELOPMENT, V124, P3565; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; NAKATO H, 1995, DEVELOPMENT, V121, P3687; Neumann CJ, 1997, DEVELOPMENT, V124, P871; PERRIMON N, 1996, GENETICS, V144, P168; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sen J, 1998, CELL, V95, P471, DOI 10.1016/S0092-8674(00)81615-3; SIEGFRIED E, 1994, BIOESSAYS, V16, P395, DOI 10.1002/bies.950160607; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; Zhang J, 1998, DEVELOPMENT, V125, P3075	20	396	401	1	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					281	284		10.1038/22343	http://dx.doi.org/10.1038/22343			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421372				2022-12-24	WOS:000081503800048
J	Cheasty, T; Said, B; Threlfall, EJ				Cheasty, T; Said, B; Threlfall, EJ			V cholerae non-01: Implications for man?	LANCET			English	Editorial Material							VIBRIO-CHOLERAE; EPIDEMIOLOGY; HEMOLYSINS		PHLS Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England		Threlfall, EJ (corresponding author), PHLS Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England.							ALDOVA E, 1968, J INFECT DIS, V118, P25, DOI 10.1093/infdis/118.1.25; ARITA M, 1986, INFECT IMMUN, V52, P45, DOI 10.1128/IAI.52.1.45-49.1986; BOOTH BA, 1986, J INFECT DIS, V154, P183, DOI 10.1093/infdis/154.1.183; DAKIN WPH, 1974, MED J AUSTRALIA, V2, P487, DOI 10.5694/j.1326-5377.1974.tb70935.x; DATTAROY K, 1986, APPL ENVIRON MICROB, V52, P875, DOI 10.1128/AEM.52.4.875-879.1986; KAMAL AM, 1971, J EGYPT PUBLIC HLTH, V46, P125; KAPER JB, 1986, J CLIN MICROBIOL, V23, P652, DOI 10.1128/JCM.23.3.652-654.1986; MORRIS JG, 1990, EPIDEMIOL REV, V12, P179, DOI 10.1093/oxfordjournals.epirev.a036052; MORRIS JG, 1990, J CLIN INVEST, V85, P679; RHODES JB, 1985, J CLIN MICROBIOL, V22, P572, DOI 10.1128/JCM.22.4.572-575.1985; ROBERTS D, 1979, J HYG-CAMBRIDGE, V82, P123, DOI 10.1017/S0022172400025547; SANYAL SC, 1974, J INFECT DIS, V130, P575, DOI 10.1093/infdis/130.6.575; SHIMADA T, 1993, LANCET, V341, P1347; Visser IJR, 1999, VET REC, V144, P451, DOI 10.1136/vr.144.16.451; YAMAMOTO K, 1986, INFECT IMMUN, V51, P927, DOI 10.1128/IAI.51.3.927-931.1986	15	11	12	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					89	90		10.1016/S0140-6736(99)00151-8	http://dx.doi.org/10.1016/S0140-6736(99)00151-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408479				2022-12-24	WOS:000081377100005
J	Weng, J; Mata, NL; Azarian, SM; Tzekov, RT; Birch, DG; Travis, GH				Weng, J; Mata, NL; Azarian, SM; Tzekov, RT; Birch, DG; Travis, GH			Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice	CELL			English	Article							RETINAL-PIGMENT EPITHELIUM; ROD DARK-ADAPTATION; PERFORMANCE LIQUID-CHROMATOGRAPHY; GENE ABCR; RETINITIS-PIGMENTOSA; FUNDUS FLAVIMACULATUS; MACULAR DEGENERATION; FATTY-ACIDS; LIGHT ADAPTATION; OUTER SEGMENTS	Rim protein (RmP) is an ABC transporter of unknown function in rod outer segment discs. The human gene for RmP (ABCR) is affected in several recessive retinal degenerations. Here, we characterize the ocular phenotype in abcr knockout mice. Mice lacking RmP show delayed dark adaptation, increased all-trans-retinaldehyde (all-trans-RAL) following light exposure, elevated phosphatidylethanolamine (PE) in outer segments, accumulation of the protonated Schiff base complex of all-trans-RAL and PE (N-retinylidene-PE), and striking deposition of a major lipofuscin fluorophore (A2-E) in retinal pigment epithelium (RPE). These data suggest that RmP functions as an outwardly directed flippase for N-retinylidene-PE. Delayed dark adaptation is likely due to accumulation in discs of the noncovalent complex between opsin and all-trans-RAL. Finally, ABCR-mediated retinal degeneration may result from "poisoning" of the RPE due to A2-E accumulation, with secondary photoreceptor degeneration due to loss of the RPE support role.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75235 USA; Retina Fdn SW, Dallas, TX 75231 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Retina Foundation of the Southwest	Travis, GH (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	travis@utsw.swmed.edu	Travis, Gabriel Harvey/AIF-1062-2022	Travis, Gabriel Harvey/0000-0003-4020-9493; Birch, David/0000-0002-6594-2897; Tzekov, Radouil/0000-0002-3662-9818				ALEXANDER KR, 1984, BRIT J OPHTHALMOL, V68, P561, DOI 10.1136/bjo.68.8.561; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805; ANDERSON RE, 1970, BIOCHEMISTRY-US, V9, P3624, DOI 10.1021/bi00820a019; Azarian SM, 1998, HUM GENET, V102, P699, DOI 10.1007/s004390050765; Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6; BERGSMA DR, 1977, NATURE, V265, P66, DOI 10.1038/265066a0; Birch DG, 1995, DEGENERATIVE DISEASES OF THE RETINA, P359; BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHEN HM, 1992, J CHROMATOGR-BIOMED, V578, P124, DOI 10.1016/0378-4347(92)80234-H; Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355; DAEMEN FJM, 1969, NATURE, V222, P879, DOI 10.1038/222879a0; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; DELAEY JJ, 1995, RETINA-J RET VIT DIS, V15, P399, DOI 10.1097/00006982-199515050-00005; Dogra S, 1999, YEAST, V15, P111, DOI 10.1002/(SICI)1097-0061(19990130)15:2&lt;111::AID-YEA350&gt;3.0.CO;2-E; EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189; Eldred GE, 1995, GERONTOLOGY, V41, P15; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; Fain GL, 1996, TRENDS NEUROSCI, V19, P502, DOI 10.1016/S0166-2236(96)10056-4; FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416; FISHMAN GA, 1991, OPHTHALMOLOGY, V98, P957; FISHMAN GA, 1994, AM J OPHTHALMOL, V118, P362, DOI 10.1016/S0002-9394(14)72961-7; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GRANIT R, 1947, SENSORY MECHANISM RE; GROENENDIJK GWT, 1984, VISION RES, V24, P1623, DOI 10.1016/0042-6989(84)90320-1; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; HOOD DC, 1993, VISUAL NEUROSCI, V10, P857, DOI 10.1017/S0952523800006076; HUBBARD R., 1971, Methods in Enzymology, V18C, P615, DOI 10.1016/S0076-6879(71)18045-7; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; Jager S, 1996, BIOCHEMISTRY-US, V35, P2901, DOI 10.1021/bi9524068; JIN J, 1994, VISUAL NEUROSCI, V11, P389, DOI 10.1017/S0952523800001735; JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P505, DOI 10.1007/BF00181769; Kedzierski W, 1999, J NEUROCHEM, V72, P430, DOI 10.1046/j.1471-4159.1999.0720430.x; Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.3.CO;2-E; KOLB H, 1974, INVEST OPHTH VISUAL, V13, P487; Lee BL, 1999, RETINA VITREOUS MACU, P978; Leibrock CS, 1998, EYE, V12, P511, DOI 10.1038/eye.1998.139; Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; MILJANICH GP, 1981, J MEMBRANE BIOL, V60, P249, DOI 10.1007/BF01992562; NAKATANI K, 1991, J GEN PHYSIOL, V97, P413, DOI 10.1085/jgp.97.3.413; PAPERMASTER DS, 1978, J CELL BIOL, V78, P415, DOI 10.1083/jcb.78.2.415; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Pepperberg DR, 1997, VISUAL NEUROSCI, V14, P73, DOI 10.1017/S0952523800008774; POINCELOT RP, 1969, NATURE, V221, P256, DOI 10.1038/221256a0; Reinboth JJ, 1997, EXP EYE RES, V65, P639, DOI 10.1006/exer.1997.0367; Rozet JM, 1998, EUR J HUM GENET, V6, P291, DOI 10.1038/sj.ejhg.5200221; Saari JC, 1998, VISION RES, V38, P1325, DOI 10.1016/S0042-6989(97)00198-3; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301; STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922; STEINMETZ RL, 1991, OPHTHALMOLOGY, V98, P953; STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549; Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15; SURYA A, 1995, J BIOL CHEM, V270, P5024, DOI 10.1074/jbc.270.10.5024; SUZUKI T, 1986, VISION RES, V26, P425, DOI 10.1016/0042-6989(86)90185-9; TAMURA T, 1989, SCIENCE, V245, P755, DOI 10.1126/science.2772634; Travis GH, 1998, AM J HUM GENET, V62, P503, DOI 10.1086/301772; Tsang SH, 1998, SCIENCE, V282, P117, DOI 10.1126/science.282.5386.117; WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601; WOOD R, 1983, J CHROMATOGR, V254, P237, DOI 10.1016/S0021-9673(01)88338-2; Zhou ZM, 1998, J BIOL CHEM, V273, P12466, DOI 10.1074/jbc.273.20.12466	68	678	711	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					13	23		10.1016/S0092-8674(00)80602-9	http://dx.doi.org/10.1016/S0092-8674(00)80602-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412977	Bronze			2022-12-24	WOS:000081451000004
J	Salmon, DA; Haber, M; Gangarosa, EJ; Phillips, L; Smith, NJ; Chen, RT				Salmon, DA; Haber, M; Gangarosa, EJ; Phillips, L; Smith, NJ; Chen, RT			Health consequences of religious and philosophical exemptions from immunization laws - Individual and societal risk of measles	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION; OUTBREAK	Context All US states require proof of immunization for school entry. Exemptions are generally offered for medical, religious, or philosophical reasons, but the health consequences of claiming such exemptions are poorly documented. Objectives To quantify the risk of contracting measles among individuals claiming religious and/or philosophical exemptions from immunization (exemptors) compared with vaccinated persons, and to examine the risk that exemptors pose to the nonexempt population. Design, Setting, and Participants Population-based, retrospective cohort study of data from 1985 through 1992, collected by the Measles Surveillance System of the Centers for Disease Control and Prevention, as well as from annual state immunization program reports on prevalence of exemptors and vaccination coverage. The study group was restricted to individuals aged 5 to 19 years. To empirically determine and quantify community risk, a mathematical model was developed that examines the spread of measles through communities with varying proportions of exemptors and vaccinated children. Main Outcome Measures Relative risk of contracting measles for exemptors vs vaccinated individuals based on cohort study data. Community risk of contracting measles derived from a mathematical model. Results On average, exemptors were 35 times more likely to contract measles than were vaccinated persons (95% confidence interval, 34-37), Relative risk varied by age and year. Comparing the incidence among exemptors with that among vaccinated children and adolescents during the years 1985-1992 indicated that the 1989-1991 measles resurgence may have occurred 1 year earlier among exemptors. Mapping of exemptors by county in California indicated that exempt populations tended to be clustered in certain geographic regions. Depending on assumptions of the model about the degree of mixing between exemptors and nonexemptors, an increase or decrease in the number of exemptors would affect the incidence of measles in nonexempt populations. If the number of exemptors doubled, the incidence of measles infection in nonexempt individuals would increase by 5.5%, 18.6%, and 30.8%, respectively, for intergroup mixing ratios of 20%, 40%, and 60%. Conclusions These data suggest the need for systematic review of vaccine-preventable incidents to examine the effect of exemptors, increased surveillance of the number of exemptors and cases among them, and research to determine the reasons why individuals claim exemptions.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA; Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Calif Dept Human Serv, Immunizat Branch, Berkeley, CA USA	Centers for Disease Control & Prevention - USA; Emory University; Rollins School Public Health	Salmon, DA (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Room 580,624 N Broadway, Baltimore, MD 21205 USA.		Chen, Robert T/AIA-8164-2022	Chen, Robert T/0000-0002-3094-8367; salmon, daniel/0000-0002-1035-4422	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032042] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI32042] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATKINSON W, 1995, EPIDEMIOLOGY PREVENT; CDC, 1991, MMWR 40, P369; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P414; *CDCP, 1996, MMWR-MORBID MORTAL W, V45, pR3; *CDCP, 1996, STAT IMM REQ 1994 95; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P766; CHEN RT, 1994, VACCINE, V12, P542, DOI 10.1016/0264-410X(94)90315-8; Chen RT, 1998, LANCET, V351, P611, DOI 10.1016/S0140-6736(05)78423-3; ETKIND P, 1992, AM J DIS CHILD, V146, P173, DOI 10.1001/archpedi.1992.02160140039017; FINE PEM, 1986, AM J EPIDEMIOL, V124, P1012, DOI 10.1093/oxfordjournals.aje.a114471; Gangarosa EJ, 1998, LANCET, V351, P356, DOI 10.1016/S0140-6736(97)04334-1; HABER M, 1991, INT J EPIDEMIOL, V20, P300, DOI 10.1093/ije/20.1.300; HARDIN G, 1968, SCIENCE, V162, P1243, DOI 10.1126/science.162.3859.1243; HERSHEY JC, 1994, ORGAN BEHAV HUM DEC, V59, P177, DOI 10.1006/obhd.1994.1055; JACKSON CL, 1969, PUBLIC HEALTH REP, V84, P787, DOI 10.2307/4593678; MELLINGER AK, 1995, PEDIATR INFECT DIS J, V14, P573, DOI 10.1097/00006454-199507000-00004; *NAT HEART LUNG BL, 1998, NIH PUBL, P1; *NAT VAC ADV COMM, 1991, MEASL EP PROBL BARR; NOVOTNY T, 1988, PUBLIC HEALTH REP, V103, P49; OOSTVOGEL PM, 1994, LANCET, V344, P665, DOI 10.1016/S0140-6736(94)92091-5; Plotkin Stanley A., 1994, VACCINES; ROBBINS KB, 1981, AM J PUBLIC HEALTH, V71, P270, DOI 10.2105/AJPH.71.3.270; SUTTER RW, 1991, J INFECT DIS, V163, P12, DOI 10.1093/infdis/163.1.12; WHITE FM, 1979, MMWR-MORBID MORTAL W, V28, P345	24	196	198	0	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					47	53		10.1001/jama.282.1.47	http://dx.doi.org/10.1001/jama.282.1.47			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	212BE	10404911				2022-12-24	WOS:000081195800028
J	Moss, ME; Lanphear, BP; Auinger, P				Moss, ME; Lanphear, BP; Auinger, P			Association of dental caries and blood lead levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; NATIONAL-HEALTH; NHANES-III; CHILDREN; POPULATION; DENTITION	Context Experiments show that dental caries rates are higher among lead-exposed animals, but this association has not been established in humans. Objective To examine the relationship between blood lead levels and dental caries. Design Cross-sectional survey conducted from 1988 to 1994 that included a dental examination and venipuncture blood lead assay. Setting and Participants A total of 24 901 persons aged 2 years and older who participated in the Third National Health and Nutrition Examination Survey, which assessed the health and nutritional status of children and adults in the United States. Main Outcome Measures For children aged 2 to 11 years, the sum of decayed and filled deciduous or primary surfaces; for persons aged 6 years and older, the sum of decayed and filled permanent surfaces; for those 12 years and older, the sum of decayed, missing, and filled surfaces. Results The log of blood lead level was significantly associated with the number of affected surfaces for both deciduous and permanent teeth in all age groups, even after adjusting for sociodemographic characteristics, diet, and dental care. Among children aged 5 to 17 years, a 0.24-mu mol/L (5-mu g/dL) change in blood lead level was associated with an elevated risk of dental caries (odds ratio, 1.8; 95% confidence interval, 1.3-2.5). Differences in blood lead level explained some of the differences in caries prevalence in different income levels and regions of the United States. We estimated the population attributable risk of lead exposure to be 13.5% and 9.6% of dental caries occurring in 5- to 17-year-olds exposed to the high and moderate levels, respectively. Conclusions Environmental lead exposure is associated with an increased prevalence of dental caries in the US population, Findings may help explain the distribution of caries by income and region of the United States.	Univ Rochester, Sch Med & Dent, Eastman Dept Dent, Rochester, NY USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Childrens Hosp, Med Ctr, Dept Pediat, Rochester, NY USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA	University of Rochester; University of Rochester; University System of Ohio; University of Cincinnati	Moss, ME (corresponding author), Univ Rochester, Med Ctr, Dept Community & Prevent Med, Box 644,601 Elmwood Ave, Rochester, NY 14642 USA.	moss@prevmed.rochester.edu	Moss, Mark E/Q-3014-2019; Moss, Mark E/AAF-1697-2020	Moss, Mark E/0000-0003-0105-0416	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D15PE010027] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01-ES-08338] Funding Source: Medline; BHP HRSA HHS [1T-32 PE-10027] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); BHP HRSA HHS		BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; BRUDEVOLD F, 1977, J DENT RES, V56, P1165, DOI 10.1177/00220345770560100701; Brunelle J A, 1990, J Dent Res, V69 Spec No, P723; BRUNELLE JA, 1982, J DENT RES, V61, P1346; *CDC, 1992, MMWR-MORBID MORTAL W, V41, P381; *CDC, 1992, MMWR-MORBID MORTAL W, V41, P372; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P141; Curzon M.E.J., 1983, TRACE ELEMENTS DENT; DAVIES BE, 1987, EXPERIENTIA, V43, P87, DOI 10.1007/BF01940359; Drury TF, 1996, J DENT RES, V75, P620, DOI 10.1177/002203459607502S02; EDELSTEIN BL, 1995, PUBLIC HEALTH REP, V110, P522; Gil F, 1996, SCI TOTAL ENVIRON, V192, P183, DOI 10.1016/S0048-9697(96)05313-2; GIL F, 1994, SCI TOTAL ENVIRON, V156, P145, DOI 10.1016/0048-9697(94)90351-4; HAYES EB, 1994, PEDIATRICS, V93, P195; Kaste LM, 1996, J DENT RES, V75, P631, DOI 10.1177/002203459607502S03; McClure Frank J., 1970, WATER FLUORIDATION S; RAO GS, 1984, ANNU REV NUTR, V4, P115, DOI 10.1146/annurev.nu.04.070184.000555; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; Stack MV, 1983, TRACE ELEMENTS DENTA, P357; Stamm J. W., 1991, RISK MARKERS ORAL DI, V1, P132; Vargas CM, 1998, J AM DENT ASSOC, V129, P1229, DOI 10.14219/jada.archive.1998.0420; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; Watson GE, 1997, NAT MED, V3, P1024, DOI 10.1038/nm0997-1024; Winn DM, 1996, J DENT RES, V75, P642, DOI 10.1177/002203459607502S04; [No title captured]	26	81	85	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2294	2298		10.1001/jama.281.24.2294	http://dx.doi.org/10.1001/jama.281.24.2294			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386553				2022-12-24	WOS:000080925600028
J	Bashaw, GJ; Goodman, CS				Bashaw, GJ; Goodman, CS			Chimeric axon guidance receptors: The cytoplasmic domains of slit and netrin receptors specify attraction versus repulsion	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; GENETIC-ANALYSIS; CNS MIDLINE; COLORECTAL-CANCER; SEMAPHORIN-III; MOTOR AXONS; DROSOPHILA; PROTEIN; COMPLEMENTARY	Frazzled (Fra) is the DCC-like Netrin receptor in Drosophila that mediates attraction; Roundabout (Robo) is a Slit receptor that mediates repulsion. Both ligands are expressed at the midline; both receptors have related structures and are often expressed by the same neurons. To determine if attraction versus repulsion is a modular function encoded in the cytoplasmic domain of these receptors, we created chimeras carrying the ectodomain of one receptor and the cytoplasmic domain of the other and tested their function in transgenic Drosophila. Fra-Robo (Fra's ectodomain and Robe's cytoplasmic domain) functions as a repulsive Netrin receptor; neurons expressing Fra-Robo avoid the Netrin-expressing midline and muscles. Robo-Fra (Robo's ectodomain and Fra's cytoplasmic domain) is an attractive Slit receptor; neurons and muscle precursors expressing Robo-Fra are attracted to the Slit-expressing midline.	Univ Calif Berkeley, Dept Cell & Mol Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Goodman, CS (corresponding author), Univ Calif Berkeley, Dept Cell & Mol Biol, Howard Hughes Med Inst, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagnard D, 1998, DEVELOPMENT, V125, P5043; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Hong KS, 1999, CELL, V97, P927, DOI 10.1016/S0092-8674(00)80804-1; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; Kidd T, 1999, CELL, V96, P785, DOI 10.1016/S0092-8674(00)80589-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; Li HS, 1999, CELL, V96, P807, DOI 10.1016/S0092-8674(00)80591-7; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; Wang KH, 1999, CELL, V96, P771, DOI 10.1016/S0092-8674(00)80588-7; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Wong JTW, 1997, DEVELOPMENT, V124, P3597	37	161	171	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					917	926		10.1016/S0092-8674(00)80803-X	http://dx.doi.org/10.1016/S0092-8674(00)80803-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399919	Bronze			2022-12-24	WOS:000081162800012
J	Bacon, BR; Olynyk, JK; Brunt, EM; Britton, RS; Wolff, RK				Bacon, BR; Olynyk, JK; Brunt, EM; Britton, RS; Wolff, RK			HFE genotype in patients with hemochromatosis and other liver diseases	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEPATIC IRON INDEX; HEREDITARY HEMOCHROMATOSIS; NONALCOHOLIC STEATOHEPATITIS; GENETIC HEMOCHROMATOSIS; MUTATION ANALYSIS; HLA-H; FIBROSIS; HETEROZYGOTES; OVERLOAD	Background: Hereditary hemochromatosis is a common inherited disorder of iron metabolism. The gene HFE, which contains two missense mutations (C282Y and H63D), was recently identified. Objective: To determine how HFE genotyping for the C282Y and H63D mutations contributes to the diagnosis of hemochromatosis and to determine the prevalence of HFE mutations in a group of patients with liver disease. Design: Cross-sectional study. Setting: Academic medical center. Patients: 66 patients with hereditary hemochromatosis and 132 referred patients with other liver diseases. Measurements: At initial diagnosis, fasting transferrin saturation, ferritin level, routine chemistry panel, and complete blood count were determined. Percutaneous liver biopsy was done on all patients for histologic analysis and measurement of hepatic iron concentration and hepatic iron index. HFE genotyping for the C282Y and H63D mutations was done on all patients by using genomic DNA samples. Results: Of the 66 patients with hemochromatosis diagnosed on the basis of serum iron studies and liver biopsy findings, 60 (91%) were C282Y homozygotes, 2 (3%) were compound heterozygotes, 1 (1.5%)was a C282Y heterozygote, 2 (3%) were H63D heterozygotes, and 1 (1.5%) was negative for both mutations, Of the 132 patients with liver disease, 6 (5%) were C282Y homozygotes, 8 (6%) were compound heterozygotes, 6 (5%) were C282Y heterozygotes, 5 (4%) were H63D homozygotes, 20 (15%) were H63D heterozygotes, and 87 (66%) were negative for both mutations, All 66 C282Y homozygotes had an elevated hepatic iron concentration, and 65 of the 66 patients (98%) had a transferrin saturation of at least 45%, Ten of the 66 patients (15% [95% Cl, 7.5% to 26%]) had a hepatic iron index less than 1.9 mmol/kg per year; hemochromatosis was not suspected in 6 of the 10 patients before genotyping. Cirrhosis or substantial hepatic fibrosis was not seen in any (0% [Cl, 0% to 18%]) of the 19 patients younger than 40 years of age who were homozygous for the C282Y mutation. Conclusions: All 66 patients homozygous for the C282Y mutation of HFE had an elevated hepatic iron concentration, but approximately 15% of these patients did not meet a previous diagnostic criterion for hemochromatosis (hepatic iron index > 1.9 mmol/kg per year). Determination of HFE genotype is clinically useful in patients with liver disease and suspected iron overload and may lead to identification of otherwise unsuspected C282Y homozygotes.	Univ Dept Med, Dept Gastroenterol, Fremantle Hosp, Fremantle 6160, Australia; St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Sch Med,Dept Pathol, St Louis, MO 63110 USA; Progenitor Inc, Menlo Pk, CA 94025 USA	University of Western Australia; Saint Louis University	Bacon, BR (corresponding author), St Louis Univ, Hlth Sci Ctr, Div Gastroenterol & Hepatol, Sch Med,Dept Pathol, 3635 Vista Ave, St Louis, MO 63110 USA.	baconbr@slu.edu		Olynyk, John/0000-0003-0417-3411	NIDDK NIH HHS [DK-41816] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041816] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; Bacon BR, 1997, AM J GASTROENTEROL, V92, P784; BACON BR, 1994, GASTROENTEROLOGY, V107, P1103, DOI 10.1016/0016-5085(94)90235-6; Bacon Bruce R., 1999, Gastroenterology, V116, P193, DOI 10.1016/S0016-5085(99)70244-1; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Beutler Ernest, 1996, Blood Cells Molecules and Diseases, V22, P187, DOI 10.1006/bcmd.1996.0027; BONKOVSKY HL, 1990, GASTROENTEROLOGY, V99, P1079, DOI 10.1016/0016-5085(90)90629-F; Bothwell, 1980, METHODS HEMATOLOGY, V1, P90; Burke W, 1998, JAMA-J AM MED ASSOC, V280, P172, DOI 10.1001/jama.280.2.172; Carella M, 1997, AM J HUM GENET, V60, P828; CHAPMAN RW, 1982, DIGEST DIS SCI, V27, P909, DOI 10.1007/BF01316575; DEUGNIER YM, 1993, HEPATOLOGY, V17, P30, DOI 10.1002/hep.1840170107; DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; FARGION S, 1994, HEPATOLOGY, V20, P1426, DOI 10.1002/hep.1840200608; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; George DK, 1998, GASTROENTEROLOGY, V114, P311, DOI 10.1016/S0016-5085(98)70482-2; Grove J, 1998, GUT, V43, P262, DOI 10.1136/gut.43.2.262; Guyader D, 1998, GASTROENTEROLOGY, V115, P929, DOI 10.1016/S0016-5085(98)70265-3; Jawaid O, 1998, GASTROENTEROLOGY, V114, pA1264; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kazemi-Shirazi L, 1999, GASTROENTEROLOGY, V116, P127, DOI 10.1016/S0016-5085(99)70236-2; Kowdley KV, 1997, GASTROENTEROLOGY, V113, P1270, DOI 10.1053/gast.1997.v113.pm9322522; Ludwig J, 1997, GASTROENTEROLOGY, V112, P882, DOI 10.1053/gast.1997.v112.pm9041250; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OLYNYK J, 1990, HEPATOLOGY, V12, P26, DOI 10.1002/hep.1840120106; Piperno A, 1998, HEPATOLOGY, V28, P1105, DOI 10.1002/hep.510280427; SEARLE JW, 1994, PATHOLOGY LIVER, P223; Smith BC, 1998, HEPATOLOGY, V27, P1695, DOI 10.1002/hep.510270631	32	153	158	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					953	962		10.7326/0003-4819-130-12-199906150-00002	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383365				2022-12-24	WOS:000080894700001
J	Adams, JFA; Scholvinck, EH; Gie, RP; Potter, PC; Beyers, N; Beyers, AD				Adams, JFA; Scholvinck, EH; Gie, RP; Potter, PC; Beyers, N; Beyers, AD			Decline in total serum IgE after treatment for tuberculosis	LANCET			English	Article							CELLULAR IMMUNE-RESPONSES; T-CELL; RECEPTOR DEFICIENCY; SKIN-TEST; INFECTION; MYCOBACTERIAL; HELMINTH; MICE; MODULATION	Background. Infection with Mycobacterium tuberculosis induces a type-1 immune response, whereas intestinal parasites elicit a type-2 response. Given that type-1 and type-2 responses inhibit each other, we investigated. if M tuberculosis downregulates serum IgE, a marker of a type-2 response. Methods. A prospective study was done in the Western Cape Province of South Africa, where tuberculosis and intestinal-parasite infection are common. Total serum IgE was determined for 37 controls and for 33 adolescent patients at presentation with tuberculosis and after successful completion of treatment. IgE specific for ascaris and allergens were measured in a subset of these individuals. Mantoux skin tests were done on 35 controls and on 31 patients at diagnosis. Findings. Total IgE concentrations were high in controls (mean 313 kU/L) and in patients before treatment (mean 457 kU/L, p = 0.085) and declined in all patients following successful treatment (mean 175 kU/L, p < 0.0001). Posttreatment IgE concentrations did not differ from concentrations in controls. Ascaris-specific IgE was lower in controls (mean 1.73 kU/L) than in patients before treatment (4.62 kU/L, p = 0.023) and was 2.39 kU/L in patients after treatment (p = 0.0625). Tuberculin induration correlated inversely with IgE in patients but not in controls. Interpretation. Infection with M tuberculosis as such is not incompatible with a prominent IgE response. IgE concentrations decreased after successful treatment of tuberculosis, showing that IgE concentrations in human beings can be downregulated under these circumstances, presumably due to enhancement of a type-1 response.	Univ Stellenbosch, Sch Med, Ctr Cellular & Mol Biol, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Sch Med, Dept Biochem Med, ZA-7505 Tygerberg, South Africa; Univ Stellenbosch, Sch Med, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa; Univ Cape Town, Sch Med, Dept Immunol, ZA-7700 Rondebosch, South Africa	Stellenbosch University; Stellenbosch University; Stellenbosch University; University of Cape Town	Beyers, AD (corresponding author), Univ Stellenbosch, Sch Med, Ctr Cellular & Mol Biol, POB 19063, ZA-7505 Tygerberg, South Africa.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; Arnadottir T, 1996, TUBERCLE LUNG DIS, V77, P1, DOI 10.1016/S0962-8479(96)90127-6; BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; Beyers N, 1996, S AFR MED J, V86, P40; BUNDY DAP, 1991, PARASITE IMMUNOL, V13, P629, DOI 10.1111/j.1365-3024.1991.tb00558.x; Calleja C, 1998, NAT MED, V4, P92, DOI 10.1038/nm0198-092; CHAN MS, 1994, PARASITOLOGY, V109, P373, DOI 10.1017/S0031182000078410; de Jong R, 1998, SCIENCE, V280, P1435; *DEP HLTH, 1996, EPIDEMIOLOGICAL COMM, V23, P22; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; FERREIRA AP, 1995, CELL IMMUNOL, V162, P202, DOI 10.1006/cimm.1995.1070; GREENE BM, 1985, REV INFECT DIS, V7, P789; Gunders AE, 1993, S AFR J EPIDEMIOL IN, V8, P48; Israel HL., 1941, JAMA-J AM MED ASSOC, V117, P461; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; KAHN EA, 1995, EMERG INFECT DIS, V1, P115; MAHER J, 1992, RESP MED, V86, P481, DOI 10.1016/S0954-6111(96)80006-0; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; NEEDHAM CS, 1992, PARASITOLOGY, V105, P273, DOI 10.1017/S0031182000074205; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; PEARLMAN E, 1993, J IMMUNOL, V151, P4857; Ramirez F, 1996, J IMMUNOL, V156, P2406; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; SARTONO E, 1995, J INFECT DIS, V171, P1683, DOI 10.1093/infdis/171.6.1683; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SNIDER DE, 1982, AM REV RESPIR DIS, V125, P108; SPENCE DPS, 1993, BRIT MED J, V307, P759, DOI 10.1136/bmj.307.6907.759; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; Wang CC, 1998, IMMUNOLOGY, V93, P307; Wilkinson RJ, 1998, J INFECT DIS, V178, P760, DOI 10.1086/515336; YONG AJ, 1989, TUBERCLE, V70, P273, DOI 10.1016/0041-3879(89)90021-4	35	52	56	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 12	1999	353	9169					2030	2033		10.1016/S0140-6736(98)08510-9	http://dx.doi.org/10.1016/S0140-6736(98)08510-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	205GD	10376618				2022-12-24	WOS:000080812200013
J	Jacob, J; Baltimore, D				Jacob, J; Baltimore, D			Modelling T-cell memory by genetic marking of memory T cells in vivo	NATURE			English	Article							LYMPHOCYTES-T; IMMUNOLOGICAL MEMORY; GERMINAL-CENTERS; VIRUS-INFECTION; ANTIGEN; PERSISTENCE; EXPRESSION; REGION; CD2	Immunological memory is the ability of the immune system to respond with enhanced vigour to pathogens that have been encountered in the past. Following infection or immunization, most effector T cells undergo apoptotic cell death, but a small fraction of these cells, proportional to the early antigen load and initial clonal burst size(1), persist in the host as a stable pool of memory T cells(2-7). The existence of immunological memory has been recognized for over 2,000 years, but our understanding of this phenomenon is limited, primarily because memory lymphocytes cannot be unequivocally identified as they lack specific, permanent markers. Here we have developed a transgenic mouse model system whereby memory T cells and their precursors can be irreversibly marked with a reporter gene and thus can be unambiguously identified. Adoptive transfer of marked CD8(+) T cells specific for lymphocytic choriomeningitis virus protected naive recipients following viral challenge, demonstrating that we have marked memory T cells. We also show that cytotoxic effector lymphocytes that develop into memory T cells can be identified in the primary response.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; AHMED R, 1984, J VIROL, V51, P34, DOI 10.1128/JVI.51.1.34-41.1984; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Castan J, 1997, IMMUNOLOGY, V90, P265, DOI 10.1046/j.1365-2567.1997.00162.x; CEPKO C, 1995, METHOD ENZYMOL, V254, P387; Doherty PC, 1996, IMMUNOL REV, V150, P23, DOI 10.1111/j.1600-065X.1996.tb00694.x; FULLER KA, 1993, J IMMUNOL, V151, P4505; GulbransonJudge A, 1996, EUR J IMMUNOL, V26, P1830, DOI 10.1002/eji.1830260825; HANSON RD, 1991, J BIOL CHEM, V266, P24433; HOU S, 1994, NATURE, V369, P652, DOI 10.1038/369652a0; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; Kundig TM, 1996, IMMUNOL REV, V150, P63, DOI 10.1111/j.1600-065X.1996.tb00696.x; LASKO M, 1992, P NATL ACAD SCI USA, V89, P6232; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; Mullbacher A, 1996, IMMUNOL REV, V150, P113, DOI 10.1111/j.1600-065X.1996.tb00698.x; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; Nagy A, 1998, CURR BIOL, V8, P661, DOI 10.1016/S0960-9822(98)70254-4; NAHILL SR, 1993, J EXP MED, V177, P317, DOI 10.1084/jem.177.2.317; SELIN LK, 1994, J EXP MED, V179, P1933, DOI 10.1084/jem.179.6.1933; Swain SL, 1996, IMMUNOL REV, V150, P143, DOI 10.1111/j.1600-065X.1996.tb00700.x; TOUGH DF, 1995, IMMUNOL RES, V14, P1, DOI 10.1007/BF02918494; Welsh RM, 1997, IMMUNOL REV, V159, P79, DOI 10.1111/j.1600-065X.1997.tb01008.x; WILLIAMS AF, 1987, J EXP MED, V165, P368, DOI 10.1084/jem.165.2.368; WOTTON D, 1989, P NATL ACAD SCI USA, V86, P4195, DOI 10.1073/pnas.86.11.4195; YANG HY, 1989, J IMMUNOL, V142, P1710; Zheng B, 1996, NATURE, V384, P263, DOI 10.1038/384263a0; ZHUMABEKOV T, 1991, J BIOL CHEM, V266, P24433; Zimmermann C, 1996, J EXP MED, V183, P1367, DOI 10.1084/jem.183.4.1367; Zinkernagel RM, 1996, ANNU REV IMMUNOL, V14, P333, DOI 10.1146/annurev.immunol.14.1.333	30	235	239	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					593	597		10.1038/21208	http://dx.doi.org/10.1038/21208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376601				2022-12-24	WOS:000080778400058
J	Mackenbach, JP; Kunst, AE				Mackenbach, JP; Kunst, AE			Heterogeneity of populations should be taken into account - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Mackenbach, JP (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.			Kunst, Anton/0000-0002-3313-5273				Cavelaars A E, 1997, J Health Psychol, V2, P353, DOI 10.1177/135910539700200306; KAPLAN GA, 1993, CIRCULATION, V88, P1973, DOI 10.1161/01.CIR.88.4.1973; Kunst AE, 1999, AM J PUBLIC HEALTH, V89, P47, DOI 10.2105/AJPH.89.1.47; MANCIA G, 1988, AM HEART J, V115, P240, DOI 10.1016/0002-8703(88)90643-6; *WHO, 1997, WHO REG UBL EUR SER, V75	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1999	318	7196					1478	1479						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419295				2022-12-24	WOS:000080668200031
J	Donald, PR				Donald, PR			Children and tuberculosis: protecting the next generation?	LANCET			English	Article									Univ Stellenbosch, Fac Med, Dept Paediat & Child Hlth, ZA-7505 Tygerberg, South Africa	Stellenbosch University	Donald, PR (corresponding author), Univ Stellenbosch, Fac Med, Dept Paediat & Child Hlth, POB 19063, ZA-7505 Tygerberg, South Africa.	aec1@maties.sun.ac.za						BENTLEY FJ, 1954, TUBERCULOSIS CHILDHO, P232; Beyers N, 1996, S AFR MED J, V86, P40; FOURIE PB, 1999, TUBERCULOSIS CHILDRE, P27; FOX W, 1981, Bulletin of the International Union Against Tuberculosis, V56, P135; Halsey NA, 1998, LANCET, V351, P786, DOI 10.1016/S0140-6736(97)06532-X; LINCOLN EM, 1951, AM REV TUBERC PULM, V64, P499; MITCHISON DA, 1982, B INT UNION TUBERC, V42, P140; RICH AR, 1951, PATHOGENESIS TUBERCU, P182; SETH V, 1991, TUBERCULOSIS CHILDRE, P1; van Helden PD, 1998, NOVART FDN SYMP, V217, P178, DOI 10.1002/0470846526.ch13	10	19	20	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1001	1002		10.1016/S0140-6736(99)02010-3	http://dx.doi.org/10.1016/S0140-6736(99)02010-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459927				2022-12-24	WOS:000079421600048
J	Greengold, NL				Greengold, NL			Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1999	282	8					716	717		10.1001/jama.282.8.716	http://dx.doi.org/10.1001/jama.282.8.716			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	228CJ	10463694				2022-12-24	WOS:000082118800001
J	Margolis, D				Margolis, D			Neuroscience 2000: A new era of discovery	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					318	320		10.7326/0003-4819-131-4-199908170-00102	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00102			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454964				2022-12-24	WOS:000082012500025
J	Plenz, D; Kital, ST				Plenz, D; Kital, ST			A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus	NATURE			English	Article							INTRACELLULAR ANALYSIS; FUNCTIONAL-ANATOMY; PARKINSONS-DISEASE; NEURONAL-ACTIVITY; MPTP MODEL; RAT; MONKEY; DISINHIBITION; STIMULATION; LESION	The subthalamic nucleus of the basal ganglia (STN) is important for normal movement(1,2) as well as in movement disorders(3-5). Lesioning(6) or deep-brain stimulation(7,8) of the STN can alleviate resting tremor in Parkinson's disease. The STN5 and its target nuclei(9,10) display synchronized oscillatory burst discharge at low frequencies, some of which correlate with tremor, but the mechanism underlying this synchronized bursting is unknown. Here we show that the excitatory STN and inhibitory, external globus pallidus (GPe) form a feedback system that engages in synchronized bursting. In mature organotypic cortex-striatum-STN-GPe cultures, neurons in the STN and GPe spontaneously produce synchronized oscillating bursts at 0.4, 0.8 and 1.8 Hz. Pallidal lesion abolishes this bursting, whereas cortical lesion favours bursting at 0.8 Hz. Pallidal bursts, although weaker than STN bursts, were required for synchronized oscillatory burst generation by recruitment of subthalmic rebound excitation. We propose that the STN and GPe constitute a central pacemaker modulated by striatal inhibition of GPe neurons. This pacemaker could be responsible for synchronized oscillatory activity in the normal and pathological basal ganglia.	Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Plenz, D (corresponding author), Univ Tennessee, Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA.							ABELES M, 1982, J NEUROSCI METH, V5, P317, DOI 10.1016/0165-0270(82)90002-4; ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; ALDRIDGE JW, 1991, BRAIN RES, V543, P123; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Chesselet MF, 1996, TRENDS NEUROSCI, V19, P417; CHEVALIER G, 1990, TRENDS NEUROSCI, V13, P277, DOI 10.1016/0166-2236(90)90109-N; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; DELONG MR, 1971, J NEUROPHYSIOL, V34, P414, DOI 10.1152/jn.1971.34.3.414; FILION M, 1979, BRAIN RES, V178, P425, DOI 10.1016/0006-8993(79)90704-2; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hurtado JM, 1999, P NATL ACAD SCI USA, V96, P1674, DOI 10.1073/pnas.96.4.1674; KITA H, 1992, BRAIN RES, V589, P84, DOI 10.1016/0006-8993(92)91164-A; KITA H, 1983, BRAIN RES, V264, P255, DOI 10.1016/0006-8993(83)90823-5; KITAI ST, 1981, BRAIN RES, V214, P411, DOI 10.1016/0006-8993(81)91204-X; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; MATSUMURA M, 1992, J NEUROPHYSIOL, V67, P1615, DOI 10.1152/jn.1992.67.6.1615; NAKANISHI H, 1987, BRAIN RES, V437, P35, DOI 10.1016/0006-8993(87)91524-1; NINI A, 1995, J NEUROPHYSIOL, V74, P1800, DOI 10.1152/jn.1995.74.4.1800; PAN HS, 1988, SYNAPSE, V2, P650, DOI 10.1002/syn.890020612; PARENT A, 1995, BRAIN RES REV, V20, P128, DOI 10.1016/0165-0173(94)00008-D; Plenz D, 1998, J COMP NEUROL, V397, P437, DOI 10.1002/(SICI)1096-9861(19980810)397:4<437::AID-CNE1>3.0.CO;2-2; Rodriguez MC, 1998, MOVEMENT DISORD, V13, P111; Ruskin DN, 1999, J NEUROPHYSIOL, V81, P2046, DOI 10.1152/jn.1999.81.5.2046; Shink E, 1996, NEUROSCIENCE, V73, P335, DOI 10.1016/0306-4522(96)00022-X; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P494, DOI 10.1152/jn.1994.72.2.494; Wichmann T, 1996, CURR OPIN NEUROBIOL, V6, P751, DOI 10.1016/S0959-4388(96)80024-9; WURTZ RH, 1986, PROG BRAIN RES, V64, P175	30	529	537	2	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					677	682		10.1038/23281	http://dx.doi.org/10.1038/23281			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458164				2022-12-24	WOS:000082032900057
J	Liu, JJ; Lindquist, S				Liu, JJ; Lindquist, S			Oligopeptide-repeat expansions modulate 'protein-only' inheritance in yeast	NATURE			English	Article							HUMAN PRION PROTEIN; DE-NOVO APPEARANCE; SACCHAROMYCES-CEREVISIAE; SUP35 GENE; PROPAGATION; PSI; DETERMINANT; TRANSLATION; TERMINATION; HYPOTHESIS	The yeast [PSI+] element represents a new type of genetic inheritance, in which changes in phenotype are transmitted by a 'protein only' mechanism(1-3) reminiscent of the 'protein-only' transmission of mammalian prion diseases(1,4). The underlying molecular mechanisms for both are poorly understood and it is not clear how similar they might be. Sup35, the [PSI+] protein determinant, and PrP, the mammalian prion determinant, have different functions, different cellular locations and no sequence similarity; however, each contains five imperfect oligopeptide repeats-PQGGYQQYN in Sup35 and PHGGGWGQ in PrP5,6. Repeat expansions in PrP produce spontaneous prion diseases(7,8). Here we show that replacing the wild-type SUP35 gene with a repeat-expansion mutation induces new [PSI+] elements, the first mutation of its type among these newly described elements of inheritance. In vitro, fully denatured repeat-expansion peptides can adopt conformations rich in beta-sheets and form higher-order structures much more rapidly than wild-type peptides. Our results provide insight into the nature of the conformational changes underlying protein-based mechanisms of inheritance and suggest a link between this process and those producing neurodegenerative prion diseases in mammals.	Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	Lindquist, S (corresponding author), Univ Chicago, Howard Hughes Med Inst, Dept Mol Genet & Cell Biol, 5841 S Maryland Ave,MC1028, Chicago, IL 60637 USA.							Ausubel FM., 2006, ENZYMATIC MANIPULATI; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHERNOFF YO, 1993, CURR GENET, V24, P268, DOI 10.1007/BF00351802; Chiesa R, 1998, NEURON, V21, P1339, DOI 10.1016/S0896-6273(00)80653-4; DePace AH, 1998, CELL, V93, P1241, DOI 10.1016/S0092-8674(00)81467-1; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Glover JR, 1997, CELL, V89, P811, DOI 10.1016/S0092-8674(00)80264-0; Goldmann W, 1998, J GEN VIROL, V79, P3173, DOI 10.1099/0022-1317-79-12-3173; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; MCCUTCHEN SL, 1995, BIOCHEMISTRY-US, V34, P13527, DOI 10.1021/bi00041a032; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1997, SCIENCE, V277, P381, DOI 10.1126/science.277.5324.381; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1997, ANNU REV GENET, V31, P139, DOI 10.1146/annurev.genet.31.1.139; SERIO TR, IN PRESS METHODS ENZ; SIKORSKI RS, 1989, GENETICS, V122, P19; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; THIELE DJ, 1988, MOL CELL BIOL, V8, P2745, DOI 10.1128/MCB.8.7.2745; TUITE MF, 1981, GENETICS, V98, P691; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; ZHOURAVLEVA G, 1995, EMBO J, V14, P4065, DOI 10.1002/j.1460-2075.1995.tb00078.x	29	176	180	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 5	1999	400	6744					573	576		10.1038/23048	http://dx.doi.org/10.1038/23048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223RT	10448860				2022-12-24	WOS:000081854800058
J	Stoddard, PK				Stoddard, PK			Predation enhances complexity in the evolution of electric fish signals	NATURE			English	Article							ORDER GYMNOTIFORMES; ELECTRORECEPTION; LEPIDOPTERA; COURTSHIP; ARCTIIDAE	Theories of sexual selection assume that predation is a restrictive, simplifying force in the evolution of animal display characters' and many empirical studies have shown that predation opposes excessive elaboration of sexually selected traits(2). In an unexpected turnaround, I show here that predation pressure on neotropical, weakly electric fish (order Gymnotiformes) seems to have selected for greater signal complexity, by favouring characters that have enabled further signal elaboration by sexual selection. Most gymnotiform fish demonstrate adaptations that lower detectability of their electrolocation/communication signals by key predators. A second wave phase added to the ancestral monophasic signal shifts the emitted spectrum above the most sensitive frequencies of electroreceptive predators. By using playback trials with the predatory electric eel (Electrophorus electricus), I show that these biphasic signals are less detectable than the primitive monophasic signals. But sexually mature males of many species in the family Hypopomidae extend the duration of the second phase of their electric signal pulses(3) and further amplify this sexual dimorphism nightly during the peak hours of reproduction(4). Thus a signal element that evolved for crypsis has itself been modified by sexual selection.	Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA	State University System of Florida; Florida International University	Stoddard, PK (corresponding author), Florida Int Univ, Dept Biol Sci, Miami, FL 33199 USA.	stoddard@fiu.edu	Stoddard, Philip K/AAY-4188-2020					Albert JS, 1996, COPEIA, P85; ALVESGOMES JA, 1995, MOL BIOL EVOL, V12, P298; Andersson Malte, 1994; BENNETT LA, 1971, J RES CRIME DELINQ, V8, P1, DOI 10.1177/002242787100800101; BENNETT MV, 1961, ANN NY ACAD SCI, V94, P458, DOI 10.1111/j.1749-6632.1961.tb35555.x; BULLOCK TH, 1982, ANNU REV NEUROSCI, V5, P121, DOI 10.1146/annurev.ne.05.030182.001005; Crampton William G. R., 1998, Anais da Academia Brasileira de Ciencias, V70, P805; Darwin C., 1871, DESCENT MAN SELECTIO; DUNNING BB, 1973, THESIS U MINNESOTA; EHRLICH PR, 1964, EVOLUTION, V18, P586, DOI 10.2307/2406212; Franchina CR, 1998, J COMP PHYSIOL A, V183, P759, DOI 10.1007/s003590050299; HAGEDORN M, 1988, COPEIA, P324; Hopkins C.D., 1986, P527; HOPKINS CD, 1990, BRAIN BEHAV EVOLUT, V35, P350, DOI 10.1159/000115880; HOPKINS CD, 1978, BEHAV ECOL SOCIOBIOL, V3, P113, DOI 10.1007/BF00294985; HOPKINS CD, 1976, J COMP PHYSIOL, V111, P171, DOI 10.1007/BF00605531; KIRSCHBAUM F, 1995, ELECT FISHES HIST BE, P267; LISSMANN HW, 1958, J EXP BIOL, V35, P156; MCCREERY DB, 1977, J COMP PHYSIOL, V113, P317, DOI 10.1007/BF00620405; MERRON GS, 1993, J FISH BIOL, V43, P575; MILLER RR, 1966, COPEIA, P773, DOI 10.2307/1441406; Moller P., 1995, ELECT FISHES HIST BE; PETERS RC, 1972, J COMP PHYSIOL, V79, P29, DOI 10.1007/BF00693616; REID S, 1983, REV UNELLEZ CIENC TE, V0001, P00013; SANDERFORD MV, 1995, J INSECT BEHAV, V8, P19, DOI 10.1007/BF01990967; SHUMWAY CA, 1988, J COMP PHYSIOL A, V163, P465, DOI 10.1007/BF00604901; Simmons RB, 1996, J INSECT BEHAV, V9, P909, DOI 10.1007/BF02208978; SULLIVAN JP, 1997, THESIS DUKE U; Szabo T., 1974, P59; WESTBY GWM, 1988, BEHAV ECOL SOCIOBIOL, V22, P341	30	128	134	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					254	256		10.1038/22301	http://dx.doi.org/10.1038/22301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421365				2022-12-24	WOS:000081503800041
J	Johnson, RE; Kondratick, CM; Prakash, S; Prakash, L				Johnson, RE; Kondratick, CM; Prakash, S; Prakash, L			hRAD30 mutations in the variant form of xeroderma pigmentosum	SCIENCE			English	Article							ESCHERICHIA-COLI DINB; POSTREPLICATION REPAIR; EXCISION-REPAIR; DNA-SYNTHESIS; REPLICATION; SENSITIVITY; HOMOLOG; BYPASS; DIMER; CELLS	Xeroderma pigmentosum (XP) is an autosomal recessive disease characterized by a high incidence of skin cancers. Yeast RAD30 encodes a DNA polymerase involved in the error-free bypass of ultraviolet (UV) damage. Here it is shown that XP variant (XP-V) cell lines harbor nonsense or frameshift mutations in hRAD30, the human counterpart of yeast RAD30. Of the eight mutations identified, seven would result in a severely truncated hRad30 protein. These results indicate that defects in hRAD30 cause XP-V, and they suggest that error-free replication of UV lesions by hRad30 plays an important role in minimizing the incidence of sunlight-induced skin cancers.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Prakash, L (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 6-104 Med Res Bldg,11th & Mech St, Galveston, TX 77555 USA.		Prakash, Louise/C-7891-2012; Prakash, Satya/C-6420-2013	Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444	NIGMS NIH HHS [GM19261] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOYER JC, 1990, CANCER RES, V50, P2593; CLEAVER JE, 1980, CARCINOGENESIS, V1, P647, DOI 10.1093/carcin/1.8.647; CLEAVER JE, 1972, J INVEST DERMATOL, V58, P124, DOI 10.1111/1523-1747.ep12538913; CLEAVER JE, 1981, CYTOGENET CELL GENET, V31, P188, DOI 10.1159/000131646; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; KONDRATICK CM, UNPUB; KRAEMER KH, 1994, J INVEST DERMATOL, V103, pS96, DOI 10.1111/1523-1747.ep12399329; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; McDonald JP, 1997, GENETICS, V147, P1557; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Roush AA, 1998, MOL GEN GENET, V257, P686; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Svoboda DL, 1998, CANCER RES, V58, P2445; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276	17	657	669	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					263	265		10.1126/science.285.5425.263	http://dx.doi.org/10.1126/science.285.5425.263			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398605				2022-12-24	WOS:000081346000045
J	Benedetti, JK; Zeh, J; Corey, L				Benedetti, JK; Zeh, J; Corey, L			Clinical reactivation of genital herpes simplex virus infection decreases in frequency over time	ANNALS OF INTERNAL MEDICINE			English	Article						herpes genitalis; virus activation; recurrence; time factors; antiviral agents	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; ORAL ACYCLOVIR; SUPPRESSION; ANTIBODIES; THERAPY; TYPE-2; WOMEN; POPULATIONS; RECURRENCES	Background: Visits to physicians for genital herpes simplex virus (HSV) infection continue to increase. Most patients with symptomatic infections have recurrences, but no studies of the long-term clinical course of genital herpes are available. Objective: To determine whether the frequency of HSV recurrences decreases over time. Design: Observational cohort study. Setting: University-based research clinic. Patients: 664 persons with genital herpes followed for at least 14 months. Measurements: Patients were classified as having initial or recurrent HSV-1 or HSV-2 infection. Patient-reported recurrences and observed recurrences were recorded in a database; more than 12 000 recurrences were analyzed. Results: Median recurrence rates in the first year of follow-up were one and five per year in patients with newly acquired HSV-1 and HSV-2 infection, respectively; second-year rates were significantly lower in both groups. Patients presenting with recurrent HSV-2 infection had higher rates of recurrence in the first and second years and no significant decrease; significant decreases were detected with longer follow-up. One third of all patients experienced a decrease of two or more recurrences per year between years 1 and 2. Patients infected with HSV-2 who were followed for more than 4 years had a median decrease of two recurrences between years 1 and 5. However, 25% of these patients had an increase of at least one recurrence in year 5, illustrating the variability among HSV-infected persons. Decreases overtime among patients who never received suppressive therapy were similar to decreases during untreated periods in patients who received suppressive therapy. Conclusions: Herpes simplex virus type 2 infection continues to be a chronic remitting illness. Over time, however, clinically significant reductions occur in a majority of patients. Physicians may wish to periodically assess the need for continued treatment with daily suppressive antiviral chemotherapy.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Stat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Corey, L (corresponding author), 1100 Fairview Ave N D3-100,Box 19024, Seattle, WA 98109 USA.		Corey, Lawrence/AAE-1796-2020	Corey, Lawrence/0000-0002-2179-2436	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030619, P01AI030731] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-30619, AI-30731] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY R, 1998, LAB DIAGNOSIS VIRAL, P489; BASSETT I, 1994, MED J AUSTRALIA, V160, P697, DOI 10.5694/j.1326-5377.1994.tb125907.x; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; BENEDETTI JK, 1995, AM J MED, V98, P237, DOI 10.1016/S0002-9343(99)80369-6; CATOTTI DN, 1993, SEX TRANSM DIS, V20, P77, DOI 10.1097/00007435-199303000-00004; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P20; COREY L, 1983, ANN INTERN MED, V98, P958, DOI 10.7326/0003-4819-98-6-958; COREY L, 1983, ANN INTERN MED, V98, P973, DOI 10.7326/0003-4819-98-6-973; COREY L, 1999, SEXUALLY TRANSMITTED, P285; Cowan FM, 1996, J INFECT DIS, V174, P470, DOI 10.1093/infdis/174.3.470; COWAN FM, 1994, BRIT MED J, V309, P1325, DOI 10.1136/bmj.309.6965.1325; FIFE KH, 1994, J INFECT DIS, V169, P1338, DOI 10.1093/infdis/169.6.1338; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; FORSGREN M, 1994, INT J STD AIDS, V5, P113, DOI 10.1177/095646249400500207; GARLAND SM, 1995, J VIROL METHODS, V55, P285, DOI 10.1016/0166-0934(95)00061-9; HARGER JH, 1986, OBSTET GYNECOL, V67, P637, DOI 10.1097/00006250-198605000-00007; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; KNOX SR, 1982, SEX TRANSM DIS, V9, P15, DOI 10.1097/00007435-198201000-00003; KOUTSKY LA, 1992, NEW ENGL J MED, V326, P1533, DOI 10.1056/NEJM199206043262305; LAFFERTY WE, 1987, NEW ENGL J MED, V316, P1444, DOI 10.1056/NEJM198706043162304; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; MATTISON HR, 1988, AM J MED, V85, P20; Mertz GJ, 1997, ARCH INTERN MED, V157, P343, DOI 10.1001/archinte.157.3.343; MINDEL A, 1988, LANCET, V1, P926; NAHMIAS AJ, 1990, SCAND J INFECT DIS, P19; NILSEN AE, 1982, LANCET, V2, P571; Oliver L, 1995, Arch Fam Med, V4, P228, DOI 10.1001/archfami.4.3.228; Sacks SL, 1996, JAMA-J AM MED ASSOC, V276, P44, DOI 10.1001/jama.276.1.44; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; Velleman P. F., 1981, APPL BASICS COMPUTIN; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Wald A, 1997, J CLIN INVEST, V99, P1092, DOI 10.1172/JCI119237; Weinberg Adriana, 1993, Revista do Instituto de Medicina Tropical de Sao Paulo, V35, P285	33	126	131	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 6	1999	131	1					14	+		10.7326/0003-4819-131-1-199907060-00004	http://dx.doi.org/10.7326/0003-4819-131-1-199907060-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214UD	10391810				2022-12-24	WOS:000081345200003
J	Freed, LA; Levy, D; Levine, RA; Larson, MG; Evans, JC; Fuller, DL; Lehman, B; Benjamin, EJ				Freed, LA; Levy, D; Levine, RA; Larson, MG; Evans, JC; Fuller, DL; Lehman, B; Benjamin, EJ			Prevalence and clinical outcome of mitral-valve prolapse	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENERAL-POPULATION; FOLLOW-UP; REGURGITATION; FEATURES; IDENTIFICATION; ASSOCIATION; DIAGNOSIS; WOMEN; RISK; MEN	Background Mitral-valve prolapse has been described as a common disease with frequent complications. To determine the prevalence of mitral-valve prolapse in the general population, as diagnosed with the use of current two-dimensional echocardiographic criteria, we examined the echocardiograms of 1845 women and 1646 men (mean [+/-SD] age, 54.7+/-10.0 years) who participated in the fifth examination of the offspring cohort of the Framingham Heart Study. Methods Classic mitral-valve prolapse was defined as superior displacement of the mitral leaf lets of more than 2 mm during systole and as a maximal leaflet thickness of at least 5 mm during diastasis, and nonclassic prolapse was defined as displacement of more than 2 mm, with a maximal thickness of less than 5 mm. Results A total of 84 subjects (2.4 percent) had mitral-valve prolapse: 47 (1.3 percent) had classic prolapse, and 37 (1.1 percent) had nonclassic prolapse. Their age and sex distributions were similar to those of the subjects without prolapse. None of the subjects with prolapse had a history of heart failure, one (1.2 percent) had atrial fibrillation, one (1.2 percent) had cerebrovascular disease, and three (3.6 percent) had syncope, as compared with unadjusted prevalences of these findings in the subjects without prolapse of 0.7, 1.7, 1.5, and 3.0 percent, respectively. The frequencies of chest pain, dyspnea, and electrocardiographic abnormalities were similar among subjects with prolapse and those without prolapse. The subjects with prolapse were leaner (P<0.001) and had a greater degree of mitral regurgitation than those without prolapse, but on average the regurgitation was classified as trace or mild. Conclusions In a community-based sample of the population, the prevalence of mitral-valve prolapse was lower than previously reported. The prevalence of adverse sequelae commonly associated with mitral-valve prolapse in studies of patients referred for that diagnosis was also low. (N Engl J Med 1999;341:1-7.) (C)1999, Massachusetts Medical Society.	NHLBI, Framingham Heart Study, Framingham, MA USA; Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NHLBI, Bethesda, MD 20892 USA; Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Clin Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Div Cardiol, Boston, MA 02118 USA; Boston Univ, Sch Med, Div Epidemiol & Prevent Med, Boston, MA 02118 USA	Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Boston University; Boston University	Benjamin, EJ (corresponding author), Boston Univ, Sch Med, Framingham Heart Study, 5 Thurber St, Framingham, MA 01702 USA.		Levy, Daniel/ABF-6873-2021; Levy, Daniel/ABB-2752-2021; Benjamin, Emelia/E-7103-2011	Levy, Daniel/0000-0003-1843-8724; Benjamin, Emelia/0000-0003-4076-2336; Larson, Martin/0000-0002-9631-1254	NHLBI NIH HHS [2-R01-HL-38176-06, N01-HC-38038] Funding Source: Medline; NINDS NIH HHS [5-R01-NS-17950-16] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BRYHN M, 1984, ACTA MED SCAND, V215, P157; CHANDRARATNA PAN, 1984, AM J CARDIOL, V54, P1283; COHEN JL, 1987, AM HEART J, V113, P341, DOI 10.1016/0002-8703(87)90275-4; DAWBER TR, 1951, AM J PUBLIC HEALTH, V41, P279; DEVEREUX R B, 1986, Journal of the American College of Cardiology, V8, P763; DEVEREUX RB, 1989, ANN INTERN MED, V111, P305, DOI 10.7326/0003-4819-111-4-305; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DEVEREUX RB, 1986, AM J MED, V81, P751, DOI 10.1016/0002-9343(86)90339-6; DEVEREUX RB, 1982, LANCET, V2, P792; DUREN DR, 1988, J AM COLL CARDIOL, V11, P42; HELMCKE F, 1987, CIRCULATION, V75, P175, DOI 10.1161/01.CIR.75.1.175; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; KANNEL WB, 1988, NIH PUBLICATION; KANNEL WB, 1974, DHEW PUBLICATION; LEATHAM A, 1980, AM HEART J, V99, P659, DOI 10.1016/0002-8703(80)90740-1; LEVINE RA, 1989, CIRCULATION, V80, P589, DOI 10.1161/01.CIR.80.3.589; LEVINE RA, 1988, J AM COLL CARDIOL, V11, P1010, DOI 10.1016/S0735-1097(98)90059-6; LEVINE RA, 1987, CIRCULATION, V75, P756, DOI 10.1161/01.CIR.75.4.756; LEVY D, 1990, CIRCULATION, V81, P815, DOI 10.1161/01.CIR.81.3.815; LEVY D, 1987, AM HEART J, V113, P1281, DOI 10.1016/0002-8703(87)90956-2; Louie EK, 1996, J AM COLL CARDIOL, V28, P465, DOI 10.1016/0735-1097(96)00160-X; MARKIEWICZ W, 1978, AM HEART J, V96, P555, DOI 10.1016/0002-8703(78)90172-2; MARKIEWICZ W, 1976, CIRCULATION, V53, P464, DOI 10.1161/01.CIR.53.3.464; MARKS AR, 1989, NEW ENGL J MED, V320, P1031, DOI 10.1056/NEJM198904203201602; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; NIDORF SM, 1993, J AM SOC ECHOCARDIOG, V6, pS8; NISHIMURA RA, 1985, NEW ENGL J MED, V313, P305; PERLOFF JK, 1989, CIRCULATION, V80, P710, DOI 10.1161/01.CIR.80.3.710; PROCACCI PM, 1976, NEW ENGL J MED, V294, P1086, DOI 10.1056/NEJM197605132942004; SAHN DJ, 1977, AM J CARDIOL, V39, P422, DOI 10.1016/S0002-9149(77)80100-8; SAVAGE DD, 1983, AM HEART J, V106, P571, DOI 10.1016/0002-8703(83)90704-4; SAVAGE DD, 1983, AM HEART J, V106, P577, DOI 10.1016/0002-8703(83)90705-6; Shah P M, 1994, J Am Soc Echocardiogr, V7, P286; SPIRITO P, 1989, NEW ENGL J MED, V320, P749, DOI 10.1056/NEJM198903233201201; VIVALDI MT, 1994, CIRCULATION, V90, P222; WALLER BF, 1982, AM HEART J, V104, P276, DOI 10.1016/0002-8703(82)90204-6; WARTH DC, 1985, J AM COLL CARDIOL, V5, P1173, DOI 10.1016/S0735-1097(85)80021-8; WEISSMAN NJ, 1994, AM J CARDIOL, V73, P1080, DOI 10.1016/0002-9149(94)90287-9; WILCKEN DEL, 1988, CIRCULATION, V78, P10, DOI 10.1161/01.CIR.78.1.10; ZUPPIROLI A, 1995, AM J CARDIOL, V75, P1028, DOI 10.1016/S0002-9149(99)80718-8	40	665	686	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1999	341	1					1	7		10.1056/NEJM199907013410101	http://dx.doi.org/10.1056/NEJM199907013410101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BC	10387935				2022-12-24	WOS:000081195600001
J	Hart, CL; Smith, GD; Hole, DJ; Hawthorne, VM				Hart, CL; Smith, GD; Hole, DJ; Hawthorne, VM			Alcohol consumption and mortality from all causes, coronary heart disease, and stroke: Results from a prospective cohort study of Scottish men with 21 years of follow up	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MIDDLE-AGED MEN; ALL-CAUSE MORTALITY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; SOCIOECONOMIC POSITION; BLOOD-PRESSURE; BRITISH MEN; BEER; POPULATION; WOMEN	Objectives To relate alcohol consumption to mortality. Design Prospective cohort study. Setting 27 workplaces in the west of Scotland. Participants 5766 men aged 35-64 when screened in 1970-3 who answered questions on their usual weekly alcohol consumption. Main outcome measures Mortality from all causes, coronary heart disease, stroke, and alcohol related causes over 21 years of follow up related to units of alcohol consumed per week. Results Risk for all cause mortality was similar for non-drinkers and men drinking up to 14 units a week. Mortality risk then showed a graded association with alcohol consumption (relative rate compared with non-drinkers 1.34 (95% confidence interval 1.14 to 1.58) for 15-21 units a week, 1.49 (1.27 to 1.75) for 22-34 units, 1.74 (1.47 to 2.06) for 35 or more units). Adjustment for risk factors attenuated the increased relative risks, but they remained significantly above 1 for men drinking 22 or more units a week. There was no strong relation between alcohol consumption and mortality from coronary heart disease after adjustment A strong positive relation was seen between alcohol consumption and risk of mortality from stroke,with men drinking 35 or more units having double the risk of non-drinkers, even after adjustment. Conclusions The overall association between alcohol consumption and mortality is unfavourable for men drinking over 22 units a week, and there is no clear evidence of any protective effect for men drinking less than this.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Univ Glasgow, Dept Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; Univ Glasgow, W Scotland Canc Surveillance Unit, Glasgow G12 8RZ, Lanark, Scotland; Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA	University of Bristol; University of Glasgow; University of Glasgow; University of Michigan System; University of Michigan	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				[Anonymous], 1965, LANCET, V1, P775; Blane D, 1996, BMJ-BRIT MED J, V313, P1434, DOI 10.1136/bmj.313.7070.1434; Brenner H, 1997, INT J EPIDEMIOL, V26, P85, DOI 10.1093/ije/26.1.85; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHOUDHURY SR, 1994, INT J EPIDEMIOL, V23, P940, DOI 10.1093/ije/23.5.940; COX DR, 1972, J R STAT SOC B, V34, P187; DAVEYSMITH G, 1992, JAMA-J AM MED ASSOC, V267, P70; DIGHT S, 1976, SCOTTISH DRINKING HA; DOLL R, 1994, BRIT MED J, V309, P911, DOI 10.1136/bmj.309.6959.911; General Register Office, 1966, CLASS OCC 1966; GILL JS, 1991, AM J MED, V90, P489, DOI 10.1016/0002-9343(91)80090-9; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; Hart CL, 1997, INT J EPIDEMIOL, V26, P508, DOI 10.1093/ije/26.3.508; HAWTHORNE VM, 1995, SCOT MED J, V40, P102, DOI 10.1177/003693309504000402; HOLE D, 1993, J EPIDEMIOL COMMUNIT, V47, P402; ISO H, 1995, STROKE, V26, P767, DOI 10.1161/01.STR.26.5.767; Kauhanen J, 1997, EPIDEMIOLOGY, V8, P310, DOI 10.1097/00001648-199705000-00014; Kauhanen J, 1997, BMJ-BRIT MED J, V315, P846, DOI 10.1136/bmj.315.7112.846; Keil U, 1997, EPIDEMIOLOGY, V8, P150, DOI 10.1097/00001648-199703000-00005; MARMOT MG, 1994, BRIT MED J, V308, P1263, DOI 10.1136/bmj.308.6939.1263; McKee M, 1998, J ROY SOC MED, V91, P402, DOI 10.1177/014107689809100802; *OFF NAT STAT, 1997, HLTH AD BRIT 1841 19; PALOMAKI H, 1993, STROKE, V24, P1828, DOI 10.1161/01.STR.24.12.1828; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; Prineas R.J, 1982, MINNESOTA MANUAL ELE; Rehm JT, 1997, AM J EPIDEMIOL, V146, P495, DOI 10.1093/oxfordjournals.aje.a009303; Renaud SC, 1998, EPIDEMIOLOGY, V9, P184, DOI 10.1097/00001648-199803000-00014; Rimm EB, 1996, BRIT MED J, V312, P731, DOI 10.1136/bmj.312.7033.731; Rose G, 1982, CARDIOVASCULAR SURVE; SANDERCOCK PAG, 1989, BRIT MED J, V298, P75, DOI 10.1136/bmj.298.6666.75; *SAS I, 1991, P217 SAS I; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, J HUM HYPERTENS, V2, P71; SHINTON R, 1993, J NEUROL NEUROSUR PS, V56, P458, DOI 10.1136/jnnp.56.5.458; SMIT JWA, 1995, AM J CARDIOL, V76, pA89; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; Smith GD, 1997, BMJ-BRIT MED J, V314, P547, DOI 10.1136/bmj.314.7080.547; Smith GD, 1998, BMJ-BRIT MED J, V316, P1631, DOI 10.1136/bmj.316.7145.1631; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P153; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; Thun MJ, 1997, NEW ENGL J MED, V337, P1705, DOI 10.1056/NEJM199712113372401; Wannamethee SG, 1996, STROKE, V27, P1033, DOI 10.1161/01.STR.27.6.1033; WESTIN S, 1995, BRIT MED J, V311, P1167, DOI 10.1136/bmj.311.7013.1167a; White IR, 1996, BRIT MED J, V312, P1179; *WHO, 1977, CLASS DIS 9 REV; WOODWARD M, 1995, J EPIDEMIOL COMMUN H, V49, P354, DOI 10.1136/jech.49.4.354; Yuan JM, 1997, BRIT MED J, V314, P18, DOI 10.1136/bmj.314.7073.18	47	197	204	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1725	1729		10.1136/bmj.318.7200.1725	http://dx.doi.org/10.1136/bmj.318.7200.1725			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381706	Green Published, Green Submitted, Bronze, Green Accepted			2022-12-24	WOS:000081216900028
J	Stirrat, GM				Stirrat, GM			Choice of treatment for menorrhagia	LANCET			English	Editorial Material							INTRAUTERINE SYSTEM; HYSTERECTOMY		St Michaels Hosp, Dept Obstet & Gynaecol, Bristol BS2 8EG, Avon, England		Stirrat, GM (corresponding author), St Michaels Hosp, Dept Obstet & Gynaecol, Bristol BS2 8EG, Avon, England.							Crossman DC, 1997, QJM-MON J ASSOC PHYS, V90, P157, DOI 10.1093/qjmed/90.3.157; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Garry R, 1997, BRIT J OBSTET GYNAEC, V104, P1329, DOI 10.1111/j.1471-0528.1997.tb10998.x; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; Higham JM, 1999, EUR J OBSTET GYN R B, V82, P73, DOI 10.1016/S0301-2115(98)00224-3; Irvine GA, 1998, BRIT J OBSTET GYNAEC, V105, P592, DOI 10.1111/j.1471-0528.1998.tb10172.x; KILLETSEN N, 1998, GYNECOL ENDOSC, V7, P61; LAHTEENMAKI, 1998, BMJ, V316, P1122; Lilford RJ, 1997, BRIT MED J, V314, P160, DOI 10.1136/bmj.314.7075.160; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL; *U LEEDS, 1995, EFF HLTH CAR, V9, P1	11	25	33	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 26	1999	353	9171					2175	2176		10.1016/S0140-6736(99)00132-4	http://dx.doi.org/10.1016/S0140-6736(99)00132-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392977				2022-12-24	WOS:000081091300005
J	Masutani, C; Kusumoto, R; Yamada, A; Dohmae, N; Yokoi, M; Yuasa, M; Araki, M; Iwai, S; Takio, K; Hanaoka, F				Masutani, C; Kusumoto, R; Yamada, A; Dohmae, N; Yokoi, M; Yuasa, M; Araki, M; Iwai, S; Takio, K; Hanaoka, F			The XPV (xeroderma pigmentosum variant) gene encodes human DNA polymerase eta	NATURE			English	Article							ESCHERICHIA-COLI DINB; SACCHAROMYCES-CEREVISIAE; THYMINE DIMER; EXCISION-REPAIR; HUMAN HOMOLOG; REPLICATION; MUTAGENESIS; BYPASS; CELLS; ZETA	Xeroderma pigmentosum variant (XP-V) is an inherited disorder which is associated with increased incidence of sunlight-induced skin cancers, Unlike other xeroderma pigmentosum cells (belonging to groups XP-A to XP-G), XP-V cells carry out normal nucleotide-excision repair processes but are defective in their replication of ultraviolet-damaged DNA(1,2). It has been suspected for some time that the XPV gene encodes a protein that is involved in trans-lesion DNA synthesis; but the gene product has never been isolated Using an improved cell-free assay for trans-lesion DNA synthesis, we have recently isolated a DNA polymerase from HeLa cells that continues replication on damaged DNA by bypassing ultraviolet-induced thymine dimers in XP-V cell extracts(3). Here we show that this polymerase is a human homologue of the yeast Rad30 protein, recently identified as DNA polymerase eta (ref. 4). This polymerase and yeast Rad30 are members of a family of damage-bypass replication proteins(5-10) which comprises the Escherichia coli proteins UmuC and DinB and the yeast Rev1 protein. We found that all XP-V cells examined carry mutations in their DNA polymerase eta gene. Recombinant human DNA polymerase eta corrects the inability of XP-V cell extracts to carry out DNA replication by bypassing thymine dimers on damaged DNA. Together these results indicate that DNA polymerase eta could be the XPV gene product.	Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 5650871, Japan; Nara Inst Sci & Technol, Nara 63001, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan; Inst Phys & Chem Res, Wako, Saitama 3510198, Japan; Biomol Engn Res Inst, Osaka 5650874, Japan	Osaka University; Nara Institute of Science & Technology; Osaka University; RIKEN	Hanaoka, F (corresponding author), Osaka Univ, Inst Mol & Cellular Biol, 1-3 Yamada Oka, Suita, Osaka 5650871, Japan.		Dohmae, Naoshi/C-2040-2011; Araki, Marito/T-4283-2019; Masutani, Chikahide/I-6160-2014	Dohmae, Naoshi/0000-0002-5242-9410; Araki, Marito/0000-0002-3502-5000; Masutani, Chikahide/0000-0002-8600-8227; Yamada, Ayumi/0000-0002-6085-8928				Baynton K, 1998, MOL CELL BIOL, V18, P960, DOI 10.1128/MCB.18.2.960; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; JASPERS NGJ, 1981, EXP CELL RES, V136, P81, DOI 10.1016/0014-4827(81)90039-2; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; MASAKI T, 1981, BIOCHIM BIOPHYS ACTA, V660, P44, DOI 10.1016/0005-2744(81)90106-6; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MASUTANI C, IN PRESS EMBO J; McDonald JP, 1997, GENETICS, V147, P1557; McGregor WG, 1999, MOL CELL BIOL, V19, P147; MURATA T, 1990, NUCLEIC ACIDS RES, V18, P7279, DOI 10.1093/nar/18.24.7279; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; Roush AA, 1998, MOL GEN GENET, V257, P686; Smith BT, 1998, GENETICS, V148, P1599; Svoboda DL, 1998, CANCER RES, V58, P2445; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WANG YC, 1991, P NATL ACAD SCI USA, V88, P7810, DOI 10.1073/pnas.88.17.7810; WANG YC, 1993, MOL CELL BIOL, V13, P4276, DOI 10.1128/MCB.13.7.4276; Xiao W, 1998, CARCINOGENESIS, V19, P945, DOI 10.1093/carcin/19.5.945	24	1103	1130	0	238	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					700	704		10.1038/21447	http://dx.doi.org/10.1038/21447			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385124				2022-12-24	WOS:000080932800064
J	Jasmer, RM; Hahn, JA; Small, PM; Daley, CL; Behr, MA; Moss, AR; Creasman, JM; Schecter, GF; Paz, EA; Hopewell, PC				Jasmer, RM; Hahn, JA; Small, PM; Daley, CL; Behr, MA; Moss, AR; Creasman, JM; Schecter, GF; Paz, EA; Hopewell, PC			A molecular epidemiologic analysis of tuberculosis trends in San Francisco, 1991-1997	ANNALS OF INTERNAL MEDICINE			English	Article							NEW-YORK-CITY; RESISTANT MYCOBACTERIUM-TUBERCULOSIS; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; OUTBREAK; POPULATION; HOMELESS; PTBN12	Background: To decrease tuberculosis case rates and cases due to recent infection (clustered cases) in San Francisco, California, tuberculosis control measures were intensified beginning in 1991 by focusing on prevention of Mycobacterium tuberculosis transmission and on the use of preventive therapy. Objective: To describe trends in rates of tuberculosis cases and clustered cases in San Francisco from 1991 through 1997. Design: Population-based study. Setting: San Francisco, California. Patients: Persons with tuberculosis diagnosed between 1 January 1991 and 31 December 1997. Measurements: DNA fingerprinting was performed. During sequential 1-year intervals, changes in annual case rates per 100 000 persons for all cases, clustered cases (cases with M. tuberculosis isolates having identical fingerprint patterns), and cases in specific subgroups with high rates of clustering (persons born in the United States and HIV-infected persons) were examined. Results: Annual tuberculosis case rates peaked at 51.2 cases per 100 000 persons in 1992 and decreased significantly thereafter to 29.8 cases per 100 000 persons in 1997 (P < 0.001). The rate of clustered cases decreased significantly over time in the entire study sample (from 10.4 cases per 100 000 persons in 1991 to 3.8 cases per 100 000 persons in 1997 [P < 0.001]), in persons born in the United States (P < 0.001), and in HIV-infected persons (P = 0.003). Conclusions: The rates of tuberculosis cases and clustered tuberculosis cases decreased both overall and among persons in high-risk groups. This occurred in a period during which tuberculosis control measures were intensified.	Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, Ctr Med, San Francisco, CA 94110 USA; Francis J Curry Natl TB Ctr, San Francisco, CA 94110 USA; Dept Publ Hlth, San Francisco, CA USA; Stanford Univ, Dept Med, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Stanford University	Jasmer, RM (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco Gen Hosp, Ctr Med, Room K1,1001 Potrero Ave, San Francisco, CA 94110 USA.		Daley, Charles L./AAC-3231-2021; Hahn, Judith/J-5813-2014	Hahn, Judith/0000-0002-2697-8264	NHLBI NIH HHS [HL 07185] Funding Source: Medline; NIAID NIH HHS [AI 34238, AI 35969] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034238, U01AI035969] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1994, Morbidity and Mortality Weekly Report, V43, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; Braden CR, 1997, J INFECT DIS, V175, P1446, DOI 10.1086/516478; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; *CA DEP HLTH SERV, 1998, REP TUB CAL 1997; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DWYER B, 1993, J INFECT DIS, V167, P490, DOI 10.1093/infdis/167.2.490; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; FRIEDEN TR, 1995, NEW ENGL J MED, V333, P229, DOI 10.1056/NEJM199507273330406; GENEWEIN A, 1993, LANCET, V342, P841, DOI 10.1016/0140-6736(93)92698-S; Glynn JR, 1999, AM J EPIDEMIOL, V149, P366, DOI 10.1093/oxfordjournals.aje.a009822; HOPEWELL PC, 1996, TUBERCULOSIS, P113; Kalbfleisch JD, 1980, STAT ANAL FAILURE TI; MCGOWAN JE, 1995, J HOSP INFECT, V30, P282, DOI 10.1016/0195-6701(95)90031-4; NARDELL E, 1986, NEW ENGL J MED, V315, P1570, DOI 10.1056/NEJM198612183152502; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; POULET S, 1995, ARCH MICROBIOL, V163, P87, DOI 10.1007/s002030050176; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P604; ROSS BC, 1992, J CLIN MICROBIOL, V30, P942, DOI 10.1128/JCM.30.4.942-946.1992; *SF DEP PUBL HLTH, 1997, 1997 HIV CONS REP HI; SMALL PM, 1993, J CLIN MICROBIOL, V31, P1677, DOI 10.1128/JCM.31.7.1677-1682.1993; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; *US BUR CENS, 1992, 1990 CENS POP HOUS; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Woelffer GB, 1996, AM J MED SCI, V311, P17, DOI 10.1097/00000441-199601000-00004; Yang ZH, 1996, J CLIN MICROBIOL, V34, P3044, DOI 10.1128/JCM.34.12.3044-3048.1996; Yeh RW, 1998, J INFECT DIS, V177, P1107, DOI 10.1086/517406; 1998, MMWR MORB MORTAL WKL, V47, P253	33	153	156	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					971	978		10.7326/0003-4819-130-12-199906150-00004	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383367				2022-12-24	WOS:000080894700003
J	Opie, LH				Opie, LH			Proof that glucose-insulin-potassium provides metabolic protection of ischaemic myocardium?	LANCET			English	Editorial Material							INFARCTION; MAGNESIUM		Univ Cape Town, Sch Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa	University of Cape Town	Opie, LH (corresponding author), Univ Cape Town, Sch Med, Cape Heart Ctr, ZA-7925 Cape Town, South Africa.							Antman EM, 1996, CARDIOVASC DRUG THER, V10, P297; Apstein CS, 1997, CIRCULATION, V96, P1074, DOI 10.1161/01.CIR.96.4.1074; Apstein CS, 1998, CIRCULATION, V98, P2223, DOI 10.1161/01.CIR.98.21.2223; CEREMUZYNSKI L, 1997, EUR HEART J, V18, pP1054; DEVILLALOBOS DH, 1995, LANCET, V345, P1552; Diaz R, 1998, CIRCULATION, V98, P2227, DOI 10.1161/01.CIR.98.21.2227; FATHORDOUBADI F, 1997, CIRCULATION, V96, P1074; GD Lopaschuk, 1998, METABOLIC APPROACHES, P44; JONASSEN AK, UNPUB; King LM, 1998, CARDIOVASC RES, V39, P381, DOI 10.1016/S0008-6363(98)00100-X; LAZAR HL, 1997, J THORACIC CARDIOVAS, V113, P345; Malmberg K, 1996, EUR HEART J, V17, P1337; OLDFIELD GS, 1986, J THORAC CARDIOV SUR, V91, P874; OPIE LH, 1995, LANCET, V345, P1520, DOI 10.1016/S0140-6736(95)91080-8; SHECHTER M, 1995, AM J CARDIOL, V75, P321, DOI 10.1016/S0002-9149(99)80546-3; SODIPALLARES D, 1962, AM J CARDIOL, V9, P166, DOI 10.1016/0002-9149(62)90035-8; STANLEY AW, 1975, AM J CARDIOL, V36, P929, DOI 10.1016/0002-9149(75)90085-5; Young LH, 1997, CIRCULATION, V95, P415	18	28	30	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 6	1999	353	9155					768	769		10.1016/S0140-6736(98)00385-7	http://dx.doi.org/10.1016/S0140-6736(98)00385-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459953				2022-12-24	WOS:000079089100003
J	Stahl-Hennig, C; Steinman, RM; Tenner-Racz, K; Pope, M; Stolte, N; Matz-Rensing, K; Grobschupff, G; Raschdorff, B; Hunsmann, G; Racz, P				Stahl-Hennig, C; Steinman, RM; Tenner-Racz, K; Pope, M; Stolte, N; Matz-Rensing, K; Grobschupff, G; Raschdorff, B; Hunsmann, G; Racz, P			Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus	SCIENCE			English	Article							DENDRITIC CELLS; IMMUNE-RESPONSES; T-CELLS; HIV-1; REPLICATION; MACAQUES; SIV; PLASMA; SKIN; TRANSMISSION	The early events during infection with an immunodeficiency virus were followed by application of pathogenic simian immunodeficiency virus atraumatically to the tonsils of macaques. Analyses by virologic assays and in situ hybridization revealed that the infection started Locally in the tonsils, a mucosal-associated Lymphoid organ, and quickly spread to other Lymphoid tissues. At day 3, there were few infected cells, but then the number increased rapidly, reaching a high plateau between days 4 and 7. The infection was not detected in the dendritic cell-rich squamous epithelium to which the virus was applied; instead, it was primarily in CD4(+) tonsillar T cells, close to the specialized antigen-transporting epithelium of the tonsillar crypts. Transport of the virus and immune-activating stimuli across this epithelium would allow mucosal Lymphoid tissue to function in the atraumatic transmission of immunodeficiency viruses.	German Primate Ctr, D-37077 Gottingen, Germany; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany	Deutsches Primatenzentrum (DPZ); Rockefeller University; Bernhard Nocht Institut fur Tropenmedizin	Stahl-Hennig, C (corresponding author), German Primate Ctr, D-37077 Gottingen, Germany.		Abrams, William R/A-5782-2008; Steinman, Ralph/F-7729-2012		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040874, R01AI042129, R01AI040877] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 40877, AI 42129, AI 40874] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMERONGEN HM, 1991, J ACQ IMMUN DEF SYND, V4, P760; Baba TW, 1996, SCIENCE, V272, P1486, DOI 10.1126/science.272.5267.1486; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brandtzaeg P, 1987, IMMUNOLOGY EAR, V1987, P63; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Frankel SS, 1997, AM J PATHOL, V151, P89; Frankel SS, 1996, SCIENCE, V272, P115, DOI 10.1126/science.272.5258.115; Frey A, 1996, J EXP MED, V184, P1045, DOI 10.1084/jem.184.3.1045; Granelli-Piperno A, 1998, J VIROL, V72, P2733, DOI 10.1128/JVI.72.4.2733-2737.1998; Granelli-Piperno A, 1999, CURR BIOL, V9, P21, DOI 10.1016/S0960-9822(99)80043-8; GranelliPiperno A, 1996, J EXP MED, V184, P2433, DOI 10.1084/jem.184.6.2433; Ignatius R, 1998, J MED PRIMATOL, V27, P121, DOI 10.1111/j.1600-0684.1998.tb00236.x; Kelsall BL, 1996, J EXP MED, V183, P237, DOI 10.1084/jem.183.1.237; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Molnar-Kimber KL, 1998, HUM GENE THER, V9, P2121, DOI 10.1089/hum.1998.9.14-2121; Neildez O, 1998, VIROLOGY, V243, P12, DOI 10.1006/viro.1997.9026; Neutra MR, 1996, CELL, V86, P345, DOI 10.1016/S0092-8674(00)80106-3; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NORLEY SG, 1993, BIOLOGICALS, V21, P251, DOI 10.1006/biol.1993.1082; OWEN RL, 1990, SPRINGER SEMIN IMMUN, V12, P139; Pope M, 1997, AIDS RES HUM RETROV, V13, P819, DOI 10.1089/aid.1997.13.819; POPE M, 1995, J EXP MED, V182, P2045, DOI 10.1084/jem.182.6.2045; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; Rothenberg RB, 1998, AIDS, V12, P2095, DOI 10.1097/00002030-199816000-00004; Ruprecht RM, 1998, AIDS RES HUM RETROV, V14, pS97; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; StahlHennig C, 1996, J GEN VIROL, V77, P2969, DOI 10.1099/0022-1317-77-12-2969; STAHLHENNIG C, 1992, VIROLOGY, V186, P588, DOI 10.1016/0042-6822(92)90025-K; TENNERRACZ K, 1988, AIDS, V2, P299, DOI 10.1097/00002030-198808000-00010; TENNERRACZ K, 1979, LAB INVEST, V41, P106; WINTHER B, 1994, ARCH OTOLARYNGOL, V120, P144; WOLF JL, 1981, SCIENCE, V212, P471, DOI 10.1126/science.6259737	32	191	193	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1261	1265		10.1126/science.285.5431.1261	http://dx.doi.org/10.1126/science.285.5431.1261			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455052				2022-12-24	WOS:000082130200042
J	Ramamoorthy, S; Blakely, RD				Ramamoorthy, S; Blakely, RD			Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants	SCIENCE			English	Article							PROTEIN-KINASE-C; HUMAN DOPAMINE TRANSPORTER; IMIPRAMINE BINDING-SITES; TRITIATED IMIPRAMINE; NEUROTRANSMITTER TRANSPORTERS; NOREPINEPHRINE TRANSPORTER; STRIATAL SYNAPTOSOMES; FUNCTIONAL REGULATION; SURFACE EXPRESSION; XENOPUS-OOCYTES	Many psychotropic drugs interfere with the reuptake of dopamine, norepinephrine, and serotonin. Transport capacity is regulated by kinase-linked pathways, particularly those involving protein kinase C (PKC), resulting in transporter phosphorylation and sequestration. Phosphorylation and sequestration of the serotonin transporter (SERT) were substantially impacted by ligand occupancy. Ligands that can permeate the transporter, such as serotonin or the amphetamines, prevented PKC-dependent SERT phosphorylation. Nontransported SERT antagonists such as cocaine and antidepressants were permissive for SERT phosphorylation but blocked serotonin effects. PKC-dependent SEPT sequestration was also blocked by serotonin. These findings reveal activity-dependent modulation of neurotransmitter reuptake and identify previously unknown consequences of amphetamine, cocaine, and antidepressant action.	Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Mol Neurosci, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Dept Pharmacol, Sch Med, Nashville, TN 37232 USA.	randy.blakely@mcmail.vanderbilt.edu			NIDA NIH HHS [DA07390] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ANDERSON GM, 1992, BIOCHIM BIOPHYS ACTA, V1137, P331, DOI 10.1016/0167-4889(92)90154-4; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P733; Apparsundaram S, 1998, J PHARMACOL EXP THER, V287, P744; APPARSUNDARAM S, 1996, SOC NEUR ABSTR, V22; Barker Eric L., 1995, P321; BAUMAN AL, 1998, SOC NEUR ABSTR, V24; Beckman ML, 1998, J NEUROSCI, V18, P6103; Bengel D, 1998, MOL PHARMACOL, V53, P649, DOI 10.1124/mol.53.4.649; BERGER UV, 1992, EUR J PHARMACOL, V215, P153, DOI 10.1016/0014-2999(92)90023-W; Bernstein EM, 1999, J BIOL CHEM, V274, P889, DOI 10.1074/jbc.274.2.889; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bonisch H, 1998, Adv Pharmacol, V42, P183; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Cinquanta M, 1997, NEUROPHARMACOLOGY, V36, P803, DOI 10.1016/S0028-3908(97)00064-6; Cook EH, 1997, MOL PSYCHIATR, V2, P247; Copeland BJ, 1996, J PHARMACOL EXP THER, V277, P1527; COREY JL, 1994, J BIOL CHEM, V269, P14759; CORNEZA J, 1991, BIOCHEM J, V275, P435; Crespi D, 1997, BRIT J PHARMACOL, V121, P1735, DOI 10.1038/sj.bjp.0701325; DeFelice LJ, 1996, BIOPHYS J, V70, P579, DOI 10.1016/S0006-3495(96)79604-2; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Fozzard J., 1989, PERIPHERAL ACTIONS 5; FULLER RW, 1994, LIFE SCI, V55, P163, DOI 10.1016/0024-3205(94)00876-0; FULLER RW, 1990, ANN N Y ACAD SCI, V600, P68; Furlong RA, 1998, AM J MED GENET, V81, P58, DOI 10.1002/(SICI)1096-8628(19980207)81:1<58::AID-AJMG11>3.0.CO;2-V; Gainetdinov RR, 1999, SCIENCE, V283, P397, DOI 10.1126/science.283.5400.397; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Huff RA, 1997, J NEUROCHEM, V68, P225; Hyman SE, 1996, NEURON, V16, P901, DOI 10.1016/S0896-6273(00)80111-7; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; JAYANTHI LD, 1994, J BIOL CHEM, V269, P14424; Jones SR, 1998, J NEUROSCI, V18, P1979; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KITAYAMA S, 1994, EUR J PHARM-MOLEC PH, V268, P115, DOI 10.1016/0922-4106(94)90180-5; LAUNAY JM, 1994, AM J PHYSIOL, V266, pR526, DOI 10.1152/ajpregu.1994.266.2.R526; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; LESCH KP, 1993, J NEUROCHEM, V60, P2319, DOI 10.1111/j.1471-4159.1993.tb03522.x; Lester HA, 1996, NEURON, V17, P807, DOI 10.1016/S0896-6273(00)80213-5; Little KY, 1998, AM J PSYCHIAT, V155, P207; MABJEESH NJ, 1993, BIOCHEMISTRY-US, V32, P8540, DOI 10.1021/bi00084a021; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; MARCUSSON JO, 1989, PSYCHOPHARMACOLOGY, V99, P17, DOI 10.1007/BF00634446; MELTZER HY, 1981, ARCH GEN PSYCHIAT, V38, P1322; MELTZER HY, 1990, ANN NY ACAD SCI, V600, P486; MILLER KJ, 1994, J BIOL CHEM, V269, P27351; Morgan AE, 1997, EUR J PHARMACOL, V331, pR1, DOI 10.1016/S0014-2999(97)01035-2; MYERS CL, 1988, J APPL PHYSIOL, V65, P377, DOI 10.1152/jappl.1988.65.1.377; NEMEROFF CB, 1988, ARCH GEN PSYCHIAT, V45, P919; NISHIO H, 1995, EUR J PHARM-MOLEC PH, V288, P149, DOI 10.1016/0922-4106(95)90189-2; OWENS MJ, 1994, CLIN CHEM, V40, P288; PAUL SM, 1981, ARCH GEN PSYCHIAT, V38, P1315; Pierce RC, 1997, J NEUROSCI, V17, P3254; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, J BIOL CHEM, V273, P2458, DOI 10.1074/jbc.273.4.2458; RAMAMOORTHY S, UNPUB; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; Reith MEA., 1997, NEUROTRANSMITTER TRA, P29, DOI 10.1007/978-1-59259-470-2_2; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; ROSS SB, 1964, ACTA PHARMACOL TOX, V21, P226; ROSS SB, 1982, BIOL SEROTONERGIC TR, P160; RUDNICK G, 1992, P NATL ACAD SCI USA, V89, P1817, DOI 10.1073/pnas.89.5.1817; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Rudnick G, 1998, METHOD ENZYMOL, V296, P233; Sakai N, 1997, J NEUROCHEM, V68, P2618; Sora I, 1998, P NATL ACAD SCI USA, V95, P7699, DOI 10.1073/pnas.95.13.7699; STANLEY M, 1982, SCIENCE, V216, P1337, DOI 10.1126/science.7079769; SULZER D, 1993, J NEUROCHEM, V60, P527, DOI 10.1111/j.1471-4159.1993.tb03181.x; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; Vaughan RA, 1997, J BIOL CHEM, V272, P15541, DOI 10.1074/jbc.272.24.15541; Weiger WA, 1997, BIOL REV, V72, P61, DOI 10.1017/S0006323196004975; White FJ, 1998, NATURE, V393, P118, DOI 10.1038/30105; Yura A, 1996, BRAIN RES, V738, P96, DOI 10.1016/0006-8993(96)00762-7; Zhang L, 1997, BIOCHEM PHARMACOL, V53, P677, DOI 10.1016/S0006-2952(96)00898-2; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	79	292	296	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					763	766		10.1126/science.285.5428.763	http://dx.doi.org/10.1126/science.285.5428.763			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427004				2022-12-24	WOS:000081765100063
J	Krishnan, B; Dryer, SE; Hardin, PE				Krishnan, B; Dryer, SE; Hardin, PE			Circadian rhythms in olfactory responses of Drosophila melanogaster	NATURE			English	Article							MUTANTS; PHYSIOLOGY; EXPRESSION; CLOCK; LIGHT; FLY	The core mechanism of circadian timekeeping in arthropods and vertebrates consists of feedback loops involving several clock genes, including period (per) and timeless (tim)(1,2). In the fruitfly Drosophila, circadian oscillations in per expression occur in chemosensory cells of the antennae, even when the antennae are excised and maintained in isolated organ culture(3). Here we demonstrate a robust circadian rhythm in Drosophila in electrophysiological responses to two classes of olfactory stimuli. These rhythms are observed in wild-type flies during light-dark cycles and in constant darkness, but are abolished in per or tim null-mutant flies (per(01) and tim(01)) which lack rhythms in adult emergence and locomotor behaviour. Olfactory rhythms are also abolished in the per 7.2:2 transgenic line in which per expression is restricted to the lateral neurons of the optic lobe(4). Because per 7.2:2 flies do not express per in peripheral oscillators, our results provide evidence that peripheral circadian oscillators are necessary for circadian rhythms in olfactory responses. As olfaction is essential for food acquisition, social interactions and predator avoidance in many animals, circadian regulation of olfactory systems could have profound effects on the behaviour of organisms that rely on this sensory modality.	Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA; Univ Houston, Biol Clocks Program, Houston, TX 77204 USA	University of Houston System; University of Houston; University of Houston System; University of Houston	Dryer, SE (corresponding author), Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA.		Krishnan, Balaji/M-9914-2019; Krishnan, Balaji/C-7572-2009	Krishnan, Balaji/0000-0003-2074-4165; Hardin, Paul/0000-0002-3370-9011				ALCORTA E, 1991, J NEUROPHYSIOL, V65, P702, DOI 10.1152/jn.1991.65.3.702; Anholt RRH, 1996, GENETICS, V143, P293; AYER RK, 1992, J NEUROBIOL, V23, P965, DOI 10.1002/neu.480230804; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DUBIN AE, 1995, J NEUROBIOL, V28, P214, DOI 10.1002/neu.480280208; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Hardin PE, 1998, CURR OPIN NEUROBIOL, V8, P642, DOI 10.1016/S0959-4388(98)80093-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Marrus SB, 1996, EMBO J, V15, P6877, DOI 10.1002/j.1460-2075.1996.tb01080.x; Plautz JD, 1997, SCIENCE, V278, P1632, DOI 10.1126/science.278.5343.1632; Qiu J, 1996, MOL CELL BIOL, V16, P4182; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Suri VP, 1998, NEURON, V21, P225, DOI 10.1016/S0896-6273(00)80529-2; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033	16	239	243	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					375	378		10.1038/22566	http://dx.doi.org/10.1038/22566			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432117				2022-12-24	WOS:000081590000053
J	Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA				Fried, TR; van Doorn, C; O'Leary, JR; Tinetti, ME; Drickamer, MA			Older persons' preferences for site of terminal care	ANNALS OF INTERNAL MEDICINE			English	Article							PALLIATIVE CARE; DEATH; PLACE; HOME; TEAM; LIFE; END	Background: Little is known about patients' preferences for site of terminal care, Objective: To describe older persons' preferences for home or hospital as the site of terminal care and to explore potential reasons for their preferences. Design: Cross-sectional quantitative and qualitative interviews. Setting: Participants' homes. Patients: Community-dwelling persons 65 years of age or older who were recently hospitalized with congestive heart failure, chronic obstructive pulmonary disease, or pneumonia and were not selected according to life expectancy; 246 patients participated in quantitative interviews and 29 participated in qualitative interviews. Measurements: Preference for site of terminal care and the reasons for that preference. Results: In quantitative interviews, 118 patients (48%) preferred terminal care in the hospital, 106 (43%) preferred home, and 22 (9%) did not know. One third changed their preference when asked about their preference in the event of a nonterminal illness. Reasons for preference identified during qualitative interviews included the desire to be with family members and concerns about burden to family members and their ability to provide necessary care. Concern about long-term care needs resulted in preference for a nursing home when choice was not constrained to home and hospital. Conclusions: Preference for home as the site of care for terminal illness exceeds existing practice. However, the current debate about home versus hospital as the ideal site for end-of-life care may ignore an important issue to older persons-namely, the care of disabilities that precede death.	Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, West Haven, CT 06516 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale Univ, Program Aging, New Haven, CT 06511 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University; Yale University	Fried, TR (corresponding author), Vet Affairs Connecticut Healthcare Syst, Geriatr & Extended Care 240, 950 Campbell Ave, West Haven, CT 06516 USA.	terri.fried@yale.edu						Allen JP, 1996, JAMA-J AM MED ASSOC, V275, P474; Annas GJ, 1995, HASTINGS CENT REP, V25, pS12, DOI 10.2307/3527850; Cassel CK, 1996, NEW ENGL J MED, V335, P1232, DOI 10.1056/NEJM199610173351612; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gilbar O, 1996, Hosp J, V11, P31, DOI 10.1300/J011v11n01_03; Glaser B. G., 1978, AWARENESS DYING; GROTHJUNCKER A, 1983, J AM GERIATR SOC, V31, P457, DOI 10.1111/j.1532-5415.1983.tb05116.x; Hanson LC, 1997, ANN INTERN MED, V126, P381, DOI 10.7326/0003-4819-126-5-199703010-00007; MCWHINNEY IR, 1995, CAN MED ASSOC J, V152, P361; Meier DE, 1997, ANN INTERN MED, V127, P225, DOI 10.7326/0003-4819-127-3-199708010-00008; Miles SH, 1996, ARCH INTERN MED, V156, P1062, DOI 10.1001/archinte.156.10.1062; *NAT CTR HLTH STAT, 1990, VIT STAT US  A, V2; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415	13	108	110	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					109	112		10.7326/0003-4819-131-2-199907200-00006	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419426				2022-12-24	WOS:000081509700005
J	von Kries, R; Koletzko, B; Sauerwald, T; von Mutius, E; Barnert, D; Grunert, V; von Voss, H				von Kries, R; Koletzko, B; Sauerwald, T; von Mutius, E; Barnert, D; Grunert, V; von Voss, H			Breast feeding and obesity: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ENDOCRINE RESPONSES; GROWTH; CHILDHOOD; ADIPOSITY; PROTEIN; INFANTS; NUTRITION; CHILDREN; WEIGHT; ADULTS	Objective To assess the impact of breast feeding on the risk of obesity and risk of being overweight in children at the time of entry to school. Design Cross sectional survey. Setting Bavaria, southern Germany. Methods Routine data were collected on the height and weight of 134 577 children participating in the obligatory health examination at the time of school entry in Bavaria. In a subsample of 13 345 children, early feeding, diet, and lifestyle factors were assessed using responses to a questionnaire completed by parents. Subjects 9357 children aged 5 and 6 who had German nationality. Main outcome measures Being overweight was defined as having a body mass index above the 90th centile and obesity was defined as body mass index above the 97th centile of all enrolled German children. Exclusive breast feeding was defined as the child being fed no food other than breast milk. Results The prevalence of obesity in children who had never been breast fed was 4.5% as compared with 2.8% in breastfed children. A clear dose-response effect was identified for the duration of breast feeding on the prevalence of obesity: the prevalence was 3.8% for 2 months of exclusive breast feeding, 2.3% for 3-5 months, 1.7% for 6-12 months, and 0.8% for more than 12 months. Similar relations were found with the prevalence of being overweight. The protective effect of breast feeding was not attributable to differences in social class or lifestyle. After adjusting for potential confounding factors, breast feeding remained a significant protective factor against the development of obesity (odds ratio 0.75, 95% CI 0.57 to 0.98) and being overweight (0.79, 0.68 to 0.93). Conclusions In industrialised countries promoting prolonged breast feeding may help decrease the prevalence of obesity in childhood. Since obese children have a high risk of becoming obese adults, such preventive measures may eventually result in a reduction in the prevalence of cardiovascular diseases and other diseases related to obesity.	Univ Munich, Inst Social Paediat & Adolescent Med, D-81377 Munich, Germany; Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany	University of Munich; University of Munich	von Kries, R (corresponding author), Univ Munich, Inst Social Paediat & Adolescent Med, Heiglhofstr 63, D-81377 Munich, Germany.			von Mutius, Erika/0000-0002-8893-4515				ABRAHAM S, 1971, HSMHA HEALTH REP, V86, P273, DOI 10.2307/4594149; BARANOWSKI T, 1990, J DEV BEHAV PEDIATR, V11, P234; Burns SP, 1997, J CLIN INVEST, V100, P1768, DOI 10.1172/JCI119703; CHARNEY E, 1976, NEW ENGL J MED, V295, P6, DOI 10.1056/NEJM197607012950102; Deheeger M, 1996, PHYSIOL BEHAV, V59, P403, DOI 10.1016/0031-9384(95)02011-X; Desai M, 1997, BIOL REV, V72, P329, DOI 10.1017/S0006323196005026; Desai M, 1997, AM J PHYSIOL-GASTR L, V272, pG1083, DOI 10.1152/ajpgi.1997.272.5.G1083; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Freedman DS, 1997, PEDIATRICS, V99, P420, DOI 10.1542/peds.99.3.420; GOLDBLOOM R, 1994, CAN MED ASSOC J, V150, P871; HAUNER H, 1995, EUR J CLIN INVEST, V25, P90, DOI 10.1111/j.1365-2362.1995.tb01532.x; HEINIG MJ, 1993, AM J CLIN NUTR, V58, P152, DOI 10.1093/ajcn/58.2.152; KRAMER MS, 1981, J PEDIATR-US, V98, P883, DOI 10.1016/S0022-3476(81)80579-3; LUCAS A, 1980, LANCET, V1, P1267; LUCAS A, 1981, ACTA PAEDIATR SCAND, V70, P195, DOI 10.1111/j.1651-2227.1981.tb05541.x; PETRUSCHKE T, 1994, INT J OBESITY, V18, P532; POSKITT EME, 1978, BRIT MED J, V1, P603, DOI 10.1136/bmj.1.6113.603; Power C, 1997, INT J OBESITY, V21, P507, DOI 10.1038/sj.ijo.0800454; ROLLANDCACHERA MF, 1995, INT J OBESITY, V19, P573; ROLLANDCACHERA MF, 1991, EUR J CLIN NUTR, V45, P13; RollandCachera MF, 1996, AM J CLIN NUTR, V64, P663, DOI 10.1093/ajcn/64.4.663; STARK O, 1981, BMJ-BRIT MED J, V283, P13, DOI 10.1136/bmj.283.6283.13; VONEHRENSTEIN O, 1999, IN PRESS CLIN EXP AL; WHITEHEAD RG, 1995, PEDIATR RES, V37, P239, DOI 10.1203/00006450-199502000-00019; WILKINSON PW, 1977, LANCET, V1, P350	25	541	564	0	47	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					147	150		10.1136/bmj.319.7203.147	http://dx.doi.org/10.1136/bmj.319.7203.147			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406746	Green Published, Bronze			2022-12-24	WOS:000081619300017
J	Jiang, ZY; Swem, LR; Rushing, BG; Devanathan, S; Tollin, G; Bauer, CE				Jiang, ZY; Swem, LR; Rushing, BG; Devanathan, S; Tollin, G; Bauer, CE			Bacterial photoreceptor with similarity to photoactive yellow protein and plant phytochromes	SCIENCE			English	Article							HALOPHILIC PHOTOTROPHIC BACTERIUM; ECTOTHIORHODOSPIRA-HALOPHILA; PHOTOCYCLE INTERMEDIATE; SIGNAL-TRANSDUCTION; HISTIDINE KINASE; QUANTUM YIELD; GENE; CHROMOPHORE; RHODOPSIN; KINETICS	A phytochrome-like protein called Ppr was discovered in the purple photosynthetic bacterium Rhodospirillum centenum, Ppr has a photoactive yellow protein (PYP) amino-terminal domain, a central domain with similarity to phytochrome, and a carboxyl-terminal histidine kinase domain. Reconstitution experiments demonstrate that Ppr covalently attaches the blue light-absorbing chromophore p-hydroxycinnamic acid and that it has a photocycle that is spectrally similar to, but kinetically slower than, that of PYP. Ppr also regulates chalcone synthase gene expression in response to blue light with autophosphorylation inhibited in vitro by blue light. Phylogenetic analysis demonstrates that R. centenum Ppr may be ancestral to cyanobacterial and plant phytochromes.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Arizona, Dept Biochem, Tucson, AZ 85721 USA	Indiana University System; Indiana University Bloomington; University of Arizona	Bauer, CE (corresponding author), Indiana Univ, Dept Biol, Jordan Hall, Bloomington, IN 47405 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040941, R01GM040941, R01GM053940, R37GM040941] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053940, GM 40941, R01 GM040941] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; BORGSTAHL GEO, 1995, BIOCHEMISTRY-US, V34, P6278, DOI 10.1021/bi00019a004; Christie JM, 1998, SCIENCE, V282, P1698, DOI 10.1126/science.282.5394.1698; Devanathan S, 1997, ARCH BIOCHEM BIOPHYS, V340, P83, DOI 10.1006/abbi.1997.9902; Dux P, 1998, BIOCHEMISTRY-US, V37, P12689, DOI 10.1021/bi9806652; Elich TD, 1997, CELL, V91, P713, DOI 10.1016/S0092-8674(00)80458-4; *GENB, AF121274 GENB; Genick UK, 1998, NATURE, V392, P206, DOI 10.1038/32462; HOFF WD, 1994, BIOCHEMISTRY-US, V33, P13959, DOI 10.1021/bi00251a001; Hughes J, 1997, NATURE, V386, P663, DOI 10.1038/386663a0; Jiang Z., UNPUB; Jiang ZY, 1997, J BACTERIOL, V179, P5720, DOI 10.1128/jb.179.18.5720-5727.1997; Kehoe DM, 1996, SCIENCE, V273, P1409, DOI 10.1126/science.273.5280.1409; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; MARTIN CR, 1993, INT REV CYTOL, V147, P233, DOI 10.1016/S0074-7696(08)60770-6; MEYER TE, 1991, BIOPHYS J, V59, P988, DOI 10.1016/S0006-3495(91)82313-X; MEYER TE, 1989, BIOPHYS J, V56, P559, DOI 10.1016/S0006-3495(89)82703-1; MEYER TE, 1987, BIOCHEMISTRY-US, V26, P418, DOI 10.1021/bi00376a012; MEYER TE, 1985, BIOCHIM BIOPHYS ACTA, V806, P175, DOI 10.1016/0005-2728(85)90094-5; Meyer TE, 1998, SCIENCE, V281, P1964; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; QUAIL PH, 1991, ANNU REV GENET, V25, P389, DOI 10.1146/annurev.ge.25.120191.002133; RAGATZ L, 1995, ARCH MICROBIOL, V163, P1; SCHNEIDERPOETSCH HAW, 1992, PHOTOCHEM PHOTOBIOL, V56, P839, DOI 10.1111/j.1751-1097.1992.tb02241.x; SPRENGER WW, 1993, J BACTERIOL, V175, P3096, DOI 10.1128/JB.175.10.3096-3104.1993; Ujj L, 1998, BIOPHYS J, V75, P406, DOI 10.1016/S0006-3495(98)77525-3; Xiong J, 1998, P NATL ACAD SCI USA, V95, P14851, DOI 10.1073/pnas.95.25.14851; Yeh KC, 1998, P NATL ACAD SCI USA, V95, P13976, DOI 10.1073/pnas.95.23.13976; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505	29	150	156	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					406	409		10.1126/science.285.5426.406	http://dx.doi.org/10.1126/science.285.5426.406			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411503				2022-12-24	WOS:000081465900054
J	Chambers, J; Ames, RS; Bergsma, D; Muir, A; Fitzgerald, LR; Hervieu, G; Dytko, GM; Foley, JJ; Martin, J; Liu, WS; Park, J; Ellis, C; Ganguly, S; Konchar, S; Cluderay, J; Leslie, R; Wilson, S; Sarau, HM				Chambers, J; Ames, RS; Bergsma, D; Muir, A; Fitzgerald, LR; Hervieu, G; Dytko, GM; Foley, JJ; Martin, J; Liu, WS; Park, J; Ellis, C; Ganguly, S; Konchar, S; Cluderay, J; Leslie, R; Wilson, S; Sarau, HM			Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1	NATURE			English	Article							RAT-BRAIN; GENE; PEPTIDES; NEUROPEPTIDES; EXPRESSION; CLONING; BINDING; FAMILY; ACID	The underlying causes of obesity are poorly understood but probably involve complex interactions between many neurotransmitter and neuropeptide systems involved in the regulation of food intake and energy balance. Three pieces of evidence indicate that the neuropeptide melanin-concentrating hormone (MCH) is an important component of this system. First, MCH stimulates feeding when injected directly into rat brains(1,2); second, the messenger RNA for the MCH precursor is upregulated in the hypothalamus of genetically obese mice and in fasted animals'; and third, mice lacking MCH eat less and are lean(3). MCH antagonists might, therefore, provide a treatment for obesity. However, the development of such molecules has been hampered because the identity of the MCH receptor has been unknown until now. Here we show that the 353-amino-acid human orphan G-protein-coupled receptor SLC-1 (ref, 4) expressed in HEK293 cells binds MCH with sub-nanomolar affinity, and is stimulated by MCH to mobilize intracellular Ca2+ and reduce forskolin-elevated cyclic AMP levels. We also show that SLC-1 messenger RNA and protein is expressed in the ventromedial and dorsomedial nuclei of the hypothalamus, consistent with a role for SLC-1 in mediating the effects of MCH on feeding.	SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Neurosci, Harlow CM19 5AW, Essex, England; SmithKline Beecham Pharmaceut, Dept Mol Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Renal Pharmaceut, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Prot Biochem, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Gene Express Sci, King Of Prussia, PA 19406 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Chambers, J (corresponding author), SmithKline Beecham Pharmaceut, Dept Mol Screening Technol, New Frontier Sci Pk,So Way, Harlow CM19 5AW, Essex, England.							AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; BERGSMA DJ, 1992, BIOCHEM BIOPH RES CO, V183, P989, DOI 10.1016/S0006-291X(05)80288-8; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRETON C, 1993, MOL BRAIN RES, V18, P297, DOI 10.1016/0169-328X(93)90093-5; Burgaud JL, 1997, BIOCHEM BIOPH RES CO, V241, P622, DOI 10.1006/bbrc.1997.7849; DROZDZ R, 1995, FEBS LETT, V359, P199, DOI 10.1016/0014-5793(95)00043-9; Fitzgerald LW, 1998, J PHARMACOL EXP THER, V287, P448; HERVIEU G, 1995, NEUROENDOCRINOLOGY, V61, P348, DOI 10.1159/000126857; Hervieu G, 1998, NEUROSCIENCE, V85, P1263, DOI 10.1016/S0306-4522(98)00024-4; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; Kolakowski LF, 1996, FEBS LETT, V398, P253, DOI 10.1016/S0014-5793(96)01160-X; Lakaye B, 1998, BBA-MOL CELL RES, V1401, P216, DOI 10.1016/S0167-4889(97)00135-3; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; Miller CL, 1998, BRAIN RES, V803, P86, DOI 10.1016/S0006-8993(98)00626-X; MORO O, 1993, J BIOL CHEM, V268, P22273; PRESSE F, 1990, MOL ENDOCRINOL, V4, P632, DOI 10.1210/mend-4-4-632; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; TAM JP, 1991, J AM CHEM SOC, V113, P6657, DOI 10.1021/ja00017a044; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; Tritos NA, 1998, DIABETES, V47, P1687, DOI 10.2337/diabetes.47.11.1687	25	418	450	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					261	265		10.1038/22313	http://dx.doi.org/10.1038/22313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421367				2022-12-24	WOS:000081503800043
J	Reid, FDA; Cook, DG; Majeed, A				Reid, FDA; Cook, DG; Majeed, A			Explaining variation in hospital admission rates between general practices: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY ADMISSIONS; REFERRAL RATES; EAST LONDON; PRACTITIONERS; DEPRIVATION; PATIENT; ASTHMA	Objectives To quantify the extent of the variation in hospital admission rates between general practices, and to investigate whether this variation can be explained by factors relating to the patient, the hospital, and the general practice. Design Cross sectional analysis of routine data. Setting Merton, Sutton, and Wandsworth Health Authority, which includes areas of inner and outer London. Subjects 209 136 hospital admissions in 1995-6 in patients registered with 120 general practices in the study area. Main outcome measures Hospital admission rate for general practices for overall, emergency, and elective admissions. Results Crude admission rates for general practices displayed a twofold difference between the 10th and the 90th centile for all, emergency, and elective admissions. This difference was only minimally reduced by standardising for age and sex. Sociodemographic patient factors derived from census data accounted for 42% of the variation in overall admission rates; 45% in emergency admission rates; and 25% in elective admission rates. There was a strong positive correlation between factors related to deprivation and emergency, but not elective, admission rates, raising questions about equity of provision of health care. The percentage of each practice's admissions to different local hospitals added significantly to the explanation of variation, while the general practice characteristics considered added very little. Conclusions Hospital admission rates varied greatly between general practices; this was largely explained by differences in patient populations. The lack of significant factors related to general practice is of little help for the direct management of admission rates, although the effect of sociological rather than organisational practice variables should routinely be standardised for differences in patient populations and hospitals used.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Gen Practice & Primary Care, London, England	St Georges University London; St Georges University London	Reid, FDA (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.			Majeed, Azeem/0000-0002-2357-9858; Cook, Derek/0000-0002-9723-5759				[Anonymous], 1993, SPSS WINDOWS BASE SY; ARMITAGE P, 1987, STATISTICAL METHODS, P403; Capewell S, 1996, BRIT MED J, V312, P991; CARRHILL RA, 1991, BRIT MED J, V302, P393, DOI 10.1136/bmj.302.6773.393; COULTER A, 1990, BMJ-BRIT MED J, V301, P273, DOI 10.1136/bmj.301.6746.273; Crombie D L, 1988, Health Trends, V20, P53; DEMARCO P, 1993, BRIT MED J, V307, P1465, DOI 10.1136/bmj.307.6917.1465; FERTIG A, 1993, BRIT MED J, V307, P1467, DOI 10.1136/bmj.307.6917.1467; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Griffiths C, 1996, BRIT MED J, V312, P481, DOI 10.1136/bmj.312.7029.481; HippisleyCox J, 1997, BRIT MED J, V314, P1458, DOI 10.1136/bmj.314.7092.1458; MAJEED A, 1996, HLTH TRENDS, V28, P52; Majeed A, 1998, CLIN MANAGE, V7, P160; Majeed F A, 1995, J Med Screen, V2, P119; MAJEED FA, 1994, BRIT MED J, V308, P1272, DOI 10.1136/bmj.308.6939.1272; MAJEED FA, 1995, BRIT J GEN PRACT, V45, P531; MAJEED FA, 1995, BRIT MED J, V310, P1511, DOI 10.1136/bmj.310.6993.1511; NEWTON J, 1991, FAM PRACT, V8, P308, DOI 10.1093/fampra/8.4.308; NOONE A, 1989, J ROY COLL GEN PRACT, V39, P404; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; THAKKER Y, 1994, ARCH DIS CHILD, V70, P488, DOI 10.1136/adc.70.6.488; Whynes DK, 1996, FAM PRACT, V13, P174, DOI 10.1093/fampra/13.2.174; Whynes DK, 1996, BRIT MED J, V312, P488, DOI 10.1136/bmj.312.7029.488; WILKIN D, 1987, FAM PRACT, V4, P160, DOI 10.1093/fampra/4.3.160	24	82	82	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					98	103		10.1136/bmj.319.7202.98	http://dx.doi.org/10.1136/bmj.319.7202.98			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398636	Green Published, Bronze			2022-12-24	WOS:000081438200035
J	Hughes, PM; Turton, P; Evans, CDH				Hughes, PM; Turton, P; Evans, CDH			Stillbirth as risk factor for depression and anxiety in the subsequent pregnancy: cohort study	BRITISH MEDICAL JOURNAL			English	Article							POSTNATAL DEPRESSION; PERINATAL DEATH	Objective To assess women's symptoms of depression and anxiety during pregnancy and the postpartum year in the pregnancy after stillbirth; to assess relevance of time since loss. Design Cohort study with four assessments: in third trimester and 6 weeks, 6 months, and 12 months after birth. Setting Outpatient departments of three district general hospitals; subjects' homes. Subjects 60 women whose previous pregnancy ended in stillbirth after 18 weeks' gestation; 60 matched controls. Main outcome measures Depression and anxiety measured by Edinburgh postnatal depression scale, Beck depression inventory, and Spielberger state-trait anxiety scale. Results In the third trimester women whose previous pregnancy had ended in stillbirth were significantly more depressed than control women (10.8 v 8.2; P = 0.004) and had greater state anxiety (39.8 v 32.8, P = 0.003) The difference was accounted for by those women who conceived less than 12 months after the stillbirth, who were also more depressed at 1 year. Results in those who conceived 12 months or more after stillbirth were similar to those in their controls at all points and showed lower trait anxiety 1 year post partum. One year after the birth 8% of control women and 19% of subjects scored high for depression (P = 0.39), with most of the depression among the more recently bereaved (28% v 11%; P = 0.18). In the women who had experienced stillbirth, depression in the third trimester was highly predictive of depression 1 year after subsequent birth (P less than or equal to 0.0005). Conclusion Vulnerability to depression and anxiety in the next pregnancy and puerperium is related to time since stillbirth, with more recently bereaved women at significantly greater risk than controls. As there are problems for mother and infant associated with high anxiety and depression during and after pregnancy, there may be advantage in waiting 12 months before the next conception.	St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Tavistock & Portman NHS Trust, Tavistock Clin, London NW3 5BA, England	St Georges University London	Hughes, PM (corresponding author), St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.		Evans, Chris/E-7526-2011	Evans, Chris/0000-0002-4197-4202				BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BOURNE S, 1984, BRIT MED J, V289, P147, DOI 10.1136/bmj.289.6438.147; Copper RL, 1996, AM J OBSTET GYNECOL, V175, P1286, DOI 10.1016/S0002-9378(96)70042-X; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; DAVIS DL, 1989, J AM ACAD CHILD PSY, V28, P481, DOI 10.1097/00004583-198907000-00002; FORREST CG, 1982, BRIT MED J, V285, P1475; Gitau R, 1998, LANCET, V352, P707, DOI 10.1016/S0140-6736(05)60824-0; Hunfeld JAM, 1997, PRENATAL DIAG, V17, P843, DOI 10.1002/(SICI)1097-0223(199709)17:9<843::AID-PD147>3.0.CO;2-Q; LEWIS E, 1979, BRIT MED J, V2, P27, DOI 10.1136/bmj.2.6181.27; LOU HC, 1994, DEV MED CHILD NEUROL, V36, P826; Murray D, 1990, J REPROD INFANT PSYC, V8, P99, DOI DOI 10.1080/02646839008403615; MURRAY L, 1992, J CHILD PSYCHOL PSYC, V33, P543, DOI 10.1111/j.1469-7610.1992.tb00890.x; *OFF NAT STAT, 1998, SER FMI, V15, P1; PHIPPS S, 1985, INT J PSYCHIAT MED, V15, P243, DOI 10.2190/GDC5-KA60-JPNH-PND2; ROWE J, 1978, PEDIATRICS, V62, P166; SPIELBERGER CD, 1970, TEST STATE TRAIT ANX; SROUFE LA, 1983, MINN SYM CHILD PSYCH, V16, P41; TEIXEIRA JMA, IN PRESS BMJ; THEUT SK, 1988, J AM ACAD CHILD PSY, V27, P289, DOI 10.1097/00004583-198805000-00004; WADWA PD, 1993, AM J OBSTET GYNECOL, V169, P858; ZUCKERMAN B, 1989, AM J OBSTET GYNECOL, V160, P1107, DOI 10.1016/0002-9378(89)90170-1	21	159	161	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1999	318	7200					1721	1724		10.1136/bmj.318.7200.1721	http://dx.doi.org/10.1136/bmj.318.7200.1721			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10381705	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000081216900022
J	de Rosa, R; Grenier, JK; Andreeva, T; Cook, CE; Adoutte, A; Akam, M; Carroll, SB; Balavoine, G				de Rosa, R; Grenier, JK; Andreeva, T; Cook, CE; Adoutte, A; Akam, M; Carroll, SB; Balavoine, G			Hox genes in brachiopods and priapulids and protostome evolution	NATURE			English	Article							HOMEOBOX GENES; CLUSTER; IDENTIFICATION; ARTHROPODS; ANNELIDA; ANIMALS; ELEGANS; ORIGIN; CLADE	Understanding the early evolution of animal body plans requires knowledge both of metazoan phylogeny and of the genetic and developmental changes involved in the emergence of particular forms. Recent 18S ribosomal RNA phylogenies suggest a three-branched tree for the Bilateria comprising the deuterostomes and two great protostome clades, the lophotrochozoans(1) and ecdysozoans(2). Here, we show that the complement of Nor genes in critical protostome phyla reflects these phylogenetic relationships and reveals the early evolution of developmental regulatory potential in bilaterians. We have identified Hox genes that are shared by subsets of protostome phyla. These include a diverged pair of posterior (Abdominal-B-like) genes in both a brachiopod and a polychaete annelid, which supports the lophotrochozoan assemblage, and a distinct posterior Hox gene shared by a priapulid, a nematode and the arthropods, which supports the ecdysozoan dade. The ancestors of each of these two major protostome lineages had a minimum of eight to ten Hox genes. The major period of Hox gene expansion and diversification thus occurred before the radiation of each of the three great bilaterian clades.	Univ Paris Sud, CNRS, UPRESA Q8080, Lab Biol Cellulaire 4, F-91405 Orsay, France; Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; Univ Wisconsin, Mol Biol Lab, Madison, WI 53706 USA; St Petersburg State Univ, Inst Biol, Dept Embryol, St Petersburg 199034, Russia; Univ Cambridge, Museum Zool, Dept Zool, Lab Dev & Evolut, Cambridge CB2 3EJ, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Saint Petersburg State University; University of Cambridge	Balavoine, G (corresponding author), CNRS, Ctr Genet Mol, UPR 9061, Ave Terrasse,Batiment 26, F-91198 Gif Sur Yvette, France.	Guillaume.Balavoine@cgm.cnrs-gif.fr		de Rosa, Renaud/0000-0002-3239-6324; Cook, Charles E/0000-0002-4145-8048	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Adoutte A, 1999, TRENDS GENET, V15, P104, DOI 10.1016/S0168-9525(98)01671-0; Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; AKAM M, 1989, CELL, V57, P347, DOI 10.1016/0092-8674(89)90909-4; AVEROF M, 1993, CURR BIOL, V3, P73, DOI 10.1016/0960-9822(93)90158-K; Balavoine G, 1996, NUCLEIC ACIDS RES, V24, P1547, DOI 10.1093/nar/24.8.1547; Balavoine G, 1998, AM ZOOL, V38, P843; BOARDMANN RS, 1987, FOSSIL INVERTEBRATES; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; Degnan Bernard M., 1993, Molecular Marine Biology and Biotechnology, V2, P1; DICK MH, 1994, MOL PHYLOGENET EVOL, V3, P146, DOI 10.1006/mpev.1994.1017; DUBOULE D, 1990, GENOMICS, V7, P458, DOI 10.1016/0888-7543(90)90185-W; GARCIAFERNANDEZ J, 1994, NATURE, V370, P563, DOI 10.1038/370563a0; Grenier JK, 1997, CURR BIOL, V7, P547, DOI 10.1016/S0960-9822(06)00253-3; HALANYCH KM, 1995, SCIENCE, V267, P1641, DOI 10.1126/science.7886451; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Kmita-Cunisse M, 1998, P NATL ACAD SCI USA, V95, P3030, DOI 10.1073/pnas.95.6.3030; Mackey LY, 1996, J MOL EVOL, V42, P552, DOI 10.1007/BF02352285; Martinez P, 1999, P NATL ACAD SCI USA, V96, P1469, DOI 10.1073/pnas.96.4.1469; Nielsen C., 1995, ANIMAL EVOLUTION; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCHUBERT FR, 1993, P NATL ACAD SCI USA, V90, P143, DOI 10.1073/pnas.90.1.143; SHANKLAND M, 1991, DEVELOPMENT, P29; SNOW P, 1994, MOL PHYLOGENET EVOL, V3, P360, DOI 10.1006/mpev.1994.1042; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD D.L., 2003, PAUP PHYLOGENETIC AN; WANG BB, 1993, CELL, V74, P29, DOI 10.1016/0092-8674(93)90292-X; WONG VY, 1995, J NEUROSCI, V15, P5551; WYSOCKADILLER JW, 1989, NATURE, V341, P760, DOI 10.1038/341760a0; [No title captured]	30	389	393	3	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					772	776						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391241				2022-12-24	WOS:000081101600051
J	Joo, H; Lin, ZL; Arnold, FH				Joo, H; Lin, ZL; Arnold, FH			Laboratory evolution of peroxide-mediated cytochrome P450 hydroxylation	NATURE			English	Article							DIRECTED EVOLUTION; HYDROGEN-PEROXIDE; GENE; CRYSTALLOGRAPHY; SUPERFAMILY; OXIDATION; ESTERASE; OXYGEN; H2O2	Enzyme-based chemical transformations typically proceed with high selectivity under mild conditions, and are;becoming increasingly important in the pharmaceutical and chemical industries. Cytochrome P450 monooxygenases (P450s) constitute a large family(1) of enzymes of particular interest in this regard. Their biological functions, such as detoxification of xenobiotics and steroidogenesis(2-5), are based on the ability to catalyse the insertion of oxygen into:a wide variety of compounds(6). Such a catalytic transformation might find technological applications in areas ranging from gene therapy and environmental remediation to the selective synthesis of pharmaceuticals and chemicals(7-10). But relatively low turnover rates (particularly towards non-natural substrates), low stability and the need for electron-donating cofactors prohibit the practical use of P450s as isolated enzymes. Here we report the directed evolution(11) of the P450 from Pseudomonas putida to create mutants that hydroxylate naphthalene in the absence of cofactors through the 'peroxide shunt' pathway(12,13) with more than 20-fold higher activity than the native enzyme. We are able to screen efficiently for improved mutants by coexpressing them with horseradish peroxidase, which converts the products of the P450 reaction into fluorescent compounds amenable to digital imaging screening. This system should allow us to select and develop mono- and di-oxygenases into practically useful biocatalysts for the hydroxylation of a wide range of aromatic compounds.	CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA	California Institute of Technology	Arnold, FH (corresponding author), CALTECH, Div Chem & Chem Engn 210 41, Pasadena, CA 91125 USA.		Lin, Zhanglin/A-7232-2011	Arnold, Frances H./0000-0002-4027-364X				Arnold FH, 1998, ACCOUNTS CHEM RES, V31, P125, DOI 10.1021/ar960017f; Cerniglia Carl E., 1992, Biodegradation, V3, P351, DOI 10.1007/BF00129093; Cook DL, 1997, BIOCHEMISTRY-US, V36, P10801, DOI 10.1021/bi971284b; Crameri A, 1998, NATURE, V391, P288, DOI 10.1038/34663; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Duport C, 1998, NAT BIOTECHNOL, V16, P186, DOI 10.1038/nbt0298-186; England PA, 1998, FEBS LETT, V424, P271, DOI 10.1016/S0014-5793(98)00189-6; FABER K, 1997, BIOTRANSFORMATIONS O, P208; Giver L, 1998, P NATL ACAD SCI USA, V95, P12809, DOI 10.1073/pnas.95.22.12809; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GrahamLorence S, 1996, FASEB J, V10, P206, DOI 10.1096/fasebj.10.2.8641554; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; HRYCAY EG, 1975, BIOCHEM BIOPH RES CO, V66, P209, DOI 10.1016/S0006-291X(75)80315-9; HUMMEL W, 1989, EUR J BIOCHEM, V184, P1, DOI 10.1111/j.1432-1033.1989.tb14983.x; Jounaidi Y, 1998, CANCER RES, V58, P4391; Lin ZL, 1999, BIOTECHNOL PROGR, V15, P467, DOI 10.1021/bp990037r; MCKAY CP, 1991, ORIGINS LIFE EVOL B, V21, P157, DOI 10.1007/BF01809444; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NORDBLOM GD, 1976, ARCH BIOCHEM BIOPHYS, V175, P524, DOI 10.1016/0003-9861(76)90541-5; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; Samuilov VD, 1997, BIOCHEMISTRY-MOSCOW+, V62, P451; Seelbach K, 1996, TETRAHEDRON LETT, V37, P1377, DOI 10.1016/0040-4039(96)00010-X; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; UNGER BP, 1986, J BIOL CHEM, V261, P1158; vanDeurzen MPJ, 1997, TETRAHEDRON, V53, P13183, DOI 10.1016/S0040-4020(97)00477-8; WACKETT LP, 1994, NATURE, V368, P627, DOI 10.1038/368627a0; Waxman David J., 1995, P391; Zhao H., 1999, MANUAL IND MICROBIOL, P597; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47; Zhao HM, 1998, NAT BIOTECHNOL, V16, P258, DOI 10.1038/nbt0398-258	32	337	401	3	120	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					670	673		10.1038/21395	http://dx.doi.org/10.1038/21395			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385118				2022-12-24	WOS:000080932800054
J	Kuroda, MI; Kelley, RL				Kuroda, MI; Kelley, RL			Developmental biology - Sex and repression	SCIENCE			English	Editorial Material							CHROMOSOME DOSAGE COMPENSATION; X-CHROMOSOME; C-ELEGANS; NEMATODE; PROTEIN; HOMOLOG; GENE		Baylor Univ, Howard Hughes Med Inst, Dept Cell Biol, Houston, TX 77030 USA; Baylor Univ, Dept Mol & Human Genet, Houston, TX 77030 USA	Baylor University; Howard Hughes Medical Institute; Baylor University	Kuroda, MI (corresponding author), Baylor Univ, Howard Hughes Med Inst, Dept Cell Biol, Houston, TX 77030 USA.							Carmi I, 1998, NATURE, V396, P168, DOI 10.1038/24164; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; Dawes HE, 1999, SCIENCE, V284, P1800, DOI 10.1126/science.284.5421.1800; DELONG L, 1993, GENETICS, V133, P875; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; Lee JT, 1997, CURR OPIN GENET DEV, V7, P274, DOI 10.1016/S0959-437X(97)80138-4; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579	13	2	2	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 11	1999	284	5421					1787	1788		10.1126/science.284.5421.1787	http://dx.doi.org/10.1126/science.284.5421.1787			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	205EU	10391797				2022-12-24	WOS:000080809000037
J	Gaidos, EJ; Nealson, KH; Kirschvink, JL				Gaidos, EJ; Nealson, KH; Kirschvink, JL			Biogeochemistry - Life in ice-covered oceans	SCIENCE			English	Editorial Material							EARLY EARTH; HYDROTHERMAL SYSTEMS; SNC METEORITES; LIQUID WATER; EUROPA; MARS; SURFACE; SATELLITES; REDUCTION; JUPITER		CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA; Univ Wisconsin, Ctr Great Lakes Studies, Milwaukee, WI 53204 USA	California Institute of Technology; University of Wisconsin System; University of Wisconsin Milwaukee	Gaidos, EJ (corresponding author), CALTECH, Dept Geol & Planetary Sci, Pasadena, CA 91125 USA.	gaidos@gps.caltech.edu		Gaidos, Eric/0000-0002-5258-6846				Anderson JD, 1998, SCIENCE, V281, P2019, DOI 10.1126/science.281.5385.2019; BALLHAUS C, 1990, NATURE, V348, P437, DOI 10.1038/348437a0; Carlson RW, 1999, SCIENCE, V283, P2062, DOI 10.1126/science.283.5410.2062; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CHANG S, 1993, NATO ADV SCI INST SE, V416, P259; CRAWFORD GD, 1988, ICARUS, V73, P66, DOI 10.1016/0019-1035(88)90085-1; Delitsky ML, 1997, J GEOPHYS RES-PLANET, V102, P16385, DOI 10.1029/97JE01250; DICHRISTINA TJ, 1988, WATER SCI TECHNOL, V20, P69, DOI 10.2166/wst.1988.0268; DSON FJ, 1997, ATL MON, V280, P71; Elderfield H, 1996, ANNU REV EARTH PL SC, V24, P191, DOI 10.1146/annurev.earth.24.1.191; Greeley R, 1998, ICARUS, V135, P4, DOI 10.1006/icar.1998.5969; GREELEY R, 1991, SCIENCE, V254, P996, DOI 10.1126/science.254.5034.996; HALL DT, 1995, NATURE, V373, P677, DOI 10.1038/373677a0; HOBBS PV, 1974, ICE PHYSICS; Hoffman PF, 1998, SCIENCE, V281, P1342, DOI 10.1126/science.281.5381.1342; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Jean-Baptiste P, 1998, EARTH PLANET SC LETT, V158, P81, DOI 10.1016/S0012-821X(98)00045-4; Johnson RE, 1997, J GEOPHYS RES-PLANET, V102, P10985, DOI 10.1029/97JE00068; Johnson RE, 1997, ASTROPHYS J, V480, pL79, DOI 10.1086/310614; Khurana KK, 1998, NATURE, V395, P777, DOI 10.1038/27394; Kirschvink J. L., 1992, PROTEROZOIC BIOSPHER, P51; KNAUER GA, 1993, BIOGEOCHEMICAL CYCLE, P211; LOVLEY DR, 1986, APPL ENVIRON MICROB, V51, P683, DOI 10.1128/AEM.51.4.683-689.1986; MAHER KA, 1988, NATURE, V331, P612, DOI 10.1038/331612a0; McCollom TM, 1997, GEOCHIM COSMOCHIM AC, V61, P4375, DOI 10.1016/S0016-7037(97)00241-X; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MOOD S, 1983, ASTRONOMY, V11, P16; Moore JM, 1998, ICARUS, V135, P127, DOI 10.1006/icar.1998.5973; MURRELL JC, 1992, FEMS MICROBIOL LETT, V88, P233, DOI 10.1016/0378-1097(92)90805-X; MYERS CR, 1990, J BACTERIOL, V172, P6232, DOI 10.1128/jb.172.11.6232-6238.1990; Navarro-Gonzalez R, 1998, GEOPHYS RES LETT, V25, P3123, DOI 10.1029/98GL02423; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Orton GS, 1996, SCIENCE, V274, P389, DOI 10.1126/science.274.5286.389; OVERMANN J, 1992, LIMNOL OCEANOGR, V37, P150, DOI 10.4319/lo.1992.37.1.0150; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Powell CS, 1997, SCI AM, V276, P28, DOI 10.1038/scientificamerican0497-28; Priscu JC, 1998, SCIENCE, V280, P2095, DOI 10.1126/science.280.5372.2095; Rathbun JA, 1998, GEOPHYS RES LETT, V25, P4157, DOI 10.1029/1998GL900135; Reynolds R T, 1987, Adv Space Res, V7, P125, DOI 10.1016/0273-1177(87)90364-4; REYNOLDS RT, 1983, ICARUS, V56, P246, DOI 10.1016/0019-1035(83)90037-4; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; Shock EL, 1997, J GEOPHYS RES-PLANET, V102, P23687, DOI 10.1029/97JE01087; Shock EL, 1996, CIBA F SYMP, V202, P40; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; Spaun NA, 1998, GEOPHYS RES LETT, V25, P4277, DOI 10.1029/1998GL900176; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; Stumm W., 1981, AQUATIC CHEM; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; YUNG YL, 1996, AM ASTR SOC DIV PLAN; Zahnle K, 1998, ICARUS, V136, P202, DOI 10.1006/icar.1998.6015	55	132	138	1	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 4	1999	284	5420					1631	1633		10.1126/science.284.5420.1631	http://dx.doi.org/10.1126/science.284.5420.1631			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	202TM	10383341				2022-12-24	WOS:000080668300031
J	Banatvala, N; Peremitin, GG				Banatvala, N; Peremitin, GG			Tuberculosis, Russia, and the Holy Grail	LANCET			English	Article									MERLIN, London W1M 4HW, England; Tomsk Reg TB Dispensary, Tomsk, Russia		Banatvala, N (corresponding author), MERLIN, 14 David Mews, London W1M 4HW, England.			Banatvala, Nick/0000-0001-8130-154X				Blower SM, 1996, SCIENCE, V273, P497, DOI 10.1126/science.273.5274.497; Drobniewski F, 1996, TUBERCLE LUNG DIS, V77, P297, DOI 10.1016/S0962-8479(96)90092-1; Farmer P, 1998, BRIT MED J, V317, P671, DOI 10.1136/bmj.317.7159.671	3	5	5	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					999	1000		10.1016/S0140-6736(99)02059-0	http://dx.doi.org/10.1016/S0140-6736(99)02059-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459925				2022-12-24	WOS:000079421600046
J	Chintu, C; Mwinga, A				Chintu, C; Mwinga, A			An African perspective on the threat of tuberculosis and HIV/AIDS - can despair be turned to hope?	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS		Univ Lusaka, Teaching Hosp, UNZA UCLMS TB HIV Res & Training Project, Lusaka, Zambia	University of Zambia	Chintu, C (corresponding author), Univ Lusaka, Teaching Hosp, UNZA UCLMS TB HIV Res & Training Project, Lusaka, Zambia.	cchintu@zamnet.zm						Department for International Development, 1997, WHIT PAP INT DEV; DOLIN P, 1998, GENDER TUBERCULOSIS; ELLIOTT AM, 1993, J TROP MED HYG, V96, P1; ELLIOTT AM, 1995, T ROY SOC TROP MED H, V89, P78, DOI 10.1016/0035-9203(95)90668-1; LUO C, 1994, TUBERCLE LUNG DIS, V75, P110, DOI 10.1016/0962-8479(94)90039-6; Zumla A, 1998, INT J TUBERC LUNG D, V2, P179	6	27	30	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					997	997		10.1016/S0140-6736(99)01141-1	http://dx.doi.org/10.1016/S0140-6736(99)01141-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459923				2022-12-24	WOS:000079421600044
J	Kelly, M				Kelly, M		Hlth Population Div Dept Int Dev	A donor's perspective on tuberculosis in international health	LANCET			English	Article									DFID, HPD, London SW1E 5JL, England		Kelly, M (corresponding author), DFID, HPD, 94 Victoria St, London SW1E 5JL, England.							Department for International Development, 1997, EL WORLD POV CHALL 2; *GLOB TUB PROGR, 1998, TUB GLOB SURV; *GLOB TUB PROGR, 1994, FRAM ESS TB CONTR; GWATKIN DR, 1998, 981 WHO TDR ER RD; Styblo K, 1991, TUBERCULOSIS CAN BE, V2, P60	5	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					1006	1006						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459930				2022-12-24	WOS:000079421600051
J	Graham, WJ; Newell, ML				Graham, WJ; Newell, ML			Seizing the opportunity: collaborative initiatives to reduce HIV and maternal mortality	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; TO-CHILD TRANSMISSION; INFECTION; ZIDOVUDINE; MORBIDITY; HEALTH; IMPACT; TRIAL		Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland; UCL, Inst Child Hlth, Dept Epidemiol & Publ Hlth, London, England	University of Aberdeen; University of London; University College London	Graham, WJ (corresponding author), Univ Aberdeen, Dept Obstet & Gynaecol, Dugald Baird Ctr Res Womens Hlth, Aberdeen Matern Hosp, Aberdeen AB25 2ZL, Scotland.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699; Graham, Wendy/0000-0003-1473-5342				ABOUZAHR C, 1998, GLOBAL BURDEN DIS IN, V3, P111; [Anonymous], 1997, CONFR AIDS PUBL PRIO; [Anonymous], 1996, UNICEF REVISED 1990; AsiimweOkiror G, 1997, AIDS, V11, P1757, DOI 10.1097/00002030-199714000-00013; BARNETT T, 1992, AIDS AFRICA; Cassels A, 1998, LANCET, V352, P1777, DOI 10.1016/S0140-6736(98)05350-1; *CDC, 1998, MMWR-MORBID MORTAL W, V47, P151; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DABIS F, 1995, AIDS, V9, P204, DOI 10.1097/00002030-199509020-00015; Diczfalusy E, 1994, World Health Forum, V15, P1; *EUR COLL STUD, 1997, BRIT J OBSTET GYNAEC, V105, P704; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; Graham W, 1998, BRIT J OBSTET GYNAEC, V105, P375, DOI 10.1111/j.1471-0528.1998.tb10116.x; GRAHAM WJ, 1992, SOC SCI MED, V35, P967, DOI 10.1016/0277-9536(92)90236-J; Graham WJ, 1998, SOC SCI MED, V47, P1925, DOI 10.1016/S0277-9536(98)00334-7; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; HANSLUWKA HE, 1985, SOC SCI MED, V20, P1207, DOI 10.1016/0277-9536(85)90374-0; Leroy V, 1998, LANCET, V352, P597, DOI 10.1016/S0140-6736(98)01419-6; LOWBEER D, 1998, HLTH DIMENSIONS SEX, V3, P297; MAHLER H, 1987, LANCET, V1, P668; Mansergh G, 1998, JAMA-J AM MED ASSOC, V280, P30, DOI 10.1001/jama.280.1.30; Mayaud P, 1998, LANCET, V351, P29; McDonagh M, 1996, HEALTH POLICY PLANN, V11, P1, DOI 10.1093/heapol/11.1.1; Mertens T E, 1995, AIDS, V9 Suppl A, pS259; Murray C. J. L., 1998, GLOBAL BURDEN DIS IN, V3, P1; Newell ML, 1997, AIDS, V11, pS165; OVER M, 1993, 9 INT C AIDS 3 STD W; *PREV MAT MORT NET, 1995, SOC SCI MED, V40, P657; ROWLEY JT, 1990, AIDS, V4, P47, DOI 10.1097/00002030-199001000-00007; Strong MA, 1992, HLTH TRANSITION REV, V2, P215; Taha TE, 1997, BRIT MED J, V315, P216, DOI 10.1136/bmj.315.7102.216; *UNAIDS, 1998, REP GLOB HIV AIDS EP; VILLAR J, 1995, ACTA OBSTET GYNECOL, V76, P1; World Health Organization, 1997, MON REPR HLTH SEL SH; World Health Organization, 1997, COV MAT CAR LIST AV	36	40	42	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					836	839		10.1016/S0140-6736(98)12374-7	http://dx.doi.org/10.1016/S0140-6736(98)12374-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459980				2022-12-24	WOS:000079089100048
J	Node, K; Huo, YQ; Ruan, XL; Yang, BC; Spiecker, M; Ley, K; Zeldin, DC; Liao, JK				Node, K; Huo, YQ; Ruan, XL; Yang, BC; Spiecker, M; Ley, K; Zeldin, DC; Liao, JK			Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids	SCIENCE			English	Article							EPOXYEICOSATRIENOIC ACIDS; ENDOTHELIAL-CELLS; MOLECULAR-CLONING; EXPRESSION; HEART	The epoxyeicosatrienoic acids (EETs) are products of cytochrome P450 epoxy-genases that have vasodilatory properties similar to that of endothelium-derived hyperpolarizing factor. The cytochrome P450 isoform CYP2J2 was cloned and identified as a potential source of EETs in human endothelial cells. Physiological concentrations of EETs or overexpression of CYP2J2 decreased cytokine-induced endothelial cell adhesion molecule expression, and EETs prevented leukocyte adhesion to the vascular wall by a mechanism involving inhibition of transcription factor NF-kappa B and I kappa B kinase. The inhibitory effects of EETs were independent of their membrane-hyperpolarizing effects, suggesting that these molecules play an important nonvasodilatory role in vascular inflammation.	Brigham & Womens Hosp, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Virginia, Ctr Hlth Sci, Dept Biomed Engn, Charlottesville, VA 22908 USA; NIEHS, Pulm Pathobiol Lab, NIH, Res Triangle Pk, NC 27709 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Virginia; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liao, JK (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, Vasc Med & Atherosclerosis Unit, 75 Francis St, Boston, MA 02115 USA.		TATSUTA, HARUKI/F-2997-2010; Zeldin, Darryl C/Y-7091-2018	Zeldin, Darryl C/0000-0002-2087-7307	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048743, R01HL058108, R01HL052233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES025034] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL048743-090008, P01 HL048743, R01 HL052233-05, HL-58108, P01 HL048743-080008, R01 HL052233-06, R01 HL052233, HL-52233] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Campbell WB, 1999, CIRC RES, V84, P484, DOI 10.1161/01.RES.84.4.484; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; DE CR, 1995, J CLIN INVEST, V96, P60; FARIN FM, 1994, TOXICOL APPL PHARM, V124, P1, DOI 10.1006/taap.1994.1001; Hoebel BG, 1998, CLIN EXP PHARMACOL P, V25, P826, DOI 10.1111/j.1440-1681.1998.tb02162.x; Kozak W, 1998, AM J PHYSIOL-REG I, V275, pR1031, DOI 10.1152/ajpregu.1998.275.4.R1031; LIAO J, UNPUB, P63509; LIN JHC, 1996, ENDOTHELIUM, V4, P219; MIYAKE K, 1991, J CELL BIOL, V114, P557, DOI 10.1083/jcb.114.3.557; Nakashima T, 1996, AM J PHYSIOL-REG I, V271, pR1274, DOI 10.1152/ajpregu.1996.271.5.R1274; Oltman CL, 1998, CIRC RES, V83, P932; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; Ramos CL, 1999, CIRC RES, V84, P1237, DOI 10.1161/01.RES.84.11.1237; Rosolowsky M, 1996, BBA-LIPID LIPID MET, V1299, P267, DOI 10.1016/0005-2760(95)00216-2; VANROLLINS M, 1993, J LIPID RES, V34, P1931; Wu S, 1996, J BIOL CHEM, V271, P3460; Wu S, 1997, J BIOL CHEM, V272, P12551, DOI 10.1074/jbc.272.19.12551	20	955	1018	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1276	1279		10.1126/science.285.5431.1276	http://dx.doi.org/10.1126/science.285.5431.1276			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455056	Green Accepted			2022-12-24	WOS:000082130200046
J	Brentnall, TA; Bronner, MP; Byrd, DR; Haggitt, PC; Kimmey, MB				Brentnall, TA; Bronner, MP; Byrd, DR; Haggitt, PC; Kimmey, MB			Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer	ANNALS OF INTERNAL MEDICINE			English	Article							LARGE BOWEL; ADENOCARCINOMA; LESIONS; CARCINOMA	Background: Pancreatic cancer, the fourth most common cause of cancer death in the United States, is hereditary in an estimated 10% of cases. Surveillance of patients with a familial predisposition for pancreatic cancer has not been systematically evaluated. Objective: To develop a surveillance program that can identify and treat patients who have precancerous conditions of the pancreas and a family history of pancreatic cancer. Design: Prospective cohort study. Setting: University medical center. Patients: 14 patients from three kindreds with a history of pancreatic cancer. Interventions: Endoscopic ultrasonography, endoscopic retrograde cholangiopancreatography (ERCP), spiral computed tomography, and serum carcinoembryonic antigen and CA19-9 analysis were performed in all patients. Four affected patients were tested for the K-ras mutation. Main Outcome Measurement: Pancreatic dysplasia was determined by histologic evaluation. Results: Seven of the 14 patients were believed to have dysplasia on the basis of clinical history and abnormalities on endoscopic ultrasonography and ERCP and were referred for pancreatectomy. All 7 patients had histologic evidence of dysplasia in pancreatectomy specimens. Findings on endoscopic ultrasonography were subtle, nonspecific, and similar to those seen in patients with chronic pancreatitis. Findings on ERCP ranged from mild and focal side-branch duct irregularities and small sacculations to main-duct strictures and grapelike clusters of saccules. Some of these changes are typical of chronic pancreatitis, but others are more distinctive. Spiral computed tomography and serum tumor markers had low sensitivity in the detection of pancreatic dysplasia. Analysis for the K-ras mutation yielded positive results in 3 of 4 patients with dysplasia. Conclusions: Thorough screening of patients with a family history of pancreatic cancer is feasible. Clinical data combined with imaging studies (endoscopic ultrasonography and ERCP) can be used to identify high-risk patients who have dysplasia. The role of molecular genetic testing is uncertain at this time.	Univ Washington, Div Gastroenterol, Seattle, WA 98195 USA; Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Brentnall, TA (corresponding author), Univ Washington, Div Gastroenterol, Box 356424, Seattle, WA 98195 USA.	teribr@u.washington.edu						BARBOSA JJD, 1946, SURG GYNECOL OBSTET, V82, P527; Brat DJ, 1998, AM J SURG PATHOL, V22, P163, DOI 10.1097/00000478-199802000-00003; BRENTNALL TA, 1995, CANCER RES, V55, P4264; BUSARD JM, 1950, ARCH SURG-CHICAGO, V60, P674, DOI 10.1001/archsurg.1950.01250010695003; CUBILLA AL, 1976, CANCER RES, V36, P2690; Enterline H T, 1976, Curr Top Pathol, V63, P95; EVANS JP, 1995, J MED GENET, V32, P330, DOI 10.1136/jmg.32.5.330; GUDJONSSON B, 1987, CANCER, V60, P2284, DOI 10.1002/1097-0142(19871101)60:9<2284::AID-CNCR2820600930>3.0.CO;2-V; KLIMSTRA DS, 1994, INT J PANCREATOL, V16, P224; KLOPPEL G, 1980, VIRCHOWS ARCH A, V387, P221, DOI 10.1007/BF00430702; KOZUKA S, 1979, CANCER, V43, P1419, DOI 10.1002/1097-0142(197904)43:4<1418::AID-CNCR2820430431>3.0.CO;2-O; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LONGNECKER DS, 1994, INT J PANCREATOL, V16, P201; Lynch HT, 1996, SEMIN ONCOL, V23, P251; MORSON B, 1974, P ROY SOC MED, V67, P451, DOI 10.1177/00359157740676P115; POUR P, 1977, AM J PATHOL, V88, P291; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Wiersema M J, 1995, Gastrointest Endosc Clin N Am, V5, P487	18	290	301	1	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 17	1999	131	4					247	+		10.7326/0003-4819-131-4-199908170-00003	http://dx.doi.org/10.7326/0003-4819-131-4-199908170-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	226GR	10454945				2022-12-24	WOS:000082012500002
J	McBride, HM; Rybin, V; Murphy, C; Giner, A; Teasdale, R; Zerial, M				McBride, HM; Rybin, V; Murphy, C; Giner, A; Teasdale, R; Zerial, M			Oligomeric complexes link Rab5 effectors with NSF and drive membrane fusion via interactions between EEA1 and syntaxin 13	CELL			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; SMALL GTPASE RAB5; VESICLE DOCKING; SNARE COMPLEX; AMPA RECEPTORS; PROTEIN; TRANSPORT; ENDOSOME; EXOCYTOSIS; BINDING	SNAREs and Rab GTPases cooperate in vesicle transport through a mechanism yet poorly understood. We now demonstrate that the Rab5 effecters EEA1 and Rabaptin-5/Rabex-5 exist on the membrane in high molecular weight oligomers, which also contain NSF. Oligomeric assembly is modulated by the ATPase activity of NSF. Syntaxin 13, the t-SNARE required for endosome fusion, is transiently incorporated into the large oligomers via direct interactions with EEA1. This interaction is required to drive fusion, since both dominant-negative EEA1 and synthetic peptides encoding the MIE Zn2+ finger hinder the interaction and block fusion. We propose a novel mechanism whereby oligomeric EEA1 and NSF mediate the local activation of syntaxin 13 upon membrane tethering and, by analogy with viral fusion proteins, coordinate the assembly of a fusion pore.	European Mol Biol Lab, D-69117 Heidelberg, Germany; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Univ Ioannina, Sch Med, Biol Chem Lab, Ioannina 45110, Greece; Alfred Hosp, Monash Med Sch, Dept Pathol & Immunol, Prahran, Vic 3181, Australia	European Molecular Biology Laboratory (EMBL); Max Planck Society; University of Ioannina; Florey Institute of Neuroscience & Mental Health; Monash University	Zerial, M (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69117 Heidelberg, Germany.		Murphy, Carol/ABE-4282-2021; Teasdale, Rohan D/B-2538-2009; McBride, Heidi M./ABD-5774-2021; McBride, Heidi M/C-1162-2008; Teasdale, Rohan/AAD-6698-2019	Murphy, Carol/0000-0003-1353-8558; Teasdale, Rohan D/0000-0001-7455-5269; McBride, Heidi M./0000-0003-4666-2280; McBride, Heidi M/0000-0003-4666-2280; Teasdale, Rohan/0000-0001-7455-5269				Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Barnard RJO, 1997, J CELL BIOL, V139, P875, DOI 10.1083/jcb.139.4.875; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Burd CG, 1997, MOL BIOL CELL, V8, P1089, DOI 10.1091/mbc.8.6.1089; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; Callaghan J, 1999, BIOCHEM J, V338, P539, DOI 10.1042/0264-6021:3380539; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chao DS, 1999, J CELL BIOL, V144, P869, DOI 10.1083/jcb.144.5.869; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Coorssen JR, 1998, J CELL BIOL, V143, P1845, DOI 10.1083/jcb.143.7.1845; Danieli T, 1996, J CELL BIOL, V133, P559, DOI 10.1083/jcb.133.3.559; Davanger S, 1997, MOL BIOL CELL, V8, P1261, DOI 10.1091/mbc.8.7.1261; DOMS RW, 1986, J VIROL, V60, P833, DOI 10.1128/JVI.60.3.833-839.1986; Finger FP, 1998, CELL, V92, P559, DOI 10.1016/S0092-8674(00)80948-4; Fujita Y, 1998, NEURON, V20, P905, DOI 10.1016/S0896-6273(00)80472-9; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Gournier H, 1998, EMBO J, V17, P1930, DOI 10.1093/emboj/17.7.1930; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; Hay JC, 1998, J CELL BIOL, V141, P1489, DOI 10.1083/jcb.141.7.1489; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Hohl TM, 1998, MOL CELL, V2, P539, DOI 10.1016/S1097-2765(00)80153-7; Holthuis JCM, 1998, EMBO J, V17, P113, DOI 10.1093/emboj/17.1.113; Horiuchi H, 1997, CELL, V90, P1149, DOI 10.1016/S0092-8674(00)80380-3; Klumperman J, 1998, J CELL BIOL, V141, P359, DOI 10.1083/jcb.141.2.359; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lin JW, 1998, NEURON, V21, P267, DOI 10.1016/S0896-6273(00)80534-6; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Markovic I, 1998, J CELL BIOL, V143, P1155, DOI 10.1083/jcb.143.5.1155; Mills IG, 1998, CURR BIOL, V8, P881, DOI 10.1016/S0960-9822(07)00351-X; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Murphy C, 1996, NATURE, V384, P427, DOI 10.1038/384427a0; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nishimune A, 1998, NEURON, V21, P87, DOI 10.1016/S0896-6273(00)80517-6; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Osten P, 1998, NEURON, V21, P99, DOI 10.1016/S0896-6273(00)80518-8; Patki V, 1998, NATURE, V394, P433, DOI 10.1038/28771; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Poirier MA, 1998, NAT STRUCT BIOL, V5, P765, DOI 10.1038/1799; Prekeris R, 1998, J CELL BIOL, V143, P957, DOI 10.1083/jcb.143.4.957; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Rybin V, 1996, NATURE, V383, P266, DOI 10.1038/383266a0; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Song I, 1998, NEURON, V21, P393, DOI 10.1016/S0896-6273(00)80548-6; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Tang BL, 1998, J BIOL CHEM, V273, P6944, DOI 10.1074/jbc.273.12.6944; Ungermann C, 1998, NATURE, V396, P543, DOI 10.1038/25069; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; vonMollard GF, 1997, J CELL BIOL, V137, P1511, DOI 10.1083/jcb.137.7.1511; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; Xu ZY, 1998, CELL, V93, P1125, DOI 10.1016/S0092-8674(00)81457-9; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649	64	393	398	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 6	1999	98	3					377	386		10.1016/S0092-8674(00)81966-2	http://dx.doi.org/10.1016/S0092-8674(00)81966-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	225GP	10458612	Bronze			2022-12-24	WOS:000081950300012
J	Neugebauer, R; Hoek, HW; Susser, E				Neugebauer, R; Hoek, HW; Susser, E			Prenatal exposure to wartime famine and development of antisocial personality disorder in early adulthood	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DUTCH-HUNGER-WINTER; BIRTH COMPLICATIONS; VIOLENT CRIME; FOLLOW-UP; CHILDREN; PREGNANCY; BEHAVIOR; SCHIZOPHRENIA; ADOLESCENCE; STARVATION	Context Several observational epidemiological studies report an association of pregnancy and obstetric complications with development of antisocial personality disorder (ASPD) in offspring. However, the precise nature and timing of the hypothesized biological insults are not known. Objective To test whether severe maternal nutritional deficiency early in gestation is associated with risk for ASPD in offspring. Design and Setting Retrospective cohort study. From October 1944 to May 1945, the German army blockaded food supplies to the Netherlands, subjecting the western Netherlands first to moderate (official food rations, 4200-6300 kJ/d) then to severe (<4200 kJ/d) nutritional deficiency. The north and south were subjected to moderate nutritional deficiency only. Participants Dutch men born in large urban areas in 1944-1946 who were given psychiatric examinations for military induction at age 18 years (N = 100 543) were classified by the degree and timing of their prenatal exposure to nutritional deficiency based on their birthdate and birthplace. Main Outcome Measure Diagnosis of ASPD by psychiatric interview at time of medical examination for military induction, using the International Classification of Diseases, Sixth Revision (ICD-6). Results Men exposed prenatally to severe maternal nutritional deficiency during the first and/or second trimesters of pregnancy exhibited increased risk for ASPD (adjusted odds ratio [OR], 2.5; 95% confidence interval [CI], 1.5-4.2). Third-trimester exposure to severe nutritional deficiency and prenatal exposure to moderate nutritional deficiency were not associated with risk for ASPD. Conclusions Our data suggest that severe nutritional insults to the developing brain in utero may be capable of increasing the risk for antisocial behaviors in offspring. The possible implications of these findings for both developed countries and developing countries, where severe nutritional deficiency is widespread and often exacerbated by war, natural disaster, and forced migration, warrant study.	Columbia Univ, New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, New York, NY 10032 USA; Columbia Univ, GH Sergievsky Ctr, Fac Med, New York, NY 10032 USA; Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Leiden Univ, Parnassia Hague Psychiat Inst, The Hague, Netherlands	Columbia University; New York State Psychiatry Institute; Columbia University; Columbia University; Leiden University; Leiden University - Excl LUMC; Parnassia Psychiatric Institute	Neugebauer, R (corresponding author), Columbia Univ, New York State Psychiat Inst, Epidemiol Dev Brain Disorders Dept, Box 53,722 W 168th St, New York, NY 10032 USA.			Hoek, Hans/0000-0001-6353-5465				[Anonymous], 1994, DIAGNOSTIC STAT MANU; Baker R. L., 1984, INFLUENCES HUMAN DEV; BRENNAN P, 1993, DEV TREATMENT CHILDH, P81; BRESLAU N, 1988, J AM ACAD CHILD PSY, V27, P605, DOI 10.1097/00004583-198809000-00015; BROWN AS, 1995, BRIT J PSYCHIAT, V166, P601, DOI 10.1192/bjp.166.5.601; Brown AS, 1997, EPIDEMIOLOGY, V8, P55, DOI 10.1097/00001648-199701000-00009; BUKA S L, 1988, Acta Paediatrica Japonica, V30, P537; BUKA SL, 1993, ARCH GEN PSYCHIAT, V50, P151; Burger G., 1948, MALNUTRITION STARVAT; CARP EAD, 1947, MED PSYCHOL PATHOP 3; COHEN P, 1989, CHILD DEV, V60, P701, DOI 10.2307/1130735; COHLER BJ, 1975, SOC BIOL, V22, P269, DOI 10.1080/19485565.1975.9988176; Elwood J. M., 1992, EPIDEMIOLOGY CONTROL; FIELD T, 1986, DEV PSYCHOBIOL, V21, P1152; GERSHON ES, 1995, ARCH GEN PSYCHIAT, V50, P900; GRAHAM GG, 1993, NEW ENGL J MED, V328, P1058, DOI 10.1056/NEJM199304083281429; GRIGOROIUSERBANESCU M, 1984, INT J BEHAV DEV, V7, P307, DOI 10.1177/016502548400700304; HALVERSON CF, 1976, CHILD DEV, V47, P281; Hoek HW, 1996, AM J PSYCHIAT, V153, P1637; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KANDEL E, 1991, CRIMINOLOGY, V29, P519, DOI 10.1111/j.1745-9125.1991.tb01077.x; KAPLAN HI, 1991, SYNOPSIS PSYCHIAT, P532; KATES RW, 1993, NEW ENGL J MED, V328, P1055, DOI 10.1056/NEJM199304083281428; Kline J.S., 1989, CONCEPTION BIRTH EPI; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; LYONS MJ, 1995, ARCH GEN PSYCHIAT, V52, P906; MCGEE R, 1984, J CHILD PSYCHOL PSYC, V25, P573, DOI 10.1111/j.1469-7610.1984.tb00173.x; MEDNICK SA, 1988, BIOL CONTRIBUTIONS C; Neugebauer R, 1997, AM J PUBLIC HEALTH, V87, P726, DOI 10.2105/AJPH.87.5.726; OLDS H, 1998, JAMA-J AM MED ASSOC, V280, P1238; PAULHUS DL, 1986, J PERS SOC PSYCHOL, V50, P1235, DOI 10.1037/0022-3514.50.6.1235; Pine DS, 1997, AM J PUBLIC HEALTH, V87, P1303, DOI 10.2105/AJPH.87.8.1303; RAINE A, 1994, ARCH GEN PSYCHIAT, V51, P984; Raine A, 1996, ARCH GEN PSYCHIAT, V53, P544; RAINE A, 1988, SOCIAL PSYCHOPHYSIOL, P231; RAINE A, PSYCHOPATHOLOGY CRIM; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Reiss A., 1993, UNDERSTANDING PREVEN; ROBINSON NM, 1965, PEDIATRICS, V35, P425; Rothman K., 1998, MODERN EPIDEMIOLOGY; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; SCRIMSHAW NS, 1907, ANNU REV NUTR, V7, P1; SHAFFER D, 1985, CLIN GUIDE CHILD PSY, P29; SOUTH MA, 1985, TERATOLOGY, V31, P297, DOI 10.1002/tera.1420310216; STEIN Z, 1972, SCIENCE, V178, P708, DOI 10.1126/science.178.4062.708; Stein Z., 1975, FAMINE HUM DEV DUTCH; Susser E, 1998, AM J EPIDEMIOL, V147, P213; Susser E, 1996, ARCH GEN PSYCHIAT, V53, P25; SUSSER ES, 1992, ARCH GEN PSYCHIAT, V49, P983; SZATMARI P, 1990, DEV MED CHILD NEUROL, V32, P954; SZATMARI P, 1986, CAN J PSYCHIAT, V31, P513, DOI 10.1177/070674378603100606; WALDROP MF, 1978, SCIENCE, V199, P536; Wali Sima, 1995, WOMENS RIGHTS HUMAN, P335; WEISSMAN MM, 1996, PSYCHIATRY, P6; *WHO, 1948, MAN INT CLASS DIS IN; ZELDENRUST ELK, 1966, NED TIJDSCHR GENEES, V110, P1737; 1948, MANUAL INT CLASSIFIC	59	235	242	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1999	282	5					455	462		10.1001/jama.282.5.455	http://dx.doi.org/10.1001/jama.282.5.455			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	222KP	10442661				2022-12-24	WOS:000081784900022
J	Lovey, PY; Morabia, A; Bleed, D; Peter, O; Dupuis, G; Petite, J				Lovey, PY; Morabia, A; Bleed, D; Peter, O; Dupuis, G; Petite, J			Long term vascular complications of Coxiella burnetii infection in Switzerland: cohort study	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Epidemiological-Research	JUN 24-26, 1998	CHICAGO, ILLINOIS	Soc Epidemiol Res			CORONARY HEART-DISEASE; Q-FEVER ENDOCARDITIS; HELICOBACTER-PYLORI SEROPOSITIVITY; ACUTE MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; ATHEROSCLEROTIC PLAQUES; AORTIC-ANEURYSMS; RISK FACTOR; WALLS; TWAR	Objective To evaluate the range of long term vascular manifestations of Coxiella burnetii infection. Design Cohort study in Switzerland of people affected in 1983 by the largest reported outbreak of Q fever and who were followed up 12 rears later. Follow up information about possible vascular disease and endocarditis was obtained through a mailed questionnaire and death certificates. Setting Val de Bagnes, a rural Alpine valley in Switzerland. Participants 2044 (87%) of 2355 people who had serum testing for Coxiella burnetii infection in 1983: 1247 were classed as not hating been infected, 411 were classed as having been acutely infected, and 386 were classed as having been infected before 1983. Main outcome measures Relative risk controlled for age and sex and 12 year risk of vascular diseases and endocarditis among infected participants as compared with those who had never been infected. Results The 12 year risk of endocarditis or venous thromboembolic disease was not increased among those who had been acutely infected. The 12 rear risk of arterial disease was significantly higher among those who had been acutely infected (7%) as compared with those who had never been infected (4%) (relative risk 2.2, 95% confidence interval 1.4 to 3.6). Specifically, there was an increased risk of developing a cerebrovascular accident (relative risk 3.7, 1.6 to 8.4) and cardiac ischaemia (relative risk 1.9, 1.04 to 3.4). 12 year mortality was significantly higher among the 411 people who had been acutely infected in 1983 (9.7%; age adjusted relative risk 1.8, 1.2 to 2.6) when compared with the 1247 participants who had remained serologically negative in 1983 (7.0%) Conclusions Coxiella burnetii infection may cause long term complications including vascular disease.	Univ Hosp Geneva, Dept Internal Med, CH-1211 Geneva 14, Switzerland; Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland; Hop Valaisans, Inst Cent, Div Infect Dis & Immunol, CH-1951 Sion, Switzerland; Hop Reg, Serv Med Interne, CH-1920 Martigny, Switzerland; Etat Valais, CH-1950 Sion, Switzerland	University of Geneva; University of Geneva	Lovey, PY (corresponding author), Univ Hosp Geneva, Dept Internal Med, Rue Micheli Crest 24, CH-1211 Geneva 14, Switzerland.							BACA OG, 1983, MICROBIOL REV, V47, P127, DOI 10.1128/MMBR.47.2.127-149.1983; Blasi F, 1996, J CLIN MICROBIOL, V34, P2766, DOI 10.1128/JCM.34.11.2766-2769.1996; BROUQUI P, 1993, ARCH INTERN MED, V153, P642, DOI 10.1001/archinte.153.5.642; COYLE PV, 1985, J CLIN PATHOL, V38, P743, DOI 10.1136/jcp.38.7.743; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; DUPUIS G, 1985, J CLIN MICROBIOL, V22, P484, DOI 10.1128/JCM.22.4.484-487.1985; DUPUIS G, 1987, INT J EPIDEMIOL, V16, P282, DOI 10.1093/ije/16.2.282; ELLIS ME, 1983, Q J MED, V52, P54; FABRICANT CG, 1985, ADV VET SCI COMP MED, V30, P39; FERNANDEZGUERRERO ML, 1988, ANN INTERN MED, V108, P209, DOI 10.7326/0003-4819-108-2-209; Folsom AR, 1998, CIRCULATION, V98, P845, DOI 10.1161/01.CIR.98.9.845; GILBERT A, 1889, CR HEBD ACAD SCI, V6, P583; GRAYSTON JT, 1995, CIRCULATION, V92, P3397, DOI 10.1161/01.CIR.92.12.3397; HACKSTADT T, 1986, INFECT IMMUN, V52, P337, DOI 10.1128/IAI.52.1.337-340.1986; HALDANE EV, 1983, J INFECT DIS, V148, P978, DOI 10.1093/infdis/148.6.978; HENDRIX LR, 1991, J GEN MICROBIOL, V137, P269, DOI 10.1099/00221287-137-2-269; Juvonen JJ, 1997, J VASC SURG, V25, P499, DOI 10.1016/S0741-5214(97)70260-X; Kuo CC, 1997, J VASC SURG, V26, P29, DOI 10.1016/S0741-5214(97)70143-5; Libby P, 1997, CIRCULATION, V96, P4095; MALLAVIA LP, 1991, EUR J EPIDEMIOL, V7, P213, DOI 10.1007/BF00145669; Nieto FJ, 1996, CIRCULATION, V94, P922, DOI 10.1161/01.CIR.94.5.922; Nieto FJ, 1998, AM J EPIDEMIOL, V148, P937, DOI 10.1093/oxfordjournals.aje.a009570; PETER O, 1985, EUR J CLIN MICROBIOL, V4, P394, DOI 10.1007/BF02148690; Rathbone B, 1996, HEART, V76, P308, DOI 10.1136/hrt.76.4.308; REIMER LG, 1993, CLIN MICROBIOL REV, V6, P193, DOI 10.1128/CMR.6.3.193-198.1993; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; SAMUEL JE, 1985, INFECT IMMUN, V49, P775, DOI 10.1128/IAI.49.3.775-779.1985; SiegmanIgra Y, 1997, SCAND J INFECT DIS, V29, P41, DOI 10.3109/00365549709008663; WILSON HG, 1976, CIRCULATION, V53, P680, DOI 10.1161/01.CIR.53.4.680	30	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 31	1999	319	7205					284	286		10.1136/bmj.319.7205.284	http://dx.doi.org/10.1136/bmj.319.7205.284			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224QE	10426735	Bronze, Green Published			2022-12-24	WOS:000081909100019
J	Brightbill, HD; Libraty, DH; Krutzik, SR; Yang, RB; Belisle, JT; Bleharski, JR; Maitland, M; Norgard, MV; Plevy, SE; Smale, ST; Brennan, PJ; Bloom, BR; Godowski, PJ; Modlin, RL				Brightbill, HD; Libraty, DH; Krutzik, SR; Yang, RB; Belisle, JT; Bleharski, JR; Maitland, M; Norgard, MV; Plevy, SE; Smale, ST; Brennan, PJ; Bloom, BR; Godowski, PJ; Modlin, RL			Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors	SCIENCE			English	Article							BORRELIA-BURGDORFERI LIPOPROTEINS; NITRIC-OXIDE SYNTHASE; MYCOBACTERIUM-TUBERCULOSIS INFECTION; SYNTHETIC LIPOPEPTIDE ANALOGS; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; TREPONEMA-PALLIDUM; BACTERIAL LIPOPROTEIN; LEISHMANIA-MAJOR; INTERFERON-GAMMA	The generation of cell-mediated immunity against many infectious pathogens involves the production of interleukin-12 (IL-12), a key signal of the innate immune system. Yet, for many pathogens, the molecules that induce IL-12 production by macrophages and the mechanisms by which they do so remain undefined. Here it is shown that microbial lipoproteins are potent stimulators of IL-12 production by human macrophages, and that induction is mediated by Toll-like receptors (TLRs). Several lipoproteins stimulated TLR-dependent transcription of inducible nitric oxide synthase and the production of nitric oxide, a powerful microbicidal pathway. Activation of TLRs by microbial lipoproteins may initiate innate defense mechanisms against infectious pathogens.	Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Genentech Inc, San Francisco, CA 94080 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA; CUNY Mt Sinai Sch Med, Ctr Immunol, New York, NY 10029 USA; Harvard Univ, Sch Publ Hlth, Off Dean, Boston, MA 02115 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Roche Holding; Genentech; Colorado State University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Harvard University; Harvard T.H. Chan School of Public Health	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA.	rmodlin@mednet.ucla.edu	Modlin, Robert L/M-7941-2014; Yang, Ruey-Bing/O-1494-2018; Belisle, John T/B-8944-2017	Modlin, Robert L/0000-0003-4720-031X; Yang, Ruey-Bing/0000-0003-3017-3714; Belisle, John T/0000-0002-2539-2798				AFONSO LCC, 1994, SCIENCE, V263, P235, DOI 10.1126/science.7904381; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Altare F, 1998, SCIENCE, V280, P1432, DOI 10.1126/science.280.5368.1432; ASHBRIDGE KR, 1989, NUCLEIC ACIDS RES, V17, P1249, DOI 10.1093/nar/17.3.1249; BESSLER WG, 1977, BIOCHEM BIOPH RES CO, V76, P239, DOI 10.1016/0006-291X(77)90717-3; BESSLER WG, 1985, J IMMUNOL, V135, P1900; BIESERT L, 1987, EUR J BIOCHEM, V162, P651, DOI 10.1111/j.1432-1033.1987.tb10687.x; BRAUN V, 1974, ANNU REV BIOCHEM, V43, P89, DOI 10.1146/annurev.bi.43.070174.000513; BRICKER TM, 1988, INFECT IMMUN, V56, P295, DOI 10.1128/IAI.56.2.295-301.1988; CHAMBERLAIN NR, 1989, INFECT IMMUN, V57, P2872, DOI 10.1128/IAI.57.9.2872-2877.1989; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; COOPER AM, 1995, IMMUNOLOGY, V84, P423; de Jong R, 1998, SCIENCE, V280, P1435; DOBOS KM, 1995, INFECT IMMUN, V63, P2846, DOI 10.1128/IAI.63.8.2846-2853.1995; FLYNN JL, 1995, J IMMUNOL, V155, P2515; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HAUSCHILDT S, 1990, EUR J IMMUNOL, V20, P63, DOI 10.1002/eji.1830200110; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HOFFMANN P, 1988, IMMUNOBIOLOGY, V177, P158, DOI 10.1016/S0171-2985(88)80036-6; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Libraty DH, 1997, J CLIN INVEST, V99, P336, DOI 10.1172/JCI119162; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MA Y, 1994, INFECT IMMUN, V62, P3663, DOI 10.1128/IAI.62.9.3663-3671.1994; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MAILLARD J, 1972, J EXP MED, V136, P185, DOI 10.1084/jem.136.1.185; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MELCHERS F, 1975, J EXP MED, V142, P473, DOI 10.1084/jem.142.2.473; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; NORGARD MV, 1995, INFECT IMMUN, V63, P1507, DOI 10.1128/IAI.63.4.1507-1515.1995; Norgard MV, 1996, INFECT IMMUN, V64, P3845, DOI 10.1128/IAI.64.9.3845-3852.1996; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; RADOLF JD, 1995, J IMMUNOL, V154, P2866; RADOLF JD, 1988, INFECT IMMUN, V56, P490, DOI 10.1128/IAI.56.2.490-498.1988; SCHARTON TM, 1993, J EXP MED, V178, P567, DOI 10.1084/jem.178.2.567; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SIELING PA, 1994, J IMMUNOL, V153, P3639; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; Vogel SN, 1999, J IMMUNOL, V162, P5666; WALLIS RS, 1990, P NATL ACAD SCI USA, V87, P3348, DOI 10.1073/pnas.87.9.3348; WEIS JJ, 1994, INFECT IMMUN, V62, P4632, DOI 10.1128/IAI.62.10.4632-4636.1994; Wooten RM, 1998, J IMMUNOL, V160, P5485; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YOUNG DB, 1991, RES MICROBIOL, V142, P55, DOI 10.1016/0923-2508(91)90097-T; ZHANG M, 1994, J CLIN INVEST, V93, P1733, DOI 10.1172/JCI117157	52	1327	1392	0	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1999	285	5428					732	736		10.1126/science.285.5428.732	http://dx.doi.org/10.1126/science.285.5428.732			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426995				2022-12-24	WOS:000081765100054
J	Blat, Y; Kleckner, N				Blat, Y; Kleckner, N			Cohesins bind to preferential sites along yeast chromosome III, with differential regulation along arms versus the centric region	CELL			English	Article							SISTER-CHROMATID COHESION; SMC PROTEIN COMPLEXES; SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; NUCLEAR SCAFFOLD; S-PHASE; DYNAMICS; CONDENSATION; MITOSIS; MEIOSIS	Sister chromatid cohesion is mediated by evolutionary conserved chromosomal proteins, termed "cohesins." Using an extension of chromatin immunoprecipitation, we have analyzed the distribution of cohesins Mcd1/Scc1 and Smc1 along yeast chromosome III. Both proteins occur preferentially at the same similar to 23 positions. Sites in a similar to 50 kb region around the centromere give especially intense signals. Prominent centric region binding appears to emerge from a more even distribution, probably by differential loss of cohesins along the chromosome arms. Cohesin binding peaks correspond closely to peaks of high local AT composition, a base composition periodicity of similar to 15 kb that is distinct from the similar to 50 kb periodicity of base composition isochores, consistent with axis association of cohesins. The methodology described can be used to analyze the distribution of any DNA-binding protein and, via microchips, along entire genomes.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Blat, Y (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044794] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM44794] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akhmedov AT, 1998, J BIOL CHEM, V273, P24088, DOI 10.1074/jbc.273.37.24088; AMATI B, 1990, EMBO J, V9, P4007, DOI 10.1002/j.1460-2075.1990.tb07622.x; AMATI BB, 1988, CELL, V54, P967, DOI 10.1016/0092-8674(88)90111-0; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Biggins S, 1998, CURR OPIN CELL BIOL, V10, P769, DOI 10.1016/S0955-0674(98)80120-8; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dujon B, 1996, TRENDS GENET, V12, P263, DOI 10.1016/0168-9525(96)10027-5; Furuya K, 1998, GENE DEV, V12, P3408, DOI 10.1101/gad.12.21.3408; GASSER SM, 1995, CURR BIOL, V5, P357, DOI 10.1016/S0960-9822(95)00071-6; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1995, J HERED, V86, P330, DOI 10.1093/oxfordjournals.jhered.a111600; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOENS PB, 1988, BIOESSAYS, V9, P151, DOI 10.1002/bies.950090503; MOLEBAJER J, 1958, CHROMOSOMA, V9, P322; Murphy TD, 1998, CELL, V93, P317, DOI 10.1016/S0092-8674(00)81158-7; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; NICKLAS RB, 1988, ANNU REV BIOPHYS BIO, V17, P431, DOI 10.1146/annurev.bb.17.060188.002243; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Pryde FE, 1997, CURR OPIN GENET DEV, V7, P822, DOI 10.1016/S0959-437X(97)80046-9; SAITOH Y, 1993, COLD SPRING HARB SYM, V58, P755, DOI 10.1101/SQB.1993.058.01.083; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHARP PM, 1993, NUCLEIC ACIDS RES, V21, P179, DOI 10.1093/nar/21.2.179; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; SUMNER AT, 1991, CHROMOSOMA, V100, P36; SUROSKY RT, 1986, P NATL ACAD SCI USA, V83, P414, DOI 10.1073/pnas.83.2.414; Swedlow JR, 1996, CURR BIOL, V6, P544, DOI 10.1016/S0960-9822(02)00538-9; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	45	331	339	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 23	1999	98	2					249	259		10.1016/S0092-8674(00)81019-3	http://dx.doi.org/10.1016/S0092-8674(00)81019-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	219XA	10428036	Bronze			2022-12-24	WOS:000081632300014
J	Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P				Pilla, M; Perachon, S; Sautel, F; Garrido, F; Mann, A; Wermuth, CG; Schwartz, JC; Everitt, BJ; Sokoloff, P			Selective inhibition of cocaine-seeking behaviour by a partial dopamine D-3 receptor agonist	NATURE			English	Article							NUCLEUS-ACCUMBENS; RAT; LESIONS; REINFORCEMENT; MODULATION; DEPENDENCE; ACTIVATION; SCHEDULES; ADDICTION; CIRCUITS	Environmental stimuli that are reliably associated with the effects of many abused drugs, especially stimulants such as cocaine, can produce craving and relapse in abstinent human substance abusers(1-4). In animals, such cues can induce and maintain drug-seeking behaviour and also reinstate drug-seeking after extinction(5-7). Reducing the motivational effects of drug-related cues might therefore be useful in the treatment of addiction(3). Converging pharmacological(8,9), human post-mortem(10) and genetic(11) studies implicate the dopamine D-3 receptor(12) in drug addiction. Here we have designed BP 897, the first D-3-receptor-selective agonist, as assessed in vitro with recombinant receptors and in vivo with mice bearing disrupted D-3-receptor genes. BP 897 is a partial agonist in vitro and acts in vivo as either an agonist or an antagonist. We show that BP 897 inhibits cocaine-seeking behaviour that depends upon the presentation of drug-associated cues, without having any intrinsic, primary rewarding effects. Our data indicate that compounds like BP 897 could be used for reducing the drug craving and vulnerability to relapse that are elicited by drug-associated environmental stimuli.	Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England; Lab Bioprojet, F-75002 Paris, France; Ctr Paul Broca, INSERM, U109, Unite Neurobiol & Pharmacol Mol, F-75014 Paris, France; Fac Pharm, CNRS, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch, France	University of Cambridge; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Everitt, BJ (corresponding author), Univ Cambridge, Dept Expt Psychol, Downing St, Cambridge CB2 3EB, England.			Everitt, Barry/0000-0003-4431-6536	Medical Research Council [G9537855] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Accili D, 1996, P NATL ACAD SCI USA, V93, P1945, DOI 10.1073/pnas.93.5.1945; Arroyo M, 1998, PSYCHOPHARMACOLOGY, V140, P331, DOI 10.1007/s002130050774; Bordet R, 1997, P NATL ACAD SCI USA, V94, P3363, DOI 10.1073/pnas.94.7.3363; CAINE SB, 1993, SCIENCE, V260, P1814, DOI 10.1126/science.8099761; CAINE SB, 1995, BEHAV PHARMACOL, V6, P333; Caine SB, 1997, NEUROREPORT, V8, P2373, DOI 10.1097/00001756-199707070-00054; COSTA T, 1992, MOL PHARMACOL, V41, P549; DEWIT H, 1981, PSYCHOPHARMACOLOGY, V75, P134, DOI 10.1007/BF00432175; Di Ciano P, 1998, EUR J NEUROSCI, V10, P1121, DOI 10.1046/j.1460-9568.1998.00125.x; Duaux E, 1998, MOL PSYCHIATR, V3, P333, DOI 10.1038/sj.mp.4000409; EVERITT B J, 1992, P401; FONTANA DJ, 1993, BRAIN RES, V629, P31, DOI 10.1016/0006-8993(93)90477-5; Grant S, 1996, P NATL ACAD SCI USA, V93, P12040, DOI 10.1073/pnas.93.21.12040; Grech DM, 1996, PSYCHOPHARMACOLOGY, V125, P97, DOI 10.1007/BF02249407; LEFF P, 1995, TRENDS PHARMACOL SCI, V16, P89, DOI 10.1016/S0165-6147(00)88989-0; LEVESQUE D, 1992, P NATL ACAD SCI USA, V89, P8155, DOI 10.1073/pnas.89.17.8155; Meil WM, 1997, BEHAV BRAIN RES, V87, P139, DOI 10.1016/S0166-4328(96)02270-X; OBRIEN CP, 1992, RES P ARNMD, V70, P157; OBrien CP, 1996, LANCET, V347, P237, DOI 10.1016/S0140-6736(96)90409-2; PILON C, 1994, EUR J PHARM-MOLEC PH, V268, P129, DOI 10.1016/0922-4106(94)90182-1; PULVIRENTI L, 1994, TRENDS PHARMACOL SCI, V15, P374, DOI 10.1016/0165-6147(94)90158-9; Ridray S, 1998, EUR J NEUROSCI, V10, P1676, DOI 10.1046/j.1460-9568.1998.00173.x; Sautel F, 1995, J PHARMACOL EXP THER, V275, P1239; Self DW, 1996, SCIENCE, V271, P1586, DOI 10.1126/science.271.5255.1586; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; Staley JK, 1996, J NEUROSCI, V16, P6100; Weissenborn R, 1997, PSYCHOPHARMACOLOGY, V134, P242, DOI 10.1007/s002130050447; Whitelaw RB, 1996, PSYCHOPHARMACOLOGY, V127, P213, DOI 10.1007/BF02805996; WIKLER A, 1973, ARCH GEN PSYCHIAT, V28, P611; Xu M, 1999, SYNAPSE, V31, P210, DOI 10.1002/(SICI)1098-2396(19990301)31:3<210::AID-SYN6>3.3.CO;2-S	30	512	535	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					371	375		10.1038/43944	http://dx.doi.org/10.1038/43944			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432116				2022-12-24	WOS:000081590000052
J	Syngal, S; Fox, EA; Li, C; Dovidio, M; Eng, C; Kolodner, RD; Garber, JE				Syngal, S; Fox, EA; Li, C; Dovidio, M; Eng, C; Kolodner, RD; Garber, JE			Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer - Implications for clinical predisposition testing	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISMATCH REPAIR GENES; COLON-CANCER; MICROSATELLITE INSTABILITY; MLH1 MUTATIONS; HMSH2 MUTATIONS; HNPCC FAMILIES; HMLH1 GENES; HOMOLOG; MSH2; CARCINOMA	Context Genetic testing for cancer predisposition is evolving from purely research applications to affecting clinical management. Objective To determine how often genetic lest results for hereditary nonpolyposis colorectal cancer (HNPCC) can be definitively interpreted and used to guide clinical management. Design Case-series study conducted in 1996 to 1998 in which a complete sequence analysis of hMSH2 and hMLH1 coding sequence and flanking intronic regions was performed. Mutations were categorized as protein truncating and missense. In the case of missense alterations, additional analyses were performed in an effort to assess pathogenicity. Setting and Participants Families were identified by self-referral or health care provider referral to a cancer genetics program. Participants and kindreds were classified into 1 of 4 categories: (1) Amsterdam criteria for HNPCC, (2) modified Amsterdam criteria for HNPCC, (3) young age at onset, or (4) HNPCC-variant. In addition, each proband was classified according to the Bethesda guidelines for identification of individuals with HNPCC. Main Outcome Measure Alterations of hMSH2 and hMLH1 genes. Results Twenty-seven alterations of hMSH2 and hMLH1 were found in 24 of 70 families (34.3 %), Of these, deleterious mutations that could be used with confidence in clinical management were identified in 25.7% (18/70) of families. The rates of definitive results for families fulfilling Amsterdam criteria, modified Amsterdam criteria, young age at onset, HNPCC-variant, and Bethesda guidelines were 27 (39.3%), 13 (18.2%), 12 (16.7%), 11 (15.8%), and 21 (30.4%), respectively. The prevalence of missense mutations, genetic heterogeneity of the syndrome, and limited availability of validated functional assays present a challenge in the interpretation of genetic test results of HNPCC families. Conclusions The identification of pathogenic mutations in a significant subset of families for whom the results may have marked clinical importance makes genetic testing an important option for HNPCC and HNPCC-like kindreds. However, for the majority of individuals in whom sequence analysis of hMSH2 and hMLH1 does not give a definitive result, intensive follow-up is still warranted.	Dana Farber Canc Inst, Dept Populat Sci, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Dana Farber Canc Inst, Charles A Dana Human Canc Genet Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Ludwig Inst Canc Res, La Jolla, CA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Ludwig Institute for Cancer Research	Garber, JE (corresponding author), Dana Farber Canc Inst, Dept Populat Sci, 44 Binney St,Smith 208, Boston, MA 02115 USA.	judy_garber@dfci.harvard.edu		Eng, Charis/0000-0002-3693-5145				AALTONEN LA, 1994, CANCER RES, V54, P1645; AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Antonarakis SE, 1998, HUM MUTAT, V11, P1; Bellacosa A, 1996, AM J MED GENET, V62, P353, DOI 10.1002/(SICI)1096-8628(19960424)62:4<353::AID-AJMG7>3.0.CO;2-S; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BUERSTEDDE JM, 1995, J MED GENET, V32, P909, DOI 10.1136/jmg.32.11.909; Cotton RGH, 1998, HUM MUTAT, V12, P1, DOI 10.1002/(SICI)1098-1004(1998)12:1<1::AID-HUMU1>3.0.CO;2-M; Dunlop MG, 1997, HUM MOL GENET, V6, P105, DOI 10.1093/hmg/6.1.105; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FROGGATT NJ, 1995, LANCET, V345, P727, DOI 10.1016/S0140-6736(95)90900-1; Froggatt NJ, 1996, EUR J CANCER, V32A, P178, DOI 10.1016/0959-8049(95)00464-5; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Hackman P, 1997, NAT GENET, V17, P135, DOI 10.1038/ng1097-135; HAMILTON SR, 1995, NEW ENGL J MED, V332, P839, DOI 10.1056/NEJM199503303321302; Herfarth KKF, 1997, GENE CHROMOSOME CANC, V18, P42, DOI 10.1002/(SICI)1098-2264(199701)18:1<42::AID-GCC5>3.0.CO;2-1; Holtzman NA., 1998, PROMOTING SAFE EFFEC; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; KohonenCorish M, 1996, AM J HUM GENET, V59, P818; KOLBERG R, 1994, J NIH RES, V6, P37; KOLODNER RD, 1995, CANCER RES, V55, P242; Kowalski LD, 1997, GENE CHROMOSOME CANC, V18, P219, DOI 10.1002/(SICI)1098-2264(199703)18:3<219::AID-GCC8>3.0.CO;2-4; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; LIU B, 1994, CANCER RES, V54, P4590; LUCE MC, 1995, GASTROENTEROLOGY, V109, P1368, DOI 10.1016/0016-5085(95)90600-2; Lynch HT, 1998, NEW ENGL J MED, V338, P1537, DOI 10.1056/NEJM199805213382109; Maliaka YK, 1996, HUM GENET, V97, P251, DOI 10.1007/BF02265276; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MARY JL, 1994, HUM MOL GENET, V3, P2067; MAUILLON JL, 1996, CANCER RES, V56, P242; Moslein G, 1996, HUM MOL GENET, V5, P1245, DOI 10.1093/hmg/5.9.1245; NAN HJ, 1995, HUM MOL GENET, V4, P237, DOI 10.1093/hmg/4.2.237; NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203; NystromLahti M, 1996, HUM MOL GENET, V5, P763, DOI 10.1093/hmg/5.6.763; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Offit K, 1998, CLINICAL CANCER GENETICS, P1; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pensotti V, 1997, GENE CHROMOSOME CANC, V19, P135; Risinger JI, 1996, CANCER, V77, P1836, DOI 10.1002/(SICI)1097-0142(19960501)77:9<1836::AID-CNCR12>3.0.CO;2-0; RodriguezBigas MA, 1997, J NATL CANCER I, V89, P1758, DOI 10.1093/jnci/89.23.1758; Shimodaira H, 1998, NAT GENET, V19, P384, DOI 10.1038/1277; TANNERGARD P, 1995, CANCER RES, V55, P6092; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988; WATSON P, 1994, AM J MED, V96, P516, DOI 10.1016/0002-9343(94)90091-4; Weber TK, 1997, CANCER RES, V57, P3798; WIJNEN J, 1995, AM J HUM GENET, V56, P1060; Wijnen J, 1997, AM J HUM GENET, V61, P329, DOI 10.1086/514847; Wijnen J, 1996, AM J HUM GENET, V58, P300; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804; Wu Y, 1997, GENE CHROMOSOME CANC, V18, P269, DOI 10.1002/(SICI)1098-2264(199704)18:4<269::AID-GCC4>3.0.CO;2-Z	53	97	110	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					247	253		10.1001/jama.282.3.247	http://dx.doi.org/10.1001/jama.282.3.247			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422993				2022-12-24	WOS:000081504400030
J	Evans, JMM; Newton, RW; Ruta, DA; MacDonald, TM; Stevenson, RJ; Morris, AD				Evans, JMM; Newton, RW; Ruta, DA; MacDonald, TM; Stevenson, RJ; Morris, AD			Frequency of blood glucose monitoring in relation to glycaemic control: observational study with diabetes database	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GLYCEMIC CONTROL; POPULATION; MELLITUS; IMPACT	Objectives To investigate patterns of self monitoring of blood glucose concentration in diabetic patients who use insulin and to determine whether frequency of self monitoring is related to glycaemic control. Setting Diabetes database, Tayside, Scotland. Subjects Patients resident in Tayside in 1993-5 who were using insulin and were registered on the database and diagnosed with insulin dependent (type 1) or non-insulin dependent (type 2) diabetes before 1993. Main outcome measures Number of glucose monitoring reagent strips dispensed (reagent strip uptake) derived from records of prescriptions. First recorded haemoglobin A(1c), concentration in the study period, and reagent strips dispensed in the previous 6 months. Results Among 807 patients with type 1 diabetes, 128 (16%) did not redeem any prescriptions for glucose monitoring reagent strips in the 3 year study period. Only 161 (20%) redeemed prescriptions for enough reagent strips to test glucose daily. The corresponding figures for the 790 patients with type 2 diabetes who used insulin were 162 (21%; no strips) and 131 (17%; daily tests). Reagent strip uptake was influenced both by age and by deprivation category. There was a direct relation between uptake and glycaemic control for 258 patients (with recorded haemoglobin A(1c) concentrations) with type 1 diabetes. In a linear regression model the decrease in haemoglobin A(1c) concentration for every extra 180 reagent strips dispensed was 0.7%. For the 290 patients with type 2 diabetes who used insulin there was no such relation. Conclusions Self monitoring of blood glucose concentration is associated with improved glycaemic control in patients with type 1 diabetes. Regular self monitoring in patients with type 1 and type 2 diabetes is uncommon.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Med Monitoring Unit, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Med, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Evans, JMM (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Clin Pharmacol, Med Monitoring Unit, Dundee DD1 9SY, Scotland.	josie@memo.dundee.ac.uk	Morris, Andrew D/C-2837-2009; Ruta, Danny A/E-4472-2013	Ruta, Danny/0000-0002-2024-3267; MacDonald, Thomas/0000-0001-5189-6669	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, DIABETES CARE, V10, P95; BEARDON PHG, 1993, BRIT MED J, V307, P846, DOI 10.1136/bmj.307.6908.846; BELMONTE MM, 1988, DIABETES CARE, V11, P484, DOI 10.2337/diacare.11.6.484; *BRIT MED ASS, 1998, BRIT NAT FORM, V35; CARSTAIRS V R M, 1990, Health Bulletin (Edinburgh), V48, P162; DANEMAN D, 1985, DIABETES CARE, V8, P1, DOI 10.2337/diacare.8.1.1; DCCT Research Group, 1989, NEW ENGL J MED, V329, P977; Evans J. M. M., 1995, Pharmaceutical Medicine (London), V9, P177; Gallichan M, 1997, BRIT MED J, V314, P964, DOI 10.1136/bmj.314.7085.964; GILL GV, 1989, PRACTICAL DIABETES, V6, P77; GORDON D, 1991, DIABETIC MED, V8, P679, DOI 10.1111/j.1464-5491.1991.tb01677.x; HARRIS MI, 1993, DIABETES CARE, V16, P1116, DOI 10.2337/diacare.16.8.1116; *INF STAT DIV, 1996, SCOTT HLTH STAT 1996; Kurtz S M, 1990, Diabetes Educ, V16, P50, DOI 10.1177/014572179001600112; MOLITCH ME, 1994, DIABETES CARE, V17, P81; Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X; Morris AD, 1997, BMJ-BRIT MED J, V315, P524, DOI 10.1136/bmj.315.7107.524; Morris AD, 1997, DIABETES CARE, V20, P1363, DOI 10.2337/diacare.20.9.1363; Morris AD, 1998, DIABETES CARE, V21, P738, DOI 10.2337/diacare.21.5.738; NEWMAN WP, 1990, ARCH INTERN MED, V150, P107, DOI 10.1001/archinte.150.1.107; PATRICK AW, 1994, DIABETIC MED, V11, P62, DOI 10.1111/j.1464-5491.1994.tb00231.x; Ray NF, 1998, DIABETES CARE, V21, P296; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; WORTH R, 1982, BRIT MED J, V285, P1233, DOI 10.1136/bmj.285.6350.1233	24	179	182	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1999	319	7202					83	86		10.1136/bmj.319.7202.83	http://dx.doi.org/10.1136/bmj.319.7202.83			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398627	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000081438200023
J	Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD				Ness, AR; Frankel, SJ; Gunnell, DJ; Smith, GD			Are we really dying for a tan?	BRITISH MEDICAL JOURNAL			English	Article							NON-HODGKINS-LYMPHOMA; VITAMIN-D; EXPOSURE; SUNLIGHT; POPULATION; MORTALITY; MELANOMA		Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England	University of Bristol	Ness, AR (corresponding author), Univ Bristol, Dept Social Med, Bristol BS6 7DP, Avon, England.		Ness, Andy R/M-7612-2013; Davey Smith, George/A-7407-2013; Gunnell, David/ABE-6653-2020	Ness, Andy R/0000-0003-3548-9523; Davey Smith, George/0000-0002-1407-8314; Gunnell, David/0000-0002-0829-6470				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; ARTHEY S, 1995, SOC SCI MED, V40, P265, DOI 10.1016/0277-9536(94)E0063-X; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; Bridgwood A, 1996, HLTH ENGLAND 1995 WH; CARTER S, 1997, TOURISM HLTH; CHEW KSY, 1995, SOC SCI MED, V40, P223, DOI 10.1016/0277-9536(94)E0070-9; Elwood JM, 1997, INT J CANCER, V73, P198, DOI 10.1002/(SICI)1097-0215(19971009)73:2<198::AID-IJC6>3.0.CO;2-R; Finkel E, 1998, LANCET, V351, P1866, DOI 10.1016/S0140-6736(05)78819-X; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Freedman DM, 1997, BRIT MED J, V314, P1451, DOI 10.1136/bmj.314.7092.1451; Grimes DS, 1996, QJM-INT J MED, V89, P579; Haines A, 1997, BRIT MED J, V315, P870, DOI 10.1136/bmj.315.7112.870; HUTTON D, 1998, VOGUE            MAY, P114; KHAW KT, 1995, LANCET, V345, P337, DOI 10.1016/S0140-6736(95)90336-4; LUND B, 1978, HORM METAB RES, V10, P553, DOI 10.1055/s-0028-1093390; MARKS R, 1995, ARCH DERMATOL, V131, P415, DOI 10.1001/archderm.131.4.415; McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005; MELIA J, 1995, HLTH HYG, V16, P153; *OFF NAT STAT, 1997, MORT STAT CAUS ENGL; SCRAGG R, 1990, INT J EPIDEMIOL, V19, P559, DOI 10.1093/ije/19.3.559; *SECR STAT HLTH, 1992, HLTH NAT; Utiger RD, 1998, NEW ENGL J MED, V338, P828, DOI 10.1056/NEJM199803193381209; VIK T, 1979, BMJ-BRIT MED J, V2, P176, DOI 10.1136/bmj.2.6183.176; WEHR TA, 1989, AM J PSYCHIAT, V146, P829; West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714	25	42	42	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					114	116		10.1136/bmj.319.7202.114	http://dx.doi.org/10.1136/bmj.319.7202.114			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398641	Green Published			2022-12-24	WOS:000081438200040
J	Maser, P; Sutterlin, C; Kralli, A; Kaminsky, R				Maser, P; Sutterlin, C; Kralli, A; Kaminsky, R			A nucleoside transporter from Trypanosoma brucei involved in drug resistance	SCIENCE			English	Article							UNUSUAL ADENOSINE TRANSPORTER; MOLECULAR-CLONING	Drug resistance of pathogens is an increasing problem whose underlying mechanisms are not fully understood, Cellular uptake of the major drugs against Trypanosoma brucei spp,, the causative agents of sleeping sickness, is thought to occur through an unusual, so far unidentified adenosine transporter, Saccharomyces cerevisiae was used in a functional screen to clone a gene (TbAT1) from Trypanosoma brucei brucei that encodes a nucleoside transporter. When expressed in yeast, TbAT1 enabled adenosine uptake and conferred susceptibility to melaminophenyl arsenicals. Drug-resistant trypanosomes harbor a defective TbAT1 variant. The molecular identification of the entry route of trypanocides opens the way to approaches for diagnosis and treatment of drug-resistant sleeping sickness.	Swiss Trop Inst, CH-4002 Basel, Switzerland; Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Kaminsky, R (corresponding author), Novartis CRA, CH-1566 St Aubin, Switzerland.			Maser, Pascal/0000-0003-3122-1941				Barrett MP, 1999, PARASITOL TODAY, V15, P136, DOI 10.1016/S0169-4758(99)01414-3; BARRETT MP, 1995, MOL BIOCHEM PARASIT, V73, P223, DOI 10.1016/0166-6851(95)00120-P; Borst P, 1998, ANNU REV MICROBIOL, V52, P745, DOI 10.1146/annurev.micro.52.1.745; CARTER NS, 1995, J BIOL CHEM, V270, P28153, DOI 10.1074/jbc.270.47.28153; CARTER NS, 1993, NATURE, V361, P173, DOI 10.1038/361173a0; FAIRLAMB AH, 1989, P NATL ACAD SCI USA, V86, P2607, DOI 10.1073/pnas.86.8.2607; FROMMEL TO, 1987, MOL BIOCHEM PARASIT, V26, P183, DOI 10.1016/0166-6851(87)90142-3; FULTON JD, 1955, ANN TROP MED PARASIT, V49, P377; GIBSON WC, 1983, T ROY SOC TROP MED H, V77, P114, DOI 10.1016/0035-9203(83)90033-0; Griffiths M, 1997, NAT MED, V3, P89, DOI 10.1038/nm0197-89; Griffiths M, 1997, BIOCHEM J, V328, P739, DOI 10.1042/bj3280739; Hernandez A, 1998, BIOINFORMATICS, V14, P227, DOI 10.1093/bioinformatics/14.2.227; Maser P, 1997, RRD ANTIMICROB AG CH, V2, P113; MASER P, UNPUB; MazhariTabrizi R, 1996, BIOCHEM J, V316, P853, DOI 10.1042/bj3160853; POSPICHAL H, 1994, ACTA TROP, V58, P187, DOI 10.1016/0001-706X(94)90013-2; Tye CK, 1998, BIOORG MED CHEM LETT, V8, P811, DOI 10.1016/S0960-894X(98)00095-X; Vasudevan G, 1998, P NATL ACAD SCI USA, V95, P9873, DOI 10.1073/pnas.95.17.9873; Yao SYM, 1997, J BIOL CHEM, V272, P28423, DOI 10.1074/jbc.272.45.28423; YORKE WARRINGTON, 1931, Annals of Tropical Medicine and Parasitology, V25, P351	20	221	228	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					242	244		10.1126/science.285.5425.242	http://dx.doi.org/10.1126/science.285.5425.242			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398598				2022-12-24	WOS:000081346000038
J	Trieman, N; Leff, J; Glover, G				Trieman, N; Leff, J; Glover, G			Outcome of long stay psychiatric patients resettled in the community: prospective cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TAPS PROJECT; FOLLOW-UP; POPULATIONS; HOSPITALS; DIFFICULT; CLOSURE	Objective To examine the outcome of a population of long stay psychiatric patients resettled in the community. Design Prospective study with 5 year follow up. Setting Over 140 residential settings in north London. Subjects 670 long stay patients from two London hospitals (Friern and Claybury) discharged to the community from 1985 to 1993. Main outcome measures Continuity and quality of residential care, readmission to hospital, mortality, crime, and vagrancy. Results Of the 523 patients who survived the 5 year follow up period, 469 (89.6%) were living in the community by the end of follow up, 310 (59.2%) in their original community placement A third (210) of all patients were readmitted at least once. Crime and homelessness presented few problems. Standardised mortality ratios for the group were comparable with those reported for similar populations. Conclusions When carefully planned and adequately resourced, community care for long star psychiatric patients is beneficial to most individuals and has minimal detrimental effects on society.	UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England; Inst Psychiat, Sect Community Psychiat, London SE5 8AF, England	University of London; University College London; UCL Medical School; University of London; King's College London	Trieman, N (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Psychiat & Behav Sci, London NW3 2PF, England.	n.trieman@fleet69.demon.co.uk						CLIFFORD P, 1991, BRIT J PSYCHIAT, V158, P190, DOI 10.1192/bjp.158.2.190; Gooch C, 1996, PSYCHOL MED, V26, P511, DOI 10.1017/S0033291700035595; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; HAUGLAND G, 1983, AM J PSYCHIAT, V140, P848; HAZEL M, 1998, BRIT J PSYCHIAT, V172, P35; JONES D, 1993, BRIT J PSYCHIAT, V162, P36, DOI 10.1192/S0007125000292234; *KINGS FUND, 1997, LOND MENT HLTH; LAMB HR, 1993, BRIT J PSYCHIAT, V162, P587, DOI 10.1192/bjp.162.5.587; Leff J, 1996, AM J PSYCHIAT, V153, P1318; LEFF J, 1994, BRIT J PSYCHIAT, V165, P13, DOI 10.1192/S000712500029315X; MODESTIN J, 1995, BRIT J PSYCHIAT, V166, P667, DOI 10.1192/bjp.166.5.667; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P30, DOI 10.1192/S0007125000292222; ODRISCOLL C, 1993, BRIT J PSYCHIAT, V162, P18, DOI 10.1192/S0007125000292209; Timms P W, 1989, Health Trends, V21, P70; Trieman N, 1998, ACTA PSYCHIAT SCAND, V98, P354, DOI 10.1111/j.1600-0447.1998.tb10098.x; Trieman N, 1996, BRIT J PSYCHIAT, V169, P289, DOI 10.1192/bjp.169.3.289; Trieman N, 1996, PSYCHOL MED, V26, P765, DOI 10.1017/S0033291700037788; WELLER MPI, 1989, NATURE, V339, P249, DOI 10.1038/339249a0	18	39	45	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 3	1999	319	7201					13	16		10.1136/bmj.319.7201.13	http://dx.doi.org/10.1136/bmj.319.7201.13			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214KE	10390451	Bronze, Green Published			2022-12-24	WOS:000081326500022
J	Sartori, C; Allemann, Y; Trueb, L; Delabays, A; Nicod, P; Scherrer, U				Sartori, C; Allemann, Y; Trueb, L; Delabays, A; Nicod, P; Scherrer, U			Augmented vasoreactivity in adult life associated with perinatal vascular insult	LANCET			English	Article							PERSISTENT PULMONARY-HYPERTENSION; NITRIC-OXIDE; HYPOXIA; VASOCONSTRICTION; RESISTANCE; NEWBORN	Background Adverse environmental events occurring early in life have received little attention as predictors of disease in the later stages of life. At birth, the transition from gas exchange by the placenta to gas exchange by the lungs requires dramatic changes in the pulmonary circulation, which during this period is particularly vulnerable to noxious stimuli. We measured pulmonary-artery pressure responses to high-altitude exposure, a stimulus that causes pronounced pulmonary vasoconstriction, in young adults who had had transient perinatal hypoxic pulmonary hypertension and in controls of similar age and sex distribution. Methods Review of neonatal-care records at the Lausanne University Hospital for Children identified 15 individuals who met the eligibility criteria (birth at greater than or equal to 34 weeks of gestation, persistence of hypoxaemia during ventilation with oxygen during the first week of life, and persistence of fetal circulation), Ten of these individuals agreed to take part; the control group was ten volunteers without any history of perinatal complications. Systolic pulmonary-artery pressure (by echocardiography) and arterial oxygen saturation were measured at baseline and at high altitude (4559 m). Findings The mean increase in pulmonary-artery pressure at high altitude was significantly greater (p=0.01) in the participants who had had perinatal pulmonary hypertension (from 26.2 mm Hg [SD 2.1] to 62.3 mm Hg [7.3]) than in the controls (from 25.8 mm Hg [2.3] to 49.7 mm Hg [11.3]). The fall in arterial oxygen saturation was similar in the two groups. Interpretation These findings suggest that a transient perinatal insult to the pulmonary circulation leaves a persistent and potentially fatal imprint, which when activated in adult life predisposes to a pathological response. Survivors of perinatal pulmonary hypertension may be at risk of developing this disorder in later life.	CHU Vaudois, Dept Internal Med, CH-1011 Lausanne, Switzerland; CHU Vaudois, Div Cardiol, CH-1011 Lausanne, Switzerland; Univ Hosp, Dept Cariol, Bern, Switzerland; Univ Lausanne, Inst Physiol, Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Bern; University Hospital of Bern; University of Lausanne	Scherrer, U (corresponding author), CHU Vaudois, Dept Internal Med, BH 10-642, CH-1011 Lausanne, Switzerland.	Urs.Scherrer@chuv.hospvd.ch		Sartori, Claudio/0000-0002-8172-3002				Barker D. J. P., 1994, MOTHERS BABIES DIS L; Blitzer ML, 1996, J AM COLL CARDIOL, V28, P591, DOI 10.1016/0735-1097(96)00218-5; CASLIN A, 1991, J PATHOL, V163, P133, DOI 10.1002/path.1711630209; DOLLBERG S, 1995, PEDIATR RES, V37, P31, DOI 10.1203/00006450-199501000-00007; Fagan KA, 1999, J CLIN INVEST, V103, P291, DOI 10.1172/JCI3862; HAKIM TS, 1990, CAN J PHYSIOL PHARM, V68, P419, DOI 10.1139/y90-059; HAMPL V, 1990, AM REV RESPIR DIS, V142, P619, DOI 10.1164/ajrccm/142.3.619; HAWORTH SG, 1988, CHEST, V3, pS133; MORIN FC, 1995, AM J RESP CRIT CARE, V151, P2010, DOI 10.1164/ajrccm.151.6.7767553; PERRELLA MA, 1992, AM J PHYSIOL, V263, pR45, DOI 10.1152/ajpregu.1992.263.1.R45; RABINOVITCH M, 1981, AM J PHYSIOL, V240, pH62, DOI 10.1152/ajpheart.1981.240.1.H62; Sartori C, 1997, Cardiologia, V42, P559; Scherrer U, 1996, NEW ENGL J MED, V334, P624, DOI 10.1056/NEJM199603073341003; Smith A. P. L., 1997, European Respiratory Journal Supplement, V10, p433S; STENMARK KR, 1988, CHEST, V3, pS127; Steudel W, 1997, CIRC RES, V81, P34, DOI 10.1161/01.RES.81.1.34; VENDER RL, 1996, CHEST, V106, P206	17	127	130	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 26	1999	353	9171					2205	2207		10.1016/S0140-6736(98)08352-4	http://dx.doi.org/10.1016/S0140-6736(98)08352-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210EC	10392986				2022-12-24	WOS:000081091300014
J	Bell, E; Wingate, RJT; Lumsden, A				Bell, E; Wingate, RJT; Lumsden, A			Homeotic transformation of rhombomere identity after localized Hoxb1 misexpression	SCIENCE			English	Article							TARGETED DISRUPTION; CHICK HINDBRAIN; CRANIAL NERVES; MOTOR-NEURONS; NEURAL CREST; MUTANT MICE; HOXA-1; EXPRESSION; MIGRATION; ALTERS	Segmentation of the hindbrain and branchial region is a conserved feature of head development, involving the nested expression of Hox genes. Although it is presumed that vertebrate Hox genes function as segment identifiers, responsible for mediating registration between elements of diverse embryonic origin, this assumption has remained untested. To assess this, retroviral misexpression was combined with orthotopic grafting in chick embryos to generate a mismatch in Hox coding between a specific rhombomere and its corresponding branchial arch. Rhombomere-restricted misexpression of a single gene, Hoxb1, resulted in the homeotic transformation of the rhombomere, revealed by reorganization of motor axon projections.	Kings Coll London, Guys Hosp, Dept Dev Neurobiol, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Lumsden, A (corresponding author), Kings Coll London, Guys Hosp, Dept Dev Neurobiol, London SE1 9RT, England.	andrew.lumsden@kcl.ac.uk	Lumsden, Andrew/C-5146-2009; Bell, Esther/C-5329-2009; Wingate, Richard JT/C-5341-2009	Wingate, Richard JT/0000-0002-1662-6097	NICHD NIH HHS [N01-HD-7-3263] Funding Source: Medline; Wellcome Trust Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073263] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Wellcome Trust(Wellcome TrustEuropean Commission); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alexandre D, 1996, DEVELOPMENT, V122, P735; Bateson W., 1894, MAT STUDY VARIATION, DOI 10.5962/bhl.title.88017; BELL E, IN PRESS MECH DEV; CARPENTER EM, 1993, DEVELOPMENT, V118, P1063; CHISAKA O, 1992, NATURE, V355, P516, DOI 10.1038/355516a0; Gavalas A, 1997, DEVELOPMENT, V124, P3693; Gavalas A, 1998, DEVELOPMENT, V125, P1123; GENDRONMAGUIRE M, 1993, CELL, V75, P1317, DOI 10.1016/0092-8674(93)90619-2; Goddard JM, 1996, DEVELOPMENT, V122, P3217; Goulding M, 1998, NEURON, V21, P943, DOI 10.1016/S0896-6273(00)80612-1; GUTHRIE S, 1992, DEVELOPMENT, V114, P663; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HILL J, 1995, MECH DEVELOP, V50, P3, DOI 10.1016/0925-4773(94)00321-D; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; LUMSDEN A, 1989, NATURE, V337, P424, DOI 10.1038/337424a0; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARK M, 1993, DEVELOPMENT, V119, P319; MARSHALL H, 1992, NATURE, V360, P737, DOI 10.1038/360737a0; MORGAN BA, 1996, METHOD CELL BIOL, V51, P186; PATA I, UNPUB; POURQUIE O, 1990, DEVELOPMENT, V109, P743; SIMON H, 1993, NEURON, V11, P209, DOI 10.1016/0896-6273(93)90179-U; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SUNDIN OH, 1990, GENE DEV, V4, P1267, DOI 10.1101/gad.4.8.1267; Tiret L, 1998, DEVELOPMENT, V125, P279; Wingate RJT, 1996, DEVELOPMENT, V122, P2143; ZHANG MB, 1994, DEVELOPMENT, V120, P2431	28	121	121	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1999	284	5423					2168	2171		10.1126/science.284.5423.2168	http://dx.doi.org/10.1126/science.284.5423.2168			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210HP	10381880				2022-12-24	WOS:000081099300049
J	Hoogerwaard, EM; Bakker, E; Ippel, PF; Oosterwijk, JC; Majoor-Krakauer, DF; Leschot, NJ; Van Essen, AJ; Brunner, HG; van der Wouw, PA; Wilde, AAM; de Visser, M				Hoogerwaard, EM; Bakker, E; Ippel, PF; Oosterwijk, JC; Majoor-Krakauer, DF; Leschot, NJ; Van Essen, AJ; Brunner, HG; van der Wouw, PA; Wilde, AAM; de Visser, M			Signs and symptoms of Duchenne muscular dystrophy and Becker muscular dystrophy among carriers in the Netherlands: a cohort study	LANCET			English	Article							POLYMERASE CHAIN-REACTION; MANIFESTING CARRIERS; FEMALE CARRIERS; CARDIOMYOPATHY; INACTIVATION; DIAGNOSIS; GIRLS	Background Carriers of Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD) may show muscle weakness or dilated cardiomyopathy. Studies focusing on skeletal-muscle involvement were done before DNA analysis was possible. We undertook a cross-sectional study in a population of definite carriers to estimate the proportion and to assess the clinical profile of carriers with symptoms. We also assessed a possible correlation between genotype and phenotype. Methods Carriers of DMD and BMD, aged 18-60 years, were traced through the files of the central register kept at the Department of Human Genetics in Leiden, Netherlands. For each carrier who agreed to participate a medical history was taken, and muscle-strength assessment by hand-held dynamometry and manual muscle testing and cardiological assessment were done. Findings 129 carriers of muscular dystrophy (85 DMD, 44 BMD) participated in the study. In 90 women from 52 (70%) families, 37 different mutations were found. 28 (22%) women had symptoms. 22 (17%) had muscle weakness, varying from mild to moderately severe, Muscle weakness was found in carriers of DMD and BMD, but dilated cardiomyopathy was found only in seven (8%) carriers of DMD, of whom one had concomitant muscle weakness. There was an unexpectedly high proportion of left-ventricle dilation (18%). No genotype-phenotype correlation was found. Interpretation Clinical manifestation of muscle weakness, dilated cardiomyopathy, or both can be found in about a fifth of carriers of DMD and BMD. If left-ventricle dilation is taken into account, the proportion of carriers with symptoms is even higher, amounting to 40%.	Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Human Genet, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Cardiol, NL-1105 AZ Amsterdam, Netherlands; Leiden Univ, Dept Human Genet, NL-2300 RA Leiden, Netherlands; Univ Utrecht, Dept Human Genet, Utrecht, Netherlands; Univ Rotterdam, Dept Human Genet, Rotterdam, Netherlands; Univ Groningen, Dept Human Genet, Groningen, Netherlands; Univ Nijmegen, Dept Human Genet, Nijmegen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University - Excl LUMC; Utrecht University; Erasmus University Rotterdam; University of Groningen; Radboud University Nijmegen	Hoogerwaard, EM (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Brunner, Han/C-9928-2013; Majoor-Krakauer, Danielle/AAC-3939-2020; Bakker, Egbert/D-3525-2009; Oosterwijk, Jan C./G-5770-2011	Bakker, Egbert/0000-0002-2843-7357; 				ABBADI N, 1994, AM J MED GENET, V52, P198, DOI 10.1002/ajmg.1320520215; AZOFEIFA J, 1995, HUM GENET, V96, P167, DOI 10.1007/BF00207374; BAKKER E, 1986, J MED GENET, V23, P573, DOI 10.1136/jmg.23.6.573; BEGGS AH, 1990, HUM GENET, V86, P45; BOYD Y, 1986, J MED GENET, V23, P484, DOI 10.1136/jmg.23.6.484; BUSHBY KMD, 1993, NEUROMUSCULAR DISORD, V3, P57, DOI 10.1016/0960-8966(93)90042-I; CARLQUIST JF, 1991, CIRCULATION, V83, P515, DOI 10.1161/01.CIR.83.2.515; CHAMBERLAIN JS, 1992, JAMA-J AM MED ASSOC, V267, P2609; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COMI LI, 1992, INT J CARDIOL, V34, P297, DOI 10.1016/0167-5273(92)90028-2; EMERY AEH, 1969, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5654.418; FEIGENBAUM H, 1994, ECHOCARDIOGR-J CARD, P658; FROUHAR ZR, 1975, AM J HUM GENET, V27, P37; GLASS IA, 1992, J MED GENET, V29, P578, DOI 10.1136/jmg.29.8.578; HAGINOYA K, 1991, J NEUROL, V238, P375, DOI 10.1007/BF00319855; HORDER M, 1991, EUR J CLIN CHEM CLIN, V29, P435; IONASESCU VV, 1989, ACTA NEUROL SCAND, V79, P500, DOI 10.1111/j.1600-0404.1989.tb03821.x; MATTHEWS PM, 1995, NEUROMUSCULAR DISORD, V5, P209, DOI 10.1016/0960-8966(94)00057-G; MIRABELLA M, 1993, NEUROLOGY, V43, P2342, DOI 10.1212/WNL.43.11.2342; MOSER H, 1974, CLIN GENET, V5, P271; MOSER H, 1971, HUMANGENETIK, V11, P328, DOI 10.1007/BF00278661; *MRC, 1986, AIDS INV PER NERV SY; NORMAN A, 1989, CLIN GENET, V36, P31; PENN AS, 1970, NEUROLOGY, V20, P147, DOI 10.1212/WNL.20.2.147; PERLOFF JK, 1967, AM J MED, V42, P179, DOI 10.1016/0002-9343(67)90017-4; Politano L, 1996, JAMA-J AM MED ASSOC, V275, P1335, DOI 10.1001/jama.275.17.1335; REDDY BK, 1984, HUM GENET, V67, P460, DOI 10.1007/BF00291412; RICHARDS CS, 1990, AM J HUM GENET, V46, P672; SCHMIDTACHERT M, 1992, LANCET, V340, P1235, DOI 10.1016/0140-6736(92)92942-9; SEWRY CA, 1993, NEUROMUSCULAR DISORD, V3, P141, DOI 10.1016/0960-8966(93)90006-6; VANDERPLOEG RJO, 1991, J NEUROL NEUROSUR PS, V54, P244, DOI 10.1136/jnnp.54.3.244; vanEssen AJ, 1997, J MED GENET, V34, P805, DOI 10.1136/jmg.34.10.805; YOSHIOKA M, 1981, CLIN GENET, V20, P6	33	156	165	1	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 19	1999	353	9170					2116	2119		10.1016/S0140-6736(98)10028-4	http://dx.doi.org/10.1016/S0140-6736(98)10028-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382696				2022-12-24	WOS:000080969300012
J	Goodman, SN				Goodman, SN			Toward evidence-based medical statistics. 1: The P value fallacy	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; CONFIDENCE-INTERVALS; MULTIPLE COMPARISONS; JOURNALS; TESTS; HYPOTHESES; INFERENCE; TRENDS; FUTURE; DEBATE		Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Goodman, SN (corresponding author), Johns Hopkins Univ, Sch Med, 550 N Broadway,Suite 409, Baltimore, MD 21205 USA.	sgoodman@jhu.edu		Goodman, Steven/0000-0002-3872-5723				ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P129, DOI 10.1001/jama.272.2.129; ALTMAN DG, 1991, J R STAT SOC A STAT, V154, P223, DOI 10.2307/2983040; ANSCOMBE FJ, 1963, J AM STAT ASSOC, V58, P365, DOI 10.2307/2283272; BAILAR JC, 1988, ANN INTERN MED, V108, P266, DOI 10.7326/0003-4819-108-2-266; Barnett ML, 1997, J DENT RES, V76, P534, DOI 10.1177/00220345970760010201; BARNETT V, 1982, COMP STAT INFERENCE; BEGG CB, 1990, BIOMETRIKA, V77, P467; Berger J.O., 1985, P BERKELEY C HONOR J, P15; Berkson J, 1942, J AM STAT ASSOC, V37, P325, DOI 10.2307/2279000; BERRY G, 1986, MED J AUSTRALIA, V144, P618, DOI 10.5694/j.1326-5377.1986.tb112339.x; BORAK J, 1982, SOC SCI MED, V16, P1939, DOI 10.1016/0277-9536(82)90393-8; BRAITMAN LE, 1988, ANN INTERN MED, V108, P296, DOI 10.7326/0003-4819-108-2-296; BROPHY JM, 1995, JAMA-J AM MED ASSOC, V273, P871, DOI 10.1001/jama.273.11.871; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; Carnap R., 1950, LOGICAL FDN PROBABIL; Carroll L, 1996, AM J CARDIOL, V78, P608, DOI 10.1016/S0002-9149(96)90531-7; Chia KS, 1997, SCAND J WORK ENV HEA, V23, P152, DOI 10.5271/sjweh.193; Clarke M, 1998, JAMA-J AM MED ASSOC, V280, P280, DOI 10.1001/jama.280.3.280; Colton T, 1974, STAT MED; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CORNFIELD J, 1966, AM STAT, V20, P18, DOI 10.2307/2682711; CORNFIELD J, 1969, BIOMETRICS, V25, P617, DOI 10.2307/2528565; Cox D. R., 1974, THEORETICAL STAT; COX DR, 1982, BRIT J CLIN PHARMACO, V14, P325, DOI 10.1111/j.1365-2125.1982.tb01987.x; DAR R, 1994, J CONSULT CLIN PSYCH, V62, P75, DOI 10.1037/0022-006X.62.1.75; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; DUPONT WD, 1983, CONTROL CLIN TRIALS, V4, P3, DOI 10.1016/S0197-2456(83)80003-8; EDWARDS Anthony William Fairbank, 1972, LIKELIHOOD; ETZIONI RD, 1995, ANNU REV PUBL HEALTH, V16, P23; EVANS SJW, 1988, BRIT HEART J, V60, P177; Feinstein AR, 1997, AM J MED, V103, P529, DOI 10.1016/S0002-9343(97)00244-1; Feinstein AR, 1998, J CLIN EPIDEMIOL, V51, P355, DOI 10.1016/S0895-4356(97)00295-3; FEINSTEIN AR, 1977, CLIN BIOSTATISTICS; Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P1, DOI 10.1016/S0197-2456(98)00052-X; Fisher LD, 1999, CONTROL CLIN TRIALS, V20, P16, DOI 10.1016/S0197-2456(98)00054-3; Fisher R.A., 1958, STAT METHODS RES WOR; Fisher Ronald A., 1973, STAT METHODS SCI INF; Freedman L, 1996, BMJ-BRIT MED J, V313, P569; FREEMAN PR, 1993, STAT MED, V12, P1443, DOI 10.1002/sim.4780121510; Gigerenzer G., 1989, EMPIRE CHANCE; Goodman SN, 1998, AM J EPIDEMIOL, V147, P807, DOI 10.1093/oxfordjournals.aje.a009531; GOODMAN SN, 1988, AM J PUBLIC HEALTH, V78, P1568, DOI 10.2105/AJPH.78.12.1568; GOODMAN SN, 1993, AM J EPIDEMIOL, V137, P485, DOI 10.1093/oxfordjournals.aje.a116700; Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003-4819-130-12-199906150-00008; GREENLAND S, 1991, EPIDEMIOLOGY, V2, P387, DOI 10.1097/00001648-199109000-00015; Hacking Ian, 1975, EMERGENCE PROBABILIT; HAYDEN GF, 1983, PEDIATRICS, V72, P84; KADANE JB, 1995, CONTROL CLIN TRIALS, V16, P313, DOI 10.1016/0197-2456(95)00072-0; Lang JM, 1998, EPIDEMIOLOGY, V9, P7, DOI 10.1097/00001648-199805000-00019; LEHMANN EL, 1993, J AM STAT ASSOC, V88, P1242; Lilford RJ, 1996, BRIT MED J, V313, P603; LUDBROOK J, 1994, AUST NZ J SURG, V64, P630, DOI 10.1111/j.1445-2197.1994.tb02308.x; MAINLAND D, 1963, CLIN PHARMACOL THER, V4, P580; MAINLAND D, 1984, BMJ-BRIT MED J, V288, P841, DOI 10.1136/bmj.288.6420.841; MAINLAND D, 1984, BMJ-BRIT MED J, V288, P920, DOI 10.1136/bmj.288.6421.920; Marks H., 1997, PROGR EXPT SCI THERA; Matthews JR., 1995, QUANTIFICATION QUEST, DOI 10.1515/9781400821808; McKenzie R, 1998, JAMA-J AM MED ASSOC, V280, P1061, DOI 10.1001/jama.280.12.1061; Morrison D.E., 1970, SIGNIFICANCE TEST CO; Moye LA, 1999, CONTROL CLIN TRIALS, V20, P40, DOI 10.1016/S0197-2456(98)00051-8; Neyman J, 1933, PHILOS T R SOC LOND, V231, P289, DOI 10.1098/rsta.1933.0009; Oakes M. W., 1986, STAT INFERENCE COMME; PEARSON ES, 1962, ANN MATH STAT, V33, P394, DOI 10.1214/aoms/1177704566; PEARSON ES, 1938, BIOMETRIKA, V30, P210, DOI DOI 10.2307/2332648; POCOCK SJ, 1987, NEW ENGL J MED, V317, P426, DOI 10.1056/NEJM198708133170706; POOLE C, 1987, AM J PUBLIC HEALTH, V77, P195, DOI 10.2105/AJPH.77.2.195; Porter T.M., 1996, TRUST NUMBERS PURSUI, DOI DOI 10.1515/9781400821617; ROTHMAN KJ, 1986, ANN INTERN MED, V105, P445, DOI 10.7326/0003-4819-105-3-445; Royall R, 1997, MONOGRAPHS STAT APPL, V71; ROZEBOOM WW, 1960, PSYCHOL BULL, V57, P416, DOI 10.1037/h0042040; Salmon WC., 1966, FDN SCI INFERENCE; SALSBURG DS, 1985, AM STAT, V39, P220, DOI 10.2307/2683942; SAVITZ DA, 1995, AM J EPIDEMIOL, V142, P904, DOI 10.1093/oxfordjournals.aje.a117737; SAVITZ DA, 1993, REPROD TOXICOL, V7, P95, DOI 10.1016/0890-6238(93)90242-Y; Seidenfeld T., 1979, PHILOS PROBLEMS STAT; SIMON R, 1994, BRIT J CANCER, V69, P979, DOI 10.1038/bjc.1994.192; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429; SKELLAM JG, 1969, BIOMETRICS, V25, P457, DOI 10.2307/2528899; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; Stigler, 1986, HIST STAT MEASUREMEN; Tannock IF, 1996, J NATL CANCER I, V88, P206, DOI 10.1093/jnci/88.3-4.206; THOMAS DC, 1985, AM J EPIDEMIOL, V122, P1080, DOI 10.1093/oxfordjournals.aje.a114189; Tonelli MR, 1998, ACAD MED, V73, P1234, DOI 10.1097/00001888-199812000-00011; Urbach P., 1993, SCI REASONING BAYESI, V2; WULFF HR, 1987, STAT MED, V6, P3, DOI 10.1002/sim.4780060103; [No title captured]; [No title captured]; [No title captured]; [No title captured]	89	1032	1050	0	86	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					995	1004		10.7326/0003-4819-130-12-199906150-00008	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00008			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	206TE	10383371				2022-12-24	WOS:000080894700007
J	Bontempi, B; Laurent-Demir, C; Destrade, C; Jaffard, R				Bontempi, B; Laurent-Demir, C; Destrade, C; Jaffard, R			Time-dependent reorganization of brain circuitry underlying long-term memory storage	NATURE			English	Article							POSTERIOR CINGULATE CORTICES; POSITRON EMISSION TOMOGRAPHY; COGNITIVE NEUROSCIENCE; HIPPOCAMPAL-FORMATION; RETROGRADE-AMNESIA; EPISODIC MEMORY; CONSOLIDATION; MICE; PERSPECTIVE; RETRIEVAL	Retrogade amnesia observed following hippocampal lesions in humans and animals is typically temporally graded(1,2), with recent memory being impaired while remote memories remain intact, indicating that the hippocampal formation has a time-limited role in memory storage(3,4). However, this claim remains controversial because studies involving hippocampal lesions tell us nothing about the contribution of the hippocampus to memory storage if this region was present at the time of memory retrieval(5,6). We therefore used non-invasive functional brain imaging using (C-14)2-deoxyglucose uptake to examine how the brain circuitry underlying long-term memory storage is reorganized over time in an intact brain. Regional metabolic activity in the brain was mapped in mice tested at different times for retention of a spatial discrimination task. Here we report that increasing the retention interval from 5 days to 25 days resulted in both decreased hippocampal metabolic activity during retention testing and a loss of correlation between hippocampal metabolic activity and memory performance. Concomitantly, a recruitment of certain cortical areas was observed. These results indicate that there is a time-dependent reorganization of the neuronal circuitry underlying long-term memory storage, in which a transitory interaction between the hippocampal formation and the neocortex would mediate the establishment of long-lived cortical memory representations.	Univ Bordeaux 1, CNRS, UMR 5807, Cognit Neurosci Lab, F-33405 Talence, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux	Bontempi, B (corresponding author), Univ Bordeaux 1, CNRS, UMR 5807, Cognit Neurosci Lab, Ave Fac, F-33405 Talence, France.							Alkire MT, 1998, P NATL ACAD SCI USA, V95, P14506, DOI 10.1073/pnas.95.24.14506; Anagnostaras SG, 1999, J NEUROSCI, V19, P1106; Bontempi B, 1996, EUR J NEUROSCI, V8, P2348, DOI 10.1111/j.1460-9568.1996.tb01198.x; Buckner RL, 1999, NAT NEUROSCI, V2, P311, DOI 10.1038/7221; Buzsaki G, 1998, J SLEEP RES, V7, P17, DOI 10.1046/j.1365-2869.7.s1.3.x; CHO YH, 1993, J NEUROSCI, V13, P1759; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; Dudai Y, 1996, NEURON, V17, P367, DOI 10.1016/S0896-6273(00)80168-3; FINCH DM, 1984, EXP NEUROL, V83, P468, DOI 10.1016/0014-4886(84)90116-X; Fink GR, 1996, J NEUROSCI, V16, P4275; Gabrieli JDE, 1998, ANNU REV PSYCHOL, V49, P87, DOI 10.1146/annurev.psych.49.1.87; Knowlton BJ, 1998, CURR OPIN NEUROBIOL, V8, P293, DOI 10.1016/S0959-4388(98)80154-2; LEHMAN A, 1974, ATLAS STEREOTAXIQUE; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCINTOSH AR, 1994, J NEUROPHYSIOL, V72, P1717, DOI 10.1152/jn.1994.72.4.1717; MEUNIER M, 1991, BEHAV BRAIN RES, V44, P133, DOI 10.1016/S0166-4328(05)80018-X; Moscovitch M, 1998, CURR OPIN NEUROBIOL, V8, P297, DOI 10.1016/S0959-4388(98)80155-4; Nyberg L, 1996, J NEUROSCI, V16, P3753; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; POLSTER MR, 1991, J COGNITIVE NEUROSCI, V3, P95, DOI 10.1162/jocn.1991.3.2.95; Reed JM, 1998, J NEUROSCI, V18, P3943; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SIF J, 1989, NEUROSCI LETT, V101, P223, DOI 10.1016/0304-3940(89)90535-1; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; TEYLER TJ, 1986, BEHAV NEUROSCI, V100, P147, DOI 10.1037/0735-7044.100.2.147; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; ZOLAMORGAN SM, 1990, SCIENCE, V250, P288, DOI 10.1126/science.2218534	29	454	458	0	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					671	675		10.1038/23270	http://dx.doi.org/10.1038/23270			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458162				2022-12-24	WOS:000082032900055
J	Beswich, AJ; Lawley, B; Fraise, AP; Pahor, AL; Brown, NL				Beswich, AJ; Lawley, B; Fraise, AP; Pahor, AL; Brown, NL			Detection of Alloiococcus otitis in mixed bacterial populations from middle-ear effusions of patients with otitis media	LANCET			English	Article							POLYMERASE CHAIN-REACTION; PCR; IDENTIFICATION; PERSISTENT; PATHOGENS; CHILDREN; RNA; DNA	Background Otitis media is a potentially serious disorder, since there is a risk of permanent hearing loss. Culture methods are not useful in characterisation of populations of bacteria in the middle ear. We have used a PCR-based method that does not depend on prior knowledge of the bacteria identified by culture. Methods Middle-ear effusion fluid was obtained from 12 patients with chronic otitis media with effusion. Total DNA was extracted from the samples, and the hypervariable regions of bacterial 16S rRNA genes were amplified by means of broad-range PCR primers. Individual PCR products were segregated by cloning to allow analysis of mixed bacterial populations. Findings Many bacterial species were detected by PCR, whereas with culture-based approaches, no bacterial growth was detected for ten of the 12 patients. The gram-positive bacterium Alloiococcus otitis (A otitidis) was detected by 16S rDNA amplification in six of the twelve samples, but not by culture techniques. Interpretation The method may have general usefulness in characterising bacterial populations at the site of infection and may indicate, from small sample numbers, organisms that are candidates for further investigation.	Univ Birmingham, Sch Biol Sci, Birmingham, W Midlands, England; City Hosp NHS Trust, Hosp Infect Res Lab, Birmingham, W Midlands, England; City Hosp NHS Trust, Dept Otorhinolaryngol, Birmingham, W Midlands, England	University of Birmingham	Beswich, AJ (corresponding author), Hlth & Safety Lab, Broad Lane, Sheffield S3 7HQ, S Yorkshire, England.	alan.beswick@hsl.gov.uk						AGUIRRE M, 1992, INT J SYST BACTERIOL, V42, P79, DOI 10.1099/00207713-42-1-79; ALVAREZ AJ, 1994, APPL ENVIRON MICROB, V60, P374, DOI 10.1128/AEM.60.1.374-376.1994; AMANN RI, 1995, MICROBIOL REV, V59, P143, DOI 10.1128/MMBR.59.1.143-169.1995; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; FADEN H, 1992, ANN OTO RHINOL LARYN, V101, P87, DOI 10.1177/000348949210100119; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; Hinton A, 1996, CLIN OTOLARYNGOL, V21, P158, DOI 10.1111/j.1365-2273.1996.tb01322.x; HOTOMI M, 1993, INT J PEDIATR OTORHI, V27, P119, DOI 10.1016/0165-5876(93)90127-O; HOWIE VM, 1975, AM J DIS CHILD, V129, P679, DOI 10.1001/archpedi.1975.02120430016006; Jero J, 1997, ACTA OTO-LARYNGOL, P22; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; Liederman EM, 1998, ANN OTO RHINOL LARYN, V107, P10; Matar GM, 1998, J CLIN MICROBIOL, V36, P1185, DOI 10.1128/JCM.36.5.1185-1188.1998; Ohtani H, 1998, NEPHROL DIAL TRANSPL, V13, P177, DOI 10.1093/ndt/13.1.177; PICHICHERO ME, 1995, PEDIATR INFECT DIS J, V14, P178, DOI 10.1097/00006454-199503000-00002; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; Saffer M, 1996, ACTA OTO-LARYNGOL, V116, P836, DOI 10.3109/00016489609137936; Sambrook JFE, 1989, MOL CLONING LAB MANU; Stackebrandt E, 1996, MICROBIAL DIVERSITY IN TIME AND SPACE, P19, DOI 10.1007/978-0-585-34046-3_3; TEBBE CC, 1993, APPL ENVIRON MICROB, V59, P2657, DOI 10.1128/AEM.59.8.2657-2665.1993; Wilbrink B, 1998, ARTHRITIS RHEUM-US, V41, P535, DOI 10.1002/1529-0131(199803)41:3<535::AID-ART20>3.0.CO;2-4	22	39	45	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 31	1999	354	9176					386	389		10.1016/S0140-6736(98)09295-2	http://dx.doi.org/10.1016/S0140-6736(98)09295-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437868				2022-12-24	WOS:000081764900014
J	Caparros-Lefebvre, D; Elbaz, A				Caparros-Lefebvre, D; Elbaz, A		Caribbean Parkinsonism Study Grp	Possible relation of atypical parkinsonism in the French West Indies with consumption of tropical plants: a case-control study	LANCET			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRESSIVE SUPRANUCLEAR PALSY; DOPAMINE TRANSPORTER; DEMENTIA COMPLEX; ENDOGENOUS AMINE; ANNONA-MURICATA; DISEASE; GUAM; DERIVATIVES; ACCURACY	Background In Europe and North America, Parkinson's disease is the major form of parkinsonism; less than 4% of cases are progressive supranuclear palsy (PSP) and about 20% are atypical parkinsonism. The distribution of these subgroups is different in the French West Indies. We aimed to define the clinical and demographic specificity of these disorders in Guadeloupe and to investigate a postulated link with consumption of herbal tea and fruits from the Annonaceae family (Annona muricata and Annona squamosa), which contain neurotoxic benzyltetrahydroisoquinoline alkaloids. Methods Between September, 1996, and August, 1998, 87 consecutive patients with parkinsonism were referred to the single neurological department in Guadeloupe. After detailed clinical, neurophysiological, cognitive, and neuroradiological assessment, they were classified by generally accepted criteria as having Parkinson's disease, PSP, or atypical parkinsonism. We compared the amount of tropical fruits and herbal tea consumed by the various parkinsonian subgroups and by frequency-matched controls (patients with benign symptoms and no neurodegenerative disease). Findings Of the 87 patients, 22 had Parkinson's disease, 31 had PSP, 30 had atypical parkinsonism, and four had atypical parkinsonism associated with motor neuron disease, 44 of the patients with PSP or atypical parkinsonism were male. The patients with atypical parkinsonism had symmetrical rigidity and bradykinesia, and no levodopa peak-dose dyskinesias. Patients with PSP differed from those with atypical parkinsonism because they had supranuclear vertical down-gaze palsy, severe gait and balance problems, and frontal-lobe syndrome. 29 Patients with PSP reported regular consumption of pawpaw fruit, and 26 drank herbal tea. 30 patients with atypical parkinsonism reported regular consumption of pawpaw fruit, and 24 drank herbal tea. Both of these groups consumed significantly more fruit and herbal tea than patients with Parkinson's disease (fruit: odds ratio 23.6; herbal tea: 28.2); and controls (fruit: 20.7; herbal tea: 6.48). Both of these groups and herbal tea than Interpretation Our study confirms the over-representation of atypical parkinsonism and PSP in patients with parkinsonism in the French West Indies. Chronic exposure to neurotoxic alkaloids could be an important aetiological factor because these compounds induce parkinsonism in animals. A larger epidemiological study, to clarify the link between these fruits with atypical parkinsonism and PSP, is proposed.	CHU Antilles & Guyane, Dept Neurol, F-97159 Pointe A Pitre, Guadeloupe, France; Hop La Pitie Salpetriere, INSERM, U360, F-75013 Paris, France	CHU Guadeloupe; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Caparros-Lefebvre, D (corresponding author), CHU Antilles & Guyane, Dept Neurol, Route de Chauvel, F-97159 Pointe A Pitre, Guadeloupe, France.	lefebvdo@ais.gp	Elbaz, Alexis/F-8952-2017	Elbaz, Alexis/0000-0001-9724-5490				AMARENCO P, 1991, J NEUROL NEUROSUR PS, V54, P1121, DOI 10.1136/jnnp.54.12.1121-a; BOOTH RG, 1989, NEUROSCI LETT, V100, P306, DOI 10.1016/0304-3940(89)90704-0; BRUNETON J, 1993, TECHNIQUE DOCUMENTAT, P707; Cabedo N, 1998, J NAT PROD, V61, P709, DOI 10.1021/np980008a; CHAUDHURI KR, 1996, MOV DISORD S1, V11, P534; Coleman T, 1996, J PHARMACOL EXP THER, V277, P685; deRijk MC, 1997, J NEUROL NEUROSUR PS, V62, P10, DOI 10.1136/jnnp.62.1.10; ELIZAN TS, 1966, ARCH NEUROL-CHICAGO, V14, P356, DOI 10.1001/archneur.1966.00470100012002; ESTEGUY M, 1985, REV NEUROL, V141, P413; Fahn S.E., 1987, RECENT DEV PARKINSON, V153, P293; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; Hasrat JA, 1997, J PHARM PHARMACOL, V49, P1145, DOI 10.1111/j.2042-7158.1997.tb06058.x; Hasrat JA, 1997, PHYTOMEDICINE, V4, P133, DOI 10.1016/S0944-7113(97)80059-1; HIRANO A, 1961, BRAIN, V84, P662, DOI 10.1093/brain/84.4.662; HOF PR, 1994, ACTA NEUROPATHOL, V88, P397; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JOSEPH H, 1983, THESIS U MONTPELLIER; Kawai H, 1998, J NEUROCHEM, V70, P745; KOTAKE Y, 1995, J NEUROCHEM, V65, P2633; Kotake Y, 1996, NEUROSCI LETT, V217, P69; KOVAR J, 1983, ARCH BIOCHEM BIOPHYS, V221, P271, DOI 10.1016/0003-9861(83)90144-3; LEBOEUF M, 1981, PLANTA MED, V42, P37, DOI 10.1055/s-2007-971543; Litvan I, 1996, NEUROLOGY, V46, P922, DOI 10.1212/WNL.46.4.922; Litvan I, 1998, ARCH NEUROL-CHICAGO, V55, P969, DOI 10.1001/archneur.55.7.969; MARTIN RO, 1967, BIOCHEMISTRY-US, V6, P2355, DOI 10.1021/bi00860a010; McGeer PL, 1997, NEUROLOGY, V49, P400, DOI 10.1212/WNL.49.2.400; Nagatsu T, 1997, NEUROSCI RES, V29, P99, DOI 10.1016/S0168-0102(97)00083-7; Okada T, 1998, NEUROSCI RES, V30, P87, DOI 10.1016/S0168-0102(97)00121-1; OYANAGI K, 1994, ACTA NEUROPATHOL, V88, P405; REED D, 1987, AM J EPIDEMIOL, V125, P92, DOI 10.1093/oxfordjournals.aje.a114515; RODGERSJOHNSON P, 1986, NEUROLOGY, V36, P7, DOI 10.1212/WNL.36.1.7; Schatz IJ, 1996, NEUROLOGY, V46, P1470, DOI 10.1212/wnl.46.5.1470; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Uitti R J, 1995, Parkinsonism Relat Disord, V1, P21, DOI 10.1016/1353-8020(95)00004-P; WU YC, 1989, PLANTA MED, P163, DOI 10.1055/s-2006-961913	35	165	172	1	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 24	1999	354	9175					281	286		10.1016/S0140-6736(98)10166-6	http://dx.doi.org/10.1016/S0140-6736(98)10166-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440304				2022-12-24	WOS:000081646000010
J	Bendor, R				Bendor, R			Arthritis and I	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	8	8	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					150	152		10.7326/0003-4819-131-2-199907200-00015	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00015			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419434				2022-12-24	WOS:000081509700013
J	Nobbenhuis, MAE; Walboomers, JMM; Helmerhorst, TJM; Rozendaal, L; Remmink, AJ; Risse, EKJ; van der Linden, HC; Voorhorst, FJ; Kenemans, P; Meijer, CJLM				Nobbenhuis, MAE; Walboomers, JMM; Helmerhorst, TJM; Rozendaal, L; Remmink, AJ; Risse, EKJ; van der Linden, HC; Voorhorst, FJ; Kenemans, P; Meijer, CJLM			Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; NATURAL-HISTORY; HIGH-RISK; INFECTION; GENOTYPES; WOMEN; CIN	Background A relation has been established between infection with high-risk types of human papillomavirus and development of cervical cancer. We investigated a role for testing for human papillomavirus as part of cervical-cancer screening. Methods We monitored by cytology, colposcopy, and testing for high-risk human papillomavirus 353 women referred to gynaecologists with mild to moderate and severe dyskaryosis. The median follow-up time was 33 months. At the last visit we took biopsy samples. Our primary endpoint was clinical progression, defined as cervical intraepithelial neoplasia (CIN) 3, covering three or more cervical quadrants on colposcopy, or a cervical-smear result of suspected cervical cancer. Findings 33 women reached clinical progression. All had persistent infection with high-risk human papillomavirus. The cumulative 6-year incidence of clinical progression among these women was 40% (95% CI 21-59). in women with end histology CIN 3, 98 (95%) of 103 had persistent infection with high-risk human papillomavirus from baseline. Among women with mild to moderate dyskaryosis at baseline, a second test for human papillomavirus at 6 months predicted end histology CIN 3 better than a second cervical smear. Interpretation Persistent infection with high-risk human papillomavirus is necessary for development and maintenance of CIN 3. All women with severe dyskaryosis should be referred to gynaecologists, whereas women with mild to moderate dyskaryosis should be referred only after a second positive test for high-risk human papillomavirus at 6 months.	Univ Hosp Vrije Univ, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Obstet & Gynaecol, NL-1007 MB Amsterdam, Netherlands; Univ Hosp Vrije Univ, Dept Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands; Univ Rotterdam Hosp, Dept Obstet & Gynecol, Rotterdam, Netherlands	Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Erasmus University Rotterdam; Erasmus MC	Meijer, CJLM (corresponding author), Univ Hosp Vrije Univ, Dept Pathol, POB 7057, NL-1007 MB Amsterdam, Netherlands.							Anderson MC, 1995, HAINES TAYLOR OBSTET, P292; BAUER HM, 1993, SEX TRANSM DIS, V20, P274, DOI 10.1097/00007435-199309000-00007; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; Chichareon S, 1998, J NATL CANCER I, V90, P50, DOI 10.1093/jnci/90.1.50; CUZICK J, 1995, LANCET, V345, P1533, DOI 10.1016/S0140-6736(95)91086-7; HELMERHORST TJM, 1987, EUR J OBSTET GYN R B, V24, P221, DOI 10.1016/0028-2243(87)90021-9; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Hopman E H, 1998, Obstet Gynecol Surv, V53, P97, DOI 10.1097/00006254-199802000-00021; HOPMAN EH, 1995, GYNECOL ONCOL, V58, P206, DOI 10.1006/gyno.1995.1212; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; Jacobs MV, 1997, J CLIN MICROBIOL, V35, P791, DOI 10.1128/JCM.35.3.791-795.1997; KATAJA V, 1992, SEX TRANSM DIS, V19, P154, DOI 10.1097/00007435-199205000-00009; Kjaer SK, 1996, INT J CANCER, V65, P601, DOI 10.1002/(SICI)1097-0215(19960301)65:5<601::AID-IJC8>3.0.CO;2-6; KOSS LG, 1989, JAMA-J AM MED ASSOC, V261, P737, DOI 10.1001/jama.261.5.737; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Meijer CJLM, 1998, HISTOPATHOLOGY, V33, P83, DOI 10.1046/j.1365-2559.1998.00436.x; Meijer CJLM, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P338; NGEANGEL C, 1998, J NATL CANCER I, V90, P43; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958; SCHIFFMAN MH, 1995, CANCER-AM CANCER SOC, V76, P1888, DOI 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H; Syrjanen KJ, 1997, NEW DEVELOPMENTS IN CERVICAL CANCER SCREENING AND PREVENTION, P93; VANDERGRAAF Y, 1988, J CLIN EPIDEMIOL, V41, P21, DOI 10.1016/0895-4356(88)90005-4; Vooijs G P, 1987, Ned Tijdschr Geneeskd, V131, P1662; WALBOOMERS JMM, 1999, IN PRESS J PATHOL; WALBOOMERS JMM, 1997, HUMAN PAPILLOMAVIRUS, P341; Wright TC, 1995, BLAUSTEINS PATHOLOGY, P248	30	510	543	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 3	1999	354	9172					20	25		10.1016/S0140-6736(98)12490-X	http://dx.doi.org/10.1016/S0140-6736(98)12490-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212XP	10406360				2022-12-24	WOS:000081243200009
J	Urban, BC; Ferguson, DJP; Pain, A; Willcox, N; Plebanski, M; Austyn, JM; Roberts, DJ				Urban, BC; Ferguson, DJP; Pain, A; Willcox, N; Plebanski, M; Austyn, JM; Roberts, DJ			Plasmodium falciparum-infected erythrocytes modulate the maturation of dendritic cells	NATURE			English	Article							MALARIA-PARASITIZED ERYTHROCYTES; ANTIGENIC VARIATION; RECEPTOR; CYTOADHERENCE; SEQUESTRATION; ASSOCIATION; PHENOTYPES; IMMUNITY; ADHESION; INVITRO	The malaria parasite Plasmodium falciparum is one of the most successful human pathogens. Specific virulence factors remain poorly defined, although the adhesion of infected erythrocytes to the venular endothelium has been associated with some of the syndromes of severe disease(1). Immune responses cannot prevent the development of symptomatic infections throughout life, and clinical immunity to the disease develops only slowly during childhood. An understanding of the obstacles to the development of protective immunity is crucial for developing rational approaches to prevent the disease. Here we show that intact malaria-infected erythrocytes adhere to dendritic cells, inhibit the maturation of dendritic cells and subsequently reduce their capacity to stimulate T cells. These data demonstrate both a novel mechanism by which malaria parasites induce immune dysregulation and a functional role beyond endothelial adhesion for the adhesive phenotypes expressed at the surface of infected erythrocytes.	John Radcliffe Hosp, Oxford Ctr, Inst Mol Med, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Nuffield Dept Pathol, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Mol Immunol Grp, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Nuffield Dept Surg, Oxford OX3 9DU, England; John Radcliffe Hosp, Oxford Ctr, Natl Blood Serv, Oxford OX3 9DU, England	University of Oxford; University of Oxford; University of Oxford; University of Oxford; University of Oxford	Roberts, DJ (corresponding author), John Radcliffe Hosp, Oxford Ctr, Inst Mol Med, Oxford OX3 9DU, England.		Plebanski, Magdalena/AAU-3144-2021; Pain, Arnab/L-5766-2015; Urban, Britta/W-6087-2018	Pain, Arnab/0000-0002-1755-2819; Urban, Britta/0000-0002-4197-8393; Ferguson, David/0000-0001-5045-819X; , Magdalena/0000-0001-6889-3667	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Austyn J M, 1998, Curr Opin Hematol, V5, P3, DOI 10.1097/00062752-199801000-00002; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; BERENDT AR, 1992, CELL, V68, P71, DOI 10.1016/0092-8674(92)90207-S; Brown K.N., 1993, Parassitologia (Rome), V35, P13; Coppel R L, 1998, Curr Opin Hematol, V5, P132; Gardner JP, 1996, P NATL ACAD SCI USA, V93, P3503, DOI 10.1073/pnas.93.8.3503; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; GILKS CF, 1990, PARASITE IMMUNOL, V12, P45, DOI 10.1111/j.1365-3024.1990.tb00935.x; GREENWOOD BM, 1980, T ROY SOC TROP MED H, V74, P340, DOI 10.1016/0035-9203(80)90095-4; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HOWARD RJ, 1984, CONTEMP TOP IMMUNOBI, V12, P127; HOWARD RJ, 1983, P NATL ACAD SCI-BIOL, V80, P4129, DOI 10.1073/pnas.80.13.4129; LANGRETH SG, 1985, INFECT IMMUN, V47, P760, DOI 10.1128/IAI.47.3.760-766.1985; MACPHERSON GG, 1985, AM J PATHOL, V119, P385; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; Nagvekar N, 1998, J CLIN INVEST, V101, P2268, DOI 10.1172/JCI2068; Newbold C, 1997, AM J TROP MED HYG, V57, P389, DOI 10.4269/ajtmh.1997.57.389; PLEBANSKI M, 1992, IMMUNOLOGY, V75, P86; ROBERTS DD, 1985, NATURE, V318, P64, DOI 10.1038/318064a0; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SCHWARZER E, 1994, BRIT J HAEMATOL, V88, P740, DOI 10.1111/j.1365-2141.1994.tb05112.x; SMITH JD, 1995, CELL, V82, P101, DOI 10.1016/0092-8674(95)90056-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; UDEINYA IJ, 1981, SCIENCE, V213, P555, DOI 10.1126/science.7017935; Udomsangpetch R, 1995, T ROY SOC TROP MED H, V89, P635, DOI 10.1016/0035-9203(95)90422-0; WALSH DS, 1995, CLIN IMMUNOL IMMUNOP, V77, P89, DOI 10.1016/0090-1229(95)90141-8; WILLIAMSON WA, 1978, LANCET, V1, P1328; ZHOU LJ, 1995, J IMMUNOL, V154, P3821	30	470	488	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					73	77		10.1038/21900	http://dx.doi.org/10.1038/21900			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403251				2022-12-24	WOS:000081255700053
J	Simon, JA; Hudes, ES				Simon, JA; Hudes, ES			Relationship of ascorbic acid to blood lead levels	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VITAMIN-C	Context Some animal studies suggest that orally administered ascorbic acid may chelate lead and decrease the risk of the toxic effects of lead. However, results from. several small studies in humans have yielded inconclusive evidence of a beneficial effect of ascorbic acid on lead toxicity. Objective To examine the relationship between serum ascorbic acid levels and prevalence of elevated blood lead levels. Design, Setting, and Participants Cross-sectional analysis of a probability sample of the US population enrolled in the Third National Health and Nutrition Examination Survey, 1988-1994 (4213 youths aged 6-16 years and 15 365 adults aged greater than or equal to 17 years) without a history of lead poisoning. Main Outcome Measures Elevated and log blood lead levels by serum ascorbic acid level. Results A total of 22 youths (0.5%) and 57 adults (0.4%) had elevated blood lead levels (defined as greater than or equal to 0.72 mu mol/L [15 mu g/dL]) and greater than or equal to 0.97 mu mol/L [20 mu g/dL], respectively). After controlling for the effects of age, race, sex, income level, and dietary energy, fat, calcium, iron, and zinc intake, youths in the highest serum ascorbic acid tertile had an 89% decreased prevalence of elevated blood lead levels compared with youths in the lowest serum ascorbic acid tertile (odds ratio, 0.11; 95% confidence interval, 0.04-0.35; P for trend =.002), Adults in the highest 2 serum ascorbic acid tertiles had a 65% to 68% decreased prevalence of elevated blood lead levels compared with adults in the lowest serum ascorbic acid tertile (P for trend =.03). As a continuous predictor, serum ascorbic acid level was independently associated with decreased log blood lead levels among adults (P<.001), but not among youths (P=.14). Conclusions Our data suggest that high serum levels of ascorbic acid are independently associated with a decreased prevalence of elevated blood lead levels. If these associations are related causally, ascorbic acid intake may have public health implications for control of lead toxicity.	San Francisco VA Med Ctr, Med Serv, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); San Francisco VA Medical Center; University of California System; University of California San Francisco	Simon, JA (corresponding author), San Francisco VA Med Ctr, Med Serv, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	jasimon@itsa.ucsf.edu			NHLBI NIH HHS [HL53479] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1994, VITAL HLTH STAT, V1, P1, DOI DOI 10.1136/BMJ.L42; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; CALABRESE EJ, 1987, ANN NY ACAD SCI, V498, P347, DOI 10.1111/j.1749-6632.1987.tb23773.x; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DAWSON EB, 1997, J AM COLL NUTR, V16, P480; FLANAGAN PR, 1982, AM J CLIN NUTR, V36, P823, DOI 10.1093/ajcn/36.5.823; GEY KF, 1994, BIBL NUTR DIET, P84; GOYER RA, 1979, LIFE SCI, V24, P433, DOI 10.1016/0024-3205(79)90215-7; Gunter EW, 1996, LAB PROCEDURES USED; Holmes HN, 1939, J LAB CLIN MED, V24, P1119; JACOB RA, 1987, AM J CLIN NUTR, V46, P818, DOI 10.1093/ajcn/46.5.818; JACOB RA, 1992, J NUTR, V122, P1111, DOI 10.1093/jn/122.5.1111; JACQUES PF, 1993, AM J CLIN NUTR, V57, P182, DOI 10.1093/ajcn/57.2.182; LAUWERYS R, 1983, J OCCUP ENVIRON MED, V25, P668, DOI 10.1097/00043764-198309000-00015; MARCHMONTROBINS.SW, 1940, J LAB CLIN MED, V26, P1478; MILLER DT, 1987, ANALYST, V112, P1701, DOI 10.1039/an9871201701; SASIENI P, 1995, STATA TECHNICAL B, V24; SASIENI P, 1998, STATA TECHNICAL B, V41; SIMON JA, 1992, J AM COLL NUTR, V11, P107; SOHLER A, 1977, J ORTHOMOL MED, V6, P272; *STATA STAT SOFTW, 1996, REL 5 0; SUZUKI T, 1979, J NUTR, V109, P1974, DOI 10.1093/jn/109.11.1974; SUZUKI T, 1979, J NUTR, V109, P982, DOI 10.1093/jn/109.6.982; Tukey J.W., 1977, EXPLORATORY DATA ANA; U.S. Department of Health and Human Services Public Health Service Agency for Toxic Substances and Disease Registry, 1988, NAT EXT LEAD POIS CH; U.S. Preventive Service Task Force, 1989, GUID CLIN PREV SERV	26	83	91	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2289	2293		10.1001/jama.281.24.2289	http://dx.doi.org/10.1001/jama.281.24.2289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207FN	10386552				2022-12-24	WOS:000080925600027
J	Gulbis, JM; Mann, S; MacKinnon, R				Gulbis, JM; Mann, S; MacKinnon, R			Structure of a voltage-dependent K+ channel beta subunit	CELL			English	Article							KETO REDUCTASE SUPERFAMILY; HUMAN ALDOSE REDUCTASE; 3-ALPHA-HYDROXYSTEROID DIHYDRODIOL DEHYDROGENASE; SHAKER POTASSIUM CHANNEL; CRYSTAL-STRUCTURE; SEQUENCE ALIGNMENTS; ALDEHYDE REDUCTASE; BOVINE BRAIN; INACTIVATION; EXPRESSION	The integral membrane subunits of many voltage-dependent potassium channels are associated with an additional protein known as the beta subunit. One function of beta subunits is to modify K+ channel gating. We have determined the structure of the conserved core of mammalian beta subunits by X-ray crystallography at 2.8 Angstrom resolution. Like the integral membrane component of K+ channels, beta subunits form a fourfold symmetric structure. Each subunit is an oxidoreductase enzyme complete with a nicotinamide cofactor in its active site. Several structural features of the enzyme active site, including its location with respect to the four-fold axis, imply that it may interact directly or indirectly with the K+ channel's voltage sensor. This structure suggests a mechanism for coupling membrane electrical excitability directly to chemistry of the cell.	Rockefeller Univ, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockvax.rockefeller.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM47400] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BENNER SA, 1982, EXPERIENTIA, V38, P633, DOI 10.1007/BF02327092; Bennett MJ, 1997, STRUCTURE, V5, P799, DOI 10.1016/S0969-2126(97)00234-7; BOHREN KM, 1994, BIOCHEMISTRY-US, V33, P2021, DOI 10.1021/bi00174a007; BORHANI DW, 1992, J BIOL CHEM, V267, P24841; Branden C., 1999, INTRO PROTEIN STRUCT; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOUINARD SW, 1995, P NATL ACAD SCI USA, V92, P6763, DOI 10.1073/pnas.92.15.6763; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; ELKABBANI O, 1995, NAT STRUCT BIOL, V2, P687, DOI 10.1038/nsb0895-687; HARRISON DH, 1994, BIOCHEMISTRY-US, V33, P2011, DOI 10.1021/bi00174a006; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Hille B., 1992, IONIC CHANNELS EXCIT; Holm L, 1998, NUCLEIC ACIDS RES, V26, P316, DOI 10.1093/nar/26.1.316; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAPLAN WD, 1969, GENETICS, V61, P399; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; MCCORMACK K, 1995, FEBS LETT, V370, P32, DOI 10.1016/0014-5793(95)00785-8; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; Nagaya N, 1997, J BIOL CHEM, V272, P3022, DOI 10.1074/jbc.272.5.3022; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; REHM H, 1988, P NATL ACAD SCI USA, V85, P4919, DOI 10.1073/pnas.85.13.4919; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Tang HX, 1996, PLANT CELL, V8, P1545, DOI 10.1105/tpc.8.9.1545; TEMPEL BL, 1987, SCIENCE, V237, P770, DOI 10.1126/science.2441471; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098; Xu J, 1997, J BIOL CHEM, V272, P11728, DOI 10.1074/jbc.272.18.11728	45	239	245	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 25	1999	97	7					943	952		10.1016/S0092-8674(00)80805-3	http://dx.doi.org/10.1016/S0092-8674(00)80805-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399921	Bronze			2022-12-24	WOS:000081162800014
J	Xu, L; Furukawa, S; Middlebrooks, JC				Xu, L; Furukawa, S; Middlebrooks, JC			Auditory cortical responses in the cat to sounds that produce spatial illusions	NATURE			English	Article							HUMAN LISTENERS; SPECTRAL CUES; MEDIAN PLANE; LOCALIZATION; CORTEX	Humans and cats can localize a sound source accurately if its spectrum is fairly broad and flat(1-3), as is typical of most natural sounds. However, if sounds are filtered to reduce the width of the spectrum, they result:in illusions of sources that are very different from the actual locations, particularly in the up/down and front/back dimensions(4-6). Such illusions reveal that the auditory system relies on specific characteristics of sound spectra to obtain cues for localization(7). In the-auditory cortex of cats, temporal firing patterns of neurons can signal the locations of broad-band sounds(8-9). Here we show that such spike patterns systematically mislocalize sounds that have been passed through a narrow-band filter. Both correct and incorrect locations signalled by neurons can be predicted quantitatively by a model of spectral processing that also predicts correct and incorrect localization judgements by human listeners(6). Similar cortical mechanisms, if present in humans, could underlie human auditory spatial perception.	Univ Michigan, Kresge Hearing Res Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Middlebrooks, JC (corresponding author), Univ Michigan, Kresge Hearing Res Inst, 1301 E Ann St, Ann Arbor, MI 48109 USA.		Xu, Li/C-5908-2008	Xu, Li/0000-0002-0988-7934; Furukawa, Shigeto/0000-0002-5833-7891				BLAUERT J, 1969, ACUSTICA, V22, P205; HEBRANK J, 1974, J ACOUST SOC AM, V56, P1829, DOI 10.1121/1.1903520; Huang AY, 1996, J ACOUST SOC AM, V100, P1070, DOI 10.1121/1.416293; MAKOUS JC, 1990, J ACOUST SOC AM, V87, P2188, DOI 10.1121/1.399186; MIDDLEBROOKS JC, 1990, J ACOUST SOC AM, V87, P2149, DOI 10.1121/1.399183; MIDDLEBROOKS JC, 1992, J ACOUST SOC AM, V92, P2607, DOI 10.1121/1.404400; Middlebrooks JC, 1998, J NEUROPHYSIOL, V80, P863, DOI 10.1152/jn.1998.80.2.863; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; MIDDLEBROOKS JC, IN PRESS J ACOUST SO; NAJAFI K, 1985, IEEE T ELECTRON DEV, V32, P1206, DOI 10.1109/T-ED.1985.22102; Populin LC, 1998, J NEUROSCI, V18, P2147; Xu L, 1998, J NEUROPHYSIOL, V80, P882, DOI 10.1152/jn.1998.80.2.882	12	22	23	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 17	1999	399	6737					688	691		10.1038/21424	http://dx.doi.org/10.1038/21424			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	207JB	10385120	Green Published			2022-12-24	WOS:000080932800060
J	Trommsdorff, M; Gotthardt, M; Hiesberger, T; Shelton, J; Stockinger, W; Nimpf, J; Hammer, RE; Richardson, JA; Herz, J				Trommsdorff, M; Gotthardt, M; Hiesberger, T; Shelton, J; Stockinger, W; Nimpf, J; Hammer, RE; Richardson, JA; Herz, J			Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2	CELL			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-E RECEPTOR-2; REELER-LIKE PHENOTYPE; LAMINAR ORGANIZATION; TARGETED DISRUPTION; ADAPTER PROTEINS; CEREBRAL-CORTEX; MOUSE; GENE; SCRAMBLER	Layering of neurons in the cerebral cortex and cerebellum requires Reelin, an extracellular matrix protein, and mammalian Disabled (mDab1), a cytosolic protein that activates tyrosine kinases. Here, we report the requirement for two other proteins, cell surface receptors termed very low density lipoprotein receptor (VLDLR) and apolipoprotein E receptor 2 (ApoER2). Both receptors can bind mDab1 on their cytoplasmic tails and are expressed in cortical and cerebellar layers adjacent to layers that express Reelin. mDab1 expression is upregulated in knockout mice that lack both VLDLR and ApoER2. Inversion of cortical layers and absence of cerebellar foliation in these animals precisely mimic the phenotype of mice lacking Reelin or mDab1. These findings suggest that VLDLR and ApoER2 participate in transmitting the extracellular Reelin signal to intracellular signaling processes initiated by mDab1.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	herz@utsw.swmed.edu	Gotthardt, Michael/ABE-8274-2021	Gotthardt, Michael/0000-0003-1788-3172; Hammer, Robert E./0000-0001-5487-7551; Nimpf, Johannes/0000-0002-9273-3492	NHLBI NIH HHS [R37 HL063762, HL20948] Funding Source: Medline; NIA NIH HHS [AG12300] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948, R37HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG012300] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANGEVINE JAY B., 1965, EXP NEUROL SUPPL, V2, P1; Brandes C, 1997, GENOMICS, V42, P185, DOI 10.1006/geno.1997.4702; Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Curran T, 1998, BRAIN RES REV, V26, P285, DOI 10.1016/S0165-0173(97)00035-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; FALCONER DS, 1951, J GENET, V50, P192, DOI 10.1007/BF02996215; FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453; Gage FH, 1998, CURR OPIN NEUROBIOL, V8, P671, DOI 10.1016/S0959-4388(98)80098-6; Gallagher E, 1998, J COMP NEUROL, V402, P238; Goldowitz D, 1997, J NEUROSCI, V17, P8767; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; HOWELL BW, 1999, IN PRESS MOL CELL BI; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Ishida T, 1999, J CLIN INVEST, V103, P789, DOI 10.1172/JCI4189; Janz R, 1998, J NEUROSCI, V18, P9269; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Komuro H, 1998, J NEUROSCI, V18, P1478; KORNACK DR, 1995, NEURON, V15, P311, DOI 10.1016/0896-6273(95)90036-5; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Miyata T, 1997, J NEUROSCI, V17, P3599; Novak S, 1996, J BIOL CHEM, V271, P11732, DOI 10.1074/jbc.271.20.11732; NOVAK S, 1996, J BIOL CHEM, V271; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pearlman AL, 1998, CURR OPIN NEUROBIOL, V8, P45, DOI 10.1016/S0959-4388(98)80007-X; Rice DS, 1998, DEVELOPMENT, V125, P3719; Schillace RV, 1999, J CLIN INVEST, V103, P761, DOI 10.1172/JCI6491; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Sweet HO, 1996, MAMM GENOME, V7, P798, DOI 10.1007/s003359900240; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WILLNOW TE, 1994, METHOD CELL BIOL, V43, P305	45	1026	1057	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 11	1999	97	6					689	701		10.1016/S0092-8674(00)80782-5	http://dx.doi.org/10.1016/S0092-8674(00)80782-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380922	Bronze			2022-12-24	WOS:000080886300008
J	Fulton, D; Gratton, JP; McCabe, TJ; Fontana, J; Fujio, Y; Walsh, K; Franke, TF; Papapetropoulos, A; Sessa, WC				Fulton, D; Gratton, JP; McCabe, TJ; Fontana, J; Fujio, Y; Walsh, K; Franke, TF; Papapetropoulos, A; Sessa, WC			Regulation of endothelium-derived nitric oxide production by the protein kinase Akt	NATURE			English	Article							FLUID SHEAR-STRESS; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; CELL-SURVIVAL; MICE LACKING; SYNTHASE; ACTIVATION; CALCIUM; CAVEOLAE; PALMITOYLATION	Endothelial nitric oxide synthase (eNOS) is the nitric oxide synthase isoform responsible for maintaining systemic blood pressure, vascular remodelling and angiogenesis(1-4), eNOS is phosphorylated in response to various forms of cellular stimulation(5-7), but the role of phosphorylation in the regulation of nitric oxide (NO) production and the kinase(s) responsible are not known. Here we show that the serine/threonine protein kinase Akt (protein kinase B) can directly phosphorylate eNOS on serine 1179 and activate the enzyme, leading to NO production, whereas mutant eNOS (S1179A) is resistant to phosphorylation and activation by Akt. Moreover, using adenovirus-mediated gene transfer, activated Akt increases basal NO release from endothelial cells, and activation-deficient Akt attenuates NO production stimulated by vascular endothelial growth factor. Thus, eNOS is a newly described Akt substrate linking signal transduction by Akt to the release of the gaseous second messenger NO.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06536 USA; Yale Univ, Sch Med, Mol Cardiobiol Program, Boyer Ctr Mol Med, New Haven, CT 06536 USA; St Elizabeths Med Ctr, Boston, MA 02135 USA; Columbia Univ, Dept Pharmacol, New York, NY 10032 USA	Yale University; Yale University; St. Elizabeth's Medical Center; Columbia University	Sessa, WC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06536 USA.		Andreas, Papapetropoulos/AAJ-3089-2020; Fujio, Yasushi/H-3421-2017; Sessa, William C/B-6844-2011	Fujio, Yasushi/0000-0003-0828-2930; Sessa, William C/0000-0001-5759-1938; Walsh, Kenneth/0000-0001-7580-2276; Gratton, Jean-Philippe/0000-0001-9877-8520; Papapetropoulos, Andreas/0000-0002-4253-5930	NIAMS NIH HHS [R01 AR040197] Funding Source: Medline; NIA NIH HHS [R01 AG015052] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015052] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Ayajiki K, 1996, CIRC RES, V78, P750, DOI 10.1161/01.RES.78.5.750; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Coffer PJ, 1998, BIOCHEM J, V335, P1; Corson MA, 1996, CIRC RES, V79, P984, DOI 10.1161/01.RES.79.5.984; Dimmeler S, 1998, CIRC RES, V83, P334, DOI 10.1161/01.RES.83.3.334; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; Liu JW, 1997, J CELL BIOL, V137, P1525, DOI 10.1083/jcb.137.7.1525; Liu JW, 1996, BIOCHEMISTRY-US, V35, P13277, DOI 10.1021/bi961720e; MICHEL T, 1993, P NATL ACAD SCI USA, V90, P6252, DOI 10.1073/pnas.90.13.6252; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Smith RC, 1997, GENE DEV, V11, P1674, DOI 10.1101/gad.11.13.1674; Yano S, 1998, NATURE, V396, P584, DOI 10.1038/25147; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	30	2133	2196	3	91	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 10	1999	399	6736					597	601		10.1038/21218	http://dx.doi.org/10.1038/21218			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376602	Green Accepted			2022-12-24	WOS:000080778400059
J	Glass, TA; de Leon, CM; Marottoli, RA; Berkman, LF				Glass, TA; de Leon, CM; Marottoli, RA; Berkman, LF			Population based study of social and productive activities as predictors of survival among elderly Americans	BRITISH MEDICAL JOURNAL			English	Article							TIME PHYSICAL-ACTIVITY; ALL-CAUSE MORTALITY; MIDDLE-AGED MEN; CARDIOVASCULAR-DISEASE; PLASMA-FIBRINOGEN; COLLEGE ALUMNI; OLDER ADULTS; RISK-FACTORS; HEALTH; DETERMINANTS	Objectives To examine any association between social, productive, and physical activity and 13 year survival in older people. Design Prospective cohort study with annual mortality follow up. Activity and other measures were assessed by structured interviews at baseline in the participants' homes. Proportional hazards models were used to model survival from time of initial interview. Setting City of New Haven, Connecticut, United States. Participants 2761 men and women from a random population sample of 2812 people aged 65 and older. Main outcome measure Mortality from all causes during 13 years of follow up. Results All three types of activity were independently associated with survival after age, sex, race/ethnicity, marital status, income, body mass index; smoking functional disability and history of cancer, diabetes, stroke, and myocardial infarction were controlled for. Conclusions Social and productive activities that involve little or no enhancement, of fitness lower the risk of all cause mortality as much as fitness activities do. This suggests that in addition to increased cardiopulmonary fitness, activity may confer survival benefits through psychosocial pathways. Social and productive activities that require less physical exertion may complement exercise programmes and may constitute alternative interventions for frail elderly people.	Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Rush Presbyterian St Lukes Med Ctr, Rush Inst Healthy Aging, Chicago, IL 60612 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06504 USA	Harvard University; Harvard T.H. Chan School of Public Health; Rush University; Yale University	Glass, TA (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA.			Glass, Thomas/0000-0003-4399-612X	NATIONAL INSTITUTE ON AGING [N01AG002105, R01AG011042, R29AG010170] Funding Source: NIH RePORTER; NIA NIH HHS [N01-AG-02105, R29-AG-10170, R01-AG-11042] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADELMANN PK, 1994, J GERONTOL, V49, pS277, DOI 10.1093/geronj/49.6.S277; BERKMAN L, 1979, AM J EPIDEMIOL, V2, P186; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; Brunner E, 1996, LANCET, V347, P1008, DOI 10.1016/S0140-6736(96)90147-6; Bygren LO, 1996, BRIT MED J, V313, P1577, DOI 10.1136/bmj.313.7072.1577; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crespo CJ, 1996, ARCH INTERN MED, V156, P93, DOI 10.1001/archinte.156.1.93; GOLDBERG L, 1985, MED CLIN N AM, V69, P41; HELMERT U, 1994, INT J EPIDEMIOL, V23, P285, DOI 10.1093/ije/23.2.285; HERBERT TB, 1994, PSYCHOSOM MED, V56, P337, DOI 10.1097/00006842-199407000-00009; HOUSE JS, 1982, AM J EPIDEMIOL, V116, P123, DOI 10.1093/oxfordjournals.aje.a113387; KANNEL WB, 1986, AM HEART J, V112, P820, DOI 10.1016/0002-8703(86)90480-1; Kaplan GA, 1996, AM J EPIDEMIOL, V144, P793, DOI 10.1093/oxfordjournals.aje.a009003; KAPLAN GA, 1988, AM J EPIDEMIOL, V128, P370, DOI 10.1093/oxfordjournals.aje.a114977; LaVange L M, 1996, Stat Methods Med Res, V5, P311, DOI 10.1177/096228029600500306; Mendes de Leon CF, 1996, J GERONTOL PSYCHOL S, V51, P183; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; ORTHGOMER K, 1993, PSYCHOSOM MED, V55, P37, DOI 10.1097/00006842-199301000-00007; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PAFFENBARGER RS, 1978, AM J EPIDEMIOL, V108, P161, DOI 10.1093/oxfordjournals.aje.a112608; PHILLIPS DP, 1988, LANCET, V2, P728; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; ROSENGREN A, 1993, BRIT MED J, V306, P243, DOI 10.1136/bmj.306.6872.243; Rowe JW, 1997, SCIENCE, V278, P367, DOI 10.1126/science.278.5337.367; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; TEASDALE TW, 1993, BRAIN INJURY, V7, P535, DOI 10.3109/02699059309008181; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; WELIN L, 1992, J EPIDEMIOL COMMUN H, V46, P127, DOI 10.1136/jech.46.2.127; YAMANOUCHI K, 1992, J APPL PHYSIOL, V73, P2241, DOI 10.1152/jappl.1992.73.6.2241; YATES EF, 1988, EMERGENT THEORIES AG, P90; ZIMMER Z, 1995, GERONTOLOGIST, V35, P463, DOI 10.1093/geront/35.4.463	33	559	566	1	38	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 21	1999	319	7208					478	483		10.1136/bmj.319.7208.478	http://dx.doi.org/10.1136/bmj.319.7208.478			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229NA	10454399	Green Published, Bronze			2022-12-24	WOS:000082199600018
J	Koff, RS				Koff, RS			Advances in the treatment of chronic viral hepatitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERFERON; COMBINATION; RIBAVIRIN		MetroWest Med Ctr, Dept Med, Framingham, MA 01702 USA; Univ Massachusetts, Sch Med, Worcester, MA USA	University of Massachusetts System; University of Massachusetts Worcester	Koff, RS (corresponding author), MetroWest Med Ctr, Dept Med, 115 Lincoln St, Framingham, MA 01702 USA.							Bonkovsky HL, 1999, HEPATOLOGY, V29, P264, DOI 10.1002/hep.510290124; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; Heathcote EJL, 1998, HEPATOLOGY, V27, P1136, DOI 10.1002/hep.510270431; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Malaguarnera M, 1996, PHARMACOTHERAPY, V16, P609; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; McQuillan GM, 1999, AM J PUBLIC HEALTH, V89, P14, DOI 10.2105/AJPH.89.1.14; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; Wong JB, 1998, JAMA-J AM MED ASSOC, V280, P2088, DOI 10.1001/jama.280.24.2088	12	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1999	282	6					511	512		10.1001/jama.282.6.511	http://dx.doi.org/10.1001/jama.282.6.511			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	224UV	10450697				2022-12-24	WOS:000081919100001
J	Kanzaki, M; Nagasawa, M; Kojima, I; Sato, C; Naruse, K; Sokabe, M; Iida, H				Kanzaki, M; Nagasawa, M; Kojima, I; Sato, C; Naruse, K; Sokabe, M; Iida, H			Molecular identification of a eukaryotic, stretch-activated nonselective cation channel	SCIENCE			English	Article							MECHANOSENSITIVE ION-CHANNEL; EPITHELIAL NA+ CHANNEL; BALB/C 3T3 CELLS; PLASMA-MEMBRANE; PROTEIN; CD20; EXPRESSION; INFLUX; GENE	Calcium-permeable, stretch-activated nonselective cation (SA Cat) channels mediate cellular responses to mechanical stimuli. However, genes encoding such channels have not been identified in eukaryotes. The yeast MID1 gene product (Mid1) is required for calcium influx in the yeast Saccharomyces cerevisiae. Functional expression of Midi in Chinese hamster ovary cells conferred sensitivity to mechanical stress that resulted in increases in both calcium conductance and the concentration of cytosolic free calcium. These increases were dependent on the presence of extracellular calcium and were reduced by gadolinium, a blocker of SA Cat channels. Single-channel analyses with cell-attached patches revealed that Midi acts as a calcium-permeable, cation-selective stretch-activated channel with a conductance of 32 picosiemens at 150 millimolar cesium chloride in the pipette. Thus, Midi appears to be a eukaryotic, SA Cat channel.	Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan; Nagoya Univ, Sch Med, Dept Physiol, Aichi 4668550, Japan; Electrotech Lab, Supermol Sci Div, Tsukuba, Ibaraki 3058568, Japan; Gunma Univ, Inst Mol & Cellular Regulat, Cell Biol Lab, Gunma 3718510, Japan	Tokyo Gakugei University; Nagoya University; National Institute of Advanced Industrial Science & Technology (AIST); Gunma University	Iida, H (corresponding author), Tokyo Gakugei Univ, Dept Biol, Tokyo 1848501, Japan.	iida@u-gakugei.ac.jp	NARUSE, Keiji/B-1620-2011; Iida, Hidetoshi/AAO-5506-2020; Sato, Chikara/M-7183-2016; Sokabe, Masahiro/I-1565-2012; Kanzaki, Makoto/H-6680-2017	Sato, Chikara/0000-0001-5543-4496; Kanzaki, Makoto/0000-0002-6884-2955; naruse, keiji/0000-0003-4100-6444				Awayda MS, 1998, J GEN PHYSIOL, V112, P97, DOI 10.1085/jgp.112.2.97; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Chang G, 1998, SCIENCE, V282, P2220, DOI 10.1126/science.282.5397.2220; Drummond HA, 1998, NEURON, V21, P1435, DOI 10.1016/S0896-6273(00)80661-3; FRENCH AS, 1992, ANNU REV PHYSIOL, V54, P135, DOI 10.1146/annurev.physiol.54.1.135; GUSTIN MC, 1988, SCIENCE, V242, P762, DOI 10.1126/science.2460920; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Ismailov II, 1996, J BIOL CHEM, V271, P807, DOI 10.1074/jbc.271.2.807; JACKSON MB, 1992, METHOD ENZYMOL, V207, P729; Kanzaki M, 1997, J BIOL CHEM, V272, P14733, DOI 10.1074/jbc.272.23.14733; KANZAKI M, 1995, J BIOL CHEM, V270, P13099, DOI 10.1074/jbc.270.22.13099; Kanzaki M, 1997, J BIOL CHEM, V272, P4964, DOI 10.1074/jbc.272.8.4964; KANZAKI M, UNPUB; Kizer N, 1997, P NATL ACAD SCI USA, V94, P1013, DOI 10.1073/pnas.94.3.1013; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; MARSH L, 1997, MOL CELLULAR BIOL YE, V3, P827; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Naruse K, 1998, AM J PHYSIOL-HEART C, V274, pH1532; NARUSE K, 1993, AM J PHYSIOL, V264, pC1037, DOI 10.1152/ajpcell.1993.264.4.C1037; PAOLETTI P, 1994, NEURON, V13, P645, DOI 10.1016/0896-6273(94)90032-9; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; SACHS F, 1992, SENSORY TRANSDUCTION, P242; SACKIN H, 1995, ANNU REV PHYSIOL, V57, P333, DOI 10.1146/annurev.ph.57.030195.002001; Sukharev SI, 1997, ANNU REV PHYSIOL, V59, P633, DOI 10.1146/annurev.physiol.59.1.633; TASAKA Y, UNPUB; Tavernarakis N, 1997, ANNU REV PHYSIOL, V59, P659, DOI 10.1146/annurev.physiol.59.1.659	27	171	178	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					882	886		10.1126/science.285.5429.882	http://dx.doi.org/10.1126/science.285.5429.882			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436155				2022-12-24	WOS:000081860900047
J	Adams, ME				Adams, ME			Hype about glucosamine	LANCET			English	Editorial Material							INSULIN-RESISTANCE; OSTEOARTHRITIS		Univ Calgary, Dept Rheumat Dis, Calgary, AB T2N 4N1, Canada	University of Calgary	Adams, ME (corresponding author), Univ Calgary, Dept Rheumat Dis, Calgary, AB T2N 4N1, Canada.							ADAMS ME, 1994, OSTEOARTHR CARTILAGE, P45; Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; Baron AD, 1995, J CLIN INVEST, V96, P2792, DOI 10.1172/JCI118349; Bassleer C, 1998, OSTEOARTHR CARTILAGE, V6, P427, DOI 10.1053/joca.1998.0146; MALEMUD CJ, 1992, BIOL REGULATION CHON, P295; MANKIN HJ, 1970, J BONE JOINT SURG AM, VA 52, P424, DOI 10.2106/00004623-197052030-00002; MATYAS JR, 1995, ARTHRITIS RHEUM, V38, P420, DOI 10.1002/art.1780380320; McAlindon TE, 1998, ARTHRITIS RHEUM, V41, pS198; McClain DA, 1996, DIABETES, V45, P1003, DOI 10.2337/diabetes.45.8.1003; Muller-Fassbender H, 1994, Osteoarthritis Cartilage, V2, P61, DOI 10.1016/S1063-4584(05)80007-X; Noack W, 1994, Osteoarthritis Cartilage, V2, P51, DOI 10.1016/S1063-4584(05)80006-8; POOS MD, 1998, P ASS AM PHYS, V110, P422; *QUACKW, 1999, GLUC ARTHR; REICHELT A, 1994, ARZNEIMITTELFORSCH, V44-1, P75; Roos MD, 1996, AM J PHYSIOL-CELL PH, V270, pC803, DOI 10.1152/ajpcell.1996.270.3.C803; SEMIKAR I, 1986, ARZNEIMITTELFORSGUNG, V36, P729	16	46	48	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 31	1999	354	9176					353	354		10.1016/S0140-6736(99)90040-5	http://dx.doi.org/10.1016/S0140-6736(99)90040-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222CB	10437858				2022-12-24	WOS:000081764900003
J	Nicod, LP				Nicod, LP			Pirfenidone in idiopathic pulmonary fibrosis	LANCET			English	Editorial Material							LUNG FIBROSIS; PREDNISONE		Univ Geneva, Hop Cantonal, Div Pulm, Geneva 14, Switzerland	University of Geneva	Nicod, LP (corresponding author), Univ Geneva, Hop Cantonal, Div Pulm, Geneva 14, Switzerland.		Nicod, Laurent/ABD-3360-2020	Nicod, Laurent P/0000-0002-0905-916X				Cain WC, 1998, INT J IMMUNOPHARMACO, V20, P685, DOI 10.1016/S0192-0561(98)00042-3; Douglas WW, 1998, AM J RESP CRIT CARE, V158, P220, DOI 10.1164/ajrccm.158.1.9709089; GANESH R, 1999, AM J RESP CRIT CARE, V159, P1061; Iyer SN, 1998, EXP LUNG RES, V24, P119, DOI 10.3109/01902149809046058; Kaneko M, 1998, CLIN EXP IMMUNOL, V113, P72, DOI 10.1046/j.1365-2249.1998.00618.x; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Lee BS, 1998, J CLIN ENDOCR METAB, V83, P219, DOI 10.1210/jc.83.1.219; Lemjabbar H, 1999, AM J RESP CELL MOL, V20, P903, DOI 10.1165/ajrcmb.20.5.3260; MCANULTY RJ, 1995, EXP NEPHROL, V3, P96; MEIERSYDOW J, 1979, PRAX KLIN PNEUMOL, V33, P680; Nicod LP, 1998, DRUGS, V55, P555, DOI 10.2165/00003495-199855040-00006; RAGHU G, 1991, AM REV RESPIR DIS, V144, P191; Stewart JP, 1999, AM J RESP CRIT CARE, V159, P1336, DOI 10.1164/ajrccm.159.4.9807077	13	15	17	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					268	269		10.1016/S0140-6736(99)00178-6	http://dx.doi.org/10.1016/S0140-6736(99)00178-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440298				2022-12-24	WOS:000081646000004
J	Serageldin, I				Serageldin, I			Biotechnology and food security in the 21st century	SCIENCE			English	Editorial Material								Biotechnology can contribute to future food security if it benefits sustainable small-farm agriculture in developing countries. Presently, agrobiotechnology research cites ethical, safety, and intellectual property rights issues. Protection of intellectual property rights encourages private sector investment in agrobiotechnology, but in developing countries the needs of smallholder farmers and environmental conservation are unlikely to attract private funds. Public investment will be needed, and new and imaginative public-private collaboration can make the gene revolution beneficial to developing countries. This is crucial for the well-being of today's hungry people and future generations.	World Bank, Consultat Grp Int Agr Res, Washington, DC 20433 USA; World Bank, Special Programs, Washington, DC 20433 USA	The World Bank; The World Bank	Serageldin, I (corresponding author), World Bank, Consultat Grp Int Agr Res, 1818 H St NW, Washington, DC 20433 USA.							BORGSTROM G, 1973, FOOD PEOPLE DILEMMA; *CGIAR, 1998, SHAP CGIARS FUT SUMM, P52; CONWAY G, 1998, DOUBLY GREEN REVOLUT, P44; Eckholm EP, 1976, LOSING GROUND; Hayenga M., 1998, AGBIOFORUM, V1; HAZELL PBR, 1998, AGR ENV PERSPECTIVES; IFPRI, 1995, 2020 VIS FOOD AGR EN; JOHNSON B, 1999, COMMUNICATION   0326; KENDALL H, 1999, BIOTECHNOLOGY BIOSAF, P1; Leisinger K.M., 1995, 2 INT FOOD POL RES I; PINSTRUPANDERSE.PP, 1997, WORLD FOOD SITUATION; Rifkin Jeremy, 1998, BIOTECH CENTURY; SERAGELDIN I, 1997, RURAL WELL BEING VIS, P43; *UN DEV PROGR, 1998, HUM DEV REP 1998, P19; *UN POP DIV, 1999, WORLD POP PROSP 1998; WRIGHT BD, 1996, 19 INT FOOD POL RES; [No title captured]	17	88	106	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					387	389		10.1126/science.285.5426.387	http://dx.doi.org/10.1126/science.285.5426.387			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411497				2022-12-24	WOS:000081465900048
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Tolerating differences	SCIENCE			English	Article																		Guinan EC, 1999, NEW ENGL J MED, V340, P1704, DOI 10.1056/NEJM199906033402202	1	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					357	358						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10438301				2022-12-24	WOS:000081465900038
J	Feher, VA; Cavanagh, J				Feher, VA; Cavanagh, J			Millisecond-timescale motions contribute to the function of the bacterial response regulator protein Spo0F	NATURE			English	Article							N-15 NMR RELAXATION; HIGH-RESOLUTION NMR; BACKBONE DYNAMICS; BACILLUS-SUBTILIS; STAPHYLOCOCCAL NUCLEASE; MOLECULAR RECOGNITION; SIGNAL-TRANSDUCTION; PHOSPHORYLATION; DOMAIN; SPECTROSCOPY	Protein backbones and side chains display varying degrees of flexibility, which allows many slightly different but related conformational substates to occur(1). Such fluctuations are known to differ in both timescale and magnitude, from rotation of methyl groups (nanoseconds) to the flipping of buried tyrosine rings (seconds)(2,3), Because many mechanisms for protein function require conformational change, it has been proposed that some of these ground-state fluctuations are related to protein function(4). But exactly which aspects of motion are functionally relevant remains to be determined. Only a few examples so far exist where function can be correlated to structural fluctuations with known magnitude and timescale(5,6). As part of an investigation of the mechanism of action of the Bacillus subtilis response regulator Spo0F, we have explored the relationship between the motional characteristics and protein-protein interactions. Here we use a set of nuclear magnetic resonance N-15 relaxation measurements to determine the relative timescales of Spo0F backbone fluctuations on the picosecond-to-millisecond timescale, We show that regions having motion on the millisecond timescale correlate with residues and surfaces that are known to be critical for protein-protein interactions.	New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Cavanagh, J (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12201 USA.	johnc@wadsworth.org						AKKE M, 1994, J MAGN RESON SER B, V104, P298, DOI 10.1006/jmrb.1994.1090; ANSARI A, 1985, P NATL ACAD SCI USA, V82, P5000, DOI 10.1073/pnas.82.15.5000; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Feher VA, 1998, FEBS LETT, V425, P1, DOI 10.1016/S0014-5793(98)00182-3; Feher VA, 1997, BIOCHEMISTRY-US, V36, P10015, DOI 10.1021/bi970816l; FEHER VA, 1995, PROTEIN SCI, V4, P1801, DOI 10.1002/pro.5560040915; FRAUENFELDER H, 1979, NATURE, V280, P558, DOI 10.1038/280558a0; FRAUENFELDER H, 1988, ANNU REV BIOPHYS BIO, V17, P451; Gryk MR, 1996, PROTEIN SCI, V5, P1195; Jiang MY, 1997, J BIOL CHEM, V272, P11850, DOI 10.1074/jbc.272.18.11850; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; Kay LE, 1998, NAT STRUCT BIOL, V5, P156, DOI 10.1038/nsb0298-156; KAYL E, 1998, NAT STRUCT BIOL, V5, P156; Kriwacki RW, 1996, P NATL ACAD SCI USA, V93, P11504, DOI 10.1073/pnas.93.21.11504; LEE UK, 1987, B KOR CHEM SOC, V8, P1; LOWRY DF, 1994, J BIOL CHEM, V269, P26358; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; NICHOLSON LK, 1995, NAT STRUCT BIOL, V2, P274, DOI 10.1038/nsb0495-274; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; STONE MJ, 1992, BIOCHEMISTRY-US, V31, P4394, DOI 10.1021/bi00133a003; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Tzeng YL, 1997, J MOL BIOL, V272, P200, DOI 10.1006/jmbi.1997.1226; Tzeng YL, 1998, BIOCHEMISTRY-US, V37, P16538, DOI 10.1021/bi981340o; Volz K., 1995, 2 COMPONENT SIGNAL T, P53; WUTHRICH K, 1975, FEBS LETT, V50, P265, DOI 10.1016/0014-5793(75)80504-7; Wyss DF, 1997, PROTEIN SCI, V6, P534; Zhu XY, 1997, J BIOL CHEM, V272, P5000, DOI 10.1074/jbc.272.8.5000	30	196	197	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 15	1999	400	6741					289	293		10.1038/22357	http://dx.doi.org/10.1038/22357			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421374				2022-12-24	WOS:000081503800050
J	Atroshi, I; Gummesson, C; Johnssson, R; Ornstein, E; Ranstam, J; Rosen, I				Atroshi, I; Gummesson, C; Johnssson, R; Ornstein, E; Ranstam, J; Rosen, I			Prevalence of carpal tunnel syndrome in a general population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NERVE-CONDUCTION; WORK DISABILITY	Context Carpal tunnel syndrome (CTS) is a cause of pain, numbness, and tingling in the hands and is an important cause of work disability. Although high prevalence rates of CTS in certain occupations have been reported, little is known about its prevalence in the general population. Objective To estimate the prevalence of CTS in a general population. Design General health mail survey sent in February 1997, inquiring about symptoms of pain, numbness, and tingling in any part of the body, followed 2 months later by clinical examination and nerve conduction testing of responders reporting symptoms in the median nerve distribution in the hands, as well as of a sample of those not reporting these symptoms (controls). Setting A region in southern Sweden with a population of 170 000. Participants A sex- and age-stratified sample of 3000 subjects (age range, 25-74 years) was randomly selected from the general population register and sent the survey, with a response rate of 83% (n = 2466; 46% men). Of the symptomatic responders, 81% underwent clinical examination. Main Outcome Measures Population prevalence rates, calculated as the number of symptomatic responders diagnosed on examination as having clinically certain CTS and/or electrophysiological median neuropathy divided by the total number of responders. Results Of the 2466 responders, 354 reported pain, numbness, and/or tingling in the median nerve distribution in the hands (prevalence, 14.4%; 95% confidence interval [CI], 13.0%-15.8%). On clinical examination, 94 symptomatic subjects were diagnosed as having clinically certain CTS (prevalence, 3.8%; 95% CI, 3.1%-4.6%). Nerve conduction testing showed median neuropathy at the carpal tunnel in 120 symptomatic subjects (prevalence, 4.9%; 95% CI, 4.1%-5.8%), Sixty-six symptomatic subjects had clinically and electrophysiologically confirmed CTS (prevalence, 2.7%; 95% CI, 2.1%-3.4%). Of 125 control subjects clinically examined, electrophysiological median neuropathy was found in 23 (18.4%; 95% CI, 12.0%-26.3%). Conclusion Symptoms of pain, numbness, and tingling in the hands are common in the general population. Based on our data, 1 in 5 symptomatic subjects would be expected to have CTS based on clinical examination and electrophysiologic testing.	Hassleholm Kristianstad Hosp, Dept Orthoped, S-29185 Kristianstad, Sweden; Univ Lund, Lund, Sweden; Univ Lund Hosp, Dept Orthoped, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Clin Neurosci, Div Clin Neurophysiol, S-22185 Lund, Sweden; Malmo Univ, Dept Hlth & Soc, Malmo, Sweden	Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Malmo University	Atroshi, I (corresponding author), Hassleholm Kristianstad Hosp, Dept Orthoped, S-29185 Kristianstad, Sweden.		Ranstam, Jonas/A-4386-2009	Ranstam, Jonas/0000-0002-8287-7273				Altman D.G., 1991, PRACTICAL STATISTIC; Bingham RC, 1996, AM J IND MED, V30, P355, DOI 10.1002/(SICI)1097-0274(199609)30:3<355::AID-AJIM15>3.0.CO;2-V; DAWSON DM, 1993, NEW ENGL J MED, V329, P2013, DOI 10.1056/NEJM199312303292707; DEKROM MCTFM, 1992, J CLIN EPIDEMIOL, V45, P373, DOI 10.1016/0895-4356(92)90038-O; Feuerstein M, 1998, J OCCUP ENVIRON MED, V40, P546, DOI 10.1097/00043764-199806000-00007; HAGBERG M, 1992, SCAND J WORK ENV HEA, V18, P337, DOI 10.5271/sjweh.1564; JABLECKI CK, 1993, MUSCLE NERVE, V16, P1392; Katz JN, 1998, AM J IND MED, V33, P543, DOI 10.1002/(SICI)1097-0274(199806)33:6<543::AID-AJIM4>3.0.CO;2-R; KATZ JN, 1990, ANN INTERN MED, V112, P321, DOI 10.7326/0003-4819-112-5-321; KIMURA J, 1989, ELECTRODIAGNOSIS DIS, P105; Rempel D, 1998, AM J PUBLIC HEALTH, V88, P1447, DOI 10.2105/AJPH.88.10.1447; ROSEN I, 1993, SCAND J PLAST RECONS, V27, P95, DOI 10.3109/02844319309079790; ROSENBERG JH, 1993, NEUROLOGY, V43, P2404; Salerno DF, 1998, MUSCLE NERVE, V21, P999, DOI 10.1002/(SICI)1097-4598(199808)21:8<999::AID-MUS3>3.0.CO;2-0; SILVERSTEIN BA, 1987, AM J IND MED, V11, P343, DOI 10.1002/ajim.4700110310; *STAT SWED, 1999, OFF STAT SWED POP ST; STEVENS JC, 1988, NEUROLOGY, V38, P134, DOI 10.1212/WNL.38.1.134; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Werner RA, 1998, AM J IND MED, V33, P374, DOI 10.1002/(SICI)1097-0274(199804)33:4<374::AID-AJIM7>3.0.CO;2-U; Yassi A, 1997, LANCET, V349, P943, DOI 10.1016/S0140-6736(96)07221-2; 1985, LANCET, V1, P854	21	1073	1132	4	47	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1999	282	2					153	158		10.1001/jama.282.2.153	http://dx.doi.org/10.1001/jama.282.2.153			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HT	10411196				2022-12-24	WOS:000081376800032
J	Henschke, CI; McCauley, DI; Yankelevitz, DF; Naidich, DP; McGuinness, G; Miettinen, OS; Libby, DM; Pasmantier, MW; Koizumi, J; Altorki, NK; Smith, JP				Henschke, CI; McCauley, DI; Yankelevitz, DF; Naidich, DP; McGuinness, G; Miettinen, OS; Libby, DM; Pasmantier, MW; Koizumi, J; Altorki, NK; Smith, JP			Early Lung Cancer Action Project: overall design and findings from baseline screening	LANCET			English	Article							SURGICAL-TREATMENT; PULMONARY NODULE; STAGE-I; SURVIVAL; CT	Background The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) in people at high risk of lung cancer. We report the baseline experience. Methods ELCAP has enrolled 1000 symptom-free volunteers, aged 60 years or older, with at least 10 pack years of cigarette smoking and no previous cancer, who were medically fit to undergo thoracic surgery. After a structured interview and informed consent, chest radiographs and low-dose CT were done for each participant. The diagnostic investigation of screen-detected non-calcified pulmonary nodules was guided by ELCAP recommendations, which included short-term high-resolution CT follow-up for the smallest non-calcified nodules. Findings Non-calcified nodules were detected in 233 (23% [95%; CI 21-26]) participants by low-dose CT at baseline, compared with 68 (7% [5-9]) by chest radiography. Malignant disease was detected in 27 (2.7% [1.8-3.8]) by CT and seven (0.7% [0.3-1.3]) by chest radiography, and stage malignant disease in 23 (2.3% [1.5-3.3]) and four (0.4% [0.1-0.9]), respectively. Of the 27 CT-detected cancers, 26 were resectable. Biopsies were done on 28 of the 233 participants with non-calcified nodules; 27 had malignant non-calcified nodules and one had a benign nodule. Another three individuals underwent biopsy against the ELCAP recommendations; all had benign non-calcified nodules. No participant had thoracotomy for a benign nodule. Interpretation low-dose CT can greatly improve the likelihood of detection of small non-calcified nodules, and thus of lung cancer at an earlier and potentially more curable stage. Although false-positive CT results are common. they can be managed with little use of invasive diagnostic procedures.	New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York, NY USA; NYU Med Ctr, New York, NY 10016 USA; McGill Univ, Montreal, PQ, Canada	Cornell University; NewYork-Presbyterian Hospital; Cornell University; New York University; McGill University	Henschke, CI (corresponding author), New York Presbyterian Hosp, Weill Cornell Med Ctr, Dept Radiol, 525 E 68th St, New York, NY 10021 USA.			McGuinness, Georgeann/0000-0002-5326-9180; naidich, david/0000-0003-3751-5836	NCI NIH HHS [R01-CA-63393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BUCKSHEE N, 1999, ALA ATS INT C SAN DI; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; COLLINS VP, 1956, AMER J ROENTGENOL RA, V76, P988; EDDY DM, 1989, ANN INTERN MED, V111, P232, DOI 10.7326/0003-4819-111-3-232; FLEHINGER BJ, 1992, CHEST, V101, P1013, DOI 10.1378/chest.101.4.1013; FLEHINGER BJ, 1993, CANCER, V72, P1573, DOI 10.1002/1097-0142(19930901)72:5<1573::AID-CNCR2820720514>3.0.CO;2-9; FONTANA RS, 1991, CANCER-AM CANCER SOC, V67, P1155, DOI 10.1002/1097-0142(19910215)67:4+<1155::AID-CNCR2820671509>3.0.CO;2-0; FONTANA RS, 1984, AM REV RESPIR DIS, V130, P561; FONTANA RS, 1998, INT C PREV EARL DIAG, P15; HENSCHKE CI, 1994, CLIN IMAG, V18, P6; Inoue K, 1998, J THORAC CARDIOV SUR, V116, P407, DOI 10.1016/S0022-5223(98)70006-6; KANEKO M, 1998, INT C PREV EARL DIAG, P144; KANEKO M, IN PRESS CANCER; LAIRD AK, 1965, BRIT J CANCER, V19, P278, DOI 10.1038/bjc.1965.32; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; LIBBY DM, 1995, AM J MED, V99, P491, DOI 10.1016/S0002-9343(99)80225-3; MELAMED MR, 1987, SURG CLIN N AM, V67, P909; MIETTINEN OS, IN PRESS CANCER; MIETTINEN OS, 1998, INT C PREV EARL DIAG, P98; Mountain CF, 1997, CHEST, V111, P1710, DOI 10.1378/chest.111.6.1710; NAIDICH DP, 1990, RADIOLOGY, V175, P729, DOI 10.1148/radiology.175.3.2343122; NATHAN MH, 1962, RADIOLOGY, V79, P221, DOI 10.1148/79.2.221; NESBITT JC, 1995, ANN THORAC SURG, V60, P466, DOI 10.1016/0003-4975(95)00169-L; Shah R, 1996, J CARDIOVASC SURG, V37, P169; SOBUE T, 1992, CANCER, V69, P685, DOI 10.1002/1097-0142(19920201)69:3<685::AID-CNCR2820690315>3.0.CO;2-W; Sone S, 1998, LANCET, V351, P1242, DOI 10.1016/S0140-6736(97)08229-9; Yankelevitz DF, 1997, CLIN IMAG, V21, P107, DOI 10.1016/S0899-7071(96)00011-3; YANKELEVITZ DF, IN PRESS RADIOLOGY; ZERHOUNI EA, 1986, RADIOLOGY, V160, P319, DOI 10.1148/radiology.160.2.3726107	29	1825	1911	2	120	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 10	1999	354	9173					99	105		10.1016/S0140-6736(99)06093-6	http://dx.doi.org/10.1016/S0140-6736(99)06093-6			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	215HW	10408484				2022-12-24	WOS:000081377100011
J	Megee, PC; Koshland, D				Megee, PC; Koshland, D			A functional assay for centromere-associated sister chromatid cohesion	SCIENCE			English	Article							BUDDING YEAST; SACCHAROMYCES-CEREVISIAE; CHROMOSOME CONDENSATION; GENETIC-ANALYSIS; MINICHROMOSOMES; PLASMID	Cohesion of sister chromatids occurs along the entire Length of chromosomes, including the centromere where it plays essential roles in chromosome segregation. Here, minichromosomes in the budding yeast Saccharomyces cerevisiae are exploited to generate a functional assay for DNA sequences involved in cohesion. The centromeric DNA element CDEIII was found to be necessary but not sufficient for cohesion. This element was shown previously to be required for assembly of the kinetochore, the centromere-associated protein complex that attaches chromosomes to the spindle. These observations establish a link between centromere-proximal cohesion and kinetochore assembly.	Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, Baltimore, MD 21210 USA	Carnegie Institution for Science; Howard Hughes Medical Institute	Koshland, D (corresponding author), Carnegie Inst Washington, Dept Embryol, Howard Hughes Med Inst, 115 W Univ Pkwy, Baltimore, MD 21210 USA.			Megee, Paul/0000-0002-9397-2161	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41718] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI H, 1992, J MOL BIOL, V225, P25, DOI 10.1016/0022-2836(92)91023-I; GUACCI V, 1994, J CELL BIOL, V125, P517, DOI 10.1083/jcb.125.3.517; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; KOSHLAND D, 1987, CELL, V48, P801, DOI 10.1016/0092-8674(87)90077-8; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MATSUZAKI H, 1990, J BACTERIOL, V172, P610, DOI 10.1128/jb.172.2.610-618.1990; MEGEE PC, UNPUB; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; Skibbens RV, 1999, GENE DEV, V13, P307, DOI 10.1101/gad.13.3.307; Sorger PK, 1995, P NATL ACAD SCI USA, V92, P12026, DOI 10.1073/pnas.92.26.12026; Straight AF, 1996, CURR BIOL, V6, P1599, DOI 10.1016/S0960-9822(02)70783-5; SUMNER AT, 1991, CHROMOSOMA, V100, P410, DOI 10.1007/BF00337519; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320	19	63	64	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					254	257		10.1126/science.285.5425.254	http://dx.doi.org/10.1126/science.285.5425.254			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398602				2022-12-24	WOS:000081346000042
J	Roder, B; Teder-Salejarvi, W; Sterr, A; Rosler, F; Hillyard, SA; Neville, HJ				Roder, B; Teder-Salejarvi, W; Sterr, A; Rosler, F; Hillyard, SA; Neville, HJ			Improved auditory spatial tuning in blind humans	NATURE			English	Article							CONGENITALLY DEAF ADULTS; SIGHTED SUBJECTS; VISUAL-CORTEX; PLASTICITY; POTENTIALS; ACTIVATION; ATTENTION	Despite reports of improved auditory discrimination capabilities in blind humans(1-3) and visually deprived animals(4), there is no general agreement as to the nature or pervasiveness of such compensatory sensory enhancements(5). Neuroimaging studies have pointed out differences in cerebral organization between blind and sighted humans(6-12), but the relationship between these altered cortical activation patterns and auditory sensory acuity remains unclear. Here we compare behavioural and electrophysiological indices of spatial tuning within central and peripheral auditory space in congenitally blind and normally sighted but blindfolded adults to test the hypothesis (raised by earlier studies of the effects of auditory deprivation on visual processing(13,14)) that the effects of visual deprivation might be more pronounced for processing peripheral sounds. We find that blind participants displayed localization abilities that were superior to those of sighted controls, but only when attending to sounds in peripheral auditory space. Electrophysiological recordings obtained at the same time revealed sharper tuning of early spatial attention mechanisms in the blind subjects. Differences in the scalp distribution of brain electrical activity between the two groups suggest a compensatory reorganization of brain areas in the blind that may contribute to the improved spatial resolution for peripheral sound sources.	Univ Marburg, Dept Psychol, D-35037 Marburg, Germany; Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; Univ Konstanz, Dept Psychol, D-78457 Constance, Germany; Univ Oregon, Dept Psychol, Eugene, OR 97403 USA	Philipps University Marburg; University of California System; University of California San Diego; University of Konstanz; University of Oregon	Roder, B (corresponding author), Univ Marburg, Dept Psychol, Gutenbergstr 18, D-35037 Marburg, Germany.		Roeder, Brigitte/A-4652-2009					Ashmead DH, 1998, PERCEPTION, V27, P105, DOI 10.1068/p270105; Brainard MS, 1998, J NEUROSCI, V18, P3929; Clark V.P., 1994, HUMAN BRAIN MAPPING, V2, P170, DOI [DOI 10.1002/HBM.460020306, 10.1002/hbm.460020306]; Cohen LG, 1997, NATURE, V389, P180, DOI 10.1038/38278; Downing C. J., 1985, ATTENTION PERFORM, P171; Hillyard Steven A., 1995, P665; Huynh H, 1976, J EDUC STATIST, V1, P69, DOI DOI 10.3102/10769986001001069; HYVARINEN J, 1981, EXP BRAIN RES, V42, P1; Knudsen EI, 1998, SCIENCE, V279, P1531, DOI 10.1126/science.279.5356.1531; KUJALA T, 1992, ELECTROEN CLIN NEURO, V84, P469, DOI 10.1016/0168-5597(92)90034-9; Lessard N, 1998, NATURE, V395, P278, DOI 10.1038/26228; MIDDLEBROOKS JC, 1991, ANNU REV PSYCHOL, V42, P135, DOI 10.1146/annurev.ps.42.020191.001031; MILLER L, 1992, J VISUAL IMPAIR BLIN, V86, P206; MILLS AW, 1972, FDN MODERN AUDITORY, P303; MONDOR TA, 1995, J EXP PSYCHOL HUMAN, V21, P387, DOI 10.1037/0096-1523.21.2.387; MORRONGIELLO BA, 1994, DEV INTERSENSORY PER, P235; MUCHNIK C, 1991, SCAND AUDIOL, V20, P19, DOI 10.3109/01050399109070785; Naatanen R., 2018, ATTENTION BRAIN FUNC; NEVILLE HJ, 1987, BRAIN RES, V405, P268, DOI 10.1016/0006-8993(87)90296-4; NEVILLE HJ, 1983, BRAIN RES, V266, P127, DOI 10.1016/0006-8993(83)91314-8; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; RAUSCHECKER JP, 1983, EXP BRAIN RES, V50, P63; RICE C, 1970, AM F BLIND RES B, V22, P1, DOI DOI 10.3758/S13414-011-0160-4; Roder B, 1996, COGNITIVE BRAIN RES, V4, P77, DOI 10.1016/0926-6410(96)00024-9; Roder B, 1997, PSYCHOPHYSIOLOGY, V34, P292, DOI 10.1111/j.1469-8986.1997.tb02400.x; ROSLER F, 1993, COGNITIVE BRAIN RES, V1, P145, DOI 10.1016/0926-6410(93)90022-W; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; Teder-Salejarvi WA, 1998, PERCEPT PSYCHOPHYS, V60, P1228, DOI 10.3758/BF03206172; UHL F, 1993, NEUROSCI LETT, V150, P162, DOI 10.1016/0304-3940(93)90526-Q; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7	30	457	463	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					162	166		10.1038/22106	http://dx.doi.org/10.1038/22106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	214JM	10408442				2022-12-24	WOS:000081324900053
J	Zhang, ZD; Green, BR; Cavalier-Smith, T				Zhang, ZD; Green, BR; Cavalier-Smith, T			Single gene circles in dinoflagellate chloroplast genomes	NATURE			English	Article							DNA-REPLICATION; SEQUENCE; RUBISCO; ORIGIN	Photosynthetic dinoflagellates are important aquatic primary producers and notorious causes of toxic 'red tides: Typical dinoflagellate chloroplasts differ from all other plastids in having a combination of three envelope membranes' and peridinin-chlorophyll ale light-harvesting pigments'. Despite evidence of a dinoflagellete satellite DNA containing chloroplast genes(3), previous attempts to obtain chloroplast gene sequences have been uniformly unsuccessful. Here we show that the dinoflagellate chloroplast DNA genome structure is unique. Complete sequences of chloroplast ribosomal RNA genes and seven chloroplast protein genes from the dinoflagellate Heterocapsa triquetra reveal that each is located alone on a separate minicircular chromosome:'one gene-one circle: The genes are the most divergent known from chloroplast genomes. Each circle has an unusual tripartite non-coding region (putative replicon origin), which is highly conserved among the nine circles through extensive gene conversion, but is very divergent between species. Several other dinoflagellate species have minicircular chloroplast genes, indicating that this type of genomic organization may have evolved in ancestral peridinean dinoflagellates. Phylogenetic analysis indicates that dinoflagellate chloroplasts are related to chromistan and red algal chloroplasts and supports their origin by Secondary symbiogenesis(4-6)	Univ British Columbia, Canadian Inst Adv Res Evolutionary Biol Programme, Dept Bot, Vancouver, BC V6T 1Z4, Canada	Canadian Institute for Advanced Research (CIFAR); University of British Columbia	Green, BR (corresponding author), Univ British Columbia, Canadian Inst Adv Res Evolutionary Biol Programme, Dept Bot, Vancouver, BC V6T 1Z4, Canada.	brgreen@interchange.ubc.ca	Green, Beverley R./AAJ-5199-2021	Green, Beverley R./0000-0002-4021-9387				Backert S, 1997, TRENDS PLANT SCI, V2, P477, DOI 10.1016/S1360-1385(97)01148-5; BOCZAR BA, 1991, PLANT PHYSIOL, V97, P613, DOI 10.1104/pp.97.2.613; BOORE JL, 1994, GENETICS, V138, P423; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CAVALIERSMITH T, 1995, BIODIVERSITY EVOLUTI, P75; DODGE J D, 1975, Phycologia, V14, P253, DOI 10.2216/i0031-8884-14-4-253.1; Douglas SE, 1999, J MOL EVOL, V48, P236, DOI 10.1007/PL00006462; GAJADHAR AA, 1991, MOL BIOCHEM PARASIT, V45, P147, DOI 10.1016/0166-6851(91)90036-6; GIBBS SP, 1981, ANN NY ACAD SCI, V361, P193; JACOBS JD, 1992, MOL GEN GENET, V233, P302, DOI 10.1007/BF00587592; JEFFREY SW, 1975, J PHYCOL, V11, P374, DOI 10.1111/j.1529-8817.1975.tb02799.x; La Claire JW, 1998, CURR GENET, V34, P204, DOI 10.1007/s002940050387; Martin W, 1998, NATURE, V393, P162, DOI 10.1038/30234; MORSE D, 1995, SCIENCE, V268, P1622, DOI 10.1126/science.7777861; Palmer J.D., 1998, MOL SYSTEMATICS PLAN, P375, DOI [10.1007/978-1-4615-5419-6_13, DOI 10.1007/978-1-4615-5419-6_13]; Rowan R, 1996, PLANT CELL, V8, P539, DOI 10.1105/tpc.8.3.539; Sambrook JFE, 1989, MOL CLONING LAB MANU; Saunders GW, 1997, PLANT SYST EVOL, P237; SCHLUNEGGER B, 1984, CURR GENET, V8, P629, DOI 10.1007/BF00395709; SMITH SW, 1994, COMPUT APPL BIOSCI, V10, P671; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; Wakasugi T, 1997, P NATL ACAD SCI USA, V94, P5967, DOI 10.1073/pnas.94.11.5967; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WU M, 1986, P NATL ACAD SCI USA, V83, P6761, DOI 10.1073/pnas.83.18.6761	25	267	288	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 8	1999	400	6740					155	159		10.1038/22099	http://dx.doi.org/10.1038/22099			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408440				2022-12-24	WOS:000081324900051
J	Brown, SL; Hansen, SL; Langone, JJ				Brown, SL; Hansen, SL; Langone, JJ			Role of serology in the diagnosis of Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROFICIENCY TESTING PROGRAM; BORRELIA-BURGDORFERI; OVERDIAGNOSIS; LABORATORIES; VACCINATION; ANTIBODY	Numerous concerns regarding the potential for misdiagnosis of Lyme disease using commercial assays have been voiced by the US Food and Drug Administration (FDA). We attempted to clarify the clinical value of serologic testing for Lyme disease using the results of commonly marketed assays for detecting antibody to Borrelia burgdorferi, the organism that causes Lyme disease, We reviewed published studies on B burgdorferi test performance published through 1998, package insert labeling from FDA-cleared test kits for B burgdorferi, and Lyme Disease Survey Set LY-A from the College of American Pathologists. We assessed the sensitivity and specificity of commercial serologic tests (enzyme-linked immunosorbent assay [ELISA], immunofluorescence antibody [IFA], and immunodot) for diagnosis of Lyme disease. To reduce this risk of misdiagnosis, it is important that clinicians understand the performance characteristics and limitations of these tests. These tests, in common use in clinical or commercial laboratories, should be used only to support a clinical diagnosis of Lyme disease, not as the primary basis for making diagnostic or treatment decisions. Serologic testing is not useful early in the course of Lyme disease because of the low sensitivity of tests in early disease. Serologic testing may be more useful in later disease, at which time sensitivity and specificity of the test are improved. Positive or equivocal results on an ELISA, IFA, or immunodot assay requires supplemental testing with a Western blot assay. A negative result on the Western blot or ELISA indicates that there is no serologic evidence of infection by B burgdorferi at the time the sample was drawn.	US FDA, Off Surveillance & Biometr, Div Postmarket Surveillance, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Off Device Evaluat, Div Clin Lab Devices, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA; US FDA, Off Sci & Technol, Div Life Sci, Ctr Devices & Radiol Hlth, Rockville, MD 20857 USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Brown, SL (corresponding author), 1350 Piccard Dr,HFZ-541, Rockville, MD 20850 USA.							AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; Bakken LL, 1997, J CLIN MICROBIOL, V35, P537, DOI 10.1128/JCM.35.3.537-543.1997; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1998, INFECT DIS; DURAY PH, 1997, PATHOLOGY INFECT DIS, V1; *FDA PUBL HLTH ADV, 1999, ASS ANT BORR BURGD L; Fix AD, 1998, JAMA-J AM MED ASSOC, V279, P206, DOI 10.1001/jama.279.3.206; Hofmann H, 1996, INFECTION, V24, P470, DOI 10.1007/BF01713052; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1990, J CLIN MICROBIOL, V28, P1276, DOI 10.1128/JCM.28.6.1276-1279.1990; Reid MC, 1998, ANN INTERN MED, V128, P354, DOI 10.7326/0003-4819-128-5-199803010-00003; SCHMITZ JL, 1993, EUR J CLIN MICROBIOL, V12, P419, DOI 10.1007/BF01967435; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; Sigal LH, 1997, ANNU REV IMMUNOL, V15, P63, DOI 10.1146/annurev.immunol.15.1.63; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; SIGAL LH, 1995, ADV INTERNAL MED, V40, P69; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; Strickland GT, 1997, J INFECT DIS, V176, P819, DOI 10.1086/517311; Tierno PM, 1996, LAB MED, V27, P542, DOI 10.1093/labmed/27.8.542; Tugwell P, 1997, ANN INTERN MED, V127, P1106, DOI 10.7326/0003-4819-127-12-199712150-00011; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; *US FDA, 1996, FDA ADV PAN M 1996 M, V2; Zhang YQ, 1997, J CLIN MICROBIOL, V35, P233, DOI 10.1128/JCM.35.1.233-238.1997; 1997, MMWR MORB MORTAL WKL, V46, P531	30	82	89	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1999	282	1					62	66		10.1001/jama.282.1.62	http://dx.doi.org/10.1001/jama.282.1.62			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212BE	10404913				2022-12-24	WOS:000081195800030
J	Emery, J; Walton, R; Coulson, A; Glasspool, D; Ziebland, S; Fox, J				Emery, J; Walton, R; Coulson, A; Glasspool, D; Ziebland, S; Fox, J			Computer support for recording and interpreting family histories of breast and ovarian cancer in primary care (RAGs): qualitative evaluation with simulated patients	BRITISH MEDICAL JOURNAL			English	Article							EXPERT-SYSTEMS; TECHNOLOGY; KNOWLEDGE; PROFORMA; GENETICS; SERVICES	Objectives To explore general practitioners' attitudes ton ards and use of a computer program for assessing genetic risk of cancer in primary care. Design Qualitative analysis of semistructured interviews and video recordings of simulated consultations. Participants Purposive sample of 15 general practitioners covering a range of computer literacy; interest in genetics, age, and sex. Interventions Each doctor used the program in two consultations in which an actor played a woman concerned about her family history of cancer. Consultations were videotaped and followed by interviews with the video as a prompt to questioning, Main outcome measures Use of computer program in the consultation. Results The program was viewed as an appropriate application of information technology because of the complexity of cancer genetics and a sense of "guideline chaos" in primary care. Doctors found the program easy to use, but it often affected their control of the consultation. They needed to balance their desire to share the computer screen with the patient, driven by their concerns about the effect of the computer on doctor-patient communication against the risk of premature disclosure of bad news. Conclusions This computer program could provide the necessary. support to assist assessment of genetic risk of cancer in primary care. The potential impact of computer software on the consultation should not be underestimated. This study highlights the need for careful evaluation when developing medical information systems.	Inst Hlth Sci, Div Publ Hlth & Primary Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England; Imperial Canc Res Fund, Adv Computat Lab, London WC2A 3PX, England	University of Oxford; Cancer Research UK	Emery, J (corresponding author), Inst Hlth Sci, Div Publ Hlth & Primary Care, Gen Practice Res Grp, Imperial Canc Res Fund, Oxford OX3 7LF, England.			Ziebland, Sue/0000-0002-6496-4859				ARBORELIUS E, 1991, Scandinavian Journal of Primary Health Care, V9, P71, DOI 10.3109/02813439109026587; *CANC RES CAMP, 1998, 1 CRC; EMERY J, IN PRESS BR J GEN PR; ERIKSON F, 1982, SOCIOL METHOD RES, V11, P213; Fischer C, 1996, HUM GENET, V97, P129, DOI 10.1007/BF02265253; Fox J, 1998, ARTIF INTELL MED, V14, P157, DOI 10.1016/S0933-3657(98)00021-9; Fox J, 1997, COMPUT METH PROG BIO, V54, P59, DOI 10.1016/S0169-2607(97)00034-5; Friedman C.P., 1997, EVALUATION METHODS M, P41; FRY A, IN PRESS FAM PRACT; GREATBATCH D, 1995, FAM PRACT, V12, P32, DOI 10.1093/fampra/12.1.32; Harris R, 1996, J MED GENET, V33, P346, DOI 10.1136/jmg.33.4.346; HARRIS R, 1995, BRIT MED J, V311, P275; Heathfield H, 1998, BRIT MED J, V316, P1959, DOI 10.1136/bmj.316.7149.1959; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; Mays N, 1996, QUALITATIVE RES HLTH; OHAGAN JJ, 1986, NEW ZEAL MED J, V99, P948; Patton M. Q., 1990, QUALITATIVE EVALUATI; Ridsdale L, 1997, SCAND J PRIM HEALTH, V15, P180, DOI 10.3109/02813439709035024; *ROYAL COLL GEN PR, 1998, 77 ROYAL COLL GEN PR; Silverman D., 2015, INTERPRETING QUALITA; Strauss A., 1990, BASICS QUALITATIVE R; SULLIVAN F, 1995, BMJ-BRIT MED J, V311, P848, DOI 10.1136/bmj.311.7009.848; Timpka T, 1994, Artif Intell Med, V6, P501, DOI 10.1016/0933-3657(94)90027-2; Walton RT, 1997, BRIT MED J, V315, P791; WYATT J, 1990, MED INFORM, V15, P205, DOI 10.3109/14639239009025268; 1997, QSR NUD IST PROGRAM	27	61	62	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1999	319	7201					32	36		10.1136/bmj.319.7201.32	http://dx.doi.org/10.1136/bmj.319.7201.32			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	214KE	10390458	Green Published, Bronze			2022-12-24	WOS:000081326500032
J	Lohmann, V; Korner, F; Koch, JO; Herian, U; Theilmann, L; Bartenschlager, R				Lohmann, V; Korner, F; Koch, JO; Herian, U; Theilmann, L; Bartenschlager, R			Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line	SCIENCE			English	Article							CDNA CLONE; GENOME; IDENTIFICATION; 3'-TERMINUS; POLYMERASE; TRANSLATION; TRANSCRIPTS; CHIMPANZEE; GROWTH; REGION	An estimated 170 million persons worldwide are infected with hepatitis C virus (HCV), a major cause of chronic liver disease. Despite increasing knowledge of genome structure and individual viral proteins, studies on virus replication and pathogenesis have been hampered by the lack of reliable and efficient cell culture systems. A full-length consensus genome was cloned from viral RNA isolated from an infected human liver and used to construct subgenomic selectable replicons. Upon transfection into a human hepatoma cell line, these RNAs were found to replicate to high levels, permitting metabolic radiolabeling of viral RNA and proteins. This work defines the structure of HCV replicons functional in cell culture and provides the basis fora long-sought cellular system that should allow detailed molecular studies of HCV and the development of antiviral drugs.	Johannes Gutenberg Univ Mainz, Inst Virol, D-55131 Mainz, Germany; Stadt Klinikum Pforzheim, Med Klin 2, D-75116 Pforzheim, Germany	Johannes Gutenberg University of Mainz; University of Hamburg; University Medical Center Hamburg-Eppendorf	Bartenschlager, R (corresponding author), Johannes Gutenberg Univ Mainz, Inst Virol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	bartnsch@mail.uni-mainz.de	Lohmann, Volker/H-4211-2019; Bartenschlager, Ralf/L-2582-2015	Lohmann, Volker/0000-0001-8719-7608; Bartenschlager, Ralf/0000-0001-5601-9307				Bartenschlager R, 1997, INTERVIROLOGY, V40, P378, DOI 10.1159/000150570; BARTENSCHLAGER R, 1995, J VIROL, V69, P7519, DOI 10.1128/JVI.69.12.7519-7528.1995; Behrens SE, 1998, J VIROL, V72, P2364, DOI 10.1128/JVI.72.3.2364-2372.1998; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Fournier C, 1998, J GEN VIROL, V79, P2367, DOI 10.1099/0022-1317-79-10-2367; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; Gong YH, 1996, J GEN VIROL, V77, P2729, DOI 10.1099/0022-1317-77-11-2729; HOUGHTON M, 1996, FIELDS VIROLOGY, V1, P1035; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; KEDZIERSKI W, 1991, BIOTECHNIQUES, V10, P210; Khromykh AA, 1997, J VIROL, V71, P1497, DOI 10.1128/JVI.71.2.1497-1505.1997; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 1996, J VIROL, V70, P3363, DOI 10.1128/JVI.70.6.3363-3371.1996; LANFORD RE, 1994, VIROLOGY, V202, P606, DOI 10.1006/viro.1994.1381; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; LOHMANN V, UNPUB; Mizutani T, 1996, J VIROL, V70, P7219, DOI 10.1128/JVI.70.10.7219-7223.1996; NAKABAYASHI H, 1982, CANCER RES, V42, P3858; REYNOLDS JE, 1995, EMBO J, V14, P6010, DOI 10.1002/j.1460-2075.1995.tb00289.x; RICE CM, 1996, FIELDS VIROLOGY, V1, P931; RIJNBRAND R, 1995, FEBS LETT, V365, P115, DOI 10.1016/0014-5793(95)00458-L; SHIMIZU YK, 1992, P NATL ACAD SCI USA, V89, P5477, DOI 10.1073/pnas.89.12.5477; TANAKA T, 1995, BIOCHEM BIOPH RES CO, V215, P744, DOI 10.1006/bbrc.1995.2526; Tanaka T, 1996, J VIROL, V70, P3307, DOI 10.1128/JVI.70.5.3307-3312.1996; Yamada N, 1996, VIROLOGY, V223, P255, DOI 10.1006/viro.1996.0476; Yanagi M, 1998, VIROLOGY, V244, P161, DOI 10.1006/viro.1998.9092; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yanagi M, 1999, P NATL ACAD SCI USA, V96, P2291, DOI 10.1073/pnas.96.5.2291; YOO BJ, 1995, J VIROL, V69, P32, DOI 10.1128/JVI.69.1.32-38.1995	32	2326	2699	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1999	285	5424					110	113		10.1126/science.285.5424.110	http://dx.doi.org/10.1126/science.285.5424.110			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390360				2022-12-24	WOS:000081199800042
J	York, JD; Odom, AR; Murphy, R; Ives, EB; Wente, SR				York, JD; Odom, AR; Murphy, R; Ives, EB; Wente, SR			A phospholipase C-dependent inositol polyphosphate kinase pathway required for efficient messenger RNA export	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; NUCLEAR EXPORT; SCHIZOSACCHAROMYCES-POMBE; PORE; HEXAKISPHOSPHATE; TRISPHOSPHATE; NUCLEOPORIN; METABOLISM; PHOSPHATES; TRANSPORT	In order to identify additional factors required for nuclear export of messenger RNA, a genetic screen was conducted with a yeast mutant deficient in a factor Gle1p, which associates with the nuclear pore complex (NPC). The three genes identified encode phospholipase C and two potential inositol polyphosphate kinases. Together, these constitute a signaling pathway from phosphatidylinositol 4,5-bisphosphate to inositol hexakisphosphate (IP6). The common downstream effects of mutations in each component were deficiencies in IP6 synthesis and messenger RNA export, indicating a role for IP6 in GLE7 function and messenger RNA export.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Duke University; Duke University; Washington University (WUSTL)	York, JD (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, DUMC 3813, Durham, NC 27710 USA.		John, Audrey Odom/AAF-1300-2019	John, Audrey Odom/0000-0001-8395-8537				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Daneholt B, 1997, CELL, V88, P585, DOI 10.1016/S0092-8674(00)81900-5; DelPriore V, 1996, MOL BIOL CELL, V7, P1601, DOI 10.1091/mbc.7.10.1601; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; ESTEVEZ F, 1994, BIOCHEM J, V302, P709, DOI 10.1042/bj3020709; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; Lee MS, 1997, CURR OPIN GENET DEV, V7, P212, DOI 10.1016/S0959-437X(97)80131-1; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; MAJERUS PW, 1992, ANNU REV BIOCHEM, V61, P225, DOI 10.1146/annurev.bi.61.070192.001301; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Murphy R, 1996, MOL BIOL CELL, V7, P1921, DOI 10.1091/mbc.7.12.1921; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Ongusaha PP, 1998, BIOCHEM J, V335, P671, DOI 10.1042/bj3350671; PHILLIPPY B, 1994, J BIOL CHEM, V269, P28693; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Safrany ST, 1998, EMBO J, V17, P1710, DOI 10.1093/emboj/17.6.1710; Shears SB, 1998, BBA-MOL CELL BIOL L, V1436, P49, DOI 10.1016/S0005-2760(98)00131-3; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STEPHENS L, 1990, NATURE, V326, P580; Stolz LE, 1998, J BIOL CHEM, V273, P11852, DOI 10.1074/jbc.273.19.11852; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; VOGLMAIER SM, 1992, BIOCHEM BIOPH RES CO, V187, P158, DOI 10.1016/S0006-291X(05)81473-1; Watkins JL, 1998, P NATL ACAD SCI USA, V95, P6779, DOI 10.1073/pnas.95.12.6779; WENTE SR, 1993, J CELL BIOL, V123, P275, DOI 10.1083/jcb.123.2.275	29	429	447	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 2	1999	285	5424					96	100		10.1126/science.285.5424.96	http://dx.doi.org/10.1126/science.285.5424.96			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	212CY	10390371				2022-12-24	WOS:000081199800038
J	Lin, YX; Fletcher, CM; Zhou, JX; Allis, CD; Wagner, G				Lin, YX; Fletcher, CM; Zhou, JX; Allis, CD; Wagner, G			Solution structure of the catalytic domain of GCN5 histone acetyltransferase bound to coenzyme A	NATURE			English	Article							GCN5-RELATED N-ACETYLTRANSFERASE; YEAST GCN5P; IN-VIVO; PROTEIN; ACTIVATION; ACETYLATION; SUPERFAMILY; COMPLEX; CBP	Gene transcription requires the release of inactive DNA from its packaging of histone proteins. Following the discovery of the first transcription-associated histone acetyltransferase, tetrahymena GCN5(1), it was shown that yeast GCN5 is recruited to the promoter and causes hyper-acetylation of histones and transcriptional activation of target genes(2,3), establishing a direct connection between histone acetylation and transcriptional activation. Many other important transcription regulators have been found to have histone acetyltransferase activity, including TAFII230/250, p300/CBP and its associated factor PCAF(4-9). Here we present the solution structure of the catalytic domain of tGCN5 (residues 47-210) in complex with coenzyme A. The structure contains two domains; the amino-terminal domain is similar to those of other GCN5-related N-acetyltransferases(10,11) but the carboxy-terminal domain is not. Coenzyme A binds in a deep hydrophobic pocket between the two domains. Chemical shift changes upon titration with histone H3 peptides indicate a binding site at the domain boundary opposite to the coenzyme A site. The structural data indicate a single-step acetyl-transfer reaction mechanism catalysed by a hydrogen bond to the backbone amide group of leucine 126 and the side-chain carboxyl group of a conserved acidic residue.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; MIT, Harvard Ctr Magnet Resonance, Cambridge, MA 02139 USA; Harvard Univ, Dept Phys, Cambridge, MA 02138 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; University of Virginia	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.			/0000-0002-7002-1275				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bhatnagar RS, 1998, NAT STRUCT BIOL, V5, P1091, DOI 10.1038/4202; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Fletcher CM, 1999, EMBO J, V18, P2631, DOI 10.1093/emboj/18.9.2631; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LIN Y, UNPUB J AM CHEM SOC; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parthun MR, 1996, CELL, V87, P85, DOI 10.1016/S0092-8674(00)81325-2; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Wang LA, 1997, MOL CELL BIOL, V17, P519, DOI 10.1128/MCB.17.1.519; Wolf E, 1998, CELL, V94, P439, DOI 10.1016/S0092-8674(00)81585-8; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	21	78	81	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					86	89		10.1038/21922	http://dx.doi.org/10.1038/21922			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403255				2022-12-24	WOS:000081255700057
J	Motulsky, AG				Motulsky, AG			If I had a gene test, what would I have and who would I tell?	LANCET			English	Editorial Material							FAMILIAL ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; POPULATION; MUTATIONS; RISKS		Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Genet, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Motulsky, AG (corresponding author), Univ Washington, Dept Med, Box 356723, Seattle, WA 98195 USA.							Baron H, 1996, NAT BIOTECHNOL, V14, P1279, DOI 10.1038/nbt1096-1279; Bernstein T, 1994, RADON RENTAL HOUSING; Beutler E, 1997, BLOOD CELL MOL DIS, V23, P95, DOI 10.1006/bcmd.1997.0125; BOTHWELL TH, 1995, METABOLIC MOL BASES; Brodaty H, 1995, ALZ DIS ASSOC DIS, V9, P182; BURKE W, 1998, JAMA-J AM MED ASSOC, V280, P173; Devilee P, 1999, AM J HUM GENET, V64, P943, DOI 10.1086/302350; Farrington SM, 1998, AM J HUM GENET, V63, P749, DOI 10.1086/301996; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; Gryfe R, 1999, AM J HUM GENET, V64, P378, DOI 10.1086/302262; Hartge P, 1999, AM J HUM GENET, V64, P963, DOI 10.1086/302320; HERRERA VLM, 1994, J HYPERTENS, V12, pS47; Levy-Lahad E, 1998, J GERIATR PSYCH NEUR, V11, P42, DOI 10.1177/089198879801100202; Lynch HT, 1998, AM J HUM GENET, V62, P1288, DOI 10.1086/301890; MOTULSKY AG, 1992, GENETIC BASIS COMMON, P150; Poirier J, 1999, J PSYCHIATR NEUROSCI, V24, P147; Powell SM, 1998, METH MOL B, V92, P251; Reilly PR, 1998, AM J HUM GENET, V63, P682, DOI 10.1086/302028; Ruschoff J, 1998, P NATL ACAD SCI USA, V95, P11301, DOI 10.1073/pnas.95.19.11301; Sachse C, 1997, AM J HUM GENET, V60, P284; Salomon O, 1999, ARTERIOSCL THROM VAS, V19, P511, DOI 10.1161/01.ATV.19.3.511; Soravia C, 1998, AM J HUM GENET, V62, P1290, DOI 10.1086/301883; Wijnen JT, 1998, NEW ENGL J MED, V339, P511, DOI 10.1056/NEJM199808203390804	24	17	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL	1999	354			1			SI35	SI37						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	223DV	10437855				2022-12-24	WOS:000081825900010
J	Jennett, B				Jennett, B			Brain stem death defines death in law	BMJ-BRITISH MEDICAL JOURNAL			English	Article									So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland	University of Glasgow	Jennett, B (corresponding author), So Gen Hosp, Inst Neurol Sci, Dept Neurosurg, Glasgow G51 4TF, Lanark, Scotland.							BLACK D, 1995, J ROY COLL PHYS LOND, V29, P381; *HLTH DEP GREAT BR, 1983, CAD ORG TRANSPL COD; JENNETT B, 1981, BRIT J ANAESTH, V53, P1111, DOI 10.1093/bja/53.11.1111; SPRUNG CL, 1995, CRIT CARE MED, V23, P618, DOI 10.1097/00003246-199504000-00004	4	7	7	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	1999	318	7200					1755	1755						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	212KY	10428564				2022-12-24	WOS:000081216900041
J	Hofmann, MA; Drury, S; Fu, CF; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM				Hofmann, MA; Drury, S; Fu, CF; Qu, W; Taguchi, A; Lu, Y; Avila, C; Kambham, N; Bierhaus, A; Nawroth, P; Neurath, MF; Slattery, T; Beach, D; McClary, J; Nagashima, M; Morser, J; Stern, D; Schmidt, AM			RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides	CELL			English	Article							GLYCATION END-PRODUCTS; CALCIUM-BINDING PROTEINS; ADHESION MOLECULE-1; ALZHEIMERS-DISEASE; CALGRANULIN-C; DIABETIC COMPLICATIONS; NEURITE OUTGROWTH; SOLUBLE RECEPTOR; OXIDANT STRESS; S100 FAMILY	S100/calgranulin polypeptides are present at sites of inflammation, likely released by inflammatory cells targeted to such loci by a range of environmental cues. We report here that receptor for AGE (RAGE) is a central cell surface receptor for EN-RAGE (extracellular newly identified RAGE-binding protein) and related members of the S100/calgranulin superfamily. Interaction of EN-RAGEs with cellular RAGE on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Blockade of EN-RAGE/RAGE quenches delayed-type hypersensitivity and inflammatory colitis in murine models by arresting activation of central signaling pathways and expression of inflammatory gene mediators. These data highlight a novel paradigm in inflammation and identify roles for EN-RAGEs and RAGE in chronic cellular activation and tissue injury.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Berlex Biosci, Richmond, CA 94804 USA; Univ Tubingen, D-72076 Tubingen, Germany; Univ Mainz, D-55101 Mainz, Germany	Columbia University; Eberhard Karls University of Tubingen; Johannes Gutenberg University of Mainz	Schmidt, AM (corresponding author), Columbia Univ Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.			Kambham, Neeraja/0000-0003-1136-3686	NHLBI NIH HHS [HL60901, HL56881] Funding Source: Medline; NIDDK NIH HHS [DK52495] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056881, P01HL060901] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052495] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; DELLANGELICA EC, 1994, J BIOL CHEM, V269, P28929; DUNN CJ, 1993, J PHARMACOL EXP THER, V266, P1691; Geczy C, 1996, BBA-MOL CELL RES, V1313, P246, DOI 10.1016/0167-4889(96)00096-1; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; GOTTSCH JD, 1997, T AM OPTHALMOL SOC, V14, P111; Hitomi J, 1996, J CELL SCI, V109, P805; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; Ilg EC, 1996, BIOCHEM BIOPH RES CO, V225, P146, DOI 10.1006/bbrc.1996.1144; King GL, 1996, ENDOCRIN METAB CLIN, V25, P255, DOI 10.1016/S0889-8529(05)70324-8; KLOTZ IM, 1984, J BIOL CHEM, V259, P60; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Kuehn Ralf, 1993, Cell, V75, P263; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; LI J, 1997, J BIOL CHEM, V271, P16498; Li JF, 1998, J BIOL CHEM, V273, P30870, DOI 10.1074/jbc.273.47.30870; LUGERING N, 1995, EUR J CLIN INVEST, V25, P659, DOI 10.1111/j.1365-2362.1995.tb01982.x; Mackic JB, 1998, J CLIN INVEST, V102, P734, DOI 10.1172/JCI2029; MARSHAK DR, 1992, NEUROBIOL AGING, V13, P1, DOI 10.1016/0197-4580(92)90002-F; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; NEEPER M, 1992, J BIOL CHEM, V267, P14998; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Rammes A, 1997, J BIOL CHEM, V272, P9496; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SCHMIDT AM, 1998, HORM SIGNAL, V1, P41; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUGAYA K, 1994, GENOMICS, V23, P408, DOI 10.1006/geno.1994.1517; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wautier JL, 1996, J CLIN INVEST, V97, P238, DOI 10.1172/JCI118397; Wicki R, 1996, CELL CALCIUM, V20, P459, DOI 10.1016/S0143-4160(96)90087-1; Yamamura T, 1996, BIOCHEM BIOPH RES CO, V221, P356, DOI 10.1006/bbrc.1996.0600; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yan SD, 1997, P NATL ACAD SCI USA, V94, P5296, DOI 10.1073/pnas.94.10.5296; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	42	1527	1602	3	75	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					889	901		10.1016/S0092-8674(00)80801-6	http://dx.doi.org/10.1016/S0092-8674(00)80801-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399917	hybrid			2022-12-24	WOS:000081162800010
J	Teter, SA; Houry, WA; Ang, D; Tradler, T; Rockabrand, D; Fischer, G; Blum, P; Georgopoulos, C; Hartl, FU				Teter, SA; Houry, WA; Ang, D; Tradler, T; Rockabrand, D; Fischer, G; Blum, P; Georgopoulos, C; Hartl, FU			Polypeptide flux through bacterial Hsp70: DnaK cooperates with trigger factor in chaperoning nascent chains	CELL			English	Article							HEAT-SHOCK-PROTEIN; ESCHERICHIA-COLI; MOLECULAR CHAPERONES; IN-VIVO; PRESECRETORY PROTEINS; CELLULAR DEFECTS; GENE; RECOGNITION; SYSTEM; TEMPERATURES	A role for DnaK, the major E. coli Hsp70, in chaperoning de novo protein folding has remained elusive. Here we show that under nonstress conditions DnaK transiently associates with a wide variety of nascent and newly synthesized polypeptides, with a preference for chains larger than 30 kDa. Deletion of the nonessential gene encoding trigger factor, a ribosome-associated chaperone, results in a doubling of the fraction of nascent polypeptides interacting with DnaK. Combined deletion of the trigger factor and DnaK genes is lethal under normal growth conditions. These findings indicate important, partially overlapping functions of DnaK and trigger factor in de novo protein folding and explain why the loss of either chaperone can be tolerated by E. coli.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany; Ctr Med Univ Geneva, Dept Biochim Med, CH-1211 Geneva, Switzerland; Max Planck Gesell Forschungsstelle Enzymol Protei, D-06120 Halle, Germany; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA	Max Planck Society; University of Geneva; Max Planck Society; University of Nebraska System; University of Nebraska Lincoln	Hartl, FU (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.		Hartl, F. Ulrich/Y-8206-2019					ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Ayling A, 1996, PROTEIN SCI, V5, P478; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; BUKAU B, 1990, EMBO J, V9, P4027, DOI 10.1002/j.1460-2075.1990.tb07624.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Chattopadhyay S, 1999, BBA-PROTEIN STRUCT M, V1429, P293, DOI 10.1016/S0167-4838(98)00179-4; Checa SK, 1997, EUR J BIOCHEM, V248, P848, DOI 10.1111/j.1432-1033.1997.00848.x; Eggers DK, 1997, MOL BIOL CELL, V8, P1559, DOI 10.1091/mbc.8.8.1559; Ellis RJ, 1996, FASEB J, V10, P20, DOI 10.1096/fasebj.10.1.8566542; ELLIS RJ, 1993, PHILOS T ROY SOC B, V339, P257, DOI 10.1098/rstb.1993.0023; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Freeman BC, 1996, EMBO J, V15, P2969, DOI 10.1002/j.1460-2075.1996.tb00660.x; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gothel SF, 1998, BIOCHEMISTRY-US, V37, P13392, DOI 10.1021/bi981253w; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hesterkamp T, 1996, P NATL ACAD SCI USA, V93, P4437, DOI 10.1073/pnas.93.9.4437; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; Johnson JL, 1997, CELL, V90, P201, DOI 10.1016/S0092-8674(00)80327-X; Kandror O, 1997, P NATL ACAD SCI USA, V94, P4978, DOI 10.1073/pnas.94.10.4978; Kandror O, 1997, J BIOL CHEM, V272, P1730, DOI 10.1074/jbc.272.3.1730; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KRSKA J, 1993, J BACTERIOL, V175, P6433, DOI 10.1128/jb.175.20.6433-6440.1993; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LILL R, 1988, CELL, V54, P1013, DOI 10.1016/0092-8674(88)90116-X; LLOYD RG, 1985, J BACTERIOL, V164, P836, DOI 10.1128/JB.164.2.836-844.1985; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Rockabrand D, 1998, J BACTERIOL, V180, P846, DOI 10.1128/JB.180.4.846-854.1998; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; Schneider C, 1996, P NATL ACAD SCI USA, V93, P14536, DOI 10.1073/pnas.93.25.14536; Scholz C, 1997, EMBO J, V16, P54, DOI 10.1093/emboj/16.1.54; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; STOLLER G, 1995, EMBO J, V14, P4939, DOI 10.1002/j.1460-2075.1995.tb00177.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Thulasiraman V, 1999, EMBO J, V18, P85, DOI 10.1093/emboj/18.1.85; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VALENT QA, 1995, EMBO J, V14, P5494, DOI 10.1002/j.1460-2075.1995.tb00236.x; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Yoshimune K, 1998, BIOCHEM BIOPH RES CO, V250, P115, DOI 10.1006/bbrc.1998.9255	49	335	340	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					755	765		10.1016/S0092-8674(00)80787-4	http://dx.doi.org/10.1016/S0092-8674(00)80787-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380927	Bronze			2022-12-24	WOS:000080886300013
J	Stampfer, M; Rimm, E				Stampfer, M; Rimm, E			Alcohol and other dietary factors may be important - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY HEART-DISEASE; NUT CONSUMPTION; RISK; FOLATE; WOMEN; FIBER; MEN; PREVENTION; COHORT		Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Stampfer, M (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, 75 Francis St, Boston, MA 02115 USA.	meir.stampfer@channing.harvard.edu						DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; Hu FB, 1998, BMJ-BRIT MED J, V317, P1341, DOI 10.1136/bmj.317.7169.1341; HU FB, IN PRESS AM J CLIN N; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; Liu S, 1998, FASEB J, V12, pA260; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; Parodi PW, 1997, MED HYPOTHESES, V49, P313, DOI 10.1016/S0306-9877(97)90197-3; Pietinen P, 1996, CIRCULATION, V94, P2720, DOI 10.1161/01.CIR.94.11.2720; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472	14	5	5	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	1999	318	7196					1476	1477						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	202TL	10419293				2022-12-24	WOS:000080668200029
J	Ing, AJ; Ngu, MC				Ing, AJ; Ngu, MC			Cough and gastro-oesophageal reflux	LANCET			English	Editorial Material							GASTROESOPHAGEAL REFLUX; DIAGNOSTIC EVALUATION; KEY COMPONENTS; THERAPY; FREQUENCY; SPECTRUM		Concord Hosp, Dept Thorac Med, Concord, NSW, Australia; Concord Hosp, Dept Gastroenterol, Concord, NSW, Australia	Concord Repatriation General Hospital; Concord Repatriation General Hospital	Ing, AJ (corresponding author), Concord Hosp, Dept Thorac Med, Concord, NSW, Australia.			Ing, Alvin/0000-0002-6391-020X				Allen CJ, 1998, THORAX, V53, P963, DOI 10.1136/thx.53.11.963; *AM COLL CHEST PHY, 1998, CHEST, V114, pS133; DEMEESTER TR, 1990, ANN SURG, V211, P337, DOI 10.1097/00000658-199003000-00005; GIUDICELLI R, 1990, ANN CHIR, V47, P552; Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9; ING A J, 1992, American Review of Respiratory Disease, V145, pA11; ING AJ, 1994, AM J RESP CRIT CARE, V149, P160, DOI 10.1164/ajrccm.149.1.8111576; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640, DOI 10.1164/ajrccm/141.3.640; IRWIN RS, 1989, AM REV RESPIR DIS, V140, P1294, DOI 10.1164/ajrccm/140.5.1294; MEIER JH, 1994, DIGEST DIS SCI, V39, P2127, DOI 10.1007/BF02090360; SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991; WARING JP, 1995, DIGEST DIS SCI, V40, P1093	13	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					944	946		10.1016/S0140-6736(98)00354-7	http://dx.doi.org/10.1016/S0140-6736(98)00354-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459900				2022-12-24	WOS:000079421600006
J	Jana, N; Vasishta, K; Saha, SC; Ghosh, K				Jana, N; Vasishta, K; Saha, SC; Ghosh, K			Obstetrical outcomes among women with extrapulmonary tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PULMONARY TUBERCULOSIS; PREGNANCY	Background The prevalence of tuberculosis, especially extrapulmonary tuberculosis, is increasing worldwide. Because information on the outcome of pregnancy among women with extrapulmonary tuberculosis is limited, we studied the course of pregnancy and labor and the perinatal outcome in these women and their infants. Methods From 1983 to 1993, we followed 33 pregnant women who had extrapulmonary tuberculosis (12 with tuberculous lymphadenitis and 9 with intestinal, 7 with skeletal, 2 with renal, 2 with meningeal, and 1 with endometrial tuberculosis) through their deliveries. Of the 33, 29 received antituberculosis treatment during pregnancy. The antenatal complications, intrapartum events, and perinatal outcomes were compared with those among 132 healthy pregnant women without tuberculosis who were matched for age, parity, and socioeconomic status. Results Tuberculous lymphadenitis did not affect the course of pregnancy or labor or the perinatal outcome. However, as compared with the control women, the 21 women with tubercular involvement of other extrapulmonary sites had higher rates of antenatal hospitalization (24 percent vs. 2 percent, P< 0.001), infants with low Apgar scores (less than or equal to 6) soon after birth (19 percent vs. 3 percent, P=0.01), and low-birth-weight (<2500 g) infants (33 percent vs. 11 percent, P=0.01). Conclusions Extrapulmonary tuberculosis that is confined to the lymph nodes has no effect on obstetrical outcomes, but tuberculosis at other extrapulmonary sites does adversely affect the outcome of pregnancy. (N Engl J Med 1999;341:645-9.) (C) 1999, Massachusetts Medical Society.	Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India; Mem Hosp, Dept Obstet & Gynaecol, Darlington, Durham, England; W Middlesex Univ Hosp, Dept Obstet & Gynaecol, Isleworth, Middx, England	Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh; Imperial College London	Vasishta, K (corresponding author), Postgrad Inst Med Educ & Res, Dept Obstet & Gynaecol, Chandigarh 160012, India.		JANA, NARAYAN/AAE-5437-2020					BROOKS JH, 1986, BRIT J OBSTET GYNAEC, V93, P1009, DOI 10.1111/j.1471-0528.1986.tb08027.x; CASPER GR, 1995, AUST NZ J OBSTET GYN, V35, P398, DOI 10.1111/j.1479-828X.1995.tb02151.x; CUNNINGHAM FG, 1993, WILLIAMS OBSTETRICS, P1083; DARBYSHIRE JH, 1995, BRIT MED J, V310, P954, DOI 10.1136/bmj.310.6985.954; DAVIES PDO, 1993, THORAX, V48, P193, DOI 10.1136/thx.48.3.193; DWYER DE, 1987, AUST NZ J MED, V17, P507, DOI 10.1111/j.1445-5994.1987.tb00110.x; FARER LS, 1979, AM J EPIDEMIOL, V109, P205, DOI 10.1093/oxfordjournals.aje.a112675; GOVENDER S, 1989, S AFR MED J, V75, P190; Hayward A C, 1995, Commun Dis Rep CDR Rev, V5, pR29; JANA N, 1994, INT J GYNECOL OBSTET, V44, P119, DOI 10.1016/0020-7292(94)90064-7; KINGDOM JCP, 1989, BRIT J OBSTET GYNAEC, V96, P233, DOI 10.1111/j.1471-0528.1989.tb01668.x; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; LAU SK, 1991, J LARYNGOL OTOL, V105, P558, DOI 10.1017/S0022215100116603; MARGONO F, 1994, OBSTET GYNECOL, V83, P911, DOI 10.1097/00006250-199406000-00001; SCHAEFER G, 1954, AM J OBSTET GYNECOL, V67, P605, DOI 10.1016/0002-9378(54)90050-2; SIMPSON ML, 1989, ORTHOPAEDIC INFECT D, P205; SNIDER DE, 1980, AM REV RESPIR DIS, V122, P65; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; TULI SM, 1991, TUBERCULOSIS SKELETA, P162; VARMA TR, 1991, INT J GYNECOL OBSTET, V35, P1, DOI 10.1016/0020-7292(91)90056-B; *WHO, 1993, TREATM TUB GUID NAT, P3; 1985, INDIAN J TUBERC, V32, P115	22	76	80	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1999	341	9					645	649		10.1056/NEJM199908263410903	http://dx.doi.org/10.1056/NEJM199908263410903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	229JY	10460815	Bronze			2022-12-24	WOS:000082192500003
J	Luo, RZT; Beniac, DR; Fernandes, A; Yip, CC; Ottensmeyer, FP				Luo, RZT; Beniac, DR; Fernandes, A; Yip, CC; Ottensmeyer, FP			Quaternary structure of the insulin-insulin receptor complex	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE; CRYSTAL-STRUCTURE; BINDING; DOMAIN; IMAGES; FAMILY; SITE	The three-dimensional (3D) structure of the intrinsically dimeric insulin receptor bound to its ligand, insulin, was determined by electron cryomicroscopy. Gold-labeled insulin served to locate the insulin-binding domain. The 3D structure was then fitted with available known high-resolution domain substructures to obtain a detailed contiguous model for this heterotetrameric transmembrane receptor. The 3D reconstruction indicates that the two alpha subunits jointly participate in insulin binding and that the kinase domains in the two beta subunits are in a juxtaposition that permits autophosphorylation of tyrosine residues in the first step of insulin receptor activation.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Yip, CC (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.							BAJAJ M, 1987, BIOCHIM BIOPHYS ACTA, V916, P220, DOI 10.1016/0167-4838(87)90112-9; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; CANALS F, 1992, BIOCHEMISTRY-US, V31, P4493, DOI 10.1021/bi00133a016; CHRISTENSEN C, 1998, J BIOL CHEM, V273, P17780; CZARNOTA GJ, 1994, J STRUCT BIOL, V113, P35, DOI 10.1006/jsbi.1994.1030; DEMEYTS P, 1976, J BIOL CHEM, V251, P1877; DEMEYTS P, 1993, EXP CLIN ENDOCRINOL, V101, P17; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EGERTON RF, 1996, ELECT ENERGY LOSS SP, P145; FABRY M, 1992, J BIOL CHEM, V267, P8950; FARROW NA, 1992, J OPT SOC AM A, V9, P1749, DOI 10.1364/JOSAA.9.001749; FARROW NA, 1993, ULTRAMICROSCOPY, V52, P141, DOI 10.1016/0304-3991(93)90185-Z; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GEIGER R, 1971, Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, V352, P1487, DOI 10.1515/bchm2.1971.352.2.1487; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Mulhern TD, 1998, TRENDS BIOCHEM SCI, V23, P465, DOI 10.1016/S0968-0004(98)01288-2; MURRAYRUST J, 1992, BIOESSAYS, V14, P325, DOI 10.1002/bies.950140507; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SCHAFFER L, 1993, EXP CLIN ENDOCRINOL, V101, P7; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Smith GD, 1996, PROTEIN SCI, V5, P1502, DOI 10.1002/pro.5560050806; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; UILRICH A, 1990, CELL, V61, P203; WHITE MF, 1994, J BIOL CHEM, V269, P1; YIP CC, 1992, J CELL BIOCHEM, V48, P19, DOI 10.1002/jcb.240480105	28	106	113	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 13	1999	285	5430					1077	1080		10.1126/science.285.5430.1077	http://dx.doi.org/10.1126/science.285.5430.1077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QV	10446056				2022-12-24	WOS:000082033100049
J	Sassone-Corsi, P; Mizzen, CA; Cheung, P; Crosio, C; Monaco, L; Jacquot, S; Hanauer, A; Allis, CD				Sassone-Corsi, P; Mizzen, CA; Cheung, P; Crosio, C; Monaco, L; Jacquot, S; Hanauer, A; Allis, CD			Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3	SCIENCE			English	Article							MITOTIC CHROMOSOME CONDENSATION; PROTEIN; TRANSCRIPTION; PP90(RSK); KINASES; SIGNAL; CBP; MAP; ACETYLTRANSFERASE; HYPERACETYLATION	During the immediate-early response of mammalian cells to mitogens, histone H3 is rapidly and transiently phosphorylated by one or more unidentified kinases. Rsk-2, a member of the pp90(rsk) family of kinases implicated in growth control, was required for epidermal growth factor (EGF)-stimulated phosphorylation of H3. RSK-2 mutations in humans are Linked to Coffin-Lowry syndrome (CLS). Fibroblasts derived from a CLS patient failed to exhibit EGF-stimulated phosphorylation of H3, although H3 was phosphorylated during mitosis. Introduction of the wild-type RSK-2 gene restored EGF-stimulated phosphorylation of H3 in CLS cells. In addition, disruption of the RSK-2 gene by homologous recombination in murine embryonic stem cells abolished EGF-stimulated phosphorylation of H3. H3 appears to be a direct or indirect target of Rsk-2, suggesting that chromatin remodeling might contribute to mitogen-activated protein kinase-regulated gene expression.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Strasbourg, France; Univ Virginia, Dept Mol Genet & Biochem, Charlottesville, VA 22908 USA	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Virginia	Sassone-Corsi, P (corresponding author), ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, BP 163, F-67404 Illkirch Strasbourg, France.		Monaco, Lucia/A-4031-2010; Sassone-Corsi, Paolo/H-6182-2011		NIGMS NIH HHS [GM40922] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALLIS CD, UNPUB; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADBURY EM, 1992, BIOESSAYS, V14, P9; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CHADEE DN, IN PRESS J BIOL CHEM; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; De Cesare D, 1998, P NATL ACAD SCI USA, V95, P12202, DOI 10.1073/pnas.95.21.12202; Dierich A, 1997, METHODS IN DEVELOPMENTAL TOXICOLOGY AND BIOLOGY, P111; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Felsenfeld G, 1996, CELL, V86, P13, DOI 10.1016/S0092-8674(00)80073-2; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Jacquot S, 1998, AM J HUM GENET, V63, P1631, DOI 10.1086/302153; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; SASSONECORSI P, UNPUB; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Wei Y, 1998, P NATL ACAD SCI USA, V95, P7480, DOI 10.1073/pnas.95.13.7480; Wolffe AP, 1997, BIOCHEM SOC T, V25, P354, DOI 10.1042/bst0250354; Zhao Y, 1996, J BIOL CHEM, V271, P29773, DOI 10.1074/jbc.271.47.29773; ZHAO Y, 1995, MOL CELL BIOL, V15, P4353	29	405	418	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 6	1999	285	5429					886	891		10.1126/science.285.5429.886	http://dx.doi.org/10.1126/science.285.5429.886			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436156				2022-12-24	WOS:000081860900048
J	Winzeler, EA; Shoemaker, DD; Astromoff, A; Liang, H; Anderson, K; Andre, B; Bangham, R; Benito, R; Boeke, JD; Bussey, H; Chu, AM; Connelly, C; Davis, K; Dietrich, F; Dow, SW; EL Bakkoury, M; Foury, F; Friend, SH; Gentalen, E; Giaever, G; Hegemann, JH; Jones, T; Laub, M; Liao, H; Liebundguth, N; Lockhart, DJ; Lucau-Danila, A; Lussier, M; M'Rabet, N; Menard, P; Mittmann, M; Pai, C; Rebischung, C; Revuelta, JL; Riles, L; Roberts, CJ; Ross-MacDonald, P; Scherens, B; Snyder, M; Sookhai-Mahadeo, S; Storms, RK; Veronneau, S; Voet, M; Volckaert, G; Ward, TR; Wysocki, R; Yen, GS; Yu, KX; Zimmermann, K; Philippsen, P; Johnston, M; Davis, RW				Winzeler, EA; Shoemaker, DD; Astromoff, A; Liang, H; Anderson, K; Andre, B; Bangham, R; Benito, R; Boeke, JD; Bussey, H; Chu, AM; Connelly, C; Davis, K; Dietrich, F; Dow, SW; EL Bakkoury, M; Foury, F; Friend, SH; Gentalen, E; Giaever, G; Hegemann, JH; Jones, T; Laub, M; Liao, H; Liebundguth, N; Lockhart, DJ; Lucau-Danila, A; Lussier, M; M'Rabet, N; Menard, P; Mittmann, M; Pai, C; Rebischung, C; Revuelta, JL; Riles, L; Roberts, CJ; Ross-MacDonald, P; Scherens, B; Snyder, M; Sookhai-Mahadeo, S; Storms, RK; Veronneau, S; Voet, M; Volckaert, G; Ward, TR; Wysocki, R; Yen, GS; Yu, KX; Zimmermann, K; Philippsen, P; Johnston, M; Davis, RW			Functional characterization of the S-cerevisiae genome by gene deletion and parallel analysis	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; YEAST GENOME; DNA-SEQUENCE; PROTEIN; IDENTIFICATION; DISRUPTION; EXPRESSION; LOCALIZATION; REDUCTASE	The functions of many open reading frames (ORFs) identified in genome-sequencing projects are unknown. New, whole-genome approaches are required to systematically determine their function. A total of 6925 Saccharomyces cerevisiae strains were constructed, by a high-throughput strategy, each with a precise deletion of one of 2026 ORFs (more than one-third of the ORFs in the genome). Of the deleted ORFs, 17 percent were essential for viability in rich medium. The phenotypes of more than 500 deletion strains were assayed in parallel. Of the deletion strains, 40 percent showed quantitative growth defects in either rich or minimal medium.	Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Rosetta Inpharmat Inc, Kirkland, WA 98034 USA; Free Univ Brussels, Lab Physiol Cellulaire & Genet Levures, Brussels, Belgium; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Salamanca, Dipartimento Microbiol & Genet, Edificio Dept 323, CSIC, E-37007 Salamanca, Spain; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; McGill Univ, Dept Biol, Montreal, PQ H3A 1B1, Canada; Univ Basel, Biozentrum, Dept Mol Microbiol, CH-4003 Basel, Switzerland; ULB, IRMW, B-1070 Brussels, Belgium; Catholic Univ Louvain, FYSA, B-1348 Louvain, Belgium; Affymetrix, Santa Clara, CA 95051 USA; Inst Microbiol, D-40225 Dusseldorf, Germany; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium	Stanford University; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Yale University; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Johns Hopkins University; McGill University; University of Basel; Universite Libre de Bruxelles; Universite Catholique Louvain; Affymetrix; Washington University (WUSTL); KU Leuven	Davis, RW (corresponding author), Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	dbowe@cmgm.stanford.edu	Johnston, Mark/R-6156-2019; Storms, Reginald/B-2405-2013; Winzeler, Elizabeth/AAP-6752-2020; Johnston, Mark/K-3543-2019; BENITO, ROCIO/B-4271-2017; André, Bruno/D-1725-2010; Revuelta, Jose L/C-2324-2012; Revuelta, Jose Luis/ABG-1502-2020; Lucau-Danila, Anca/AAE-7674-2021; Zhang, Ning/F-1387-2014	Winzeler, Elizabeth/0000-0002-4049-2113; Johnston, Mark/0000-0002-4932-7229; BENITO, ROCIO/0000-0001-9781-4198; Revuelta, Jose L/0000-0001-7838-5308; Revuelta, Jose Luis/0000-0001-7838-5308; LUCAU-DANILA, Anca/0000-0002-9379-6241; Gentalen, Erik/0000-0002-7982-2431; Menard, Patrice/0000-0001-8844-3727; Wysocki, Robert/0000-0002-3274-2629; Snyder, Michael/0000-0003-0784-7987	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001627, R01HG001633] Funding Source: NIH RePORTER; NHGRI NIH HHS [HG01627, HG00185-02, HG01633] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Baganz F, 1998, YEAST, V14, P1417, DOI 10.1002/(SICI)1097-0061(199811)14:15<1417::AID-YEA334>3.0.CO;2-N; Bassett DE, 1997, NAT GENET, V15, P339, DOI 10.1038/ng0497-339; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bickle M, 1998, EMBO J, V17, P2235, DOI 10.1093/emboj/17.8.2235; Brachmann CB, 1998, YEAST, V14, P115; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; CHOW TYK, 1992, J CELL SCI, V101, P709; COROMINAS J, 1992, FEBS LETT, V310, P182, DOI 10.1016/0014-5793(92)81325-G; Du LL, 1998, J BIOL CHEM, V273, P3253, DOI 10.1074/jbc.273.6.3253; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Foury F, 1997, GENE, V195, P1, DOI 10.1016/S0378-1119(97)00140-6; Giaever G, 1999, NAT GENET, V21, P278, DOI 10.1038/6791; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; KASAHARA S, 1994, J BACTERIOL, V176, P1488, DOI 10.1128/jb.176.5.1488-1499.1994; LASHKARI DA, 1995, P NATL ACAD SCI USA, V92, P7912, DOI 10.1073/pnas.92.17.7912; Leidich SD, 1996, J BIOL CHEM, V271, P27829, DOI 10.1074/jbc.271.44.27829; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Machado AK, 1997, J BIOL CHEM, V272, P17045, DOI 10.1074/jbc.272.27.17045; Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28; NIEDENTHAL R, IN PRESS YEAST; PEASE AC, 1994, P NATL ACAD SCI USA, V91, P5022, DOI 10.1073/pnas.91.11.5022; Rad MR, 1997, YEAST, V13, P281; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; SANTOS MA, 1995, J BIOL CHEM, V270, P437, DOI 10.1074/jbc.270.1.437; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SMITH V, 1995, P NATL ACAD SCI USA, V92, P6479, DOI 10.1073/pnas.92.14.6479; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Storms RK, 1997, GENOME, V40, P151, DOI 10.1139/g97-022; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85	37	3049	3191	3	183	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1999	285	5429					901	906		10.1126/science.285.5429.901	http://dx.doi.org/10.1126/science.285.5429.901			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	223UX	10436161				2022-12-24	WOS:000081860900053
J	Yoshida, H; Shiratori, Y; Moriyama, M; Arakawa, Y; Ide, T; Sata, M; Inoue, O; Yano, M; Tanaka, M; Fujiyama, S; Nishiguchi, S; Kuroki, T; Imazeki, F; Yokosuka, O; Kinoyama, S; Yamada, G; Omata, M				Yoshida, H; Shiratori, Y; Moriyama, M; Arakawa, Y; Ide, T; Sata, M; Inoue, O; Yano, M; Tanaka, M; Fujiyama, S; Nishiguchi, S; Kuroki, T; Imazeki, F; Yokosuka, O; Kinoyama, S; Yamada, G; Omata, M		IHIT Study Grp	Interferon therapy reduces the risk for hepatocellular carcinoma: National surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C; carcinoma, hepatocellular; interferon; liver cirrhosis; alanine aminotransferase	POLYMERASE CHAIN-REACTION; PLACEBO-CONTROLLED TRIAL; NON-B-HEPATITIS; VIRUS-RNA; NON-A; SUSTAINED RESPONSE; LIVER-DISEASE; ALFA THERAPY; DOUBLE-BLIND; EFFICACY	Background: Previous studies on the effect of interferon therapy on the incidence of hepatocellular carcinoma have not sufficiently assessed degree of liver fibrosis, a major risk factor for hepatocellular carcinoma. Objective: To evaluate the effect of interferon therapy on incidence of hepatocellular carcinoma, adjusting for risk factors, including the degree of liver fibrosis. Design: Retrospective cohort study. Setting: Seven university hospitals and one regional core hospital in Japan. Patients: 2890 patients with chronic hepatitis C who had undergone liver biopsy since 1986. Of these patients, 2400 received interferon and 490 were untreated. Measurements: The degree of liver fibrosis was assessed from stage F0 (no fibrosis) to stage F4 (cirrhosis). Response to interferon was determined virologically and biochemically. Screening for development of hepatocellular carcinoma was performed periodically during an average follow-up of 4.3 years. Effect of interferon therapy on the risk for hepatocellular carcinoma was analyzed by using Cox proportional hazards regression. Results: Hepatocellular carcinoma developed in 89 interferon-treated patients and in 59 untreated patients. Among untreated patients, the annual incidence of hepatocellular carcinoma increased with the degree of liver fibrosis, from 0.5% among patients with stage F0 or F1 fibrosis to 7.9% among patients with stage F4 fibrosis. The cumulative incidence in treated and untreated patients differed significantly for patients with stage F2 fibrosis (P = 0.0128) and for those with stage F3 fibrosis (P = 0.0011). In multivariate analysis, interferon therapy was associated with a reduced risk for hepatocellular carcinoma (adjusted risk ratio, 0.516 [95% CI, 0.358 to 0.742]; P < 0.001), especially among patients with sustained virologic response (risk ratio, 0.197 [CI, 0.099 to 0.392]), among those with persistently normal serum alanine aminotransferase levels (risk ratio, 0.197 [CI, 0.104 to 0.375]), and among those with alanine aminotransferase levels less than two times the upper limit of normal (risk ratio, 0.358 [CI, 0.206 to 0.622]). Conclusions: Interferon therapy significantly reduces the risk for hepatocellular carcinoma, especially among virologic or biochemical responders.	Univ Tokyo, Dept Gastroenterol, Tokyo 1138655, Japan; Univ Tokyo, Dept Gastroenterol, Tokyo 113, Japan; Nihon Univ, Dept Internal Med 3, Tokyo 173, Japan; Kurume Univ, Dept Internal Med 2, Fukuoka 830, Japan; Nagasaki Chuo Natl Hosp, Dept Clin Res, Nagasaki 856, Japan; Kumamoto Univ, Dept Internal Med 3, Kumamoto 860, Japan; Osaka City Univ, Dept Internal Med 3, Osaka 545, Japan; Chiba Univ, Dept Internal Med 1, Chiba 260, Japan; Kawasaki Med Sch, Ctr Liver, Okayama 700, Japan	University of Tokyo; University of Tokyo; Nihon University; Kurume University; Kumamoto University; Osaka Metropolitan University; Chiba University; Kawasaki Medical School	Yoshida, H (corresponding author), Univ Tokyo, Dept Gastroenterol, Hongo 7-3-1, Tokyo 1138655, Japan.	yoshida-2im@h.u-tokyo.ac.jp						Chemello L, 1996, ANN INTERN MED, V124, P1058, DOI 10.7326/0003-4819-124-12-199606150-00005; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; DIBISCEGLIE AM, 1995, SEMIN LIVER DIS, V15, P64, DOI 10.1055/s-2007-1007263; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Kasahara A, 1998, HEPATOLOGY, V27, P1394, DOI 10.1002/hep.510270529; KATO N, 1993, HEPATOLOGY, V18, P16, DOI 10.1002/hep.1840180104; KATO Y, 1994, CANCER, V74, P2234, DOI 10.1002/1097-0142(19941015)74:8<2234::AID-CNCR2820740805>3.0.CO;2-6; KAWANO SI, 1994, J GASTROEN HEPATOL, V9, P217, DOI 10.1111/j.1440-1746.1994.tb01712.x; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OMATA M, 1991, DIGEST DIS SCI, V36, P1217, DOI 10.1007/BF01307512; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1996, HEPATOLOGY, V24, P778; REICHARD O, 1995, HEPATOLOGY, V21, P918, DOI 10.1016/0270-9139(95)90234-1; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Shiratori Y, 1997, GASTROENTEROLOGY, V113, P558, DOI 10.1053/gast.1997.v113.pm9247476; Shiratori Y, 1996, J GASTROEN HEPATOL, V11, P705, DOI 10.1111/j.1440-1746.1996.tb00318.x; Silini E, 1996, GASTROENTEROLOGY, V111, P199, DOI 10.1053/gast.1996.v111.pm8698200; TAKANO S, 1994, GASTROENTEROLOGY, V107, P805, DOI 10.1016/0016-5085(94)90130-9; TAKANO S, 1995, HEPATOLOGY, V21, P650; TAKEDA T, 1993, GASTROENTEROL JPN, V28, P104, DOI 10.1007/BF02989218; TANAKA E, 1995, J GASTROEN HEPATOL, V10, P538, DOI 10.1111/j.1440-1746.1995.tb01344.x; TANAKA T, 1994, HEPATOLOGY, V19, P1347, DOI 10.1016/0270-9139(94)90226-7; Tarao K, 1997, CANCER, V79, P688, DOI 10.1002/(SICI)1097-0142(19970215)79:4<688::AID-CNCR5>3.0.CO;2-A; YAMADA G, 1993, GUT, V34, pS133, DOI 10.1136/gut.34.2_Suppl.S133; YAMADA G, 1995, HEPATOLOGY, V22, P1351, DOI 10.1002/hep.1840220502; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; YOKOSUKA O, 1995, GUT, V37, P721, DOI 10.1136/gut.37.5.721; Yoshida H, 1996, RECENT ADVANCES IN GASTROENTEROLOGICAL CARCINOGENESIS I, P543	36	900	931	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 3	1999	131	3					174	+		10.7326/0003-4819-131-3-199908030-00003	http://dx.doi.org/10.7326/0003-4819-131-3-199908030-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	222ME	10428733				2022-12-24	WOS:000081788700002
J	Kondrashov, AS; Kondrashov, FA				Kondrashov, AS; Kondrashov, FA			Interactions among quantitative traits in the course of sympatric speciation	NATURE			English	Article							SEXUAL SELECTION; LAKE-VICTORIA; MODEL; EVOLUTION; CICHLIDS; BARBS	Sympatric speciation, the origin of two or more species from a single local population, has almost certainly been involved in formation of several species flocks(1-4), and may be fairly common in nature(5). The most straightforward scenario for sympatric speciation requires disruptive selection favouring two substantially different phenotypes, and consists of the evolution of reproductive isolation between them followed by the elimination of all intermediate phenotypes(6). Here we use the hypergeometric phenotypic model(7-10) to show that sympatric speciation is possible even when fitness and mate choice depend on different quantitative traits, so that speciation must involve formation of covariance between these traits. The increase in the number of variable loci affecting fitness facilitates sympatric speciation, whereas the increase in the number of variable loci affecting mate choice has the opposite effect. These predictions may enable more cases of sympatric speciation to be identified.	Simons Rock Coll, Great Barrington, MA 01230 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Kondrashov, FA (corresponding author), Simons Rock Coll, 84 Alford Rd, Great Barrington, MA 01230 USA.		Kondrashov, Fyodor Alexeevich/H-6331-2015	Kondrashov, Fyodor Alexeevich/0000-0001-8243-4694				AXELROD HR, 1996, MOST COMPLETE COLORE; BARTON NH, 1992, EVOLUTION, V46, P551, DOI [10.2307/2409871, 10.1111/j.1558-5646.1992.tb02058.x]; Berrebi P, 1998, BIOL J LINN SOC, V64, P369; Darwin C., 1859, ORIGIN SPECIES MEANS; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Galis F, 1998, TRENDS ECOL EVOL, V13, P1, DOI 10.1016/S0169-5347(97)01239-1; Johnson TC, 1996, SCIENCE, V273, P1091, DOI 10.1126/science.273.5278.1091; KARLIN S, 1975, THEOR POPUL BIOL, V7, P364, DOI 10.1016/0040-5809(75)90025-8; Kondrashov AS, 1998, P ROY SOC B-BIOL SCI, V265, P2273, DOI 10.1098/rspb.1998.0570; KONDRASHOV AS, 1986, THEOR POPUL BIOL, V29, P1, DOI 10.1016/0040-5809(86)90002-X; KONDRASHOV AS, 1986, BIOL J LINN SOC, V27, P201, DOI 10.1111/j.1095-8312.1986.tb01734.x; KONDRASHOV AS, 1984, GENETIKA+, V20, P408; Kondrashov AS, 1998, ENDLESS FORMS, P90; Lewontin R.C., 1966, SYST ZOOL, V15, P141, DOI [10.2307/sysbio/15.2.141, DOI 10.2307/SYSBIO/15.2.141, DOI 10.2307/2411632]; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; Mina MV, 1996, J FISH BIOL, V48, P383, DOI 10.1111/j.1095-8649.1996.tb01435.x; RICE WR, 1984, EVOLUTION, V38, P1251, DOI 10.1111/j.1558-5646.1984.tb05647.x; RICE WR, 1993, EVOLUTION, V47, P1637, DOI 10.1111/j.1558-5646.1993.tb01257.x; Ritchie MG, 1998, ENDLESS FORMS, P291; SCHLIEWEN UK, 1994, NATURE, V368, P629, DOI 10.1038/368629a0; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Seehausen O, 1998, BEHAV ECOL SOCIOBIOL, V42, P1, DOI 10.1007/s002650050405; Shpak M, 1999, EVOLUTION, V53, P600, DOI 10.1111/j.1558-5646.1999.tb03794.x; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093; van Doorn GS, 1998, P ROY SOC B-BIOL SCI, V265, P1915, DOI 10.1098/rspb.1998.0520; Wallace A.R., 1989, DARWINISM	27	418	431	3	82	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 22	1999	400	6742					351	354		10.1038/22514	http://dx.doi.org/10.1038/22514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219CH	10432111				2022-12-24	WOS:000081590000046
J	Ghose, RP; Hall, PM; Bravo, EL				Ghose, RP; Hall, PM; Bravo, EL			Medical management of aldosterone-producing adenomas	ANNALS OF INTERNAL MEDICINE			English	Article						aldosterone; adenoma; hypertension; potassium; aldosteronism	DIAGNOSIS	Background: No data are available on the long-term medical management of aldosterone-producing adenomas. Objective: To demonstrate the efficacy of medical management of aldosterone-producing adenomas in terms of blood pressure and serum potassium concentration and to discuss morbidity associated with medical management. Design: Retrospective cohort study. Setting: Large tertiary care referral center. Patients: 24 patients with documented aldosterone-producing adenomas who were treated medically for at least 5 years. Measurements: Aldosterone excretion rate, plasma renin activity, and size and location of adenomas (by computed tomography). Blood pressure and serum electrolytes were measured at the time of diagnosis and last follow-up. Results: From the time of diagnosis to the time of last follow-up, systolic blood pressure decreased from 175 mm Hg to 129 mm Hg (95% CI for difference, 37.1 to 53.8 mm Hg) and diastolic blood pressure decreased from 106 mm Hg to 79 mm Hg (CI for difference, 20.8 to 33.9 mm Hg). Serum potassium concentration increased from 3.0 mmol/L to 4.3 mmol/L (CI for difference, 1.1 to 1.5 mmol/L). Conclusions: Medical management of aldosterone-producing adenomas is a viable option for controlling blood pressure and serum potassium concentration.	Cleveland Clin Fdn, Dept Hypertens & Nephrol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hall, PM (corresponding author), Cleveland Clin Fdn, Dept Hypertens & Nephrol, 9500 Euclid Ave,Desk A101, Cleveland, OH 44195 USA.	hallpm@ccf.org						BRAVO EL, 1983, AM J MED, V74, P641, DOI 10.1016/0002-9343(83)91022-7; BRAVO EL, 1993, CLEV CLIN J MED, V60, P379; BRAVO EL, 1988, HYPERTENSION, V11, P207; CONN JN, 1965, J LAB CLIN MED, V45, P3; LITCHFIELD WR, 1995, ENDOCRIN METAB CLIN, V24, P593, DOI 10.1016/S0889-8529(18)30033-1; Lo CY, 1996, ANN SURG, V224, P125, DOI 10.1097/00000658-199608000-00003; Quarmby CJ, 1995, S AFR MED J, V85, P1353; YOUNG WF, 1990, MAYO CLIN PROC, V65, P96, DOI 10.1016/S0025-6196(12)62114-4	8	88	91	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 20	1999	131	2					105	+		10.7326/0003-4819-131-2-199907200-00005	http://dx.doi.org/10.7326/0003-4819-131-2-199907200-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217QD	10419425				2022-12-24	WOS:000081509700004
J	Caceres, M; Ranz, JM; Barbadilla, A; Long, M; Ruiz, A				Caceres, M; Ranz, JM; Barbadilla, A; Long, M; Ruiz, A			Generation of a widespread Drosophila inversion by a transposable element	SCIENCE			English	Article							EVOLUTIONARY HISTORY; MOLECULAR CHARACTERIZATION; CHROMOSOME REARRANGEMENTS; BODY-SIZE; MELANOGASTER; BUZZATII; POPULATIONS; HOBO; RECOMBINATION; BREAKPOINTS	Although polymorphic inversions in Drosophila are very common, the origin of these chromosomal rearrangements is unclear. The breakpoints of the cosmopolitan inversion 2j of D. buzzatii were cloned and sequenced. Both breakpoints contain large insertions corresponding to a transposable element. It appears that the two pairs of target site duplications generated upon insertion were exchanged during the inversion event, and that the inversion arose by ectopic recombination between two copies of the transposon that were in opposite orientations. This is apparently the mechanism by which transposable elements generate natural inversions in Drosophila.	Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain; Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	Autonomous University of Barcelona; University of Chicago	Caceres, M (corresponding author), Univ Autonoma Barcelona, Dept Genet & Microbiol, E-08193 Barcelona, Spain.		jose, ranz/A-5432-2008; Ruiz, Alfredo/ABH-2402-2020; Barbadilla, Antonio/A-6915-2017; Cáceres, Mario/A-6379-2009	Barbadilla, Antonio/0000-0002-0374-1475; Cáceres, Mario/0000-0002-7736-3251				[Anonymous], 1992, DROSOPHILA INVERSION; BARKER JSF, 1994, GENETICA, V92, P165, DOI 10.1007/BF00132535; Betran E, 1998, EVOLUTION, V52, P144, DOI [10.2307/2410929, 10.1111/j.1558-5646.1998.tb05147.x]; BRAND S, 1993, NUCLEIC ACIDS RES, V21, P3699, DOI 10.1093/nar/21.16.3699; BUSSEAU I, 1989, MOL GEN GENET, V218, P222, DOI 10.1007/BF00331272; CAPY P, 1998, DYNAMICS EVOLUTION T; CIRERA S, 1995, GENETICS, V139, P321; Daveran-Mingot ML, 1998, J BACTERIOL, V180, P4834, DOI 10.1128/JB.180.18.4834-4842.1998; DOMBRADI V, 1990, EUR J BIOCHEM, V194, P739, DOI 10.1111/j.1432-1033.1990.tb19464.x; Eggleston WB, 1996, GENETICS, V144, P647; ENGELS WR, 1990, CELL, V62, P515, DOI 10.1016/0092-8674(90)90016-8; ENGELS WR, 1984, GENETICS, V107, P657; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; FONTDEVILA A, 1981, EVOLUTION, V35, P148, DOI 10.1111/j.1558-5646.1981.tb04867.x; HASSON E, 1995, J EVOLUTION BIOL, V8, P369, DOI 10.1046/j.1420-9101.1995.8030369.x; KOMODA Y, 1991, GENETICS, V129, P639; Ladeveze V, 1998, P ROY SOC B-BIOL SCI, V265, P1157, DOI 10.1098/rspb.1998.0412; LAKICH D, 1993, NAT GENET, V5, P236, DOI 10.1038/ng1193-236; LIM JK, 1994, BIOESSAYS, V16, P269, DOI 10.1002/bies.950160410; LYTTLE TW, 1992, GENETICA, V86, P113, DOI 10.1007/BF00133715; MARIN I, 1995, MOL GEN GENET, V248, P423, DOI 10.1007/BF02191642; Mathiopoulos KD, 1998, P NATL ACAD SCI USA, V95, P12444, DOI 10.1073/pnas.95.21.12444; MONTGOMERY EA, 1991, GENETICS, V129, P1085; NASSIF N, 1993, P NATL ACAD SCI USA, V90, P1262, DOI 10.1073/pnas.90.4.1262; NAYLOR JA, 1995, HUM MOL GENET, V4, P1217, DOI 10.1093/hmg/4.7.1217; Nei M, 1987, MOL EVOLUTIONARY GEN; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PETES TD, 1988, ANNU REV GENET, V22, P147, DOI 10.1146/annurev.ge.22.120188.001051; PLASTERK RHA, 1991, EMBO J, V10, P1919, DOI 10.1002/j.1460-2075.1991.tb07718.x; Powell J.R., 1997, PROGR PROSPECTS EVOL; Ranz JM, 1999, CHROMOSOMA, V108, P32; Ranz JM, 1997, GENETICS, V145, P281; ROEDER GS, 1983, MOBILE GENETIC ELEME, P299; Rost A.K., 1995, QUANTITATION MRNA PO, P93; RUIZ A, 1991, GENETICS, V128, P739; RUIZ A, 1993, HEREDITY, V70, P582, DOI 10.1038/hdy.1993.85; Ruiz A., 1984, Genetica Iberica, V36, P13; SAWRUK E, 1990, FEBS LETT, V273, P177, DOI 10.1016/0014-5793(90)81078-3; SCHNEUWLY S, 1987, EMBO J, V6, P201, DOI 10.1002/j.1460-2075.1987.tb04739.x; Small K, 1997, NAT GENET, V16, P96, DOI 10.1038/ng0597-96; STRECK RD, 1986, EMBO J, V5, P3615, DOI 10.1002/j.1460-2075.1986.tb04690.x; TAKASUISHIKAWA E, 1992, MOL GEN GENET, V232, P17, DOI 10.1007/BF00299132; WESLEY CS, 1994, P NATL ACAD SCI USA, V91, P3132, DOI 10.1073/pnas.91.8.3132; WOJTAS KM, 1992, GENETICS, V132, P789	44	163	166	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 16	1999	285	5426					415	418		10.1126/science.285.5426.415	http://dx.doi.org/10.1126/science.285.5426.415			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	216VV	10411506				2022-12-24	WOS:000081465900057
J	Drickamer, MA				Drickamer, MA			Commentary: Honesty is the best policy	BRITISH MEDICAL JOURNAL			English	Editorial Material									Yale Univ, Sch Med, New Haven, CT 06504 USA	Yale University	Drickamer, MA (corresponding author), Yale Univ, Sch Med, 20 York St, New Haven, CT 06504 USA.							Hall MA, 1998, ANN INTERN MED, V128, P395, DOI 10.7326/0003-4819-128-5-199803010-00009; Kitchens LW, 1998, ANN INTERN MED, V128, P576, DOI 10.7326/0003-4819-128-7-199804010-00012; SULMASY DP, 1992, ANN INTERN MED, V116, P920, DOI 10.7326/0003-4819-116-11-920	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1999	318	7198					1618	1618						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	207AL	10428555				2022-12-24	WOS:000080913100040
J	Pym, AS; Cole, ST				Pym, AS; Cole, ST			PostDOTS, postgenomics: the next century of tuberculosis control	LANCET			English	Article							VACCINE		Inst Pasteur, Unite Genet Mol Bacterienne, F-75724 Paris 15, France; Univ Liverpool, Wellcome Trust Trop Ctr, Liverpool L69 3BX, Merseyside, England	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Liverpool	Cole, ST (corresponding author), Inst Pasteur, Unite Genet Mol Bacterienne, 28 Rue Dr Roux, F-75724 Paris 15, France.			Pym, Alexander/0000-0002-6260-8180				BAYER R, 1995, LANCET, V345, P1545, DOI 10.1016/S0140-6736(95)91090-5; Berthet FX, 1998, SCIENCE, V282, P759, DOI 10.1126/science.282.5389.759; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; DOLIN PJ, 1994, B WORLD HEALTH ORGAN, V72, P213; Huygen K, 1996, NAT MED, V2, P893, DOI 10.1038/nm0896-893; India Single-lesion Multicentre Trial Group, 1997, Indian Journal of Leprosy, V69, P121; Jacobs GG, 1997, TUBERCLE LUNG DIS, V78, P159, DOI 10.1016/S0962-8479(97)90022-8; Kenyon TA, 1999, INT J TUBERC LUNG D, V3, P4; Murray CJL, 1998, P NATL ACAD SCI USA, V95, P13881, DOI 10.1073/pnas.95.23.13881; Murray PJ, 1996, P NATL ACAD SCI USA, V93, P934, DOI 10.1073/pnas.93.2.934; Pelicic V, 1998, MOL MICROBIOL, V28, P413, DOI 10.1046/j.1365-2958.1998.00807.x; STOVER CK, 1993, J EXP MED, V178, P197, DOI 10.1084/jem.178.1.197; STRAUS SJE, 1998, SCIENCE, V276, P707; Tascon RE, 1996, NAT MED, V2, P888, DOI 10.1038/nm0896-888; *WHO GLOB TUB PROG, 1998, WHOTB98237; Zhao FZ, 1996, LANCET, V347, P358, DOI 10.1016/S0140-6736(96)90537-1; Zwarenstein M, 1998, LANCET, V352, P1340, DOI 10.1016/S0140-6736(98)04022-7	17	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1004	1005		10.1016/S0140-6736(99)02118-2	http://dx.doi.org/10.1016/S0140-6736(99)02118-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459929				2022-12-24	WOS:000079421600050
J	Tobin, EH				Tobin, EH			Prosthetic joint infections: controversies and clues	LANCET			English	Editorial Material							ULTRACLEAN AIR		Albany Med Coll, Div Infect Dis, Albany, NY 12208 USA	Albany Medical College	Tobin, EH (corresponding author), Albany Med Coll, Div Infect Dis, Albany, NY 12208 USA.							BACKE HA, 1996, CLIN ORTHOP RELAT R, V331, P125; BARRACK RL, 1997, CLIN ORTHOP RELAT R, V345, P8; Berbari EF, 1998, CLIN INFECT DIS, V27, P1247, DOI 10.1086/514991; BLASER J, 1995, ANTIMICROB AGENTS CH, V39, P1134, DOI 10.1128/AAC.39.5.1134; Christensen Gordon D., 1994, P45; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DUNCAN CP, 1994, J BONE JOINT SURG AM, V76A, P1742, DOI 10.2106/00004623-199411000-00020; Lachiewicz PF, 1996, J BONE JOINT SURG AM, V78A, P749, DOI 10.2106/00004623-199605000-00015; LIDWELL OM, 1982, BRIT MED J, V285, P10, DOI 10.1136/bmj.285.6334.10; NORDEN C, 1994, INFECT BONES JOINTS, P291; Proctor Richard A., 1994, P79; Segreti J, 1998, CLIN INFECT DIS, V27, P711, DOI 10.1086/514951; STECKELBERGJM, 1994, INFECT ASS INDWELLIN, P259; TAYLOR GJS, 1993, J BONE JOINT SURG BR, V75, P503, DOI 10.1302/0301-620X.75B3.8496233; Tunney MM, 1998, J BONE JOINT SURG BR, V80B, P568, DOI 10.1302/0301-620X.80B4.8473; Zimmerli W, 1998, JAMA-J AM MED ASSOC, V279, P1537, DOI 10.1001/jama.279.19.1537	16	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 6	1999	353	9155					770	771		10.1016/S0140-6736(99)00071-9	http://dx.doi.org/10.1016/S0140-6736(99)00071-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	175JC	10459955				2022-12-24	WOS:000079089100005
J	Apse, MP; Aharon, GS; Snedden, WA; Blumwald, E				Apse, MP; Aharon, GS; Snedden, WA; Blumwald, E			Salt tolerance conferred by overexpression of a vacuolar Na+/H+ antiport in Arabidopsis	SCIENCE			English	Article							ION-TRANSPORT; TONOPLAST VESICLES; EXCHANGER; MEMBRANE; YEAST	Agricultural productivity is severely affected by soil salinity, One possible mechanism by which plants could survive salt stress is to compartmentalize sodium ions away from the cytosol. Overexpression of a vacuolar Na+/H+ antiport from Arabidopsis thaliana in Arabidopsis plants promotes sustained growth and development in soil watered with up to 200 millimolar sodium chloride. This salinity tolerance was correlated with higher-than-normal levels of AtNHX1 transcripts, protein, and vacuolar Na+/H+ (sodium/proton) antiport activity, These results demonstrate the feasibility of engineering salt tolerance in plants.	Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of Toronto	Blumwald, E (corresponding author), Univ Toronto, Dept Bot, 25 Willcocks St, Toronto, ON M5S 3B2, Canada.		Blumwald, Eduardo/Y-2751-2019					APSE MP, 1998, P 11 INT WORKSH PLAN, P84; Barkla BJ, 1996, ANNU REV PLANT PHYS, V47, P159, DOI 10.1146/annurev.arplant.47.1.159; BLUMWALD E, 1985, PLANT PHYSIOL, V78, P163, DOI 10.1104/pp.78.1.163; Blumwald E, 1997, ADV BOT RES, V25, P401, DOI 10.1016/S0065-2296(08)60159-7; BLUMWALD E, 1987, PLANT PHYSIOL, V85, P30, DOI 10.1104/pp.85.1.30; BLUMWALD E, 1987, PHYSIOL PLANTARUM, V69, P731, DOI 10.1111/j.1399-3054.1987.tb01993.x; DARLEY CP, 1998, P 11 INT WORKSH PLAN, P8; Gaxiola RA, 1999, P NATL ACAD SCI USA, V96, P1480, DOI 10.1073/pnas.96.4.1480; Glenn EP, 1999, CRIT REV PLANT SCI, V18, P227, DOI 10.1016/S0735-2689(99)00388-3; HARLOW E, 1988, ANTIBODIES LAB MANUA, P498; Hechenberger M, 1996, J BIOL CHEM, V271, P33632, DOI 10.1074/jbc.271.52.33632; Johnson C.B., 1981, PHYSL PROCESSES LIMI, P271; Narasimhulu SB, 1996, PLANT CELL, V8, P873, DOI 10.1105/tpc.8.5.873; Nass R, 1997, J BIOL CHEM, V272, P26145, DOI 10.1074/jbc.272.42.26145; Numata M, 1998, J BIOL CHEM, V273, P6951, DOI 10.1074/jbc.273.12.6951; PLANT PJ, 1994, J MEMBRANE BIOL, V140, P1; REA PA, 1987, PHYSIOL PLANTARUM, V71, P131, DOI 10.1111/j.1399-3054.1987.tb04630.x; Ros R, 1998, J BACTERIOL, V180, P3131, DOI 10.1128/JB.180.12.3131-3136.1998	18	1381	1657	13	349	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1256	1258		10.1126/science.285.5431.1256	http://dx.doi.org/10.1126/science.285.5431.1256			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455050				2022-12-24	WOS:000082130200040
J	Wald, NJ; Watt, HC; Hackshaw, AK				Wald, NJ; Watt, HC; Hackshaw, AK			Integrated screening for Down's syndrome based on tests performed during the first and second trimesters	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NUCHAL-TRANSLUCENCY THICKNESS; MATERNAL SERUM; FETAL TRISOMIES; INHIBIN-A; PREGNANCY; RISK; AGE; TRISOMY-21; GESTATION; MARKER	Background Both first-trimester screening and second-trimester screening for Down's syndrome are effective means of selecting women for chorionic-villus sampling or amniocentesis, but there is uncertainty about which screening method should be used in practice. We propose a new screening method in which measurements obtained during both trimesters are integrated to provide a single estimate of a woman's risk of having a pregnancy affected by Down's syndrome. Methods We used data from published studies of various screening methods employed during the first and second trimesters. The first-trimester screening consisted of measurement of serum pregnancy-associated plasma protein A in 77 pregnancies affected by Down's syndrome and 383 unaffected pregnancies and measurements of nuchal translucency obtained by ultrasonography in 326 affected and 95,476 unaffected pregnancies. The second-trimester tests were various combinations of measurements of serum alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin, and inhibin A in 77 affected and 385 unaffected pregnancies. Results When we used a risk of 1 in 120 or greater as the cutoff to define a positive result on the integrated screening test, the rate of detection of Down's syndrome was 85 percent, with a false positive rate of 0.9 percent. To achieve the same rate of detection, current screening tests would have higher false positive rates (5 to 22 percent). If the integrated test were to replace the triple test (measurements of serum alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin), currently used with a 5 percent false positive rate, for screening during the second trimester, the detection rate would be higher (85 percent vs. 69 percent), with a reduction of four fifths in the number of invasive diagnostic procedures and consequent losses of normal fetuses. Conclusions The integrated test detects more cases of Down's syndrome with a much lower false positive rate than the best currently available test. (N Engl J Med 1999;341:461-7.) (C) 1999, Massachusetts Medical Society.	St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London EC1M 6BQ, England	University of London; Queen Mary University London	Wald, NJ (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Wolfson Inst Prevent Med, Dept Environm & Prevent Med, Charterhouse Sq, London EC1M 6BQ, England.		Wald, Nicholas/AAY-2814-2021; Wald, Nicholas/AAY-8924-2021					BRIZOT ML, 1995, BRIT J OBSTET GYNAEC, V102, P127, DOI 10.1111/j.1471-0528.1995.tb09065.x; BRIZOT ML, 1994, OBSTET GYNECOL, V84, P918; Canick JA, 1998, PRENATAL DIAG, V18, P413; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; De Biasio P, 1999, PRENATAL DIAG, V19, P360, DOI 10.1002/(SICI)1097-0223(199904)19:4<360::AID-PD556>3.0.CO;2-U; Hackshaw AK, 1996, LANCET, V348, P1740, DOI 10.1016/S0140-6736(05)65871-0; Haddow JE, 1998, LANCET, V352, P336, DOI 10.1016/S0140-6736(98)22031-9; Haddow JE, 1998, J MED SCREEN, V5, P115, DOI 10.1136/jms.5.3.115; Haddow JE, 1998, NEW ENGL J MED, V338, P955, DOI 10.1056/NEJM199804023381404; LAM YH, 1998, ULTRASOUND OBSTET S1, V12, pA62; Nicolaides KH, 1998, PRENATAL DIAG, V18, P519, DOI 10.1002/(SICI)1097-0223(199805)18:5<519::AID-PD398>3.0.CO;2-U; Nicolaides KH, 1996, LANCET, V347, P906, DOI 10.1016/S0140-6736(96)91391-4; NIELSON JP, 1997, LANCET, V350, P754; Noble PL, 1995, ULTRASOUND OBST GYN, V6, P390, DOI 10.1046/j.1469-0705.1995.06060390.x; Onda T, 1998, PRENATAL DIAG, V18, P956, DOI 10.1002/(SICI)1097-0223(199809)18:9<956::AID-PD370>3.3.CO;2-I; Pandya PP, 1995, BRIT J OBSTET GYNAEC, V102, P957, DOI 10.1111/j.1471-0528.1995.tb10902.x; ROYSTON P, 1992, STAT MED, V11, P257, DOI 10.1002/sim.4780110211; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Wald N J, 1996, J Med Screen, V3, P185; Wald N J, 1997, J Med Screen, V4, P181; WALD NJ, 1988, BRIT MED J, V297, P1029; Wald NJ, 1997, PRENATAL DIAG, V17, P821, DOI 10.1002/(SICI)1097-0223(199709)17:9<821::AID-PD154>3.3.CO;2-X; Wald NJ, 1996, BRIT J OBSTET GYNAEC, V103, P407, DOI 10.1111/j.1471-0528.1996.tb09765.x; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; Wald NJ, 1996, PRENATAL DIAG, V16, P143, DOI 10.1002/(SICI)1097-0223(199602)16:2<143::AID-PD825>3.0.CO;2-F; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; Wald NJ, 1997, PRENATAL DIAG, V17, P285, DOI 10.1002/(SICI)1097-0223(199703)17:3<285::AID-PD71>3.0.CO;2-A; WALD NJ, 1994, PRENATAL DIAG, V14, P707, DOI 10.1002/pd.1970140810; Wald NJ, 1998, J MED SCREEN, V5, P110; Wald NJ, 1998, J MED SCREEN, V5, P166	30	377	396	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1999	341	7					461	467		10.1056/NEJM199908123410701	http://dx.doi.org/10.1056/NEJM199908123410701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	225LG	10441601				2022-12-24	WOS:000081962600001
J	Seder, RA; Gurunathan, S				Seder, RA; Gurunathan, S			DNA vaccines - Designer vaccines for the 21st Century	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							LYMPHOCYTES		NIAID, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Seder, RA (corresponding author), NIAID, 9000 Rockville Pike, Bethesda, MD 20892 USA.							Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; McDonnell WM, 1996, NEW ENGL J MED, V334, P42, DOI 10.1056/NEJM199601043340110; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Wang RB, 1998, SCIENCE, V282, P476, DOI 10.1126/science.282.5388.476	5	42	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					277	278		10.1056/NEJM199907223410410	http://dx.doi.org/10.1056/NEJM199907223410410			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413742				2022-12-24	WOS:000081528800010
J	Poulin, JF; Sekaly, RP				Poulin, JF; Sekaly, RP			Function of the thymus in HIV-infected adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Clin Res Inst Montreal, Immunol Lab, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Poulin, JF (corresponding author), Clin Res Inst Montreal, Immunol Lab, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; FRANCIS IR, 1985, AM J ROENTGENOL, V145, P249, DOI 10.2214/ajr.145.2.249; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; McCune J M, 1997, Semin Immunol, V9, P397, DOI 10.1006/smim.1997.0098; PICKER LJ, 1993, J IMMUNOL, V150, P1105; STEINMANN GG, 1986, HUMAN THYMUS HISTOPA, P43; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0	7	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1999	282	3					219	219		10.1001/jama.282.3.219	http://dx.doi.org/10.1001/jama.282.3.219			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217MW	10422975				2022-12-24	WOS:000081504400002
J	Giuffrida, A; Gravelle, H; Roland, M				Giuffrida, A; Gravelle, H; Roland, M			Measuring quality of care with routine data: avoiding confusion between performance indicators and health outcomes	BRITISH MEDICAL JOURNAL			English	Article							PREVENTABLE HOSPITALIZATIONS; ACCESS; RATES; POPULATION; ADMISSIONS; CHILDREN	Objective To investigate the impact of factors outside the control of primary care on performance indicators proposed as measures of the quality of primary care. Design Multiple regression analysis relating admission rates standardised for age and sex for asthma, diabetes, and epilepsy to socioeconomic population characteristics and to the supply of secondary care resources. Setting 90 family health services authorities in England, 1989-90 to 1994-5. Results At health authority level socioeconomic characteristics, health status, and secondary care supply factors explained 45% of the variation in admission rates for asthma, 33% for diabetes, and 55% for epilepsy. When health authorities were ranked, only four of the 10 with the highest age-sex standardised admission rates for asthma in 1994-5 remained in the top 10 when allowance was made for socioeconomic characteristics, health status, and secondary care supply factors. There was also substantial year to year variation in the rates. Conclusion Health outcomes should relate to crude rates of adverse events in the population. These give the best indication of the size of a health problem. Performance indicators, however, should relate to those aspects of care which can be altered by the staff whose performance is being measured.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO10 5DD, N Yorkshire, England	University of Manchester; University of York - UK	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Williamson Bldg,Oxford Rd, Manchester M13 9PL, Lancs, England.			Gravelle, Hugh/0000-0002-7753-4233				ARNOLD J, 1989, USING HLTH OUTCOMES; Aveyard P, 1997, J Eval Clin Pract, V3, P275, DOI 10.1046/j.1365-2753.1997.t01-1-00004.x; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BEGLEY CE, 1994, J COMMUN HEALTH, V19, P377, DOI 10.1007/BF02260406; Billings J, 1996, HEALTH AFFAIR, V15, P239, DOI 10.1377/hlthaff.15.3.239; Billings J, 1989, USE SMALL AREA ANAL; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; CASANOVA C, 1995, INT J HEALTH SERV, V25, P283, DOI 10.2190/PCF7-ALX9-6CN3-7X9G; DUROJAIYE LIA, 1989, PUBLIC HEALTH, V103, P181, DOI 10.1016/S0033-3506(89)80073-3; FARMER A, 1990, BRIT J GEN PRACT, V40, P56; Griffiths C, 1997, BRIT MED J, V314, P482, DOI 10.1136/bmj.314.7079.482; Lambrew JM, 1996, MED CARE, V34, P138, DOI 10.1097/00005650-199602000-00006; *MA DIV HLTH CAR F, 1995, IMPR PRIM CAR US PRE; MACKINNON JG, 1983, J ECONOMETRICS, V21, P53, DOI 10.1016/0304-4076(83)90119-7; Marshall EG, 1998, BRIT MED J, V316, P1701, DOI 10.1136/bmj.316.7146.1701; McColl A, 1998, BMJ-BRIT MED J, V317, P1354, DOI 10.1136/bmj.317.7169.1354; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; *NHS EX, 1998, NEW NHS NAT FRAM ASS; *NHS EX, 1994, HLTH SERV IND HDB 19; *SECR STAT HLTH, 1997, CM3807; Smith P., 1994, FORMULA DISTRIBUTING; WATTS JP, 1996, EUR RESPIR J, V9, P2087; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITE H, 1978, ECONOMETRICA, V46, P817	24	118	121	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					94	98		10.1136/bmj.319.7202.94	http://dx.doi.org/10.1136/bmj.319.7202.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	216JD	10398635	Bronze, Green Published, Green Accepted			2022-12-24	WOS:000081438200034
J	Philips, DP; Christenfeld, N; Ryan, NM				Philips, DP; Christenfeld, N; Ryan, NM			An increase in the number of deaths in the United States in the first week of the month - An association with substance abuse and other causes of death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; ALCOHOL-CONSUMPTION; EMERGENCY ROOM; DISABILITY; MORTALITY; WORKING; INCOME	Background and Methods There are regular changes in mortality rates, such as increased rates of death from influenza in the winter and from motor vehicle accidents on long holiday weekends. Previous research has shown that among persons with schizophrenia, the rates of cocaine use and hospital admissions increase at the beginning of the month, after the receipt of disability payments, Using computerized data from all death certificates in the United States between 1973 and 1988, we compared the number of deaths in the fi rst week of the month with the number of deaths in the last week of the preceding month. Results The average number of deaths was about 5500 per day, or about 165,000 in a 30-day month. There were 100.9 deaths (95 percent confidence interval, 100.8 to 101.0) in the first week of the month for every 100 deaths in the last week of the preceding month, This was equivalent to about 4320 more deaths in the first week of each month than in the last week of the preceding month in an average year. Between 1983 and 1988, for deaths involving substance abuse and an external cause (such as suicides, accidents, and homicides), there were 114.2 deaths (95 percent confidence interval, 110.5 to 117.9) in the first week of the month for every 100 in the last week of the preceding month. There were significant increases in the number of deaths in the first week of the month for many causes of death, including substance abuse, natural causes, homicides, suicides, and motor vehicle accidents. Conclusions In the United States, the number of deaths is higher in the first week of the month than in the last week of the preceding month. The increase at the beginning of the month is associated with substance abuse and other causes of death. (N Engl J Med 1999;341:93-8.) (C) 1999, Massachusetts Medical Society.	Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Philips, DP (corresponding author), Univ Calif San Diego, Dept Sociol, La Jolla, CA 92093 USA.							Borges G, 1996, J STUD ALCOHOL, V57, P543, DOI 10.15288/jsa.1996.57.543; CHERPITEL CJ, 1994, ALCOHOL ALCOHOLISM, V29, P211; Chou SP, 1996, ALCOHOL CLIN EXP RES, V20, P1423, DOI 10.1111/j.1530-0277.1996.tb01144.x; Collins JJ, 1993, ALCOHOL HEALTH RES W, V17, P93; Cornelius JR, 1996, ALCOHOL CLIN EXP RES, V20, P1451, DOI 10.1111/j.1530-0277.1996.tb01148.x; *DEP COMM, 1998, STAT ABSTR US 1998; *DEP COMM, 1998, STAT ABSTR US 1988; DUFFY JC, 1995, INT J EPIDEMIOL, V24, P100, DOI 10.1093/ije/24.1.100; Durkheim E, 1897, SUICIDE; Gardner M. J., 1989, STAT CONFIDENCE; Gresenz CR, 1998, COMMUNITY MENT HLT J, V34, P337, DOI 10.1023/A:1018779805833; *NAT CTR HLTH STAT, 1977, VIT STAT US 1973 1 A, V2; *NAT CTR HLTH STAT, 1985, MULT CAUS DEATH 1983; *NAT CTR HLTH STAT, 1991, VIT STAT US 1973 1 A, V2; *NAT CTR HLTH STAT, 1984, MORT DET FIL 1973 19; *NAT CTR HLTH STAT, 1984, VIT STAT US 1979 1 A, V2; PHILLIPS DP, 1988, LANCET, V2, P728; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS DP, 1992, PSYCHOSOM MED, V54, P532, DOI 10.1097/00006842-199209000-00001; POIKOLAINEN K, 1995, J CLIN EPIDEMIOL, V48, P455, DOI 10.1016/0895-4356(94)00174-O; POIKOLAINEN K, 1995, J CIN EPIDEMIOL, V48, P1; Rosenheck R, 1997, PSYCHIATR SERV, V48, P789; SATEL SL, 1995, NEW ENGL J MED, V333, P794, DOI 10.1056/NEJM199509213331210; SHANER A, 1995, NEW ENGL J MED, V333, P777, DOI 10.1056/NEJM199509213331207; Spielberg C, 1996, AM HEART J, V132, P579, DOI 10.1016/S0002-8703(96)90241-0; VANDERPALEN J, 1995, NEW ZEAL MED J, V108, P332; WILLICH SN, 1994, CIRCULATION, V90, P87, DOI 10.1161/01.CIR.90.1.87	27	97	98	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 8	1999	341	2					93	98		10.1056/NEJM199907083410206	http://dx.doi.org/10.1056/NEJM199907083410206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	214ET	10395634	Bronze			2022-12-24	WOS:000081316200006
J	Schenk, D; Barbour, R; Dunn, W; Gordon, G; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Liao, ZM; Lieberburg, I; Motter, R; Mutter, L; Soriano, F; Shopp, G; Vasquez, N; Vandevert, C; Walker, S; Wogulis, M; Yednock, T; Games, D; Seubert, P				Schenk, D; Barbour, R; Dunn, W; Gordon, G; Grajeda, H; Guido, T; Hu, K; Huang, JP; Johnson-Wood, K; Khan, K; Kholodenko, D; Lee, M; Liao, ZM; Lieberburg, I; Motter, R; Mutter, L; Soriano, F; Shopp, G; Vasquez, N; Vandevert, C; Walker, S; Wogulis, M; Yednock, T; Games, D; Seubert, P			Immunization with amyloid-beta attenuates Alzheimer disease-like pathology in the PDAPP mouse	NATURE			English	Article							PRECURSOR PROTEIN; TRANSGENIC MICE; SENILE PLAQUES; IN-VIVO; PRESENILIN-1; DEPOSITION; PEPTIDE	Amyloid-beta peptide (A beta) seems to have a central role in the neuropathology of Alzheimer's disease (AD)(1). Familial forms of the disease have been linked to mutations in the amyloid precursor protein (APP) and the presenilin genes(2,3). Disease-linked mutations in these genes result in increased production of the 42-amino-acid form of the peptide (A beta(42))(4-8), which is the predominant form found in the amyloid plaques of Alzheimer's disease(9,10). The PDAPP transgenic mouse, which overexpresses mutant human APP (in which the amino acid at position 717 is phenylalanine instead of the normal valine), progressively develops many of the neuropathological hallmarks of Alzheimer's disease in an age- and brain-region-dependent manner(11,12). In the present study, transgenic animals were immunized with A beta(42), either before the onset of AD-type neuropathologies (at 6 weeks of age) or at an older age (11 months), when amyloid-beta deposition and several of the subsequent neuropathological changes were well established. We report that immunization of the young animals essentially prevented the development of beta-amyloid-plaque formation, neuritic dystrophy and astrogliosis. Treatment of the older animals also markedly reduced the extent and progression of these AD-like neuropathologies. Our results raise the possibility that immunization with amyloid-beta may be effective in preventing and treating Alzheimer's disease.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Schenk, D (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; Hardy J, 1996, ANN MED, V28, P255, DOI 10.3109/07853899609033127; Hyman BT, 1998, ARCH NEUROL-CHICAGO, V55, P1174, DOI 10.1001/archneur.55.9.1174; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Liang JS, 1997, NEUROSCI LETT, V225, P73, DOI 10.1016/S0304-3940(97)00196-1; Lippa CF, 1998, LANCET, V352, P1117, DOI 10.1016/S0140-6736(05)79757-9; McGeer EG, 1997, MOVEMENT DISORD, V12, P855, DOI 10.1002/mds.870120604; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SEUBERT P, 1992, NATURE, V359, P325, DOI 10.1038/359325a0; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016	16	2596	2986	3	322	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 8	1999	400	6740					173	177		10.1038/22124	http://dx.doi.org/10.1038/22124			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214JM	10408445				2022-12-24	WOS:000081324900056
J	Shapiro, MF; Morton, SC; McCaffrey, DF; Senterfitt, JW; Fleishman, JA; Perlman, JF; Athey, LA; Keesey, JW; Goldman, DP; Berry, SH; Bozzette, SA				Shapiro, MF; Morton, SC; McCaffrey, DF; Senterfitt, JW; Fleishman, JA; Perlman, JF; Athey, LA; Keesey, JW; Goldman, DP; Berry, SH; Bozzette, SA		HCSUS Consortium	Variations in the care of HIV-infected adults in the United States - Results from the HIV Cost and Services Utilization Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIRETROVIRAL THERAPY; MANAGED CARE; DRUG-USE; DISEASE; GROWTH; RECOMMENDATIONS; LESSONS; PANEL; RACE	Context Studies of selected populations suggest that not all persons infected with human immunodeficiency virus (HIV) receive adequate care. Objective To examine variations in the care received by a national sample representative of the adult US population infected with HIV. Design Cohort study that consisted of 3 interviews from January 1996 to January 1998 conducted by the HIV Cost and Services Utilization Consortium. Patients and Setting Multistage probability sample of 2864 respondents (68% of those targeted for sampling), who represent the 231 400 persons at least 18 years old, with known HIV infection receiving medical care in the 48 contiguous United States in early 1996 in facilities other than emergency departments, the military, or prisons. The first follow-up consisted of 2466 respondents and the second had 2267 (65% of all surviving sampled subjects). Main Outcome Measures Service utilization (<2 ambulatory visits, at least 1 emergency department visit that did not lead to hospitalization, at least 1 hospitalization) and medication utilization (receipt of antiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia), Results Inadequate HIV care was commonly reported at the time of interviews conducted from early 1996 to early 1997 but declined to varying degrees by late 1997, Twenty-three percent of patients initially and 15% of patients subsequently had emergency department visits that did not lead to hospitalization, 30% initially and 26% subsequently of those who had CD4 cell counts below 0.20 x 10(9)/L did not receive P carinii pneumonia prophylaxis, and 41% initially and 15% subsequently of those who had CD4 cell counts below 0.50 x 10(9)/L did not receive antiretroviral therapy (protease inhibitor or nonnucleoside reverse transcriptase inhibitor). Inferior patterns of care were seen far many of these measures in blacks and Latinos compared with whites, the uninsured and Medicaid-insured compared with the privately insured, women compared with men, and other risk and/or exposure groups compared with men who had sex with men even after CD4 cell count adjustment. With multivariate adjustment, many differences remained statistically significant. Even by early 1998, fewer blacks, women, and uninsured and Medicaid-insured persons had started taking antiretroviral medication (CD4 cell count adjusted P Values <.001 to <.005). Conclusions Access to care improved from 1996 to 1998 but remained suboptimal. Blacks, Latinos, women, the uninsured, and Medicaid-insured all had less desirable patterns of care. Strategies to ensure optimal care for patients with HIV requires identifying the causes of deficiency and addressing these important shortcomings in care.	Rand Corp, HCSUS Off, Hlth Program, Santa Monica, CA 90407 USA; Rand Corp, Survey Res Grp, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90024 USA; Cty Los Angeles, AIDS Off, Los Angeles, CA USA; Agcy Hlth Care Policy & Res, Ctr Cost & Financing Studies, Rockville, MD 20852 USA; Univ Chicago, Natl Opin Res Ctr, Survey Operat Ctr, Chicago, IL 60637 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA; Vet Affairs San Diego Healthcare Syst, Hlth Serv Res & Dev Unit, San Diego, CA USA	RAND Corporation; RAND Corporation; University of California System; University of California Los Angeles; Agency for Healthcare Research & Quality; University of Chicago; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System	Shapiro, MF (corresponding author), Rand Corp, HCSUS Off, Hlth Program, 1700 Main St, Santa Monica, CA 90407 USA.		Goldman, Dana P/E-7667-2013	Goldman, Dana P/0000-0001-8498-6396				BERRY SH, 1988, MR1090AHCPR RAND; Bozzette SA, 1998, NEW ENGL J MED, V339, P1897, DOI 10.1056/NEJM199812243392606; Brick J M, 1996, Stat Methods Med Res, V5, P215, DOI 10.1177/096228029600500302; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Cunningham WE, 1997, J CLIN EPIDEMIOL, V50, P829, DOI 10.1016/S0895-4356(97)00061-9; DUAN N, 1998, MR1060AHCPR RAND; FLEISHMAN JA, 1994, HEALTH SERV RES, V29, P527; FRANKEL MR, IN PRESS HLTH SERV R; Gold M, 1996, HEALTH AFFAIR, V15, P153, DOI 10.1377/hlthaff.15.3.153; GRAVES EJ, 1997, VITAL HLTH STAT 13, V128, P1; KISH L, 1974, J ROY STAT SOC B MET, V36, P1; Kish L, 1965, SURVEY SAMPLING; Lam NSN, 1996, PROF GEOGR, V48, P321, DOI 10.1111/j.0033-0124.1996.00321.x; MILLER RH, 1994, ANNU REV PUBL HEALTH, V15, P437; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; Niemcryk SJ, 1998, J COMMUN HEALTH, V23, P137, DOI 10.1023/A:1018713524788; ROBINSON JC, 1995, NEW ENGL J MED, V333, P1684, DOI 10.1056/NEJM199512213332506; SHALALA D, 1998, BRIEFING PRESS ELIMI; SHAPIRO MF, IN PRESS HLTH SERV R; SIRKEN MG, 1970, J AM STAT ASSOC, V65, P257, DOI 10.2307/2283590; Stone VE, 1997, J GEN INTERN MED, V12, P150, DOI 10.1046/j.1525-1497.1997.012003150.x; Welch WP, 1996, HEALTH AFFAIR, V15, P201, DOI 10.1377/hlthaff.15.3.201	24	594	599	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 30	1999	281	24					2305	2315		10.1001/jama.281.24.2305	http://dx.doi.org/10.1001/jama.281.24.2305			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	207FN	10386555	Bronze			2022-12-24	WOS:000080925600030
J	Ascherio, A; Katan, MB; Zock, PL; Stampfer, MJ; Willett, WC				Ascherio, A; Katan, MB; Zock, PL; Stampfer, MJ; Willett, WC			Trans fatty acids and coronary heart disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MYOCARDIAL-INFARCTION; PLASMA-LIPOPROTEIN; HEALTHY-SUBJECTS; UNITED-STATES; STEARIC-ACID; DIETARY-FAT; RISK; HUMANS; LIPIDS; SERUM		Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Wageningen Ctr Food Sci, NL-6703 HD Wageningen, Netherlands	Harvard University; Harvard T.H. Chan School of Public Health; Wageningen University & Research	Ascherio, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Robles-Sardin, Alma E/M-7714-2015	Robles-Sardin, Alma E/0000-0003-2044-7793; Zock, Peter/0000-0002-0322-0565				ALMENDINGEN K, 1995, J LIPID RES, V36, P370; ANDERSON JT, 1961, J NUTR, V75, P388, DOI 10.1093/jn/75.4.388; ARO A, 1995, LANCET, V345, P273, DOI 10.1016/S0140-6736(95)90273-2; Aro A, 1997, AM J CLIN NUTR, V65, P1419, DOI 10.1093/ajcn/65.5.1419; Aro A, 1998, NUTR METAB CARDIOVAS, V8, P402; ASCHERIO A, 1994, CIRCULATION, V89, P94, DOI 10.1161/01.CIR.89.1.94; Ascherio A, 1996, BMJ-BRIT MED J, V313, P84, DOI 10.1136/bmj.313.7049.84; BoltonSmith C, 1996, EUR HEART J, V17, P837; Clevidence BA, 1997, ARTERIOSCL THROM VAS, V17, P1657, DOI 10.1161/01.ATV.17.9.1657; *EXP PAN T FATT AC, 1995, AM J CLIN NUTR, V62, pS655; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; HUNTER JE, 1991, AM J CLIN NUTR, V54, P363, DOI 10.1093/ajcn/54.2.363; Judd J, 1998, FASEB J, V12, pA229; JUDD JT, 1994, AM J CLIN NUTR, V59, P861, DOI 10.1093/ajcn/59.4.861; KATAN MB, 1995, LANCET, V346, P1245, DOI 10.1016/S0140-6736(95)91858-2; KATAN MB, 1995, ANNU REV NUTR, V15, P473, DOI 10.1146/annurev.nutr.15.1.473; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; KROMHOUT D, 1995, PREV MED, V24, P308, DOI 10.1006/pmed.1995.1049; Lichtenstein AH, 1999, NEW ENGL J MED, V340, P1933, DOI 10.1056/NEJM199906243402501; LICHTENSTEIN AH, 1993, ARTERIOSCLER THROMB, V13, P154, DOI 10.1161/01.ATV.13.2.154; LITIN L, 1993, NEW ENGL J MED, V329, P1969, DOI 10.1056/NEJM199312233292620; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; Pietinen P, 1997, AM J EPIDEMIOL, V145, P876, DOI 10.1093/oxfordjournals.aje.a009047; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Sundram K, 1997, J NUTR, V127, pS514, DOI 10.1093/jn/127.3.514S; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WILLETT WC, 1994, AM J PUBLIC HEALTH, V84, P722, DOI 10.2105/AJPH.84.5.722; Zock PL, 1997, ATHEROSCLEROSIS, V131, P7, DOI 10.1016/S0021-9150(96)06063-7; ZOCK PL, 1992, J LIPID RES, V33, P399	31	351	379	0	20	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 24	1999	340	25					1994	1998		10.1056/NEJM199906243402511	http://dx.doi.org/10.1056/NEJM199906243402511			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	210CX	10379026				2022-12-24	WOS:000081088500011
J	Zoller, H; Pietrangelo, A; Vogel, W; Weiss, G				Zoller, H; Pietrangelo, A; Vogel, W; Weiss, G			Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis	LANCET			English	Article							TRANSFERRIN RECEPTOR; NUCLEOTIDE-SEQUENCE; IRON-METABOLISM; HEMOCHROMATOSIS; GENE; MICE; HFE	Background Although the gene for hereditary haemochromatosis has been cloned, the mechanism by which iron uptake is inappropriately increased in this disorder is unclear. Iron absorption is regulated by the duodenal metal transporter, DMT-1, also called NRAMP-2. We investigated the expression of NRAMP-2 in patients with hereditary haemochromatosis. Methods Duodenal biopsy samples were taken from 20 patients with haemochromatosis homozygous for the C282Y mutation and from ten controls. NRAMP-2 expression was assessed by northern blotting and competitive PCR, NRAMP-2 mRNA was sequenced in seven patients and two controls. Findings Duodenal NRAMP-2 mRNA concentrations were increased in patients as estimated by Northern blotting. Accordingly, competitive PCR showed significantly higher NRAMP-2 cDNA concentrations in patients than in controls (mean 3.43 [SD 0.61] vs 1.11 [0.74] log ng competitorx10(4); p<0.001). No mutations were found within the NRAMP-2 mRNA. Duodenal NRAMP-2 mRNA expression was correlated with serum ferritin in controls (r=-0.94, p=0.001) but not in patients (r=-0.18, p=0.8). Interpretation Increased NRAMP-2 mRNA expression in duodenal mucosa of patients with hereditary haemochromatosis may promote duodenal iron uptake and lead to iron overload.	Univ Innsbruck Hosp, Dept Internal Med, A-6020 Innsbruck, Austria; Univ Modena, Dept Med, I-41100 Modena, Italy	Medical University of Innsbruck; Universita di Modena e Reggio Emilia	Weiss, G (corresponding author), Univ Innsbruck Hosp, Dept Internal Med, Anichstr 35, A-6020 Innsbruck, Austria.	guenter.weiss@uibk.ac.at	Pietrangelo, Antonello/K-1517-2016; Zoller, Heinz/AAD-7225-2019	Pietrangelo, Antonello/0000-0002-7411-935X; Weiss, Guenter/0000-0003-0709-2158	Telethon [E.0609] Funding Source: Medline	Telethon(Fondazione Telethon)		Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; Fleming MD, 1998, P NATL ACAD SCI USA, V95, P1148, DOI 10.1073/pnas.95.3.1148; Gilliland G., 1990, PCR PROTOCOLS GUIDE, P60; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Jazwinska EC, 1996, NAT GENET, V14, P249, DOI 10.1038/ng1196-249; Jouanolle AM, 1996, NAT GENET, V14, P251, DOI 10.1038/ng1196-251; Kishi F, 1997, MOL IMMUNOL, V34, P839, DOI 10.1016/S0161-5890(97)00110-7; LAWN RM, 1980, CELL, V21, P647, DOI 10.1016/0092-8674(80)90428-6; Lebron JA, 1998, CELL, V93, P111, DOI 10.1016/S0092-8674(00)81151-4; Lee PL, 1998, BLOOD CELL MOL DIS, V24, P199, DOI 10.1006/bcmd.1998.0186; Parkkila S, 1997, P NATL ACAD SCI USA, V94, P13198, DOI 10.1073/pnas.94.24.13198; PIETRANGELO A, 1992, GASTROENTEROLOGY, V102, P802, DOI 10.1016/0016-5085(92)90161-Q; PIETRANGELO A, 1995, GASTROENTEROLOGY, V108, P208, DOI 10.1016/0016-5085(95)90026-8; POWELL LW, 1994, IRON METABOLISM HLTH, P228; Rothenberg BE, 1996, P NATL ACAD SCI USA, V93, P1529, DOI 10.1073/pnas.93.4.1529; Santos M, 1996, J EXP MED, V184, P1975, DOI 10.1084/jem.184.5.1975; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; Zhou XY, 1998, P NATL ACAD SCI USA, V95, P2492, DOI 10.1073/pnas.95.5.2492	21	145	148	1	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 19	1999	353	9170					2120	2123		10.1016/S0140-6736(98)11179-0	http://dx.doi.org/10.1016/S0140-6736(98)11179-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	208BA	10382697				2022-12-24	WOS:000080969300013
J	Quill, TE				Quill, TE			Same old seventeen-dollar lamps	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Genesee Hosp, Rochester, NY 14607 USA		Quill, TE (corresponding author), Genesee Hosp, 224 Alexander St, Rochester, NY 14607 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1999	130	12					1022	1024		10.7326/0003-4819-130-12-199906150-00023	http://dx.doi.org/10.7326/0003-4819-130-12-199906150-00023			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	206TE	10383354				2022-12-24	WOS:000080894700012
J	Chowdhury, AMR				Chowdhury, AMR			Success with the DOTS strategy	LANCET			English	Article									BRAC, Dhaka 1212, Bangladesh	Bangladesh Rural Advancement Committee BRAC	Chowdhury, AMR (corresponding author), BRAC, 75 Mohakhall, Dhaka 1212, Bangladesh.							Chowdhury A.M.R., 1996, SIMPLE SOLUTION TEAC; Chowdhury AMR, 1997, LANCET, V350, P169, DOI 10.1016/S0140-6736(96)11311-8; CHOWDHURY AMR, 1991, IUATLD NEWSLETTER, P1; CHOWDHURY AMR, IN PRESS TUBERCULOSI; GRANGE JM, 1997, LANCET, V350, P158; LOVELL CH, 1992, BREAKING CYCLE PROVE	6	17	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 20	1999	353	9157					1003	1004		10.1016/S0140-6736(99)02119-4	http://dx.doi.org/10.1016/S0140-6736(99)02119-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459928				2022-12-24	WOS:000079421600049
J	Grange, JM; Zumla, A				Grange, JM; Zumla, A			Paradox of the global emergency of tuberculosis	LANCET			English	Article									UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis, London W1P 6DB, England; Natl Heart & Lung Inst, Imperial Coll Sch Med, London, England	University of London; University College London; UCL Medical School; Imperial College London	Zumla, A (corresponding author), UCL Royal Free & Univ Coll Med Sch, Ctr Infect Dis, 46 Cleveland St, London W1P 6DB, England.	a.zumla@ucl.ac.uk	ZUMLA, Alimuddin/ABA-8208-2020	ZUMLA, Alimuddin/0000-0002-5111-5735				Department for International Development, 1997, WHIT PAP INT DEV; Farmer P, 1997, SOC SCI MED, V44, P347, DOI 10.1016/S0277-9536(96)00143-8; Kochi A, 1997, WORLD HEALTH FORUM, V18, P225; WHO (World Health Organization), 1998, WORLD HLTH REP 1998; 1998, INT J TUBERC LUNG DI, V2, P1044	5	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 20	1999	353	9157					996	996		10.1016/S0140-6736(99)01196-4	http://dx.doi.org/10.1016/S0140-6736(99)01196-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	181BW	10459922				2022-12-24	WOS:000079421600043
J	Huang, CC; Wang, ST; Chang, YC; Lin, KP; Wu, PL				Huang, CC; Wang, ST; Chang, YC; Lin, KP; Wu, PL			Measurement of the urinary lactate : creatinine ratio for the early identification of newborn infants at risk for hypoxic-ischemic encephalopathy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CEREBROSPINAL-FLUID; BIRTH ASPHYXIA; PERINATAL ASPHYXIA; MAGNETIC-RESONANCE; TERM INFANTS; ORGANIC-ACID; EXCRETION; PROGNOSIS; SYSTEM; BRAIN	Background Newborn infants with perinatal asphyxia are prone to the development of hypoxic-ischemic encephalopathy. There are no reliable methods For identifying infants at risk for this disorder. Methods We measured the ratio of lactate to creatinine in urine by proton nuclear magnetic resonance spectroscopy within 6 hours and again 48 to 72 hours after birth in 58 normal infants and 40 infants with asphyxia. The results were correlated with the subsequent presence or absence of hypoxic-ischemic encephalopathy. Results Hypoxic-ischemic encephalopathy did not develop in any of the normal newborns but did develop in 16 of the 40 newborns with asphyxia. Within six hours after birth, the mean (+/-SD) ratio of urinary lactate to creatinine was 16.75+/-27.38 in the infants who subsequently had hypoxic-ischemic encephalopathy, as compared with 0.09+/-0.02 in the normal infants (P<0.001) and 0.19+/-0.12 in the infants with asphyxia in whom hypoxic-ischemic encephalopathy did not develop (P<0.001). A ratio of 0.64 or higher within six hours after birth had a sensitivity of 94 percent and a specificity of 100 percent for predicting the development of hypoxic-ischemic encephalopathy. The sensitivity and specificity of measurements obtained 48 to 72 hours after birth were much lower. The mean ratio of urinary lactate to creatinine was significantly higher in the infants who had adverse outcomes at one year (25.36+/-32.02) than in the infants with favorable outcomes (0.63+/-1.50) (P<0.001). Conclusions Measurement of the urinary lactate:creatinine ratio soon after birth may help identify infants at high risk for hypoxic-ischemic encephalopathy. (N Engl J Med 1999;341:328-35.) (C) 1999, Massachusetts Medical Society.	Natl Cheng Kung Univ, Med Ctr, Dept Pediat, Tainan 704, Taiwan; Natl Cheng Kung Univ, Med Ctr, Dept Publ Hlth, Tainan 704, Taiwan; Natl Cheng Kung Univ, Dept Chem, Tainan 704, Taiwan; Kaohsiung Chang Gung Childrens Hosp, Dept Pediat, Kaohsiung, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Chang Gung Memorial Hospital	Huang, CC (corresponding author), Natl Cheng Kung Univ, Med Ctr, Dept Pediat, 138 Sheng Li Rd, Tainan 704, Taiwan.			Huang, Chao-Ching/0000-0003-2799-7181				AMICLTISON C, 1986, NEUROLOGICAL ASSESSM; BLENNOW M, 1995, PEDIATR RES, V37, P260, DOI 10.1203/00006450-199503000-00002; Carter BS, 1998, J PEDIATR-US, V132, P619, DOI 10.1016/S0022-3476(98)70349-X; Cheung PY, 1996, ARCH DIS CHILD-FETAL, V74, pF47, DOI 10.1136/fn.74.1.F47; DAWES GS, 1968, J PHYSIOL-LONDON, V195, P55, DOI 10.1113/jphysiol.1968.sp008446; DEPRAETER C, 1991, PEDIATRICS, V88, P1204; Ekert P, 1997, J PEDIATR-US, V131, P613, DOI 10.1016/S0022-3476(97)70072-6; FERNANDES J, 1976, CLIN CHIM ACTA, V66, P345, DOI 10.1016/0009-8981(76)90233-3; GARCIA J, 1984, J PEDIATR-US, V104, P268, DOI 10.1016/S0022-3476(84)81010-0; HAGBERG H, 1993, ACTA PAEDIATR, V82, P925, DOI 10.1111/j.1651-2227.1993.tb12601.x; HELLSTROMWESTAS L, 1995, ARCH DIS CHILD-FETAL, V72, pF34, DOI 10.1136/fn.72.1.F34; Huang CC, 1998, RADIOLOGY, V209, P49, DOI 10.1148/radiology.209.1.9769811; ILES RA, 1986, CLIN CHIM ACTA, V161, P173, DOI 10.1016/0009-8981(86)90211-1; Johnston MV, 1998, ANN NEUROL, V44, P155, DOI 10.1002/ana.410440202; Lombroso CT, 1993, ELECTROENCEPHALOGRAP, P803; MA S, 1995, APPL BIOCHEM BIOTECH, V53, P37, DOI 10.1007/BF02783480; MartinAncel A, 1997, PEDIATRICS, V100, P789, DOI 10.1542/peds.100.5.789; MCCORMICK K, 1985, AM J MED GENET, V22, P291, DOI 10.1002/ajmg.1320220211; NICHOLSON JK, 1989, PROG NUCL MAG RES SP, V21, P449, DOI 10.1016/0079-6565(89)80008-1; PERLMAN JM, 1988, J PEDIATR-US, V113, P875; Perlman JM, 1996, PEDIATRICS, V97, P456; RUDOLPH AM, 1984, J DEV PHYSIOL, V6, P11; RUTH V, 1988, J PEDIATR-US, V113, P880, DOI 10.1016/S0022-3476(88)80024-6; SARNAT HB, 1976, ARCH NEUROL-CHICAGO, V33, P696, DOI 10.1001/archneur.1976.00500100030012; Savman K, 1998, PEDIATR RES, V43, P746; SIEGEL MJ, 1984, RADIOLOGY, V152, P395, DOI 10.1148/radiology.152.2.6739805; THORNBERG E, 1995, ARCH DIS CHILD-FETAL, V72, pF39, DOI 10.1136/fn.72.1.F39; Vannucci RC, 1997, PEDIATRICS, V100, P1004, DOI 10.1542/peds.100.6.1004; VOLPE JJ, 1995, NEUROLOGY NEWBORN, P221; Walker V, 1996, PEDIATR RES, V40, P309, DOI 10.1203/00006450-199608000-00020; WALKER V, 1992, BIOL NEONATE, V61, P162; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Zuppi C, 1997, CLIN CHIM ACTA, V265, P85, DOI 10.1016/S0009-8981(97)00110-1	33	80	81	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1999	341	5					328	335		10.1056/NEJM199907293410504	http://dx.doi.org/10.1056/NEJM199907293410504			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220LF	10423467				2022-12-24	WOS:000081666900004
J	Fisher, RS; Blum, D				Fisher, RS; Blum, D			Epilepsy surgery where there is dual pathology	LANCET			English	Editorial Material							TEMPORAL-LOBE EPILEPSY; RESECTION; LOBECTOMY; SEIZURES; EXTENT		St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA	Barrow Neurological Institute; St. Joseph's Hospital and Medical Center	Fisher, RS (corresponding author), St Josephs Hosp & Med Ctr, Barrow Neurol Inst, Phoenix, AZ 85013 USA.			Fisher, Robert/0000-0003-0287-613X				Arruda F, 1996, ANN NEUROL, V40, P446, DOI 10.1002/ana.410400314; AWAD IA, 1991, NEUROSURGERY, V28, P510, DOI 10.1227/00006123-199104000-00005; CASCINO GD, 1993, EPILEPSY RES, V14, P175, DOI 10.1016/0920-1211(93)90022-Y; FRIED I, 1992, J NEUROSURG, V76, P735, DOI 10.3171/jns.1992.76.5.0735; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; GOLDENSOHN ES, 1984, EPILEPSIA, V25, pS156, DOI 10.1111/j.1528-1157.1984.tb05648.x; Li LM, 1999, BRAIN, V122, P799, DOI 10.1093/brain/122.5.799; MATHERN GW, 1995, EPILEPSY RES, V21, P133, DOI 10.1016/0920-1211(95)00014-2; NAYEL MH, 1991, NEUROSURGERY, V29, P55, DOI 10.1227/00006123-199107000-00009; O'Brien TJ, 1999, ANN NEUROL, V45, P526, DOI 10.1002/1531-8249(199904)45:4<526::AID-ANA17>3.3.CO;2-E; SLOVITER RS, 1983, BRAIN RES BULL, V10, P675, DOI 10.1016/0361-9230(83)90037-0; WYLER AR, 1995, NEUROSURGERY, V37, P982, DOI 10.1227/00006123-199511000-00019	12	10	10	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					267	268		10.1016/S0140-6736(99)00180-4	http://dx.doi.org/10.1016/S0140-6736(99)00180-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440297				2022-12-24	WOS:000081646000003
J	Sigwart, U				Sigwart, U			Prevention of restenosis after stenting	LANCET			English	Editorial Material							CORONARY-ARTERY DISEASE; BALLOON ANGIOPLASTY; IMPLANTATION; PLACEMENT		Royal Brompton Hosp, Dept Invas Cardiol, London SW3 6NP, England	Royal Brompton Hospital	Sigwart, U (corresponding author), Royal Brompton Hosp, Dept Invas Cardiol, London SW3 6NP, England.							CAMPBELL EJ, 1999, AM SOC ARTIF INT ORG, V40, pM853; Chronos NAF, 1998, CIRCULATION, V98, P189; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Hanekamp CEE, 1999, CIRCULATION, V99, P1015, DOI 10.1161/01.CIR.99.8.1015; HINOHARA T, 1992, J AM COLL CARDIOL, V20, P623, DOI 10.1016/0735-1097(92)90017-H; Kastrati A, 1997, J AM COLL CARDIOL, V30, P1428, DOI 10.1016/S0735-1097(97)00334-3; Kimura T, 1996, NEW ENGL J MED, V334, P561, DOI 10.1056/NEJM199602293340903; Prati F, 1999, CIRCULATION, V99, P1011, DOI 10.1161/01.CIR.99.8.1011; ROSENSCHEIN U, 1996, ENDOLUMINAL STENTING; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; SIGWART U, 1987, NEW ENGL J MED, V316, P701, DOI 10.1056/NEJM198703193161201; WAKSMAN R, 1995, CIRCULATION, V91, P1553	12	3	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 24	1999	354	9175					269	270		10.1016/S0140-6736(99)00137-3	http://dx.doi.org/10.1016/S0140-6736(99)00137-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	220CB	10440299				2022-12-24	WOS:000081646000005
J	Wagner, D; Sablowski, RWM; Meyerowitz, EM				Wagner, D; Sablowski, RWM; Meyerowitz, EM			Transcriptional activation of APETALA1 by LEAFY	SCIENCE			English	Article							FLORAL HOMEOTIC GENES; FLOWER DEVELOPMENT; MERISTEM IDENTITY; ARABIDOPSIS; INITIATION; EXPRESSION	Plants produce new appendages reiteratively from groups of stem cells called shoot apical meristems. LEAFY (LFY) and APETALA1 (AP1) are pivotal for the switch to the reproductive phase, where instead of leaves the shoot apical meristem produces flowers. Use of steroid-inducible activation of LFY demonstrated that early expression of AP1 is a result of transcriptional induction by LFY. This AP1 induction is independent of protein synthesis and occurs specifically in the tissues and at the developmental stage in which floral fate is assumed. Later expression of AP1 appears to be only indirectly affected by LFY.	CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 156 29, Pasadena, CA 91125 USA.		Wagner, Doris/F-1811-2013; Meyerowitz, Elliot M/A-7118-2009	Wagner, Doris/0000-0003-4656-2490; Sablowski, Robert/0000-0002-1732-2909				Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; Hempel FD, 1998, PLANT CELL, V10, P1663, DOI 10.1105/tpc.10.10.1663; Hempel FD, 1997, DEVELOPMENT, V124, P3845; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; Liljegren SJ, 1996, CURR OPIN CELL BIOL, V8, P865, DOI 10.1016/S0955-0674(96)80089-5; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; Sablowski RWM, 1998, CELL, V92, P93, DOI 10.1016/S0092-8674(00)80902-2; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Tilly JJ, 1998, DEVELOPMENT, V125, P1647; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	24	336	377	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 23	1999	285	5427					582	584		10.1126/science.285.5427.582	http://dx.doi.org/10.1126/science.285.5427.582			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	219LV	10417387				2022-12-24	WOS:000081609500037
J	Saito, Y; Nothacker, HP; Wang, ZW; Lin, SHS; Leslie, F; Civelli, O				Saito, Y; Nothacker, HP; Wang, ZW; Lin, SHS; Leslie, F; Civelli, O			Molecular characterization of the melanin-concentrating-hormone receptor	NATURE			English	Article							ALPHA-MSH; RAT; NEUROPEPTIDE; PROTEIN; BRAIN; GENE; HYPOTHALAMUS; PEPTIDE; ENCODES; SYSTEM	Orphan G-protein-coupled receptors (GPCRs) are cloned proteins with structural characteristics common to the GPCRs but that bind unidentified ligands. Orphan GPCRs have been used as targets to identify novel transmitter molecules(1). Here we describe the isolation from brain extracts and the characterization of the natural ligand of a particular orphan GPCR (SLC-1) that is sequentially homologous to the somatostatin receptors(2,3). We show that the natural ligand of this receptor is the neuropeptide melanin-concentrating hormone (MCH)(4), MCH is a cyclic peptide that regulates a variety of functions in the mammalian brain, in particular feeding behaviour(5,6). We demonstrate that nanomolar concentrations of MCH strongly activate SLC-1-related pathways through G alpha(i) and/or G alpha(q) proteins. We have analysed the tissue localization of the MCH receptor and find that it is expressed in several brain regions, in particular those involved in olfactory learning and reinforcement mechanisms, indicating that therapies targeting the MCH receptor should act on the neuronal regulation of food consumption.	Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Civelli, O (corresponding author), Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA.		Civelli, Olivier/A-8392-2012					BAKER BI, 1993, ANN NY ACAD SCI, V680, P279, DOI 10.1111/j.1749-6632.1993.tb19690.x; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; Civelli O, 1998, FEBS LETT, V430, P55, DOI 10.1016/S0014-5793(98)00524-9; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; Coward P, 1998, P NATL ACAD SCI USA, V95, P352, DOI 10.1073/pnas.95.1.352; deLecea L, 1996, NATURE, V381, P242, DOI 10.1038/381242a0; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; GANTZ I, 1993, J BIOL CHEM, V268, P15174; Gonzalez MI, 1996, PEPTIDES, V17, P171, DOI 10.1016/0196-9781(95)02092-6; Hinuma S, 1998, NATURE, V393, P272, DOI 10.1038/30515; JEZOVA D, 1992, ENDOCRINOLOGY, V130, P1024, DOI 10.1210/en.130.2.1024; KAWAUCHI H, 1983, NATURE, V305, P321, DOI 10.1038/305321a0; KOLAKOWSKI LF, 1996, FEBS LETT, V398, P255; Komatsuzaki K, 1997, FEBS LETT, V406, P165, DOI 10.1016/S0014-5793(97)00257-3; LAKAYE B, 1997, BIOCHIM BIOPHYS ACTA, V1401, P216; Ludwig DS, 1998, AM J PHYSIOL-ENDOC M, V274, pE627, DOI 10.1152/ajpendo.1998.274.4.E627; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MILLER CL, 1993, PEPTIDES, V14, P1; NAHON JL, 1989, ENDOCRINOLOGY, V125, P2056, DOI 10.1210/endo-125-4-2056; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Saito Y, 1997, J NEUROSCI RES, V48, P397, DOI 10.1002/(SICI)1097-4547(19970601)48:5<397::AID-JNR2>3.0.CO;2-9; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Sanchez M, 1997, PEPTIDES, V18, P393, DOI 10.1016/S0196-9781(96)00327-0; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SKOFITSCH G, 1985, BRAIN RES B, V15; Tatemoto K, 1998, BIOCHEM BIOPH RES CO, V251, P471, DOI 10.1006/bbrc.1998.9489; Toumaniantz G, 1996, ENDOCRINOLOGY, V137, P4518, DOI 10.1210/en.137.10.4518; VAUGHAN JM, 1989, ENDOCRINOLOGY, V125, P1660, DOI 10.1210/endo-125-3-1660; Winzer-Serhan UH, 1999, BRAIN RES PROTOC, V3, P229, DOI 10.1016/S1385-299X(98)00043-9	30	431	466	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					265	269		10.1038/22321	http://dx.doi.org/10.1038/22321			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421368				2022-12-24	WOS:000081503800044
J	Galitski, T; Saldanha, AJ; Styles, CA; Lander, ES; Fink, GR				Galitski, T; Saldanha, AJ; Styles, CA; Lander, ES; Fink, GR			Ploidy regulation of gene expression	SCIENCE			English	Article							CELL-SURFACE FLOCCULIN; SACCHAROMYCES-CEREVISIAE; YEAST; CHROMOSOMES; GROWTH; FLO11	Microarray-based gene expression analysis identified genes showing ploidy-dependent expression in isogenic Saccharomyces cerevisiae strains that varied in ploidy from haploid to tetraploid. These genes were induced or repressed in proportion to the number of chromosome sets, regardless of the mating type. Ploidy-dependent repression of some G(1) cyclins can explain the greater cell size associated with higher ploidies, and suggests ploidy-dependent modifications of cell cycle progression. Moreover, ploidy regulation of the FLO11 gene had direct consequences for yeast development.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Fink, GR (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	fink@wi.mit.edu			NIGMS NIH HHS [GM35010] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035010, R01GM035010] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIGNER SH, 1984, PROG EXP TUMOR RES, V27, P67; Broach J.R., 1992, MOL CELLULAR BIOL SA, P583; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Futcher B, 1996, YEAST, V12, P1635; Guo M, 1996, GENETICS, V142, P1349; Henikoff S, 1998, CELL, V93, P329, DOI 10.1016/S0092-8674(00)81161-7; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KURANDA MJ, 1991, J BIOL CHEM, V266, P19758; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Lo WS, 1996, J BACTERIOL, V178, P7144, DOI 10.1128/jb.178.24.7144-7151.1996; Lo WS, 1998, MOL BIOL CELL, V9, P161, DOI 10.1091/mbc.9.1.161; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; MORTIMER RK, 1958, RADIAT RES, V9, P312, DOI 10.2307/3570795; NAGL W, 1978, ENDOPOLYPLOIDY POLYL; Nelson MA, 1996, TRENDS GENET, V12, P69, DOI 10.1016/0168-9525(96)81403-X; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Royzman I, 1998, GENES CELLS, V3, P767, DOI 10.1046/j.1365-2443.1998.00232.x; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; Wakimoto BT, 1998, CELL, V93, P321, DOI 10.1016/S0092-8674(00)81159-9; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359	26	509	545	3	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 9	1999	285	5425					251	254		10.1126/science.285.5425.251	http://dx.doi.org/10.1126/science.285.5425.251			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398601				2022-12-24	WOS:000081346000041
J	Klein, F; Mahr, P; Galova, M; Buonomo, SBC; Michaelis, C; Nairz, K; Nasmyth, K				Klein, F; Mahr, P; Galova, M; Buonomo, SBC; Michaelis, C; Nairz, K; Nasmyth, K			A central role for cohesions in sister chromatid cohesion, formation of axial elements, and recombination during yeast meiosis	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX PROTEINS; SINGLE-DIVISION MEIOSIS; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; SCHIZOSACCHAROMYCES-POMBE; CHROMOSOME SEGREGATION; TOPOISOMERASE-II; DNA-REPLICATION; BUDDING YEAST	A multisubunit complex, called cohesin, containing Smc1p, Smc3p, Scc1p, and Scc3p, is required for sister chromatid cohesion in mitotic cells. We show here that Smc3p and a meiotic version of Scc1p called Rec8p are required for cohesion between sister chromatids, for formation of axial elements, for reciprocal recombination, and for preventing hyperresection of double-strand breaks during meiosis. Both Rec8p and Smc3p colocalize with chromosome cores independently of synapsis during prophase I and largely disappear from chromosome arms after pachytene but persist in the neighborhood of centromeres until the onset of anaphase II. The eukaryotic cell's cohesion apparatus is required both for the repair of recombinogenic lesions and for chromosome segregation and therefore appears to lie at the heart of the meiotic process.	Univ Vienna, Inst Bot, A-1030 Vienna, Austria; IMP Res Inst Mol Pathol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Klein, F (corresponding author), Univ Vienna, Inst Bot, Rennweg 14, A-1030 Vienna, Austria.	fklein@s1.botanik.univvie.ac.at		Nasmyth, Kim/0000-0001-7030-4403; Klein, Franz/0000-0001-7204-1432; Buonomo, Sara/0000-0002-0177-2884				Bailis JM, 1998, GENE DEV, V12, P3551, DOI 10.1101/gad.12.22.3551; Bergerat A, 1997, NATURE, V386, P414, DOI 10.1038/386414a0; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Dernburg AF, 1998, CELL, V94, P387, DOI 10.1016/S0092-8674(00)81481-6; DEVEAUX LC, 1994, GENE DEV, V8, P203, DOI 10.1101/gad.8.2.203; DOBSON MJ, 1994, J CELL SCI, V107, P2749; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hayashi A, 1998, GENES CELLS, V3, P587, DOI 10.1046/j.1365-2443.1998.00215.x; Heo SJ, 1998, MOL GEN GENET, V257, P149, DOI 10.1007/s004380050634; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HUGERAT Y, 1993, GENETICS, V135, P297; Jin QW, 1998, J CELL BIOL, V141, P21, DOI 10.1083/jcb.141.1.21; Keeney S, 1997, CELL, V88, P375, DOI 10.1016/S0092-8674(00)81876-0; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; KLAPHOLZ S, 1980, GENETICS, V96, P567; KLAPHOLZ S, 1980, GENETICS, V96, P589; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; LAMMERS JHM, 1995, CHROMOSOMA, V104, P154, DOI 10.1007/s004120050103; Li YF, 1997, MOL MICROBIOL, V23, P869, DOI 10.1046/j.1365-2958.1997.2691632.x; Loidl J, 1998, METHOD CELL BIOL, V53, P257; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; MAGUIRE MP, 1974, J THEOR BIOL, V48, P485, DOI 10.1016/S0022-5193(74)80017-2; MCKEE BD, 1990, CELL, V61, P61, DOI 10.1016/0092-8674(90)90215-Z; McKim KS, 1998, SCIENCE, V279, P876, DOI 10.1126/science.279.5352.876; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; Moore DP, 1998, CURR TOP DEV BIOL, V37, P263; MOSES MJ, 1958, J BIOPHYS BIOCHEM CY, V4, P633, DOI 10.1083/jcb.4.5.633; Nairz K, 1997, GENE DEV, V11, P2272, DOI 10.1101/gad.11.17.2272; Nasmyth K, 1999, TRENDS BIOCHEM SCI, V24, P98, DOI 10.1016/S0968-0004(99)01358-4; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Prinz S, 1997, GENETICS, V146, P781; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; ROSSMACDONALD P, 1994, CELL, V79, P1069, DOI 10.1016/0092-8674(94)90037-X; Schalk JAC, 1998, CHROMOSOMA, V107, P540, DOI 10.1007/s004120050340; Schmekel K, 1996, EXP CELL RES, V226, P20, DOI 10.1006/excr.1996.0198; Smith AV, 1997, J CELL BIOL, V136, P957, DOI 10.1083/jcb.136.5.957; STORLAZZI A, 1995, P NATL ACAD SCI USA, V92, P8512, DOI 10.1073/pnas.92.18.8512; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; Toth A, 1999, GENE DEV, V13, P320, DOI 10.1101/gad.13.3.320; Uhlmann F, 1998, CURR BIOL, V8, P1095, DOI 10.1016/S0960-9822(98)70463-4; UHLMANN F, 1999, IN PRESS NATURE; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; XU LH, 1995, EMBO J, V14, P5115, DOI 10.1002/j.1460-2075.1995.tb00194.x	58	560	579	1	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	1999	98	1					91	103		10.1016/S0092-8674(00)80609-1	http://dx.doi.org/10.1016/S0092-8674(00)80609-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412984	Bronze			2022-12-24	WOS:000081451000011
J	Novak, R; Henriques, B; Charpentier, E; Normark, S; Tuomanen, E				Novak, R; Henriques, B; Charpentier, E; Normark, S; Tuomanen, E			Emergence of vancomycin tolerance in Streptococcus pneumoniae	NATURE			English	Article							MULTIPLE ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; ENTEROCOCCUS-FAECIUM; PENICILLIN TOLERANCE; BACTERIAL-MENINGITIS; PROTEINS; IDENTIFICATION; PNEUMOCOCCI; INFECTIONS; MECHANISMS	Streptococcus pneumoniae, the pneumococcus, is the most common cause of sepsis and meningitis(1). Mwultiple-antibiotic-resistant strains are widespread, and vancomycin is the antibiotic of last resort(2,3). Emergence of vancomycin resistance In this community-acquired bacterium would be catastrophic. Antibiotic tolerance, the ability of bacteria to survive but not grow in the presence of antibiotics, is a precursor phenotype to resistance(4) Here we show that loss of function of the VncS histidine kinase of a two-component sensor-regulator system in S. pneumoniae produced tolerance to vancomycin and other classes of antibiotic. Bacterial two-component systems monitor environmental parameters through a sensor histidine-kinase/phosphatase, which phosphorylates/dephosphorylates a response regulator that in turn mediates changes in gene expression. These results indicate that signal transduction is critical for the bactericidal activity of antibiotics. Experimental meningitis caused by the vncS mutant failed to respond to vancomycin. Clinical isolates tolerant to vancomycin were identified and DNA sequencing revealed nucleotide alterations in vncS. We conclude that broad antibiotic tolerance of S. pneumoniae has emerged in the community by a molecular mechanism that eliminates sensitivity to the current cornerstone of therapy vancomycin.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA; Karolinska Inst, Swedish Inst Infect Dis Control, S-17182 Stockholm, Sweden	St Jude Children's Research Hospital; Karolinska Institutet; Swedish Institute for Infectious Disease Control	Tuomanen, E (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	elaine.tuomanen@stjude.org	Tuomanen, Elaine I/N-3081-2018	Tuomanen, Elaine I/0000-0003-0349-8716				*AM AC PED, 1997, RED BOOK REP COMM IN, P410; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P626; CHEN JD, 1987, GENE, V55, P179, DOI 10.1016/0378-1119(87)90278-2; Dowson CG, 1997, J APPL MICROBIOL, V83, pS42, DOI 10.1046/j.1365-2672.83.s1.5.x; Evers S, 1996, J BACTERIOL, V178, P1302, DOI 10.1128/jb.178.5.1302-1309.1996; FRIEDLAND IR, 1992, PEDIATR INFECT DIS J, V11, P433, DOI 10.1097/00006454-199206000-00002; HOLMAN TR, 1994, BIOCHEMISTRY-US, V33, P4625, DOI 10.1021/bi00181a024; HOLTJE JV, 1991, J GEN MICROBIOL, V137, P441, DOI 10.1099/00221287-137-3-441; LACKS S, 1960, BIOCHIM BIOPHYS ACTA, V39, P508, DOI 10.1016/0006-3002(60)90205-5; LIU HH, 1985, J INFECT DIS, V152, P365, DOI 10.1093/infdis/152.2.365; MartinezHackert E, 1997, STRUCTURE, V5, P109, DOI 10.1016/S0969-2126(97)00170-6; MOREILLON P, 1990, ANTIMICROB AGENTS CH, V34, P33, DOI 10.1128/AAC.34.1.33; MURAKAMI K, 1989, J BACTERIOL, V171, P874, DOI 10.1128/jb.171.2.874-879.1989; Novak R, 1998, MOL MICROBIOL, V29, P1285, DOI 10.1046/j.1365-2958.1998.01016.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; PEARCE BJ, 1993, MOL MICROBIOL, V9, P1037, DOI 10.1111/j.1365-2958.1993.tb01233.x; QUAGLIARELLO V, 1992, NEW ENGL J MED, V327, P864, DOI 10.1056/NEJM199209173271208; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; SHOCKLEY TE, 1970, GENETICS, V64, P397; Silva JC, 1998, P NATL ACAD SCI USA, V95, P11951, DOI 10.1073/pnas.95.20.11951; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAUBER MG, 1994, METHOD ENZYMOL, V235, P92; TOMASZ A, 1964, P NATL ACAD SCI USA, V51, P480, DOI 10.1073/pnas.51.3.480; TOMASZ A, 1970, NATURE, V227, P138, DOI 10.1038/227138a0; TUOMANEN E, 1988, J INFECT DIS, V158, P36, DOI 10.1093/infdis/158.1.36; WILLIAMSON R, 1980, J BACTERIOL, V144, P105, DOI 10.1128/JB.144.1.105-113.1980; ZIGHELBOIM S, 1981, REV INFECT DIS, V3, P267	29	271	287	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 10	1999	399	6736					590	593		10.1038/21202	http://dx.doi.org/10.1038/21202			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	204RR	10376600				2022-12-24	WOS:000080778400057
J	Hull, CM; Johnson, AD				Hull, CM; Johnson, AD			Identification of a mating type-like locus in the asexual pathogenic yeast Candida albicans	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; SEXUAL DEVELOPMENT; HOMOLOG; FUNGUS	Candida albicans, the most prevalent fungal pathogen in humans, is thought to lack a sexual cycle. A set of C. albicans genes has been identified that corresponds to the master sexual cycle regulators a1, alpha 1, and alpha 2 of the Saccharomyces cerevisiae mating-type (MAT) Locus. The C. albicans genes are arranged in a way that suggests that these genes are part of a mating type-like Locus that is similar to the mating-type Loci of other fungi. In addition to the transcriptional regulators a1, alpha 1, and alpha 2, the C. albicans mating type-like Locus contains several genes not seen in other fungal MAT Loci, including those encoding proteins similar to poly(A) polymerases, oxysterol binding proteins, and phosphatidylinositol kinases.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Johnson, AD (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.				NIGMS NIH HHS [GM37049] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037049] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andre AD, 1995, INT J AVIAT PSYCHOL, V5, P1, DOI 10.1207/s15327108ijap0501_1; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; Casselton LA, 1998, MICROBIOL MOL BIOL R, V62, P55, DOI 10.1128/MMBR.62.1.55-70.1998; Chibana H, 1998, GENETICS, V149, P1739; Coppin E, 1997, MICROBIOL MOL BIOL R, V61, P411, DOI 10.1128/.61.4.411-428.1997; Cormack BP, 1997, MICROBIOL-UK, V143, P303, DOI 10.1099/00221287-143-2-303; Diener AC, 1996, GENETICS, V143, P769; FONZI WA, 1993, GENETICS, V134, P717; HERSKOWITZ I, 1992, MOL CELLULAR BIOL YE, V2, P583; HULL CM, UNPUB; Jin YS, 1999, MOL CELL BIOL, V19, P585; JOHNSON AD, 1985, CELL, V42, P237, DOI 10.1016/S0092-8674(85)80119-7; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELLY M, 1988, EMBO J, V7, P1537, DOI 10.1002/j.1460-2075.1988.tb02973.x; Keogh RS, 1998, YEAST, V14, P443, DOI 10.1002/(SICI)1097-0061(19980330)14:5<443::AID-YEA243>3.0.CO;2-L; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; MILLER AM, 1984, EMBO J, V3, P1061, DOI 10.1002/j.1460-2075.1984.tb01927.x; Odds FC., 1988, CANDIDA CANDIDOSIS; Raymond M, 1998, MOL MICROBIOL, V27, P587, DOI 10.1046/j.1365-2958.1998.00704.x; SADHU C, 1992, MOL CELL BIOL, V12, P1977, DOI 10.1128/MCB.12.5.1977; Sharon A, 1996, MOL GEN GENET, V251, P60, DOI 10.1007/BF02174345; Turgeon BG, 1998, ANNU REV PHYTOPATHOL, V36, P115, DOI 10.1146/annurev.phyto.36.1.115	22	278	319	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 20	1999	285	5431					1271	1275		10.1126/science.285.5431.1271	http://dx.doi.org/10.1126/science.285.5431.1271			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	228HC	10455055				2022-12-24	WOS:000082130200045
J	Teng, E; Squire, LR				Teng, E; Squire, LR			Memory for places learned long ago is intact after hippocampal damage	NATURE			English	Article							TOPOGRAPHIC DISORIENTATION; RETROGRADE-AMNESIA; LESIONS; MONKEYS; HUMANS; RATS	The hippocampus is part of a system of structures in the medial temporal lobe that are essential for memory(1-3). One influential view of hippocampal function emphasizes its role in the acquisition and retrieval of spatial knowledge(4,5). By this view, the hippocampus constructs and stores spatial maps and is therefore essential for learning and remembering places, including those learned about long ago. We tested a profoundly amnesic patient (E.P.), who has virtually complete bilateral damage to the hippocampus and extensive damage to adjacent structures in the medial temporal lobe. We asked him to recall the spatial layout of the region where he grew up, from which he moved away more than 50 years ago. E.P. performed as well as or better than age-matched control subjects who grew up in the same region and also moved away. In contrast, E.P. has no knowledge of his current neighbourhood, to which he moved after he became amnesic. Our results show that the medial temporal lobe is not the permanent repository of spatial maps, and support the view that the hippocampus and other structures in the medial temporal lobe are essential for the formation of long-term declarative memories, both spatial and non-spatial, but not for the retrieval of very remote memories, either spatial or non-spatial(3,6).	Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Psychol, La Jolla, CA 92093 USA; Vet Affairs Med Ctr, San Diego, CA 92161 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Squire, LR (corresponding author), Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA.							Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Batschelet E, 1965, STAT METHODS ANAL PR; BOTTINI G, 1990, NEUROPSYCHOLOGIA, V28, P309, DOI 10.1016/0028-3932(90)90024-I; Cave C B, 1991, Hippocampus, V1, P329, DOI 10.1002/hipo.450010323; Cohen NJ, 1993, MEMORY AMNESIA HIPPO; dellaRocchetta AI, 1996, CORTEX, V32, P727, DOI 10.1016/S0010-9452(96)80042-6; DERENZI E, 1977, J NEUROL NEUROSUR PS, V40, P498, DOI 10.1136/jnnp.40.5.498; Hamann SB, 1997, BEHAV NEUROSCI, V111, P850, DOI 10.1037/0735-7044.111.4.850; Jarrard LE, 1995, BEHAV BRAIN RES, V71, P1, DOI 10.1016/0166-4328(95)00034-8; LEVINE DN, 1985, NEUROLOGY, V35, P1010, DOI 10.1212/WNL.35.7.1010; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; Maguire EA, 1996, P ROY SOC B-BIOL SCI, V263, P1745, DOI 10.1098/rspb.1996.0255; Maguire EA, 1996, NEUROPSYCHOLOGIA, V34, P993, DOI 10.1016/0028-3932(96)00022-X; Maguire EA, 1997, J NEUROSCI, V17, P7103; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nadel L, 1997, CURR OPIN NEUROBIOL, V7, P217, DOI 10.1016/S0959-4388(97)80010-4; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Pai MC, 1997, J FORMOS MED ASSOC, V96, P660; PATERSON A, 1945, BRAIN, V68, P188, DOI 10.1093/brain/68.3.188; Reed JM, 1997, BEHAV NEUROSCI, V111, P1163, DOI 10.1037/0735-7044.111.6.1163; Reed JM, 1998, J NEUROSCI, V18, P3943; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Takahashi N, 1997, NEUROLOGY, V49, P464, DOI 10.1212/WNL.49.2.464; Wechsler D., 1997, WECHSLER MEMORY SCAL, Vthird	28	256	260	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 12	1999	400	6745					675	677		10.1038/23276	http://dx.doi.org/10.1038/23276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	226QU	10458163				2022-12-24	WOS:000082032900056
J	Kurachi, S; Deyashiki, Y; Takeshita, L; Kurachi, K				Kurachi, S; Deyashiki, Y; Takeshita, L; Kurachi, K			Genetic mechanisms of age regulation of human blood coagulation factor IX	SCIENCE			English	Article							GLASGOW MONICA SURVEY; RISK-FACTORS; CARDIOVASCULAR-DISEASE; ACTIVATION MARKERS; BINDING MOTIF; FACTOR-VIII; ETS-DOMAIN; SEX; L1; EXPRESSION	Blood coagulation capacity increases with age in healthy individuals. Through extensive Longitudinal analyses of human factor IX gene expression in transgenic mice, two essential age-regulatory elements, AE5' and AE3', have been identified. These elements are required and together are sufficient for normal age regulation of factor IX expression. AE5', a PEA-3 related element present in the 5' upstream region of the gene encoding factor IX, is responsible for age-stable expression of the gene. AE3', in the middle of the 3' untranslated region, is responsible for age-associated elevation in messenger RNA Levels. In a concerted manner, AE5' and AE3' recapitulate natural patterns of the advancing age-associated increase in factor IX gene expression.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Kurachi, K (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038644, R01HL053713] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013283] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53713, HL38644] Funding Source: Medline; NIA NIH HHS [AG13283] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDREW M, 1988, BLOOD, V72, P1651; ANDREW M, 1987, BLOOD, V70, P165, DOI 10.1182/blood.V70.1.165.165; ANDREW M, 1992, BLOOD, V80, P1998, DOI 10.1182/blood.V80.8.1998.1998; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; CONLAN MG, 1993, THROMB HAEMOSTASIS, V70, P380; CONLON MG, 1994, THROMB HAEMOSTASIS, V72, P551; DOMBROSKI BA, 1994, MOL CELL BIOL, V14, P4485, DOI 10.1128/MCB.14.7.4485; DOMBROSKI BA, 1993, P NATL ACAD SCI USA, V90, P6513, DOI 10.1073/pnas.90.14.6513; FISHER RJ, 1991, ONCOGENE, V6, P2249; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HOGAN F, 1994, MANIPULATING MOUSE E; HSU WK, UNPUB; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; KONKEL DA, 1978, CELL, V15, P1125, DOI 10.1016/0092-8674(78)90040-5; KURACHI K, 1993, BLOOD COAGUL FIBRIN, V4, P953, DOI 10.1097/00001721-199304060-00013; Kurachi S, 1996, THROMB HAEMOSTASIS, V76, P965; KURACHI S, 1994, BIOCHEMISTRY-US, V33, P1580, DOI 10.1021/bi00172a039; KURACHI S, 1995, J BIOL CHEM, V270, P5276, DOI 10.1074/jbc.270.10.5276; KURACHI S, 1998, BIOCHEMICA, V3, P43; KURACHI S, UNPUB; Lowe GDO, 1997, BRIT J HAEMATOL, V97, P775, DOI 10.1046/j.1365-2141.1997.1222936.x; MARI D, 1995, BLOOD, V85, P3144, DOI 10.1182/blood.V85.11.3144.bloodjournal85113144; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MINAKAMI R, 1992, NUCLEIC ACIDS RES, V20, P3139, DOI 10.1093/nar/20.12.3139; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; RODE JJ, 1996, NAT MED, V2, P293; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAITO H, 1991, DISORDERS HEMOSTASIS, P18; SALIER JP, 1990, J BIOL CHEM, V265, P7062; SWEENEY JD, 1993, AM J CLIN PATHOL, V99, P687, DOI 10.1093/ajcp/99.6.687; Woodward M, 1997, BRIT J HAEMATOL, V97, P785, DOI 10.1046/j.1365-2141.1997.1232935.x; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; YAO SN, 1991, THROMB HAEMOSTASIS, V65, P52; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049	36	41	45	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					739	743		10.1126/science.285.5428.739	http://dx.doi.org/10.1126/science.285.5428.739			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10426997				2022-12-24	WOS:000081765100056
J	Marcotte, EM; Pellegrini, M; Ng, HL; Rice, DW; Yeates, TO; Eisenberg, D				Marcotte, EM; Pellegrini, M; Ng, HL; Rice, DW; Yeates, TO; Eisenberg, D			Detecting protein function and protein-protein interactions from genome sequences	SCIENCE			English	Article							ESCHERICHIA-COLI; DNA; ASSOCIATION; STABILITY; SRC	A computational method is proposed for inferring protein interactions from genome sequences on the basis of the observation that some pairs of interacting proteins have homologs in another organism fused into a single protein chain. Searching sequences from many genomes revealed 6809 such putative protein-protein interactions in Escherichia coli and 45,502 in yeast. Many members of these pairs were confirmed as functionally related; computational filtering further enriches for interactions. Some proteins have links to several other proteins; these coupled links appear to represent functional interactions such as complexes or pathways. Experimentally confirmed interacting pairs are documented in a Database of interacting Proteins.	Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Dept Energy Lab Struct Biol & Mol Med, Dept Chem & Biochem, Box 951570, Los Angeles, CA 90095 USA.		Ng, Ho Leung/E-3419-2010	Ng, Ho Leung/0000-0002-6415-1938; Rice, Danny/0000-0002-1123-4617; Yeates, Todd/0000-0001-5709-9839; Marcotte, Edward/0000-0001-8808-180X; Pellegrini, Matteo/0000-0001-9355-9564	NIGMS NIH HHS [P01 GM 31299] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM031299] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1994, MOL BIOL CELL; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; FIELDS S, 1989, NATURE, V340, P243; HORTON N, 1992, PROTEIN SCI, V1, P169; Lodish H., 1995, MOL CELL BIOL; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; PEDERSEN S, 1978, CELL, V14, P179, DOI 10.1016/0092-8674(78)90312-4; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Robinson CR, 1998, P NATL ACAD SCI USA, V95, P5929, DOI 10.1073/pnas.95.11.5929; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SUGINO A, 1980, NUCLEIC ACIDS RES, V8, P3865, DOI 10.1093/nar/8.17.3865; Tsai CJ, 1996, J MOL BIOL, V260, P604, DOI 10.1006/jmbi.1996.0424; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YEH WK, 1981, J BIOL CHEM, V256, P1565	21	1242	1307	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 30	1999	285	5428					751	753		10.1126/science.285.5428.751	http://dx.doi.org/10.1126/science.285.5428.751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	222CD	10427000	Green Submitted			2022-12-24	WOS:000081765100059
J	Chin, L; Tam, A; Pomerantz, J; Wong, M; Holash, J; Bardeesy, N; Shen, Q; O'Hagan, R; Pantginis, J; Zhou, H; Horner, JW; Cordon-Cardo, C; Yancopoulos, GD; DePinho, RA				Chin, L; Tam, A; Pomerantz, J; Wong, M; Holash, J; Bardeesy, N; Shen, Q; O'Hagan, R; Pantginis, J; Zhou, H; Horner, JW; Cordon-Cardo, C; Yancopoulos, GD; DePinho, RA			Essential role for oncogenic Ras in tumour maintenance	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; TRANSGENIC MICE; FACTOR EXPRESSION; UP-REGULATION; ANGIOGENESIS; MELANOMA; CELLS; INDUCTION; HYPOXIA	Advanced malignancy in tumours represents the phenotypic endpoint of successive genetic lesions that affect the function and regulation of oncogenes and tumour-suppressor genes(1). The established tumour is maintained through complex and poorly understood host-tumour interactions that guide processes such as angiogenesis and immune sequestration. The many different genetic alterations that accompany tumour genesis raise questions as to whether experimental cancer-promoting mutations remain relevant during tumour maintenance. Here we show thar melanoma genesis and maintenance are strictly dependent upon expression of H-Ras(V12G) in a doxycycline-inducible H-Ras mouse melanoma model null for the tumour suppressor INK4a. Withdrawal of doxycycline and H-Ras(V12G) down-regulation resulted in clinical and histological regression of primary and explanted tumours. The initial stages of regression involved marked apoptosis in the tumour cells and host-derived endothelial cells. Although the regulation of vascular endothelial growth factor (VEGF) was found td be Ras-dependent in vitro, the failure of persistent endogenous and enforced VEGF expression to sustain tumour viability indicates that the tumour-maintaining actions of activated Ras extend beyond the regulation of VEGF expression in vivo. Our results provide genetic evidence that H-Ras(V12G) is important in both the genesis and maintenance of solid tumours.	Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA; Albert Einstein Coll Med, Bronx, NY 10461 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Yeshiva University; Albert Einstein College of Medicine; Memorial Sloan Kettering Cancer Center; Regeneron	DePinho, RA (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.			DePinho, Ronald/0000-0002-5625-577X				Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; BIRD IN, 1993, IMMUNOLOGY, V80, P553; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; Cheng LZ, 1996, NAT BIOTECHNOL, V14, P606, DOI 10.1038/nbt0596-606; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; DOHERTY PC, 1994, CIBA F SYMP, V187, P245; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; Gause PR, 1997, MOL CARCINOGEN, V20, P78, DOI 10.1002/(SICI)1098-2744(199709)20:1<78::AID-MC9>3.0.CO;2-E; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDBERG MA, 1994, J BIOL CHEM, V269, P4355; GRUGEL S, 1995, J BIOL CHEM, V270, P25915, DOI 10.1074/jbc.270.43.25915; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Larcher F, 1996, CANCER RES, V56, P5391; Mazure NM, 1996, CANCER RES, V56, P3436; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 1995, CANCER METAST REV, V14, P263, DOI 10.1007/BF00690598; Schreiber-Agus N, 1998, NATURE, V393, P483, DOI 10.1038/31008; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; THOMSON TM, 1988, J INVEST DERMATOL, V90, P459, DOI 10.1111/1523-1747.ep12460906; TRAWEEK ST, 1991, AM J CLIN PATHOL, V96, P25, DOI 10.1093/ajcp/96.1.25; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9	25	698	748	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 29	1999	400	6743					468	472		10.1038/22788	http://dx.doi.org/10.1038/22788			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	221FZ	10440378				2022-12-24	WOS:000081715000055
J	Chen, DK; McGeer, A; de Azavedo, JC; Low, DE				Chen, DK; McGeer, A; de Azavedo, JC; Low, DE		Canadian Bacterial Surveillance Network	Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PENICILLIN-RESISTANT PNEUMOCOCCI; ANTIMICROBIAL RESISTANCE; DNA GYRASE; IN-VITRO; CIPROFLOXACIN RESISTANCE; RESPIRATORY PATHOGENS; MULTIRESISTANT CLONE; TOPOISOMERASE-IV; UNITED-STATES; OTITIS-MEDIA	Background Fluoroquinolones are now recommended for the treatment of respiratory tract infections due to Streptococcus pneumoniae, particularly when the isolates are resistant to beta-lactam antibiotics. Although pneumococci with reduced susceptibility to fluoroquinolones have been identified, their prevalence has not been determined in a defined population. Methods We performed susceptibility testing on 7551 isolates of S. pneumoniae obtained from surveillance in Canada in 1988 and from 1993 to 1998. Pneumococci with reduced susceptibility to fluoroquinolones (defined as a minimal inhibitory concentration of ciprofloxacin of at least 4 mu g per milliliter) were further characterized. We also examined antibiotic prescriptions dispensed in Canadian retail pharmacies, Results Between 1988 and 1997 fluoroquinolone prescriptions increased from 0.8 to 5.5 per 100 persons per year. The prevalence of pneumococci with reduced susceptibility to fluoroquinolones increased from 0 percent in 1993 to 1.7 percent in 1997 and 1998 (P=0.01). Among adults, the prevalence increased from 1.5 percent in 1993 and 1994 combined to 2.9 percent in 1997 and 1998 combined. The prevalence was higher in isolates from older patients (2.6 percent among those 65 years of age or older vs. 1.0 percent among those 15 to 64 years of age, P<0.001) and among those from Ontario (1.5 percent, vs. 0.4 percent among those from the rest of Canada; P<0.001). Fluoroquinolone use was greatest among the elderly and in Ontario, The 75 isolates (17 serotypes) of pneumococci with reduced susceptibility to fluoroquinolones were submitted by 40 laboratories in eight provinces. Reduced susceptibility to fluoroquinolones was associated with resistance to penicillin. Conclusions The prevalence of pneumococci with reduced susceptibility to fluoroquinolones is increasing in Canada, probably as a result of selective pressure from the increased use of fluoroquinolones, (N Engl J Med 1999;341:233-9.) (C) 1999 Massachusetts Medical Society.	Mt Sinai Hosp, Dept Microbiol, Toronto, ON M5G 1X5, Canada; Toronto Hosp, Dept Microbiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Low, DE (corresponding author), Mt Sinai Hosp, Dept Microbiol, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		McGeer, Allison/AAB-6885-2020; Low, Donald/B-1726-2012; mcgeer, allison/H-7747-2014	McGeer, Allison/0000-0001-5647-6137; mcgeer, allison/0000-0001-5647-6137				Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Ballow CH, 1997, DIAGN MICR INFEC DIS, V29, P173, DOI 10.1016/S0732-8893(97)81807-X; Barry AL, 1996, J ANTIMICROB CHEMOTH, V37, P365, DOI 10.1093/jac/37.2.365; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; Brook I, 1996, CLIN INFECT DIS, V22, P143, DOI 10.1093/clinids/22.1.143; Butler JC, 1996, J INFECT DIS, V174, P986, DOI 10.1093/infdis/174.5.986; Campbell GD, 1999, CHEST, V115, p14S, DOI 10.1378/chest.115.suppl_1.14S; Chodosh S, 1998, CLIN INFECT DIS, V27, P730, DOI 10.1086/514934; Coffey TJ, 1996, MICROBIOL-UK, V142, P2747, DOI 10.1099/13500872-142-10-2747; DALHOFF A, 1998, 8 INT C INF DIS BOST, P124; Doern GV, 1998, CLIN INFECT DIS, V27, P764, DOI 10.1086/514953; Doern GV, 1996, ANTIMICROB AGENTS CH, V40, P1208, DOI 10.1128/AAC.40.5.1208; DOUIDAR SM, 1989, REV INFECT DIS, V11, P878; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; Fuchs PC, 1997, J ANTIMICROB CHEMOTH, V39, P671, DOI 10.1093/jac/39.5.671; Goldsmith CE, 1998, J ANTIMICROB CHEMOTH, V41, P420, DOI 10.1093/jac/41.3.420; Goldsmith CE, 1997, J ANTIMICROB CHEMOTH, V40, P11, DOI 10.1093/jac/40.suppl_1.11; Goldstein FW, 1996, J ANTIMICROB CHEMOTH, V38, P71, DOI 10.1093/jac/38.suppl_A.71; Gruneberg RN, 1996, DIAGN MICR INFEC DIS, V25, P169, DOI 10.1016/S0732-8893(96)00135-6; Hall LMC, 1998, J CLIN PATHOL, V51, P270, DOI 10.1136/jcp.51.4.270; Hooper DC, 1998, ANN INTERN MED, V129, P908, DOI 10.7326/0003-4819-129-11_Part_1-199812010-00015; JANOIR C, 1998, CLIN INFECT DIS   S1, V27, pS54; KAM KM, 1995, ANTIMICROB AGENTS CH, V39, P2667, DOI 10.1128/AAC.39.12.2667; KRISTINSSON KG, 1992, LANCET, V339, P1606, DOI 10.1016/0140-6736(92)91868-9; LEE BL, 1991, NEW ENGL J MED, V325, P520; LOVGREN M, 1998, CMAJ, V158, P27; MARCHESE A, 1995, J ANTIMICROB CHEMOTH, V36, P833, DOI 10.1093/jac/36.5.833; Mittermayer H, 1996, EUR J CLIN MICROBIOL, V15, P817, DOI 10.1007/BF01701526; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; Munoz R, 1996, ANTIMICROB AGENTS CH, V40, P2252, DOI 10.1128/AAC.40.10.2252; MURRAY BE, 1990, J CLIN MICROBIOL, V28, P2059, DOI 10.1128/JCM.28.9.2059-2063.1990; MURRAY BE, 1991, J CLIN MICROBIOL, V29, P418; *NAT COMM CLIN LAB, 1998, M100SB NCCLS; Pan XS, 1996, ANTIMICROB AGENTS CH, V40, P2321, DOI 10.1128/AAC.40.10.2321; Rahal K, 1997, CLIN INFECT DIS, V24, pS169, DOI 10.1093/clinids/24.Supplement_1.S169; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; Richard MP, 1998, J ANTIMICROB CHEMOTH, V41, P207, DOI 10.1093/jac/41.2.207; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; Setchanova L, 1995, MICROB DRUG RESIST, V1, P79, DOI 10.1089/mdr.1995.1.79; Simor AE, 1996, ANTIMICROB AGENTS CH, V40, P2190, DOI 10.1128/AAC.40.9.2190; SOARES S, 1993, J INFECT DIS, V168, P158, DOI 10.1093/infdis/168.1.158; SREEDHARAN S, 1991, ANTIMICROB AGENTS CH, V35, P2151, DOI 10.1128/AAC.35.10.2151; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; Tankovic J, 1996, ANTIMICROB AGENTS CH, V40, P2505, DOI 10.1128/AAC.40.11.2505; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; Thornsberry C, 1997, DIAGN MICR INFEC DIS, V29, P249, DOI 10.1016/S0732-8893(97)00195-8; Wang EEL, 1998, CAN FAM PHYSICIAN, V44, P1881; Wise R, 1996, LANCET, V348, P1660, DOI 10.1016/S0140-6736(05)65724-8; Wise R, 1997, J ANTIMICROB CHEMOTH, V40, P27, DOI 10.1093/jac/40.suppl_1.27; YOSHIDA R, 1995, ANTIMICROB AGENTS CH, V39, P1196, DOI 10.1128/AAC.39.5.1196; Zhao XL, 1997, P NATL ACAD SCI USA, V94, P13991, DOI 10.1073/pnas.94.25.13991	51	843	867	0	44	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					233	239		10.1056/NEJM199907223410403	http://dx.doi.org/10.1056/NEJM199907223410403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413735				2022-12-24	WOS:000081528800003
J	Cline, GW; Petersen, KF; Krssak, M; Shen, J; Hundal, RS; Trajanoski, Z; Inzucchi, S; Dresner, A; Rothman, DL; Shulman, GI				Cline, GW; Petersen, KF; Krssak, M; Shen, J; Hundal, RS; Trajanoski, Z; Inzucchi, S; Dresner, A; Rothman, DL; Shulman, GI			Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBCUTANEOUS ADIPOSE-TISSUE; SKELETAL-MUSCLE; SYNTHASE ACTIVITY; HEXOKINASE-II; BETA-CELL; NIDDM; RESISTANCE; MELLITUS; PHOSPHORYLATION; DEFICIENCY	Background Insulin resistance, a major factor in the pathogenesis of type 2 diabetes mellitus, is due mostly to decreased stimulation of glycogen synthesis in muscle by insulin. The primary rate-controlling step responsible for the decrease in muscle glycogen synthesis is not known, although hexokinase activity and glucose transport have been implicated. Methods We used a novel nuclear magnetic resonance approach with carbon-13 and phosphorus-31 to measure intramuscular glucose, glucose-6-phosphate, and glycogen concentrations under hyperglycemic conditions (plasma glucose concentration, approximately 180 mg per deciliter [10 mmol per liter]) and hyperinsulinemic conditions in six patients with type 2 diabetes and seven normal subjects. In vivo microdialysis of muscle tissue was used to determine the gradient between plasma and interstitial-fluid glucose concentrations, and open-flow microperfusion was used to determine the concentrations of insulin in interstitial fluid. Results The time course and concentration of insulin in interstitial fluid were similar in the patients with diabetes and the normal subjects. The rates of whole-body glucose metabolism and muscle glycogen synthesis and the glucose-6-phosphate concentrations in muscle were approximately 80 percent lower in the patients with diabetes than in the normal subjects under conditions of matched plasma insulin concentrations. The mean (+/-SD) intracellular glucose concentration was 2.0+/-8.2 mg per deciliter (0.11+/-0.46 mmol per liter) in the normal subjects. In the patients with diabetes, the intracellular glucose concentration was 4.3+/-4.9 mg per deciliter (0.24+/-0.27 mmol per liter), a value that was 1/25 of what it would be if hexokinase were the rate-controlling enzyme in glucose metabolism. Conclusions Impaired insulin-stimulated glucose transport is responsible for the reduced rate of insulin-stimulated muscle glycogen synthesis in patients with type 2 diabetes mellitus. (N Engl J Med 1999;341:240-6.) (C) 1999, Massachusetts Medical Society.	Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Internal Med, New Haven, CT 06536 USA; Yale Univ, Sch Med, Dept Diagnost Radiol, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	Shulman, GI (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Boyer Ctr Mol Med,Dept Internal Med, POB 9812, New Haven, CT 06536 USA.		Trajanoski, Zlatko/AAT-6703-2021; Inzucchi, Silvio/ABF-4121-2021; Krssak, Martin/AAU-8183-2020; Shulman, Gerald I./P-7176-2019	Krssak, Martin/0000-0001-9717-803X; Shulman, Gerald I./0000-0003-1529-5668	NCRR NIH HHS [MO1 RR-00125] Funding Source: Medline; NIDDK NIH HHS [R01 DK-49230, P30 DK-45735] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000125] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK045735, R01DK049230] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOGARDUS C, 1984, J CLIN INVEST, V73, P1185, DOI 10.1172/JCI111304; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; CAHILL GF, 1988, NEW ENGL J MED, V318, P1268, DOI 10.1056/NEJM198805123181909; Cline GW, 1999, DIABETES, V48, pA273; Cline GW, 1998, AM J PHYSIOL-ENDOC M, V274, pE381, DOI 10.1152/ajpendo.1998.274.2.E381; DAMSBO P, 1991, DIABETOLOGIA, V34, P239, DOI 10.1007/BF00405082; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; DOHM GL, 1988, J CLIN INVEST, V82, P486, DOI 10.1172/JCI113622; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; HAFFNER SM, 1990, METABOLISM, V39, P842, DOI 10.1016/0026-0495(90)90130-5; KASANICKI MA, 1990, DIABETES CARE, V13, P219, DOI 10.2337/diacare.13.3.219; Kelley DE, 1996, J CLIN INVEST, V97, P2705, DOI 10.1172/JCI118724; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; LILLIOJA S, 1988, NEW ENGL J MED, V318, P1217, DOI 10.1056/NEJM198805123181901; LILLIOJA S, 1986, J CLIN ENDOCR METAB, V62, P922, DOI 10.1210/jcem-62-5-922; Moberg E, 1997, DIABETOLOGIA, V40, P1320, DOI 10.1007/s001250050827; *NAT DIS DAT GROUP, 1995, NIH PUBL; Nolan JJ, 1997, DIABETES, V46, P994, DOI 10.2337/diabetes.46.6.994; REAVEN GM, 1976, AM J MED, V60, P80, DOI 10.1016/0002-9343(76)90536-2; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Saccomani MP, 1996, AM J PHYSIOL-ENDOC M, V270, pE170, DOI 10.1152/ajpendo.1996.270.1.E170; Shen J, 1996, J MAGN RESON SER B, V112, P131, DOI 10.1006/jmrb.1996.0123; SHULMAN GI, 1990, NEW ENGL J MED, V322, P223, DOI 10.1056/NEJM199001253220403; SHULMAN RG, 1995, P NATL ACAD SCI USA, V92, P8535, DOI 10.1073/pnas.92.19.8535; Trajanoski Z, 1997, DIABETES CARE, V20, P1114, DOI 10.2337/diacare.20.7.1114; WARRAM JH, 1990, ANN INTERN MED, V113, P909, DOI 10.7326/0003-4819-113-12-909; WRIGHT KS, 1988, DIABETES, V37, P436, DOI 10.2337/diabetes.37.4.436; YANG YJ, 1989, J CLIN INVEST, V84, P1620, DOI 10.1172/JCI114339; Zierath JR, 1996, DIABETOLOGIA, V39, P1180, DOI 10.1007/BF02658504	30	464	479	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1999	341	4					240	246		10.1056/NEJM199907223410404	http://dx.doi.org/10.1056/NEJM199907223410404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	217ZL	10413736				2022-12-24	WOS:000081528800004
J	Torrance, CJ; Das, R; Allison, MC				Torrance, CJ; Das, R; Allison, MC			Use of chaperones in clinics for genitourinary medicine: survey of consultants	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTITIONERS		Royal Gwent Hosp, Dept Genitourinary Med, Newport NP9 2UB, Gwent, Wales; Royal Gwent Hosp, Dept Adult Med, Newport NP9 2UB, Gwent, Wales	Royal Gwent Hospital; Royal Gwent Hospital	Allison, MC (corresponding author), Royal Gwent Hosp, Dept Genitourinary Med, Newport NP9 2UB, Gwent, Wales.							JONES RH, 1983, J ROY COLL GEN PRACT, V33, P25; PENN MA, 1992, J FAM PRACTICE, V35, P639; *ROYAL COLL OBST G, 1997, INT EX REP WORK PART; SPEELMAN A, 1993, BRIT MED J, V307, P986, DOI 10.1136/bmj.307.6910.986	4	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1999	319	7203					159	160		10.1136/bmj.319.7203.159	http://dx.doi.org/10.1136/bmj.319.7203.159			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	219QY	10406750	Bronze, Green Published			2022-12-24	WOS:000081619300021
J	Tsuda, M; Kamimura, K; Nakato, H; Archer, M; Staatz, W; Fox, B; Humphrey, M; Olson, S; Futch, T; Kaluza, V; Siegfried, E; Stam, L; Selleck, SB				Tsuda, M; Kamimura, K; Nakato, H; Archer, M; Staatz, W; Fox, B; Humphrey, M; Olson, S; Futch, T; Kaluza, V; Siegfried, E; Stam, L; Selleck, SB			The cell-surface proteoglycan Dally regulates Wingless signalling in Drosophila	NATURE			English	Article							SEGMENT POLARITY GENES; NERVOUS-SYSTEM; EMBRYO; PROTEIN; GLYCOSAMINOGLYCANS; TRANSCRIPTION; MELANOGASTER; BIOSYNTHESIS; EXPRESSION; SECRETION	Wingless (Wg) is a member of the Wnt family of growth factors, secreted proteins that control proliferation and differentiation during development. Studies in Drosophila have shown that responses to Wg require cell-surface heparan sulphate, a glycosaminoglycan component of proteoglycans(1-4). These findings suggest that a cell-surface proteoglycan is a component of a Wg/Wnt receptor complex. We demonstrate here that the protein encoded by the division abnormally delayed (dally) gene is a cell-surface, heparan-sulphate-modified proteoglycan(5,6). dally partial loss-of-function mutations compromise Wg-directed events, and disruption of daily function with RNA interference produces phenotypes comparable to those found with RNA interference of wg or frizzled (fz)/Dfz2 (ref. 7). Ectopic expression of Daily potentiates Wg signalling without altering levels of Wg and can rescue a wg partial loss-of-function mutant, We also show that dally a regulator of Decapentaplegic (DFP) signalling during post-embryonic development, has tissue-specific effects on Wg and Dpp signalling. Daily can therefore differentially influence signalling mediated by two growth factors, and may form a regulatory component of both Wg and Dpp receptor complexes.	Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Div Neurobiol, Tucson, AZ 85721 USA; Tokyo Metropolitan Univ, Dept Biol, Hachioji, Tokyo, Japan; Penn State Univ, Dept Biol, University Pk, PA 16802 USA; Novartis Inc, Res Triangle Pk, NC 27709 USA	University of Arizona; University of Arizona; Tokyo Metropolitan University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Novartis	Selleck, SB (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.			Archer, Michael/0000-0002-0304-4039				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bhat KM, 1998, CELL, V95, P1027, DOI 10.1016/S0092-8674(00)81726-2; Binari RC, 1997, DEVELOPMENT, V124, P2623; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; Emerald BS, 1998, DEV GENES EVOL, V208, P504, DOI 10.1007/s004270050209; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GUO Y, 1989, ANAL BIOCHEM, V176, P96, DOI 10.1016/0003-2697(89)90278-9; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; HEMPEL J, 1994, PROTEIN SCI, V3, P1074, DOI 10.1002/pro.5560030710; HERNDON ME, 1990, NEURON, V4, P949, DOI 10.1016/0896-6273(90)90148-9; INGHAM PW, 1985, GENETICS, V111, P463; INGHAM PW, 1993, DEVELOPMENT, V117, P283; Jackson SM, 1997, DEVELOPMENT, V124, P4113; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; Lindahl B, 1997, J BIOL CHEM, V272, P26091, DOI 10.1074/jbc.272.42.26091; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller HAJ, 1999, DEVELOPMENT, V126, P577; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; PATEL NH, 1994, METHOD CELL BIOL, V44, P445, DOI 10.1016/S0091-679X(08)60927-9; PEIFER M, 1994, DEVELOPMENT, V120, P369; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; VANDENHEUVEL M, 1993, EMBO J, V12, P5293, DOI 10.1002/j.1460-2075.1993.tb06225.x; VANLEEUWEN F, 1994, NATURE, V368, P342, DOI 10.1038/368342a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	29	333	343	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 15	1999	400	6741					276	280		10.1038/22336	http://dx.doi.org/10.1038/22336			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	217MP	10421371				2022-12-24	WOS:000081503800047
J	Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG				Hassan, TB; MacNamara, AF; Davy, A; Bing, A; Bodiwala, GG			Lesson of the week - Managing patients with deliberate self harm who refuse treatment in the accident and emergency department	BRITISH MEDICAL JOURNAL			English	Article									Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England		Hassan, TB (corresponding author), Leicester Royal Infirm NHS Trust, Dept Accid & Emergency Med, Leicester LE1 5WW, Leics, England.							*BRIT ASS ACC EM M, 1996, DIR 1996; *BRIT MED ASS, 1993, RIGHTS RESP DOCT; British Medical Association, 1995, ASS MENT CAP GUID DO; HAWTON K, 1996, ATTEMPTED SUICIDE OX; *MED DEF UN, 1996, CONS TREATM; *MEN PROT SOC, 1998, CONS	6	14	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1999	319	7202					107	109		10.1136/bmj.319.7202.107	http://dx.doi.org/10.1136/bmj.319.7202.107			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	216JD	10398639	Green Published			2022-12-24	WOS:000081438200038
J	Wang, HC; Bloom, O; Zhang, MH; Vishnubhakat, JM; Ombrellino, M; Che, JT; Frazier, A; Yang, H; Ivanova, S; Borovikova, L; Manogue, KR; Faist, E; Abraham, E; Andersson, J; Andersson, U; Molina, PE; Abumrad, NN; Sama, A; Tracey, KJ				Wang, HC; Bloom, O; Zhang, MH; Vishnubhakat, JM; Ombrellino, M; Che, JT; Frazier, A; Yang, H; Ivanova, S; Borovikova, L; Manogue, KR; Faist, E; Abraham, E; Andersson, J; Andersson, U; Molina, PE; Abumrad, NN; Sama, A; Tracey, KJ			HMG-1 as a late mediator of endotoxin lethality in mice	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; GROUP-1 PROTEIN HMG1; SEPTIC SHOCK; CHROMOSOMAL-PROTEINS; RECEPTOR ANTAGONIST; DEFICIENT MICE; FACTOR-ALPHA; GENE; AMPHOTERIN; CACHECTIN	Endotoxin, a constituent of Gram-negative bacteria, stimulates macrophages to release Large quantities of tumor necrosis factor (TNF) and interleukin-1 (IL-1), which can precipitate tissue injury and lethal shock (endotoxemia). Antagonists of TNF and IL-1 have shown Limited efficacy in clinical trials, possibly because these cytokines are early mediators in pathogenesis, Here a potential Late mediator of Lethality is identified and characterized in a mouse model. High mobility group-1 (HMG-1) protein was found to be released by cultured macrophages more than 8 hours after stimulation with endotoxin, TNF, or IL-1. Mice showed increased serum Levels of HMG-1 from 8 to 32 hours after endotoxin exposure. Delayed administration of antibodies to HMG-1 attenuated endotoxin lethality in mice, and administration of HMG-1 itself was lethal. Septic patients who succumbed to infection had increased serum HMG-1 levels, suggesting that this protein warrants investigation as a therapeutic target.	NYU, Sch Med, N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA; NYU, Sch Med, N Shore Univ Hosp, Dept Surg, Manhasset, NY 11030 USA; Picower Inst Med Res, Manhasset, NY 11030 USA; Univ Munich, Klinikum Grosshadern, Dept Surg, D-8000 Munich, Germany; Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Huddinge Univ Hosp, Karolinska Inst, Dept Infect Dis, Stockholm, Sweden; Karolinska Inst, Astrid Lindgrens Childrens Hosp, Dept Rheumatol, Stockholm, Sweden	New York University; Northwell Health; North Shore University Hospital; New York University; Northwell Health; North Shore University Hospital; Northwell Health; University of Munich; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Karolinska Institutet; Karolinska Institutet	Wang, HC (corresponding author), NYU, Sch Med, N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA.		Andersson, Ulf/ABD-5162-2021; Wang, Haichao/AAU-2237-2021; Molina, Patricia E./AAK-9814-2021; Wang, Haichao/K-6310-2012	Andersson, Ulf/0000-0003-0316-3860; Wang, Haichao/0000-0002-0211-9000; Molina, Patricia E./0000-0002-3598-384X; Wang, Haichao/0000-0002-0211-9000; BLOOM, ONA/0000-0002-8340-2392; Tracey, Kevin J/0000-0003-1884-6314				ALEXANDER HR, 1991, J EXP MED, V173, P1029, DOI 10.1084/jem.173.4.1029; Amiot F, 1997, MOL MED, V3, P864, DOI 10.1007/BF03401722; Bao J, UNPUB; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; Bianchi M, 1996, J EXP MED, V183, P927, DOI 10.1084/jem.183.3.927; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BUSTIN M, 1979, CELL, V16, P181, DOI 10.1016/0092-8674(79)90199-5; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; Ferrari S, 1996, GENOMICS, V35, P367, DOI 10.1006/geno.1996.0369; FERRARI S, 1994, J BIOL CHEM, V269, P28803; FINK MP, 1995, CRIT CARE MED, V23, P989, DOI 10.1097/00003246-199506000-00001; FINK MP, 1990, J SURG RES, V49, P186, DOI 10.1016/0022-4804(90)90260-9; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; HORI O, 1995, J BIOL CHEM, V270, P25752, DOI 10.1074/jbc.270.43.25752; KILLION JW, 1986, INFECT IMMUN, V54, P1; LANDSMAN D, 1993, BIOESSAYS, V15, P539, DOI 10.1002/bies.950150807; LEE KLD, 1987, NUCLEIC ACIDS RES, V15, P5051, DOI 10.1093/nar/15.13.5051; Maher JF, 1996, P NATL ACAD SCI USA, V93, P6716, DOI 10.1073/pnas.93.13.6716; Marino MW, 1997, P NATL ACAD SCI USA, V94, P8093, DOI 10.1073/pnas.94.15.8093; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; MOLDAWER LL, 1994, CRIT CARE MED, V22, pS3; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PARKKINEN J, 1993, J BIOL CHEM, V268, P19726; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; REMICK DG, 1990, AM J PATHOL, V136, P49; SALMIVIRTA M, 1992, EXP CELL RES, V200, P444, DOI 10.1016/0014-4827(92)90194-D; Tracey KJ, 1999, SHOCK, V11, P224, DOI 10.1097/00024382-199903000-00012; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; WAKABAYASHI GO, 1991, FASEB J, V5, P338, DOI 10.1096/fasebj.5.3.1825816; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4; Walker RE, 1996, J INFECT DIS, V174, P63, DOI 10.1093/infdis/174.1.63	37	2712	3144	2	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 9	1999	285	5425					248	251		10.1126/science.285.5425.248	http://dx.doi.org/10.1126/science.285.5425.248			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	214UM	10398600				2022-12-24	WOS:000081346000040
J	Wingrove, JA; O'Farrell, PH				Wingrove, JA; O'Farrell, PH			Nitric oxide contributes to behavioral, cellular, and developmental responses to low oxygen in Drosophila	CELL			English	Article							HYPOXIA-INDUCIBLE FACTOR-1; DEPENDENT PROTEIN-KINASE; GUANYLATE-CYCLASE; RIBONUCLEOTIDE REDUCTASE; RELAXING FACTOR; GENE ENCODES; CELLS; GROWTH; MELANOGASTER; SYNTHASE	A nitric oxide (NO)/cyclic GMP (cGMP) signaling pathway is thought to play an important role in mammalian vasodilation during hypoxia. We show that Drosophila utilizes components of this pathway to respond to hypoxia. Hypoxic exposure rapidly induced exploratory behavior in larvae and arrested the cell cycle. These behavioral and cellular responses were diminished by an inhibitor of NO synthase and by a polymorphism affecting a form of cGMP-dependent protein kinase. Conversely, these responses were induced by ectopic expression of NO synthase. Perturbing components of the NO/cGMP pathway altered both tracheal development and survival during prolonged hypoxia. These results indicate that NO and protein kinase G contribute to Drosophila's ability to respond to oxygen deprivation.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	O'Farrell, PH (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.			O'Farrell, Patrick/0000-0003-0011-2734	NIGMS NIH HHS [R01 GM037193, R01 GM037193-10, R01 GM037193-14] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037193] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; DEBELLE JS, 1989, GENETICS, V123, P157; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOE VE, 1989, DEVELOPMENT, V107, P1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GERZER R, 1981, FEBS LETT, V132, P71, DOI 10.1016/0014-5793(81)80429-2; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Guillemin K, 1997, CELL, V89, P9, DOI 10.1016/S0092-8674(00)80176-2; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Ishida A, 1997, J BIOL CHEM, V272, P10050; KALDERON D, 1989, J BIOL CHEM, V264, P10738; Kantrow SP, 1997, AM J PHYSIOL-LUNG C, V272, pL1167, DOI 10.1152/ajplung.1997.272.6.L1167; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuzin B, 1996, CELL, V87, P639, DOI 10.1016/S0092-8674(00)81384-7; LEPOIVRE M, 1994, J BIOL CHEM, V269, P21891; Manning Gerards, 1993, P609; MEULEMANS A, 1994, NEUROSCI LETT, V171, P89, DOI 10.1016/0304-3940(94)90612-2; Millar Timothy M., 1997, Biochemical Society Transactions, V25, p528S; Nambu JR, 1996, GENE, V172, P249, DOI 10.1016/0378-1119(96)00060-1; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Poluha W, 1997, J BIOL CHEM, V272, P24002, DOI 10.1074/jbc.272.38.24002; Reutov VP, 1998, BIOCHEMISTRY-MOSCOW+, V63, P874; ROY B, 1995, BIOCHEMISTRY-US, V34, P5411, DOI 10.1021/bi00016a012; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Sciorati C, 1997, BRIT J PHARMACOL, V122, P687, DOI 10.1038/sj.bjp.0701413; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Sonnenfeld M, 1997, DEVELOPMENT, V124, P4571; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Truman JW, 1996, DEVELOPMENT, V122, P3949; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Whorton AR, 1997, AM J PHYSIOL-LUNG C, V272, pL1161, DOI 10.1152/ajplung.1997.272.6.L1161; Wildemann B, 1999, J NEUROBIOL, V38, P1, DOI 10.1002/(SICI)1097-4695(199901)38:1<1::AID-NEU1>3.0.CO;2-L; YAO KS, 1995, J NATL CANCER I, V87, P117, DOI 10.1093/jnci/87.2.117; Zhang Z, 1998, BIOCHEM BIOPH RES CO, V249, P767, DOI 10.1006/bbrc.1998.9226; [No title captured]	45	206	222	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUL 9	1999	98	1					105	114		10.1016/S0092-8674(00)80610-8	http://dx.doi.org/10.1016/S0092-8674(00)80610-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	216PL	10412985	Green Accepted, Green Submitted, Bronze			2022-12-24	WOS:000081451000012
J	Mellitzer, G; Xu, QL; Wilkinson, DG				Mellitzer, G; Xu, QL; Wilkinson, DG			Eph receptors and ephrins restrict cell intermingling and communication	NATURE			English	Article							NEURAL CREST MIGRATION; TRANSMEMBRANE LIGANDS; TYROSINE PHOSPHORYLATION; MOLECULAR-BASIS; GAP-JUNCTIONS; CHICK-EMBRYO; ADHESION; PERMEABILITY; RHOMBOMERES; ATTACHMENT	Eph proteins are receptors with tyrosine-kinase activity which, with their ephrin ligands, mediate contact-dependent cell interactions' that are implicated in the repulsion mechanisms that guide migrating cells and neuronal growth cones to specific destinations(2,3). Ephrin-B proteins have conserved cytoplasmic tyrosine residues that are phosphorylated upon interaction with an EphB receptor(4,5), and may transduce signals that regulate a cellular response(6). Because Eph receptors and ephrins have complementary expression in many tissues during embryogenesis(7), bidirectional activation of Eph receptors and ephrin-B proteins could occur at interfaces of their expression domains, for example at segment boundaries in the vertebrate hindbrain, Previous work(8,9) has implicated Eph receptors and ephrin-B proteins in the restriction of cell intermingling between hindbrain segments(10). We therefore analysed whether complementary expression of Eph receptors and ephrins restricts cell intermingling, and whether this requires bidirectional or unidirectional signalling. Here we report that bidirectional but not unidirectional signalling restricts the intermingling of adjacent cell populations, whereas unidirectional activation is sufficient to restrict cell communication through gap junctions. These results reveal that Eph receptors and ephrins regulate two aspects of cell behaviour that can stabilize a distinct identity of adjacent cell populations.	Natl Inst Med Res, Div Dev Neurobiol, London NW7 1AA, England	MRC National Institute for Medical Research	Wilkinson, DG (corresponding author), Natl Inst Med Res, Div Dev Neurobiol, Ridgeway,Mill Hill, London NW7 1AA, England.		Georg, Mellitzer/R-4180-2016	Georg, Mellitzer/0000-0003-4467-0789; Wilkinson, David/0000-0001-6757-7080				BAGNALL KM, 1992, ANAT EMBRYOL, V186, P195; Bruckner K, 1998, CURR OPIN NEUROBIOL, V8, P375, DOI 10.1016/S0959-4388(98)80064-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; FRASER S, 1990, NATURE, V344, P431, DOI 10.1038/344431a0; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Lo CW, 1996, J BIOENERG BIOMEMBR, V28, P379, DOI 10.1007/BF02110114; MARTINEZ S, 1992, DEVELOPMENT, V116, P1069; MARTINEZ S, 1995, MECH DEVELOP, V51, P289, DOI 10.1016/0925-4773(95)00376-2; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WARNER AE, 1982, CELL, V28, P243, DOI 10.1016/0092-8674(82)90342-7; Wizenmann A, 1997, MOL CELL NEUROSCI, V9, P448, DOI 10.1006/mcne.1997.0642; Xu QL, 1999, NATURE, V399, P267, DOI 10.1038/20452; Xu QL, 1995, DEVELOPMENT, V121, P4005; Zisch AH, 1997, J NEUROSCI RES, V47, P655, DOI 10.1002/(SICI)1097-4547(19970315)47:6<655::AID-JNR12>3.0.CO;2-U	28	398	411	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 1	1999	400	6739					77	81		10.1038/21907	http://dx.doi.org/10.1038/21907			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	213DA	10403252				2022-12-24	WOS:000081255700054
J	Hing, H; Xiao, J; Harden, N; Lim, L; Zipursky, SL				Hing, H; Xiao, J; Harden, N; Lim, L; Zipursky, SL			Pak functions downstream of dock to regulate photoreceptor axon guidance in Drosophila	CELL			English	Article							SH2/SH3 ADAPTER PROTEIN; GROWTH CONE GUIDANCE; KINASE PAK; ALPHA-PAK; ACTIN; GTPASES; FAMILY; CDC42; RAC; NCK	The SH2/SH3 adaptor protein Dock has been proposed to transduce signals from guidance receptors to the actin cytoskeleton in Drosophila photoreceptor (R cell) growth cones. Here, we demonstrate that Drosophila p21-activated kinase (Pak) is required in a Dock pathway regulating R cell axon guidance and targeting. Dock and Pak colocalize to R cell axons and growth cones, physically interact, and their loss-of-function phenotypes are indistinguishable. Normal patterns of R cell connectivity require Pak's kinase activity and binding sites for both Dock and Cdc42/Rac. A membrane-tethered form of Pak (Pak(myr)) acts as a dominant gain-of-function protein. Retinal expression of Pak(myr) rescues the R cell connectivity phenotype in dock mutants. These data establish Pak as a critical regulator of axon guidance and a downstream effector of Dock in vivo.	Calif State Univ Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore; Inst Neurol, London WC1N 1PJ, England	California State University System; California State University Los Angeles; Howard Hughes Medical Institute; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; University of London; University College London	Zipursky, SL (corresponding author), Calif State Univ Los Angeles, Sch Med, Dept Biol Chem, Howard Hughes Med Inst, Los Angeles, CA 90095 USA.	zipursky@hhmi.ucla.edu		Zipursky, Stephen/0000-0001-5630-7181				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Clemens JC, 1996, J BIOL CHEM, V271, P17002, DOI 10.1074/jbc.271.29.17002; DELATORRE JR, 1997, CELL, V19, P1211; Frost JA, 1998, J BIOL CHEM, V273, P28191, DOI 10.1074/jbc.273.43.28191; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; Garrity PA, 1996, CELL, V85, P639, DOI 10.1016/S0092-8674(00)81231-3; Garrity PA, 1999, NEURON, V22, P707, DOI 10.1016/S0896-6273(00)80730-8; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Harden N, 1996, MOL CELL BIOL, V16, P1896; Kochhar KS, 1996, CANCER LETT, V104, P163, DOI 10.1016/0304-3835(96)04244-9; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leeuw T, 1998, NATURE, V391, P191, DOI 10.1038/34448; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; McCarty JH, 1998, BIOESSAYS, V20, P913, DOI 10.1002/(SICI)1521-1878(199811)20:11<913::AID-BIES6>3.0.CO;2-T; Melzig J, 1998, CURR BIOL, V8, P1223, DOI 10.1016/S0960-9822(07)00514-3; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Obermeier A, 1998, EMBO J, V17, P4328, DOI 10.1093/emboj/17.15.4328; Rao Y, 1998, P NATL ACAD SCI USA, V95, P2077, DOI 10.1073/pnas.95.5.2077; Salecker I, 1998, CELL, V95, P587, DOI 10.1016/S0092-8674(00)81627-X; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Stein E, 1998, J BIOL CHEM, V273, P1303, DOI 10.1074/jbc.273.3.1303; Suter DM, 1998, CURR OPIN NEUROBIOL, V8, P106, DOI 10.1016/S0959-4388(98)80014-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Winberg ML, 1998, CELL, V93, P581, DOI 10.1016/S0092-8674(00)81187-3; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	36	244	249	0	1	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 25	1999	97	7					853	863		10.1016/S0092-8674(00)80798-9	http://dx.doi.org/10.1016/S0092-8674(00)80798-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	211LP	10399914	Bronze			2022-12-24	WOS:000081162800007
J	Meneghini, MD; Ishitani, T; Carter, JC; Hisamoto, N; Ninomiya-Tsuji, J; Thorpe, CJ; Hamill, DR; Matsumoto, K; Bowerman, B				Meneghini, MD; Ishitani, T; Carter, JC; Hisamoto, N; Ninomiya-Tsuji, J; Thorpe, CJ; Hamill, DR; Matsumoto, K; Bowerman, B			MAP kinase and Wnt pathways converge to downregulate an HMG-domain repressor in Caenorhabditis elegans	NATURE			English	Article							BETA SIGNAL-TRANSDUCTION; C-ELEGANS; GENE; SPECIFICATION; DROSOPHILA; WINGLESS; EMBRYOS; ACTIVATOR; MESODERM; ENDODERM	The signalling protein Wnt regulates transcription factors containing high-mobility-group (HMG) domains to direct decisions on cell fate during animal development(1). In Caenorhabditis elegans, the HMG-domain-containing repressor POP-1 distinguishes the fates of anterior daughter cells from their posterior sisters throughout development(2,3), and Wnt signalling downregulates POP-1 activity in one posterior daughter cell called E (refs 2, 4, 5). Here we show that the genes mom-4 and lit-1 are also required to downregulate POP-1, not only in E but also in other posterior daughter cells. Consistent with action in a common pathway, mom-4 and lit-1 exhibit similar mutant phenotypes and encode components of the mitogen-activated protein kinase (MAPK) pathway that are homologous to vertebrate transforming-growth-factor-beta-activated kinase (TAK1) and NEMO-like kinase (NLK), respectively. Furthermore, MOM-4 and TAK1 bind related proteins that promote their kinase activities. We conclude that: a MAPK-related pathway cooperates with Wnt signal transduction to downregulate POP-1 activity. These functions are likely to be conserved in vertebrates, as TAK1 and NLK can downregulate HMG-domain-containing proteins related to POP-1 (ref. 6).	Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA; Nagoya Univ, Grad Sch Sci, Dept Mol Biol, Nagoya, Aichi 4648602, Japan; Japan Sci & Technol Corp, CREST, Chkusa Ku, Nagoya, Aichi 4648602, Japan	University of Oregon; Nagoya University; Japan Science & Technology Agency (JST)	Bowerman, B (corresponding author), Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.	bbowerman@molbio.uoregon.edu	, Tohru/AAH-8979-2020; Ishitani, Tohru/E-9781-2014	, Tohru/0000-0002-6200-7043; Ninomiya-Tsuji, Jun/0000-0002-5584-0176	PHS HHS [R01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; BRENNER S, 1974, GENETICS, V77, P71; Brott BK, 1998, P NATL ACAD SCI USA, V95, P963, DOI 10.1073/pnas.95.3.963; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; CHOI KW, 1994, CELL, V78, P125, DOI 10.1016/0092-8674(94)90579-7; EPSTEIN HF, 1995, MODERN BIOL ANAL ORG; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; GOLDSTEIN B, 1995, DEVELOPMENT, V121, P1221; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Kaletta T, 1997, NATURE, V390, P294, DOI 10.1038/36869; Lin RL, 1998, CELL, V92, P229, DOI 10.1016/S0092-8674(00)80917-4; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; PRIESS JR, 1987, CELL, V34, P85; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	28	231	243	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 24	1999	399	6738					793	797						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	210JP	10391246				2022-12-24	WOS:000081101600056
J	Wang, J; Smolyar, A; Tan, KM; Liu, J; Kim, MY; Sun, ZJ; Wagner, G; Reinherz, EL				Wang, J; Smolyar, A; Tan, KM; Liu, J; Kim, MY; Sun, ZJ; Wagner, G; Reinherz, EL			Structure of a heterophilic adhesion complex between the human CD2 and CD58 (LFA-3) counterreceptors	CELL			English	Article							T-CELL ACTIVATION; FUNCTION-ASSOCIATED ANTIGEN-3; PROTEIN-PROTEIN INTERFACES; CRYSTAL-STRUCTURE; MOLECULE CD2; IMMUNOGLOBULIN SUPERFAMILY; RECEPTOR CD2; MOUSE CHROMOSOME-1; GLYCOPROTEIN CD2; LIGAND-BINDING	Interaction between CD2 and its counterreceptor, CD58 (LFA-3), on opposing cells optimizes immune recognition, facilitating contacts between helper T lymphocytes and antigen-presenting cells as well as between cytolytic effecters and target cells. Here, we report the crystal structure of the heterophilic adhesion complex between the amino-terminal domains of human CD2 and CD58. A strikingly asymmetric, orthogonal, face-to-face interaction involving the major beta sheets of the respective immunoglobulin-like domains with poor shape complementarity is revealed. In the virtual absence of hydrophobic forces, interdigitating charged amino acid side chains form hydrogen bonds and salt links at the interface (similar to 1200 Angstrom(2)), imparting a high degree of specificity albeit with low affinity (K-D of similar to mu M). These features explain CD2-CD58 dynamic binding, offering insights into interactions of related immunoglobulin superfamily receptors.	Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wang, J (corresponding author), Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	jwang@red.dfci.harvard.edu; ellis_reinherz@dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021226, R01AI037581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21226, AI37581] Funding Source: Medline; NIGMS NIH HHS [GM56008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARULANANDAM ARN, 1993, P NATL ACAD SCI USA, V90, P11613, DOI 10.1073/pnas.90.24.11613; ARULANANDAM ARN, 1994, J EXP MED, V180, P1861, DOI 10.1084/jem.180.5.1861; ARULANANDAM ARN, 1993, J EXP MED, V177, P1439, DOI 10.1084/jem.177.5.1439; Atwell S, 1997, SCIENCE, V278, P1125, DOI 10.1126/science.278.5340.1125; BIERER BE, 1989, ANNU REV IMMUNOL, V7, P579, DOI 10.1146/annurev.immunol.7.1.579; BIERER BE, 1988, J EXP MED, V168, P1145, DOI 10.1084/jem.168.3.1145; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BOUSSIOTIS VA, 1994, J EXP MED, V180, P1665, DOI 10.1084/jem.180.5.1665; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Casasnovas JM, 1997, NATURE, V387, P312, DOI 10.1038/387312a0; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CHOTHIA C, 1982, BIOCHEMISTRY-US, V21, P3955, DOI 10.1021/bi00260a009; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; DAVIS SJ, 1995, J BIOL CHEM, V270, P369, DOI 10.1074/jbc.270.1.369; Davis SJ, 1998, IMMUNOL REV, V163, P217, DOI 10.1111/j.1600-065X.1998.tb01199.x; Davis SJ, 1998, P NATL ACAD SCI USA, V95, P5490, DOI 10.1073/pnas.95.10.5490; DENGLER TJ, 1992, EUR J IMMUNOL, V22, P2809, DOI 10.1002/eji.1830221109; DRISCOLL PC, 1991, NATURE, V353, P762, DOI 10.1038/353762a0; Dustin ML, 1997, J BIOL CHEM, V272, P15782, DOI 10.1074/jbc.272.25.15782; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fan QR, 1997, NATURE, V389, P96, DOI 10.1038/38028; Freedman SJ, 1996, BIOCHEMISTRY-US, V35, P13733, DOI 10.1021/bi9610257; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GOLLOB JA, 1995, J EXP MED, V182, P721, DOI 10.1084/jem.182.3.721; Gollob JA, 1996, J IMMUNOL, V157, P1886; GRAVES BJ, 1994, NATURE, V367, P532, DOI 10.1038/367532a0; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; JONES EY, 1992, NATURE, V360, P232, DOI 10.1038/360232a0; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KOYASU S, 1990, P NATL ACAD SCI USA, V87, P2603, DOI 10.1073/pnas.87.7.2603; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENSKY AM, 1983, J IMMUNOL, V131, P611; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lehninger A.L., 1975, BIOCH MOL BASIS CELL, Vsecond; Li J, 1998, EMBO J, V17, P7320, DOI 10.1093/emboj/17.24.7320; Li J, 1996, J MOL BIOL, V263, P209, DOI 10.1006/jmbi.1996.0570; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MEUER SC, 1984, CELL, V36, P897, DOI 10.1016/0092-8674(84)90039-4; MOINGEON P, 1989, NATURE, V339, P312, DOI 10.1038/339312a0; MOINGEON P, 1989, IMMUNOL REV, V111, P111, DOI 10.1111/j.1600-065X.1989.tb00544.x; MOINGEON PE, 1991, EUR J IMMUNOL, V21, P605, DOI 10.1002/eji.1830210311; Monks CRF, 1998, NATURE, V395, P82, DOI 10.1038/25764; MOSELEY WS, 1989, GENOMICS, V5, P899, DOI 10.1016/0888-7543(89)90132-8; MUSAFIA B, 1995, J MOL BIOL, V254, P761, DOI 10.1006/jmbi.1995.0653; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; OSBORN L, 1995, J EXP MED, V181, P429, DOI 10.1084/jem.181.1.429; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PARISH CR, 1988, J IMMUNOL, V141, P3498; PETERSON A, 1987, NATURE, V329, P842, DOI 10.1038/329842a0; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; RECNY MA, 1990, J BIOL CHEM, V265, P8542; RECNY MA, 1992, J BIOL CHEM, V267, P22428; REINHOLD BB, 1992, TECHNIQUES PROTEIN C, V3, P287; SANCHEZMADRID F, 1982, P NATL ACAD SCI-BIOL, V79, P7489, DOI 10.1073/pnas.79.23.7489; SAYRE PH, 1989, J EXP MED, V169, P995, DOI 10.1084/jem.169.3.995; SELVARAJ P, 1987, NATURE, V326, P400, DOI 10.1038/326400a0; SEWELL WA, 1988, IMMUNOGENETICS, V28, P278, DOI 10.1007/BF00345506; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; SHER PK, 1987, PEDIATR NEUROL, V3, P197; SOMOZA C, 1993, J EXP MED, V178, P549, DOI 10.1084/jem.178.2.549; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SUN ZYJ, 1999, IN PRESS EMBO J; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; Wang JH, 1998, IMMUNOL REV, V163, P197, DOI 10.1111/j.1600-065X.1998.tb01198.x; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WILLIAMS AF, 1987, IMMUNOL TODAY, V8, P298, DOI 10.1016/0167-5699(87)90016-8; WITHKA JM, 1993, STRUCTURE, V1, P69, DOI 10.1016/0969-2126(93)90009-6; WONG YW, 1990, J EXP MED, V171, P2115, DOI 10.1084/jem.171.6.2115; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412	86	196	201	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 11	1999	97	6					791	803		10.1016/S0092-8674(00)80790-4	http://dx.doi.org/10.1016/S0092-8674(00)80790-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	206NQ	10380930	Bronze			2022-12-24	WOS:000080886300016
